<SEC-DOCUMENT>0000896262-20-000010.txt : 20200507
<SEC-HEADER>0000896262-20-000010.hdr.sgml : 20200507
<ACCEPTANCE-DATETIME>20200507080503
ACCESSION NUMBER:		0000896262-20-000010
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		56
CONFORMED PERIOD OF REPORT:	20200331
FILED AS OF DATE:		20200507
DATE AS OF CHANGE:		20200507

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMEDISYS INC
		CENTRAL INDEX KEY:			0000896262
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-HOME HEALTH CARE SERVICES [8082]
		IRS NUMBER:				113131700
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-24260
		FILM NUMBER:		20854657

	BUSINESS ADDRESS:	
		STREET 1:		3854 AMERICAN WAY
		STREET 2:		SUITE A
		CITY:			BATON ROUGE
		STATE:			LA
		ZIP:			70816
		BUSINESS PHONE:		2252922031

	MAIL ADDRESS:	
		STREET 1:		3854 AMERICAN WAY
		STREET 2:		SUITE A
		CITY:			BATON ROUGE
		STATE:			LA
		ZIP:			70816

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANALYTICAL NURSING MANAGEMENT CORP
		DATE OF NAME CHANGE:	19940819

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	M&N CAPITAL CORP
		DATE OF NAME CHANGE:	19930125
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>amed-20200331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:dde64841-3e1e-49e6-96d6-a911d3f838cb,g:d3a0c63a-9ddc-46a6-b2f9-35d46ac243f3,d:793e68cdccb44b98a73aef6e33f497bf--><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:amed="http://www.amedisys.com/20200331" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:srt="http://fasb.org/srt/2019-01-31"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>amed-20200331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80L2ZyYWc6YmZlODQ0NjRkZmVkNDIxZjk4Njc0MTA4ZmFiYTkzZWUvdGFibGU6M2YxZDZkMjFiY2M5NDA1MjhmNzdhMzE5NWEzNGZmZTUvdGFibGVyYW5nZTozZjFkNmQyMWJjYzk0MDUyOGY3N2EzMTk1YTM0ZmZlNV80LTEtMS0xLTA_b9b236a3-014e-4ea8-b687-338262d45bbe">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80L2ZyYWc6YmZlODQ0NjRkZmVkNDIxZjk4Njc0MTA4ZmFiYTkzZWUvdGFibGU6M2YxZDZkMjFiY2M5NDA1MjhmNzdhMzE5NWEzNGZmZTUvdGFibGVyYW5nZTozZjFkNmQyMWJjYzk0MDUyOGY3N2EzMTk1YTM0ZmZlNV82LTEtMS0xLTA_5f6f8d42-92ca-44a3-b3e6-0f2f4f3fac91">2020</ix:nonNumeric><ix:nonNumeric contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80L2ZyYWc6YmZlODQ0NjRkZmVkNDIxZjk4Njc0MTA4ZmFiYTkzZWUvdGFibGU6M2YxZDZkMjFiY2M5NDA1MjhmNzdhMzE5NWEzNGZmZTUvdGFibGVyYW5nZTozZjFkNmQyMWJjYzk0MDUyOGY3N2EzMTk1YTM0ZmZlNV83LTEtMS0xLTA_07a06634-a139-47ed-b00b-af5ea75ca680">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80L2ZyYWc6YmZlODQ0NjRkZmVkNDIxZjk4Njc0MTA4ZmFiYTkzZWUvdGFibGU6M2YxZDZkMjFiY2M5NDA1MjhmNzdhMzE5NWEzNGZmZTUvdGFibGVyYW5nZTozZjFkNmQyMWJjYzk0MDUyOGY3N2EzMTk1YTM0ZmZlNV85LTEtMS0xLTA_c047e51d-5245-463d-aace-6109ba6bc74f">AMEDISYS INC</ix:nonNumeric><ix:nonNumeric contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80L2ZyYWc6YmZlODQ0NjRkZmVkNDIxZjk4Njc0MTA4ZmFiYTkzZWUvdGFibGU6M2YxZDZkMjFiY2M5NDA1MjhmNzdhMzE5NWEzNGZmZTUvdGFibGVyYW5nZTozZjFkNmQyMWJjYzk0MDUyOGY3N2EzMTk1YTM0ZmZlNV8xMC0xLTEtMS0w_8de8000a-fe5b-4439-84f2-d2672b4cb8ef">0000896262</ix:nonNumeric><ix:nonNumeric contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80L2ZyYWc6YmZlODQ0NjRkZmVkNDIxZjk4Njc0MTA4ZmFiYTkzZWUvdGFibGU6M2YxZDZkMjFiY2M5NDA1MjhmNzdhMzE5NWEzNGZmZTUvdGFibGVyYW5nZTozZjFkNmQyMWJjYzk0MDUyOGY3N2EzMTk1YTM0ZmZlNV8xMS0xLTEtMS0w_deef310e-f49f-4903-ae4e-961bfe08a0ef">--12-31</ix:nonNumeric><ix:nonFraction unitRef="usdPerShare" contextRef="i014c385050454730837d592e15bca5e0_I20191231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yMi9mcmFnOjRmMjcyZDI2ODc4ZjRkZjc4YzA3ODA5OWQ5ZDY5Y2NiL3RhYmxlOjg3MGQ5YTcyYWU5ZjQxMDBhZTZkMmEzYTU1ZDA1OTU4L3RhYmxlcmFuZ2U6ODcwZDlhNzJhZTlmNDEwMGFlNmQyYTNhNTVkMDU5NThfMy0yLTEtMS0w_6c0e7389-8090-48da-831a-be6d56b5b066">0.001</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i014c385050454730837d592e15bca5e0_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yMi9mcmFnOjRmMjcyZDI2ODc4ZjRkZjc4YzA3ODA5OWQ5ZDY5Y2NiL3RhYmxlOjg3MGQ5YTcyYWU5ZjQxMDBhZTZkMmEzYTU1ZDA1OTU4L3RhYmxlcmFuZ2U6ODcwZDlhNzJhZTlmNDEwMGFlNmQyYTNhNTVkMDU5NThfNC0yLTEtMS0w_da0d385f-d88b-4ad1-9bb6-a5a88ab15e82">5,000,000</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331" decimals="INF" format="ixt:zerodash" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yMi9mcmFnOjRmMjcyZDI2ODc4ZjRkZjc4YzA3ODA5OWQ5ZDY5Y2NiL3RhYmxlOjg3MGQ5YTcyYWU5ZjQxMDBhZTZkMmEzYTU1ZDA1OTU4L3RhYmxlcmFuZ2U6ODcwZDlhNzJhZTlmNDEwMGFlNmQyYTNhNTVkMDU5NThfNS0xLTEtMS0w_c0e99f91-a6ab-4dbf-80b9-ca6a873b7fc7">&#8212;</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i014c385050454730837d592e15bca5e0_I20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yMi9mcmFnOjRmMjcyZDI2ODc4ZjRkZjc4YzA3ODA5OWQ5ZDY5Y2NiL3RhYmxlOjg3MGQ5YTcyYWU5ZjQxMDBhZTZkMmEzYTU1ZDA1OTU4L3RhYmxlcmFuZ2U6ODcwZDlhNzJhZTlmNDEwMGFlNmQyYTNhNTVkMDU5NThfNS0yLTEtMS0w_f5144afa-7687-434b-8157-27012ca9591d">&#8212;</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331" decimals="INF" format="ixt:zerodash" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yMi9mcmFnOjRmMjcyZDI2ODc4ZjRkZjc4YzA3ODA5OWQ5ZDY5Y2NiL3RhYmxlOjg3MGQ5YTcyYWU5ZjQxMDBhZTZkMmEzYTU1ZDA1OTU4L3RhYmxlcmFuZ2U6ODcwZDlhNzJhZTlmNDEwMGFlNmQyYTNhNTVkMDU5NThfNi0xLTEtMS0w_1b3574ec-ea14-47f5-b44b-6fb28d350721">&#8212;</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i014c385050454730837d592e15bca5e0_I20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yMi9mcmFnOjRmMjcyZDI2ODc4ZjRkZjc4YzA3ODA5OWQ5ZDY5Y2NiL3RhYmxlOjg3MGQ5YTcyYWU5ZjQxMDBhZTZkMmEzYTU1ZDA1OTU4L3RhYmxlcmFuZ2U6ODcwZDlhNzJhZTlmNDEwMGFlNmQyYTNhNTVkMDU5NThfNi0yLTEtMS0w_4747b684-d60b-4662-90bc-8172a9e093af">&#8212;</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="i014c385050454730837d592e15bca5e0_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yMi9mcmFnOjRmMjcyZDI2ODc4ZjRkZjc4YzA3ODA5OWQ5ZDY5Y2NiL3RhYmxlOjg3MGQ5YTcyYWU5ZjQxMDBhZTZkMmEzYTU1ZDA1OTU4L3RhYmxlcmFuZ2U6ODcwZDlhNzJhZTlmNDEwMGFlNmQyYTNhNTVkMDU5NThfNy0yLTEtMS0w_23f3db62-fe60-4684-9b3c-26bb0d106db8">0.001</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i014c385050454730837d592e15bca5e0_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yMi9mcmFnOjRmMjcyZDI2ODc4ZjRkZjc4YzA3ODA5OWQ5ZDY5Y2NiL3RhYmxlOjg3MGQ5YTcyYWU5ZjQxMDBhZTZkMmEzYTU1ZDA1OTU4L3RhYmxlcmFuZ2U6ODcwZDlhNzJhZTlmNDEwMGFlNmQyYTNhNTVkMDU5NThfOC0yLTEtMS0w_da7b4776-2788-43d8-be89-9a50e1abfd3f">60,000,000</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i1b4727e37ed3465f9d534f1fb6bb413c_D20190101-20190331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80MC9mcmFnOjQ4Mjg0YzcxODc4YTQyZDk5YzRlNDJiNTE5ZWUxNGY3L3RhYmxlOjNkNGM5YTcxNGYwNDQ1MDU4ZTg2NDAzN2Y2MGY1MGU0L3RhYmxlcmFuZ2U6M2Q0YzlhNzE0ZjA0NDUwNThlODY0MDM3ZjYwZjUwZTRfMy0xLTEtMS0w_72ded738-a504-4b59-b6fd-3d7c76dd013d">74</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i1b4727e37ed3465f9d534f1fb6bb413c_D20190101-20190331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80Ni9mcmFnOjU5MjlkNjhkZjM0MDQzZmQ5Y2RkZWUyNzc5NjQ5NmQ3L3RleHRyZWdpb246NTkyOWQ2OGRmMzQwNDNmZDljZGRlZTI3Nzk2NDk2ZDdfNDM_a2aeb4dc-dea7-4a83-97c7-1a972cd5e84e">74</ix:nonFraction><ix:nonNumeric contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" format="ixt-sec:durday" name="amed:EpisodeOfCareAsEpisodicBasedRevenueDuration" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80Ni9mcmFnOjU5MjlkNjhkZjM0MDQzZmQ5Y2RkZWUyNzc5NjQ5NmQ3L3RleHRyZWdpb246NTkyOWQ2OGRmMzQwNDNmZDljZGRlZTI3Nzk2NDk2ZDdfNTEz_64a8dd3b-63e8-4a29-9270-8bfc85896305">60</ix:nonNumeric><ix:nonNumeric contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" format="ixt-sec:durday" name="amed:PeriodOfCareAsEpisodicBasedRevenueDuration" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80Ni9mcmFnOjU5MjlkNjhkZjM0MDQzZmQ5Y2RkZWUyNzc5NjQ5NmQ3L3RleHRyZWdpb246NTkyOWQ2OGRmMzQwNDNmZDljZGRlZTI3Nzk2NDk2ZDdfMzI5ODUzNDg4NDczOQ_ae579688-9cae-4c1d-916c-4ebafc377d7c">30</ix:nonNumeric><ix:nonNumeric contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" format="ixt-sec:durday" name="amed:NetServiceRevenuePeriodOfCarePaymentRateDuration" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80Ni9mcmFnOjU5MjlkNjhkZjM0MDQzZmQ5Y2RkZWUyNzc5NjQ5NmQ3L3RleHRyZWdpb246NTkyOWQ2OGRmMzQwNDNmZDljZGRlZTI3Nzk2NDk2ZDdfNjY0_e527415a-e6e5-42d8-9c74-f36622edcb95">30</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i014c385050454730837d592e15bca5e0_I20191231" decimals="2" name="amed:AccountsReceivablePortionDerivedFromMedicare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80Ni9mcmFnOjU5MjlkNjhkZjM0MDQzZmQ5Y2RkZWUyNzc5NjQ5NmQ3L3RleHRyZWdpb246NTkyOWQ2OGRmMzQwNDNmZDljZGRlZTI3Nzk2NDk2ZDdfMTY0OTI2NzQ0MzAzOQ_a89e8bc9-1ca2-4292-931e-aee5e4311819">58</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i75590cbf7a2a42d792be47ee29fed5a2_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl81Mi9mcmFnOjkxMWZmY2IzMWRjNTQ4OTNhZjQwMTliODU1ODgxMDRmL3RhYmxlOjJjZDI1ZTI0MjA0ZjRmODZiYWFjYTNhYmQwZTMzZTc1L3RhYmxlcmFuZ2U6MmNkMjVlMjQyMDRmNGY4NmJhYWNhM2FiZDBlMzNlNzVfMS0xLTEtMS0w_8e421f79-5a89-42b9-b9ad-b4e63c115ded">1.3</ix:nonFraction><ix:nonNumeric contextRef="i63c633d2b51b42baa61a11b822bb68a4_D20200101-20200331" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl81Mi9mcmFnOjkxMWZmY2IzMWRjNTQ4OTNhZjQwMTliODU1ODgxMDRmL3RleHRyZWdpb246OTExZmZjYjMxZGM1NDg5M2FmNDAxOWI4NTU4ODEwNGZfMTY0OTI2NzQ0MTc3NQ_48c32b0c-1a79-4072-94cc-e8edac41b1b9">2.0</ix:nonNumeric><ix:nonNumeric contextRef="ib06e3eda34d04dff97bdcb1a32a5c655_D20190204-20190204" name="us-gaap:DebtInstrumentDescriptionOfVariableRateBasis" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82NC9mcmFnOmIyZDQzYTFhZjQzZjQxN2U5NGVlM2ZiNmY4MTA0MTkzL3RleHRyZWdpb246YjJkNDNhMWFmNDNmNDE3ZTk0ZWUzZmI2ZjgxMDQxOTNfODEw_7ccdf412-d56e-41f2-ad2f-c74879f9c305">Fluctuating rate per annum equal to the highest of (a)&#160;the federal funds rate plus 0.50% per annum, (b)&#160;the prime rate of interest established by the Administrative Agent, and (c)&#160;the Eurodollar Rate for an interest period of one month plus 1% per annum.</ix:nonNumeric><ix:nonNumeric contextRef="iabee2409c21d4a51ab396e763ff8944e_D20190204-20190204" name="us-gaap:DebtInstrumentDescriptionOfVariableRateBasis" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82NC9mcmFnOmIyZDQzYTFhZjQzZjQxN2U5NGVlM2ZiNmY4MTA0MTkzL3RleHRyZWdpb246YjJkNDNhMWFmNDNmNDE3ZTk0ZWUzZmI2ZjgxMDQxOTNfODEx_ec6cc796-6c0e-48a3-a3da-bf882f318184">Rate at which Eurodollar deposits in the London interbank market for an interest period of one, two, three or six months</ix:nonNumeric><ix:nonFraction unitRef="usd" contextRef="i11afc1711d40400ab2e0bf09b8a0bda6_D20190101-20191231" decimals="-5" name="us-gaap:PaymentsOfFinancingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82NC9mcmFnOmIyZDQzYTFhZjQzZjQxN2U5NGVlM2ZiNmY4MTA0MTkzL3RleHRyZWdpb246YjJkNDNhMWFmNDNmNDE3ZTk0ZWUzZmI2ZjgxMDQxOTNfNjI2_b2ab0d7f-34cc-421d-9da5-eb3a1426db07">0.8</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="amed-20200331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ie94809e1cf0d453a8421029757c0fff8_I20200501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-05-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i886ddae2179d4ed793345586cc440c4e_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i014c385050454730837d592e15bca5e0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i379583ecb9374798b4c230bb394c2c67_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a5040a26fb048c0a87bf6f051f93896_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3febdb7171a24ee1801a9231cc9591f3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74e0f28f8b654d48a67abd821a86e3c4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae980ac5b3a541419edf1dafb6f4c6f5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea78279e652f4d91ae574d24a6286705_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic64b3c79c65143a4a4af6c36f8b99fcf_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife895f7907c04cc1809e6c1fec83c56f_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24fbf8ed4ce94e058258628cf71035a5_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3897e7c6671f45b2a1b361f76b28fea4_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i766b3828bac34e55bd02b261a75f847a_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4ce05f08cf04e5691c12539b7c46390_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a470325c5bc4889b266f68e9544d3e5_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac55dce70a374679bd199e04eaa5b649_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ab26af603e844e9b6bdda46662485c3_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1593f26e241b483ebd91cefceb35d199_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf11627cc0b7467f85b1368394bb2664_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30654d85149642fdae1198cad652319f_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5070e06e0c374add9463ca31e59e3d55_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89a07a7310c54227add149c2b0b87ee3_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib79791d3ae294c48a6a6f3b9d4237287_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2973a18d82d64089981faf633016e337_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6e258d79aa94c7b85ea31dd68768540_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90b913e7ac1542e6928ba4790c344cb1_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd20ee3ceb1b468ca3e169ae4b78ec43_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24ae5ea6239844c1943ccc8250cf4d3e_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8ccec4951d54e429f9b0776571c27c8_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae6e37863ef2446982ab4508cb5c6a4a_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2a1f77af6c6468e80794d3e6619da24_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3dbbd4d693549d08a550ff85e19d07e_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3202099b2aaf4cc88461f7725441d5a3_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie390be034b284f5082baf3f2f9d8d312_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if286a7fc2ab5482e927587b135cac060_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a118ef4adc642169df30733695018e7_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07447f32d01d4b719bba4d5394e101f1_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9aced020e10e41469ac1511a249cd44a_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie495d4805b994e769059ce32d0936a6c_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i58e124b0d6b94d7c921cc9069e91b8ba_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">amed:MedicareRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="care_center"><xbrli:measure>amed:care_center</xbrli:measure></xbrli:unit><xbrli:context id="i0836ed4fa3b14e54895551f7cea7ebcf_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedecd98e5aa64817971cc51d13696c31_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c4c8579b54540d3958eb43f0bb5f417_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="state"><xbrli:measure>amed:state</xbrli:measure></xbrli:unit><xbrli:context id="i1b4727e37ed3465f9d534f1fb6bb413c_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">amed:MedicareRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08f8228195d4482abb1638f4aff3246a_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4775f859e4944ad78c696d06861399db_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1585d446638b4ebaaafeda3e997809c6_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareEpisodicBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i023ad62f89a640b9bafc773ed8834c5c_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareEpisodicBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i504907be1af1401896b436e9f31ef9b2_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareNonEpisodicBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c0374d568c345b1895f99bc4c5da6a1_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareNonEpisodicBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i012f167f36504108a1f5b3c3b8746634_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbce36e4c2a04a1ab922f6c09ff1bf77_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9379225a4bef4cf6a6dc439d3252aa78_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceNonMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib45c518834644bd5a393af3f5453153c_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceNonMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i244a79cf50e84b398521caa51f9417a5_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:PersonalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id20d8630a41943e5824e25095e23ca89_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:PersonalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="visit"><xbrli:measure>amed:visit</xbrli:measure></xbrli:unit><xbrli:context id="i91721ec84cfa456ea3fe8a1300bb24f5_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib06523f2884143ccb65798237a08ecee_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1803f21995a846beaf2e5491abdaa75f_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2a5b1046a72421f919b53e916e3b7b9_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecd85c6103824b598da9159d305f569b_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:CapYearAxis">amed:CapYearTwoThousandThirteenThroughTwoThousandTwentyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ff59164cb40413fac8d060bc05c3403_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:CapYearAxis">amed:CapYearTwoThousandThirteenThroughTwoThousandTwentyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94c155e0b36a4453979995375a4118aa_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">amed:AsanaHospiceAquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6a265dc3d6143ed962cec7a4019507c_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">amed:COVID19PPEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="day"><xbrli:measure>amed:day</xbrli:measure></xbrli:unit><xbrli:context id="i0c3c88d49d1d4d8a95daf44cd924af53_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7815a32e7798440abd6d377ab708f8e5_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72f233d9e2f84fa7a940e82385eff8a4_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia13fdf76a2e04a3f85e27598086705bf_D20200301-20200301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1a12a5a1ad7439bb6eb83289bc57f39_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:CertificateOfNeedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7171631cf3944959da9674b593c9910_D20200101-20200101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AsanaHospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c5dbb2e85d34e54b0517980e6f8d0eb_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AsanaHospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75590cbf7a2a42d792be47ee29fed5a2_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AsanaHospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i758d8a3c5dd14c668b6a8284e987ffea_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AsanaHospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:MedicareLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaeb6ae8b7d9c4d529b6d4a55a4212894_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AsanaHospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AcquiredNamesOfBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19dd87f55ab74480af0f28e529fe3174_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AsanaHospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i966c726cb1b24dc69084cdec997e95f6_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AsanaHospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AcquiredNamesOfBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63c633d2b51b42baa61a11b822bb68a4_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AsanaHospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic735d35014784f0395b22a1d4852e2bb_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9683f40a00e94c1abb96d732c3041061_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ba21eb95e2e43d1b0a24756aec8f4e8_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62c497259b644d859d8f0eea7f3e524e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ff90663d1684cb09b78cf9c7fde47b7_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9224a41a12a14375adaf6a341b29f6fb_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if270e80806534123864832e895591246_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2057b301fd0c4cd39ca4cc85da07a5f6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i645e5d94ba734fb2a80140b926935a3d_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:PromissoryNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72eea6f293c44f77b3987d12a9412f37_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:PromissoryNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ef172d1bcd342b98c9cdb09d302dc65_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3608bfa9782e4bac938cc97a5f45bbc6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6972271e2cb4f179a778bd579050d45_I20190204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-02-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i686590f797e04c189494ff3b9677db0c_I20190204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffa33294d8f04f04b0db89e59138db4a_I20190204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71126d46462944a9aee1ee7aef720bee_D20190204-20190204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-04</xbrli:startDate><xbrli:endDate>2019-02-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8766fbac86e4b5a80af143791d0f409_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d6002c5f99d4721838ee0060efd407b_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i116335fec8a8410395d5970ead81815b_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d3ef9b25fd64694a1f379a432f9bb62_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03234fef29e642489ae4417c7674ca60_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c19ce09b115491883ac15a09c9fce6d_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i262c9a55a12d4a2e82c1e6f3a19cf70f_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie32195fe339a4436b4904c56998424fb_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3e4c94018794c938917b5e4762bb3a3_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id274d4e6f62045c8b0313e71c808f7a0_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3424d73450945acbfb6662c2947d02c_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i587391f59a70479592d057ca4817c53d_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10e7017e38964ada930ea223919b92d6_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40aeb3bc9f044ec2948f550127151c2f_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12d7c31ad0e442449db03a43e8ee94b2_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88e1a49559cf4832bf8d22eb47cac167_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic343676840f04990b1419f15ad513197_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01dd577fcaf548d1bf70b0a704312472_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01f445fe93c14d05abd4461abdf8ac06_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2aa959b6fa504afaa53549e81bde7718_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52efcfba53a641308fa077db50f1031f_D20190204-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-04</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ee8f60caeec4edeb0fa06f3891d0fcf_D20200401-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c02e2cca97c41ee89b6417d85253d91_D20230401-20240204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-02-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia85dd0cda56f46d88648f67dd3c62846_D20190204-20190204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-04</xbrli:startDate><xbrli:endDate>2019-02-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9def8d782364ec6a243d4e1839a987f_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia378c7f5c8aa4e24951f6ef187aefeb4_D20190204-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-04</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib409845529d94d28bc9b375ca272bc7d_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib06e3eda34d04dff97bdcb1a32a5c655_D20190204-20190204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-04</xbrli:startDate><xbrli:endDate>2019-02-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabee2409c21d4a51ab396e763ff8944e_D20190204-20190204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-04</xbrli:startDate><xbrli:endDate>2019-02-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11afc1711d40400ab2e0bf09b8a0bda6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="patient"><xbrli:measure>amed:patient</xbrli:measure></xbrli:unit><xbrli:context id="i3a33f09f3173490fa79c2009fa38ee93_D20150521-20150521"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-05-21</xbrli:startDate><xbrli:endDate>2015-05-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb70013011f74758ae2ef2a1a0de32c1_D20151103-20151103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:MorgantownWestVirginiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-11-03</xbrli:startDate><xbrli:endDate>2015-11-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i301ee02ef1954d139674e96cc1e9ee1b_D20160627-20160627"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ParkersburgWestVirginiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-06-27</xbrli:startDate><xbrli:endDate>2016-06-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia37b8daa112347b8876c86941748cb37_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i039c0407f0b846cab386767ba04caf96_D20150130-20150130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:CompassionateCareHospiceCIAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-30</xbrli:startDate><xbrli:endDate>2015-01-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfe6dd3be0b34aeba5d1341e4d23edbe_D20140423-20140423"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:AmedisysCIAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-04-23</xbrli:startDate><xbrli:endDate>2014-04-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="beneficiary"><xbrli:measure>amed:beneficiary</xbrli:measure></xbrli:unit><xbrli:context id="i563cd3af8c9d4df58214f2a851b9496f_D20080101-20100331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2008-01-01</xbrli:startDate><xbrli:endDate>2010-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i276fbb8a5a1041bba0699b8eaa7d329d_D20110606-20110606"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:ExtrapolatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2011-06-06</xbrli:startDate><xbrli:endDate>2011-06-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d397d49a7654cbabf31f8c0d4d869b8_I20160118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:UnfavorableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-01-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="claim"><xbrli:measure>amed:claim</xbrli:measure></xbrli:unit><xbrli:context id="i2968328e88e748f192feb97bbe016702_D20160118-20160118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:UnfavorableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-18</xbrli:startDate><xbrli:endDate>2016-01-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b1a1c40b9524b08903a47b4db462e1e_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:UnfavorableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaedb1c7adfc24c0e9954154d61af1ff0_I20190110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb12069843564cf694b4e3999c45bb5a_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia425738a537b4545a17322f5f6160d33_I20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:LakelandFloridaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0c2bead86ad4679b8c4aaddd217dfd0_D20170801-20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:LakelandFloridaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-01</xbrli:startDate><xbrli:endDate>2017-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fc8fa757ad24f1c8f989fa9c81c260f_I20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ClearwaterFloridaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc4bbdf502e3446cbb7600c7178a92c3_D20170801-20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ClearwaterFloridaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-01</xbrli:startDate><xbrli:endDate>2017-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98f80d9f97ca4a82bc3965056f5fa3f3_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:LakelandFloridaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2fd0246a3884dbd98fb1fee55bbb120_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ClearwaterFloridaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i935299f8f69f411d82a301973293010c_I20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:InfinityHomeCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c556fa53fa14b20ae65e1dc18d8bc25_I20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i727d1a03a2854f0a8ab0f8f940d78506_I20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc208c6318744c7da8b8a731efe00cdf_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8bb62c8d3f64b36aef46b46e53aa57a_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i749346d879b94b75885c06bedb422e0f_I20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94fb4c71db4b4aec948a8a7a52e540a1_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87ea094035bb4053a1610c6754611f97_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:InfinityHomeCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segments"><xbrli:measure>amed:Segments</xbrli:measure></xbrli:unit><xbrli:context id="i6a2423ba41a14b54bbfa09ffcbf822de_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fca8bc8c2274f6fadc2205b072e559c_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ea4477e2b7e45148118c36d32e8f280_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a6321b07a44425ca22c6f9c6f1f5d8b_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica2ca9848a114f40a419416038f9d299_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd5794f300984d0ebb27f829a61f2449_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i156f24d3122641318de844c5586c409a_I20190225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-02-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61c83eb39bd448178123272ce803cd04_D20190225-20190225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-25</xbrli:startDate><xbrli:endDate>2019-02-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba4950c59f204d1fadc805bed37fde70_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">amed:MedalogixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i814b93d2c0884001a010153e4ffc90ec_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">amed:MedalogixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b9efcf5de4c480e81af5d9bd1cdb30e_I20200327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64e606224ada41f7b469907990f9cbec_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie825c970c94741d3bc87bb70762f3d6b_I20200424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i231cc4c6c6914005bf14c4a47eaefddd_D20200423-20200423"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-23</xbrli:startDate><xbrli:endDate>2020-04-23</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i793e68cdccb44b98a73aef6e33f497bf_1"></div><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-top:12pt;"><span><br/></span></div><div style="margin-top:12pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%;">UNITED STATES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Washington D.C. 20549</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:19.444%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:2pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%;">FORM <ix:nonNumeric contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xL2ZyYWc6ZTM1NThjNTE5NTgyNGJhYmFlYzYwYjYxMGIxZTRhYWEvdGV4dHJlZ2lvbjplMzU1OGM1MTk1ODI0YmFiYWVjNjBiNjEwYjFlNGFhYV8yMjQ2_49b62220-90e2-437c-a4f1-005d89582739">10-Q</ix:nonNumeric> </span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:19.444%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:2pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Mark One)</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:1.367%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:94.633%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial Unicode MS',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xL2ZyYWc6ZTM1NThjNTE5NTgyNGJhYmFlYzYwYjYxMGIxZTRhYWEvdGFibGU6NTc1ODcwN2IzMmFiNDllOWE4ZTkwZTdjMzJlNmQ1NDcvdGFibGVyYW5nZTo1NzU4NzA3YjMyYWI0OWU5YThlOTBlN2MzMmU2ZDU0N18wLTAtMS0xLTA_a2061896-4059-41ae-a402-ed3480c793ae">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:12pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">For the quarterly period ended <ix:nonNumeric contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xL2ZyYWc6ZTM1NThjNTE5NTgyNGJhYmFlYzYwYjYxMGIxZTRhYWEvdGV4dHJlZ2lvbjplMzU1OGM1MTk1ODI0YmFiYWVjNjBiNjEwYjFlNGFhYV8xNDA_09811299-1518-4689-8aa7-64bce643ab2e">March&#160;31, 2020</ix:nonNumeric> </span></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">or</span></div><div style="text-align:center;margin-top:12pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:1.079%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:94.921%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xL2ZyYWc6ZTM1NThjNTE5NTgyNGJhYmFlYzYwYjYxMGIxZTRhYWEvdGFibGU6MzEyMzVjMWY0ZTQ2NGJjOWJiN2U4ZjAxZWQ4MGI0NTMvdGFibGVyYW5nZTozMTIzNWMxZjRlNDY0YmM5YmI3ZThmMDFlZDgwYjQ1M18wLTAtMS0xLTA_25823660-552d-4c5f-a4bb-358f4c3465dd">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:12pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">For the transition period from </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"> to </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Commission File Number: <ix:nonNumeric contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xL2ZyYWc6ZTM1NThjNTE5NTgyNGJhYmFlYzYwYjYxMGIxZTRhYWEvdGV4dHJlZ2lvbjplMzU1OGM1MTk1ODI0YmFiYWVjNjBiNjEwYjFlNGFhYV8yMjQx_f9d3a612-d23b-47e0-b4e4-d61d8152cc7b">0-24260</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:19.444%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:2pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;margin-top:3pt;"><img src="amed-20200331_g1.jpg" alt="amed-20200331_g1.jpg" style="height:82px;width:160px;"/></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%;">AMEDISYS, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Exact Name of Registrant as Specified in its Charter)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:19.444%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:2pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:47.633%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.581%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:45.586%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xL2ZyYWc6ZTM1NThjNTE5NTgyNGJhYmFlYzYwYjYxMGIxZTRhYWEvdGFibGU6NDQ5ZTVjZmQzYTFkNGNmNDg4ZjUzYTczOTUzMTRjY2MvdGFibGVyYW5nZTo0NDllNWNmZDNhMWQ0Y2Y0ODhmNTNhNzM5NTMxNGNjY18xLTAtMS0xLTA_c275c07c-3dc2-4982-a529-1d5d5a583956">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xL2ZyYWc6ZTM1NThjNTE5NTgyNGJhYmFlYzYwYjYxMGIxZTRhYWEvdGFibGU6NDQ5ZTVjZmQzYTFkNGNmNDg4ZjUzYTczOTUzMTRjY2MvdGFibGVyYW5nZTo0NDllNWNmZDNhMWQ0Y2Y0ODhmNTNhNzM5NTMxNGNjY18xLTItMS0xLTA_d86edf01-ed70-4a71-9631-286ecff476ae">11-3131700</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xL2ZyYWc6ZTM1NThjNTE5NTgyNGJhYmFlYzYwYjYxMGIxZTRhYWEvdGV4dHJlZ2lvbjplMzU1OGM1MTk1ODI0YmFiYWVjNjBiNjEwYjFlNGFhYV8yMjQ3_a4bfb04b-7de8-4b3d-a6b7-a8ed2eb90572">3854 American Way</ix:nonNumeric>, <ix:nonNumeric contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xL2ZyYWc6ZTM1NThjNTE5NTgyNGJhYmFlYzYwYjYxMGIxZTRhYWEvdGV4dHJlZ2lvbjplMzU1OGM1MTk1ODI0YmFiYWVjNjBiNjEwYjFlNGFhYV8yMjQ4_6a7ec2fa-dc1b-4ddd-b89d-545f89f5f142">Suite A</ix:nonNumeric>, <ix:nonNumeric contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xL2ZyYWc6ZTM1NThjNTE5NTgyNGJhYmFlYzYwYjYxMGIxZTRhYWEvdGV4dHJlZ2lvbjplMzU1OGM1MTk1ODI0YmFiYWVjNjBiNjEwYjFlNGFhYV8yMjQy_f10e90c2-237a-4aa1-b3ff-f5898c7dbdf1">Baton Rouge</ix:nonNumeric>, <ix:nonNumeric contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xL2ZyYWc6ZTM1NThjNTE5NTgyNGJhYmFlYzYwYjYxMGIxZTRhYWEvdGV4dHJlZ2lvbjplMzU1OGM1MTk1ODI0YmFiYWVjNjBiNjEwYjFlNGFhYV8yMjQ5_7a86daa7-5482-4beb-b78f-23f46f6c2d2d">LA</ix:nonNumeric> <ix:nonNumeric contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xL2ZyYWc6ZTM1NThjNTE5NTgyNGJhYmFlYzYwYjYxMGIxZTRhYWEvdGV4dHJlZ2lvbjplMzU1OGM1MTk1ODI0YmFiYWVjNjBiNjEwYjFlNGFhYV8yMjUw_36a9a6d9-fd86-492d-bb1e-c7220a4d5f6c">70816</ix:nonNumeric> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">(Address of principal executive offices, including zip code)</span></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(<ix:nonNumeric contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xL2ZyYWc6ZTM1NThjNTE5NTgyNGJhYmFlYzYwYjYxMGIxZTRhYWEvdGV4dHJlZ2lvbjplMzU1OGM1MTk1ODI0YmFiYWVjNjBiNjEwYjFlNGFhYV8yMjUx_3343e9b8-1677-4723-8b0d-6c7dd12e2348">225</ix:nonNumeric>) <ix:nonNumeric contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xL2ZyYWc6ZTM1NThjNTE5NTgyNGJhYmFlYzYwYjYxMGIxZTRhYWEvdGV4dHJlZ2lvbjplMzU1OGM1MTk1ODI0YmFiYWVjNjBiNjEwYjFlNGFhYV8yMjQ0_ca0cb3ac-ce2d-4a94-b7e4-bb914ff229fb">292-2031</ix:nonNumeric> or (800)&#160;467-2662</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:19.444%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:2pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center;margin-top:12pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:35.683%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:20.140%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:36.711%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Title of each class</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Trading Symbol(s)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xL2ZyYWc6ZTM1NThjNTE5NTgyNGJhYmFlYzYwYjYxMGIxZTRhYWEvdGFibGU6ZGM5ZWQ1YjU2ZjQ2NDMzYWEzNzI3YWU5YWJkN2FiYjYvdGFibGVyYW5nZTpkYzllZDViNTZmNDY0MzNhYTM3MjdhZTlhYmQ3YWJiNl8xLTAtMS0xLTA_2b6d4ca5-5fff-4fe3-ad2c-1df737a96f17">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xL2ZyYWc6ZTM1NThjNTE5NTgyNGJhYmFlYzYwYjYxMGIxZTRhYWEvdGFibGU6ZGM5ZWQ1YjU2ZjQ2NDMzYWEzNzI3YWU5YWJkN2FiYjYvdGFibGVyYW5nZTpkYzllZDViNTZmNDY0MzNhYTM3MjdhZTlhYmQ3YWJiNl8xLTItMS0xLTA_885644ab-6915-43b9-a5a4-ddda06a41d15">AMED</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xL2ZyYWc6ZTM1NThjNTE5NTgyNGJhYmFlYzYwYjYxMGIxZTRhYWEvdGFibGU6ZGM5ZWQ1YjU2ZjQ2NDMzYWEzNzI3YWU5YWJkN2FiYjYvdGFibGVyYW5nZTpkYzllZDViNTZmNDY0MzNhYTM3MjdhZTlhYmQ3YWJiNl8xLTQtMS0xLTA_15ccd024-faed-4021-b758-4dcc4887eacd">The NASDAQ Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:12pt;"><span><br/></span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xL2ZyYWc6ZTM1NThjNTE5NTgyNGJhYmFlYzYwYjYxMGIxZTRhYWEvdGV4dHJlZ2lvbjplMzU1OGM1MTk1ODI0YmFiYWVjNjBiNjEwYjFlNGFhYV8yMjQ1_101c9871-b74f-4248-b09f-13c5565e4281">Yes</ix:nonNumeric>&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9746;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;No&#160;&#9744;</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xL2ZyYWc6ZTM1NThjNTE5NTgyNGJhYmFlYzYwYjYxMGIxZTRhYWEvdGV4dHJlZ2lvbjplMzU1OGM1MTk1ODI0YmFiYWVjNjBiNjEwYjFlNGFhYV8yMjUy_32d85425-510d-4bac-a479-68264a6f07f8">Yes</ix:nonNumeric>&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9746;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in&#160;Rule&#160;12b-2 of the Exchange Act. (Check one):</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:17.124%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.573%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:48.656%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.573%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.124%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.573%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:2.577%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xL2ZyYWc6ZTM1NThjNTE5NTgyNGJhYmFlYzYwYjYxMGIxZTRhYWEvdGFibGU6NjBlN2MwNWQ3ZWQyNDI3MWIxNzE0ZTdlM2Q3N2VjNDEvdGFibGVyYW5nZTo2MGU3YzA1ZDdlZDI0MjcxYjE3MTRlN2UzZDc3ZWM0MV8xLTAtMS0xLTA_b222ef99-091c-4dac-a3dc-d33feb875913">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial Unicode MS',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#9746;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accelerated&#160;filer</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#9744;</span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="6" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="6" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-accelerated filer</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#9744;</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:justify;margin-bottom:1pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonNumeric contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xL2ZyYWc6ZTM1NThjNTE5NTgyNGJhYmFlYzYwYjYxMGIxZTRhYWEvdGFibGU6NjBlN2MwNWQ3ZWQyNDI3MWIxNzE0ZTdlM2Q3N2VjNDEvdGFibGVyYW5nZTo2MGU3YzA1ZDdlZDI0MjcxYjE3MTRlN2UzZDc3ZWM0MV8zLTYtMS0xLTA_8635d344-3db7-4d7c-a079-a0659f6814ae">&#9744;</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="6" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="6" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Emerging&#160;growth&#160;company</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:justify;margin-bottom:1pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonNumeric contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xL2ZyYWc6ZTM1NThjNTE5NTgyNGJhYmFlYzYwYjYxMGIxZTRhYWEvdGFibGU6NjBlN2MwNWQ3ZWQyNDI3MWIxNzE0ZTdlM2Q3N2VjNDEvdGFibGVyYW5nZTo2MGU3YzA1ZDdlZDI0MjcxYjE3MTRlN2UzZDc3ZWM0MV81LTItMS0xLTA_348f86c9-128e-4a01-a6ff-6336d66e566a">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9744;</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;<ix:nonNumeric contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xL2ZyYWc6ZTM1NThjNTE5NTgyNGJhYmFlYzYwYjYxMGIxZTRhYWEvdGV4dHJlZ2lvbjplMzU1OGM1MTk1ODI0YmFiYWVjNjBiNjEwYjFlNGFhYV8yMjQz_ea236f24-0a9e-4303-ae7c-240160ad4aa1">&#9744;</ix:nonNumeric>&#160;&#160;No&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9746;</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The number of shares outstanding of each of the issuer&#8217;s classes of common stock, as of the latest practicable date, is as follows: Common stock, $0.001 par value, <ix:nonFraction unitRef="shares" contextRef="ie94809e1cf0d453a8421029757c0fff8_I20200501" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xL2ZyYWc6ZTM1NThjNTE5NTgyNGJhYmFlYzYwYjYxMGIxZTRhYWEvdGV4dHJlZ2lvbjplMzU1OGM1MTk1ODI0YmFiYWVjNjBiNjEwYjFlNGFhYV8yMjA4_40c9298f-a64c-42d6-9e6e-d358e0a3f36a">32,379,165</ix:nonFraction> shares outstanding as of May&#160;1, 2020.</span></div><div style="margin-top:12pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="margin-top:12pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div></div></div><div id="i793e68cdccb44b98a73aef6e33f497bf_7"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">TABLE OF CONTENTS</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:7.370%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:84.676%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.954%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i793e68cdccb44b98a73aef6e33f497bf_10">SPECIAL CAUTION CONCERNING FORWARD-LOOKING STATEMENTS</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i793e68cdccb44b98a73aef6e33f497bf_10">1</a></span></div></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">;;;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">PART I. </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i793e68cdccb44b98a73aef6e33f497bf_13">FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ITEM 1.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i793e68cdccb44b98a73aef6e33f497bf_16">FINANCIAL STATEMENTS:</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i793e68cdccb44b98a73aef6e33f497bf_19">CONDENSED CONSOLIDATED BALANCE SHEETS AS OF MARCH 31, 2020 (UNAUDITED) AND DECEMBER&#160;31, 2019</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i793e68cdccb44b98a73aef6e33f497bf_19">2</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i793e68cdccb44b98a73aef6e33f497bf_25">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE THREE-MONTH PERIODS ENDED MARCH 31, 2020 AND 2019 (UNAUDITED)</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i793e68cdccb44b98a73aef6e33f497bf_25">3</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i793e68cdccb44b98a73aef6e33f497bf_28">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY FOR THE THREE-MONTH PERIODS ENDED MARCH 31, 2020 AND 2019 (UNAUDITED)</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i793e68cdccb44b98a73aef6e33f497bf_28">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i793e68cdccb44b98a73aef6e33f497bf_31">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE THREE-MONTH PERIODS ENDED MARCH 31, 2020 AND 2019 (UNAUDITED)</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i793e68cdccb44b98a73aef6e33f497bf_31">5</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ITEM 2.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i793e68cdccb44b98a73aef6e33f497bf_88">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i793e68cdccb44b98a73aef6e33f497bf_88">21</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ITEM 3</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i793e68cdccb44b98a73aef6e33f497bf_91">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i793e68cdccb44b98a73aef6e33f497bf_91">31</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ITEM&#160;4.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i793e68cdccb44b98a73aef6e33f497bf_94">CONTROLS AND PROCEDURES</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i793e68cdccb44b98a73aef6e33f497bf_94">31</a></span></div></td></tr><tr><td colspan="6" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i793e68cdccb44b98a73aef6e33f497bf_97">PART II. OTHER INFORMATION</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ITEM&#160;1.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i793e68cdccb44b98a73aef6e33f497bf_100">LEGAL PROCEEDINGS</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i793e68cdccb44b98a73aef6e33f497bf_100">33</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ITEM&#160;1A.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i793e68cdccb44b98a73aef6e33f497bf_103">RISK FACTORS</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i793e68cdccb44b98a73aef6e33f497bf_103">33</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ITEM 2.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i793e68cdccb44b98a73aef6e33f497bf_106">UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i793e68cdccb44b98a73aef6e33f497bf_106">33</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ITEM&#160;3.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i793e68cdccb44b98a73aef6e33f497bf_109">DEFAULTS UPON SENIOR SECURITIES</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i793e68cdccb44b98a73aef6e33f497bf_109">33</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ITEM&#160;4.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i793e68cdccb44b98a73aef6e33f497bf_112">MINE SAFETY DISCLOSURES</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i793e68cdccb44b98a73aef6e33f497bf_112">33</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ITEM&#160;5.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i793e68cdccb44b98a73aef6e33f497bf_115">OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i793e68cdccb44b98a73aef6e33f497bf_115">33</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ITEM&#160;6.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i793e68cdccb44b98a73aef6e33f497bf_118">EXHIBITS</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i793e68cdccb44b98a73aef6e33f497bf_118">34</a></span></div></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i793e68cdccb44b98a73aef6e33f497bf_121">SIGNATURES</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i793e68cdccb44b98a73aef6e33f497bf_121">35</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div></div></div><div id="i793e68cdccb44b98a73aef6e33f497bf_10"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SPECIAL CAUTION CONCERNING FORWARD-LOOKING STATEMENTS</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">When included in this Quarterly Report on Form 10-Q, or in other documents that we file with the Securities and Exchange Commission (&#8220;SEC&#8221;) or in statements made by or on behalf of the Company, words like &#8220;believes,&#8221; &#8220;belief,&#8221; &#8220;expects,&#8221; &#8220;strategy,&#8221;&#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;intends,&#8221; &#8220;projects,&#8221; &#8220;estimates,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should&#8221; and similar expressions are intended to identify forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a variety of risks and uncertainties that could cause actual results to differ materially from those described therein. These risks and uncertainties include, but are not limited to the following: the impact of the novel coronavirus pandemic ("COVID-19"), including the measures that have been and may be taken by governmental authorities to mitigate it, on our business, financial condition and results of operations, changes in or our failure to comply with existing federal and state laws or regulations or the inability to comply with new government regulations on a timely basis, changes in Medicare and other medical payment levels, our ability to open care centers, acquire additional care centers and integrate and operate these care centers effectively, competition in the healthcare industry, changes in the case mix of patients and payment methodologies, changes in estimates and judgments associated with critical accounting policies, our ability to maintain or establish new patient referral sources, our ability to consistently provide high-quality care, our ability to attract and retain qualified personnel, our ability to keep our patients and employees safe, changes in payments and covered services by federal and state governments, future cost containment initiatives undertaken by third-party payors, our access to financing, our ability to meet debt service requirements and comply with covenants in debt agreements, business disruptions due to natural disaster or acts of terrorism, our ability to integrate, manage and keep our information systems secure, our ability to realize the anticipated benefits of acquisitions, and changes in law or developments with respect to any litigation relating to the Company, including various other matters, many of which are beyond our control.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on any forward-looking statement as a prediction of future events.&#160;We expressly disclaim any obligation or undertaking and we do not intend to release publicly any updates or changes in our expectations concerning the forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based, except as required by law.&#160;For a discussion of some of the factors discussed above as well as additional factors, see our Annual Report on Form 10-K for the year ended December&#160;31, 2019, filed with the SEC on February 19, 2020, particularly, Part I, Item&#160;1A - Risk Factors therein, which are incorporated herein by reference and Part II, Item 1A. Risk Factors of this Quarterly Report on Form 10-Q. Additional risk factors may also be described in reports that we file from time to time with the SEC.</span></div><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Available Information</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Our company website address is www.amedisys.com. We use our website as a channel of distribution for important company information. Important information, including press releases, analyst presentations and financial information regarding our company, is routinely posted on and accessible on the Investor Relations subpage of our website, which is accessible by clicking on the tab labeled &#8220;Investors&#8221; on our website home page. Visitors to our website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations subpage of our website. In addition, we make available on the Investor Relations subpage of our website (under the link &#8220;SEC filings&#8221;), free of charge, our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, ownership reports on Forms 3, 4 and 5 and any amendments to those reports as soon as reasonably practicable after we electronically file or furnish such reports with the SEC. Further, copies of our Certificate of Incorporation and Bylaws, our Code of Ethical Business Conduct, our Corporate Governance Guidelines and the charters for the Audit, Compensation, Quality of Care, Compliance and Ethics and Nominating and Corporate Governance Committees of our Board are also available on the Investor Relations subpage of our website (under the link &#8220;Governance&#8221;). Reference to our website does not constitute incorporation by reference of the information contained on the website and should not be considered part of this document. Our electronically filed reports can also be obtained on the SEC&#8217;s internet site at http://www.sec.gov.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1</span></div></div></div><div id="i793e68cdccb44b98a73aef6e33f497bf_13"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PART I. FINANCIAL INFORMATION</span></div><div id="i793e68cdccb44b98a73aef6e33f497bf_16"></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM 1. FINANCIAL STATEMENTS</span></div><div id="i793e68cdccb44b98a73aef6e33f497bf_19"></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Amounts in thousands, except share data)</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:71.792%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.739%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020 (unaudited)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMy0xLTEtMS0w_bdbb7362-2beb-40ec-a046-8fdbe6f7a68e">174,756</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i014c385050454730837d592e15bca5e0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMy0zLTEtMS0w_dab6dfff-2759-4b83-8a90-f29c98bcddcc">30,294</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted cash</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfNC0xLTEtMS0zMw_311a7ef2-b9ff-4b98-9bf2-ebe2d7c92638">3,056</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i014c385050454730837d592e15bca5e0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfNC0zLTEtMS0zMA_f0255c26-a546-42df-a235-6ed46f4c3ebd">66,196</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Patient accounts receivable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfNC0xLTEtMS0w_7da6ebc6-6022-4589-ad5d-5d2c8ba703ad">268,551</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i014c385050454730837d592e15bca5e0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfNC0zLTEtMS0w_008b2f6d-22d9-4185-9616-965dae67387b">237,596</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfNS0xLTEtMS0w_d9d95af0-d8b5-4208-90e1-462902030946">12,487</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i014c385050454730837d592e15bca5e0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfNS0zLTEtMS0w_36836d27-3bdf-4131-a282-e99e14742a2f">8,243</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfNi0xLTEtMS0w_9b8eb868-593a-4a8b-868f-2aabdf6bed54">9,278</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i014c385050454730837d592e15bca5e0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfNi0zLTEtMS0w_fef5d5cd-8ea5-49b3-a99e-1e3533d216a4">8,225</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfNy0xLTEtMS0w_49ec0bd1-8f2e-4d88-afae-8b907d8b2318">468,128</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i014c385050454730837d592e15bca5e0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfNy0zLTEtMS0w_07383549-7f45-40d0-acbe-c8db12a265d6">350,554</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Property and equipment, net of accumulated depreciation of $<ix:nonFraction unitRef="usd" contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfOC0wLTEtMS0wL3RleHRyZWdpb246Nzc4N2ZlZWVmMDQ0NGI5YTkxYTZjYjIzMDRlNjA2NDdfMTY0OTI2NzQ0MTc2Mw_85d4997d-1893-4e75-8f39-793fa38c5dbe">98,472</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i014c385050454730837d592e15bca5e0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfOC0wLTEtMS0wL3RleHRyZWdpb246Nzc4N2ZlZWVmMDQ0NGI5YTkxYTZjYjIzMDRlNjA2NDdfMTY0OTI2NzQ0MTc1Mw_3d5974b0-e9be-41ec-807b-d7e993565293">96,137</ix:nonFraction></span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfOC0xLTEtMS0w_6ab4d132-0d0e-4dd9-9bfe-1936da31a5e7">26,477</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i014c385050454730837d592e15bca5e0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfOC0zLTEtMS0w_38ee4144-2f26-4ca5-8eb6-ab6ea15d1faf">28,113</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease right of use assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfOS0xLTEtMS0w_b43f2936-7d87-4b93-9cd4-42a057388fb6">83,693</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i014c385050454730837d592e15bca5e0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfOS0zLTEtMS0w_b3f5cd14-1588-4fcc-9038-ef24e3291175">84,791</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMTAtMS0xLTEtMA_cfde875f-52cc-4ae1-9c24-b72b1b6a3c59">721,049</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i014c385050454730837d592e15bca5e0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMTAtMy0xLTEtMA_022f796a-07f5-4566-8447-6ff1748a1b35">658,500</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Intangible assets, net of accumulated amortization of $<ix:nonFraction unitRef="usd" contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMTEtMC0xLTEtMC90ZXh0cmVnaW9uOjE3MTA5M2Q3ODM0ODQ3MTliNTEyOTdkYWUwNjNkY2QzXzE2NDkyNjc0NDE3NDc_4ccc0543-1bf9-4fb5-975b-980c6234f714">9,341</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i014c385050454730837d592e15bca5e0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMTEtMC0xLTEtMC90ZXh0cmVnaW9uOjE3MTA5M2Q3ODM0ODQ3MTliNTEyOTdkYWUwNjNkY2QzXzE2NDkyNjc0NDE3NTc_fe0786e5-f3cf-4bea-8548-91d93b22eef2">7,044</ix:nonFraction></span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMTEtMS0xLTEtMA_48f9c2d9-539b-4d9b-a7b6-7cc7deaf8046">68,251</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i014c385050454730837d592e15bca5e0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMTEtMy0xLTEtMA_16100f3c-cab9-4d9c-b4a8-da106361e52b">64,748</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred income taxes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMTItMS0xLTEtMA_d124ca42-f7bd-43a8-b3b6-631c6e45ada3">20,199</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i014c385050454730837d592e15bca5e0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMTItMy0xLTEtMA_d841d204-a41f-45ff-9b66-d58f0a917d74">21,427</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMTMtMS0xLTEtMA_2b81b338-4a78-4d08-8cad-e7af13b8ede9">52,287</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i014c385050454730837d592e15bca5e0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMTMtMy0xLTEtMA_115de8c6-10b4-4b2f-856b-dc1f23a2ed64">54,612</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMTQtMS0xLTEtMA_b839c514-b1e7-4848-beb4-596116260cfb">1,440,084</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i014c385050454730837d592e15bca5e0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMTQtMy0xLTEtMA_44db823c-f663-4693-bbed-f44e3f3d9487">1,262,745</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">LIABILITIES AND EQUITY</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMTctMS0xLTEtMA_e8edd55e-3609-4a4b-8ada-c7a6219737f1">31,147</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i014c385050454730837d592e15bca5e0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMTctMy0xLTEtMA_3ef3f1eb-5064-4138-8dab-72d115c1d991">31,259</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payroll and employee benefits</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMTgtMS0xLTEtMA_2f2b554a-f67e-4be2-85ba-fdbade897916">109,713</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i014c385050454730837d592e15bca5e0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMTgtMy0xLTEtMA_f3faa828-eb6d-4255-b870-4acd54b39d9d">120,877</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMTktMS0xLTEtMA_b892f384-bb19-40c6-b456-e94ed8b19f5d">136,659</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i014c385050454730837d592e15bca5e0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMTktMy0xLTEtMA_0221039c-4757-48df-a8cb-ed79fcfbb1f9">137,111</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current portion of long-term obligations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMjAtMS0xLTEtMA_ef352ce9-39ee-45c0-8931-a8d736121e6d">11,122</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i014c385050454730837d592e15bca5e0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMjAtMy0xLTEtMA_f5954305-906d-4aa1-8b62-bf38d660e1aa">9,927</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current portion of operating lease liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMjEtMS0xLTEtMA_ad31173c-0447-4763-b5b8-b20e0bad4d2e">27,465</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i014c385050454730837d592e15bca5e0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMjEtMy0xLTEtMA_f2d87782-55b4-4d78-91e2-07cd671d97d5">27,769</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMjItMS0xLTEtMA_196fec40-321d-4485-9070-4670e1ca172f">316,106</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i014c385050454730837d592e15bca5e0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMjItMy0xLTEtMA_a8a168a9-681b-4285-a689-8e9cf997d82f">326,943</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term obligations, less current portion</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMjMtMS0xLTEtMA_d70a1715-8719-4fa8-bd7a-c973851a6209">379,942</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i014c385050454730837d592e15bca5e0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMjMtMy0xLTEtMA_e0dc9aa1-562a-4a05-b164-12923d9e8cc9">232,256</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities, less current portion</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMjQtMS0xLTEtMA_5f253900-a5a4-4e96-9b07-b7d3452b0e1f">54,926</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i014c385050454730837d592e15bca5e0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMjQtMy0xLTEtMA_b9ac735e-ecfd-4249-8325-dbdddfd9ec0c">56,128</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other long-term obligations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMjUtMS0xLTEtMA_ab59c3e2-0b0d-4467-9212-dcb0d0d596c6">8,966</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i014c385050454730837d592e15bca5e0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMjUtMy0xLTEtMA_16fbba52-8025-4e4a-907b-b0e6bee431dc">5,905</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMjYtMS0xLTEtMA_9ba3cff2-79d6-485a-ab5e-b058db6f192a">759,940</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i014c385050454730837d592e15bca5e0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMjYtMy0xLTEtMA_ebf8edb8-464b-42d0-891e-6f904a10a119">621,232</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commitments and Contingencies&#8212;Note 5</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><ix:nonFraction unitRef="usd" contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMjctMS0xLTEtMA_cdfda4df-4aa2-4264-9889-d14ad017e84c"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmMxMjJmZmYzNjQzNzQyOGU4YTRlZTY5OGFkMzVlN2ZhXzE2NDkyNjc0NDE3NjQ_3dd4f1e2-646e-4482-91ce-8b44478d89a1">0.001</ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmMxMjJmZmYzNjQzNzQyOGU4YTRlZTY5OGFkMzVlN2ZhXzE2NDkyNjc0NDE3NzU_6dcaf4b0-6272-4c91-93c5-9d21f19101e5">5,000,000</ix:nonFraction> shares authorized; none issued or outstanding</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMjktMS0xLTEtMA_a74f75e2-d33b-4bb3-9c5f-ee8c34255159">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i014c385050454730837d592e15bca5e0_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMjktMy0xLTEtMA_eb58362a-5082-471f-ae97-4354fa042c11">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmYwYTlhM2Q0YmU3MjQwY2ZhZjcxMTdjNTQ5OGYwODk2XzE2NDkyNjc0NDE4MjY_61194800-c7a2-4ea7-af63-b3641af56eac">0.001</ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmYwYTlhM2Q0YmU3MjQwY2ZhZjcxMTdjNTQ5OGYwODk2XzE2NDkyNjc0NDE4Mzk_1cedb7b5-b681-4605-9b07-c053e8b02dd8">60,000,000</ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmYwYTlhM2Q0YmU3MjQwY2ZhZjcxMTdjNTQ5OGYwODk2XzE2NDkyNjc0NDE4NTE_abd3cf5e-2acc-4c8a-a324-604090f78b2a">36,746,554</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i014c385050454730837d592e15bca5e0_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmYwYTlhM2Q0YmU3MjQwY2ZhZjcxMTdjNTQ5OGYwODk2XzE2NDkyNjc0NDE4NjM_7753cb12-cac0-4c17-87bc-ac853e5ac2f0">36,638,021</ix:nonFraction> shares issued; and <ix:nonFraction unitRef="shares" contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmYwYTlhM2Q0YmU3MjQwY2ZhZjcxMTdjNTQ5OGYwODk2XzE2NDkyNjc0NDE4NzU_e1ed1fba-8021-4f88-aaf7-b004223cdf52">32,370,345</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i014c385050454730837d592e15bca5e0_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmYwYTlhM2Q0YmU3MjQwY2ZhZjcxMTdjNTQ5OGYwODk2XzE2NDkyNjc0NDE4OTA_77ff90ed-b6c0-4ed8-ba85-558733c4eda1">32,284,051</ix:nonFraction> shares outstanding</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331" decimals="-3" name="us-gaap:CommonStockValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMzAtMS0xLTEtMA_dfb6be1f-4162-47c2-9659-b7fc224c9263">37</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i014c385050454730837d592e15bca5e0_I20191231" decimals="-3" name="us-gaap:CommonStockValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMzAtMy0xLTEtMA_1fdd763a-df88-4630-8719-064aa430b188">37</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:20.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Additional paid-in capital</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMzEtMS0xLTEtMA_632b83f3-e7b4-4709-8415-3ada4e274fca">656,266</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i014c385050454730837d592e15bca5e0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMzEtMy0xLTEtMA_fcd927ec-c2a6-460f-8265-403340f9aaba">645,256</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Treasury stock, at cost <ix:nonFraction unitRef="shares" contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmNkYWM2ZTBiNWMzOTQzNDZiYTQ5YTcyMDkxMzliZTM2XzE2NDkyNjc0NDE3NDc_85b8f11e-4fc1-44a4-8669-8a7b7c352e18">4,376,209</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i014c385050454730837d592e15bca5e0_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmNkYWM2ZTBiNWMzOTQzNDZiYTQ5YTcyMDkxMzliZTM2XzE2NDkyNjc0NDE3NTg_f5acec34-d05a-41a5-a5b0-884efa3f251a">4,353,970</ix:nonFraction> shares of common stock</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMzItMS0xLTEtMA_5d46b371-c506-4c9f-b01b-6c7006d36938">255,291</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i014c385050454730837d592e15bca5e0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMzItMy0xLTEtMA_7f4250fd-94eb-4a2b-9a1b-1e44247dc6e8">251,241</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated other comprehensive income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMzMtMS0xLTEtMA_5f5888dc-06d4-4af3-bc5d-a1c415d1cd09">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i014c385050454730837d592e15bca5e0_I20191231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMzMtMy0xLTEtMA_74c2b50e-ed24-4d3c-8b4b-00a5891e3443">15</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Retained earnings</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMzQtMS0xLTEtMA_c150979f-a3b2-4fc1-a23d-2196ac15ce6d">278,185</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i014c385050454730837d592e15bca5e0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMzQtMy0xLTEtMA_2c4b428f-b95e-4476-b083-7093db11b373">246,383</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Amedisys, Inc. stockholders&#8217; equity</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMzUtMS0xLTEtMA_adadf53b-a6a9-4b48-907c-731caae70cf1">679,197</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i014c385050454730837d592e15bca5e0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMzUtMy0xLTEtMA_508d4c12-4674-4290-9873-661a7c11a106">640,450</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Noncontrolling interests</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMzYtMS0xLTEtMA_2a1930d1-065b-48a2-8ec7-ed99879260c7">947</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i014c385050454730837d592e15bca5e0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMzYtMy0xLTEtMA_d705520d-31e8-4e45-9c6e-c12947ba7228">1,063</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total equity</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMzctMS0xLTEtMA_59ca4920-c3ce-41df-a154-c7f15798f6da">680,144</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i014c385050454730837d592e15bca5e0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMzctMy0xLTEtMA_f3cd80a0-49a8-45df-851c-34d58fbb3c5a">641,513</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities and equity</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMzgtMS0xLTEtMA_63cd6e1f-6897-432d-add7-ab283e0860db">1,440,084</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i014c385050454730837d592e15bca5e0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMzgtMy0xLTEtMA_99d78495-d764-403a-a35e-989f49078164">1,262,745</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2</span></div></div></div><div id="i793e68cdccb44b98a73aef6e33f497bf_25"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Amounts in thousands, except per share data)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:71.792%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.739%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For&#160;the&#160;Three-Month&#160;<br/>Periods&#160;Ended&#160;March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net service revenue</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMi0xLTEtMS0w_29c2c494-87aa-4583-a1c1-8e0cb4a1c40b">491,685</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMi0zLTEtMS0w_bfe1f36e-8651-4457-9fc7-88a33020a90c">467,340</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMy0xLTEtMS0w_5934d60a-1541-4dbf-84f1-dc3c15861388">285,737</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMy0zLTEtMS0w_da37b35b-3328-4186-8b35-98b38e0afdf3">275,274</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative expenses:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Salaries and benefits</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LaborAndRelatedExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfNS0xLTEtMS0w_8ee3a7d9-6d76-406f-b3b5-e506eafcde0b">101,566</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LaborAndRelatedExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfNS0zLTEtMS0w_d5f50a86-aaa5-449e-9bb1-e18975f86ef5">94,830</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Non-cash compensation</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfNi0xLTEtMS0w_92aaf2df-4bfb-408c-95bc-ac6d6c108571">5,909</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfNi0zLTEtMS0w_efc3a938-12cd-4ff8-a714-366e1942070e">6,615</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfNy0xLTEtMS0w_accdd821-3f11-481d-844e-438c357d2990">49,265</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfNy0zLTEtMS0w_fb2017dd-bb96-46e3-b90e-a4961936c5e6">43,402</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation and amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfOC0xLTEtMS0w_f80dd8fe-f136-4754-8a5d-dee0d3c5d386">5,338</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfOC0zLTEtMS0w_93a112ea-c9c5-4d9f-9cf6-77c332db0459">2,895</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfOS0xLTEtMS0w_46652bdc-7bee-4a4c-aec4-526b76456889">447,815</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfOS0zLTEtMS0w_00e94191-a1c2-4d32-a2d7-7e95c3cef369">423,016</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMTAtMS0xLTEtMA_2b5f24f8-7159-41b0-9e13-fc9d71eb320a">43,870</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMTAtMy0xLTEtMA_24d88988-14f1-4697-9194-e294ca553242">44,324</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" name="us-gaap:InvestmentIncomeInterestAndDividend" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMTItMS0xLTEtMA_6dbd92f9-5479-4d16-9ff4-dd83ed1f8004">13</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" name="us-gaap:InvestmentIncomeInterestAndDividend" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMTItMy0xLTEtMA_4459e784-02a4-426e-a064-62bad916e1e7">24</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMTMtMS0xLTEtMA_a972c8ac-1142-436f-a8f3-b6f07fc7ebd8">3,231</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMTMtMy0xLTEtMA_c0a5929b-e3d4-4162-acc8-f1b8368410c3">3,349</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity in earnings from equity method investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMTQtMS0xLTEtMA_1afac7cc-5945-470a-a059-fcb6c97cda3c">477</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMTQtMy0xLTEtMA_e3b75ea1-a2f0-49a8-b948-410eb3526ae1">1,216</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Miscellaneous, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMTUtMS0xLTEtMA_424eef7a-8ef9-4acc-9f73-6ce1bd0e3bb2">263</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMTUtMy0xLTEtMA_5f825db8-cee3-4875-bf2b-98f4cb8dcfd6">236</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total other expense, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMTYtMS0xLTEtMA_0714eba1-6201-4a55-ad4b-f652964ac5b0">2,478</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMTYtMy0xLTEtMA_79670c26-5284-4532-bb52-ac5ff29cfcf5">1,873</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income before income taxes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMTctMS0xLTEtMA_a1e49ebb-045f-46cb-aeb7-ae3e2dd733bf">41,392</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMTctMy0xLTEtMA_c5efec3e-db22-4f16-a707-c628832966f4">42,451</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMTgtMS0xLTEtMA_1fff05e0-bf0e-4b44-a020-6f4b4c4d121f">9,346</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMTgtMy0xLTEtMA_76c6f8bb-4ecc-4e63-afb0-2d0b05c1f6dd">10,878</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMTktMS0xLTEtMA_a2b677f9-3530-46f0-bf31-0112d759b71f">32,046</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMTktMy0xLTEtMA_9208aa22-fda8-4845-894c-c7e87dfd0f52">31,573</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMjAtMS0xLTEtMA_73e89f53-745b-4ca3-b059-82df005d8c22">244</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMjAtMy0xLTEtMA_69543b07-9845-47cf-955c-cf413a2a2e7b">269</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income attributable to Amedisys, Inc.</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMjEtMS0xLTEtMA_9adc08bb-0053-4f64-9fe4-76779876ed85">31,802</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMjEtMy0xLTEtMA_0e0495a0-5f84-4a53-b669-44f59c2987fa">31,304</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Basic earnings per common share:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income attributable to Amedisys, Inc. common stockholders</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMjMtMS0xLTEtMA_c6fbb07d-ce40-4aa6-a260-a0c868de0050">0.98</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMjMtMy0xLTEtMA_69489146-f5a7-43e6-8d8e-7327329b5a2f">0.98</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average shares outstanding</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMjQtMS0xLTEtMA_1c8e0782-8951-4fdf-9d89-8de9577cdb9a">32,331</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMjQtMy0xLTEtMA_7484f902-a029-48d1-ad64-5621f3ca7e92">32,001</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Diluted earnings per common share:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income attributable to Amedisys, Inc. common stockholders</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMjYtMS0xLTEtMA_34eab55a-6462-4f92-aeb7-43d39cb45467">0.96</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMjYtMy0xLTEtMA_a9fd4e2f-d72e-41a2-8db9-80b77e0fbe04">0.95</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average shares outstanding</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMjctMS0xLTEtMA_c5b7220e-b56f-43be-bbe4-5593e14b304e">33,234</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMjctMy0xLTEtMA_61be274d-ab6e-4961-841c-509febb6a9c7">32,893</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3</span></div></div></div><div id="i793e68cdccb44b98a73aef6e33f497bf_28"></div><hr style="page-break-after:always"/><div style="height:22.5pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"> AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Amounts in thousands, except common stock shares)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.472%;"><tr><td style="width:1.0%;"></td><td style="width:25.503%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:5.475%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.505%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.462%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.505%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:4.629%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.505%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.039%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.505%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.334%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.505%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.283%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.505%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.475%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.505%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.865%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="45" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three-Months Ended March 31, 2020</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Treasury<br/>Stock</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>Other<br/>Comprehensive Income</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Retained<br/>Earnings </span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Noncontrolling<br/>Interests</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i014c385050454730837d592e15bca5e0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMy0xLTEtMS0w_6b4bf251-5220-4ec0-a60e-7d85ffc311f3">641,513</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i379583ecb9374798b4c230bb394c2c67_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMy0zLTEtMS0w_e86ea137-6cf8-4d9c-ad89-797c545ebb1b">36,638,021</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i379583ecb9374798b4c230bb394c2c67_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMy01LTEtMS0w_ea1e59ec-f051-4f7d-a4f5-d49c11e1ce76">37</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6a5040a26fb048c0a87bf6f051f93896_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMy03LTEtMS0w_4dca8c99-d644-4b2d-8d0d-6e1625b7258a">645,256</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3febdb7171a24ee1801a9231cc9591f3_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMy05LTEtMS0w_7e3e0689-027b-4530-91e7-7f176d656d22">251,241</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74e0f28f8b654d48a67abd821a86e3c4_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMy0xMS0xLTEtMA_fdaf3b93-446b-461e-8e72-c0aab61d4341">15</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iae980ac5b3a541419edf1dafb6f4c6f5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMy0xMy0xLTEtMA_6b7ac594-7788-430f-a471-49a1f7309318">246,383</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iea78279e652f4d91ae574d24a6286705_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMy0xNS0xLTEtMA_386234b8-007d-4787-9ca0-404768a31fc7">1,063</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of stock &#8211; employee stock purchase plan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfNC0xLTEtMS0w_1d9dde6d-e285-4c5f-9309-760ced45228e">860</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ic64b3c79c65143a4a4af6c36f8b99fcf_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfNC0zLTEtMS0w_d3aa4715-218d-4672-8ae0-171898b8637b">6,063</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ife895f7907c04cc1809e6c1fec83c56f_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfNC03LTEtMS0w_f9c25b4d-f545-4424-91d2-e06995600049">860</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of stock &#8211; 401(k) plan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfNS0xLTEtMS0w_9d95314a-2a0c-477b-bfcb-e0643acffca3">3,057</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ic64b3c79c65143a4a4af6c36f8b99fcf_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="amed:StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfNS0zLTEtMS0w_9f1d4dc6-fc56-49a6-b90f-a0c88aaf4536">18,312</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ife895f7907c04cc1809e6c1fec83c56f_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfNS03LTEtMS0w_88ae8b7e-4117-4e5c-b2a1-447cc2c95724">3,057</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance/(cancellation) of non-vested stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfNi0xLTEtMS0w_251850d2-e1ba-454a-8a12-330ec352ed9e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ic64b3c79c65143a4a4af6c36f8b99fcf_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfNi0zLTEtMS0w_4b293d7a-8596-4dc0-88fe-c951bd0573c5">55,423</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic64b3c79c65143a4a4af6c36f8b99fcf_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfNi01LTEtMS0w_a296ff57-b955-435f-9168-fd7b165f8194">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ife895f7907c04cc1809e6c1fec83c56f_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfNi03LTEtMS0w_4e4f75ce-4795-48c0-b5d1-d6cdc6a388bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercise of stock options</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfNy0xLTEtMS0w_4f70ed14-ccd9-408a-977d-8a5b009b0cdd">1,184</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ic64b3c79c65143a4a4af6c36f8b99fcf_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfNy0zLTEtMS0w_2baf77ff-f2c4-4dd8-9f6a-cf4799473201">28,735</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ife895f7907c04cc1809e6c1fec83c56f_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfNy03LTEtMS0w_67b4c242-e253-41d5-a71e-4f141d820a7c">1,184</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-cash compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfOC0xLTEtMS0w_468b063d-8587-465e-937c-2104fb1f8e4b">5,909</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ife895f7907c04cc1809e6c1fec83c56f_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfOC03LTEtMS0w_52daeb12-eb67-4a0d-a38e-8ffa1e0af9d5">5,909</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Surrendered shares</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="amed:SurrenderedShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfOS0xLTEtMS0w_e4c0d854-e86d-49bf-a017-46d746474614">4,050</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i24fbf8ed4ce94e058258628cf71035a5_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="amed:SurrenderedShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfOS05LTEtMS0w_9f729dd7-0bd6-4a8f-9cb3-fcedceda90ee">4,050</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Noncontrolling interest distribution</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMTAtMS0xLTEtMA_ed762b39-558a-42c7-a47f-d1f7c6942c4e">360</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3897e7c6671f45b2a1b361f76b28fea4_D20200101-20200331" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMTAtMTUtMS0xLTA_fd086ab2-877c-4dc2-be93-abcd2e299c3e">360</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Write-off of other comprehensive income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" name="amed:EquityImpactOfWriteOffOfOtherComprehensiveIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMTEtMS0xLTEtMTU5Mw_ce3e6d41-2305-4e8b-bcf1-a640500e63c2">15</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i766b3828bac34e55bd02b261a75f847a_D20200101-20200331" decimals="-3" name="amed:EquityImpactOfWriteOffOfOtherComprehensiveIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMTEtMTEtMS0xLTE1OTM_f12d5dfc-69b0-4eef-b4d9-c0bd690dcda9">15</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMTEtMS0xLTEtMA_18d0b2a8-e76d-4e88-ad67-952f571d9aed">32,046</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib4ce05f08cf04e5691c12539b7c46390_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMTEtMTMtMS0xLTA_cdcd3460-d27f-4d74-9b9c-db8d0076763d">31,802</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3897e7c6671f45b2a1b361f76b28fea4_D20200101-20200331" decimals="-3" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMTEtMTUtMS0xLTA_2eaa0309-070b-4887-a4c0-710c73f70288">244</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, March 31, 2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMTItMS0xLTEtMA_25ade516-3a21-4093-b47d-cd4e3160ff59">680,144</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i0a470325c5bc4889b266f68e9544d3e5_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMTItMy0xLTEtMA_ccac0c1b-02c7-42c8-b782-78dc01cf68c5">36,746,554</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0a470325c5bc4889b266f68e9544d3e5_I20200331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMTItNS0xLTEtMA_047b92a2-4b5f-464a-982a-0f55e31a2c26">37</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iac55dce70a374679bd199e04eaa5b649_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMTItNy0xLTEtMA_a2a81ecc-77a4-4377-9867-6aa8283f164d">656,266</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4ab26af603e844e9b6bdda46662485c3_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMTItOS0xLTEtMA_96b934fd-a752-432c-9549-71cb53c81bab">255,291</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1593f26e241b483ebd91cefceb35d199_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMTItMTEtMS0xLTA_24817f95-df94-4fe9-b86b-8cd4e43175e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idf11627cc0b7467f85b1368394bb2664_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMTItMTMtMS0xLTA_c45d0d7f-d40c-43f7-ae51-ecb6f4f13b2c">278,185</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i30654d85149642fdae1198cad652319f_I20200331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMTItMTUtMS0xLTA_7f00ffee-e5a5-4a29-b798-08ed714630fe">947</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="45" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three-Months Ended March 31, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Treasury<br/>Stock</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>Other<br/>Comprehensive Income</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Retained<br/>Earnings </span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Noncontrolling<br/>Interests</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2018</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5070e06e0c374add9463ca31e59e3d55_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMTctMS0xLTEtMA_6dda3e4c-c8d1-4f19-bcea-e81986dbbe01">482,633</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i89a07a7310c54227add149c2b0b87ee3_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMTctMy0xLTEtMA_b4ba4a44-1e4e-4118-ba31-22fe780a1540">36,252,280</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i89a07a7310c54227add149c2b0b87ee3_I20181231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMTctNS0xLTEtMA_a48d77cb-5eaf-478a-89af-3308895f7b0f">36</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib79791d3ae294c48a6a6f3b9d4237287_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMTctNy0xLTEtMA_c534c85f-54b1-4850-8ff7-67da30ae6173">603,666</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2973a18d82d64089981faf633016e337_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMTctOS0xLTEtMA_bb0624da-dd09-4de3-859e-8721f7f14f3b">241,685</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib6e258d79aa94c7b85ea31dd68768540_I20181231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMTctMTEtMS0xLTA_a4fd8835-7cdb-4d44-ab84-4971530e4f5b">15</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i90b913e7ac1542e6928ba4790c344cb1_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMTctMTMtMS0xLTA_9e6ddd15-9787-42a2-a59b-660768ca9e4f">119,550</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibd20ee3ceb1b468ca3e169ae4b78ec43_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMTctMTUtMS0xLTA_2ca29af7-ef9e-4cb0-9a64-ac96d81ddade">1,051</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of stock &#8211; employee stock purchase plan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMTgtMS0xLTEtMA_63d2030e-705e-4df5-b7b8-c0c2c3cfd13e">782</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i24ae5ea6239844c1943ccc8250cf4d3e_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMTgtMy0xLTEtMA_6e15cccc-41f2-4a22-a202-f5a46b8db9f5">7,856</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie8ccec4951d54e429f9b0776571c27c8_D20190101-20190331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMTgtNy0xLTEtMA_68ae70c9-0020-4188-948c-1fe6e47940fb">782</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of stock &#8211; 401(k) plan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMTktMS0xLTEtMA_7e557e31-01e9-4869-a912-27c344b06e10">2,295</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i24ae5ea6239844c1943ccc8250cf4d3e_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="amed:StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMTktMy0xLTEtMA_fdb0c951-4d31-4f15-a88f-890577e42912">19,591</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie8ccec4951d54e429f9b0776571c27c8_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMTktNy0xLTEtMA_821f366b-39b3-4498-bb81-c05434d47f2e">2,295</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance/(cancellation) of non-vested stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMjAtMS0xLTEtMA_47c7d951-6a57-4469-970c-d509f95f666b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i24ae5ea6239844c1943ccc8250cf4d3e_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMjAtMy0xLTEtMA_16d32944-9a8c-49c6-afc1-19011535365f">51,162</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i24ae5ea6239844c1943ccc8250cf4d3e_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMjAtNS0xLTEtMA_73ab1f3b-7ee7-4ef8-a9a5-ce9df2f6a68c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie8ccec4951d54e429f9b0776571c27c8_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMjAtNy0xLTEtMA_4f4e294d-6075-4ee7-afad-564011390487">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercise of stock options</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMjEtMS0xLTEtMA_e86eb856-d77d-402c-9ceb-9fe9cd65261a">356</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i24ae5ea6239844c1943ccc8250cf4d3e_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMjEtMy0xLTEtMA_41830510-5a31-41ac-bf11-f8a6b08fa82c">6,854</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie8ccec4951d54e429f9b0776571c27c8_D20190101-20190331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMjEtNy0xLTEtMA_6cac0a6a-e976-4246-8496-55468009b6df">356</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-cash compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMjItMS0xLTEtMA_80bcd415-2671-4fb7-bbde-c95c85841e27">6,615</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie8ccec4951d54e429f9b0776571c27c8_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMjItNy0xLTEtMA_c418576f-8152-44cd-9909-640a0c9ec2fd">6,615</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Surrendered shares</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="amed:SurrenderedShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMjMtMS0xLTEtMA_d4b3a1b4-01f0-4b28-854b-44ce3e6173d0">2,688</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iae6e37863ef2446982ab4508cb5c6a4a_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="amed:SurrenderedShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMjMtOS0xLTEtMA_218ec680-2829-4194-b04d-de2a5066894b">2,688</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Noncontrolling interest distribution</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMjQtMS0xLTEtMA_6cc70ef1-9f8b-4044-aa8d-d6560fe9ddfd">366</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia2a1f77af6c6468e80794d3e6619da24_D20190101-20190331" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMjQtMTUtMS0xLTA_a43e656b-31d0-4682-a87d-4601cf9f45f8">366</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMjYtMS0xLTEtMA_768616ad-2c23-4f82-884f-30528d14c63d">31,573</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia3dbbd4d693549d08a550ff85e19d07e_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMjYtMTMtMS0xLTA_31bbe0b3-ca4d-4629-b8b7-ed749e14d17e">31,304</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia2a1f77af6c6468e80794d3e6619da24_D20190101-20190331" decimals="-3" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMjYtMTUtMS0xLTA_281a8111-cb93-4399-bfc1-977156628a06">269</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, March 31, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3202099b2aaf4cc88461f7725441d5a3_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMjctMS0xLTEtMA_c7f8b475-a40d-4dfc-880b-8b83468a7872">521,200</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ie390be034b284f5082baf3f2f9d8d312_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMjctMy0xLTEtMA_87c7cb59-7022-4fcf-ac4b-ed022fae499e">36,337,743</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie390be034b284f5082baf3f2f9d8d312_I20190331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMjctNS0xLTEtMA_794bec10-f262-4804-85fa-4cf9424bd02f">36</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if286a7fc2ab5482e927587b135cac060_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMjctNy0xLTEtMA_2f353712-24c1-437e-9b6d-9ee45b620e11">613,714</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0a118ef4adc642169df30733695018e7_I20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMjctOS0xLTEtMA_5defd606-23ef-41bc-9090-7e555826e29d">244,373</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i07447f32d01d4b719bba4d5394e101f1_I20190331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMjctMTEtMS0xLTA_91641b5c-11de-42c3-b170-46318f7b8c57">15</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9aced020e10e41469ac1511a249cd44a_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMjctMTMtMS0xLTA_2d21fa98-572c-4081-853d-bd53356ac8ec">150,854</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie495d4805b994e769059ce32d0936a6c_I20190331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMjctMTUtMS0xLTA_dd45aafc-ec68-4170-bf06-94bf71ff37df">954</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="position:relative;width:100%;height:27pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4</span></div></div></div><div id="i793e68cdccb44b98a73aef6e33f497bf_31"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Amounts in thousands)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.684%;"><tr><td style="width:1.0%;"></td><td style="width:71.481%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.888%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.540%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.891%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For&#160;the&#160;Three-Month&#160;<br/>Periods&#160;Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash Flows from Operating Activities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMy0xLTEtMS0w_7c7c55fe-ff7f-4425-b379-d334f53bd943">32,046</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMy0zLTEtMS0w_c1d3331d-06fc-44f0-9973-ad7288af6738">31,573</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustments to reconcile net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation and amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfNS0xLTEtMS0w_cfe2879f-4e5d-4ec5-8798-f093da4f2781">5,338</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfNS0zLTEtMS0w_a56a91c5-f6d3-4890-abdd-4c57ed5bf432">2,895</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:20.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Non-cash compensation</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfNi0xLTEtMS0w_fe814b10-b879-49d9-9387-2a156fb7b00d">5,909</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfNi0zLTEtMS0w_88565dd3-88c1-4898-92b8-f07e31702e5d">6,615</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">401(k) employer match</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfNy0xLTEtMS0w_560ce0eb-9c29-4f7d-8c77-707cb0371fd9">3,291</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfNy0zLTEtMS0w_4f0a1b49-2b15-45d9-812f-0ba5f60ee463">2,379</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization and impairment of operating lease right of use assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="amed:AmortizationandImpairmentofOperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfOC0xLTEtMS0w_57f4463b-aed4-497a-96f4-1353086b80b8">9,058</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="amed:AmortizationandImpairmentofOperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfOC0zLTEtMS0w_a07970da-29ce-4b55-862b-80eb847832c2">8,345</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss (gain) on disposal of property and equipment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfOS0xLTEtMS0w_c2fd7686-1b0b-4956-8e8a-c5bc2706f3c1">55</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfOS0zLTEtMS0w_50ff3fea-ab3c-49d5-8675-79bc1220df53">4</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Write-off of other comprehensive income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" name="amed:WriteOffOfOtherComprehensiveIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMTAtMS0xLTEtMTc4Ng_e49da80c-d061-44c5-a978-d68b2ebce750">15</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="amed:WriteOffOfOtherComprehensiveIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMTAtMy0xLTEtMTc4Ng_53615347-1ef2-46f5-a14d-9946d8390e8d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred income taxes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMTAtMS0xLTEtMA_77e1fd52-1c34-4ee3-be66-8931f02fd2dd">1,228</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMTAtMy0xLTEtMA_b48815c9-119a-46cd-b8ea-39bed4299cad">3,269</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity in earnings from equity method investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMTEtMS0xLTEtMA_1cf4aab1-afff-4ff0-9ab2-365768ff33c0">477</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMTEtMy0xLTEtMA_48630a4b-e342-4cdb-8ed2-d9af1fd6b433">1,216</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of deferred debt issuance costs/debt discount</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMTItMS0xLTEtMA_5e552c12-439b-4869-ba3b-843e459fd890">220</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMTItMy0xLTEtMA_ab8e67ef-6abf-4b6e-9b19-dbedf18688d1">213</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Return on equity investment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMTMtMS0xLTEtMA_d2bc89dd-c1f3-4530-a5b7-395825b81cdb">2,369</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMTMtMy0xLTEtMA_ec9102d3-4088-4894-8159-d141a1dd59cf">725</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Changes in operating assets and liabilities, net of impact of acquisitions:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Patient accounts receivable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMTUtMS0xLTEtMA_aac5eee4-10a3-4d4c-bde8-1f32fe83afb9">25,459</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMTUtMy0xLTEtMA_e2ec9239-f6c6-4fa5-bcbe-d8b0f12be017">22,333</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMTYtMS0xLTEtMA_98c73e65-cb08-459d-b592-01a50b95ed4a">5,756</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMTYtMy0xLTEtMA_c1a8d14d-a161-475a-b655-ef372a35bcd2">10,635</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMTctMS0xLTEtMA_ded1276a-3c05-4711-a156-af4c1389a7a0">417</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMTctMy0xLTEtMA_e24e6687-597c-4315-b800-7be4e6981098">338</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMTgtMS0xLTEtMA_b6d8ab81-9378-45e5-8c17-67e3c448672f">2,673</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMTgtMy0xLTEtMA_5aae7927-fd4d-42e1-b601-66b3a640fd88">11,140</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMTktMS0xLTEtMA_620e097c-c25f-49ae-aeda-1fab635b9fd7">13,627</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMTktMy0xLTEtMA_b1622c95-774c-44c3-a5af-130c1c3130fe">18,838</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other long-term obligations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMjAtMS0xLTEtMA_056efae0-ee16-4d26-b523-95e415a782dc">3,060</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMjAtMy0xLTEtMA_5f470225-038e-4591-8f74-ed50414b8b84">144</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="amed:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMjEtMS0xLTEtMA_513a781b-9f05-4fa7-bd62-071879711524">8,132</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="amed:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMjEtMy0xLTEtMA_490ff027-5946-4994-b69c-489eadb819da">8,139</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease right of use assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" sign="-" name="amed:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMjItMS0xLTEtMA_b928d5cb-12b5-4620-9771-7312b17568d4">817</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" sign="-" name="amed:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMjItMy0xLTEtMA_20fbc656-fbaf-44da-9798-78268699ee12">844</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by operating activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMjMtMS0xLTEtMA_7f52e5eb-0d3a-4efb-99f4-6c9fe6820ff3">6,035</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMjMtMy0xLTEtMA_83247f61-7538-4907-b4e7-31a8aed7495d">20,059</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash Flows from Investing Activities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from sale of deferred compensation plan assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" name="us-gaap:ProceedsFromSaleOfRestrictedInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMjUtMS0xLTEtMA_226a0f26-1c2a-4eb9-bf74-79a46e9b9378">16</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" name="us-gaap:ProceedsFromSaleOfRestrictedInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMjUtMy0xLTEtMA_0ca0f4fd-31bd-4c40-80e8-554db09b3944">208</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from the sale of property and equipment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMjYtMS0xLTEtMA_331166ee-7110-439d-b53d-b9a808b47bba">12</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMjYtMy0xLTEtMA_f0f0cf40-bb43-4809-868e-2b7b27996dbe">65</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchases of property and equipment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMjctMS0xLTEtOTYz_deddf060-d7e3-4319-95b3-410b25417de7">1,434</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMjctMy0xLTEtOTYz_02ef7902-ccd7-479b-a392-31b37c2db12b">1,198</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Investments in equity method investees</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMjctMS0xLTEtMA_7fdbe7a8-9c49-4e45-8418-2175f1b3ee90">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMjctMy0xLTEtMA_a9b43013-e170-43fe-b2eb-fdffa8ea6b72">120</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acquisitions of businesses, net of cash acquired</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMjktMS0xLTEtMA_1a8fb39d-a012-425c-b927-991f1d0c3c78">69,349</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMjktMy0xLTEtMA_fbbc45af-3d94-47ee-b7f6-957608501cf1">327,867</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash used in investing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMzAtMS0xLTEtMA_254179b8-fb1d-48e2-a63c-249da8425274">70,755</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMzAtMy0xLTEtMA_30d9decb-a8ae-4efb-a32b-f96a7017436e">328,912</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash Flows from Financing Activities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from issuance of stock upon exercise of stock options</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMzItMS0xLTEtMA_51e7bdc6-192a-4fa9-9573-121717beef96">1,184</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMzItMy0xLTEtMA_7236caea-82f8-4eb1-84fd-1cf3f03aff31">356</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from issuance of stock to employee stock purchase plan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" name="us-gaap:ProceedsFromStockPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMzMtMS0xLTEtMA_be5b8967-a57f-46ef-8d58-e1e5c64c4f69">860</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" name="us-gaap:ProceedsFromStockPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMzMtMy0xLTEtMA_67221160-ebae-468b-a984-58c9b35f342c">782</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares withheld upon stock vesting</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMzQtMS0xLTEtMA_fecb6997-0131-46b5-aa7f-35a59c74f08e">4,050</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMzQtMy0xLTEtMA_2331e86d-6600-4b0d-b788-2b6cc6e06e96">2,688</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Noncontrolling interest distribution</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" name="amed:CashDistributionToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMzUtMS0xLTEtMA_34b5e529-3e5c-4f92-ac5f-71cd3de44f50">360</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" name="amed:CashDistributionToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMzUtMy0xLTEtMA_02d6825a-8b14-4a9a-9d53-0ce3c4a5b910">366</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from borrowings under term loan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="amed:ProceedsFromBorrowingsUnderTermLoan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMzYtMS0xLTEtMA_c2bf72da-5f4e-4e4c-9f4e-7051cc65eaa4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="amed:ProceedsFromBorrowingsUnderTermLoan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMzYtMy0xLTEtMA_e51cf059-2026-40d0-b6d9-6fab952cfa83">175,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from borrowings under revolving line of credit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromShortTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMzctMS0xLTEtMA_06c9e6f4-8ef4-474a-a666-3eb33af8776a">187,500</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromShortTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMzctMy0xLTEtMA_29fa6d46-9c35-4161-9f98-17fd384c473a">161,500</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Repayments of borrowings under revolving line of credit </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfShortTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMzgtMS0xLTEtMA_da9f6042-c49d-48ae-bea9-db6b6c76c9e5">37,500</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfShortTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMzgtMy0xLTEtMA_d865823e-12ce-4900-9259-7ca5374cdc81">34,000</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Principal payments of long-term obligations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMzktMS0xLTEtMA_5b7aa5ba-9751-49ca-97b8-ce06ab285a4c">1,592</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMzktMy0xLTEtMA_3d1ce3a5-d58a-4e56-9bc9-e04350b0cb9d">559</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Debt issuance costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfNDAtMS0xLTEtMA_cac370ec-e583-45e8-b1d7-ce674b3e6493">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" name="us-gaap:PaymentsOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfNDAtMy0xLTEtMA_cd2d5fec-56af-4adc-8d14-ff2e54642ad4">847</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by financing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfNDMtMS0xLTEtMA_716772b3-7630-442b-9d92-8cda0a5dea03">146,042</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfNDMtMy0xLTEtMA_27508da1-efe2-439a-a928-06a6668bd87c">299,178</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net increase (decrease) in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfNDQtMS0xLTEtMA_14bac2b1-4e3e-4da5-b855-64c173bba728">81,322</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfNDQtMy0xLTEtMA_0f7f63c8-20de-4da8-b595-65e4ea5bd174">9,675</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash, cash equivalents and restricted cash at beginning of period</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i014c385050454730837d592e15bca5e0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfNDUtMS0xLTEtMA_a1c1da4d-d03b-4ca9-ae96-4363f742d184">96,490</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5070e06e0c374add9463ca31e59e3d55_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfNDUtMy0xLTEtMA_0900596a-14da-457f-b578-d5f2882ffef9">20,229</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash, cash equivalents and restricted cash at end of period</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfNDYtMS0xLTEtMA_61f24e20-9162-4070-ab6c-4134ee5dd662">177,812</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3202099b2aaf4cc88461f7725441d5a3_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfNDYtMy0xLTEtMA_0b96509e-66fb-4cc6-bfcc-22fc0d2eedf7">10,554</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Supplemental Disclosures of Cash Flow Information:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash paid for interest</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfNDgtMS0xLTEtMA_fedebe7d-e167-4a7b-9411-2e9480c713d8">1,755</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfNDgtMy0xLTEtMA_a0c0aa1b-5c6f-43f2-952d-38140399eaf9">725</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash paid for income taxes, net of refunds received</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfNDktMS0xLTEtMA_5a48839f-7a1b-432f-87d6-8fbafc99542b">5,272</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfNDktMy0xLTEtMA_5a22cb84-040c-40dc-842b-092c77e9e3a5">404</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash paid for operating lease liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="amed:CashPaidForOperatingLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfNDktMS0xLTEtNDAyNA_49a87f49-0d93-4581-ab48-8d5428488890">8,949</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="amed:CashPaidForOperatingLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfNDktMy0xLTEtNDAyNA_41922544-914c-4566-b0b8-7159007f8c88">8,983</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash paid for finance lease liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" name="amed:CashPaidForFinanceLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfNTAtMS0xLTEtNDAyNA_c5139ffa-5f05-47b6-a878-964c5402ca78">499</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" name="amed:CashPaidForFinanceLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfNTAtMy0xLTEtNDAyNA_13bd4bc8-b79c-48a8-b29c-24b409515056">384</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Supplemental Disclosures of Non-Cash Activity:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Right of use assets obtained in exchange for operating lease liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfNTItMS0xLTEtNDAyMQ_be5aaf54-2e04-42f2-95d0-697213712c80">6,437</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfNTItMy0xLTEtNDAyMQ_96f6855e-eb9d-47e2-bed1-f62336e97add">91,743</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Right of use assets obtained in exchange for finance lease liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfNTMtMS0xLTEtNDAyMQ_9bde0ef5-4653-4ff2-96b7-2b41c646e706">254</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfNTMtMy0xLTEtNDAyMQ_e2d33e33-a0d7-4a3c-b0fc-b3ec65aa2be4">808</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Reductions to right of use assets resulting from reductions to operating lease liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" name="amed:LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfNTQtMS0xLTEtNDAyMQ_179e42d2-6e7f-43a3-8b72-fbab969a91f5">159</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" name="amed:LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfNTQtMy0xLTEtNDAyMQ_414e9ca5-36c7-4c2c-99a9-c56d0742d584">625</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">6</span></div></div></div><div id="i793e68cdccb44b98a73aef6e33f497bf_34"></div><hr style="page-break-after:always"/><div style="height:81pt;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div></div><div style="text-align:center;"><span><br/></span></div><div id="i793e68cdccb44b98a73aef6e33f497bf_37"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">1. <ix:nonNumeric contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zNy9mcmFnOmE3ZGQzNTc4OWI5YjQxMTBhODBmMWMxNzEwYWYwYWQzL3RleHRyZWdpb246YTdkZDM1Nzg5YjliNDExMGE4MGYxYzE3MTBhZjBhZDNfNjM5NA_de6f7c1f-397b-472d-91c4-62859ee5f8e4" continuedAt="i69f043c97f724367a8c1b80fd70b2220" escape="true">NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS</ix:nonNumeric></span></div><ix:continuation id="i69f043c97f724367a8c1b80fd70b2220" continuedAt="ied117fe675a3475f97e1c979b78c2d5a"><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Amedisys, Inc., a Delaware corporation, (together with its consolidated subsidiaries, referred to herein as &#8220;Amedisys,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;) is a multi-state provider of home health, hospice and personal care services with approximately <ix:nonFraction unitRef="number" contextRef="i58e124b0d6b94d7c921cc9069e91b8ba_D20200101-20200331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zNy9mcmFnOmE3ZGQzNTc4OWI5YjQxMTBhODBmMWMxNzEwYWYwYWQzL3RleHRyZWdpb246YTdkZDM1Nzg5YjliNDExMGE4MGYxYzE3MTBhZjBhZDNfMzIz_c7d6ac56-7cc5-4ea6-b6a0-15503d6fb420">74</ix:nonFraction>% of our revenue derived from Medicare for the three-month periods ended March&#160;31, 2020 and 2019. As of March&#160;31, 2020, we owned and operated <ix:nonFraction unitRef="care_center" contextRef="i0836ed4fa3b14e54895551f7cea7ebcf_I20200331" decimals="INF" name="amed:OperatingCareCenters" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zNy9mcmFnOmE3ZGQzNTc4OWI5YjQxMTBhODBmMWMxNzEwYWYwYWQzL3RleHRyZWdpb246YTdkZDM1Nzg5YjliNDExMGE4MGYxYzE3MTBhZjBhZDNfNTY5_93c8026e-7d18-44df-812a-3046454828b2">322</ix:nonFraction> Medicare-certified home health care centers, <ix:nonFraction unitRef="care_center" contextRef="iedecd98e5aa64817971cc51d13696c31_I20200331" decimals="INF" name="amed:OperatingCareCenters" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zNy9mcmFnOmE3ZGQzNTc4OWI5YjQxMTBhODBmMWMxNzEwYWYwYWQzL3RleHRyZWdpb246YTdkZDM1Nzg5YjliNDExMGE4MGYxYzE3MTBhZjBhZDNfNjE3_76e52285-afe8-4eb6-8301-57b11c0c883a">146</ix:nonFraction> Medicare-certified hospice care centers and <ix:nonFraction unitRef="care_center" contextRef="i7c4c8579b54540d3958eb43f0bb5f417_I20200331" decimals="INF" name="amed:OperatingCareCenters" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zNy9mcmFnOmE3ZGQzNTc4OWI5YjQxMTBhODBmMWMxNzEwYWYwYWQzL3RleHRyZWdpb246YTdkZDM1Nzg5YjliNDExMGE4MGYxYzE3MTBhZjBhZDNfNjY0_1729d34f-c817-403d-accf-099e9b352446">12</ix:nonFraction> personal-care care centers in <ix:nonFraction unitRef="state" contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331" decimals="INF" name="us-gaap:NumberOfStatesInWhichEntityOperates" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zNy9mcmFnOmE3ZGQzNTc4OWI5YjQxMTBhODBmMWMxNzEwYWYwYWQzL3RleHRyZWdpb246YTdkZDM1Nzg5YjliNDExMGE4MGYxYzE3MTBhZjBhZDNfNjk3_b7e677d0-15fe-4a5e-8c3f-ce010c85e21f">38</ix:nonFraction> states within the United States and the District of Columbia.</span></div><ix:nonNumeric contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zNy9mcmFnOmE3ZGQzNTc4OWI5YjQxMTBhODBmMWMxNzEwYWYwYWQzL3RleHRyZWdpb246YTdkZDM1Nzg5YjliNDExMGE4MGYxYzE3MTBhZjBhZDNfNjQxMw_366df52e-6e00-4d30-ad7a-374c986bc42a" continuedAt="if41591c9ebc2459eaab06121e78fa154" escape="true"><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Basis of Presentation</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In our opinion, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly our financial position, our results of operations, and our cash flows in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) for interim financial reporting. Our results of operations for the interim periods presented are not necessarily indicative of the results of our operations for the entire year and have not been audited by our independent auditors.</span></div></ix:nonNumeric><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="if41591c9ebc2459eaab06121e78fa154">This report should be read in conjunction with our consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December&#160;31, 2019, as filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on February 19, 2020 (the &#8220;Form 10-K&#8221;), which includes information and disclosures not included herein.</ix:continuation> Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from the interim financial information presented, as allowed by SEC rules and regulations. </span></div><ix:nonNumeric contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zNy9mcmFnOmE3ZGQzNTc4OWI5YjQxMTBhODBmMWMxNzEwYWYwYWQzL3RleHRyZWdpb246YTdkZDM1Nzg5YjliNDExMGE4MGYxYzE3MTBhZjBhZDNfMTY0OTI2NzQ1MTgzNQ_4eccd904-a497-4aa0-8638-21d65ad827b7" escape="true"><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recently Issued Accounting Pronouncements</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2019, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2019-12, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Income Taxes (Topic 740) - Simplifying the Accounting for Income Taxes,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> which simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and improves consistent application by clarifying and amending existing guidance. The ASU is effective for annual and interim periods beginning after December 15, 2020. Early adoption is permitted. While the Company does not expect a material impact upon adoption of ASU 2019-12, we are still evaluating the effect the standard will have on our consolidated financial statements and related disclosures and ongoing financial reporting.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zNy9mcmFnOmE3ZGQzNTc4OWI5YjQxMTBhODBmMWMxNzEwYWYwYWQzL3RleHRyZWdpb246YTdkZDM1Nzg5YjliNDExMGE4MGYxYzE3MTBhZjBhZDNfNjM5OA_c623f5e1-6705-4585-93e8-3f0ee2b338b9" escape="true"><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our accounting and reporting policies conform with U.S. GAAP. In preparing the unaudited condensed consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zNy9mcmFnOmE3ZGQzNTc4OWI5YjQxMTBhODBmMWMxNzEwYWYwYWQzL3RleHRyZWdpb246YTdkZDM1Nzg5YjliNDExMGE4MGYxYzE3MTBhZjBhZDNfNjQwMA_f82ff82f-0fd4-408f-bedf-e1767c729d4c" escape="true"><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Principles of Consolidation</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">These unaudited condensed consolidated financial statements include the accounts of Amedisys, Inc. and our wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in our accompanying unaudited condensed consolidated financial statements, and business combinations accounted for as purchases have been included in our unaudited condensed consolidated financial statements from their respective dates of acquisition. In addition to our wholly owned subsidiaries, we also have certain equity investments that are accounted for as set forth below.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" name="us-gaap:EquityAndCostMethodInvestmentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zNy9mcmFnOmE3ZGQzNTc4OWI5YjQxMTBhODBmMWMxNzEwYWYwYWQzL3RleHRyZWdpb246YTdkZDM1Nzg5YjliNDExMGE4MGYxYzE3MTBhZjBhZDNfNjQxNA_52073958-5dda-4cf4-a1ed-6275a48f7a3d" continuedAt="i682c00799b6e4108b3a620228ae7ab98" escape="true"><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Investments</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We consolidate investments when the entity is a variable interest entity and we are the primary beneficiary or if we have controlling interests in the entity, which is generally ownership in excess of <ix:nonFraction unitRef="number" contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331" decimals="INF" name="amed:MinimumPercentOwnershipForControllingInterestPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zNy9mcmFnOmE3ZGQzNTc4OWI5YjQxMTBhODBmMWMxNzEwYWYwYWQzL3RleHRyZWdpb246YTdkZDM1Nzg5YjliNDExMGE4MGYxYzE3MTBhZjBhZDNfNTU0OA_2973d197-f5a2-43d8-8b5d-d6d3e736f94c">50</ix:nonFraction>%. Third party equity interests in our consolidated joint ventures are reflected as noncontrolling interests in our condensed consolidated financial statements.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We account for investments in entities in which we have the ability to exercise significant influence under the equity method if we hold <ix:nonFraction unitRef="number" contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331" decimals="INF" name="amed:MaximumPercentOwnershipForEquityMethodPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zNy9mcmFnOmE3ZGQzNTc4OWI5YjQxMTBhODBmMWMxNzEwYWYwYWQzL3RleHRyZWdpb246YTdkZDM1Nzg5YjliNDExMGE4MGYxYzE3MTBhZjBhZDNfNTg0Nw_44a57c6e-12c2-439a-98b8-cc090bd85fa5">50</ix:nonFraction>% or less of the voting stock and the entity is not a variable interest entity in which we are the primary beneficiary. </span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">7</span></div></div></div><hr style="page-break-after:always"/><div style="height:81pt;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="ied117fe675a3475f97e1c979b78c2d5a"><ix:continuation id="i682c00799b6e4108b3a620228ae7ab98">The book value of investments that we account for under the equity method of accounting was $<ix:nonFraction unitRef="usd" contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentAggregateCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zNy9mcmFnOmE3ZGQzNTc4OWI5YjQxMTBhODBmMWMxNzEwYWYwYWQzL3RleHRyZWdpb246YTdkZDM1Nzg5YjliNDExMGE4MGYxYzE3MTBhZjBhZDNfNjA2MA_5670c69b-7d72-4246-90f0-0bcf923942b8">33.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i014c385050454730837d592e15bca5e0_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentAggregateCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zNy9mcmFnOmE3ZGQzNTc4OWI5YjQxMTBhODBmMWMxNzEwYWYwYWQzL3RleHRyZWdpb246YTdkZDM1Nzg5YjliNDExMGE4MGYxYzE3MTBhZjBhZDNfNjA2Nw_e9463e33-eb5f-4b4a-9109-fc195dfb80e3">35.7</ix:nonFraction> million as of March&#160;31, 2020 and December&#160;31, 2019, respectively, and is reflected in other assets within our condensed consolidated balance sheets.</ix:continuation></ix:continuation> </span></div><div id="i793e68cdccb44b98a73aef6e33f497bf_43"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">2. <ix:nonNumeric contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RleHRyZWdpb246ODc3MjBkMjEyMGFkNGY4NWIxZDk3NzQyNGNhYzBmYjVfMjA3MzE_89992ba8-b092-4d9c-898b-94b608fc3c4c" continuedAt="i6232c1ac98b94c72b3b7c54c9a713d25" escape="true">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="i6232c1ac98b94c72b3b7c54c9a713d25" continuedAt="i45fc2101cf95414da850fbf9308a525a"><ix:nonNumeric contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RleHRyZWdpb246ODc3MjBkMjEyMGFkNGY4NWIxZDk3NzQyNGNhYzBmYjVfMjA3Mzg_fa7c2b2f-1a8f-4ba8-934f-235b9b64ee25" continuedAt="i28d92af86f17453ba920db71f266b83e" escape="true"><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue Recognition</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We account for revenue from contracts with customers in accordance with ASU 2014-09, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue from Contracts with Customers (Topic 606)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> and ASU 2015-14, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (collectively, "ASC 606"), and as such, we recognize revenue in the period in which we satisfy our performance obligations under our contracts by transferring our promised services to our customers in amounts that reflect the consideration to which we expect to be entitled in exchange for providing patient care, which are the transaction prices allocated to the distinct services. The Company's cost of obtaining contracts is not material.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues are recognized as performance obligations are satisfied, which varies based on the nature of the services provided. Our performance obligation is the delivery of patient care services in accordance with the nature and frequency of services outlined in physicians' orders, which are determined by a physician based on a patient's specific goals.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company's performance obligations relate to contracts with a duration of less than one year; therefore, the Company has elected to apply the optional exemption provided by ASC 606 and is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We determine the transaction price based on gross charges for services provided, reduced by estimates for contractual and non-contractual revenue adjustments. Contractual revenue adjustments include adjustments provided to patients and third-party payors. Non-contractual revenue adjustments include discounts provided to self-pay, uninsured patients or other payors, adjustments resulting from payment reviews and adjustments arising from our inability to obtain appropriate billing documentation, authorizations or face-to-face documentation. Subsequent changes to the estimate of the transaction price are recorded as adjustments to net service revenue in the period of change. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third party payors and others for services provided. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Non-contractual revenue adjustments are recorded for self-pay, uninsured patients and other payors by major payor class based on our historical collection experience, aged accounts receivable by payor and current economic conditions. The non-contractual revenue adjustments represent the difference between amounts billed and amounts we expect to collect based on our collection history with similar payors. The Company assesses its ability to collect for the healthcare services provided at the time of patient admission based on the Company's verification of the patient's insurance coverage under Medicare, Medicaid, and other commercial or managed care insurance programs. Medicare represents approximately <ix:nonFraction unitRef="number" contextRef="i58e124b0d6b94d7c921cc9069e91b8ba_D20200101-20200331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RleHRyZWdpb246ODc3MjBkMjEyMGFkNGY4NWIxZDk3NzQyNGNhYzBmYjVfMzI1MA_c7d6ac56-7cc5-4ea6-b6a0-15503d6fb420">74</ix:nonFraction>% of the Company's consolidated net service revenue for the three-month periods ended March&#160;31, 2020 and 2019. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Amounts due from third-party payors, primarily commercial health insurers and government programs (Medicare and Medicaid), include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to payment reviews based on our historical experience and success rates in the claim appeals and adjudication process.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We determine our estimates for non-contractual revenue adjustments related to our inability to obtain appropriate billing documentation, authorizations, or face-to-face documentation based on our historical experience, which primarily includes a historical collection rate of over <ix:nonFraction unitRef="number" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="2" name="amed:HistoricalCollectionRateFromMedicare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RleHRyZWdpb246ODc3MjBkMjEyMGFkNGY4NWIxZDk3NzQyNGNhYzBmYjVfNDI2OA_83fbdfca-300b-4e08-913b-126d0c1ba721">99</ix:nonFraction>% on Medicare claims. Revenue is recorded at amounts we estimate to be realizable for services provided.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">8</span></div></div></div><hr style="page-break-after:always"/><div style="height:81pt;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div></div><ix:continuation id="i45fc2101cf95414da850fbf9308a525a" continuedAt="i3ed5d0a5616e465ebe7be62c3341c8ec"><ix:continuation id="i28d92af86f17453ba920db71f266b83e" continuedAt="ib57700eb68914b36b11c04a6beeb465d"><ix:nonNumeric contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" name="us-gaap:ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RleHRyZWdpb246ODc3MjBkMjEyMGFkNGY4NWIxZDk3NzQyNGNhYzBmYjVfMjA3NDY_ceb61c4a-7f70-4489-b16d-d65fc0e5238d" escape="true"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenue by payor class as a percentage of total net service revenue is as follows:</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:92.690%;"><tr><td style="width:1.0%;"></td><td style="width:71.659%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.618%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.904%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.619%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three-Month Periods Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Home Health:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Medicare</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i08f8228195d4482abb1638f4aff3246a_D20200101-20200331" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RhYmxlOmQ3MDM2NTFkOWRjOTRiYmFiMWMyOWQyNjYyYTY1NGZhL3RhYmxlcmFuZ2U6ZDcwMzY1MWQ5ZGM5NGJiYWIxYzI5ZDI2NjJhNjU0ZmFfMy0xLTEtMS0w_326ce964-a678-437f-8a51-2f18cf3afc02">41</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i4775f859e4944ad78c696d06861399db_D20190101-20190331" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RhYmxlOmQ3MDM2NTFkOWRjOTRiYmFiMWMyOWQyNjYyYTY1NGZhL3RhYmxlcmFuZ2U6ZDcwMzY1MWQ5ZGM5NGJiYWIxYzI5ZDI2NjJhNjU0ZmFfMy0zLTEtMS0w_9f42626b-6ff7-4817-93b5-9635cda6baa1">46</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Non-Medicare - Episodic-based</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i1585d446638b4ebaaafeda3e997809c6_D20200101-20200331" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RhYmxlOmQ3MDM2NTFkOWRjOTRiYmFiMWMyOWQyNjYyYTY1NGZhL3RhYmxlcmFuZ2U6ZDcwMzY1MWQ5ZGM5NGJiYWIxYzI5ZDI2NjJhNjU0ZmFfNC0xLTEtMS0w_b967595e-a831-4e37-afdf-a31e112a5abb">6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i023ad62f89a640b9bafc773ed8834c5c_D20190101-20190331" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RhYmxlOmQ3MDM2NTFkOWRjOTRiYmFiMWMyOWQyNjYyYTY1NGZhL3RhYmxlcmFuZ2U6ZDcwMzY1MWQ5ZGM5NGJiYWIxYzI5ZDI2NjJhNjU0ZmFfNC0zLTEtMS0w_86ab9669-ec09-4cc0-a59b-69a44195ba64">9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Non-Medicare - Non-episodic based</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i504907be1af1401896b436e9f31ef9b2_D20200101-20200331" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RhYmxlOmQ3MDM2NTFkOWRjOTRiYmFiMWMyOWQyNjYyYTY1NGZhL3RhYmxlcmFuZ2U6ZDcwMzY1MWQ5ZGM5NGJiYWIxYzI5ZDI2NjJhNjU0ZmFfNS0xLTEtMS0w_b05b1780-50fd-426b-bfbf-28d934701346">14</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i6c0374d568c345b1895f99bc4c5da6a1_D20190101-20190331" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RhYmxlOmQ3MDM2NTFkOWRjOTRiYmFiMWMyOWQyNjYyYTY1NGZhL3RhYmxlcmFuZ2U6ZDcwMzY1MWQ5ZGM5NGJiYWIxYzI5ZDI2NjJhNjU0ZmFfNS0zLTEtMS0w_596dc75e-2030-45fb-be16-9b5dccb77232">12</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Hospice (1):</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Medicare</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i012f167f36504108a1f5b3c3b8746634_D20200101-20200331" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RhYmxlOmQ3MDM2NTFkOWRjOTRiYmFiMWMyOWQyNjYyYTY1NGZhL3RhYmxlcmFuZ2U6ZDcwMzY1MWQ5ZGM5NGJiYWIxYzI5ZDI2NjJhNjU0ZmFfNy0xLTEtMS0w_a98617fd-8260-4f3d-855b-b8b039ae5513">33</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="idbce36e4c2a04a1ab922f6c09ff1bf77_D20190101-20190331" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RhYmxlOmQ3MDM2NTFkOWRjOTRiYmFiMWMyOWQyNjYyYTY1NGZhL3RhYmxlcmFuZ2U6ZDcwMzY1MWQ5ZGM5NGJiYWIxYzI5ZDI2NjJhNjU0ZmFfNy0zLTEtMS0w_e4aee3d8-82a0-4eeb-bbd9-209007bbedbc">28</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Non-Medicare</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i9379225a4bef4cf6a6dc439d3252aa78_D20200101-20200331" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RhYmxlOmQ3MDM2NTFkOWRjOTRiYmFiMWMyOWQyNjYyYTY1NGZhL3RhYmxlcmFuZ2U6ZDcwMzY1MWQ5ZGM5NGJiYWIxYzI5ZDI2NjJhNjU0ZmFfOC0xLTEtMS0w_0cd7fb44-1a36-4806-8638-c9c39e9994d3">2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ib45c518834644bd5a393af3f5453153c_D20190101-20190331" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RhYmxlOmQ3MDM2NTFkOWRjOTRiYmFiMWMyOWQyNjYyYTY1NGZhL3RhYmxlcmFuZ2U6ZDcwMzY1MWQ5ZGM5NGJiYWIxYzI5ZDI2NjJhNjU0ZmFfOC0zLTEtMS0w_edf520df-4ebd-41af-9f0a-41e361eba577">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Personal Care</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i244a79cf50e84b398521caa51f9417a5_D20200101-20200331" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RhYmxlOmQ3MDM2NTFkOWRjOTRiYmFiMWMyOWQyNjYyYTY1NGZhL3RhYmxlcmFuZ2U6ZDcwMzY1MWQ5ZGM5NGJiYWIxYzI5ZDI2NjJhNjU0ZmFfOS0xLTEtMS0w_4c2eecd1-d321-4fbb-a8ae-119c6d0d111c">4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="id20d8630a41943e5824e25095e23ca89_D20190101-20190331" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RhYmxlOmQ3MDM2NTFkOWRjOTRiYmFiMWMyOWQyNjYyYTY1NGZhL3RhYmxlcmFuZ2U6ZDcwMzY1MWQ5ZGM5NGJiYWIxYzI5ZDI2NjJhNjU0ZmFfOS0zLTEtMS0w_e7dcdbc8-5722-4459-90c3-6cd02a8dd950">4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RhYmxlOmQ3MDM2NTFkOWRjOTRiYmFiMWMyOWQyNjYyYTY1NGZhL3RhYmxlcmFuZ2U6ZDcwMzY1MWQ5ZGM5NGJiYWIxYzI5ZDI2NjJhNjU0ZmFfMTAtMS0xLTEtMA_efbef354-f185-43c1-8d9c-3e193cef77a5">100</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RhYmxlOmQ3MDM2NTFkOWRjOTRiYmFiMWMyOWQyNjYyYTY1NGZhL3RhYmxlcmFuZ2U6ZDcwMzY1MWQ5ZGM5NGJiYWIxYzI5ZDI2NjJhNjU0ZmFfMTAtMy0xLTEtMA_be317d2b-1236-4d8d-a2ba-d0a0aee1ecd8">100</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="11" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1) Acquired Compassionate Care Hospice on February 1, 2019, RoseRock Healthcare on April 1, 2019 and Asana Hospice on January 1, 2020.</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Home Health Revenue Recognition</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Medicare Revenue</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Effective January 1, 2020, the Centers for Medicare and Medicaid Services ("CMS") implemented a revised case-mix adjustment methodology, the Patient-Driven Groupings Model ("PDGM"), to better align payment with patient care needs and ensure that clinically complex and ill beneficiaries have adequate access to home health care. PDGM uses 30-day periods of care rather than 60-day episodes of care as the unit of payment, eliminates the use of the number of therapy visits provided in determining payment and relies more heavily on clinical characteristics and other patient information.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net service revenue is recorded based on the established Federal Medicare home health payment rate for a 30-day period of care ("billing period"). PDGM uses timing, admission source, functional impairment levels and principal and other diagnoses to case-mix adjust payments. The case-mix adjusted payment for a 30-day period of care is subject to additional adjustments based on certain variables, including, but not limited to (a) an outlier payment if our patient's care was unusually costly (capped at <ix:nonFraction unitRef="number" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="INF" name="amed:PercentageOfTotalReimbursementOfOutlierPayment" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RleHRyZWdpb246ODc3MjBkMjEyMGFkNGY4NWIxZDk3NzQyNGNhYzBmYjVfNDc1NQ_ce5a17b8-2af9-4006-8a24-589cdb028c02">10</ix:nonFraction>% of total reimbursement per provider number); (b)&#160;a low utilization payment adjustment (&#8220;LUPA&#8221;) if the number of visits provided was less than the established threshold, which ranges from <ix:nonFraction unitRef="visit" contextRef="i91721ec84cfa456ea3fe8a1300bb24f5_D20200101-20200331" decimals="0" format="ixt-sec:numwordsen" name="amed:LowUtilizationPaymentAdjustmentNumberOfVisits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RleHRyZWdpb246ODc3MjBkMjEyMGFkNGY4NWIxZDk3NzQyNGNhYzBmYjVfMTY0OTI2NzQ4NDcwMQ_51dd26b6-ba02-4c0d-99eb-c6751c2d013d">two</ix:nonFraction> to <ix:nonFraction unitRef="visit" contextRef="ib06523f2884143ccb65798237a08ecee_D20200101-20200331" decimals="0" format="ixt-sec:numwordsen" name="amed:LowUtilizationPaymentAdjustmentNumberOfVisits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RleHRyZWdpb246ODc3MjBkMjEyMGFkNGY4NWIxZDk3NzQyNGNhYzBmYjVfMTY0OTI2NzQ4NDcxMA_758b501b-f271-4a99-812c-312a90519c7a">six</ix:nonFraction> visits and varies for every case-mix group under PDGM; (c)&#160;a partial payment if a patient transferred to another provider or from another provider before completing the 30-day period of care; and (d) the applicable geographic wage index. Payment for non-routine supplies are now included in the 30-day payment rate.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Medicare can also make various adjustments to payments received if we are unable to produce appropriate billing documentation or acceptable authorizations. We estimate the impact of such adjustments based on our historical experience, which primarily includes a historical collection rate of over <ix:nonFraction unitRef="number" contextRef="i1803f21995a846beaf2e5491abdaa75f_D20200101-20200331" decimals="2" name="amed:HistoricalCollectionRateFromMedicare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RleHRyZWdpb246ODc3MjBkMjEyMGFkNGY4NWIxZDk3NzQyNGNhYzBmYjVfNzgyOQ_9b322763-30e5-435f-a65a-a3d66771279e">99</ix:nonFraction>% on Medicare claims, and record this estimate during the period in which services are rendered as a reduction to revenue and a corresponding reduction to patient accounts receivable. </span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Amounts due from Medicare include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to payment reviews based on our historical experience and success rates in the claim appeals and adjudication process.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Medicare home health benefit requires that beneficiaries be homebound (meaning that the beneficiary is unable to leave their home without a considerable and taxing effort), require intermittent skilled nursing, physical therapy or speech therapy services, and receive treatment under a plan of care established and periodically reviewed by a physician. In order to provide greater flexibility during the novel coronavirus pandemic ("COVID-19"), CMS has relaxed the definition of homebound status. During the pandemic, a beneficiary is considered homebound if they have been instructed by a physician not to leave their home because of a confirmed or suspected COVID-19 diagnosis or if the patient has a condition that makes them more susceptible to contracting COVID-19. Therefore, if a beneficiary is homebound due to COVID-19 and requires skilled services, the services will be covered under the Medicare home health benefit.</span></div></ix:continuation></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">9</span></div></div></div><hr style="page-break-after:always"/><div style="height:81pt;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div></div><ix:continuation id="i3ed5d0a5616e465ebe7be62c3341c8ec" continuedAt="i9605b44fc28d4ccba5fb715e26cbbfae"><ix:continuation id="ib57700eb68914b36b11c04a6beeb465d" continuedAt="i33a4d14e7f3b4271a3fb756255e1a7d2"><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">All Medicare contracts are required to have a signed plan of care which represents a single performance obligation, comprising of the delivery of a series of distinct services that are substantially similar and have a similar pattern of transfer to the customer. Accordingly, the Company accounts for the series of services ("episode") as a single performance obligation satisfied over time, as the customer simultaneously receives and consumes the benefits of the goods and services provided. An episode starts the first day a billable visit is performed and ends 60 days later or upon discharge, if earlier, with multiple continuous episodes allowed.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As noted above, under PDGM, we are now reimbursed for 30-day periods of care rather than 60-day episodes of care. ASC 606 notes that if an entity has a right to consideration from a customer in an amount that corresponds directly with the value of the entity&#8217;s performance completed to date, the entity may recognize revenue in the amount to which the entity has a right to invoice. We have elected to apply the "right to invoice&#8221; practical expedient utilizing our historical average length of stay for each 30-day payment period as the measure of progress towards the satisfaction of our performance obligation.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A portion of reimbursement from each Medicare episode is billed near the start of each 30-day period of care, and cash is typically received before all services are rendered. The amount of revenue recognized for periods of care which are incomplete at period end is based on the company's historical average percentage of days complete on each 30-day period of care. Any cash received from Medicare for a request for anticipated payment (&#8220;RAP&#8221;) for a 30-day period of care that exceeds the associated revenue earned is recorded to accrued expenses within our condensed consolidated balance sheets.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Non-Medicare Revenue</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Episodic-based Revenue.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> We recognize revenue in a similar manner as we recognize Medicare revenue for amounts that are paid by other insurance carriers, including Medicare Advantage programs; however, these amounts can vary based upon the negotiated terms which generally range from <ix:nonFraction unitRef="number" contextRef="i91721ec84cfa456ea3fe8a1300bb24f5_D20200101-20200331" decimals="INF" name="amed:NonMedicareRevenueTermRates" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RleHRyZWdpb246ODc3MjBkMjEyMGFkNGY4NWIxZDk3NzQyNGNhYzBmYjVfODk0Mw_a065316f-8485-415f-8951-1f25d077670a">90</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ib06523f2884143ccb65798237a08ecee_D20200101-20200331" decimals="INF" name="amed:NonMedicareRevenueTermRates" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RleHRyZWdpb246ODc3MjBkMjEyMGFkNGY4NWIxZDk3NzQyNGNhYzBmYjVfODk0OQ_ce4df2be-4f40-4d40-bf88-99d7c931f7f8">100</ix:nonFraction>% of Medicare rates.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Non-episodic based Revenue.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third parties and others for services provided and are deducted from gross revenue to determine net service revenue. We also make non-contractual revenue adjustments to non-episodic revenue based on historical experience, to reflect the estimated transaction price. We receive a minimal amount of our net service revenue from patients who are either self-insured or are obligated for an insurance co-payment.</span></div><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Hospice Revenue Recognition</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Hospice Medicare Revenue</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are predetermined daily or hourly rates for each of the four levels of care we deliver. The four levels of care are routine care, general inpatient care, continuous home care and respite care. Routine care accounted for <ix:nonFraction unitRef="number" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="2" name="amed:HospiceMedicareRevenueRateAccountedForRoutineCare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RleHRyZWdpb246ODc3MjBkMjEyMGFkNGY4NWIxZDk3NzQyNGNhYzBmYjVfMTAxMzE_8d6483d8-512d-454d-a554-022603ecf112">97</ix:nonFraction>%  and <ix:nonFraction unitRef="number" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="2" name="amed:HospiceMedicareRevenueRateAccountedForRoutineCare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RleHRyZWdpb246ODc3MjBkMjEyMGFkNGY4NWIxZDk3NzQyNGNhYzBmYjVfMTAyNTI_498cb30c-4b1f-4fbd-ac2e-3aa2d3adaeb9">98</ix:nonFraction>% of our total net Medicare hospice service revenue for each of the three-month periods ended March&#160;31, 2020 and March&#160;31, 2019, respectively. There are two separate payment rates for routine care: payments for the first 60 days of care and care beyond 60 days. In addition to the two routine rates, we may also receive a service intensity add-on (&#8220;SIA&#8221;). The SIA is based on visits made in the last seven days of life by a registered nurse (&#8220;RN&#8221;) or medical social worker (&#8220;MSW&#8221;) for patients in a routine level of care.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The performance obligation is the delivery of hospice services to the patient, as determined by a physician, each day the patient is on hospice care.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We make adjustments to Medicare revenue for non-contractual revenue adjustments, which include our inability to obtain appropriate billing documentation or acceptable authorizations and other reasons unrelated to credit risk. We estimate the impact of these non-contractual revenue adjustments based on our historical experience, which primarily includes a historical collection rate of over <ix:nonFraction unitRef="number" contextRef="ie2a5b1046a72421f919b53e916e3b7b9_D20200101-20200331" decimals="2" name="amed:HistoricalCollectionRateFromMedicare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RleHRyZWdpb246ODc3MjBkMjEyMGFkNGY4NWIxZDk3NzQyNGNhYzBmYjVfMTEyNTU_82f7d3c3-878a-4022-b2e2-7775cb282307">99</ix:nonFraction>% on Medicare claims, and record it during the period services are rendered.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additionally, our hospice service revenue is subject to certain limitations on payments from Medicare which are considered variable consideration. We are subject to an inpatient cap limit and an overall Medicare payment cap for each provider number. We monitor these caps on a provider-by-provider basis and estimate amounts due back to Medicare if we estimate a cap has been exceeded.&#160;We record these adjustments as a reduction to revenue and an increase in accrued expenses within our condensed consolidated balance sheet. Beginning for the cap year ending October&#160;31, 2017, providers are required to self-report </span></div></ix:continuation></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">10</span></div></div></div><hr style="page-break-after:always"/><div style="height:81pt;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div></div><ix:continuation id="i9605b44fc28d4ccba5fb715e26cbbfae" continuedAt="i97eafac56bf04cc7b805ed3ee64d194a"><ix:continuation id="i33a4d14e7f3b4271a3fb756255e1a7d2" continuedAt="i65e651f3553543f9acfdb236a371a077"><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">and pay their estimated cap liability by February 28</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">th</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of the following year. As of March&#160;31, 2020, we have recorded $<ix:nonFraction unitRef="usd" contextRef="iecd85c6103824b598da9159d305f569b_I20200331" decimals="-5" format="ixt:numdotdecimal" name="amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RleHRyZWdpb246ODc3MjBkMjEyMGFkNGY4NWIxZDk3NzQyNGNhYzBmYjVfMTIwNTM_d3fa4712-66b9-47a8-a3ba-e9d4bd9f4802">5.5</ix:nonFraction> million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2013 through September 30, 2020. As of December&#160;31, 2019, we had recorded $<ix:nonFraction unitRef="usd" contextRef="i7ff59164cb40413fac8d060bc05c3403_I20191231" decimals="-5" format="ixt:numdotdecimal" name="amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RleHRyZWdpb246ODc3MjBkMjEyMGFkNGY4NWIxZDk3NzQyNGNhYzBmYjVfMTIzNTg_faf03678-09c3-4c13-a4c7-572e12d9df58">5.7</ix:nonFraction> million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2013 through September 30, 2020.</span></div><div style="text-align:justify;margin-top:6pt;"><span><br/></span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Hospice Non-Medicare Revenue</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per day rates, as applicable. Contractual revenue adjustments are recorded for the difference between our standard rates and the contractual rates to be realized from patients, third party payors and others for services provided and are deducted from gross revenue to determine our net service revenue. We also make non-contractual adjustments to non-Medicare revenue based on historical experience, to reflect the estimated transaction price.</span></div><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Personal Care Revenue Recognition</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Personal Care Revenue</span></div></ix:continuation><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i65e651f3553543f9acfdb236a371a077">We generate net service revenues by providing our services directly to patients based on authorized hours, visits or units determined by the relevant agency, at a rate that is either contractual or fixed by legislation. Net service revenue is recognized at the time services are rendered based on gross charges for the services provided, reduced by estimates for contractual and non-contractual revenue adjustments. We receive payment for providing such services from payors, including state and local governmental agencies, managed care organizations, commercial insurers and private consumers. Payors include the following elder service agencies: Aging Services Access Points (ASAPs), Senior Care Options (SCOs), Program of All-Inclusive Care for the Elderly (PACE) and the Veterans Administration (VA).</ix:continuation> </span></div><ix:nonNumeric contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RleHRyZWdpb246ODc3MjBkMjEyMGFkNGY4NWIxZDk3NzQyNGNhYzBmYjVfMjc0ODc3OTExMjYwNg_f7af46a0-b91d-4813-bccf-afef4ba668c7" escape="true"><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash, Cash Equivalents and Restricted Cash </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash and cash equivalents include certificates of deposit and all highly liquid debt instruments with maturities of three months or less when purchased. Restricted cash includes cash that is not available for ordinary business use. As of March 31, 2020, we had $<ix:nonFraction unitRef="usd" contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RleHRyZWdpb246ODc3MjBkMjEyMGFkNGY4NWIxZDk3NzQyNGNhYzBmYjVfMTY0OTI2NzQ4NDc4OQ_070e5ab6-e756-4e88-8ad9-002ef2808f34">3.1</ix:nonFraction>&#160;million of restricted cash that was placed into escrow accounts related to the potential indemnity and working capital adjustment provisions within the Asana Hospice purchase agreement ($<ix:nonFraction unitRef="usd" contextRef="i94c155e0b36a4453979995375a4118aa_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RleHRyZWdpb246ODc3MjBkMjEyMGFkNGY4NWIxZDk3NzQyNGNhYzBmYjVfMTY0OTI2NzQ4NDgwMw_688444a3-c3ac-42c4-980e-b15fff182730">2.3</ix:nonFraction>&#160;million) and to secure the purchase of personal protective equipment from new suppliers in response to COVID-19 ($<ix:nonFraction unitRef="usd" contextRef="id6a265dc3d6143ed962cec7a4019507c_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RleHRyZWdpb246ODc3MjBkMjEyMGFkNGY4NWIxZDk3NzQyNGNhYzBmYjVfMTY0OTI2NzQ4NDgxNw_219289b4-90a6-45ca-a3fd-fc682ea769dd">0.8</ix:nonFraction>&#160;million).</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RleHRyZWdpb246ODc3MjBkMjEyMGFkNGY4NWIxZDk3NzQyNGNhYzBmYjVfMjA3MjM_a47682a6-1ec8-4db9-9dba-90ea82da12cd" continuedAt="ibf5096a225344b35b4f70e1b1dec8450" escape="true"><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Patient Accounts Receivable </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We report accounts receivable from services rendered at their estimated transaction price, which includes contractual and non-contractual revenue adjustments based on the amounts expected to be due from payors. Our patient accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other third-party payors and patients. As of March&#160;31, 2020, there is no single payor, other than Medicare, that accounts for more than <ix:nonFraction unitRef="number" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="INF" name="amed:PercentageOfPatientReceivablesOutstanding" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RleHRyZWdpb246ODc3MjBkMjEyMGFkNGY4NWIxZDk3NzQyNGNhYzBmYjVfMTQzODU_aea125b0-f170-4f1b-9217-bf363b13ec9e">10</ix:nonFraction>% of our total outstanding patient receivables. Thus, we believe there are no other significant concentrations of receivables that would subject us to any significant credit risk in the collection of our patient accounts receivable. We write off accounts on a monthly basis once we have exhausted our collection efforts and deem an account to be uncollectible. We believe the collectibility risk associated with our Medicare accounts, which represent <ix:nonFraction unitRef="number" contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331" decimals="2" name="amed:AccountsReceivablePortionDerivedFromMedicare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RleHRyZWdpb246ODc3MjBkMjEyMGFkNGY4NWIxZDk3NzQyNGNhYzBmYjVfMTQ4NDQ_7607040c-26ac-4bee-bf01-b546a5a8efbc">58</ix:nonFraction>% of our patient accounts receivable at March&#160;31, 2020 and December&#160;31, 2019 is limited due to our historical collection rate of over <ix:nonFraction unitRef="number" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="2" name="amed:HistoricalCollectionRateFromMedicare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RleHRyZWdpb246ODc3MjBkMjEyMGFkNGY4NWIxZDk3NzQyNGNhYzBmYjVfMTQ5Njc_b6d1bd40-b965-4e5e-9553-a483a7be513e">99</ix:nonFraction>% from Medicare and the fact that Medicare is a U.S. government payor. </span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We do not believe there are any significant concentrations of revenues from any payor that would subject us to any significant credit risk in the collection of our accounts receivable.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Medicare Home Health</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For our home health patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We submit a RAP for <ix:nonFraction unitRef="number" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="2" name="amed:RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RleHRyZWdpb246ODc3MjBkMjEyMGFkNGY4NWIxZDk3NzQyNGNhYzBmYjVfMTU1ODQ_f24cbd0d-bc22-436e-862f-0f91129964c5">20</ix:nonFraction>% of our estimated payment for each 30-day period of care. The full amount of the payment for each 30-day period of care is billed after the period of care has been completed (&#8220;final billed&#8221;). The RAP received for that billing period is then deducted from our final payment. If a final bill is not submitted within the greater of <ix:nonFraction unitRef="day" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="INF" name="amed:MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RleHRyZWdpb246ODc3MjBkMjEyMGFkNGY4NWIxZDk3NzQyNGNhYzBmYjVfMTYwMjE_5bf5053a-fef3-492c-9086-626613d1992d">90</ix:nonFraction> days from the start of the 30-day period of care, or <ix:nonFraction unitRef="day" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="INF" name="amed:MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RleHRyZWdpb246ODc3MjBkMjEyMGFkNGY4NWIxZDk3NzQyNGNhYzBmYjVfMTYwNjM_17956edb-850b-4398-9bad-a0cb8e97654e">60</ix:nonFraction> days from the date the RAP was paid, </span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">11</span></div></div></div><hr style="page-break-after:always"/><div style="height:81pt;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div></div><ix:continuation id="i97eafac56bf04cc7b805ed3ee64d194a" continuedAt="i70300e32e7574f9a93126b9bf19b0255"><ix:continuation id="ibf5096a225344b35b4f70e1b1dec8450"><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">any RAPs received for that billing period will be recouped by Medicare from any other claims in process for that particular provider number. The RAP claim must then be resubmitted. CMS has mandated the full elimination of RAPs in 2021.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Medicare Hospice</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For our hospice patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We bill Medicare on a monthly basis for the services provided to the patient.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Non-Medicare Home Health, Hospice and Personal Care</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For our non-Medicare patients, our pre-billing process primarily begins with verifying a patient&#8217;s eligibility for services with the applicable payor. Once the patient has been confirmed for eligibility, we will provide services to the patient and bill the applicable payor. Our review and evaluation of non-Medicare accounts receivable includes a detailed review of outstanding balances and special consideration to concentrations of receivables from particular payors or groups of payors with similar characteristics that would subject us to any significant credit risk.</span></div></ix:continuation><ix:nonNumeric contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RleHRyZWdpb246ODc3MjBkMjEyMGFkNGY4NWIxZDk3NzQyNGNhYzBmYjVfMjA3MjQ_eac9360f-b82a-4d1b-af96-19a6ab6eb89d" continuedAt="i6df569961a2e4639acfeea2b18554f3c" escape="true"><div style="text-align:justify;margin-top:16pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Fair Value of Financial Instruments</span></div><ix:nonNumeric contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" name="amed:FinancialInstrumentDetailsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RleHRyZWdpb246ODc3MjBkMjEyMGFkNGY4NWIxZDk3NzQyNGNhYzBmYjVfMjA3NDM_d56fa97f-ec49-420e-a1f5-69041285e810" escape="true"><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.076%;"><tr><td style="width:1.0%;"></td><td style="width:24.054%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:15.921%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.553%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:15.921%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.553%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:15.921%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.553%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:15.924%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value at Reporting Date Using</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Financial Instrument</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Carrying Value as of March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Quoted&#160;Prices&#160;in&#160;Active<br/>Markets for Identical<br/>Items<br/>(Level 1)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant<br/>Unobservable&#160;Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term obligations</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331" decimals="-5" name="amed:DebtInstrumentCarryingAmountExcludingFinanceLeases" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RhYmxlOmJhOTM5NWI0ODA0ZDRlYWViOTI2NDFkNTg1MGQzNDRkL3RhYmxlcmFuZ2U6YmE5Mzk1YjQ4MDRkNGVhZWI5MjY0MWQ1ODUwZDM0NGRfMi0xLTEtMS0w_ae010d80-3faa-4d86-a4d1-371bbb18b2e1">391.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0c3c88d49d1d4d8a95daf44cd924af53_I20200331" decimals="1" format="ixt:zerodash" name="us-gaap:LongTermDebtFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RhYmxlOmJhOTM5NWI0ODA0ZDRlYWViOTI2NDFkNTg1MGQzNDRkL3RhYmxlcmFuZ2U6YmE5Mzk1YjQ4MDRkNGVhZWI5MjY0MWQ1ODUwZDM0NGRfMi0zLTEtMS0w_2ce305ca-4f9c-4af7-96a0-1bfb4dec9e0d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7815a32e7798440abd6d377ab708f8e5_I20200331" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RhYmxlOmJhOTM5NWI0ODA0ZDRlYWViOTI2NDFkNTg1MGQzNDRkL3RhYmxlcmFuZ2U6YmE5Mzk1YjQ4MDRkNGVhZWI5MjY0MWQ1ODUwZDM0NGRfMi01LTEtMS0w_d8742ddd-8734-43b5-9079-7997ae4e4c64">383.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i72f233d9e2f84fa7a940e82385eff8a4_I20200331" decimals="1" format="ixt:zerodash" name="us-gaap:LongTermDebtFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RhYmxlOmJhOTM5NWI0ODA0ZDRlYWViOTI2NDFkNTg1MGQzNDRkL3RhYmxlcmFuZ2U6YmE5Mzk1YjQ4MDRkNGVhZWI5MjY0MWQ1ODUwZDM0NGRfMi03LTEtMS0w_95efb9e9-de4e-4fb0-a4ad-b958a867526a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The three levels of inputs are as follows:</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Level&#160;1 &#8211; Quoted prices in active markets for identical assets and liabilities.</span></div><div style="padding-left:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Level&#160;2 &#8211; Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="padding-left:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Level&#160;3 &#8211; Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities.</span></div></ix:nonNumeric><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i6df569961a2e4639acfeea2b18554f3c">Our deferred compensation plan assets are recorded at fair value and are considered a level 2 measurement. For our other financial instruments, including our cash and cash equivalents, patient accounts receivable, accounts payable, payroll and employee benefits and accrued expenses, we estimate the carrying amounts approximate fair value.</ix:continuation> </span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">12</span></div></div></div><hr style="page-break-after:always"/><div style="height:81pt;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div></div><ix:continuation id="i70300e32e7574f9a93126b9bf19b0255" continuedAt="i4d754ff83fe54a919b47826b569d85c2"><div style="text-align:justify;margin-top:16pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RleHRyZWdpb246ODc3MjBkMjEyMGFkNGY4NWIxZDk3NzQyNGNhYzBmYjVfMjA3MzQ_7fffc18d-32eb-4339-9c0f-1c3199600a6e" continuedAt="i40d662085fac4c91b35211c3531f96a5" escape="true">Weighted-Average Shares Outstanding</ix:nonNumeric></span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i40d662085fac4c91b35211c3531f96a5">Net income per share attributable to Amedisys, Inc. common stockholders, calculated on the treasury stock method, is based on the weighted average number of shares outstanding during the period.</ix:continuation> <ix:nonNumeric contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" name="us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RleHRyZWdpb246ODc3MjBkMjEyMGFkNGY4NWIxZDk3NzQyNGNhYzBmYjVfMjA3MzY_ef78005d-35ee-45fe-a043-345628d8cb8f" continuedAt="id817e1c2a35e4573be35d8d52ddd971a" escape="true">The following table sets forth, for the periods indicated, shares used in our computation of the weighted-average shares outstanding, which are used to calculate our basic and diluted net income attributable to Amedisys, Inc. common stockholders (amounts in thousands):</ix:nonNumeric></span></div><div style="text-align:center;margin-bottom:6pt;"><ix:continuation id="id817e1c2a35e4573be35d8d52ddd971a"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:90.497%;"><tr><td style="width:1.0%;"></td><td style="width:69.082%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.054%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.607%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.057%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three-<br/>Month Periods<br/>Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average number of shares outstanding - basic</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RhYmxlOjBmODA0MWY1ZjAyMTQ3ZWJhNDUzMWRiOWUwMjc1MDIxL3RhYmxlcmFuZ2U6MGY4MDQxZjVmMDIxNDdlYmE0NTMxZGI5ZTAyNzUwMjFfMi0xLTEtMS0w_20ff6ba8-f0d9-46e5-8f49-fceff46527cb">32,331</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RhYmxlOjBmODA0MWY1ZjAyMTQ3ZWJhNDUzMWRiOWUwMjc1MDIxL3RhYmxlcmFuZ2U6MGY4MDQxZjVmMDIxNDdlYmE0NTMxZGI5ZTAyNzUwMjFfMi0zLTEtMS0w_65875890-45ae-42e8-8ff0-155669bd9794">32,001</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock options</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RhYmxlOjBmODA0MWY1ZjAyMTQ3ZWJhNDUzMWRiOWUwMjc1MDIxL3RhYmxlcmFuZ2U6MGY4MDQxZjVmMDIxNDdlYmE0NTMxZGI5ZTAyNzUwMjFfNC0xLTEtMS0w_d0cf322b-789a-4187-bdf6-0bfc9bae0db0">594</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RhYmxlOjBmODA0MWY1ZjAyMTQ3ZWJhNDUzMWRiOWUwMjc1MDIxL3RhYmxlcmFuZ2U6MGY4MDQxZjVmMDIxNDdlYmE0NTMxZGI5ZTAyNzUwMjFfNC0zLTEtMS0w_e2f9835b-6362-4cbe-9fa9-68523ed05aa3">559</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:20.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Non-vested stock and stock units</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" name="amed:NonVestedStockAndStockUnits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RhYmxlOjBmODA0MWY1ZjAyMTQ3ZWJhNDUzMWRiOWUwMjc1MDIxL3RhYmxlcmFuZ2U6MGY4MDQxZjVmMDIxNDdlYmE0NTMxZGI5ZTAyNzUwMjFfNS0xLTEtMS0w_b6caee0d-9665-464e-ab6e-c3ae592bed63">309</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" name="amed:NonVestedStockAndStockUnits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RhYmxlOjBmODA0MWY1ZjAyMTQ3ZWJhNDUzMWRiOWUwMjc1MDIxL3RhYmxlcmFuZ2U6MGY4MDQxZjVmMDIxNDdlYmE0NTMxZGI5ZTAyNzUwMjFfNS0zLTEtMS0w_0f04ce76-c76c-4b64-851b-5d94fb280817">333</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average number of shares outstanding - diluted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RhYmxlOjBmODA0MWY1ZjAyMTQ3ZWJhNDUzMWRiOWUwMjc1MDIxL3RhYmxlcmFuZ2U6MGY4MDQxZjVmMDIxNDdlYmE0NTMxZGI5ZTAyNzUwMjFfNi0xLTEtMS0w_8ff411b3-ef27-46b1-a26e-9be6acaae5a0">33,234</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RhYmxlOjBmODA0MWY1ZjAyMTQ3ZWJhNDUzMWRiOWUwMjc1MDIxL3RhYmxlcmFuZ2U6MGY4MDQxZjVmMDIxNDdlYmE0NTMxZGI5ZTAyNzUwMjFfNi0zLTEtMS0w_958962bc-ea33-4c75-b539-027f09107a50">32,893</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Anti-dilutive securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RhYmxlOjBmODA0MWY1ZjAyMTQ3ZWJhNDUzMWRiOWUwMjc1MDIxL3RhYmxlcmFuZ2U6MGY4MDQxZjVmMDIxNDdlYmE0NTMxZGI5ZTAyNzUwMjFfNy0xLTEtMS0w_0845658b-24ee-40b1-a8b8-2aefa6a28b1d">57</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RhYmxlOjBmODA0MWY1ZjAyMTQ3ZWJhNDUzMWRiOWUwMjc1MDIxL3RhYmxlcmFuZ2U6MGY4MDQxZjVmMDIxNDdlYmE0NTMxZGI5ZTAyNzUwMjFfNy0zLTEtMS0w_2fa3dfad-9db0-4a32-8dd0-16c0db22cd72">148</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:continuation></div><div style="text-align:justify;margin-top:16pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RleHRyZWdpb246ODc3MjBkMjEyMGFkNGY4NWIxZDk3NzQyNGNhYzBmYjVfMjA3NTY_49266ee4-6bbb-4607-b055-a03fdccb6b23" continuedAt="i94f6a2b37e8a416eb5f7c1ffe3030fff" escape="true">Business Combinations</ix:nonNumeric></span></div></ix:continuation><div style="text-align:justify;margin-top:6pt;"><ix:continuation id="i4d754ff83fe54a919b47826b569d85c2" continuedAt="i18ce57f9b2ac43c79dba998d00c26f89"><ix:continuation id="i94f6a2b37e8a416eb5f7c1ffe3030fff" continuedAt="i0cf7f47d07774455a924a42fe5f6eaec"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We account for acquisitions using the acquisition method of accounting in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 805, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Business Combinations</span></ix:continuation></ix:continuation><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i18ce57f9b2ac43c79dba998d00c26f89"><ix:continuation id="i0cf7f47d07774455a924a42fe5f6eaec">. Acquisitions are accounted for as purchases and are included in our condensed consolidated financial statements from their respective acquisition dates. Assets acquired and liabilities assumed, if any, are measured at fair value on the acquisition date using the appropriate valuation method. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets.</ix:continuation></ix:continuation> </span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">&#160;</span></div><div id="i793e68cdccb44b98a73aef6e33f497bf_49"></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">3. <ix:nonNumeric contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80OS9mcmFnOjdjOThkNmQ0ZTFlODRmNjA4OGNiYjg2OGY2M2JhZWEzL3RleHRyZWdpb246N2M5OGQ2ZDRlMWU4NGY2MDg4Y2JiODY4ZjYzYmFlYTNfMTY0OTI2NzQ1NDczNw_08bdc3d9-6356-44a1-8ba0-e13d046b6009" continuedAt="id1e64e271fd142dba44b2fbb1b0d094f" escape="true">ACQUISITIONS</ix:nonNumeric></span></div><ix:continuation id="id1e64e271fd142dba44b2fbb1b0d094f" continuedAt="ic04de4f5ae4048ba9c0387dd35604f2a"><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We complete acquisitions from time to time in order to pursue our strategy of increasing our market presence by expanding our service base and enhancing our position in certain geographic areas as a leading provider of home health, hospice and personal care services. The purchase price paid for acquisitions is negotiated through arm&#8217;s length transactions, with consideration based on our analysis of, among other things, comparable acquisitions and expected cash flows. Acquisitions are accounted for as purchases and are included in our condensed consolidated financial statements from their respective acquisition dates. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets because of the expected contributions of the acquisitions to our overall corporate strategy. We typically engage outside appraisal firms to assist in the fair value determination of identifiable intangible assets for significant acquisitions. The preliminary purchase price allocation is adjusted, as necessary, up to one year after the acquisition closing date if management obtains more information regarding asset valuations and liabilities assumed.</span></div><div style="text-align:justify;margin-top:16pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Home Health Division</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On March 1, 2020, we acquired the regulatory assets of a home health provider in Washington for a purchase price of $<ix:nonFraction unitRef="usd" contextRef="ia13fdf76a2e04a3f85e27598086705bf_D20200301-20200301" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80OS9mcmFnOjdjOThkNmQ0ZTFlODRmNjA4OGNiYjg2OGY2M2JhZWEzL3RleHRyZWdpb246N2M5OGQ2ZDRlMWU4NGY2MDg4Y2JiODY4ZjYzYmFlYTNfMTY0OTI2NzQ1MzU5Nw_e8906adf-2fc9-4f67-9f4a-e73a55beebb7">3.0</ix:nonFraction>&#160;million. The purchase price was paid with cash on hand on the date of the transaction. Based on the Company's preliminary valuation, we recorded goodwill of $<ix:nonFraction unitRef="usd" contextRef="i1803f21995a846beaf2e5491abdaa75f_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80OS9mcmFnOjdjOThkNmQ0ZTFlODRmNjA4OGNiYjg2OGY2M2JhZWEzL3RleHRyZWdpb246N2M5OGQ2ZDRlMWU4NGY2MDg4Y2JiODY4ZjYzYmFlYTNfMTY0OTI2NzQ1MzYxMQ_8b0d5ab9-280b-47bb-956f-44445fc6c974">2.8</ix:nonFraction>&#160;million and other intangibles (certificate of need) of $<ix:nonFraction unitRef="usd" contextRef="if1a12a5a1ad7439bb6eb83289bc57f39_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80OS9mcmFnOjdjOThkNmQ0ZTFlODRmNjA4OGNiYjg2OGY2M2JhZWEzL3RleHRyZWdpb246N2M5OGQ2ZDRlMWU4NGY2MDg4Y2JiODY4ZjYzYmFlYTNfMTY0OTI2NzQ1MzYyNQ_7bbcf11f-c169-4b22-b467-94343d0f5654">0.2</ix:nonFraction>&#160;million in connection with the acquisition.</span></div><div style="text-align:justify;margin-top:16pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Hospice Division</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On January 1, 2020, we acquired Asana Hospice ("Asana"), a hospice provider with locations in Pennsylvania, Ohio, Texas, Missouri and Kansas for a purchase price of $<ix:nonFraction unitRef="usd" contextRef="ic7171631cf3944959da9674b593c9910_D20200101-20200101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80OS9mcmFnOjdjOThkNmQ0ZTFlODRmNjA4OGNiYjg2OGY2M2JhZWEzL3RleHRyZWdpb246N2M5OGQ2ZDRlMWU4NGY2MDg4Y2JiODY4ZjYzYmFlYTNfMTY0OTI2NzQ1NDU0OQ_919770a7-eec0-4094-afb6-2bf2c89a12fa">66.3</ix:nonFraction>&#160;million, net of cash acquired of $<ix:nonFraction unitRef="usd" contextRef="ic7171631cf3944959da9674b593c9910_D20200101-20200101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAcquiredFromAcquisition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80OS9mcmFnOjdjOThkNmQ0ZTFlODRmNjA4OGNiYjg2OGY2M2JhZWEzL3RleHRyZWdpb246N2M5OGQ2ZDRlMWU4NGY2MDg4Y2JiODY4ZjYzYmFlYTNfMTY0OTI2NzQ1MzY1NA_b846e4eb-5a4a-4a5f-84a6-f49faf22d9d7">0.7</ix:nonFraction>&#160;million.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80OS9mcmFnOjdjOThkNmQ0ZTFlODRmNjA4OGNiYjg2OGY2M2JhZWEzL3RleHRyZWdpb246N2M5OGQ2ZDRlMWU4NGY2MDg4Y2JiODY4ZjYzYmFlYTNfMTY0OTI2NzQ1NDczOA_0475dc18-9ee6-4ddc-ad36-5e729b8d87e3" continuedAt="ic795091c10c4486ca7470262549d9754" escape="true">The Company is in the process of finalizing its valuation of the assets acquired and liabilities assumed. Based on the Company's preliminary valuation, the total estimated consideration of $<ix:nonFraction unitRef="usd" contextRef="ic7171631cf3944959da9674b593c9910_D20200101-20200101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80OS9mcmFnOjdjOThkNmQ0ZTFlODRmNjA4OGNiYjg2OGY2M2JhZWEzL3RleHRyZWdpb246N2M5OGQ2ZDRlMWU4NGY2MDg4Y2JiODY4ZjYzYmFlYTNfMTY0OTI2NzQ1MzY2OA_2ea12b45-84b0-4242-b415-f18c440c5f5d">66.3</ix:nonFraction>&#160;million has been allocated to assets acquired and liabilities assumed as of the acquisition date as follows (amounts in millions):</ix:nonNumeric></span></div></ix:continuation><div style="text-align:justify;margin-top:6pt;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">13</span></div></div></div><hr style="page-break-after:always"/><div style="height:81pt;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div></div><ix:continuation id="ic04de4f5ae4048ba9c0387dd35604f2a"><div style="text-align:center;margin-top:6pt;margin-bottom:6pt;"><ix:continuation id="ic795091c10c4486ca7470262549d9754"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:79.970%;"><tr><td style="width:1.0%;"></td><td style="width:73.137%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:22.863%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Patient accounts receivable</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9c5dbb2e85d34e54b0517980e6f8d0eb_I20200331" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80OS9mcmFnOjdjOThkNmQ0ZTFlODRmNjA4OGNiYjg2OGY2M2JhZWEzL3RhYmxlOmIyYmJiMWU1ZDZjZjRkYmNiNDExZWQ1NDA0YzA0YmJhL3RhYmxlcmFuZ2U6YjJiYmIxZTVkNmNmNGRiY2I0MTFlZDU0MDRjMDRiYmFfMS0xLTEtMS0zMzky_b2a1cd67-58e5-4e85-9bbf-154a8ebcae87">5.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9c5dbb2e85d34e54b0517980e6f8d0eb_I20200331" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80OS9mcmFnOjdjOThkNmQ0ZTFlODRmNjA4OGNiYjg2OGY2M2JhZWEzL3RhYmxlOmIyYmJiMWU1ZDZjZjRkYmNiNDExZWQ1NDA0YzA0YmJhL3RhYmxlcmFuZ2U6YjJiYmIxZTVkNmNmNGRiY2I0MTFlZDU0MDRjMDRiYmFfMi0xLTEtMS0zMzk1_05c2271a-943c-4b1f-874c-56be6f69f04c">0.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease right of use assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9c5dbb2e85d34e54b0517980e6f8d0eb_I20200331" decimals="-5" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80OS9mcmFnOjdjOThkNmQ0ZTFlODRmNjA4OGNiYjg2OGY2M2JhZWEzL3RhYmxlOmIyYmJiMWU1ZDZjZjRkYmNiNDExZWQ1NDA0YzA0YmJhL3RhYmxlcmFuZ2U6YjJiYmIxZTVkNmNmNGRiY2I0MTFlZDU0MDRjMDRiYmFfMy0xLTEtMS0zMzk3_45c19359-0aba-4a49-a87c-5672bd507c4f">0.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Intangible assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9c5dbb2e85d34e54b0517980e6f8d0eb_I20200331" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80OS9mcmFnOjdjOThkNmQ0ZTFlODRmNjA4OGNiYjg2OGY2M2JhZWEzL3RhYmxlOmIyYmJiMWU1ZDZjZjRkYmNiNDExZWQ1NDA0YzA0YmJhL3RhYmxlcmFuZ2U6YjJiYmIxZTVkNmNmNGRiY2I0MTFlZDU0MDRjMDRiYmFfNC0xLTEtMS0zMzk5_9591035d-7847-491e-bd1a-10fe485c9a9b">5.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Total assets acquired</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9c5dbb2e85d34e54b0517980e6f8d0eb_I20200331" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80OS9mcmFnOjdjOThkNmQ0ZTFlODRmNjA4OGNiYjg2OGY2M2JhZWEzL3RhYmxlOmIyYmJiMWU1ZDZjZjRkYmNiNDExZWQ1NDA0YzA0YmJhL3RhYmxlcmFuZ2U6YjJiYmIxZTVkNmNmNGRiY2I0MTFlZDU0MDRjMDRiYmFfNS0xLTEtMS0zNDAx_89275a09-98c2-4d10-a868-19dd01332cbe">12.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9c5dbb2e85d34e54b0517980e6f8d0eb_I20200331" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80OS9mcmFnOjdjOThkNmQ0ZTFlODRmNjA4OGNiYjg2OGY2M2JhZWEzL3RhYmxlOmIyYmJiMWU1ZDZjZjRkYmNiNDExZWQ1NDA0YzA0YmJhL3RhYmxlcmFuZ2U6YjJiYmIxZTVkNmNmNGRiY2I0MTFlZDU0MDRjMDRiYmFfNi0xLTEtMS0zNDAz_e7e0b9bf-c846-411c-899f-ccc2a787e6f9">3.0</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payroll and employee benefits</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9c5dbb2e85d34e54b0517980e6f8d0eb_I20200331" decimals="-5" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80OS9mcmFnOjdjOThkNmQ0ZTFlODRmNjA4OGNiYjg2OGY2M2JhZWEzL3RhYmxlOmIyYmJiMWU1ZDZjZjRkYmNiNDExZWQ1NDA0YzA0YmJhL3RhYmxlcmFuZ2U6YjJiYmIxZTVkNmNmNGRiY2I0MTFlZDU0MDRjMDRiYmFfNy0xLTEtMS0zNDA1_282b7bee-59cb-4a98-840b-fdd3e4b8f23d">1.5</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9c5dbb2e85d34e54b0517980e6f8d0eb_I20200331" decimals="-5" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80OS9mcmFnOjdjOThkNmQ0ZTFlODRmNjA4OGNiYjg2OGY2M2JhZWEzL3RhYmxlOmIyYmJiMWU1ZDZjZjRkYmNiNDExZWQ1NDA0YzA0YmJhL3RhYmxlcmFuZ2U6YjJiYmIxZTVkNmNmNGRiY2I0MTFlZDU0MDRjMDRiYmFfOC0xLTEtMS0zNDA3_f7b900ff-6eda-4141-b0ab-233e19a5fcdc">0.2</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9c5dbb2e85d34e54b0517980e6f8d0eb_I20200331" decimals="-5" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80OS9mcmFnOjdjOThkNmQ0ZTFlODRmNjA4OGNiYjg2OGY2M2JhZWEzL3RhYmxlOmIyYmJiMWU1ZDZjZjRkYmNiNDExZWQ1NDA0YzA0YmJhL3RhYmxlcmFuZ2U6YjJiYmIxZTVkNmNmNGRiY2I0MTFlZDU0MDRjMDRiYmFfOS0xLTEtMS0zNDA5_8aea8024-3615-4e6c-8b01-54573548c7ff">0.9</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Total liabilities assumed</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9c5dbb2e85d34e54b0517980e6f8d0eb_I20200331" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80OS9mcmFnOjdjOThkNmQ0ZTFlODRmNjA4OGNiYjg2OGY2M2JhZWEzL3RhYmxlOmIyYmJiMWU1ZDZjZjRkYmNiNDExZWQ1NDA0YzA0YmJhL3RhYmxlcmFuZ2U6YjJiYmIxZTVkNmNmNGRiY2I0MTFlZDU0MDRjMDRiYmFfMTAtMS0xLTEtMzQxMQ_45e2d20d-4769-4b22-8612-0c8852e4041f">5.6</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net identifiable assets acquired</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9c5dbb2e85d34e54b0517980e6f8d0eb_I20200331" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80OS9mcmFnOjdjOThkNmQ0ZTFlODRmNjA4OGNiYjg2OGY2M2JhZWEzL3RhYmxlOmIyYmJiMWU1ZDZjZjRkYmNiNDExZWQ1NDA0YzA0YmJhL3RhYmxlcmFuZ2U6YjJiYmIxZTVkNmNmNGRiY2I0MTFlZDU0MDRjMDRiYmFfMTEtMS0xLTEtMzQxNA_9a7216a9-978e-4959-89e3-643f37827d2e">6.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i75590cbf7a2a42d792be47ee29fed5a2_D20200101-20200331" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80OS9mcmFnOjdjOThkNmQ0ZTFlODRmNjA4OGNiYjg2OGY2M2JhZWEzL3RhYmxlOmIyYmJiMWU1ZDZjZjRkYmNiNDExZWQ1NDA0YzA0YmJhL3RhYmxlcmFuZ2U6YjJiYmIxZTVkNmNmNGRiY2I0MTFlZDU0MDRjMDRiYmFfMTItMS0xLTEtMzQxNg_b4b00c63-e28b-41f1-81b6-d52bb63d3761">59.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total estimated consideration</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i75590cbf7a2a42d792be47ee29fed5a2_D20200101-20200331" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80OS9mcmFnOjdjOThkNmQ0ZTFlODRmNjA4OGNiYjg2OGY2M2JhZWEzL3RhYmxlOmIyYmJiMWU1ZDZjZjRkYmNiNDExZWQ1NDA0YzA0YmJhL3RhYmxlcmFuZ2U6YjJiYmIxZTVkNmNmNGRiY2I0MTFlZDU0MDRjMDRiYmFfMTMtMS0xLTEtMzQxOA_32ee5340-325f-42c1-8086-655ce8e41950">66.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:continuation></div><div style="text-align:justify;margin-top:6pt;"><span><br/></span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Intangible assets acquired include licenses ($<ix:nonFraction unitRef="usd" contextRef="i758d8a3c5dd14c668b6a8284e987ffea_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80OS9mcmFnOjdjOThkNmQ0ZTFlODRmNjA4OGNiYjg2OGY2M2JhZWEzL3RleHRyZWdpb246N2M5OGQ2ZDRlMWU4NGY2MDg4Y2JiODY4ZjYzYmFlYTNfMTY0OTI2NzQ1NDY4NA_c2952906-c7fa-45a1-b03a-0644dbe7269b">2.0</ix:nonFraction>&#160;million), acquired names ($<ix:nonFraction unitRef="usd" contextRef="iaeb6ae8b7d9c4d529b6d4a55a4212894_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80OS9mcmFnOjdjOThkNmQ0ZTFlODRmNjA4OGNiYjg2OGY2M2JhZWEzL3RleHRyZWdpb246N2M5OGQ2ZDRlMWU4NGY2MDg4Y2JiODY4ZjYzYmFlYTNfMTY0OTI2NzQ1NDY5OA_16dcdbff-4bcb-4fa9-b03f-00080564aab2">1.3</ix:nonFraction>&#160;million) and non-compete agreements ($<ix:nonFraction unitRef="usd" contextRef="i19dd87f55ab74480af0f28e529fe3174_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80OS9mcmFnOjdjOThkNmQ0ZTFlODRmNjA4OGNiYjg2OGY2M2JhZWEzL3RleHRyZWdpb246N2M5OGQ2ZDRlMWU4NGY2MDg4Y2JiODY4ZjYzYmFlYTNfMTY0OTI2NzQ1NDcxMg_b31aba9d-5c63-4f37-825c-03c1516f6d8f">2.3</ix:nonFraction>&#160;million). The acquired names and non-compete agreements will be amortized over a weighted-average period of <ix:nonNumeric contextRef="i966c726cb1b24dc69084cdec997e95f6_D20200101-20200331" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80OS9mcmFnOjdjOThkNmQ0ZTFlODRmNjA4OGNiYjg2OGY2M2JhZWEzL3RleHRyZWdpb246N2M5OGQ2ZDRlMWU4NGY2MDg4Y2JiODY4ZjYzYmFlYTNfMTY0OTI2NzQ1MTY0OQ_1277f1f5-06af-44cb-9c1a-e72d73fbc7ca">2.0</ix:nonNumeric> years.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Asana contributed approximately $<ix:nonFraction unitRef="usd" contextRef="i75590cbf7a2a42d792be47ee29fed5a2_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80OS9mcmFnOjdjOThkNmQ0ZTFlODRmNjA4OGNiYjg2OGY2M2JhZWEzL3RleHRyZWdpb246N2M5OGQ2ZDRlMWU4NGY2MDg4Y2JiODY4ZjYzYmFlYTNfMTY0OTI2NzQ1NDU2NQ_f0f77b2e-fe0f-4b94-a8dd-d5b0ae631eaf">7.4</ix:nonFraction>&#160;million in net service revenue and an operating loss of $1.3&#160;million (inclusive of acquisition and integration costs totaling $<ix:nonFraction unitRef="usd" contextRef="i75590cbf7a2a42d792be47ee29fed5a2_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationIntegrationRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80OS9mcmFnOjdjOThkNmQ0ZTFlODRmNjA4OGNiYjg2OGY2M2JhZWEzL3RleHRyZWdpb246N2M5OGQ2ZDRlMWU4NGY2MDg4Y2JiODY4ZjYzYmFlYTNfMTY0OTI2NzQ1NDYwOQ_fc04b832-146a-4bf9-b61c-107d7d65061a">1.1</ix:nonFraction>&#160;million and intangibles amortization totaling $<ix:nonFraction unitRef="usd" contextRef="i75590cbf7a2a42d792be47ee29fed5a2_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80OS9mcmFnOjdjOThkNmQ0ZTFlODRmNjA4OGNiYjg2OGY2M2JhZWEzL3RleHRyZWdpb246N2M5OGQ2ZDRlMWU4NGY2MDg4Y2JiODY4ZjYzYmFlYTNfMTY0OTI2NzQ1NDU5NA_2d1f0d7a-a773-4bf6-bb56-480ccb4c984f">0.5</ix:nonFraction>&#160;million) during the three-month period ended March 31, 2020.</span></div></ix:continuation><div style="text-align:justify;margin-top:6pt;"><span><br/></span></div><div id="i793e68cdccb44b98a73aef6e33f497bf_61"></div><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">4. <ix:nonNumeric contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RleHRyZWdpb246MGRkY2MwZmFlMjM3NGNmNTljNWM4MzA4Y2NkYWIyMjhfNjgxNQ_9587148d-fb1a-4724-a911-d33aa0f2e452" continuedAt="i71f122ceaa6a438489bc0cdcf1c29a28" escape="true">LONG-TERM OBLIGATIONS</ix:nonNumeric></span></div><ix:continuation id="i71f122ceaa6a438489bc0cdcf1c29a28" continuedAt="i49d04624d277463a9dca5277ba4ebf20"><ix:nonNumeric contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RleHRyZWdpb246MGRkY2MwZmFlMjM3NGNmNTljNWM4MzA4Y2NkYWIyMjhfNjgxMQ_a32da9be-9708-467b-a9b0-542a5db33363" escape="true"><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Long-term debt consisted of the following for the periods indicated (amounts in millions):</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:91.812%;"><tr><td style="width:1.0%;"></td><td style="width:65.356%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.923%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.596%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.925%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">$<ix:nonFraction unitRef="usd" contextRef="ic735d35014784f0395b22a1d4852e2bb_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjcyZjBlYThiNGMxZTRlYmY5ZWVhMTAyZmU3MjYxZmEzL3RhYmxlcmFuZ2U6NzJmMGVhOGI0YzFlNGViZjllZWExMDJmZTcyNjFmYTNfMS0wLTEtMS0zODk0L3RleHRyZWdpb246ZWExOTBiMzVjNzdhNDkzYWJiZDhhYzZmZGYwOTE0MmVfMTY0OTI2NzQ0MTg4Mg_bb8b6fe0-5af0-482a-9bd5-151a433aaaff">175.0</ix:nonFraction> million Term Loan; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate (<ix:nonFraction unitRef="number" contextRef="i9683f40a00e94c1abb96d732c3041061_I20200331" decimals="3" name="amed:DebtInstrumentInterestRateatPeriodEnd" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjcyZjBlYThiNGMxZTRlYmY5ZWVhMTAyZmU3MjYxZmEzL3RhYmxlcmFuZ2U6NzJmMGVhOGI0YzFlNGViZjllZWExMDJmZTcyNjFmYTNfMS0wLTEtMS0zODk0L3RleHRyZWdpb246ZWExOTBiMzVjNzdhNDkzYWJiZDhhYzZmZGYwOTE0MmVfMTY0OTI2NzQ0MTg4OA_1a1af7ec-316e-4a0b-9f1a-659e4130cd1f">2.5</ix:nonFraction>% at March 31, 2020); due <ix:nonNumeric contextRef="i8ba21eb95e2e43d1b0a24756aec8f4e8_D20200101-20200331" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjcyZjBlYThiNGMxZTRlYmY5ZWVhMTAyZmU3MjYxZmEzL3RhYmxlcmFuZ2U6NzJmMGVhOGI0YzFlNGViZjllZWExMDJmZTcyNjFmYTNfMS0wLTEtMS0zODk0L3RleHRyZWdpb246ZWExOTBiMzVjNzdhNDkzYWJiZDhhYzZmZGYwOTE0MmVfMTY0OTI2NzQ0MTkwNg_321999b2-13b1-4760-92c5-6a12914a4b37">February&#160;4, 2024</ix:nonNumeric></span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic735d35014784f0395b22a1d4852e2bb_I20200331" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjcyZjBlYThiNGMxZTRlYmY5ZWVhMTAyZmU3MjYxZmEzL3RhYmxlcmFuZ2U6NzJmMGVhOGI0YzFlNGViZjllZWExMDJmZTcyNjFmYTNfMS0xLTEtMS0w_1c868cc0-4eee-491a-8dca-13663a6aff9f">170.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i62c497259b644d859d8f0eea7f3e524e_I20191231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjcyZjBlYThiNGMxZTRlYmY5ZWVhMTAyZmU3MjYxZmEzL3RhYmxlcmFuZ2U6NzJmMGVhOGI0YzFlNGViZjllZWExMDJmZTcyNjFmYTNfMS0zLTEtMS0w_35eb1696-725c-4bf3-be4a-420241187bc2">171.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">$<ix:nonFraction unitRef="usd" contextRef="i0ff90663d1684cb09b78cf9c7fde47b7_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjcyZjBlYThiNGMxZTRlYmY5ZWVhMTAyZmU3MjYxZmEzL3RhYmxlcmFuZ2U6NzJmMGVhOGI0YzFlNGViZjllZWExMDJmZTcyNjFmYTNfMi0wLTEtMS0zOTI3L3RleHRyZWdpb246YzI0ZTAyOWZjMGU5NDBiNTkzYTYxNjRjZGM4NTRjN2RfMTY0OTI2NzQ0MTkzMA_c105751e-7fbe-4e47-b9ac-437faf3ce922">550.0</ix:nonFraction> million Revolving Credit Facility; interest only payments; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate (<ix:nonFraction unitRef="number" contextRef="i9224a41a12a14375adaf6a341b29f6fb_I20200331" decimals="3" name="amed:DebtInstrumentInterestRateatPeriodEnd" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjcyZjBlYThiNGMxZTRlYmY5ZWVhMTAyZmU3MjYxZmEzL3RhYmxlcmFuZ2U6NzJmMGVhOGI0YzFlNGViZjllZWExMDJmZTcyNjFmYTNfMi0wLTEtMS0zOTI3L3RleHRyZWdpb246YzI0ZTAyOWZjMGU5NDBiNTkzYTYxNjRjZGM4NTRjN2RfMTY0OTI2NzQ0MTkzNw_a4aebaa2-ca0a-4d3f-94f0-a847c4a76449">2.4</ix:nonFraction>% at March 31, 2020); due <ix:nonNumeric contextRef="if270e80806534123864832e895591246_D20200101-20200331" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjcyZjBlYThiNGMxZTRlYmY5ZWVhMTAyZmU3MjYxZmEzL3RhYmxlcmFuZ2U6NzJmMGVhOGI0YzFlNGViZjllZWExMDJmZTcyNjFmYTNfMi0wLTEtMS0zOTI3L3RleHRyZWdpb246YzI0ZTAyOWZjMGU5NDBiNTkzYTYxNjRjZGM4NTRjN2RfMTY0OTI2NzQ0MTk1Ng_191eeaa6-877e-40f2-8ba0-d34b89fbc602">February&#160;4, 2024</ix:nonNumeric></span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0ff90663d1684cb09b78cf9c7fde47b7_I20200331" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjcyZjBlYThiNGMxZTRlYmY5ZWVhMTAyZmU3MjYxZmEzL3RhYmxlcmFuZ2U6NzJmMGVhOGI0YzFlNGViZjllZWExMDJmZTcyNjFmYTNfMi0xLTEtMS0w_72c2717b-0644-445d-98c3-1e70a733c84e">220.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2057b301fd0c4cd39ca4cc85da07a5f6_I20191231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjcyZjBlYThiNGMxZTRlYmY5ZWVhMTAyZmU3MjYxZmEzL3RhYmxlcmFuZ2U6NzJmMGVhOGI0YzFlNGViZjllZWExMDJmZTcyNjFmYTNfMi0zLTEtMS0w_e15bacd0-bde5-490e-b83b-abbc9c6edc84">70.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Promissory notes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i645e5d94ba734fb2a80140b926935a3d_I20200331" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjcyZjBlYThiNGMxZTRlYmY5ZWVhMTAyZmU3MjYxZmEzL3RhYmxlcmFuZ2U6NzJmMGVhOGI0YzFlNGViZjllZWExMDJmZTcyNjFmYTNfMy0xLTEtMS0w_6e2645bb-3c1c-4d90-9990-6baa98d7c0ec">0.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i72eea6f293c44f77b3987d12a9412f37_I20191231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjcyZjBlYThiNGMxZTRlYmY5ZWVhMTAyZmU3MjYxZmEzL3RhYmxlcmFuZ2U6NzJmMGVhOGI0YzFlNGViZjllZWExMDJmZTcyNjFmYTNfMy0zLTEtMS0w_1effc58f-2470-4005-b3e9-0f616558da81">0.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finance leases</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2ef172d1bcd342b98c9cdb09d302dc65_I20200331" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjcyZjBlYThiNGMxZTRlYmY5ZWVhMTAyZmU3MjYxZmEzL3RhYmxlcmFuZ2U6NzJmMGVhOGI0YzFlNGViZjllZWExMDJmZTcyNjFmYTNfNC0xLTEtMS0w_9a492be3-93ee-4d5e-a4da-9541d4789d94">3.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3608bfa9782e4bac938cc97a5f45bbc6_I20191231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjcyZjBlYThiNGMxZTRlYmY5ZWVhMTAyZmU3MjYxZmEzL3RhYmxlcmFuZ2U6NzJmMGVhOGI0YzFlNGViZjllZWExMDJmZTcyNjFmYTNfNC0zLTEtMS0w_6e8ea1d5-b0d8-4d44-9390-0e8ddd529231">3.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Principal amount of long-term obligations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjcyZjBlYThiNGMxZTRlYmY5ZWVhMTAyZmU3MjYxZmEzL3RhYmxlcmFuZ2U6NzJmMGVhOGI0YzFlNGViZjllZWExMDJmZTcyNjFmYTNfNS0xLTEtMS0w_726354c7-7abd-4798-ae44-8af094c58e11">394.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i014c385050454730837d592e15bca5e0_I20191231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjcyZjBlYThiNGMxZTRlYmY5ZWVhMTAyZmU3MjYxZmEzL3RhYmxlcmFuZ2U6NzJmMGVhOGI0YzFlNGViZjllZWExMDJmZTcyNjFmYTNfNS0zLTEtMS0w_d30415c0-afb0-42b8-a9b1-8b1b99e067cd">245.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred debt issuance costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjcyZjBlYThiNGMxZTRlYmY5ZWVhMTAyZmU3MjYxZmEzL3RhYmxlcmFuZ2U6NzJmMGVhOGI0YzFlNGViZjllZWExMDJmZTcyNjFmYTNfNi0xLTEtMS0w_cb7d5abe-76c6-4afd-82c6-75d970b9d1ae">3.3</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i014c385050454730837d592e15bca5e0_I20191231" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjcyZjBlYThiNGMxZTRlYmY5ZWVhMTAyZmU3MjYxZmEzL3RhYmxlcmFuZ2U6NzJmMGVhOGI0YzFlNGViZjllZWExMDJmZTcyNjFmYTNfNi0zLTEtMS0w_72453f57-f947-4408-b0b0-aafd9ac7ad41">3.5</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjcyZjBlYThiNGMxZTRlYmY5ZWVhMTAyZmU3MjYxZmEzL3RhYmxlcmFuZ2U6NzJmMGVhOGI0YzFlNGViZjllZWExMDJmZTcyNjFmYTNfNy0xLTEtMS0w_fc9a8aa5-dc5e-4d58-a015-7f6943220c70">391.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i014c385050454730837d592e15bca5e0_I20191231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjcyZjBlYThiNGMxZTRlYmY5ZWVhMTAyZmU3MjYxZmEzL3RhYmxlcmFuZ2U6NzJmMGVhOGI0YzFlNGViZjllZWExMDJmZTcyNjFmYTNfNy0zLTEtMS0w_07bdf2fb-8008-4b04-b8d2-3929a8c3d686">242.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current portion of long-term obligations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331" decimals="-5" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjcyZjBlYThiNGMxZTRlYmY5ZWVhMTAyZmU3MjYxZmEzL3RhYmxlcmFuZ2U6NzJmMGVhOGI0YzFlNGViZjllZWExMDJmZTcyNjFmYTNfOC0xLTEtMS0w_dd6e62c1-7828-4fc9-a12f-ea943fa356b7">11.1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i014c385050454730837d592e15bca5e0_I20191231" decimals="-5" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjcyZjBlYThiNGMxZTRlYmY5ZWVhMTAyZmU3MjYxZmEzL3RhYmxlcmFuZ2U6NzJmMGVhOGI0YzFlNGViZjllZWExMDJmZTcyNjFmYTNfOC0zLTEtMS0w_93ec5f7c-385d-47a2-ba5b-7c5d50c91ef4">9.9</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjcyZjBlYThiNGMxZTRlYmY5ZWVhMTAyZmU3MjYxZmEzL3RhYmxlcmFuZ2U6NzJmMGVhOGI0YzFlNGViZjllZWExMDJmZTcyNjFmYTNfOS0xLTEtMS0w_eeef020e-f9b9-4173-ac09-48b5af61f48d">379.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i014c385050454730837d592e15bca5e0_I20191231" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjcyZjBlYThiNGMxZTRlYmY5ZWVhMTAyZmU3MjYxZmEzL3RhYmxlcmFuZ2U6NzJmMGVhOGI0YzFlNGViZjllZWExMDJmZTcyNjFmYTNfOS0zLTEtMS0w_4b4ccd96-b4c4-4416-a6f7-9716635d91f3">232.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">14</span></div></div></div><hr style="page-break-after:always"/><div style="height:81pt;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div></div><div style="text-align:center;"><span><br/></span></div><ix:continuation id="i49d04624d277463a9dca5277ba4ebf20" continuedAt="ieb3da3871aca454d9291ac6633667c09"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">First Amendment to Amended and Restated Credit Agreement</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On February 4, 2019, we entered into the First Amendment to our Credit Agreement (as amended by the First Amendment, the "Amended Credit Agreement"). The Amended Credit Agreement provides for a senior secured credit facility in an initial aggregate principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="ia6972271e2cb4f179a778bd579050d45_I20190204" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RleHRyZWdpb246MGRkY2MwZmFlMjM3NGNmNTljNWM4MzA4Y2NkYWIyMjhfNDU3_e1dbbd12-f962-4d08-bf27-8eebf906dd5e">725.0</ix:nonFraction> million, which includes a $<ix:nonFraction unitRef="usd" contextRef="i686590f797e04c189494ff3b9677db0c_I20190204" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RleHRyZWdpb246MGRkY2MwZmFlMjM3NGNmNTljNWM4MzA4Y2NkYWIyMjhfNDc4_bcecf6e0-cfb7-4e8f-9ae4-2188147716c1">550.0</ix:nonFraction> million Revolving Credit Facility under the Credit Agreement and a term loan facility with a principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="iffa33294d8f04f04b0db89e59138db4a_I20190204" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RleHRyZWdpb246MGRkY2MwZmFlMjM3NGNmNTljNWM4MzA4Y2NkYWIyMjhfNTky_b5962d0e-b335-49d8-9d1f-2406e022078b">175.0</ix:nonFraction> million (the "Term Loan Facility" and collectively with the Revolving Credit Facility, the "Credit Facility"), which was added by the First Amendment.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We borrowed the entire principal amount of the Term Loan Facility on February&#160;4, 2019 in order to fund a portion of the purchase price of the Compassionate Care Hospice ("CCH") acquisition, with the remainder of the purchase price and associated transactional fees and expenses funded by proceeds from the Revolving Credit Facility. </span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The loans issued under the Credit Facility bear interest on a per annum basis, at our election, at either: (i) the Base Rate plus the Applicable Rate or (ii) the Eurodollar Rate plus the Applicable Rate. The &#8220;Base Rate&#8221; means a fluctuating rate per annum equal to the highest of (a) the federal funds rate plus <ix:nonFraction unitRef="number" contextRef="i71126d46462944a9aee1ee7aef720bee_D20190204-20190204" decimals="INF" name="amed:DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RleHRyZWdpb246MGRkY2MwZmFlMjM3NGNmNTljNWM4MzA4Y2NkYWIyMjhfMTM1NA_ff5244c5-d1ff-4174-ab00-5b62b93fd6f4">0.50</ix:nonFraction>% per annum, (b) the prime rate of interest established by the Administrative Agent, and (c) the Eurodollar Rate plus <ix:nonFraction unitRef="number" contextRef="i71126d46462944a9aee1ee7aef720bee_D20190204-20190204" decimals="INF" name="amed:DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RleHRyZWdpb246MGRkY2MwZmFlMjM3NGNmNTljNWM4MzA4Y2NkYWIyMjhfMTQ3Mw_0ea23ee2-eb5d-497d-b59d-196f9c0d966c">1</ix:nonFraction>% per annum. The &#8220;Eurodollar Rate&#8221; means the quoted rate per annum equal to the London Interbank Offered Rate (&#8220;LIBOR&#8221;) or a comparable successor rate approved by the Administrative Agent for an interest period of one, two, three or six months (as selected by us). The &#8220;Applicable Rate&#8221; is based on the consolidated leverage ratio and is presented in the table below. As of March&#160;31, 2020, the Applicable Rate is <ix:nonFraction unitRef="number" contextRef="ie8766fbac86e4b5a80af143791d0f409_D20200101-20200331" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RleHRyZWdpb246MGRkY2MwZmFlMjM3NGNmNTljNWM4MzA4Y2NkYWIyMjhfMTg3NQ_615ae31b-9f20-4a0a-86a2-9743d400b76d">0.50</ix:nonFraction>% per annum for Base Rate loans and <ix:nonFraction unitRef="number" contextRef="i6d6002c5f99d4721838ee0060efd407b_D20200101-20200331" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RleHRyZWdpb246MGRkY2MwZmFlMjM3NGNmNTljNWM4MzA4Y2NkYWIyMjhfMTkxMg_660f9962-1c0e-4601-8029-b61e5aa0f4bb">1.50</ix:nonFraction>% per annum for Eurodollar Rate loans. <ix:nonNumeric contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" name="us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RleHRyZWdpb246MGRkY2MwZmFlMjM3NGNmNTljNWM4MzA4Y2NkYWIyMjhfNjgxOQ_029d796f-0569-4235-bed0-4fc5b3a8f1de" continuedAt="if33a5d91f16841fca1af70c6a1d18749" escape="true">We are also subject to a commitment fee and letter of credit fee under the terms of the Amended Credit Agreement, as presented in the table below.</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><ix:continuation id="if33a5d91f16841fca1af70c6a1d18749"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:92.251%;"><tr><td style="width:1.0%;"></td><td style="width:9.251%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:25.258%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:15.908%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.836%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:15.908%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.839%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pricing Tier</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Consolidated Leverage Ratio</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commitment Fee</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Letter of Credit Fee</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Eurodollar Rate Loans</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Base Rate Loans</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">I</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#8805; <ix:nonFraction unitRef="number" contextRef="i116335fec8a8410395d5970ead81815b_D20200101-20200331" decimals="INF" name="amed:ConsolidatedLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjgzMjA1ZTZkOGQ3ZDRiYjY4ZTAxODU0ZjJkZGIzYWViL3RhYmxlcmFuZ2U6ODMyMDVlNmQ4ZDdkNGJiNjhlMDE4NTRmMmRkYjNhZWJfMS0xLTEtMS0zOTY2L3RleHRyZWdpb246NTMzOTAwZTYwZjRhNGY2NmJkNjNlODczODZkOTcwNDRfMTY0OTI2NzQ0MTY4NQ_02a9f915-14be-4af8-b34e-ee9470b43790">3.00</ix:nonFraction> to 1.0</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i4d3ef9b25fd64694a1f379a432f9bb62_D20200101-20200331" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjgzMjA1ZTZkOGQ3ZDRiYjY4ZTAxODU0ZjJkZGIzYWViL3RhYmxlcmFuZ2U6ODMyMDVlNmQ4ZDdkNGJiNjhlMDE4NTRmMmRkYjNhZWJfMS0yLTEtMS0w_629f3c09-5c84-472c-b161-d419b111f7af">0.35</ix:nonFraction>%</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i4d3ef9b25fd64694a1f379a432f9bb62_D20200101-20200331" decimals="INF" name="amed:LetterOfCreditFee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjgzMjA1ZTZkOGQ3ZDRiYjY4ZTAxODU0ZjJkZGIzYWViL3RhYmxlcmFuZ2U6ODMyMDVlNmQ4ZDdkNGJiNjhlMDE4NTRmMmRkYjNhZWJfMS0zLTEtMS0w_089171a9-a73c-46d3-888a-6d67e2ba47a7">1.75</ix:nonFraction>%</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i03234fef29e642489ae4417c7674ca60_D20200101-20200331" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjgzMjA1ZTZkOGQ3ZDRiYjY4ZTAxODU0ZjJkZGIzYWViL3RhYmxlcmFuZ2U6ODMyMDVlNmQ4ZDdkNGJiNjhlMDE4NTRmMmRkYjNhZWJfMS00LTEtMS0w_344d43eb-e77e-41ed-9656-9c47c20006af">2.00</ix:nonFraction>%</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i2c19ce09b115491883ac15a09c9fce6d_D20200101-20200331" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjgzMjA1ZTZkOGQ3ZDRiYjY4ZTAxODU0ZjJkZGIzYWViL3RhYmxlcmFuZ2U6ODMyMDVlNmQ4ZDdkNGJiNjhlMDE4NTRmMmRkYjNhZWJfMS01LTEtMS0w_c6d9a229-7a7b-4c78-a48a-f3662310b1c0">1.00</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">II</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&lt; <ix:nonFraction unitRef="number" contextRef="i262c9a55a12d4a2e82c1e6f3a19cf70f_D20200101-20200331" decimals="INF" name="amed:ConsolidatedLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjgzMjA1ZTZkOGQ3ZDRiYjY4ZTAxODU0ZjJkZGIzYWViL3RhYmxlcmFuZ2U6ODMyMDVlNmQ4ZDdkNGJiNjhlMDE4NTRmMmRkYjNhZWJfMi0xLTEtMS0zOTcwL3RleHRyZWdpb246MTM3OTRiMzg2YWE4NDA0MjkyMDY1MjZhZmQ2MzI3OTVfMTY0OTI2NzQ0MTcwMw_0bd68f00-8089-4139-9faa-e3ec63b3c90b">3.00</ix:nonFraction> to 1.0 but &#8805; <ix:nonFraction unitRef="number" contextRef="ie32195fe339a4436b4904c56998424fb_D20200101-20200331" decimals="INF" name="amed:ConsolidatedLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjgzMjA1ZTZkOGQ3ZDRiYjY4ZTAxODU0ZjJkZGIzYWViL3RhYmxlcmFuZ2U6ODMyMDVlNmQ4ZDdkNGJiNjhlMDE4NTRmMmRkYjNhZWJfMi0xLTEtMS0zOTcwL3RleHRyZWdpb246MTM3OTRiMzg2YWE4NDA0MjkyMDY1MjZhZmQ2MzI3OTVfMTY0OTI2NzQ0MTcwOQ_7965318b-4b57-410e-b084-1e5748138cad">2.00</ix:nonFraction> to 1.0</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ie3e4c94018794c938917b5e4762bb3a3_D20200101-20200331" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjgzMjA1ZTZkOGQ3ZDRiYjY4ZTAxODU0ZjJkZGIzYWViL3RhYmxlcmFuZ2U6ODMyMDVlNmQ4ZDdkNGJiNjhlMDE4NTRmMmRkYjNhZWJfMi0yLTEtMS0w_a992615f-3e2d-4c37-b3b6-df5ea71bb4e3">0.30</ix:nonFraction>%</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ie3e4c94018794c938917b5e4762bb3a3_D20200101-20200331" decimals="INF" name="amed:LetterOfCreditFee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjgzMjA1ZTZkOGQ3ZDRiYjY4ZTAxODU0ZjJkZGIzYWViL3RhYmxlcmFuZ2U6ODMyMDVlNmQ4ZDdkNGJiNjhlMDE4NTRmMmRkYjNhZWJfMi0zLTEtMS0w_c9da63fe-4952-4b68-a5c7-db35901b554b">1.50</ix:nonFraction>%</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="id274d4e6f62045c8b0313e71c808f7a0_D20200101-20200331" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjgzMjA1ZTZkOGQ3ZDRiYjY4ZTAxODU0ZjJkZGIzYWViL3RhYmxlcmFuZ2U6ODMyMDVlNmQ4ZDdkNGJiNjhlMDE4NTRmMmRkYjNhZWJfMi00LTEtMS0w_ac0a3835-d2a9-4c16-8128-675ccf131347">1.75</ix:nonFraction>%</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ib3424d73450945acbfb6662c2947d02c_D20200101-20200331" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjgzMjA1ZTZkOGQ3ZDRiYjY4ZTAxODU0ZjJkZGIzYWViL3RhYmxlcmFuZ2U6ODMyMDVlNmQ4ZDdkNGJiNjhlMDE4NTRmMmRkYjNhZWJfMi01LTEtMS0w_3b6375fc-bb42-4866-ba4f-5d51a0544e24">0.75</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">III</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&lt; <ix:nonFraction unitRef="number" contextRef="i587391f59a70479592d057ca4817c53d_D20200101-20200331" decimals="INF" name="amed:ConsolidatedLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjgzMjA1ZTZkOGQ3ZDRiYjY4ZTAxODU0ZjJkZGIzYWViL3RhYmxlcmFuZ2U6ODMyMDVlNmQ4ZDdkNGJiNjhlMDE4NTRmMmRkYjNhZWJfMy0xLTEtMS0zOTczL3RleHRyZWdpb246YTcxNTZhZjgwNDIwNDc2MmE4M2FlN2FjMTYxZjkyODRfMTY0OTI2NzQ0MTcwMw_64b76683-9c41-443f-a6e1-d1b02bd6dbcd">2.00</ix:nonFraction> to 1.0 but &#8805; <ix:nonFraction unitRef="number" contextRef="i10e7017e38964ada930ea223919b92d6_D20200101-20200331" decimals="INF" name="amed:ConsolidatedLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjgzMjA1ZTZkOGQ3ZDRiYjY4ZTAxODU0ZjJkZGIzYWViL3RhYmxlcmFuZ2U6ODMyMDVlNmQ4ZDdkNGJiNjhlMDE4NTRmMmRkYjNhZWJfMy0xLTEtMS0zOTczL3RleHRyZWdpb246YTcxNTZhZjgwNDIwNDc2MmE4M2FlN2FjMTYxZjkyODRfMTY0OTI2NzQ0MTcwOQ_91204738-93df-46fb-8d6a-b8d48702691c">0.75</ix:nonFraction> to 1.0</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i40aeb3bc9f044ec2948f550127151c2f_D20200101-20200331" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjgzMjA1ZTZkOGQ3ZDRiYjY4ZTAxODU0ZjJkZGIzYWViL3RhYmxlcmFuZ2U6ODMyMDVlNmQ4ZDdkNGJiNjhlMDE4NTRmMmRkYjNhZWJfMy0yLTEtMS0w_652215b5-2c4f-4b10-810e-f6fc465ec536">0.25</ix:nonFraction>%</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i40aeb3bc9f044ec2948f550127151c2f_D20200101-20200331" decimals="INF" name="amed:LetterOfCreditFee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjgzMjA1ZTZkOGQ3ZDRiYjY4ZTAxODU0ZjJkZGIzYWViL3RhYmxlcmFuZ2U6ODMyMDVlNmQ4ZDdkNGJiNjhlMDE4NTRmMmRkYjNhZWJfMy0zLTEtMS0w_cda98606-c4ea-4b9e-bfca-8c9323265352">1.25</ix:nonFraction>%</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i12d7c31ad0e442449db03a43e8ee94b2_D20200101-20200331" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjgzMjA1ZTZkOGQ3ZDRiYjY4ZTAxODU0ZjJkZGIzYWViL3RhYmxlcmFuZ2U6ODMyMDVlNmQ4ZDdkNGJiNjhlMDE4NTRmMmRkYjNhZWJfMy00LTEtMS0w_ed733292-6b48-4b34-bf50-7e4a1007a4bf">1.50</ix:nonFraction>%</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i88e1a49559cf4832bf8d22eb47cac167_D20200101-20200331" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjgzMjA1ZTZkOGQ3ZDRiYjY4ZTAxODU0ZjJkZGIzYWViL3RhYmxlcmFuZ2U6ODMyMDVlNmQ4ZDdkNGJiNjhlMDE4NTRmMmRkYjNhZWJfMy01LTEtMS0w_14bba858-f0a4-4ad4-b0ae-bf01181080dd">0.50</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">IV</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&lt; <ix:nonFraction unitRef="number" contextRef="ic343676840f04990b1419f15ad513197_D20200101-20200331" decimals="INF" name="amed:ConsolidatedLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjgzMjA1ZTZkOGQ3ZDRiYjY4ZTAxODU0ZjJkZGIzYWViL3RhYmxlcmFuZ2U6ODMyMDVlNmQ4ZDdkNGJiNjhlMDE4NTRmMmRkYjNhZWJfNC0xLTEtMS0zOTc2L3RleHRyZWdpb246ODBkMDc0YTQzNTM0NDhlNzk4ODlmMzYxZWY1YTMzMzRfMTY0OTI2NzQ0MTY4NQ_879b181d-f215-4e86-9745-b26351588768">0.75</ix:nonFraction> to 1.0</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i01dd577fcaf548d1bf70b0a704312472_D20200101-20200331" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjgzMjA1ZTZkOGQ3ZDRiYjY4ZTAxODU0ZjJkZGIzYWViL3RhYmxlcmFuZ2U6ODMyMDVlNmQ4ZDdkNGJiNjhlMDE4NTRmMmRkYjNhZWJfNC0yLTEtMS0w_3ad53fbf-3159-4c71-9d39-19916a0b5be4">0.20</ix:nonFraction>%</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i01dd577fcaf548d1bf70b0a704312472_D20200101-20200331" decimals="INF" name="amed:LetterOfCreditFee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjgzMjA1ZTZkOGQ3ZDRiYjY4ZTAxODU0ZjJkZGIzYWViL3RhYmxlcmFuZ2U6ODMyMDVlNmQ4ZDdkNGJiNjhlMDE4NTRmMmRkYjNhZWJfNC0zLTEtMS0w_5450493f-f1ee-4b80-bcc8-199b097f286d">1.00</ix:nonFraction>%</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i01f445fe93c14d05abd4461abdf8ac06_D20200101-20200331" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjgzMjA1ZTZkOGQ3ZDRiYjY4ZTAxODU0ZjJkZGIzYWViL3RhYmxlcmFuZ2U6ODMyMDVlNmQ4ZDdkNGJiNjhlMDE4NTRmMmRkYjNhZWJfNC00LTEtMS0w_6ff4612d-65d3-4039-8341-aec207f68c90">1.25</ix:nonFraction>%</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i2aa959b6fa504afaa53549e81bde7718_D20200101-20200331" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjgzMjA1ZTZkOGQ3ZDRiYjY4ZTAxODU0ZjJkZGIzYWViL3RhYmxlcmFuZ2U6ODMyMDVlNmQ4ZDdkNGJiNjhlMDE4NTRmMmRkYjNhZWJfNC01LTEtMS0w_fc25e76f-0df0-4eec-b854-b6ee025f0e10">0.25</ix:nonFraction>%</span></td></tr></table></ix:continuation></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The final maturity date of the Credit Facility is <ix:nonNumeric contextRef="i71126d46462944a9aee1ee7aef720bee_D20190204-20190204" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RleHRyZWdpb246MGRkY2MwZmFlMjM3NGNmNTljNWM4MzA4Y2NkYWIyMjhfMjE1Mw_f7b60ca4-220b-4081-8bc9-18d77fe37edc">February 4, 2024</ix:nonNumeric>. The Revolving Credit Facility will terminate and be due and payable as of the final maturity date. The Term Loan Facility, however, is subject to quarterly amortization of principal in the amount of (i) <ix:nonFraction unitRef="number" contextRef="i52efcfba53a641308fa077db50f1031f_D20190204-20200331" decimals="INF" name="amed:DebtInstrumentPeriodicPaymentPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RleHRyZWdpb246MGRkY2MwZmFlMjM3NGNmNTljNWM4MzA4Y2NkYWIyMjhfMjM2MA_30efe89f-9293-4c69-b384-0f11551f761e">0.625</ix:nonFraction>% for the period commencing on February 4, 2019 and ending on March 31, 2020, (ii) <ix:nonFraction unitRef="number" contextRef="i0ee8f60caeec4edeb0fa06f3891d0fcf_D20200401-20230331" decimals="INF" name="amed:DebtInstrumentPeriodicPaymentPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RleHRyZWdpb246MGRkY2MwZmFlMjM3NGNmNTljNWM4MzA4Y2NkYWIyMjhfMjQ0NA_b0d8a79f-e974-4ff3-bf54-8954c94567e6">1.250</ix:nonFraction>% for the period commencing on April 1, 2020 and ending on March 31, 2023, and (iii) <ix:nonFraction unitRef="number" contextRef="i9c02e2cca97c41ee89b6417d85253d91_D20230401-20240204" decimals="INF" name="amed:DebtInstrumentPeriodicPaymentPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RleHRyZWdpb246MGRkY2MwZmFlMjM3NGNmNTljNWM4MzA4Y2NkYWIyMjhfMjUzMA_935c5584-c399-4ba7-9e07-de79d3b1c017">1.875</ix:nonFraction>% for the period commencing on April 1, 2023 and ending on February 4, 2024. The remaining balance of the Term Loan Facility must be paid upon the final maturity date. In addition to the scheduled amortization of the Term Loan Facility, and subject to customary exceptions and reinvestment rights, we are required to prepay the Term Loan Facility, first, and the Revolving Credit Facility, second, with 100% of all net cash proceeds received by any loan party or any subsidiary thereof in connection with (a) any asset sale or disposition where such loan party receives net cash proceeds in excess of $<ix:nonFraction unitRef="usd" contextRef="ia85dd0cda56f46d88648f67dd3c62846_D20190204-20190204" decimals="-6" format="ixt:numdotdecimal" name="amed:ProceedsReceivedFromLoanPartyOfSubsidiary" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RleHRyZWdpb246MGRkY2MwZmFlMjM3NGNmNTljNWM4MzA4Y2NkYWIyMjhfMzEzMg_1d71b609-469a-4c78-9876-1d61ea6f7b55">5</ix:nonFraction> million or (b) any debt issuance that is not permitted under the Amended Credit Agreement.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Amended Credit Agreement requires maintenance of two financial covenants: (i) a consolidated leverage ratio of funded indebtedness to Earnings Before Interest, Taxes, Depreciation and Amortization ("EBITDA"), as defined in the Amended Credit Agreement, and (ii) a consolidated interest coverage ratio of EBITDA to cash interest charges, as defined in the Amended Credit Agreement. Each of these covenants is calculated over rolling four-quarter periods and also is subject to certain exceptions and baskets. The Amended Credit Agreement also contains customary covenants, including, but not limited to, restrictions on: incurrence of liens, incurrence of additional debt, sales of assets and other fundamental corporate changes, investments, and declarations of dividends. These covenants contain customary exclusions and baskets as detailed in the Amended Credit Agreement. In connection with our entry into the Amended Credit Agreement, we recorded $0.8 million in deferred debt issuance costs as long-term obligations, less current portion within our condensed consolidated balance sheet during the year ended December 31, 2019.</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Revolving Credit Facility is guaranteed by substantially all of our wholly-owned direct and indirect subsidiaries. The Amended Credit Agreement requires at all times that we (i) provide guarantees from wholly-owned subsidiaries that in the </span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">15</span></div></div></div><hr style="page-break-after:always"/><div style="height:81pt;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div></div><ix:continuation id="ieb3da3871aca454d9291ac6633667c09"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">aggregate represent not less than <ix:nonFraction unitRef="number" contextRef="i71126d46462944a9aee1ee7aef720bee_D20190204-20190204" decimals="INF" name="amed:PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RleHRyZWdpb246MGRkY2MwZmFlMjM3NGNmNTljNWM4MzA4Y2NkYWIyMjhfNDU3MQ_6b0790c8-49cd-4e0a-8e75-8fa6071ad95e">95</ix:nonFraction>% of our consolidated net revenues and adjusted EBITDA from all wholly-owned subsidiaries and (ii) provide guarantees from subsidiaries that in the aggregate represent not less than <ix:nonFraction unitRef="number" contextRef="i71126d46462944a9aee1ee7aef720bee_D20190204-20190204" decimals="INF" name="amed:PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RleHRyZWdpb246MGRkY2MwZmFlMjM3NGNmNTljNWM4MzA4Y2NkYWIyMjhfNDc1NA_927f41b7-01f1-4a69-b6a6-317b5727fab7">70</ix:nonFraction>% of consolidated adjusted EBITDA, subject to certain exceptions.</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our weighted average interest rate for borrowings under our $<ix:nonFraction unitRef="usd" contextRef="i0ff90663d1684cb09b78cf9c7fde47b7_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RleHRyZWdpb246MGRkY2MwZmFlMjM3NGNmNTljNWM4MzA4Y2NkYWIyMjhfNDg4Mg_8b6e0c34-c598-4aa3-a9b9-56598fafad65">550.0</ix:nonFraction> million Revolving Credit Facility was <ix:nonFraction unitRef="number" contextRef="if270e80806534123864832e895591246_D20200101-20200331" decimals="3" name="us-gaap:LongTermDebtWeightedAverageInterestRateOverTime" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RleHRyZWdpb246MGRkY2MwZmFlMjM3NGNmNTljNWM4MzA4Y2NkYWIyMjhfNDkxNQ_07ef981d-8a38-428d-a0b8-d7e1cedeaa29">3.2</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ia9def8d782364ec6a243d4e1839a987f_D20190101-20190331" decimals="3" name="us-gaap:LongTermDebtWeightedAverageInterestRateOverTime" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RleHRyZWdpb246MGRkY2MwZmFlMjM3NGNmNTljNWM4MzA4Y2NkYWIyMjhfNDkyMg_995c7cb9-1048-4cc1-a515-f793811eee6d">4.2</ix:nonFraction>% for the three-month periods ended March&#160;31, 2020 and March 31, 2019, respectively. Our weighted average interest rate for borrowings under our $<ix:nonFraction unitRef="usd" contextRef="ic735d35014784f0395b22a1d4852e2bb_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RleHRyZWdpb246MGRkY2MwZmFlMjM3NGNmNTljNWM4MzA4Y2NkYWIyMjhfNTA0Ng_a407b8f9-d550-4f9f-b5ab-9115acfa0461">175.0</ix:nonFraction> million Term Loan Facility was <ix:nonFraction unitRef="number" contextRef="i8ba21eb95e2e43d1b0a24756aec8f4e8_D20200101-20200331" decimals="3" name="us-gaap:LongTermDebtWeightedAverageInterestRateOverTime" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RleHRyZWdpb246MGRkY2MwZmFlMjM3NGNmNTljNWM4MzA4Y2NkYWIyMjhfNTA3Mg_bce5a4eb-324d-4353-b1e7-476a2107dfca">3.2</ix:nonFraction>% for the three-month period ended March&#160;31, 2020 and <ix:nonFraction unitRef="number" contextRef="ia378c7f5c8aa4e24951f6ef187aefeb4_D20190204-20190331" decimals="3" name="us-gaap:LongTermDebtWeightedAverageInterestRateOverTime" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RleHRyZWdpb246MGRkY2MwZmFlMjM3NGNmNTljNWM4MzA4Y2NkYWIyMjhfNTA3OQ_366ac8e5-78e9-47ba-8490-f863b0292e23">4.2</ix:nonFraction>% for the period February 4, 2019 to March 31, 2019.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March&#160;31, 2020, our consolidated leverage ratio was <ix:nonFraction unitRef="number" contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331" decimals="INF" name="amed:TotalLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RleHRyZWdpb246MGRkY2MwZmFlMjM3NGNmNTljNWM4MzA4Y2NkYWIyMjhfNTIyMQ_8be456cb-e7a6-43a3-938f-3f422252ed9b">1.5</ix:nonFraction>, our consolidated interest coverage ratio was <ix:nonFraction unitRef="number" contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331" decimals="INF" name="amed:ConsolidatedInterestCoverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RleHRyZWdpb246MGRkY2MwZmFlMjM3NGNmNTljNWM4MzA4Y2NkYWIyMjhfNTI3MA_02efa594-5766-40c6-a888-c88ef50d8945">16.6</ix:nonFraction> and we are in compliance with our covenants under the Amended Credit Agreement. In the event we are not in compliance with our debt covenants in the future, we would pursue various alternatives in an attempt to successfully resolve the non-compliance, which might include, among other things, seeking debt covenant waivers or amendments.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March&#160;31, 2020, our availability under our $<ix:nonFraction unitRef="usd" contextRef="i0ff90663d1684cb09b78cf9c7fde47b7_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RleHRyZWdpb246MGRkY2MwZmFlMjM3NGNmNTljNWM4MzA4Y2NkYWIyMjhfNTY0OA_0a608e90-1a71-44c1-8a3a-16d371d62c47">550.0</ix:nonFraction> million Revolving Credit Facility was $<ix:nonFraction unitRef="usd" contextRef="i0ff90663d1684cb09b78cf9c7fde47b7_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RleHRyZWdpb246MGRkY2MwZmFlMjM3NGNmNTljNWM4MzA4Y2NkYWIyMjhfNTY4MQ_19558b16-035b-4839-989a-cf07110d238e">299.8</ix:nonFraction> million as we have $<ix:nonFraction unitRef="usd" contextRef="i0ff90663d1684cb09b78cf9c7fde47b7_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RleHRyZWdpb246MGRkY2MwZmFlMjM3NGNmNTljNWM4MzA4Y2NkYWIyMjhfNTY5NQ_3b931d69-aebb-4eb7-a933-e13090da2e33">220.0</ix:nonFraction> million outstanding in borrowings and $<ix:nonFraction unitRef="usd" contextRef="ib409845529d94d28bc9b375ca272bc7d_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LettersOfCreditOutstandingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RleHRyZWdpb246MGRkY2MwZmFlMjM3NGNmNTljNWM4MzA4Y2NkYWIyMjhfNTcyOA_e37339ab-8a0a-48f1-a2c8-34e8ec65601c">30.2</ix:nonFraction> million outstanding in letters of credit.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Joinder Agreement</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the CCH acquisition, we entered into a Joinder Agreement, dated as of February 4, 2019, pursuant to which CCH and its subsidiaries were made parties to, and became subject to the terms and conditions of, the Amended Credit Agreement, the Amended and Restated Security Agreement, dated as of June 29, 2018, and the Amended and Restated Pledge Agreement, dated as of June 29, 2018. Pursuant to the Joinder, the Amended and Restated Security Agreement and the Amended and Restated Pledge Agreement, CCH and its subsidiaries granted in favor of the Administrative Agent a first lien security interest in substantially all of their personal property assets and pledged to the Administrative Agent each of their respective subsidiaries' issued and outstanding equity interests. CCH and its subsidiaries also guaranteed our obligations, whether now existing or arising after the effective date of the Joinder, under the Amended Credit Agreement pursuant to the terms of the Joinder and the Amended Credit Agreement.</span></div></ix:continuation><div id="i793e68cdccb44b98a73aef6e33f497bf_67"></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">5. <ix:nonNumeric contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfMTM3NDU_9420758b-d494-40ba-870e-7c2693c8f656" continuedAt="i43e5bd7e7fe54470a8e59cddfb6b4d08" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="i43e5bd7e7fe54470a8e59cddfb6b4d08" continuedAt="i1295b41745ed46a8b0c8369287083846"><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Legal Proceedings - Ongoing</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are involved in the following legal actions:</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Subpoena Duces Tecum and Civil Investigative Demands Issued by the U.S. Department of Justice</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On May&#160;21, 2015, we received a Subpoena Duces Tecum (&#8220;Subpoena&#8221;) issued by the U.S. Department of Justice. The Subpoena requests the delivery of information regarding <ix:nonFraction unitRef="patient" contextRef="i3a33f09f3173490fa79c2009fa38ee93_D20150521-20150521" decimals="INF" name="amed:Numberofpatients" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfMzc2_0e741bf0-6f82-48d2-838c-8a7217e696b5">53</ix:nonFraction> identified hospice patients to the United States Attorney&#8217;s Office for the District of Massachusetts. It also requests the delivery of documents relating to our hospice clinical and business operations and related compliance activities. The Subpoena generally covers the period from January&#160;1, 2011 through May&#160;21, 2015. We are fully cooperating with the U.S. Department of Justice with respect to this investigation. </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On November&#160;3, 2015, we received a civil investigative demand (&#8220;CID&#8221;) issued by the U.S. Department of Justice pursuant to the federal False Claims Act relating to claims submitted to Medicare and/or Medicaid for hospice services provided through designated facilities in the Morgantown, West Virginia area. The CID requests the delivery of information to the United States Attorney&#8217;s Office for the Northern District of West Virginia regarding <ix:nonFraction unitRef="patient" contextRef="idb70013011f74758ae2ef2a1a0de32c1_D20151103-20151103" decimals="INF" name="amed:Numberofpatients" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfMTI0Mw_f244caf3-fe46-4cce-ac33-a6eeb9035323">66</ix:nonFraction> identified hospice patients, as well as documents relating to our hospice clinical and business operations in the Morgantown area. The CID generally covers the period from January&#160;1, 2009 through August 31, 2015. We are fully cooperating with the U.S. Department of Justice with respect to this investigation. </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On June&#160;27, 2016, we received a CID issued by the U.S. Department of Justice pursuant to the federal False Claims Act relating to claims submitted to Medicare and/or Medicaid for hospice services provided through designated facilities in the Parkersburg, West Virginia area. The CID requests the delivery of information to the United States Attorney&#8217;s Office for the Southern District of West Virginia regarding <ix:nonFraction unitRef="patient" contextRef="i301ee02ef1954d139674e96cc1e9ee1b_D20160627-20160627" decimals="INF" name="amed:Numberofpatients" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfMTk3MQ_26118482-64b3-47ea-bdca-36d66a2f4e50">68</ix:nonFraction> identified hospice patients, as well as documents relating to our hospice clinical and business operations in the Parkersburg area. The CID generally covers the period from January&#160;1, 2011 through June&#160;20, 2016. We are fully cooperating with the U.S. Department of Justice with respect to this investigation. </span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">16</span></div></div></div><hr style="page-break-after:always"/><div style="height:81pt;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div></div><ix:continuation id="i1295b41745ed46a8b0c8369287083846" continuedAt="ib34af6a441fa4bb6804b455199bc280a"><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Based on our analysis of sample claims data in connection with preliminary settlement discussions with the U.S. Department of Justice regarding the above matters, we have recorded a total of $<ix:nonFraction unitRef="usd" contextRef="ia37b8daa112347b8876c86941748cb37_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfMjQ3NQ_8f650946-7322-4add-ab62-3190aec06d30">6.5</ix:nonFraction> million to accrued expenses in our condensed consolidated balance sheet related to this matter. Due to the ongoing nature of the investigations and current stage of the settlement discussions, we are unable to estimate a range of potential loss at this time, and we cannot predict the timing or outcome of these investigations.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition to the matters referenced in this note, we are involved in legal actions in the normal course of business, some of which seek monetary damages, including claims for punitive damages. We do not believe that these normal course actions, when finally concluded and determined, will have a material impact on our consolidated financial condition, results of operations or cash flows.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Legal fees related to all legal matters are expensed as incurred.</span></div><div style="text-align:justify;margin-top:16pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other Investigative Matters - Ongoing</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Compassionate Care Hospice Corporate Integrity Agreement</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On January 30, 2015, CCH entered into a corporate integrity agreement ("CIA") with the Office of Inspector General-HHS (&#8220;OIG&#8221;). The CIA required that CCH provide annual on-site compliance training; develop and implement policies to ensure compliance with federal health care program requirements; screen new and current employees to ensure that they are eligible to participate in federal health care programs;&#160;establish a compliance committee that contains both a Compliance Officer and a&#160;Chief Quality Officer; retain a Governing Authority expert who will periodically complete a compliance program review; and retain an independent review organization ("IRO") to complete claims reviews for hospice services rendered in New York. The OIG waived the claims review for the final year of the CCH CIA based on the closure of the New York operations. Additionally, the CIA required that CCH report substantial overpayments that CCH discovered it had received from federal health care programs, as well as probable violations of federal criminal, civil or administrative health care laws. Upon breach of the CIA, CCH could have become liable for payment of certain stipulated penalties, or could have been excluded from participation in federal health care programs. The CIA had a term of <ix:nonNumeric contextRef="i039c0407f0b846cab386767ba04caf96_D20150130-20150130" format="ixt-sec:durwordsen" name="amed:CorporateIntegrityAgreementTerm" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfNjIxNw_35288dc5-2915-496e-b5f0-8e631e2649f3">five years</ix:nonNumeric> that ended on January 30, 2020. We filed our final annual report on March 25, 2020.</span></div><div style="text-align:justify;margin-top:16pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other Investigative Matters - Completed</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Corporate Integrity Agreement</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On April&#160;23, 2014, with no admissions of liability on our part, we entered into a settlement agreement with the U.S. Department of Justice relating to certain of our clinical and business operations. Concurrently with our entry into this agreement, we entered into a CIA with the OIG. The CIA formalized various aspects of our already existing ethics and compliance programs and contained other requirements designed to help ensure our ongoing compliance with federal health care program requirements. Among other things, the CIA required us to maintain our existing compliance program, executive compliance committee and compliance committee of the Board of Directors; provide certain compliance training; continue screening new and current employees to ensure they are eligible to participate in federal health care programs; engage an IRO to perform certain auditing and reviews and prepare certain reports regarding our compliance with federal health care programs, our billing submissions to federal health care programs and our compliance and risk mitigation programs; and provide certain reports and management certifications to the OIG. Additionally, the CIA specifically required that we report substantial overpayments that we discovered we had received from federal health care programs, as well as probable violations of federal health care laws. The corporate integrity agreement had a term of <ix:nonNumeric contextRef="ibfe6dd3be0b34aeba5d1341e4d23edbe_D20140423-20140423" format="ixt-sec:durwordsen" name="amed:CorporateIntegrityAgreementTerm" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfMTY0OTI2NzQ2NjExNw_b2a19f5d-8504-454b-8297-62acb8877806">five years</ix:nonNumeric> that ended on April 21, 2019. We filed our final annual report on July 19, 2019. On May 5, 2020, the Company received notice from the OIG that the Company's five-year CIA with the OIG has been completed. </span></div><div style="text-align:justify;margin-top:16pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Third Party Audits - Ongoing</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">From time to time, in the ordinary course of business, we are subject to audits under various governmental programs including Recovery Audit Contractors (&#8220;RACs&#8221;), Zone Program Integrity Contractors (&#8220;ZPICs&#8221;), Uniform Program Integrity Contractors ("UPICs"), Program Safeguard Contractors (&#8220;PSCs&#8221;) and Medicaid Integrity Contributors (&#8220;MICs&#8221;) in which third party firms engaged by CMS conduct extensive reviews of claims data to identify potential improper payments. We cannot predict the ultimate outcome of any regulatory reviews or other governmental audits and investigations.</span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">17</span></div></div></div><hr style="page-break-after:always"/><div style="height:81pt;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div></div><ix:continuation id="ib34af6a441fa4bb6804b455199bc280a" continuedAt="i71ac5a12f4b54476b2b105bd1f360c45"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In July 2010, our subsidiary that provides hospice services in Florence, South Carolina received from a ZPIC a request for records regarding a sample of <ix:nonFraction unitRef="beneficiary" contextRef="i563cd3af8c9d4df58214f2a851b9496f_D20080101-20100331" decimals="INF" name="amed:NumberOfBeneficiaries" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfNzA2OQ_df4c2522-c7dc-4132-bfe6-edae503377ea">30</ix:nonFraction> beneficiaries who received services from the subsidiary during the period of January&#160;1, 2008 through March&#160;31, 2010 (the &#8220;Review Period&#8221;) to determine whether the underlying services met pertinent Medicare payment requirements.&#160;We acquired the hospice operations subject to this review on August&#160;1, 2009; the Review Period covers time periods both before and after our ownership of these hospice operations.&#160;Based on the ZPIC&#8217;s findings for <ix:nonFraction unitRef="beneficiary" contextRef="i276fbb8a5a1041bba0699b8eaa7d329d_D20110606-20110606" decimals="INF" name="amed:NumberOfBeneficiaries" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfNzUxMw_7cc323ce-c1e8-430d-851b-523b11c22c6a">16</ix:nonFraction> beneficiaries, which were extrapolated to all claims for hospice services provided by the Florence subsidiary billed during the Review Period, on June&#160;6, 2011, the Medicare Administrative Contractor (&#8220;MAC&#8221;) for the subsidiary issued a notice of overpayment seeking recovery from our subsidiary of an alleged overpayment. We dispute these findings, and our Florence subsidiary has filed appeals through the Original Medicare Standard Appeals Process, in which we are seeking to have those findings overturned. An administrative law judge ("ALJ") hearing was held in early January 2015. On January&#160;18, 2016, we received a letter dated January&#160;6, 2016 referencing the ALJ hearing decision for the overpayment issued on June&#160;6, 2011. The decision was partially favorable with a new overpayment amount of $<ix:nonFraction unitRef="usd" contextRef="i2d397d49a7654cbabf31f8c0d4d869b8_I20160118" decimals="-5" format="ixt:numdotdecimal" name="amed:RecoveryAmountOfOverpaymentMadeToSubsidiary" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfODMxNg_e2ed2fb5-3537-4687-ab80-9d6514d9fee0">3.7</ix:nonFraction> million with a balance owed of $<ix:nonFraction unitRef="usd" contextRef="i2d397d49a7654cbabf31f8c0d4d869b8_I20160118" decimals="-5" format="ixt:numdotdecimal" name="amed:RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfODM0Mg_4c4e1fbc-505d-4b72-9861-beb21bbd101d">5.6</ix:nonFraction> million, including interest, based on <ix:nonFraction unitRef="claim" contextRef="i2968328e88e748f192feb97bbe016702_D20160118-20160118" decimals="INF" name="amed:NumberOfClaimsSubmittedBySubsidiary" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfODM3NQ_6f81ab25-e4ed-4121-97e1-4f2cd664cc42">9</ix:nonFraction> disputed claims (originally <ix:nonFraction unitRef="beneficiary" contextRef="i276fbb8a5a1041bba0699b8eaa7d329d_D20110606-20110606" decimals="INF" name="amed:NumberOfBeneficiaries" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfODQwNg_fd473ca8-75f5-451b-bd28-0899cb1304e8">16</ix:nonFraction>). We filed an appeal to the Medicare Appeals Council on the remaining <ix:nonFraction unitRef="claim" contextRef="i2968328e88e748f192feb97bbe016702_D20160118-20160118" decimals="INF" name="amed:NumberOfClaimsSubmittedBySubsidiary" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfODQ3OQ_b8f7d958-ffda-45d6-93f4-5e36ed17a9de">9</ix:nonFraction> disputed claims and also argued that the statistical method used to select the sample was not valid.&#160;No assurances can be given as to the timing or outcome of the Medicare Appeals Council decision. As of March&#160;31, 2020, Medicare has withheld payments of $<ix:nonFraction unitRef="usd" contextRef="i7b1a1c40b9524b08903a47b4db462e1e_I20200331" decimals="-5" format="ixt:numdotdecimal" name="amed:Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfODcyNA_9fdc09cd-5b84-46c1-9f69-957b52da4afd">5.7</ix:nonFraction> million (including additional interest) as part of their standard procedures once this level of the appeal process has been reached. In the event we are not able to recoup this alleged overpayment, we are entitled to be indemnified by the prior owners of the hospice operations for amounts relating to the period prior to August&#160;1, 2009. On January 10, 2019, an arbitration panel from the American Health Lawyers Association determined that the prior owners' liability for their indemnification obligation was $<ix:nonFraction unitRef="usd" contextRef="iaedb1c7adfc24c0e9954154d61af1ff0_I20190110" decimals="-5" format="ixt:numdotdecimal" name="amed:IndemnificationAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfOTIyOQ_52dde620-1379-4e1a-bc44-edad584d2057">2.8</ix:nonFraction> million. Accordingly, the Company reduced its indemnity receivable from $<ix:nonFraction unitRef="usd" contextRef="ifb12069843564cf694b4e3999c45bb5a_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LossContingencyReceivableNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfOTI5Ng_91cfa138-0721-4f1c-9c43-771c54b7420d">4.9</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="iaedb1c7adfc24c0e9954154d61af1ff0_I20190110" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LossContingencyReceivableNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfOTMwMg_9dcbbe88-d8a5-48d3-a825-d6d4c2043c0d">2.8</ix:nonFraction> million. </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In July 2016, the Company received a request for medical records from SafeGuard Services, L.L.C (&#8220;SafeGuard&#8221;), a ZPIC, related to services provided by some of the care centers that the Company acquired from Infinity Home Care, L.L.C. The review period covers time periods both before and after our ownership of the care centers, which were acquired on December&#160;31, 2015. In August 2017, the Company received Requests for Repayment from Palmetto GBA, LLC ("Palmetto") regarding Infinity Home Care of Lakeland, LLC ("Lakeland Care Centers") and Infinity Home Care of Pinellas, LLC ("Clearwater Care Center"). The Palmetto letters are based on a statistical extrapolation performed by SafeGuard which alleged an overpayment of $<ix:nonFraction unitRef="usd" contextRef="ia425738a537b4545a17322f5f6160d33_I20170831" decimals="-5" format="ixt:numdotdecimal" name="amed:RecoveryAmountOfOverpaymentMadeToSubsidiary" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfMTAzNDE_1b7995c1-cc55-4c44-b018-1f3342b2c84a">34.0</ix:nonFraction> million for the Lakeland Care Centers on a universe of <ix:nonFraction unitRef="claim" contextRef="ie0c2bead86ad4679b8c4aaddd217dfd0_D20170801-20170831" decimals="INF" name="amed:NumberOfClaimsSubmittedBySubsidiary" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfMTAzOTE_73f6d541-e214-41bd-b97b-3aaa1081ea96">72</ix:nonFraction> Medicare claims totaling $<ix:nonFraction unitRef="usd" contextRef="ia425738a537b4545a17322f5f6160d33_I20170831" decimals="-5" format="ixt:numdotdecimal" name="amed:ActualClaimsPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfMTA0MTk_14d70929-b683-4574-a1f7-c43e9540a2cb">0.2</ix:nonFraction> million in actual claims payments using a <ix:nonFraction unitRef="number" contextRef="ia425738a537b4545a17322f5f6160d33_I20170831" decimals="INF" name="amed:ErrorRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfMTA0NTY_31319b08-e711-40a8-99ba-247d11cd65ac">100</ix:nonFraction>% error rate and an overpayment of $<ix:nonFraction unitRef="usd" contextRef="i7fc8fa757ad24f1c8f989fa9c81c260f_I20170831" decimals="-5" format="ixt:numdotdecimal" name="amed:RecoveryAmountOfOverpaymentMadeToSubsidiary" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfMTA0OTI_4c00c500-3e98-4744-b1b2-bc958aa863c6">4.8</ix:nonFraction> million for the Clearwater Care Center on a universe of <ix:nonFraction unitRef="claim" contextRef="ibc4bbdf502e3446cbb7600c7178a92c3_D20170801-20170831" decimals="INF" name="amed:NumberOfClaimsSubmittedBySubsidiary" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfMTA1NDM_22c5dc57-2a59-4b62-a72e-7d7823a80707">70</ix:nonFraction> Medicare claims totaling $<ix:nonFraction unitRef="usd" contextRef="i7fc8fa757ad24f1c8f989fa9c81c260f_I20170831" decimals="-5" format="ixt:numdotdecimal" name="amed:ActualClaimsPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfMTA1NzE_742367f7-e4e1-45dc-a4d9-62fac1567634">0.2</ix:nonFraction> million in actual claims payments using a <ix:nonFraction unitRef="number" contextRef="i7fc8fa757ad24f1c8f989fa9c81c260f_I20170831" decimals="INF" name="amed:ErrorRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfMTA2MDg_e8b64add-9c75-450c-8974-6568645515bd">100</ix:nonFraction>% error rate.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Lakeland Request for Repayment covers claims between January 2, 2014 and September 13, 2016. The Clearwater Request for Repayment covers claims between January 2, 2015 and December 9, 2016. As a result of partially successful Level I and Level II Administrative Appeals, the alleged overpayment for the Lakeland Care Centers has been reduced to $<ix:nonFraction unitRef="usd" contextRef="i98f80d9f97ca4a82bc3965056f5fa3f3_I20200331" decimals="-5" format="ixt:numdotdecimal" name="amed:RecoveryAmountOfOverpaymentMadeToSubsidiary" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfMTA5NzI_67110ed4-c5ae-4b45-b63e-3535655f095b">26.0</ix:nonFraction> million and the alleged overpayment for the Clearwater Care Center has been reduced to $<ix:nonFraction unitRef="usd" contextRef="ie2fd0246a3884dbd98fb1fee55bbb120_I20200331" decimals="-5" format="ixt:numdotdecimal" name="amed:RecoveryAmountOfOverpaymentMadeToSubsidiary" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfMTEwNTQ_72a70048-570b-4eeb-a78c-7d538ec54500">3.3</ix:nonFraction> million. The Company has now filed Level III Administrative Appeals, and will continue to vigorously pursue its appeal rights, which include contesting the methodology used by the ZPIC contractor to perform statistical extrapolation. The Company is contractually entitled to indemnification by the prior owners for all claims prior to December 31, 2015, for up to $<ix:nonFraction unitRef="usd" contextRef="i935299f8f69f411d82a301973293010c_I20170831" decimals="-5" format="ixt:numdotdecimal" name="amed:IndemnificationAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfMTE0MTM_3d43b6b3-fe8f-4791-94ad-8c1dd62a1a94">12.6</ix:nonFraction> million.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At this stage of the review, based on the information currently available to the Company, the Company cannot predict the timing or outcome of this review. The Company estimates a low-end potential range of loss related to this review of $<ix:nonFraction unitRef="usd" contextRef="i4c556fa53fa14b20ae65e1dc18d8bc25_I20170831" decimals="-5" format="ixt:numdotdecimal" name="amed:RecoveryAmountOfOverpaymentMadeToSubsidiary" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfMTE2NTQ_b72d78a4-252d-4fb5-9747-165653363e93">6.5</ix:nonFraction> million (assuming the Company is successful in seeking indemnity from the prior owners and unsuccessful in demonstrating that the extrapolation method used by SafeGuard was erroneous). The Company has reduced its high-end potential range of loss from $<ix:nonFraction unitRef="usd" contextRef="i727d1a03a2854f0a8ab0f8f940d78506_I20170831" decimals="-5" format="ixt:numdotdecimal" name="amed:RecoveryAmountOfOverpaymentMadeToSubsidiary" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfMTE5MDA_9ee4dd35-1a76-4dbd-97b3-bc2aebd2a9d6">38.8</ix:nonFraction> million (the maximum amount Palmetto claims has been overpaid for both the Lakeland Care Centers and the Clearwater Care Center, of which amount $<ix:nonFraction unitRef="usd" contextRef="i935299f8f69f411d82a301973293010c_I20170831" decimals="-5" format="ixt:numdotdecimal" name="amed:IndemnificationAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfMTIwNDA_0026cdb9-abdf-49ba-b407-8aa3c39de8a8">12.6</ix:nonFraction> million is subject to indemnification by the prior owners) to $<ix:nonFraction unitRef="usd" contextRef="icc208c6318744c7da8b8a731efe00cdf_I20200331" decimals="-5" format="ixt:numdotdecimal" name="amed:RecoveryAmountOfOverpaymentMadeToSubsidiary" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfMTIwOTc_bd0bc584-b89d-491c-9638-d36ede03c7bd">29.3</ix:nonFraction> million based on the partial success achieved by the Company in prosecuting its Level I and II Administrative Appeals.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March&#160;31, 2020, we have an accrued liability of approximately $<ix:nonFraction unitRef="usd" contextRef="ic8bb62c8d3f64b36aef46b46e53aa57a_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfMTIyNjc_cd81250b-9fda-439a-9e63-28237eaa9de3">17.4</ix:nonFraction> million related to this matter. We expect to be indemnified by the prior owners for approximately $<ix:nonFraction unitRef="usd" contextRef="ic8bb62c8d3f64b36aef46b46e53aa57a_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LossContingencyReceivableNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfMTIzNjA_e0ee217c-33ba-45a5-acf9-c475626ed4df">10.9</ix:nonFraction> million of the total $<ix:nonFraction unitRef="usd" contextRef="i749346d879b94b75885c06bedb422e0f_I20170831" decimals="-5" format="ixt:numdotdecimal" name="amed:IndemnificationAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfMTIzNzY_a04653ef-a152-4314-9bd9-ace2d3fc0835">12.6</ix:nonFraction> million available indemnification related to this matter and have recorded this amount within other assets in our condensed consolidated balance sheet as of March&#160;31, 2020. The net of these two amounts, $<ix:nonFraction unitRef="usd" contextRef="i94fb4c71db4b4aec948a8a7a52e540a1_D20170101-20171231" decimals="-5" format="ixt:numdotdecimal" name="amed:FloridaZpicRevenueReduction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfMTI1NjI_af0d6023-922d-4038-b963-abe480dde74c">6.5</ix:nonFraction> million, was recorded as a reduction in revenue in our condensed consolidated statements of operations during 2017. As of March&#160;31, 2020, $<ix:nonFraction unitRef="usd" contextRef="i87ea094035bb4053a1610c6754611f97_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfMTI3MjY_6a45f351-24fe-4c66-85e3-d0d620ecbbe7">1.5</ix:nonFraction> million of receivables have been impacted by this payment suspension.</span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">18</span></div></div></div><hr style="page-break-after:always"/><div style="height:81pt;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div></div><ix:continuation id="i71ac5a12f4b54476b2b105bd1f360c45"><div style="text-align:justify;margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Insurance</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are obligated for certain costs associated with our insurance programs, including employee health, workers&#8217; compensation and professional liability. While we maintain various insurance programs to cover these risks, we are self-insured for a substantial portion of our potential claims. We recognize our obligations associated with these costs, up to specified deductible limits in the period in which a claim is incurred, including with respect to both reported claims and claims incurred but not reported. These costs have generally been estimated based on historical data of our claims experience. Such estimates, and the resulting reserves, are reviewed and updated by us on a quarterly basis.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our health insurance has an exposure limit of $<ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="amed:HealthInsuranceRetentionLimit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfMTM1NDg_caa54951-45c0-43d2-adf2-0571cc270e38">1.3</ix:nonFraction> million for any individual covered life. Our workers&#8217; compensation insurance has a retention limit of $<ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="amed:WorkersCompensationInsuranceRetentionLimit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfMTM2NDU_a41107da-3d61-40c4-a574-9ad0543a9eca">1.0</ix:nonFraction> million per incident and our professional liability insurance has a retention limit of $<ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="amed:ProfessionalLiabilityInsuranceRetentionLimit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfMTM3Mjc_ca93a447-1029-438e-8268-d8bca2194487">0.3</ix:nonFraction> million per incident.</span></div></ix:continuation><div id="i793e68cdccb44b98a73aef6e33f497bf_73"></div><div style="text-align:justify;margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">6. <ix:nonNumeric contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RleHRyZWdpb246NjY5N2JhZGFiNjhiNGZiNGI2ZWU1Zjc4MDFjYjE0YjFfMTM4MQ_bd977b2e-edb7-4d53-8fc3-2ef7afb3eca7" continuedAt="i0c281683896741ceb2c652fe8efb1429" escape="true">SEGMENT INFORMATION</ix:nonNumeric></span></div><ix:continuation id="i0c281683896741ceb2c652fe8efb1429"><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our operations involve servicing patients through our <ix:nonFraction unitRef="segments" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RleHRyZWdpb246NjY5N2JhZGFiNjhiNGZiNGI2ZWU1Zjc4MDFjYjE0YjFfODI_44304806-0ba8-4b8e-863d-cbb559720c17">three</ix:nonFraction> reportable business segments: home health, hospice and personal care. Our home health segment delivers a wide range of services in the homes of individuals who may be recovering from surgery, have a chronic disability or terminal illness or need assistance with completing important personal tasks. Our hospice segment provides palliative care and comfort to terminally ill patients and their families. Our personal care segment provides patients with assistance with the essential activities of daily living. The &#8220;other&#8221; column in the following tables consists of costs relating to executive management and administrative support functions, primarily information services, accounting, finance, billing and collections, legal, compliance, risk management, procurement, marketing, clinical administration, training, human resources and administration.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Management evaluates performance and allocates resources based on the operating income of the reportable segments, which includes an allocation of corporate expenses directly attributable to the specific segment and includes revenues and all other costs directly attributable to the specific segment. Segment assets are not reviewed by the company&#8217;s chief operating decision maker and therefore are not disclosed below (amounts in millions).</span></div><div style="text-align:center;margin-bottom:6pt;"><ix:nonNumeric contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RleHRyZWdpb246NjY5N2JhZGFiNjhiNGZiNGI2ZWU1Zjc4MDFjYjE0YjFfMTM4NQ_aa664355-aa61-4aa6-832b-bcbdf0776607" escape="true"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:46.023%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:7.809%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.809%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.809%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.809%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.813%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three-Month Period Ended March 31, 2020</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Home<br/>Health</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Hospice</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Personal<br/>Care</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net service revenue</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1803f21995a846beaf2e5491abdaa75f_D20200101-20200331" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMi0xLTEtMS0w_383932d0-9280-41f9-88e4-1e0be34fdeae">303.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie2a5b1046a72421f919b53e916e3b7b9_D20200101-20200331" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMi0zLTEtMS0w_6be45331-622e-4280-8f58-3d0026bbd2b3">169.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6a2423ba41a14b54bbfa09ffcbf822de_D20200101-20200331" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMi01LTEtMS0w_a53c72cd-a22c-4479-be7d-8cb263097129">18.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0fca8bc8c2274f6fadc2205b072e559c_D20200101-20200331" decimals="-5" format="ixt:zerodash" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMi03LTEtMS0w_0e2154cc-624a-4206-b0da-e4c15e60a6fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMi05LTEtMS0w_ecab8d3a-0eea-46c0-b2c1-3dc52cd45a61">491.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1803f21995a846beaf2e5491abdaa75f_D20200101-20200331" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMy0xLTEtMS0w_26ac3872-2741-42ed-9330-5d013261ff82">179.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie2a5b1046a72421f919b53e916e3b7b9_D20200101-20200331" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMy0zLTEtMS0w_d0ddd456-7e91-4dda-9ede-1b63cf082d43">91.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6a2423ba41a14b54bbfa09ffcbf822de_D20200101-20200331" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMy01LTEtMS0w_460c1825-6d57-4ec9-a52e-8a23c5cd8d44">14.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0fca8bc8c2274f6fadc2205b072e559c_D20200101-20200331" decimals="-5" format="ixt:zerodash" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMy03LTEtMS0w_ffec4212-7407-4129-b75b-b3212af5c592">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMy05LTEtMS0w_be00c156-a7fa-483c-be6b-0bcca219c6e0">285.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1803f21995a846beaf2e5491abdaa75f_D20200101-20200331" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfNC0xLTEtMS0w_8e5821d2-ebf8-4965-894e-8aa5d1e9db1e">75.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie2a5b1046a72421f919b53e916e3b7b9_D20200101-20200331" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfNC0zLTEtMS0w_a4dc887d-8ee2-46bf-86c4-14a6b70d1fdc">38.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6a2423ba41a14b54bbfa09ffcbf822de_D20200101-20200331" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfNC01LTEtMS0w_67a8cfc2-04b0-441c-b022-f31693acd2fa">3.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0fca8bc8c2274f6fadc2205b072e559c_D20200101-20200331" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfNC03LTEtMS0w_5ac0568a-cd81-4b90-bd99-ea81821adc9a">39.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfNC05LTEtMS0w_81736bc9-9e06-4c72-8dc1-c973b90c8d91">156.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation and amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1803f21995a846beaf2e5491abdaa75f_D20200101-20200331" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfNS0xLTEtMS0w_1820f514-1fa1-48f3-b553-0d843f072c8a">1.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie2a5b1046a72421f919b53e916e3b7b9_D20200101-20200331" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfNS0zLTEtMS0w_27df84e5-7ac7-4414-a03b-3c2b85e2fddb">0.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6a2423ba41a14b54bbfa09ffcbf822de_D20200101-20200331" decimals="-5" format="ixt:zerodash" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfNS01LTEtMS0w_a692e190-98f3-4ead-8f50-78d1f57e8d8c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0fca8bc8c2274f6fadc2205b072e559c_D20200101-20200331" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfNS03LTEtMS0w_75ef94dd-2db9-41f3-8473-092b4d197a7f">3.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfNS05LTEtMS0w_915c5c88-2c1f-4158-a7f8-3bd0b428cba4">5.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1803f21995a846beaf2e5491abdaa75f_D20200101-20200331" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfNi0xLTEtMS0w_b6dc7ded-35bd-466f-9747-eccbda546dfd">256.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie2a5b1046a72421f919b53e916e3b7b9_D20200101-20200331" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfNi0zLTEtMS0w_4bc78afb-ccb0-408b-8f4b-d198a80fa2f3">131.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6a2423ba41a14b54bbfa09ffcbf822de_D20200101-20200331" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfNi01LTEtMS0w_1a871ed5-283a-4a15-8cd3-d425a9a3c4b2">17.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0fca8bc8c2274f6fadc2205b072e559c_D20200101-20200331" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfNi03LTEtMS0w_aef5164b-73f9-473d-8edf-7fce02570ace">42.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfNi05LTEtMS0w_01559de0-4bf6-4a48-9f52-ea2515973240">447.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating income (loss)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1803f21995a846beaf2e5491abdaa75f_D20200101-20200331" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfNy0xLTEtMS0w_ae1b382d-3d06-40c8-8fb6-474f07cf99d2">47.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie2a5b1046a72421f919b53e916e3b7b9_D20200101-20200331" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfNy0zLTEtMS0w_7660283b-2fbb-4aab-b355-7b47ce2bd64c">38.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6a2423ba41a14b54bbfa09ffcbf822de_D20200101-20200331" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfNy01LTEtMS0w_362506f8-b18e-458b-a07b-80e85f2e2a80">1.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0fca8bc8c2274f6fadc2205b072e559c_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfNy03LTEtMS0w_efa05c46-511e-4c33-999c-9c3eb453e47e">42.7</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfNy05LTEtMS0w_3357b809-c9d8-4c53-8639-68dba25db9ea">43.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three-Month Period Ended March 31, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Home<br/>Health</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Hospice</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Personal<br/>Care</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net service revenue</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0ea4477e2b7e45148118c36d32e8f280_D20190101-20190331" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMTEtMS0xLTEtMA_2a9c921f-6bbb-4c01-8465-fc1762dee8ac">310.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2a6321b07a44425ca22c6f9c6f1f5d8b_D20190101-20190331" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMTEtMy0xLTEtMA_0511854b-4596-4aec-9b08-34c3c44a276b">137.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ica2ca9848a114f40a419416038f9d299_D20190101-20190331" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMTEtNS0xLTEtMA_552afab9-b49e-42d5-9947-1378c30b7871">20.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifd5794f300984d0ebb27f829a61f2449_D20190101-20190331" decimals="-5" format="ixt:zerodash" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMTEtNy0xLTEtMA_f356996e-df96-4abd-8000-ae2d7ab8130e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMTEtOS0xLTEtMA_e0f0813e-81ff-4523-b7aa-b966381d780e">467.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0ea4477e2b7e45148118c36d32e8f280_D20190101-20190331" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMTItMS0xLTEtMA_3babc357-ea4a-403a-9a80-c584bd30ab1b">185.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2a6321b07a44425ca22c6f9c6f1f5d8b_D20190101-20190331" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMTItMy0xLTEtMA_d3783ab3-c957-4166-89ce-9936fac73162">74.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ica2ca9848a114f40a419416038f9d299_D20190101-20190331" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMTItNS0xLTEtMA_bed68e44-e77e-4675-8ba2-f1fbe800f07f">15.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifd5794f300984d0ebb27f829a61f2449_D20190101-20190331" decimals="-5" format="ixt:zerodash" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMTItNy0xLTEtMA_20050f32-9ed1-4cd5-a523-95d42635aabd">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMTItOS0xLTEtMA_1be25ca4-2e90-4891-8099-3e26e7883e43">275.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0ea4477e2b7e45148118c36d32e8f280_D20190101-20190331" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMTMtMS0xLTEtMA_bd0465ed-21fe-40ea-ba80-814ece667f0a">71.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2a6321b07a44425ca22c6f9c6f1f5d8b_D20190101-20190331" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMTMtMy0xLTEtMA_08b8acce-acba-4417-a6f4-2a542d2ca1bd">29.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ica2ca9848a114f40a419416038f9d299_D20190101-20190331" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMTMtNS0xLTEtMA_178ed4bd-440e-4562-b72c-cb1a0b574b11">3.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifd5794f300984d0ebb27f829a61f2449_D20190101-20190331" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMTMtNy0xLTEtMA_f4c83fbf-cd70-4de8-afd0-eb88cabe35b6">41.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMTMtOS0xLTEtMA_f8861e58-ab68-48b1-8ca4-55d32a1e8727">144.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation and amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0ea4477e2b7e45148118c36d32e8f280_D20190101-20190331" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMTQtMS0xLTEtMA_cc5c6d3c-a3c9-43e4-b47a-c26880e298d5">1.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2a6321b07a44425ca22c6f9c6f1f5d8b_D20190101-20190331" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMTQtMy0xLTEtMA_d814ff51-a445-4d95-b54f-415075e418eb">0.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ica2ca9848a114f40a419416038f9d299_D20190101-20190331" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMTQtNS0xLTEtMA_2a2d4e48-f605-4961-b596-e086d05a62ba">0.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifd5794f300984d0ebb27f829a61f2449_D20190101-20190331" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMTQtNy0xLTEtMA_606f286e-41c0-437d-b4cc-7f5374ef83be">1.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMTQtOS0xLTEtMA_71303c66-6daf-46ca-9af5-62d38a1cfeda">2.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0ea4477e2b7e45148118c36d32e8f280_D20190101-20190331" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMTUtMS0xLTEtMA_5a810f82-5800-462a-a64e-d9deca1f8c0c">258.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2a6321b07a44425ca22c6f9c6f1f5d8b_D20190101-20190331" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMTUtMy0xLTEtMA_903263cf-da31-40f1-a6ac-0768d9ea9a5c">103.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ica2ca9848a114f40a419416038f9d299_D20190101-20190331" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMTUtNS0xLTEtMA_8f31c1a1-038c-474e-a401-e28c011019ff">18.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifd5794f300984d0ebb27f829a61f2449_D20190101-20190331" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMTUtNy0xLTEtMA_2565a766-54f4-469a-8a69-27ac50530f51">42.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMTUtOS0xLTEtMA_6beaf016-d361-4fee-97cd-e255b4dcd03a">423.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating income (loss)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0ea4477e2b7e45148118c36d32e8f280_D20190101-20190331" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMTYtMS0xLTEtMA_6dcb06e2-3181-43eb-8413-a10e0646fcd0">52.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2a6321b07a44425ca22c6f9c6f1f5d8b_D20190101-20190331" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMTYtMy0xLTEtMA_d195d600-0ce8-4792-9009-a68368bf3e54">33.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ica2ca9848a114f40a419416038f9d299_D20190101-20190331" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMTYtNS0xLTEtMA_14a726a1-7231-4c17-aa5c-64473ff312b9">1.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifd5794f300984d0ebb27f829a61f2449_D20190101-20190331" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMTYtNy0xLTEtMA_94fad0ba-99a9-41bc-bf85-03ded274079b">42.7</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMTYtOS0xLTEtMA_3e166053-1b56-44f1-af8c-11aa05c06d96">44.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="text-align:center;"><span><br/></span></div><div id="i793e68cdccb44b98a73aef6e33f497bf_79"></div><div style="text-align:justify;margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">7. <ix:nonNumeric contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" name="us-gaap:TreasuryStockTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83OS9mcmFnOmJkZmVhOGJkMTUzMjQ4NGFhMzE5YTdjZTg0Njc1NzZlL3RleHRyZWdpb246YmRmZWE4YmQxNTMyNDg0YWEzMTlhN2NlODQ2NzU3NmVfMTUxNQ_e8154b7f-5b2c-4e79-a242-fd0285f29894" continuedAt="i4518f2f6c1ed4f9dbe21995c3b3c71a1" escape="true">SHARE REPURCHASE </ix:nonNumeric></span></div><ix:continuation id="i4518f2f6c1ed4f9dbe21995c3b3c71a1" continuedAt="i862443ba06d24e3d88c1b85be453abbf"><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">2019 Stock Repurchase Program</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On February 25, 2019, we announced that our Board of Directors authorized a stock repurchase program, under which we may repurchase up to $<ix:nonFraction unitRef="usd" contextRef="i156f24d3122641318de844c5586c409a_I20190225" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83OS9mcmFnOmJkZmVhOGJkMTUzMjQ4NGFhMzE5YTdjZTg0Njc1NzZlL3RleHRyZWdpb246YmRmZWE4YmQxNTMyNDg0YWEzMTlhN2NlODQ2NzU3NmVfMTk0_aa28749c-b89e-425e-82b5-ce6a7c47d4ea">100</ix:nonFraction> million of our outstanding common stock through <ix:nonNumeric contextRef="i61c83eb39bd448178123272ce803cd04_D20190225-20190225" format="ixt:datemonthdayyearen" name="us-gaap:StockRepurchaseProgramExpirationDate" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83OS9mcmFnOmJkZmVhOGJkMTUzMjQ4NGFhMzE5YTdjZTg0Njc1NzZlL3RleHRyZWdpb246YmRmZWE4YmQxNTMyNDg0YWEzMTlhN2NlODQ2NzU3NmVfMjM3_76cbdf54-d495-4944-a182-041efdabc32a">March 1, 2020</ix:nonNumeric>.</span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">19</span></div></div></div><hr style="page-break-after:always"/><div style="height:81pt;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div></div><ix:continuation id="i862443ba06d24e3d88c1b85be453abbf"><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the terms of the program, we were allowed to repurchase shares from time to time in open market transactions, block purchases or in private transactions in accordance with applicable federal securities laws and other legal requirements. We were allowed to enter into Rule 10b5-1 plans to effect some or all of the repurchases. The timing and the amount of the repurchases would be determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors. </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We did not repurchase any shares pursuant to this stock repurchase program during the three-month periods ended March&#160;31, 2020 or March 31, 2019. The stock repurchase program expired on March 1, 2020.</span></div></ix:continuation><div id="i793e68cdccb44b98a73aef6e33f497bf_82"></div><div style="text-align:justify;margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">8. <ix:nonNumeric contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl84Mi9mcmFnOjEwYWE4ZTNkM2M2MzQ2MDg4MjJlOGYyODdmNjNiODY1L3RleHRyZWdpb246MTBhYThlM2QzYzYzNDYwODgyMmU4ZjI4N2Y2M2I4NjVfMzg2_803c70bf-e64a-4cda-9749-64d78345c0e6" continuedAt="i927347f0fe8d441c8cfe0cd06a9312c9" escape="true">RELATED PARTY TRANSACTIONS</ix:nonNumeric></span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i927347f0fe8d441c8cfe0cd06a9312c9">During 2018, we made a $<ix:nonFraction unitRef="usd" contextRef="iba4950c59f204d1fadc805bed37fde70_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl84Mi9mcmFnOjEwYWE4ZTNkM2M2MzQ2MDg4MjJlOGYyODdmNjNiODY1L3RleHRyZWdpb246MTBhYThlM2QzYzYzNDYwODgyMmU4ZjI4N2Y2M2I4NjVfNTg_7228a7cb-c963-45a6-81aa-aa15bf304232">7.0</ix:nonFraction> million investment in Medalogix, a healthcare predictive data and analytics company; this investment is accounted for under the equity method. During the three-month period ended March 31, 2020, we incurred costs of approximately $<ix:nonFraction unitRef="usd" contextRef="i814b93d2c0884001a010153e4ffc90ec_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl84Mi9mcmFnOjEwYWE4ZTNkM2M2MzQ2MDg4MjJlOGYyODdmNjNiODY1L3RleHRyZWdpb246MTBhYThlM2QzYzYzNDYwODgyMmU4ZjI4N2Y2M2I4NjVfMjk3_860d602e-e18d-4c50-91eb-2d88b98be757">0.6</ix:nonFraction> million  in connection with the usage of Medalogix's analytics platforms. We believe that the terms of these transactions are consistent with those negotiated at arm's length.</ix:continuation></span></div><div id="i793e68cdccb44b98a73aef6e33f497bf_85"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">9.&#160;<ix:nonNumeric contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl84NS9mcmFnOjkzMWNjMDFjZDAyNDQzY2NiYjVjMzExODI5NWJjOTM1L3RleHRyZWdpb246OTMxY2MwMWNkMDI0NDNjY2JiNWMzMTE4Mjk1YmM5MzVfMTY0OTI2NzQ0MzIzMg_932b6ed1-f9c4-4592-b314-3ba85995a883" continuedAt="i754d8901f0494a5baf4df616a5e30657" escape="true">SUBSEQUENT EVENTS</ix:nonNumeric></span></div><ix:continuation id="i754d8901f0494a5baf4df616a5e30657"><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Novel Coronavirus Pandemic ("COVID-19")</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2020, the World Health Organization declared COVID-19 a pandemic. As a healthcare at home company, we have been and will continue to be impacted by the effects of COVID-19; however, we remain committed to carrying out our mission of caring for our patients. We will continue to closely monitor the impact of COVID-19 on all aspects of our business, including the impacts to our employees, patients and suppliers; however, at this time, we are unable to estimate the ultimate impact the pandemic will have on our consolidated financial condition, results of operations or cash flows.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On March 27, 2020, the bipartisan Coronavirus Aid, Relief, and Economic Security Act ("CARES Act") was signed into legislation. The CARES Act provides for $<ix:nonFraction unitRef="usd" contextRef="i8b9efcf5de4c480e81af5d9bd1cdb30e_I20200327" decimals="-9" format="ixt:numdotdecimal" name="amed:FundingForHealthcareProvidersIncludingHospitals" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl84NS9mcmFnOjkzMWNjMDFjZDAyNDQzY2NiYjVjMzExODI5NWJjOTM1L3RleHRyZWdpb246OTMxY2MwMWNkMDI0NDNjY2JiNWMzMTE4Mjk1YmM5MzVfMTY0OTI2NzQ0Mzc4MQ_0216b23c-c6f7-4b9e-b274-13b0f6279a93">100</ix:nonFraction>&#160;billion to healthcare providers, including hospitals on the front lines of the COVID-19 pandemic. Of this total allocated amount, $<ix:nonFraction unitRef="usd" contextRef="i8b9efcf5de4c480e81af5d9bd1cdb30e_I20200327" decimals="-9" format="ixt:numdotdecimal" name="amed:FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl84NS9mcmFnOjkzMWNjMDFjZDAyNDQzY2NiYjVjMzExODI5NWJjOTM1L3RleHRyZWdpb246OTMxY2MwMWNkMDI0NDNjY2JiNWMzMTE4Mjk1YmM5MzVfMTY0OTI2NzQ0Mzc5NQ_8ff23cf9-45e4-40be-b66d-e0c18e3b1263">30</ix:nonFraction>&#160;billion was distributed immediately to providers based on their proportionate share of Medicare fee-for-service reimbursements in 2019. Healthcare providers must sign an attestation confirming receipt of the funds and agree to the terms and conditions of payment. We received approximately $<ix:nonFraction unitRef="usd" contextRef="i64e606224ada41f7b469907990f9cbec_D20200401-20200430" decimals="-6" format="ixt:numdotdecimal" name="amed:FundingReceivedFromCARESAct" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl84NS9mcmFnOjkzMWNjMDFjZDAyNDQzY2NiYjVjMzExODI5NWJjOTM1L3RleHRyZWdpb246OTMxY2MwMWNkMDI0NDNjY2JiNWMzMTE4Mjk1YmM5MzVfMTY0OTI2NzQ0MzgwOA_4eda8c5e-09c2-4859-83ac-b86dc70e7a6c">100</ix:nonFraction>&#160;million from the first $<ix:nonFraction unitRef="usd" contextRef="i8b9efcf5de4c480e81af5d9bd1cdb30e_I20200327" decimals="-9" format="ixt:numdotdecimal" name="amed:FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl84NS9mcmFnOjkzMWNjMDFjZDAyNDQzY2NiYjVjMzExODI5NWJjOTM1L3RleHRyZWdpb246OTMxY2MwMWNkMDI0NDNjY2JiNWMzMTE4Mjk1YmM5MzVfMTY0OTI2NzQ1NTM0MA_4e168f1c-b112-415d-9549-bc2fcf442059">30</ix:nonFraction>&#160;billion of funds distributed to healthcare providers in April 2020. Consistent with the terms and conditions for receipt of the payment, we will utilize the funds to cover lost revenue and health care costs related to COVID-19, and we will properly and fully document the use of these funds in required quarterly reports to the U.S. Department of Health and Human Services ("HHS").</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In order to properly attest to receipt of our payment, we are seeking clarity from HHS regarding the formula utilized to determine our receipt of funds and the total amount of funds available to us to be used towards lost revenue and health care expenses related to COVID-19. At this time, we have fully separated these funds into their own account and will not be utilizing any of them until additional clarity is received from HHS.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On April 24, 2020, HHS distributed an additional $<ix:nonFraction unitRef="usd" contextRef="ie825c970c94741d3bc87bb70762f3d6b_I20200424" decimals="-9" format="ixt:numdotdecimal" name="amed:AdditionalFundingDistributedToHealthcareProviders" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl84NS9mcmFnOjkzMWNjMDFjZDAyNDQzY2NiYjVjMzExODI5NWJjOTM1L3RleHRyZWdpb246OTMxY2MwMWNkMDI0NDNjY2JiNWMzMTE4Mjk1YmM5MzVfMTY0OTI2NzQ1NTMyNw_03768a8d-3624-4ac5-a132-89295e24d29d">20</ix:nonFraction>&#160;billion in funds to healthcare providers. We did not receive, nor apply, for any additional funds from this second distribution.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Acquisitions</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On April 23, 2020, we signed a definitive agreement to acquire Homecare Preferred Choice, Inc., doing business as AseraCare Hospice ("AseraCare Hospice"), a national hospice care provider with <ix:nonFraction unitRef="care_center" contextRef="i231cc4c6c6914005bf14c4a47eaefddd_D20200423-20200423" decimals="0" name="us-gaap:NumberOfBusinessesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl84NS9mcmFnOjkzMWNjMDFjZDAyNDQzY2NiYjVjMzExODI5NWJjOTM1L3RleHRyZWdpb246OTMxY2MwMWNkMDI0NDNjY2JiNWMzMTE4Mjk1YmM5MzVfMTY0OTI2NzQ0Mzg3MA_76dd973b-2a03-4e2a-9ade-e89d494b5c1a">44</ix:nonFraction> locations, for a purchase price of $<ix:nonFraction unitRef="usd" contextRef="i231cc4c6c6914005bf14c4a47eaefddd_D20200423-20200423" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl84NS9mcmFnOjkzMWNjMDFjZDAyNDQzY2NiYjVjMzExODI5NWJjOTM1L3RleHRyZWdpb246OTMxY2MwMWNkMDI0NDNjY2JiNWMzMTE4Mjk1YmM5MzVfMTY0OTI2NzQ0MzgyMg_32c6502e-1f4f-4709-b8a3-bdbdefa785ca">235</ix:nonFraction>&#160;million in cash, inclusive of $<ix:nonFraction unitRef="usd" contextRef="i231cc4c6c6914005bf14c4a47eaefddd_D20200423-20200423" decimals="-6" format="ixt:numdotdecimal" name="amed:Paymentsrelatedtotaxassetandworkingcapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl84NS9mcmFnOjkzMWNjMDFjZDAyNDQzY2NiYjVjMzExODI5NWJjOTM1L3RleHRyZWdpb246OTMxY2MwMWNkMDI0NDNjY2JiNWMzMTE4Mjk1YmM5MzVfMTY0OTI2NzQ0MzgzNg_5bbdda7e-d084-4db9-a116-cd640fb90941">32</ix:nonFraction>&#160;million in payments related to the present value of the tax benefits created through the transaction (subject to customary adjustments at closing for working capital, cash indebtedness and transaction expenses). We will not use any of the funds we received from the CARES Act to fund the acquisition.</span></div></ix:continuation><div style="text-align:justify;margin-top:6pt;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">20</span></div></div></div><div id="i793e68cdccb44b98a73aef6e33f497bf_88"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM&#160;2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">The following discussion and analysis provides information we believe is relevant to an assessment and understanding of our results of operations and financial condition for the three-month period ended March&#160;31, 2020. This discussion should be read in conjunction with the condensed consolidated financial statements and notes thereto included herein, and the consolidated financial statements and notes and the related Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the year ended December&#160;31, 2019 filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on February 19, 2020 (the &#8220;Form 10-K&#8221;), which are incorporated herein by this reference. Historical results that appear in the condensed consolidated financial statements should not be interpreted as being indicative of future operations.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Unless otherwise provided, &#8220;Amedisys,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; and the &#8220;Company&#8221; refer to Amedisys, Inc. and our consolidated subsidiaries.</span></div><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Overview</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are a provider of high-quality in-home healthcare and related services to the chronic, co-morbid, aging American population, with approximately 74% of our revenue derived from Medicare for the three-month periods ended March&#160;31, 2020 and 2019.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our operations involve servicing patients through our three reportable business segments: home health, hospice and personal care. Our home health segment delivers a wide range of services in the homes of individuals who may be recovering from an illness, injury or surgery. Our hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness. Our personal care segment provides patients with assistance with the essential activities of daily living. As of March&#160;31, 2020, we owned and operated 322 Medicare-certified home health care centers, 146 Medicare-certified hospice care centers and 12 personal-care care centers in 38 states within the United States and the District of Columbia.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Care Centers Summary (Includes Unconsolidated Joint Ventures)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:95.760%;"><tr><td style="width:1.0%;"></td><td style="width:59.832%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.213%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.563%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.213%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.563%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.216%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Home<br/>Health</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Hospice</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Personal<br/>Care</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">321&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">138&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acquisitions/Startups</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Closed/Consolidated</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">322&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">146&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Recent Developments</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Governmental Inquiries and Investigations and Other Litigation</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">See Note 5 &#8211; Commitments and Contingencies to our condensed consolidated financial statements for additional information regarding our corporate integrity agreements and for a discussion of and updates regarding other legal proceedings and investigations we are involved in. No assurances can be given as to the timing or outcome of these items. </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Payment</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In April 2020, the Centers for Medicare and Medicaid Services ("CMS") issued a proposed rule to update hospice payment rates and the wage index for fiscal year 2021. CMS estimates hospices serving Medicare beneficiaries would see an estimated 2.6% increase in payments. This increase is the result of a 3.0% market basket adjustment less a 0.4% productivity adjustment as required under the Patient Protection and Affordable Health Care Act and the Health Care and Education Reconciliation Act (collectively, "PPACA"). The rule also proposes changes to the hospice wage index by adopting the most recent Office of Management and Budget statistical area delineations with a five percent cap on wage index decreases. Finally, CMS proposed an increase in the aggregate cap amount by 2.6% to $30,743.86. Based on our analysis of the proposed rule, we expect our impact to be in line with the 2.6% increase.  </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The CMS Calendar Year 2020 Home Health Final Rule confirmed the implementation of the Patient-Driven Groupings Model ("PDGM") effective January 1, 2020 as well as the change in the unit of payment </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">from a 60-day payment period to a 30-day payment period</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Additionally, in an effort to eliminate fraud risks, CMS reduced requests for anticipated payment ("RAPs") for 2020 to 20% with the full elimination of RAPs in 2021. CMS estimated that the final rule would result in a 1.3% increase in payments to home health providers. The increase is the result of a statutorily mandated 1.5% market basket increase pursuant to the Bipartisan Budget Act of 2018, reduced by 0.2% for the rural add-on. In calculating the impact, CMS also assumed that the </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">21</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">industry will make certain behavioral changes related to coding practices, low utilization payment adjustment ("LUPA") management and co-morbidities. As a result, CMS reduced reimbursement by 4.36%. We have estimated the impact of the final rule on us to be a reduction in revenue of 2.8%. Our current view is that we can offset the impact via a mix of appropriate behavioral changes and cost levers which include clinician mix and utilization. The timing of our ability to fully achieve these offsets may be impacted by the novel coronavirus pandemic.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Novel Coronavirus Pandemic ("COVID-19")</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our first quarter operations and financial performance were impacted by COVID-19. We began to experience the impacts on our operations during the second week of March, as we had declines in referral volumes and an increase in missed visits. Each of our business lines was impacted; however, the disruption was greatest in our home health segment, which experienced a referral low-point the week of April 5th. Since that time, we have seen a steady recovery in referral volumes and a corresponding drop in missed visits. In our hospice segment, our referrals hit their low-point the week of March 22nd. While hospice admission volumes have improved significantly, the slowdown in March will impact our average daily census during the second quarter of 2020. The financial impact of COVID-19 during the three-month period ended March 31, 2020 is discussed in further detail under "Results of Operations" below. </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Due to the uncertainty created by COVID-19, we are unable to predict the pace of recovery, and therefore, are unable to estimate the ultimate impact the pandemic will have on our consolidated financial condition, results of operations or cash flows. The following factors could potentially impact the timing of recovery: the continued increase or decrease in the number of COVID-19 cases nationwide, the pace at which elective procedures begin and the utilization of these procedures, the return of patient confidence to enter a hospital or a doctor's office, the ability to access to our patients in their homes and in facilities, cost normalization around personal protective equipment ("PPE") and any future or prolonged shelter-in-place orders. Potential impacts of COVID-19 on our results include lower revenue, higher salary and wage expense related to quarantine pay and increased supply costs related to PPE. The impacts to revenue may consist of the following:</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">lower volumes due to interruption of the operations of our referral sources and patients' unwillingness to accept services and </span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">lower reimbursement due to missed visits resulting in an increase in LUPAs and lost billing periods.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On March 27, 2020, the bipartisan Coronavirus Aid, Relief, and Economic Security Act ("CARES Act") was signed into legislation. The CARES Act provides for the following:</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">$100 billion to healthcare providers, including hospitals on the front lines of the COVID-19 pandemic, with the intent to help defray the significant healthcare-related expenses and lost revenue attributable to the pandemic. Of this total allocated amount, $30 billion was distributed immediately to providers based on their proportionate share of Medicare fee-for-service reimbursements in 2019. We received approximately $100 million from the CARES Act in April 2020; our ability to utilize and retain this amount will depend on the magnitude, timing and nature of the impact of the pandemic, as well as on the rules and requirements of the program.</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The temporary suspension of the automatic 2% reduction of Medicare claim reimbursements for the period of May 1 through December 31, 2020. We estimate the impact will increase our 2020 net service revenue by approximately $21 million.</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The deferral of the employer share of social security tax (6.2%), effective for payments due after the enactment date. Fifty percent of the deferred payroll taxes are due on December 31, 2021 with the remaining amounts due on December 31, 2022. We estimate the impact will increase our 2020 cash flow from operations by approximately $50 million.</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The temporary suspension of Medicare patient coverage criteria and documentation and care requirements and the expansion of telehealth in providing home health and hospice care to patients.</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The ability for non-physician practitioners to certify for home health, order home health services, establish and review plans of care and certify and recertify eligibility.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The well-being of our employees has been one of our top priorities during this pandemic. We have taken the following steps to support our employees: implemented up to 14 days of paid leave during any required quarantine periods; instituted work-from-home arrangements for our corporate and administrative support employees; allowed employees to temporarily suspend any 401(k) plan loan deductions; allowed employees to make a withdrawal from the 401(k) plan for coronavirus-related distributions without incurring the additional 10% early withdrawal penalty; granted access to Teladoc services to all employees and launched a COVID-19 Resource Center, which is updated daily with employee, clinical and operational resources.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The safety of our clinicians and patients has also been a focus, and as a result, we have made the following business changes: implemented a new clinical protocol requiring all clinicians to wear a surgical ear loop mask, at a minimum, on all visits </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">22</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">performed; developed a COVID-19 positive patient treatment protocol and PPE policy for clinicians treating COVID-19 symptomatic and positive patients, which includes utilizing N-95 masks, gloves, gowns and face shields and also requires surgical masks to be worn by the patient; created a centralized distribution center for all critical PPE, allowing us to flex our inventory on a care center by care center basis, based on need and demand; sourced enough PPE to have four months of surgical masks, six months of N-95 masks, and one month of gowns with another two months of gowns on order. For all other critical PPE, we have an average of three months of inventory on hand and will be continuing to source more. We have had success in utilizing both traditional and non-traditional suppliers for our PPE needs. While we were very fortunate to secure the supplies needed, we faced significantly higher per unit cost for the purchase of PPE.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Acquisitions</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On January 1, 2020, we acquired Asana Hospice ("Asana"), a hospice provider with locations in Pennsylvania, Ohio, Texas, Missouri and Kansas for a purchase price of $66.3 million, net of cash acquired.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On March 1, 2020, we acquired the regulatory assets of a home health provider in Washington for a purchase price of $3.0 million.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As we continue to focus on inorganic expansion in all three segments, we anticipate incurring acquisition and integration costs throughout 2020. During the three-month period ended March 31, 2020, we incurred approximately $2 million in costs related to various acquisitions and the integration of Compassionate Care Hospice ("CCH") and Asana. </span></div><div style="text-align:justify;margin-top:6pt;"><span><br/></span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Results of Operations</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Three-Month Period Ended March&#160;31, 2020 Compared to the Three-Month Period Ended March&#160;31, 2019 </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Consolidated</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes our consolidated results of operations (amounts in millions):</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:85.672%;"><tr><td style="width:1.0%;"></td><td style="width:69.843%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.651%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.653%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.653%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three-Month Periods<br/>Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net service revenue</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">491.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">467.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross margin, excluding depreciation and amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">206.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">192.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">% of revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other operating expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">156.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">144.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">% of revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation and amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">43.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total other expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Effective income tax rate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income attributable to Amedisys, Inc.</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Overall, our operating income was relatively flat on a revenue increase of $24&#160;million. Our results for the three-month period ended March 31, 2020 include the acquisitions of CCH on February 1, 2019, RoseRock Healthcare ("RoseRock") on April 1, 2019 and Asana on January 1, 2020. For the quarter, these acquisitions contributed approximately $53 million in revenue and an operating loss of approximately $2 million, which is inclusive of $2 million in acquisition and integration costs and $2 million in intangibles amortization. For the first quarter of 2019, our acquisitions contributed approximately $32 million in revenue and an operating loss of $2 million, which is inclusive of $6 million in acquisition and integration costs.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our performance for the three-month period ended March 31, 2020 was impacted by disruption associated with COVID-19 and the transition to PDGM. Our home health segment experienced the largest revenue impact related to COVID-19, which reduced both volumes and reimbursement. Our home health segment was also impacted by the 2020 changes in reimbursement under PDGM; however, we were able to overcome a portion of the PDGM rate cut via changes in discipline mix and clinician </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">23</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">utilization, which are described in more detail below. Our operating results also reflect a 0.9% increase in our other operating expenses as a percentage of revenue compared to prior year; this increase is inclusive of approximately $2 million and $6 million in acquisition and integration costs in 2020 and 2019, respectively. Excluding the acquisition and integration costs in 2020 and 2019, our other operating expenses as a percentage of revenue increased 1.8% compared to prior year due to the addition of resources to support growth (primarily business development employees), investments related to PDGM and planned wage increases.</span></div><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Home Health Segment</span></div><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes our home health segment results of operations:</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:85.672%;"><tr><td style="width:1.0%;"></td><td style="width:69.843%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.651%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.653%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.653%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three-Month Periods<br/>Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Financial Information</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;">(in millions)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Medicare</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">203.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">213.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-Medicare</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">99.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">96.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net service revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">303.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">310.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of service</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">179.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">185.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross margin</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">123.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">124.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other operating expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">76.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">72.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating income</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">47.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">52.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Same Store Growth (1):</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Medicare revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-Medicare revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total admissions</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total volume (2)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Key Statistical Data - Total (3):</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Admissions</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">85,975&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">83,969&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Recertifications</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">40,541&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41,795&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total volume</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">126,516&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">125,764&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:6pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Medicare completed episodes (6)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75,636&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75,483&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Average Medicare revenue per completed episode (4) (6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,734&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,838&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Medicare visits per completed episode (5) (6)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:6pt;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:6pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Visiting Clinician Cost per Visit</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">84.01&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">81.05&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Clinical Manager Cost per Visit</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.97&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.01&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Cost per Visit</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">92.98&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">89.06&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Visits</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,933,445&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,085,088&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:-22.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(1)    Same store information represents the percent change in our Medicare, Non-Medicare and Total revenue, admissions or volume for the period as a percent of the Medicare, Non-Medicare and Total revenue, admissions or volume of the prior period. Effective July 1, 2019, same store is defined as care centers that we have operated for at least the last twelve months and startups that are an expansion of a same store care center.</span></div><div style="text-indent:-22.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(2)    Total volume includes all admissions and recertifications.</span></div><div style="text-indent:-22.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(3)    Total includes acquisitions and denovos.</span></div><div style="text-indent:-22.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(4)    Average Medicare revenue per completed episode is the average Medicare revenue earned for each Medicare completed episode of care. Average Medicare revenue per completed episode for the three-month period ended March 31, 2020 reflects the transition to PDGM during the quarter and therefore includes reimbursement under both the 60-day episode of care (pre-PDGM) payment rate and the 30-day period of care (PDGM) payment rate.</span></div><div style="text-indent:-22.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(5)    Medicare visits per completed episode are the home health Medicare visits on completed episodes divided by the home health Medicare episodes completed during the period.</span></div><div style="text-indent:-22.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(6)    Prior year amounts have been recast to conform to the current year calculation.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">24</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:-22.5pt;padding-left:49.5pt;"><span><br/></span></div><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Operating Results</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Overall, our operating income decreased $5 million on a $7 million decrease in net service revenue and a $1 million decrease in gross margin. Our revenue and gross margin were impacted by both COVID-19 and the transition to PDGM. The COVID-19 pandemic impacted both volumes and reimbursement resulting in a decrease in net service revenue of $6 million and gross margin of $4 million; the gross margin impact is inclusive of additional costs related to clinician training, quarantine pay and the purchase of personal protective equipment. As expected, our revenue and gross margin were also impacted by the 2020 changes in reimbursement under PDGM, which resulted in a decrease in net service revenue and gross margin of approximately $6 million. We were able to overcome the majority of this rate cut via changes related to clinician utilization and discipline mix, which are described in more detail below. Lastly, our operating expenses increased as a result of the addition of resources to support volume growth, planned wage increases and investments related to PDGM.</span></div><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Net Service Revenue</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our revenue decreased $7 million primarily due to the impact of the 2020 change in reimbursement under PDGM and COVID-19, partially offset by a 1% increase in total volume and a reduction in price concessions. We have estimated the impact of COVID-19 to be a reduction to revenue of approximately $6 million based on the decline in volume near the end of the quarter as well as an increase in LUPAs and lost billing periods resulting from missed visits related to COVID-19. We have estimated the impact of the 2020 change in reimbursement to be a reduction to revenue of $6 million. The 2020 change in reimbursement and the disruption related to COVID-19 are evident in our Medicare revenue per completed episode, which decreased 4%. </span></div><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Cost of Service, Excluding Depreciation and Amortization</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our cost of service consists of costs associated with direct clinician care in the homes of our patients as well as the cost of clinical managers who monitor the overall delivery of care. Overall, our total cost of service decreased 3% on a 7% decrease in total visits driven by COVID-19 disruption, improvements in clinician utilization as evidenced by a decline of 1.4 visits per completed episode year over year, and optimization of discipline mix. These items were partially offset by a 4% increase in our total cost per visit, which was driven by planned wage increases, changes in our staffing model and approximately $1 million in costs associated with COVID-19 related to clinician training, quarantine pay and the purchase of personal protective equipment. In addition, a portion of our costs are fixed, so our cost per visit metric will increase as visits decline.</span></div><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Other Operating Expenses</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Other operating expenses increased approximately $4 million primarily due to an increase in salaries and benefits expense as a result of the addition of resources to support volume growth, planned wage increases and investments related to PDGM. Additionally, changes in our home health care center staffing resulted in a shift of some office staff from cost of service to other operating expenses totaling approximately $1 million.</span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">25</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Hospice Segment</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes our hospice segment results of operations:</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:85.672%;"><tr><td style="width:1.0%;"></td><td style="width:69.843%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.651%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.653%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.653%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three-Month Periods <br/>Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Financial Information</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;">(in millions):</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Medicare</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">160.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">130.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-Medicare</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net service revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">169.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">137.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of service</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">91.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">74.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross margin</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">77.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">62.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other operating expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating income</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Same Store Growth (1):</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Medicare revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Hospice admissions</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Average daily census</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Key Statistical Data - Total (2):</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Hospice admissions</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,318&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,711&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Average daily census</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,046&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,982&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue per day, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">154.55&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">152.56&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of service per day</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">83.78&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">82.43&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Average discharge length of stay</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">98&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">98&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:-22.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(1)    Same store information represents the percent change in our Medicare revenue, Hospice admissions or average daily census for the period as a percent of the Medicare revenue, Hospice admissions or average daily census of the prior period. Effective July 1, 2019, same store is defined as care centers that we have operated for at least the last twelve months and startups that are an expansion of a same store care center.</span></div><div style="text-indent:-22.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(2)    Total includes acquisitions and denovos.</span></div><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Operating Results</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On February 1, 2019, we acquired CCH, which owned and operated 53 hospice care centers. On April 1, 2019, we acquired RoseRock, which owned and operated one hospice care center. On January 1, 2020, we acquired Asana, which owned and operated eight hospice care centers. Acquisitions are included in our consolidated financial statements from their respective acquisition dates. As a result, our hospice segment operating results for 2020 and 2019 are not fully comparable.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Overall, our operating income increased $5 million on a $32&#160;million increase in net service revenue. Our operating results for the quarter were positively impacted by continued growth and by our acquisitions. Our acquisitions contributed approximately $53 million in revenue and $5 million in operating income to our hospice segment's results for the three-month period ended March 31, 2020 and approximately $32 million in revenue and $5 million in operating income for the three-month period ended March 31, 2019. Our operating results were impacted by both COVID-19, as described in more detail below, and the 2020 change in reimbursement, which resulted in an increase in revenue of $1 million but a reduction in gross margin of less than $1 million for the quarter, as the majority of the revenue increase was passed through to our general inpatient and respite facilities. </span></div><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Net Service Revenue</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our hospice revenue increased $32&#160;million, approximately $21 million of which is attributable to our acquisition activity. The remaining $11 million increase is the result of a 4% increase in our average daily census, a 0.5% increase in reimbursement effective for services provided from October 1, 2019 and a reduction in our revenue price concessions. The impact of COVID-19 on our hospice segment was less than $1 million. We experienced a slight decline in admissions near the end of the quarter, but average daily census remained strong. A continued decline in admissions could have a negative impact on our future average daily census.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">26</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Cost of Service, Excluding Depreciation and Amortization</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our hospice cost of service increased $18&#160;million, approximately $14 million of which is attributable to our acquisition activity. The remaining $4 million increase is primarily due to a 4% increase in average daily census, planned wage increases and an increase in our general inpatient and respite facility costs as the majority of the reimbursement increase, which became effective October 1, 2019, will be passed through to these facilities. </span></div><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Other Operating Expenses</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other operating expenses increased $10&#160;million, approximately $8 million of which is related to our acquisition activity. The remaining $2 million increase is due to increases in other care center related expenses, primarily salaries and benefits due to the addition of resources to support census growth and planned wage increases. </span></div><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Personal Care Segment</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes our personal care segment results of operations:</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:85.672%;"><tr><td style="width:1.0%;"></td><td style="width:69.843%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.651%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.653%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.653%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three-Month Periods <br/>Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Financial Information</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;">(in millions):</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Medicare</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-Medicare</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net service revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of service</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross margin</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other operating expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating income</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Key Statistical Data - Total (1):</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Billable hours</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">752,077&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">833,617&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Clients served</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,770&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,801&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shifts</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">333,464&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">376,182&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue per hour</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24.87&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24.19&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue per shift</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">56.09&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53.60&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Hours per shift</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:-22.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(1)    Total includes acquisitions.</span></div><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Operating Results</span></div><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating income related to our personal care segment remained relatively flat as net service revenue and cost of service both decreased $1 million; other operating expenses also remained relatively flat. Throughout 2019, we made efforts to reduce lower margin shifts; while these efforts have resulted in lower volumes, they have led to a 130 basis point improvement in gross margin as a percentage of revenue. The net impact of COVID-19 on our personal care segment was minimal as the reduction in revenue was largely offset by a reduction in costs as most of our personal care employees are paid on an hourly basis.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">27</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Corporate</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes our corporate results of operations:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:85.672%;"><tr><td style="width:1.0%;"></td><td style="width:69.843%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.651%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.653%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.653%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three-Month Periods<br/>Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Financial Information</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;">(in millions):</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other operating expenses</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation and amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating expenses</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Corporate expenses consist of costs related to our executive management and corporate and administrative support functions, primarily information services, accounting, finance, billing and collections, legal, compliance, risk management, procurement, marketing, clinical administration, training, human resources and administration. </span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Corporate total operating expenses remained flat during the three-month period ended March 31, 2020 compared to 2019. Excluding the impact of our 2020 and 2019 acquisitions which includes corporate and administrative support functions, intangibles amortization and acquisition and integration costs, total operating expenses increased approximately $1 million which represents 3% of our $24 million increase in revenue. The increase is due to increased functional support, planned wage increases, fees related to our ClearCare partnership and lower gains on the sale of fleet vehicles in 2020 as compared to 2019; these items were partially offset by decreases in travel and training expense and IT-related expenses. </span></div><div style="text-align:justify;margin-top:6pt;"><span><br/></span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Liquidity and Capital Resources</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash Flows</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes our cash flows for the periods indicated (amounts in millions):</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:85.672%;"><tr><td style="width:1.0%;"></td><td style="width:69.843%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.651%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.653%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.653%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three-Month Periods<br/>Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash provided by operating activities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash used in investing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(70.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(328.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash provided by financing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">146.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">299.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net increase (decrease) in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">81.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash, cash equivalents and restricted cash at beginning of period</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">96.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash, cash equivalents and restricted cash at end of period</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">177.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash provided by operating activities decreased $14.1&#160;million during the three-month period ended March&#160;31, 2020 compared to the three-month period ended March&#160;31, 2019 primarily due to a decrease in our cash collections as result of our transition to PDGM. </span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash used in investing activities decreased $258.2&#160;million during the three-month period ended March&#160;31, 2020 compared to the three-month period ended March&#160;31, 2019 as a result of our acquisition of CCH in 2019.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash provided by financing activities decreased  $153.2&#160;million during the three-month period ended March&#160;31, 2020 compared to the three-month period ended March&#160;31, 2019 primarily due to borrowings under our Amended Credit Agreement to fund the CCH acquisition in 2019. </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">28</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Liquidity</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Typically, our principal source of liquidity is the collection of our patient accounts receivable, primarily through the Medicare program. In addition to our collection of patient accounts receivable, from time to time, we can and do obtain additional sources of liquidity by the incurrence of additional indebtedness. In order to mitigate the risk of any cash availability issues related to COVID-19, we borrowed $150 million under our Amended Credit Agreement in March 2020. While we have experienced disruption in our business volume, we have not seen a change in our collection trends and remain confident in our ability to fund our operations. </span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three-month period ended March&#160;31, 2020, we spent $1.4 million in capital expenditures as compared to $1.2 million during the three-month period ended March&#160;31, 2019. Our capital expenditures for 2020 are expected to be approximately $6.0 million to $8.0&#160;million, excluding the impact of any future acquisitions.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March&#160;31, 2020, we had $174.8 million in cash and cash equivalents and $299.8 million in availability under our $550.0&#160;million Revolving Credit Facility. </span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Based on our operating forecasts and our debt service requirements, we believe we will have sufficient liquidity to fund our operations, capital requirements and debt service requirements.</span></div><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Outstanding Patient Accounts Receivable</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our patient accounts receivable increased $31.0&#160;million from December&#160;31, 2019 to March&#160;31, 2020; $8.9 million of the increase is related to acquisition activity. We also experienced an increase related to the reduction in RAPs under PDGM. Our cash collection as a percentage of revenue was 102% and 101% for the three-month periods ended March&#160;31, 2020 and 2019, respectively. Our days revenue outstanding at March&#160;31, 2020 was 46.6 days which is an increase of 5.7 days from December&#160;31, 2019 and an increase of 5.4 days from March 31, 2019. As anticipated, the transition to PDGM has negatively impacted our days revenue outstanding; the estimated impact is 5.9 days. </span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our patient accounts receivable includes unbilled receivables and are aged based upon our initial service date. We monitor unbilled receivables on a care center by care center basis to ensure that all efforts are made to bill claims within timely filing deadlines. Our unbilled patient accounts receivable can be impacted by acquisition activity, probe edits or regulatory changes which result in additional information or procedures needed prior to billing. The timely filing deadline for Medicare is one year from the date the episode was completed and varies by state for Medicaid-reimbursable services and among insurance companies and other private payors.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following schedules detail our patient accounts receivable, by payor class, aged based upon initial date of service (amounts in millions, except days revenue outstanding):</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">29</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"><tr><td style="width:1.0%;"></td><td style="width:41.382%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.735%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.735%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.735%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.735%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.738%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0-90</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">91-180</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">181-365</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Over&#160;365</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">At March 31, 2020:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Medicare patient accounts receivable</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">143.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">163.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other patient accounts receivable:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Medicaid</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Private</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">69.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">76.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">88.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">105.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total patient accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">268.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Days revenue outstanding (1)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">46.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0-90</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">91-180</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">181-365</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Over 365</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">At December 31, 2019:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Medicare patient accounts receivable</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">115.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">136.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other patient accounts receivable:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Medicaid</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Private</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">60.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">68.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">82.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total patient accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">237.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Days revenue outstanding (1)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">40.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(1)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt;">Our calculation of days revenue outstanding is derived by dividing our ending patient accounts receivable at March&#160;31, 2020 and December&#160;31, 2019 by our average daily patient revenue for the three-month periods ended March&#160;31, 2020 and December&#160;31, 2019, respectively.</span></div><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Indebtedness</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">First Amendment to Amended and Restated Credit Agreement</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On February 4, 2019, we entered into the First Amendment to our Credit Agreement (as amended by the First Amendment, the "Amended Credit Agreement"). The Amended Credit Agreement provides for a senior secured credit facility in an initial aggregate principal amount of up to $725.0 million, which includes a $550.0 million Revolving Credit Facility under the Credit Agreement and a term loan facility with a principal amount of up to $175.0 million (the "Term Loan Facility" and collectively with the Revolving Credit Facility, the "Credit Facility"), which was added by the First Amendment.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We borrowed the entire principal amount of the Term Loan Facility on February 4, 2019 in order to fund a portion of the purchase price of the CCH acquisition, with the remainder of the purchase price and associated transactional fees and expenses funded by proceeds from the Revolving Credit Facility. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our weighted average interest rate for borrowings under our $550.0 million Revolving Credit Facility was 3.2% and 4.2% for the three-month periods ended March&#160;31, 2020 and March 31, 2019, respectively. Our weighted average interest rate for borrowings under our $175.0 million Term Loan Facility was 3.2% for the three-month period ended March&#160;31, 2020 and 4.2% for the period February 4, 2019 to March 31, 2019.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March&#160;31, 2020, our consolidated leverage ratio was 1.5, our consolidated interest coverage ratio was 16.6 and we are in compliance with our covenants under the Amended Credit Agreement.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March&#160;31, 2020, our availability under our $550.0&#160;million Revolving Credit Facility was $299.8 million as we have $220.0 million outstanding in borrowings and $30.2 million outstanding in letters of credit.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">See Note 4 - Long Term Obligations to our condensed consolidated financial statements for additional details on our outstanding long-term obligations.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">30</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Share Repurchase</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">2019 Stock Repurchase Program</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On February 25, 2019, we announced that our Board of Directors authorized a stock repurchase program, under which we may repurchase up to $100 million of our outstanding common stock through March 1, 2020.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the terms of the program, we were allowed to repurchase shares from time to time in open market transactions, block purchases or in private transactions in accordance with applicable federal securities laws and other legal requirements. We were allowed to enter into Rule 10b5-1 plans to effect some or all of the repurchases. The timing and the amount of the repurchases would be determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors. </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We did not repurchase any shares pursuant to this stock repurchase program during the three-month periods ended March&#160;31, 2020 or March 31, 2019. The stock repurchase program expired on March 1, 2020.</span></div><div style="text-align:justify;margin-top:6pt;"><span><br/></span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Inflation</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We do not believe inflation has significantly impacted our results of operations.</span></div><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Critical Accounting Estimates</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">See Part II, Item 7 &#8211; Critical Accounting Estimates and our consolidated financial statements and related notes in Part II, Item 8 of our 2019 Annual Report on Form 10-K, for accounting policies and related estimates we believe are the most critical to understanding our condensed consolidated financial statements, financial condition and results of operations and which require complex management judgment and assumptions, or involve uncertainties. These critical accounting estimates include revenue recognition and goodwill and other intangible assets. There have not been any changes to our significant accounting policies or their application since we filed our 2019 Annual Report on Form 10-K.</span></div><div id="i793e68cdccb44b98a73aef6e33f497bf_91"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM&#160;3.&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are exposed to market risk from fluctuations in interest rates. Our Revolving Credit Facility carries a floating interest rate which is tied to the Eurodollar rate (</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">i.e.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> LIBOR) and the Prime Rate and therefore, our condensed consolidated statements of operations and our condensed consolidated statements of cash flows are exposed to changes in interest rates. As of March&#160;31, 2020, the total amount of outstanding debt subject to interest rate fluctuations was $390.6 million. A 1.0% interest rate change would cause interest expense to change by approximately $3.9&#160;million annually, assuming the Company makes no principal repayments.</span></div><div id="i793e68cdccb44b98a73aef6e33f497bf_94"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM&#160;4.&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Evaluation of Disclosure Controls and Procedures</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have established disclosure controls and procedures which are designed to provide reasonable assurance of achieving their objectives and to ensure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), is recorded, processed, summarized, disclosed and reported within the time periods specified in the SEC&#8217;s rules and forms. This information is also accumulated and communicated to our management and Board of Directors to allow timely decisions regarding required disclosure.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the preparation of this Quarterly Report on Form 10-Q, as of March&#160;31, 2020, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures, as such term is defined under Rules 13a-15(e) and 15d-15(e) promulgated under the Exchange Act.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective at a reasonable assurance level as of March&#160;31, 2020, the end of the period covered by this Quarterly Report.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">31</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Changes in Internal Controls</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There have been no changes in our internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f)) that have occurred during the quarter ended March&#160;31, 2020, that have materially impacted, or are reasonably likely to materially impact, our internal control over financial reporting.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Inherent Limitations on Effectiveness of Controls</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our management, including our principal executive officer and principal financial officer, does not expect that our disclosure controls or our internal controls over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls&#8217; effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies and procedures. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives and, based on an evaluation of our controls and procedures, our principal executive officer and our principal financial officer concluded our disclosure controls and procedures were effective at a reasonable assurance level as of March&#160;31, 2020, the end of the period covered by this Quarterly Report.</span></div><div style="margin-top:6pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">32</span></div></div></div><div id="i793e68cdccb44b98a73aef6e33f497bf_97"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PART II. OTHER INFORMATION</span></div><div id="i793e68cdccb44b98a73aef6e33f497bf_100"></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM&#160;1. LEGAL PROCEEDINGS</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">See Note 5 - Commitments and Contingencies to the condensed consolidated financial statements for information concerning our legal proceedings.</span></div><div id="i793e68cdccb44b98a73aef6e33f497bf_103"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM&#160;1A. RISK FACTORS</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There have been no material changes in the risk factors described in our Annual Report on Form 10-K for the year ended December 31, 2019, except for the risk factor below.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our business may be materially adversely affected by the ongoing novel coronavirus ("COVID-19") pandemic.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The recent outbreak of the COVID-19 pandemic has resulted in a general economic downturn and volatility in the stock market and has also caused and may continue to cause a decrease in our patient volumes and revenues, an increase in costs and an inability to access our patients and referral sources and could lead to staffing and medical supply shortages, any of which, or a combination of which, could have a material adverse effect on our business and financial results. The ultimate impact of COVID-19, including the impact on our liquidity, financial condition and results of operations, is uncertain and will depend on many factors and future developments, which are highly uncertain and cannot be predicted at this time, including the severity, scope and length of time that the pandemic continues, its impact on the national and global economy, its effect on the demand for our services, our ability to ensure the safety of our patients and employees and the actions taken by federal, state and local authorities to contain or treat the COVID-19 pandemic.</span></div><div id="i793e68cdccb44b98a73aef6e33f497bf_106"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM&#160;2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table provides the information with respect to purchases made by us of shares of our common stock during each of the months during the three-month period ended March&#160;31, 2020:</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:32.699%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.152%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.953%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.666%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.666%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.668%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Period</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:6pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(a)&#160;Total&#160;Number<br/>of&#160;Shares&#160;(or&#160;Units)<br/>Purchased</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:6pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:6pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(b)&#160;Average&#160;Price<br/>Paid&#160;per&#160;Share&#160;(or<br/>Unit)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:6pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(c)&#160;Total&#160;Number&#160;of<br/>Shares (or Units)<br/>Purchased&#160;as&#160;Part&#160;of<br/>Publicly Announced<br/>Plans or Programs</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:6pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(d)&#160;Maximum&#160;Number&#160;(or<br/>Approximate Dollar<br/>Value) of Shares (or<br/>Units) That May Yet Be<br/>Purchased Under the<br/>Plans or Programs (2)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January 1, 2020&#160;to&#160;January 31,&#160;2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,542&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">173.73&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100,000,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">February 1,&#160;2020&#160;to February 29,&#160;2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,651&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">196.79&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100,000,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 1, 2020 to March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,046&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">180.24&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,239&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">182.10&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-18pt;padding-left:31.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(1)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt;">Includes shares of common stock surrendered to us by certain employees to satisfy tax withholding obligations in connection with the vesting of non-vested stock previously awarded to such employees under our 2008 and 2018 Omnibus Incentive Compensation Plans.</span></div><div style="text-indent:-18pt;padding-left:31.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(2)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt;">On February 25, 2019, our Board of Directors authorized a share repurchase program, pursuant to which we could repurchase up to $100 million of our outstanding shares of common stock through March 1, 2020, when the share repurchase program expired.</span></div><div id="i793e68cdccb44b98a73aef6e33f497bf_109"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM&#160;3. DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">None.</span></div><div id="i793e68cdccb44b98a73aef6e33f497bf_112"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM&#160;4. MINE SAFETY DISCLOSURES</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Not applicable.</span></div><div id="i793e68cdccb44b98a73aef6e33f497bf_115"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM&#160;5. OTHER INFORMATION</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">None.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">33</span></div></div></div><div id="i793e68cdccb44b98a73aef6e33f497bf_118"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM&#160;6. EXHIBITS</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The exhibits marked with the cross symbol (&#8224;) are filed and the exhibits marked with a double cross (&#8224;&#8224;) are furnished with this Form 10-Q. Any exhibits marked with the asterisk symbol (*) are management contracts or compensatory plans or arrangements filed pursuant to Item 601(b)(10)(iii) of Regulation S-K. </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:8.410%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:42.721%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:22.486%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.530%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.654%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exhibit<br/>Number</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Document Description</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Report or Registration Statement</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SEC File or<br/>Registration<br/>Number</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exhibit<br/>or Other<br/>Reference</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.1</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/896262/000119312507166703/dex31.htm">Composite of Certificate of Incorporation of the Company inclusive of all amendments through June&#160;14, 2007</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">The Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended June&#160;30, 2007</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0-24260</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.2</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/896262/000089626219000014/amed-20193009xexx32.htm">Composite of By-Laws of the Company inclusive of all amendments through October 17, 2019</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">The Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0-24260</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8224;31.1</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="amed-20203103xexx311.htm">Certification of Paul B. Kusserow, President and Chief Executive Officer (principal executive officer), pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8224;31.2</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="amed-20203103xexx312.htm">Certification of Scott G. Ginn, Chief Financial Officer (principal financial officer), pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8224;&#8224;32.1</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="amed-20203103xexx321.htm">Certification of Paul B. Kusserow, President and Chief Executive Officer (principal executive officer), pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8224;&#8224;32.2</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="amed-20203103xexx322.htm">Certification of Scott G. Ginn, Chief Financial Officer (principal financial officer), pursuant to 18&#160;U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8224;101.INS</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Instance - The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8224;101.SCH</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8224;101.CAL</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8224;101.DEF</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Taxonomy Extension Definition Linkbase</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8224;101.LAB</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Taxonomy Extension Labels Linkbase Document</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8224;101.PRE</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">104</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">34</span></div></div></div><div id="i793e68cdccb44b98a73aef6e33f497bf_121"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SIGNATURES</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:39.912%;"><tr><td style="width:1.0%;"></td><td style="width:18.512%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:5.326%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:70.162%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">A</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">MEDISYS</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">, I</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">NC</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">(Registrant)</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ SCOTT G. GINN</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Scott G. Ginn,</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Principal Financial Officer and</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Duly Authorized Officer</span></td></tr></table></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Date: May&#160;7, 2020</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">35</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>amed-20203103xexx311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i1428640fdf7843768b9d655b1e1b7782_1"></div><div style="height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 31.1</font></div><div style="text-align:center;margin-top:24pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">I, Paul B. Kusserow, certify that&#58;</font></div><div style="padding-left:22.5pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1. I have reviewed this Quarterly Report on Form 10-Q for the quarter ended March&#160;31, 2020, of Amedisys, Inc.&#59;</font></div><div style="padding-left:22.5pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:22.5pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:22.5pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="padding-left:49.5pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:49.5pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:49.5pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">c. Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:49.5pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">d. Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="padding-left:22.5pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="padding-left:49.5pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:49.5pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Date&#58; May&#160;7, 2020 </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-align:right;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:32.748%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#47;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">S</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#47; Paul B. Kusserow</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Paul B. Kusserow</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">President and Chief Executive Officer<br>(Principal Executive Officer)</font></td></tr></table></div><div style="text-align:right;"><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>amed-20203103xexx312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="icf26b8a1da324c36be9129792c1d5fb3_1"></div><div style="height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 31.2</font></div><div style="text-align:center;margin-top:24pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">I, Scott G. Ginn, certify that&#58;</font></div><div style="padding-left:22.5pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1. I have reviewed this Quarterly Report on Form 10-Q for the quarter ended March&#160;31, 2020, of Amedisys, Inc.&#59;</font></div><div style="padding-left:22.5pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:22.5pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:22.5pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="padding-left:49.5pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:49.5pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:49.5pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">c. Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:49.5pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">d. Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="padding-left:22.5pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="padding-left:49.5pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:49.5pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Date&#58; May&#160;7, 2020 </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-align:right;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:25.000%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#47;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">S</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#47; Scott G. Ginn</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Scott G. Ginn<br>Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Principal Financial Officer)</font></td></tr></table></div><div style="text-align:right;"><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>amed-20203103xexx321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i2f56f08a4ebb412bbbd4e3cff8ca1794_1"></div><div style="height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 32.1</font></div><div style="text-align:center;margin-top:24pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the Quarterly Report of Amedisys, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the quarter ended March&#160;31, 2020 (the &#8220;Report&#8221;), I, Paul B. Kusserow, President and Chief Executive Officer of the Company, hereby certify to my knowledge, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="padding-left:22.5pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(1) The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="padding-left:22.5pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Date&#58; May&#160;7, 2020 </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:32.748%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#47;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">S</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#47; Paul B. Kusserow</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Paul B. Kusserow<br>President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>amed-20203103xexx322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="id85f56bc29b347fbb512a8c1a1826637_1"></div><div style="height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 32.2</font></div><div style="text-align:center;margin-top:24pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the Quarterly Report of Amedisys, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the quarter ended March&#160;31, 2020 (the &#8220;Report&#8221;), I, Scott G. Ginn, Chief Financial Officer of the Company, hereby certify to my knowledge, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="padding-left:22.5pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(1) The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="padding-left:22.5pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Date&#58; May&#160;7, 2020 </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:25.000%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#47;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">S</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#47; Scott G. Ginn</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Scott G. Ginn<br>Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Principal Financial Officer)</font></td></tr></table></div><div><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>amed-20200331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:dde64841-3e1e-49e6-96d6-a911d3f838cb,g:d3a0c63a-9ddc-46a6-b2f9-35d46ac243f3-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:amed="http://www.amedisys.com/20200331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.amedisys.com/20200331">
  <xs:import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amed-20200331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amed-20200331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amed-20200331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amed-20200331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.amedisys.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement" roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement">
        <link:definition>1004005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS" roleURI="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS">
        <link:definition>2101101 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails" roleURI="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails">
        <link:definition>2402401 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>2103102 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>2204201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables">
        <link:definition>2305301 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails">
        <link:definition>2406402 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails">
        <link:definition>2407403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue by Payor Class (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails">
        <link:definition>2408404 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash and Cash Equivalents (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails">
        <link:definition>2409405 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Patient Accounts Receivable Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails">
        <link:definition>2410406 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value of Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails">
        <link:definition>2411407 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Weighted-Average Shares Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONS" roleURI="http://www.amedisys.com/role/ACQUISITIONS">
        <link:definition>2112103 - Disclosure - ACQUISITIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONSTables" roleURI="http://www.amedisys.com/role/ACQUISITIONSTables">
        <link:definition>2313302 - Disclosure - ACQUISITIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONSNarrativeDetails" roleURI="http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails">
        <link:definition>2414408 - Disclosure - ACQUISITIONS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONSProFormaDetails" roleURI="http://www.amedisys.com/role/ACQUISITIONSProFormaDetails">
        <link:definition>2415409 - Disclosure - ACQUISITIONS - Pro Forma (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LONGTERMOBLIGATIONS" roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONS">
        <link:definition>2116104 - Disclosure - LONG-TERM OBLIGATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LONGTERMOBLIGATIONSLONGTERMOBLIGATIONSTables" roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSLONGTERMOBLIGATIONSTables">
        <link:definition>2317303 - Disclosure - LONG-TERM OBLIGATIONS LONG-TERM OBLIGATIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails" roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails">
        <link:definition>2418410 - Disclosure - LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails_1" roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails_1">
        <link:definition>2418410 - Disclosure - LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails" roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails">
        <link:definition>2419411 - Disclosure - LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails" roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails">
        <link:definition>2420412 - Disclosure - LONG-TERM OBLIGATIONS - Fees and Rates Under Credit Facilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LONGTERMOBLIGATIONSNarrativeDetails" roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails">
        <link:definition>2421413 - Disclosure - LONG-TERM OBLIGATIONS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>2122105 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESNarrativeDetails" roleURI="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails">
        <link:definition>2423414 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATION" roleURI="http://www.amedisys.com/role/SEGMENTINFORMATION">
        <link:definition>2124106 - Disclosure - SEGMENT INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONTables" roleURI="http://www.amedisys.com/role/SEGMENTINFORMATIONTables">
        <link:definition>2325304 - Disclosure - SEGMENT INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONNarrativeDetails" roleURI="http://www.amedisys.com/role/SEGMENTINFORMATIONNarrativeDetails">
        <link:definition>2426415 - Disclosure - SEGMENT INFORMATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails" roleURI="http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails">
        <link:definition>2427416 - Disclosure - SEGMENT INFORMATION - Operating Income of Reportable Segments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREREPURCHASESHAREREPURCHASE" roleURI="http://www.amedisys.com/role/SHAREREPURCHASESHAREREPURCHASE">
        <link:definition>2128107 - Disclosure - SHARE REPURCHASE SHARE REPURCHASE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREREPURCHASENarrativeDetails" roleURI="http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails">
        <link:definition>2429417 - Disclosure - SHARE REPURCHASE Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONSRELATEDPARTYTRANSACTIONS" roleURI="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSRELATEDPARTYTRANSACTIONS">
        <link:definition>2130108 - Disclosure - RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONSNarrativeDetails" roleURI="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails">
        <link:definition>2431418 - Disclosure - RELATED PARTY TRANSACTIONS Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENT" roleURI="http://www.amedisys.com/role/SUBSEQUENTEVENT">
        <link:definition>2132109 - Disclosure - SUBSEQUENT EVENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTNarrativeDetails" roleURI="http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails">
        <link:definition>2433419 - Disclosure - SUBSEQUENT EVENT - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="amed_WorkersCompensationInsuranceRetentionLimit" abstract="false" name="WorkersCompensationInsuranceRetentionLimit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_Percentageofclosingstockprice" abstract="false" name="Percentageofclosingstockprice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_EpisodeOfCareAsEpisodicBasedRevenueDuration" abstract="false" name="EpisodeOfCareAsEpisodicBasedRevenueDuration" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amed_TwoHundredMillionRevolvingCreditFacilityMember" abstract="true" name="TwoHundredMillionRevolvingCreditFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_AsanaHospiceMember" abstract="true" name="AsanaHospiceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_DebtInstrumentByLeverageRatioTrancheOneMember" abstract="true" name="DebtInstrumentByLeverageRatioTrancheOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_MaximumPercentOwnershipForCostMethodPercent" abstract="false" name="MaximumPercentOwnershipForCostMethodPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_ActualClaimsPayment" abstract="false" name="ActualClaimsPayment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_IndemnificationAmount" abstract="false" name="IndemnificationAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_FirstThresholdOfTherapyServicesRequired" abstract="false" name="FirstThresholdOfTherapyServicesRequired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_AsanaHospiceAquisitionMember" abstract="true" name="AsanaHospiceAquisitionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_AmendedCreditAgreementMember" abstract="true" name="AmendedCreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_TypeofEquityMethodInvestmentDomain" abstract="true" name="TypeofEquityMethodInvestmentDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_FundingReceivedFromCARESAct" abstract="false" name="FundingReceivedFromCARESAct" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_Paymentsrelatedtotaxassetandworkingcapital" abstract="false" name="Paymentsrelatedtotaxassetandworkingcapital" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" abstract="false" name="Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_AmedisysCIAMember" abstract="true" name="AmedisysCIAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_RoseRockHealthcareMember" abstract="true" name="RoseRockHealthcareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" abstract="false" name="DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_PersonalCareMember" abstract="true" name="PersonalCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_TotalLeverageRatio" abstract="false" name="TotalLeverageRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="amed_UsDepartmentOfJusticeMember" abstract="true" name="UsDepartmentOfJusticeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_CapYearAxis" abstract="true" name="CapYearAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="amed_NetServiceRevenuePeriodOfCarePaymentRateDuration" abstract="false" name="NetServiceRevenuePeriodOfCarePaymentRateDuration" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" abstract="false" name="DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_DebtInstrumentPeriodicPaymentPercentage" abstract="false" name="DebtInstrumentPeriodicPaymentPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements" abstract="false" name="FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_MajorSinglePayorCustomerMember" abstract="true" name="MajorSinglePayorCustomerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_PayorClassAxis" abstract="true" name="PayorClassAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" abstract="false" name="StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_ProfessionalLiabilityInsuranceRetentionLimit" abstract="false" name="ProfessionalLiabilityInsuranceRetentionLimit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_ShareRepurchaseLineItems" abstract="true" name="ShareRepurchaseLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" abstract="false" name="RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_LineOfCreditFacilityAdditionalBorrowingCapacity" abstract="false" name="LineOfCreditFacilityAdditionalBorrowingCapacity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare" abstract="false" name="MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_ClearwaterFloridaMember" abstract="true" name="ClearwaterFloridaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_HospiceNonMedicareMember" abstract="true" name="HospiceNonMedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_FloridaZpicRevenueReduction" abstract="false" name="FloridaZpicRevenueReduction" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_NumberOfClaimsSubmittedBySubsidiary" abstract="false" name="NumberOfClaimsSubmittedBySubsidiary" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_OneHundredSeventyFiveMillionTermLoanFacilityMember" abstract="true" name="OneHundredSeventyFiveMillionTermLoanFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple" abstract="false" name="CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009" abstract="false" name="LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_PayorsDomain" abstract="true" name="PayorsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_NumberOfBeneficiaries" abstract="false" name="NumberOfBeneficiaries" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_ConsolidatedLeverageRatio" abstract="false" name="ConsolidatedLeverageRatio" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="amed_PeriodOfCareAsEpisodicBasedRevenueDuration" abstract="false" name="PeriodOfCareAsEpisodicBasedRevenueDuration" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amed_IncreaseDecreaseInOperatingLeaseLiability" abstract="false" name="IncreaseDecreaseInOperatingLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_PromissoryNotesMember" abstract="true" name="PromissoryNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_DebtInstrumentInterestRateatPeriodEnd" abstract="false" name="DebtInstrumentInterestRateatPeriodEnd" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" abstract="false" name="StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="amed_DebtInstrumentByLeverageRatioTrancheThreeMember" abstract="true" name="DebtInstrumentByLeverageRatioTrancheThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_HospiceMember" abstract="true" name="HospiceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations" abstract="false" name="LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_DebtIssuanceCostsPolicyPolicyTextBlock" abstract="false" name="DebtIssuanceCostsPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="amed_ErrorRatePercentage" abstract="false" name="ErrorRatePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_Creditfacilitymaximumallowableconsolidatedleverageratio" abstract="false" name="Creditfacilitymaximumallowableconsolidatedleverageratio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="amed_ShareRepurchaseTable" abstract="true" name="ShareRepurchaseTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="amed_NonMedicareRevenueTermRates" abstract="false" name="NonMedicareRevenueTermRates" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_CashPaidForOperatingLeaseLiabilities" abstract="false" name="CashPaidForOperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_EquityImpactofRepurchaseofNoncontrollingInterest" abstract="false" name="EquityImpactofRepurchaseofNoncontrollingInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_ChristianCareatHomeMember" abstract="true" name="ChristianCareatHomeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_ShareRepurchaseDomain" abstract="true" name="ShareRepurchaseDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_SecuritiesClassActionLawsuitMember" abstract="true" name="SecuritiesClassActionLawsuitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_KKRShareRepurchaseMember" abstract="true" name="KKRShareRepurchaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_OneHundredMillionTermLoanMember" abstract="true" name="OneHundredMillionTermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_FinancialInstrumentDetailsTableTextBlock" abstract="false" name="FinancialInstrumentDetailsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" abstract="false" name="PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_SecuritiesClassActionLawsuitsettlement" abstract="false" name="SecuritiesClassActionLawsuitsettlement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_PayorsAxis" abstract="true" name="PayorsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="amed_PriorCreditAgreementMember" abstract="true" name="PriorCreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_HealthInsuranceRetentionLimit" abstract="false" name="HealthInsuranceRetentionLimit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_SwingLineLoanMember" abstract="true" name="SwingLineLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_HistoricalCollectionRateFromMedicare" abstract="false" name="HistoricalCollectionRateFromMedicare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_ShareRepurchaseAxis" abstract="true" name="ShareRepurchaseAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="amed_FundingForHealthcareProvidersIncludingHospitals" abstract="false" name="FundingForHealthcareProvidersIncludingHospitals" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_CertificateOfNeedMember" abstract="true" name="CertificateOfNeedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember" abstract="true" name="FiveHundredFiftyMillionRevolvingCreditFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_WriteOffOfOtherComprehensiveIncome" abstract="false" name="WriteOffOfOtherComprehensiveIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_CompanysinsurancecarriersMember" abstract="true" name="CompanysinsurancecarriersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_ExtrapolatedMember" abstract="true" name="ExtrapolatedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_HealthcareanalyticscompanyMember" abstract="true" name="HealthcareanalyticscompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_InfinityHomeCareMember" abstract="true" name="InfinityHomeCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_ParkersburgWestVirginiaMember" abstract="true" name="ParkersburgWestVirginiaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_HomeHealthMember" abstract="true" name="HomeHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_EastTennesseePersonalCareServicesMember" abstract="true" name="EastTennesseePersonalCareServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" abstract="false" name="MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_PercentageofSharesOutstanding" abstract="false" name="PercentageofSharesOutstanding" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_PayorClassDomain" abstract="true" name="PayorClassDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset" abstract="false" name="AmortizationandImpairmentofOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_CashPaidForFinanceLeaseLiabilities" abstract="false" name="CashPaidForFinanceLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_MedicareLicenseMember" abstract="true" name="MedicareLicenseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_MedicareRevenueMember" abstract="true" name="MedicareRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_ThirdThresholdOfTherapyServicesRequired" abstract="false" name="ThirdThresholdOfTherapyServicesRequired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_Businessacquisitionproformaoperatingincomeloss" abstract="false" name="Businessacquisitionproformaoperatingincomeloss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_SupplementalDisclosuresOfNonCashActivityAbstract" abstract="true" name="SupplementalDisclosuresOfNonCashActivityAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="amed_HospiceMedicareMember" abstract="true" name="HospiceMedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome" abstract="false" name="EquityImpactOfWriteOffOfOtherComprehensiveIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_RevolvingCreditFacilityTotal" abstract="false" name="RevolvingCreditFacilityTotal" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_RecoveryAmountOfOverpaymentMadeToSubsidiary" abstract="false" name="RecoveryAmountOfOverpaymentMadeToSubsidiary" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_AcquiredNamesOfBusinessMember" abstract="true" name="AcquiredNamesOfBusinessMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue" abstract="false" name="Revenuebypayorclassasapercentageoftotalnetservicerevenue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_HomeHealthNonMedicareNonEpisodicBasedMember" abstract="true" name="HomeHealthNonMedicareNonEpisodicBasedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_RevenueAdjustmentToMedicareRevenue" abstract="false" name="RevenueAdjustmentToMedicareRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_LetterOfCreditFee" abstract="false" name="LetterOfCreditFee" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" abstract="false" name="EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_CorporateIntegrityAgreementTerm" abstract="false" name="CorporateIntegrityAgreementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amed_CompassionateCareHospiceCIAMember" abstract="true" name="CompassionateCareHospiceCIAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_ProceedsReceivedFromLoanPartyOfSubsidiary" abstract="false" name="ProceedsReceivedFromLoanPartyOfSubsidiary" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_ProceedsFromBorrowingsUnderTermLoan" abstract="false" name="ProceedsFromBorrowingsUnderTermLoan" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_PercentageOfTotalReimbursementOfOutlierPayment" abstract="false" name="PercentageOfTotalReimbursementOfOutlierPayment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_UnfavorableMember" abstract="true" name="UnfavorableMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_MorgantownWestVirginiaMember" abstract="true" name="MorgantownWestVirginiaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_TypeofEquityMethodInvestmentAxis" abstract="true" name="TypeofEquityMethodInvestmentAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="amed_SecondThresholdOfServicesRequired" abstract="false" name="SecondThresholdOfServicesRequired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare" abstract="false" name="RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_AseraCareHospiceMember" abstract="true" name="AseraCareHospiceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_DebtInstrumentByLeverageRatioTrancheTwoMember" abstract="true" name="DebtInstrumentByLeverageRatioTrancheTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_InternalAuditComplianceReviewMember" abstract="true" name="InternalAuditComplianceReviewMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_COVID19PPEMember" abstract="true" name="COVID19PPEMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_CapYearDomain" abstract="true" name="CapYearDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_DebtInstrumentByLeverageRatioTrancheFourMember" abstract="true" name="DebtInstrumentByLeverageRatioTrancheFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_DebtInstrumentCarryingAmountExcludingFinanceLeases" abstract="false" name="DebtInstrumentCarryingAmountExcludingFinanceLeases" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_SafeguardZoneProgramIntegrityContractorMember" abstract="true" name="SafeguardZoneProgramIntegrityContractorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_PercentageOfPatientReceivablesOutstanding" abstract="false" name="PercentageOfPatientReceivablesOutstanding" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" abstract="false" name="RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_CompassionateCareHospiceMember" abstract="true" name="CompassionateCareHospiceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_Discountedclosingstockprice" abstract="false" name="Discountedclosingstockprice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" abstract="false" name="PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_OperatingCareCenters" abstract="false" name="OperatingCareCenters" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_ConsolidatedInterestCoverageRatio" abstract="false" name="ConsolidatedInterestCoverageRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="amed_CashDistributionToNoncontrollingInterest" abstract="false" name="CashDistributionToNoncontrollingInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_AccountsReceivablePortionDerivedFromMedicare" abstract="false" name="AccountsReceivablePortionDerivedFromMedicare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_Numberofpatients" abstract="false" name="Numberofpatients" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_LakelandFloridaMember" abstract="true" name="LakelandFloridaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_AdditionalFundingDistributedToHealthcareProviders" abstract="false" name="AdditionalFundingDistributedToHealthcareProviders" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_MinimumPercentOwnershipForControllingInterestPercent" abstract="false" name="MinimumPercentOwnershipForControllingInterestPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_SurrenderedShares" abstract="false" name="SurrenderedShares" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_MaximumPercentOwnershipForEquityMethodPercent" abstract="false" name="MaximumPercentOwnershipForEquityMethodPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_CapYearTwoThousandThirteenThroughTwoThousandTwentyMember" abstract="true" name="CapYearTwoThousandThirteenThroughTwoThousandTwentyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_NonVestedStockAndStockUnits" abstract="false" name="NonVestedStockAndStockUnits" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="amed_HospiceMedicareRevenueRateAccountedForRoutineCare" abstract="false" name="HospiceMedicareRevenueRateAccountedForRoutineCare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_LowUtilizationPaymentAdjustmentNumberOfVisits" abstract="false" name="LowUtilizationPaymentAdjustmentNumberOfVisits" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_HomeHealthNonMedicareEpisodicBasedMember" abstract="true" name="HomeHealthNonMedicareEpisodicBasedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_HomeHealthMedicareMember" abstract="true" name="HomeHealthMedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_PaymentsForRepurchaseOfNoncontrollingInterest" abstract="false" name="PaymentsForRepurchaseOfNoncontrollingInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_MedalogixMember" abstract="true" name="MedalogixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>amed-20200331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:dde64841-3e1e-49e6-96d6-a911d3f838cb,g:d3a0c63a-9ddc-46a6-b2f9-35d46ac243f3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.amedisys.com/role/Cover" xlink:type="simple" xlink:href="amed-20200331.xsd#Cover"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/Cover" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="amed-20200331.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_b6b1b7ca-cc60-417d-9f11-7b144b73640e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_6b94f99a-130b-4fcd-82a2-60da483e45eb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_b6b1b7ca-cc60-417d-9f11-7b144b73640e" xlink:to="loc_us-gaap_LiabilitiesCurrent_6b94f99a-130b-4fcd-82a2-60da483e45eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_b9ba033a-6624-498f-b279-52e892dd26fa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_b6b1b7ca-cc60-417d-9f11-7b144b73640e" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_b9ba033a-6624-498f-b279-52e892dd26fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_04c61cb5-3875-4cef-8606-9f771c11a4e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_b6b1b7ca-cc60-417d-9f11-7b144b73640e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_04c61cb5-3875-4cef-8606-9f771c11a4e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_46529992-f7f2-440b-86d1-2b4a28a85c44" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_b6b1b7ca-cc60-417d-9f11-7b144b73640e" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_46529992-f7f2-440b-86d1-2b4a28a85c44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_682daedd-3523-4e4d-b0b7-b1dc79fb7fcf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_c7ce9990-ddd9-48ac-9150-e23e7e4fcc2a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_682daedd-3523-4e4d-b0b7-b1dc79fb7fcf" xlink:to="loc_us-gaap_Liabilities_c7ce9990-ddd9-48ac-9150-e23e7e4fcc2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0e951455-225f-4a64-a8a6-3d9fadb4995e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_682daedd-3523-4e4d-b0b7-b1dc79fb7fcf" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0e951455-225f-4a64-a8a6-3d9fadb4995e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_fab8eccc-14e4-4fd6-92b0-ec21cab4204e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_c4ced06c-a933-4e95-a886-386fbafb6b2e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_fab8eccc-14e4-4fd6-92b0-ec21cab4204e" xlink:to="loc_us-gaap_AccountsPayableCurrent_c4ced06c-a933-4e95-a886-386fbafb6b2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_5590352b-f34f-428c-93b4-de0b7b85378e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_fab8eccc-14e4-4fd6-92b0-ec21cab4204e" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_5590352b-f34f-428c-93b4-de0b7b85378e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1a7593d3-d093-4eba-b74f-ee04ff5ecd78" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_fab8eccc-14e4-4fd6-92b0-ec21cab4204e" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_1a7593d3-d093-4eba-b74f-ee04ff5ecd78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_92ae8d07-7069-4a89-8c5e-cb4d292a568e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_fab8eccc-14e4-4fd6-92b0-ec21cab4204e" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_92ae8d07-7069-4a89-8c5e-cb4d292a568e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_49beebf4-65c1-4316-83e8-76a7af25a148" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_fab8eccc-14e4-4fd6-92b0-ec21cab4204e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_49beebf4-65c1-4316-83e8-76a7af25a148" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2c4b4daf-7a90-4eac-9c65-9e4bdddbb627" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValueOutstanding_63cae569-e3a0-4c6f-bfd4-d3db5af66daa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValueOutstanding"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2c4b4daf-7a90-4eac-9c65-9e4bdddbb627" xlink:to="loc_us-gaap_PreferredStockValueOutstanding_63cae569-e3a0-4c6f-bfd4-d3db5af66daa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_1c264b51-7c0b-4c1e-9fc0-9ccda39e205c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2c4b4daf-7a90-4eac-9c65-9e4bdddbb627" xlink:to="loc_us-gaap_CommonStockValueOutstanding_1c264b51-7c0b-4c1e-9fc0-9ccda39e205c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_852fd6ac-c18d-48d3-8f48-4547acea2c4b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2c4b4daf-7a90-4eac-9c65-9e4bdddbb627" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_852fd6ac-c18d-48d3-8f48-4547acea2c4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_e85dddc6-31ab-46d2-be14-1c9c8f0e45c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2c4b4daf-7a90-4eac-9c65-9e4bdddbb627" xlink:to="loc_us-gaap_TreasuryStockValue_e85dddc6-31ab-46d2-be14-1c9c8f0e45c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_85deb2e8-a23f-40ac-9cbd-7f4f07d46373" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2c4b4daf-7a90-4eac-9c65-9e4bdddbb627" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_85deb2e8-a23f-40ac-9cbd-7f4f07d46373" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8db9fc3b-2d2d-40f1-82dd-9538ecf0ffc8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2c4b4daf-7a90-4eac-9c65-9e4bdddbb627" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8db9fc3b-2d2d-40f1-82dd-9538ecf0ffc8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_95dd5ecf-82b0-4d2e-8c7c-5f1ae6dd6ba9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_eabdb69f-07aa-46a8-ba40-ea15b4de7cd1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_95dd5ecf-82b0-4d2e-8c7c-5f1ae6dd6ba9" xlink:to="loc_us-gaap_AssetsCurrent_eabdb69f-07aa-46a8-ba40-ea15b4de7cd1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6f9290ea-e6b7-446b-9851-48a028ca032a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_95dd5ecf-82b0-4d2e-8c7c-5f1ae6dd6ba9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6f9290ea-e6b7-446b-9851-48a028ca032a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_71f1f3f6-62bd-491d-9842-db0c67c0206c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_95dd5ecf-82b0-4d2e-8c7c-5f1ae6dd6ba9" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_71f1f3f6-62bd-491d-9842-db0c67c0206c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f3e212fa-7ab8-4723-afd2-e20c38b11d9e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_95dd5ecf-82b0-4d2e-8c7c-5f1ae6dd6ba9" xlink:to="loc_us-gaap_Goodwill_f3e212fa-7ab8-4723-afd2-e20c38b11d9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5eda6cfb-56a6-47f9-84c7-f520e35ed094" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_95dd5ecf-82b0-4d2e-8c7c-5f1ae6dd6ba9" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5eda6cfb-56a6-47f9-84c7-f520e35ed094" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_33f44b5a-c82a-424c-a01d-e54760fc4505" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_95dd5ecf-82b0-4d2e-8c7c-5f1ae6dd6ba9" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_33f44b5a-c82a-424c-a01d-e54760fc4505" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_5cc514a6-afb9-40cf-ae15-f7053d4ee436" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_95dd5ecf-82b0-4d2e-8c7c-5f1ae6dd6ba9" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_5cc514a6-afb9-40cf-ae15-f7053d4ee436" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_46deb6ff-844b-4522-987b-985c022fb068" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_854214cf-3dca-40ae-9e78-e591bc4e607b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_46deb6ff-844b-4522-987b-985c022fb068" xlink:to="loc_us-gaap_StockholdersEquity_854214cf-3dca-40ae-9e78-e591bc4e607b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_7a19c67e-c2a5-4565-af24-e1def8e9f8f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_46deb6ff-844b-4522-987b-985c022fb068" xlink:to="loc_us-gaap_MinorityInterest_7a19c67e-c2a5-4565-af24-e1def8e9f8f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1b9045ea-8ea0-4d65-a96c-f02589617c0c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2c5bbc65-2c6a-4c8b-a73a-2ac2055779c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1b9045ea-8ea0-4d65-a96c-f02589617c0c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2c5bbc65-2c6a-4c8b-a73a-2ac2055779c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_c9d2bfcf-9418-4d3c-8111-604b83b0fdb6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1b9045ea-8ea0-4d65-a96c-f02589617c0c" xlink:to="loc_us-gaap_RestrictedCash_c9d2bfcf-9418-4d3c-8111-604b83b0fdb6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_af588e86-16da-49aa-9c67-980cb0e4df97" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1b9045ea-8ea0-4d65-a96c-f02589617c0c" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_af588e86-16da-49aa-9c67-980cb0e4df97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_d544bf3a-52a7-4d2f-acaa-33182c2bd365" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1b9045ea-8ea0-4d65-a96c-f02589617c0c" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_d544bf3a-52a7-4d2f-acaa-33182c2bd365" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_830cb831-db23-4e8e-96ac-e279ef3e18db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1b9045ea-8ea0-4d65-a96c-f02589617c0c" xlink:to="loc_us-gaap_OtherAssetsCurrent_830cb831-db23-4e8e-96ac-e279ef3e18db" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="amed-20200331.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="amed-20200331.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f4b280aa-982f-4987-9310-9fb997b3c9c9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_8fc75f25-f358-455f-9761-ddf8d55aaaf5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_f4b280aa-982f-4987-9310-9fb997b3c9c9" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_8fc75f25-f358-455f-9761-ddf8d55aaaf5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_d8832d59-d5d6-4066-8698-3b68c221bf68" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_f4b280aa-982f-4987-9310-9fb997b3c9c9" xlink:to="loc_us-gaap_CostsAndExpenses_d8832d59-d5d6-4066-8698-3b68c221bf68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_482518ed-41ef-4830-8846-309d1b7dc214" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_1b5bca9c-a2df-4bd7-8c4b-547ab79f325c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_482518ed-41ef-4830-8846-309d1b7dc214" xlink:to="loc_us-gaap_OperatingIncomeLoss_1b5bca9c-a2df-4bd7-8c4b-547ab79f325c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_2602dfac-8855-4978-858b-f20332f63e86" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_482518ed-41ef-4830-8846-309d1b7dc214" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_2602dfac-8855-4978-858b-f20332f63e86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_f07f3a0c-772b-4cc9-bd0a-babbf96fff6c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend_3dd1a5f7-19ca-4858-a696-85a8a9dad3a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_f07f3a0c-772b-4cc9-bd0a-babbf96fff6c" xlink:to="loc_us-gaap_InvestmentIncomeInterestAndDividend_3dd1a5f7-19ca-4858-a696-85a8a9dad3a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_27ebc558-4f21-4fa0-b4a9-9aac0cf57d5f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_f07f3a0c-772b-4cc9-bd0a-babbf96fff6c" xlink:to="loc_us-gaap_InterestExpense_27ebc558-4f21-4fa0-b4a9-9aac0cf57d5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_afb9b256-9ca6-44ca-adc9-8ec8bdab64e8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_f07f3a0c-772b-4cc9-bd0a-babbf96fff6c" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_afb9b256-9ca6-44ca-adc9-8ec8bdab64e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_e1c16446-60f3-42c6-be40-1b1da90be601" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_f07f3a0c-772b-4cc9-bd0a-babbf96fff6c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_e1c16446-60f3-42c6-be40-1b1da90be601" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_59b99023-e0f6-446e-8eff-70d44344ebef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_c755b23a-c787-4898-9c38-ad57971f8626" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_59b99023-e0f6-446e-8eff-70d44344ebef" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_c755b23a-c787-4898-9c38-ad57971f8626" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_59a58f83-6ba7-426a-bcd9-2d851eea466a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_59b99023-e0f6-446e-8eff-70d44344ebef" xlink:to="loc_us-gaap_LaborAndRelatedExpense_59a58f83-6ba7-426a-bcd9-2d851eea466a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_35a8210b-f934-4fdb-8417-5a695be5705c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_59b99023-e0f6-446e-8eff-70d44344ebef" xlink:to="loc_us-gaap_ShareBasedCompensation_35a8210b-f934-4fdb-8417-5a695be5705c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense_7356b8e6-247b-4cbd-8b61-da31f4cb84f1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_59b99023-e0f6-446e-8eff-70d44344ebef" xlink:to="loc_us-gaap_OtherGeneralAndAdministrativeExpense_7356b8e6-247b-4cbd-8b61-da31f4cb84f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_f94f37a1-317f-4815-96f9-11f3f52dc9d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_59b99023-e0f6-446e-8eff-70d44344ebef" xlink:to="loc_us-gaap_DepreciationAndAmortization_f94f37a1-317f-4815-96f9-11f3f52dc9d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_16ab0225-3d5f-4af2-bac8-b64d626398b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_19ca3e6e-672f-452b-bf03-5c1664bfc89f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_16ab0225-3d5f-4af2-bac8-b64d626398b5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_19ca3e6e-672f-452b-bf03-5c1664bfc89f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b443aef8-0c0e-4772-bcb6-0214962f02ac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_16ab0225-3d5f-4af2-bac8-b64d626398b5" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b443aef8-0c0e-4772-bcb6-0214962f02ac" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement" xlink:type="simple" xlink:href="amed-20200331.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="amed-20200331.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7c461144-3282-47b8-97f5-80e09b882762" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments_da620839-9834-431d-8af0-51e286ebc86d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfRestrictedInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7c461144-3282-47b8-97f5-80e09b882762" xlink:to="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments_da620839-9834-431d-8af0-51e286ebc86d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_c6ff8050-f4ba-4077-9647-acc1533905ad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7c461144-3282-47b8-97f5-80e09b882762" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_c6ff8050-f4ba-4077-9647-acc1533905ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_0fc94f31-7acf-44fd-b0f3-efc4bc4ce521" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7c461144-3282-47b8-97f5-80e09b882762" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_0fc94f31-7acf-44fd-b0f3-efc4bc4ce521" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_64904602-67da-4e54-84ff-76ea43eb0a1d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7c461144-3282-47b8-97f5-80e09b882762" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_64904602-67da-4e54-84ff-76ea43eb0a1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_87b1da9a-1bf8-4429-a3cb-1f6a5a242f46" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7c461144-3282-47b8-97f5-80e09b882762" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_87b1da9a-1bf8-4429-a3cb-1f6a5a242f46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c7e65ec4-e1f0-4a69-907c-bce68daa11d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_a4d20572-8f47-4411-b522-5bb5ea51282d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c7e65ec4-e1f0-4a69-907c-bce68daa11d3" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_a4d20572-8f47-4411-b522-5bb5ea51282d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_a40a2b15-c957-47d5-9663-c536c228783d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c7e65ec4-e1f0-4a69-907c-bce68daa11d3" xlink:to="loc_us-gaap_ProceedsFromStockPlans_a40a2b15-c957-47d5-9663-c536c228783d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_898839b7-e473-460e-bd7d-82e3b33704d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c7e65ec4-e1f0-4a69-907c-bce68daa11d3" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_898839b7-e473-460e-bd7d-82e3b33704d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CashDistributionToNoncontrollingInterest_0f9371f2-b2d0-448e-89b5-635b4e2fe14f" xlink:href="amed-20200331.xsd#amed_CashDistributionToNoncontrollingInterest"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c7e65ec4-e1f0-4a69-907c-bce68daa11d3" xlink:to="loc_amed_CashDistributionToNoncontrollingInterest_0f9371f2-b2d0-448e-89b5-635b4e2fe14f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProceedsFromBorrowingsUnderTermLoan_3391a01b-4ab3-4b7a-9a29-605e4c937879" xlink:href="amed-20200331.xsd#amed_ProceedsFromBorrowingsUnderTermLoan"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c7e65ec4-e1f0-4a69-907c-bce68daa11d3" xlink:to="loc_amed_ProceedsFromBorrowingsUnderTermLoan_3391a01b-4ab3-4b7a-9a29-605e4c937879" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_9deac389-4a20-4482-986d-27576d5398b7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c7e65ec4-e1f0-4a69-907c-bce68daa11d3" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_9deac389-4a20-4482-986d-27576d5398b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_cff9d2a3-6e93-4f4b-9459-2df0138ea100" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c7e65ec4-e1f0-4a69-907c-bce68daa11d3" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_cff9d2a3-6e93-4f4b-9459-2df0138ea100" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_fc298c74-853e-4242-884b-885aa3e9e2e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c7e65ec4-e1f0-4a69-907c-bce68daa11d3" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_fc298c74-853e-4242-884b-885aa3e9e2e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_1d6e3a55-5b73-4634-8570-4e9ee5db653d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c7e65ec4-e1f0-4a69-907c-bce68daa11d3" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_1d6e3a55-5b73-4634-8570-4e9ee5db653d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5d68b00e-b663-48cf-9838-5c615a4921c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_ad0c26c5-f322-4e77-9749-9e7928360cd8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5d68b00e-b663-48cf-9838-5c615a4921c4" xlink:to="loc_us-gaap_ProfitLoss_ad0c26c5-f322-4e77-9749-9e7928360cd8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_b40f4418-1513-407a-b9ed-a4eaeda17fc2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5d68b00e-b663-48cf-9838-5c615a4921c4" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_b40f4418-1513-407a-b9ed-a4eaeda17fc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_aa51ad0b-52ca-4cf9-8949-f1da0d6cdbc1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5d68b00e-b663-48cf-9838-5c615a4921c4" xlink:to="loc_us-gaap_ShareBasedCompensation_aa51ad0b-52ca-4cf9-8949-f1da0d6cdbc1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionExpense_920ddd55-abe3-4a53-be80-94fbffaa5bd9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5d68b00e-b663-48cf-9838-5c615a4921c4" xlink:to="loc_us-gaap_PensionExpense_920ddd55-abe3-4a53-be80-94fbffaa5bd9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset_af7b104a-e9ce-47e0-9d04-0aeaa51ffa7e" xlink:href="amed-20200331.xsd#amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5d68b00e-b663-48cf-9838-5c615a4921c4" xlink:to="loc_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset_af7b104a-e9ce-47e0-9d04-0aeaa51ffa7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_dad55aa7-7732-4af6-9c50-e6452459ee62" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5d68b00e-b663-48cf-9838-5c615a4921c4" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_dad55aa7-7732-4af6-9c50-e6452459ee62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_WriteOffOfOtherComprehensiveIncome_ed2e1e22-4a90-4f35-a0b5-33313a62b064" xlink:href="amed-20200331.xsd#amed_WriteOffOfOtherComprehensiveIncome"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5d68b00e-b663-48cf-9838-5c615a4921c4" xlink:to="loc_amed_WriteOffOfOtherComprehensiveIncome_ed2e1e22-4a90-4f35-a0b5-33313a62b064" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_4c053b30-8505-447e-a816-b9aea8745631" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5d68b00e-b663-48cf-9838-5c615a4921c4" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_4c053b30-8505-447e-a816-b9aea8745631" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_cd338971-f456-488a-996b-736dcc3f3b84" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5d68b00e-b663-48cf-9838-5c615a4921c4" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_cd338971-f456-488a-996b-736dcc3f3b84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_2dc35789-0dc3-4c26-8e75-189bfbdc8f9e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5d68b00e-b663-48cf-9838-5c615a4921c4" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_2dc35789-0dc3-4c26-8e75-189bfbdc8f9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_c634912e-9698-44b2-abed-1fa6fbe7a787" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5d68b00e-b663-48cf-9838-5c615a4921c4" xlink:to="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_c634912e-9698-44b2-abed-1fa6fbe7a787" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_48836575-07ab-4a9a-bffe-43d654180aa2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5d68b00e-b663-48cf-9838-5c615a4921c4" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_48836575-07ab-4a9a-bffe-43d654180aa2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0a35424f-dde2-44cc-b9b3-25d9b026de3d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5d68b00e-b663-48cf-9838-5c615a4921c4" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0a35424f-dde2-44cc-b9b3-25d9b026de3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_e2d12043-905e-43d1-8b17-212c550e04cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5d68b00e-b663-48cf-9838-5c615a4921c4" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_e2d12043-905e-43d1-8b17-212c550e04cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_cc05c777-1b13-4518-8a9d-92752756ed67" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5d68b00e-b663-48cf-9838-5c615a4921c4" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_cc05c777-1b13-4518-8a9d-92752756ed67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_4b42edc5-1dcb-4ac9-85e3-10b38f1a353a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5d68b00e-b663-48cf-9838-5c615a4921c4" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_4b42edc5-1dcb-4ac9-85e3-10b38f1a353a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_2a5b0fad-d29c-46c5-8189-287b5769bcb8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5d68b00e-b663-48cf-9838-5c615a4921c4" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_2a5b0fad-d29c-46c5-8189-287b5769bcb8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncreaseDecreaseInOperatingLeaseLiability_299135f2-be60-4417-8923-2edd5aac3524" xlink:href="amed-20200331.xsd#amed_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5d68b00e-b663-48cf-9838-5c615a4921c4" xlink:to="loc_amed_IncreaseDecreaseInOperatingLeaseLiability_299135f2-be60-4417-8923-2edd5aac3524" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_eaad216d-7b2e-44fc-ba42-3c15e3a5a4ca" xlink:href="amed-20200331.xsd#amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="19" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5d68b00e-b663-48cf-9838-5c615a4921c4" xlink:to="loc_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_eaad216d-7b2e-44fc-ba42-3c15e3a5a4ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_9f75b791-1933-427c-a537-8a655f6db8bc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_185c582e-5a3a-41d4-b504-fc834ce85068" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_9f75b791-1933-427c-a537-8a655f6db8bc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_185c582e-5a3a-41d4-b504-fc834ce85068" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_46db4b39-fcb8-4258-9eee-6d16eacea659" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_9f75b791-1933-427c-a537-8a655f6db8bc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_46db4b39-fcb8-4258-9eee-6d16eacea659" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c5b2f765-6bb5-4c17-881f-8e92cde31f27" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_9f75b791-1933-427c-a537-8a655f6db8bc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c5b2f765-6bb5-4c17-881f-8e92cde31f27" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS" xlink:type="simple" xlink:href="amed-20200331.xsd#NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails" xlink:type="simple" xlink:href="amed-20200331.xsd#NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="amed-20200331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="amed-20200331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="simple" xlink:href="amed-20200331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" xlink:type="simple" xlink:href="amed-20200331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails" xlink:type="simple" xlink:href="amed-20200331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails" xlink:type="simple" xlink:href="amed-20200331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails" xlink:type="simple" xlink:href="amed-20200331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="amed-20200331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails" xlink:type="simple" xlink:href="amed-20200331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7142dd69-e975-4e65-b450-60c8900c68fe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_bd2f9627-97c9-43ae-b85d-3cc8c19ec291" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7142dd69-e975-4e65-b450-60c8900c68fe" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_bd2f9627-97c9-43ae-b85d-3cc8c19ec291" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_3af588b2-8849-4783-8df1-9ebdd6f6e7cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7142dd69-e975-4e65-b450-60c8900c68fe" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_3af588b2-8849-4783-8df1-9ebdd6f6e7cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonVestedStockAndStockUnits_a92e0fec-22d4-4740-a9ee-df8cd5e6053c" xlink:href="amed-20200331.xsd#amed_NonVestedStockAndStockUnits"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7142dd69-e975-4e65-b450-60c8900c68fe" xlink:to="loc_amed_NonVestedStockAndStockUnits_a92e0fec-22d4-4740-a9ee-df8cd5e6053c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/ACQUISITIONS" xlink:type="simple" xlink:href="amed-20200331.xsd#ACQUISITIONS"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/ACQUISITIONS" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/ACQUISITIONSTables" xlink:type="simple" xlink:href="amed-20200331.xsd#ACQUISITIONSTables"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/ACQUISITIONSTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails" xlink:type="simple" xlink:href="amed-20200331.xsd#ACQUISITIONSNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/ACQUISITIONSProFormaDetails" xlink:type="simple" xlink:href="amed-20200331.xsd#ACQUISITIONSProFormaDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/ACQUISITIONSProFormaDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONS" xlink:type="simple" xlink:href="amed-20200331.xsd#LONGTERMOBLIGATIONS"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONS" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSLONGTERMOBLIGATIONSTables" xlink:type="simple" xlink:href="amed-20200331.xsd#LONGTERMOBLIGATIONSLONGTERMOBLIGATIONSTables"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSLONGTERMOBLIGATIONSTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails" xlink:type="simple" xlink:href="amed-20200331.xsd#LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_866caac3-db30-456b-ad57-35a708eba379" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_6498f6f8-30f6-452f-8849-de4249fe82eb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_866caac3-db30-456b-ad57-35a708eba379" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_6498f6f8-30f6-452f-8849-de4249fe82eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_131f4c5b-ec18-4418-8662-bbbd23ef3fb3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_866caac3-db30-456b-ad57-35a708eba379" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_131f4c5b-ec18-4418-8662-bbbd23ef3fb3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails_1" xlink:type="simple" xlink:href="amed-20200331.xsd#LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails_1"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_ab5bef09-9d32-43a1-bff4-41ff7d3f6643" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_1914174b-67bf-4f8a-b389-ac649ec12511" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_ab5bef09-9d32-43a1-bff4-41ff7d3f6643" xlink:to="loc_us-gaap_LongTermDebtCurrent_1914174b-67bf-4f8a-b389-ac649ec12511" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_8b812d6b-58a1-4106-ad5c-329ed76f8a7e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_ab5bef09-9d32-43a1-bff4-41ff7d3f6643" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_8b812d6b-58a1-4106-ad5c-329ed76f8a7e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails" xlink:type="simple" xlink:href="amed-20200331.xsd#LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails" xlink:type="simple" xlink:href="amed-20200331.xsd#LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails" xlink:type="simple" xlink:href="amed-20200331.xsd#LONGTERMOBLIGATIONSNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="amed-20200331.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="simple" xlink:href="amed-20200331.xsd#COMMITMENTSANDCONTINGENCIESNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/SEGMENTINFORMATION" xlink:type="simple" xlink:href="amed-20200331.xsd#SEGMENTINFORMATION"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/SEGMENTINFORMATION" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/SEGMENTINFORMATIONTables" xlink:type="simple" xlink:href="amed-20200331.xsd#SEGMENTINFORMATIONTables"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/SEGMENTINFORMATIONTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="simple" xlink:href="amed-20200331.xsd#SEGMENTINFORMATIONNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails" xlink:type="simple" xlink:href="amed-20200331.xsd#SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/SHAREREPURCHASESHAREREPURCHASE" xlink:type="simple" xlink:href="amed-20200331.xsd#SHAREREPURCHASESHAREREPURCHASE"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/SHAREREPURCHASESHAREREPURCHASE" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails" xlink:type="simple" xlink:href="amed-20200331.xsd#SHAREREPURCHASENarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSRELATEDPARTYTRANSACTIONS" xlink:type="simple" xlink:href="amed-20200331.xsd#RELATEDPARTYTRANSACTIONSRELATEDPARTYTRANSACTIONS"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSRELATEDPARTYTRANSACTIONS" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails" xlink:type="simple" xlink:href="amed-20200331.xsd#RELATEDPARTYTRANSACTIONSNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUBSEQUENTEVENT" xlink:type="simple" xlink:href="amed-20200331.xsd#SUBSEQUENTEVENT"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/SUBSEQUENTEVENT" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails" xlink:type="simple" xlink:href="amed-20200331.xsd#SUBSEQUENTEVENTNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>amed-20200331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:dde64841-3e1e-49e6-96d6-a911d3f838cb,g:d3a0c63a-9ddc-46a6-b2f9-35d46ac243f3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/Cover" xlink:type="simple" xlink:href="amed-20200331.xsd#Cover"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/Cover" xlink:type="extended" id="i2c2860252174473a9c00e05b17953c7b_Cover"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="amed-20200331.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended" id="iaf27698b5ad44f0d9862a1d234e331b2_CONSOLIDATEDBALANCESHEETS"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="amed-20200331.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended" id="ia1de89b80b094f98a0651f6c67e240d1_CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="amed-20200331.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended" id="iad6b610317b1408c8d00ca17440be2a6_CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement" xlink:type="simple" xlink:href="amed-20200331.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement" xlink:type="extended" id="i537702b0641b4be18939aa534d77ea85_CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_77970f72-5aef-4f5b-9deb-959dfcd4e224" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_04656be8-b02c-4b36-b106-709d03bb6ad9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_77970f72-5aef-4f5b-9deb-959dfcd4e224" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_04656be8-b02c-4b36-b106-709d03bb6ad9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_0abdb79c-1636-4e25-9987-a994044590fb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_77970f72-5aef-4f5b-9deb-959dfcd4e224" xlink:to="loc_us-gaap_SharesOutstanding_0abdb79c-1636-4e25-9987-a994044590fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_2d2a41c1-b5b9-4049-bb3e-9f88e66acb97" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_77970f72-5aef-4f5b-9deb-959dfcd4e224" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_2d2a41c1-b5b9-4049-bb3e-9f88e66acb97" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_10795db2-084e-4114-9c46-21830fb3dacb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_77970f72-5aef-4f5b-9deb-959dfcd4e224" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_10795db2-084e-4114-9c46-21830fb3dacb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_0ddde317-d379-4b06-8209-4065ee9cf7d7" xlink:href="amed-20200331.xsd#amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_77970f72-5aef-4f5b-9deb-959dfcd4e224" xlink:to="loc_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_0ddde317-d379-4b06-8209-4065ee9cf7d7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_ba56d976-68a3-49d0-9c6f-01d44881658a" xlink:href="amed-20200331.xsd#amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_77970f72-5aef-4f5b-9deb-959dfcd4e224" xlink:to="loc_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_ba56d976-68a3-49d0-9c6f-01d44881658a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_5101a886-91fa-499e-acfb-da29069f2e77" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_77970f72-5aef-4f5b-9deb-959dfcd4e224" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_5101a886-91fa-499e-acfb-da29069f2e77" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_9c14e591-10d0-44be-9eca-e64d31960190" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_77970f72-5aef-4f5b-9deb-959dfcd4e224" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_9c14e591-10d0-44be-9eca-e64d31960190" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_a184f3f8-fbc6-4c56-93ac-bb740582c114" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_77970f72-5aef-4f5b-9deb-959dfcd4e224" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_a184f3f8-fbc6-4c56-93ac-bb740582c114" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_63bf4f51-9c2b-4cfc-a537-f9fa88548e3d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_77970f72-5aef-4f5b-9deb-959dfcd4e224" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_63bf4f51-9c2b-4cfc-a537-f9fa88548e3d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0702124a-f65f-4d64-81dc-2df8b2585403" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_77970f72-5aef-4f5b-9deb-959dfcd4e224" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0702124a-f65f-4d64-81dc-2df8b2585403" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SurrenderedShares_aaae0202-eb3f-4aff-9436-eb0013fe661a" xlink:href="amed-20200331.xsd#amed_SurrenderedShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_77970f72-5aef-4f5b-9deb-959dfcd4e224" xlink:to="loc_amed_SurrenderedShares_aaae0202-eb3f-4aff-9436-eb0013fe661a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_2d1e2d91-f13f-496d-8e69-ceca84ddf344" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_77970f72-5aef-4f5b-9deb-959dfcd4e224" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_2d1e2d91-f13f-496d-8e69-ceca84ddf344" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_a764f90b-d3cd-4a0a-a770-24b4c1510523" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_77970f72-5aef-4f5b-9deb-959dfcd4e224" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_a764f90b-d3cd-4a0a-a770-24b4c1510523" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EquityImpactofRepurchaseofNoncontrollingInterest_8a7915c0-4940-421a-8e81-8981c8cd09c9" xlink:href="amed-20200331.xsd#amed_EquityImpactofRepurchaseofNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_77970f72-5aef-4f5b-9deb-959dfcd4e224" xlink:to="loc_amed_EquityImpactofRepurchaseofNoncontrollingInterest_8a7915c0-4940-421a-8e81-8981c8cd09c9" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome_1e7a5931-7c3c-4676-bded-9581c8069205" xlink:href="amed-20200331.xsd#amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_77970f72-5aef-4f5b-9deb-959dfcd4e224" xlink:to="loc_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome_1e7a5931-7c3c-4676-bded-9581c8069205" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_0b795668-8a80-4b22-90aa-2308e9e30e37" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_77970f72-5aef-4f5b-9deb-959dfcd4e224" xlink:to="loc_us-gaap_ProfitLoss_0b795668-8a80-4b22-90aa-2308e9e30e37" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7b2cf370-ee9a-4a50-aa28-3fcb73beff57" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_66c8f4f9-a8ff-4cea-a030-cd719cc9b122" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0b183d6f-8ea0-40cb-b152-e5a82424e33b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_77970f72-5aef-4f5b-9deb-959dfcd4e224" xlink:to="loc_us-gaap_StatementTable_0b183d6f-8ea0-40cb-b152-e5a82424e33b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_51866a3e-785a-40a0-97c2-4488479905aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_0b183d6f-8ea0-40cb-b152-e5a82424e33b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_51866a3e-785a-40a0-97c2-4488479905aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_51866a3e-785a-40a0-97c2-4488479905aa_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_51866a3e-785a-40a0-97c2-4488479905aa" xlink:to="loc_us-gaap_EquityComponentDomain_51866a3e-785a-40a0-97c2-4488479905aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e92fad79-9fb6-48ad-8a78-b4b48a7dc6da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_51866a3e-785a-40a0-97c2-4488479905aa" xlink:to="loc_us-gaap_EquityComponentDomain_e92fad79-9fb6-48ad-8a78-b4b48a7dc6da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f92a4c5f-624a-424f-8e58-d42909a3a96c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e92fad79-9fb6-48ad-8a78-b4b48a7dc6da" xlink:to="loc_us-gaap_CommonStockMember_f92a4c5f-624a-424f-8e58-d42909a3a96c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6f68ab27-a8b3-4207-9fb2-8d16babf65ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e92fad79-9fb6-48ad-8a78-b4b48a7dc6da" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_6f68ab27-a8b3-4207-9fb2-8d16babf65ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_3ee44518-4a90-4dbd-ba4c-5b869d284b14" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e92fad79-9fb6-48ad-8a78-b4b48a7dc6da" xlink:to="loc_us-gaap_TreasuryStockMember_3ee44518-4a90-4dbd-ba4c-5b869d284b14" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_547c6322-a062-4087-8496-be5a154f3833" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e92fad79-9fb6-48ad-8a78-b4b48a7dc6da" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_547c6322-a062-4087-8496-be5a154f3833" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ad2f1121-0a6f-48a2-889a-b5c049764360" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e92fad79-9fb6-48ad-8a78-b4b48a7dc6da" xlink:to="loc_us-gaap_RetainedEarningsMember_ad2f1121-0a6f-48a2-889a-b5c049764360" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_c0a6b568-fd94-465d-a4ec-b5214db69194" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e92fad79-9fb6-48ad-8a78-b4b48a7dc6da" xlink:to="loc_us-gaap_NoncontrollingInterestMember_c0a6b568-fd94-465d-a4ec-b5214db69194" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="amed-20200331.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended" id="idb05d40346144b54a9dadf50fefc6490_CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS" xlink:type="simple" xlink:href="amed-20200331.xsd#NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS" xlink:type="extended" id="iddafff78f1d74bfcbe64edad8523041c_NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails" xlink:type="simple" xlink:href="amed-20200331.xsd#NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails" xlink:type="extended" id="i676a1d2e5b3f4447b8a8dcd16bc4233d_NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_b90a3323-2057-45b4-90f8-3dd025e5f6fe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_8c907bd8-ad67-4035-947b-34960728b5e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_b90a3323-2057-45b4-90f8-3dd025e5f6fe" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_8c907bd8-ad67-4035-947b-34960728b5e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OperatingCareCenters_db27d672-9a9b-4fe8-b574-678c1ca0f4f1" xlink:href="amed-20200331.xsd#amed_OperatingCareCenters"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_b90a3323-2057-45b4-90f8-3dd025e5f6fe" xlink:to="loc_amed_OperatingCareCenters_db27d672-9a9b-4fe8-b574-678c1ca0f4f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates_533d6270-5ede-4ac8-94d4-e01bb010929e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_b90a3323-2057-45b4-90f8-3dd025e5f6fe" xlink:to="loc_us-gaap_NumberOfStatesInWhichEntityOperates_533d6270-5ede-4ac8-94d4-e01bb010929e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MinimumPercentOwnershipForControllingInterestPercent_f09c01ab-6bee-4e81-8f84-b5a8c59d15f2" xlink:href="amed-20200331.xsd#amed_MinimumPercentOwnershipForControllingInterestPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_b90a3323-2057-45b4-90f8-3dd025e5f6fe" xlink:to="loc_amed_MinimumPercentOwnershipForControllingInterestPercent_f09c01ab-6bee-4e81-8f84-b5a8c59d15f2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumPercentOwnershipForEquityMethodPercent_05ccc7ed-e2a1-4521-b161-b0448a235f7b" xlink:href="amed-20200331.xsd#amed_MaximumPercentOwnershipForEquityMethodPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_b90a3323-2057-45b4-90f8-3dd025e5f6fe" xlink:to="loc_amed_MaximumPercentOwnershipForEquityMethodPercent_05ccc7ed-e2a1-4521-b161-b0448a235f7b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_65ae5e22-186f-45b0-aa15-6e7011720ce7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_b90a3323-2057-45b4-90f8-3dd025e5f6fe" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_65ae5e22-186f-45b0-aa15-6e7011720ce7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumPercentOwnershipForCostMethodPercent_1a1f49e9-7deb-4661-a6d9-cdc16fb34430" xlink:href="amed-20200331.xsd#amed_MaximumPercentOwnershipForCostMethodPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_b90a3323-2057-45b4-90f8-3dd025e5f6fe" xlink:to="loc_amed_MaximumPercentOwnershipForCostMethodPercent_1a1f49e9-7deb-4661-a6d9-cdc16fb34430" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_ea90521f-1777-4463-a672-be39eeeb3f94" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_b90a3323-2057-45b4-90f8-3dd025e5f6fe" xlink:to="loc_us-gaap_ConcentrationRiskTable_ea90521f-1777-4463-a672-be39eeeb3f94" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_4c3347a2-f93c-47e5-9a93-aae171d20f30" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_ea90521f-1777-4463-a672-be39eeeb3f94" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_4c3347a2-f93c-47e5-9a93-aae171d20f30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_4c3347a2-f93c-47e5-9a93-aae171d20f30_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_4c3347a2-f93c-47e5-9a93-aae171d20f30" xlink:to="loc_us-gaap_TypeOfAdoptionMember_4c3347a2-f93c-47e5-9a93-aae171d20f30_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_60dec81f-3495-4a18-aa79-923cc06e4f91" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_4c3347a2-f93c-47e5-9a93-aae171d20f30" xlink:to="loc_us-gaap_TypeOfAdoptionMember_60dec81f-3495-4a18-aa79-923cc06e4f91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_45abc9ee-35b4-4449-b34a-fd305818f163" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_60dec81f-3495-4a18-aa79-923cc06e4f91" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_45abc9ee-35b4-4449-b34a-fd305818f163" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TypeofEquityMethodInvestmentAxis_dfcf5edf-44c4-4cb2-8254-12a4548031f2" xlink:href="amed-20200331.xsd#amed_TypeofEquityMethodInvestmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_ea90521f-1777-4463-a672-be39eeeb3f94" xlink:to="loc_amed_TypeofEquityMethodInvestmentAxis_dfcf5edf-44c4-4cb2-8254-12a4548031f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TypeofEquityMethodInvestmentDomain_dfcf5edf-44c4-4cb2-8254-12a4548031f2_default" xlink:href="amed-20200331.xsd#amed_TypeofEquityMethodInvestmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_amed_TypeofEquityMethodInvestmentAxis_dfcf5edf-44c4-4cb2-8254-12a4548031f2" xlink:to="loc_amed_TypeofEquityMethodInvestmentDomain_dfcf5edf-44c4-4cb2-8254-12a4548031f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TypeofEquityMethodInvestmentDomain_3d67e6fa-d1a7-4f17-b4af-8aeab3b86e53" xlink:href="amed-20200331.xsd#amed_TypeofEquityMethodInvestmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_amed_TypeofEquityMethodInvestmentAxis_dfcf5edf-44c4-4cb2-8254-12a4548031f2" xlink:to="loc_amed_TypeofEquityMethodInvestmentDomain_3d67e6fa-d1a7-4f17-b4af-8aeab3b86e53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HealthcareanalyticscompanyMember_c38d2798-babc-496e-8300-bde78a0b2e2f" xlink:href="amed-20200331.xsd#amed_HealthcareanalyticscompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_TypeofEquityMethodInvestmentDomain_3d67e6fa-d1a7-4f17-b4af-8aeab3b86e53" xlink:to="loc_amed_HealthcareanalyticscompanyMember_c38d2798-babc-496e-8300-bde78a0b2e2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a9e393d7-0778-46fa-ac19-b9f6a8fb4080" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_ea90521f-1777-4463-a672-be39eeeb3f94" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a9e393d7-0778-46fa-ac19-b9f6a8fb4080" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a9e393d7-0778-46fa-ac19-b9f6a8fb4080_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a9e393d7-0778-46fa-ac19-b9f6a8fb4080" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a9e393d7-0778-46fa-ac19-b9f6a8fb4080_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_914d1926-54e3-431f-b1c8-98a08ca9cfd9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a9e393d7-0778-46fa-ac19-b9f6a8fb4080" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_914d1926-54e3-431f-b1c8-98a08ca9cfd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_7bad22a1-f9b2-43be-8ac2-df0c6102a93c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_914d1926-54e3-431f-b1c8-98a08ca9cfd9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_7bad22a1-f9b2-43be-8ac2-df0c6102a93c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_8f984057-6a4c-426c-b6df-e7b1b2f3772e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_ea90521f-1777-4463-a672-be39eeeb3f94" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_8f984057-6a4c-426c-b6df-e7b1b2f3772e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_8f984057-6a4c-426c-b6df-e7b1b2f3772e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_8f984057-6a4c-426c-b6df-e7b1b2f3772e" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_8f984057-6a4c-426c-b6df-e7b1b2f3772e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_6f1eff7c-73c1-4da1-b926-e2bf7b2f545b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_8f984057-6a4c-426c-b6df-e7b1b2f3772e" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_6f1eff7c-73c1-4da1-b926-e2bf7b2f545b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareRevenueMember_b6bb20b9-8aa8-4b52-b64f-92f050babe38" xlink:href="amed-20200331.xsd#amed_MedicareRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_6f1eff7c-73c1-4da1-b926-e2bf7b2f545b" xlink:to="loc_amed_MedicareRevenueMember_b6bb20b9-8aa8-4b52-b64f-92f050babe38" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_d1084460-f630-4864-8711-b901470a88c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_ea90521f-1777-4463-a672-be39eeeb3f94" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_d1084460-f630-4864-8711-b901470a88c0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d1084460-f630-4864-8711-b901470a88c0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d1084460-f630-4864-8711-b901470a88c0" xlink:to="loc_us-gaap_SegmentDomain_d1084460-f630-4864-8711-b901470a88c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_6e294063-5b31-4f54-8579-5d6ee566053d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d1084460-f630-4864-8711-b901470a88c0" xlink:to="loc_us-gaap_SegmentDomain_6e294063-5b31-4f54-8579-5d6ee566053d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_95b4ee13-63e1-4207-a075-6ff60ab857ef" xlink:href="amed-20200331.xsd#amed_HomeHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_6e294063-5b31-4f54-8579-5d6ee566053d" xlink:to="loc_amed_HomeHealthMember_95b4ee13-63e1-4207-a075-6ff60ab857ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_f940d7c9-546f-49c4-b5ee-086fa782d401" xlink:href="amed-20200331.xsd#amed_HospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_6e294063-5b31-4f54-8579-5d6ee566053d" xlink:to="loc_amed_HospiceMember_f940d7c9-546f-49c4-b5ee-086fa782d401" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_5584e534-4789-48bc-a000-39922cd19da5" xlink:href="amed-20200331.xsd#amed_PersonalCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_6e294063-5b31-4f54-8579-5d6ee566053d" xlink:to="loc_amed_PersonalCareMember_5584e534-4789-48bc-a000-39922cd19da5" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="amed-20200331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended" id="ifc00b55f83e6483f8b8fccf4413e8a2e_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="amed-20200331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended" id="iec97072ba5a74507b157fa2ccbe6fb25_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="simple" xlink:href="amed-20200331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="extended" id="ib4a73459646f4da88bf198e0ab44861e_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" xlink:type="simple" xlink:href="amed-20200331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" xlink:type="extended" id="i9cb5eb7f182949b1b3a8a3a68970ccdb_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_bc8b7045-452f-411c-a66a-9a5f39aaec6e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_6f2e3eb9-347a-476e-837c-31dd04afea16" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_bc8b7045-452f-411c-a66a-9a5f39aaec6e" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_6f2e3eb9-347a-476e-837c-31dd04afea16" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration_c9148145-8a92-4b9b-a874-862a0f76778e" xlink:href="amed-20200331.xsd#amed_EpisodeOfCareAsEpisodicBasedRevenueDuration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_bc8b7045-452f-411c-a66a-9a5f39aaec6e" xlink:to="loc_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration_c9148145-8a92-4b9b-a874-862a0f76778e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_66711c13-bded-4b50-9d07-9fe08f4f8ccc" xlink:href="amed-20200331.xsd#amed_NetServiceRevenuePeriodOfCarePaymentRateDuration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_bc8b7045-452f-411c-a66a-9a5f39aaec6e" xlink:to="loc_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_66711c13-bded-4b50-9d07-9fe08f4f8ccc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PeriodOfCareAsEpisodicBasedRevenueDuration_43a5e323-562f-48d1-b795-0f5a3aad798b" xlink:href="amed-20200331.xsd#amed_PeriodOfCareAsEpisodicBasedRevenueDuration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_bc8b7045-452f-411c-a66a-9a5f39aaec6e" xlink:to="loc_amed_PeriodOfCareAsEpisodicBasedRevenueDuration_43a5e323-562f-48d1-b795-0f5a3aad798b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfTotalReimbursementOfOutlierPayment_5c4ddb6c-cd57-42c7-aafa-fce34ff55d03" xlink:href="amed-20200331.xsd#amed_PercentageOfTotalReimbursementOfOutlierPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_bc8b7045-452f-411c-a66a-9a5f39aaec6e" xlink:to="loc_amed_PercentageOfTotalReimbursementOfOutlierPayment_5c4ddb6c-cd57-42c7-aafa-fce34ff55d03" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_1081a6cf-30de-4b07-a373-81c337048561" xlink:href="amed-20200331.xsd#amed_LowUtilizationPaymentAdjustmentNumberOfVisits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_bc8b7045-452f-411c-a66a-9a5f39aaec6e" xlink:to="loc_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_1081a6cf-30de-4b07-a373-81c337048561" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FirstThresholdOfTherapyServicesRequired_9d77af5a-6ca6-4fbc-b18f-f0cc998ba967" xlink:href="amed-20200331.xsd#amed_FirstThresholdOfTherapyServicesRequired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_bc8b7045-452f-411c-a66a-9a5f39aaec6e" xlink:to="loc_amed_FirstThresholdOfTherapyServicesRequired_9d77af5a-6ca6-4fbc-b18f-f0cc998ba967" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecondThresholdOfServicesRequired_51062a56-a146-4fd5-878e-c4d981ae7d21" xlink:href="amed-20200331.xsd#amed_SecondThresholdOfServicesRequired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_bc8b7045-452f-411c-a66a-9a5f39aaec6e" xlink:to="loc_amed_SecondThresholdOfServicesRequired_51062a56-a146-4fd5-878e-c4d981ae7d21" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ThirdThresholdOfTherapyServicesRequired_90fa010d-16a3-443d-89ab-1b18e660b89d" xlink:href="amed-20200331.xsd#amed_ThirdThresholdOfTherapyServicesRequired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_bc8b7045-452f-411c-a66a-9a5f39aaec6e" xlink:to="loc_amed_ThirdThresholdOfTherapyServicesRequired_90fa010d-16a3-443d-89ab-1b18e660b89d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HistoricalCollectionRateFromMedicare_876ba7ba-20ac-4b80-8684-c136f9285919" xlink:href="amed-20200331.xsd#amed_HistoricalCollectionRateFromMedicare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_bc8b7045-452f-411c-a66a-9a5f39aaec6e" xlink:to="loc_amed_HistoricalCollectionRateFromMedicare_876ba7ba-20ac-4b80-8684-c136f9285919" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonMedicareRevenueTermRates_1b048d27-c5a6-4717-b8e1-25b6d22d5a46" xlink:href="amed-20200331.xsd#amed_NonMedicareRevenueTermRates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_bc8b7045-452f-411c-a66a-9a5f39aaec6e" xlink:to="loc_amed_NonMedicareRevenueTermRates_1b048d27-c5a6-4717-b8e1-25b6d22d5a46" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_d9ac1c12-8e94-4411-83bf-4508622fa571" xlink:href="amed-20200331.xsd#amed_HospiceMedicareRevenueRateAccountedForRoutineCare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_bc8b7045-452f-411c-a66a-9a5f39aaec6e" xlink:to="loc_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_d9ac1c12-8e94-4411-83bf-4508622fa571" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_5026f9be-1140-44b3-a68a-8b68669788e9" xlink:href="amed-20200331.xsd#amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_bc8b7045-452f-411c-a66a-9a5f39aaec6e" xlink:to="loc_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_5026f9be-1140-44b3-a68a-8b68669788e9" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_82487f1b-14ce-496b-b340-ff1c7877c068" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_bc8b7045-452f-411c-a66a-9a5f39aaec6e" xlink:to="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_82487f1b-14ce-496b-b340-ff1c7877c068" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_727f579d-c539-42ae-b228-a9c07f16c9d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_82487f1b-14ce-496b-b340-ff1c7877c068" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_727f579d-c539-42ae-b228-a9c07f16c9d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_727f579d-c539-42ae-b228-a9c07f16c9d0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_727f579d-c539-42ae-b228-a9c07f16c9d0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_727f579d-c539-42ae-b228-a9c07f16c9d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_17362bd1-96a3-4c84-96ef-30f03a5278d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_727f579d-c539-42ae-b228-a9c07f16c9d0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_17362bd1-96a3-4c84-96ef-30f03a5278d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompassionateCareHospiceMember_78cde2cc-8018-4218-ba2b-26334bb8f1d9" xlink:href="amed-20200331.xsd#amed_CompassionateCareHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_17362bd1-96a3-4c84-96ef-30f03a5278d3" xlink:to="loc_amed_CompassionateCareHospiceMember_78cde2cc-8018-4218-ba2b-26334bb8f1d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_c092e137-e086-4b5b-bbe5-d08697687a38" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_82487f1b-14ce-496b-b340-ff1c7877c068" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_c092e137-e086-4b5b-bbe5-d08697687a38" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_c092e137-e086-4b5b-bbe5-d08697687a38_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_c092e137-e086-4b5b-bbe5-d08697687a38" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_c092e137-e086-4b5b-bbe5-d08697687a38_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_70c5e50e-7b68-4c03-a057-353c958e46da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_c092e137-e086-4b5b-bbe5-d08697687a38" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_70c5e50e-7b68-4c03-a057-353c958e46da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareRevenueMember_07d95de9-94da-490a-90a7-ed69fc9c6dce" xlink:href="amed-20200331.xsd#amed_MedicareRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_70c5e50e-7b68-4c03-a057-353c958e46da" xlink:to="loc_amed_MedicareRevenueMember_07d95de9-94da-490a-90a7-ed69fc9c6dce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7ff4c4ab-01a5-4329-84ce-b837d880f382" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_82487f1b-14ce-496b-b340-ff1c7877c068" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7ff4c4ab-01a5-4329-84ce-b837d880f382" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7ff4c4ab-01a5-4329-84ce-b837d880f382_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7ff4c4ab-01a5-4329-84ce-b837d880f382" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7ff4c4ab-01a5-4329-84ce-b837d880f382_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8c328af8-bbfa-4acf-bc76-9b91549770ef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7ff4c4ab-01a5-4329-84ce-b837d880f382" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8c328af8-bbfa-4acf-bc76-9b91549770ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_cd2057af-65ac-4b3f-82fd-10affabba281" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8c328af8-bbfa-4acf-bc76-9b91549770ef" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_cd2057af-65ac-4b3f-82fd-10affabba281" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearAxis_579620d3-26ae-460f-8049-4956fa14a162" xlink:href="amed-20200331.xsd#amed_CapYearAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_82487f1b-14ce-496b-b340-ff1c7877c068" xlink:to="loc_amed_CapYearAxis_579620d3-26ae-460f-8049-4956fa14a162" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearDomain_579620d3-26ae-460f-8049-4956fa14a162_default" xlink:href="amed-20200331.xsd#amed_CapYearDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_amed_CapYearAxis_579620d3-26ae-460f-8049-4956fa14a162" xlink:to="loc_amed_CapYearDomain_579620d3-26ae-460f-8049-4956fa14a162_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearDomain_033bf732-8bee-4870-af96-032ee282722d" xlink:href="amed-20200331.xsd#amed_CapYearDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_amed_CapYearAxis_579620d3-26ae-460f-8049-4956fa14a162" xlink:to="loc_amed_CapYearDomain_033bf732-8bee-4870-af96-032ee282722d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearTwoThousandThirteenThroughTwoThousandTwentyMember_8152b8cc-0931-4e51-bc03-8fb8c736fb3e" xlink:href="amed-20200331.xsd#amed_CapYearTwoThousandThirteenThroughTwoThousandTwentyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_CapYearDomain_033bf732-8bee-4870-af96-032ee282722d" xlink:to="loc_amed_CapYearTwoThousandThirteenThroughTwoThousandTwentyMember_8152b8cc-0931-4e51-bc03-8fb8c736fb3e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_cb9beed4-c2e0-413b-9352-c1d08409879d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_82487f1b-14ce-496b-b340-ff1c7877c068" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_cb9beed4-c2e0-413b-9352-c1d08409879d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_cb9beed4-c2e0-413b-9352-c1d08409879d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_cb9beed4-c2e0-413b-9352-c1d08409879d" xlink:to="loc_us-gaap_SegmentDomain_cb9beed4-c2e0-413b-9352-c1d08409879d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_0cfae0eb-8b10-40b6-bf4b-19928909d068" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_cb9beed4-c2e0-413b-9352-c1d08409879d" xlink:to="loc_us-gaap_SegmentDomain_0cfae0eb-8b10-40b6-bf4b-19928909d068" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_6bdc4e52-a4ac-49b1-9684-d44bb28eff48" xlink:href="amed-20200331.xsd#amed_HomeHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_0cfae0eb-8b10-40b6-bf4b-19928909d068" xlink:to="loc_amed_HomeHealthMember_6bdc4e52-a4ac-49b1-9684-d44bb28eff48" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_6455b270-9d55-475d-8159-9d7c45de46bd" xlink:href="amed-20200331.xsd#amed_HospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_0cfae0eb-8b10-40b6-bf4b-19928909d068" xlink:to="loc_amed_HospiceMember_6455b270-9d55-475d-8159-9d7c45de46bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_04b9d437-711e-410a-98f2-11cfefa995ff" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_82487f1b-14ce-496b-b340-ff1c7877c068" xlink:to="loc_srt_RangeAxis_04b9d437-711e-410a-98f2-11cfefa995ff" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_04b9d437-711e-410a-98f2-11cfefa995ff_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_04b9d437-711e-410a-98f2-11cfefa995ff" xlink:to="loc_srt_RangeMember_04b9d437-711e-410a-98f2-11cfefa995ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_992a84af-dc68-4b23-bb94-edb5681e23c6" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_04b9d437-711e-410a-98f2-11cfefa995ff" xlink:to="loc_srt_RangeMember_992a84af-dc68-4b23-bb94-edb5681e23c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_782946b6-89c7-4011-81dc-7450eb67e5c3" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_992a84af-dc68-4b23-bb94-edb5681e23c6" xlink:to="loc_srt_MinimumMember_782946b6-89c7-4011-81dc-7450eb67e5c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e58cbb7c-da88-404c-8263-c0b2f4d45d3a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_992a84af-dc68-4b23-bb94-edb5681e23c6" xlink:to="loc_srt_MaximumMember_e58cbb7c-da88-404c-8263-c0b2f4d45d3a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails" xlink:type="simple" xlink:href="amed-20200331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails" xlink:type="extended" id="ie8bb0bf940ff4ac795e6f70ad6953a65_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_29f461ee-783d-482b-9daf-aa719862882c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue_4b14acef-d0bd-4531-9cc7-4b41868c2075" xlink:href="amed-20200331.xsd#amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_29f461ee-783d-482b-9daf-aa719862882c" xlink:to="loc_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue_4b14acef-d0bd-4531-9cc7-4b41868c2075" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_8115d5d8-e655-4171-b7bd-6c6880573951" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_29f461ee-783d-482b-9daf-aa719862882c" xlink:to="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_8115d5d8-e655-4171-b7bd-6c6880573951" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorClassAxis_fccc1ad0-9c6e-4b51-be1f-7274c832cf5f" xlink:href="amed-20200331.xsd#amed_PayorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_8115d5d8-e655-4171-b7bd-6c6880573951" xlink:to="loc_amed_PayorClassAxis_fccc1ad0-9c6e-4b51-be1f-7274c832cf5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorClassDomain_fccc1ad0-9c6e-4b51-be1f-7274c832cf5f_default" xlink:href="amed-20200331.xsd#amed_PayorClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_amed_PayorClassAxis_fccc1ad0-9c6e-4b51-be1f-7274c832cf5f" xlink:to="loc_amed_PayorClassDomain_fccc1ad0-9c6e-4b51-be1f-7274c832cf5f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorClassDomain_85c8612f-b962-4287-838e-21708003cd50" xlink:href="amed-20200331.xsd#amed_PayorClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_amed_PayorClassAxis_fccc1ad0-9c6e-4b51-be1f-7274c832cf5f" xlink:to="loc_amed_PayorClassDomain_85c8612f-b962-4287-838e-21708003cd50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMedicareMember_9e690ad6-f91e-4ce1-b75c-4534dc0f7d8e" xlink:href="amed-20200331.xsd#amed_HomeHealthMedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_PayorClassDomain_85c8612f-b962-4287-838e-21708003cd50" xlink:to="loc_amed_HomeHealthMedicareMember_9e690ad6-f91e-4ce1-b75c-4534dc0f7d8e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthNonMedicareEpisodicBasedMember_64f001ab-f80e-47a9-8dad-f6f2d689876a" xlink:href="amed-20200331.xsd#amed_HomeHealthNonMedicareEpisodicBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_PayorClassDomain_85c8612f-b962-4287-838e-21708003cd50" xlink:to="loc_amed_HomeHealthNonMedicareEpisodicBasedMember_64f001ab-f80e-47a9-8dad-f6f2d689876a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthNonMedicareNonEpisodicBasedMember_9f834efd-387d-4daf-be0a-a05f4ee01da7" xlink:href="amed-20200331.xsd#amed_HomeHealthNonMedicareNonEpisodicBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_PayorClassDomain_85c8612f-b962-4287-838e-21708003cd50" xlink:to="loc_amed_HomeHealthNonMedicareNonEpisodicBasedMember_9f834efd-387d-4daf-be0a-a05f4ee01da7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMedicareMember_1702b1dc-46ca-47de-8d28-e1e5c78957f3" xlink:href="amed-20200331.xsd#amed_HospiceMedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_PayorClassDomain_85c8612f-b962-4287-838e-21708003cd50" xlink:to="loc_amed_HospiceMedicareMember_1702b1dc-46ca-47de-8d28-e1e5c78957f3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceNonMedicareMember_70cb587e-9593-4210-8416-d058b05b93f0" xlink:href="amed-20200331.xsd#amed_HospiceNonMedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_PayorClassDomain_85c8612f-b962-4287-838e-21708003cd50" xlink:to="loc_amed_HospiceNonMedicareMember_70cb587e-9593-4210-8416-d058b05b93f0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_35ec1827-4d45-4557-a702-741a85f46e3a" xlink:href="amed-20200331.xsd#amed_PersonalCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_PayorClassDomain_85c8612f-b962-4287-838e-21708003cd50" xlink:to="loc_amed_PersonalCareMember_35ec1827-4d45-4557-a702-741a85f46e3a" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails" xlink:type="simple" xlink:href="amed-20200331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails" xlink:type="extended" id="i50031c104590420ea071837f4c5dbc9f_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_29951e92-dec9-4817-91c2-e231f0e70534" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_21c9fef3-25d3-4c50-9aa6-68ff38b3075a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_29951e92-dec9-4817-91c2-e231f0e70534" xlink:to="loc_us-gaap_RestrictedCash_21c9fef3-25d3-4c50-9aa6-68ff38b3075a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_475a40cd-f5c3-4b7a-8100-dfab2d10cebd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_29951e92-dec9-4817-91c2-e231f0e70534" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_475a40cd-f5c3-4b7a-8100-dfab2d10cebd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_148b1abe-bc50-4ff5-9f5a-d33fdc91f243" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_475a40cd-f5c3-4b7a-8100-dfab2d10cebd" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_148b1abe-bc50-4ff5-9f5a-d33fdc91f243" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_148b1abe-bc50-4ff5-9f5a-d33fdc91f243_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_148b1abe-bc50-4ff5-9f5a-d33fdc91f243" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_148b1abe-bc50-4ff5-9f5a-d33fdc91f243_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c3b3523e-7322-4f13-858a-370e405496d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_148b1abe-bc50-4ff5-9f5a-d33fdc91f243" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c3b3523e-7322-4f13-858a-370e405496d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AsanaHospiceAquisitionMember_69969b3c-c213-4cd8-9dca-e0346923b3ce" xlink:href="amed-20200331.xsd#amed_AsanaHospiceAquisitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c3b3523e-7322-4f13-858a-370e405496d2" xlink:to="loc_amed_AsanaHospiceAquisitionMember_69969b3c-c213-4cd8-9dca-e0346923b3ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_COVID19PPEMember_33914e05-c74e-4d0c-87e3-ac1590a73f30" xlink:href="amed-20200331.xsd#amed_COVID19PPEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c3b3523e-7322-4f13-858a-370e405496d2" xlink:to="loc_amed_COVID19PPEMember_33914e05-c74e-4d0c-87e3-ac1590a73f30" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails" xlink:type="simple" xlink:href="amed-20200331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails" xlink:type="extended" id="if59bd49024d74926b4acbc5cba85bdb7_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_b6b3aa23-c7e7-4e8b-806d-7d87eb4a9ca1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_5b22c8b0-0483-4581-93f3-7146433a8e25" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_b6b3aa23-c7e7-4e8b-806d-7d87eb4a9ca1" xlink:to="loc_us-gaap_ConcentrationRiskTable_5b22c8b0-0483-4581-93f3-7146433a8e25" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_368cc8af-1ec2-486a-a247-876252f5d0e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_5b22c8b0-0483-4581-93f3-7146433a8e25" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_368cc8af-1ec2-486a-a247-876252f5d0e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_368cc8af-1ec2-486a-a247-876252f5d0e2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_368cc8af-1ec2-486a-a247-876252f5d0e2" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_368cc8af-1ec2-486a-a247-876252f5d0e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_857f260a-505e-44cb-8c60-100d5562b062" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_368cc8af-1ec2-486a-a247-876252f5d0e2" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_857f260a-505e-44cb-8c60-100d5562b062" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_919e531b-26f0-4579-bc70-1e39cbdf35ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_857f260a-505e-44cb-8c60-100d5562b062" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_919e531b-26f0-4579-bc70-1e39cbdf35ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_59a99c4d-29c9-4ed4-8189-8421f68acbcd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_5b22c8b0-0483-4581-93f3-7146433a8e25" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_59a99c4d-29c9-4ed4-8189-8421f68acbcd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_59a99c4d-29c9-4ed4-8189-8421f68acbcd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_59a99c4d-29c9-4ed4-8189-8421f68acbcd" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_59a99c4d-29c9-4ed4-8189-8421f68acbcd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6a392f91-a973-4890-8df3-b84e6338a953" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_59a99c4d-29c9-4ed4-8189-8421f68acbcd" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6a392f91-a973-4890-8df3-b84e6338a953" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_0e84b157-b5fa-4528-a3b0-1f52be0aca62" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6a392f91-a973-4890-8df3-b84e6338a953" xlink:to="loc_us-gaap_AccountsReceivableMember_0e84b157-b5fa-4528-a3b0-1f52be0aca62" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_1a891239-9457-41b9-b585-bb4a028b8a0c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_5b22c8b0-0483-4581-93f3-7146433a8e25" xlink:to="loc_srt_MajorCustomersAxis_1a891239-9457-41b9-b585-bb4a028b8a0c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_1a891239-9457-41b9-b585-bb4a028b8a0c_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_1a891239-9457-41b9-b585-bb4a028b8a0c" xlink:to="loc_srt_NameOfMajorCustomerDomain_1a891239-9457-41b9-b585-bb4a028b8a0c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_06a58b73-67d4-4883-bca9-b58f368c67d5" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_1a891239-9457-41b9-b585-bb4a028b8a0c" xlink:to="loc_srt_NameOfMajorCustomerDomain_06a58b73-67d4-4883-bca9-b58f368c67d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MajorSinglePayorCustomerMember_53fc71f8-4900-4c8e-92c5-6c5db294f255" xlink:href="amed-20200331.xsd#amed_MajorSinglePayorCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_06a58b73-67d4-4883-bca9-b58f368c67d5" xlink:to="loc_amed_MajorSinglePayorCustomerMember_53fc71f8-4900-4c8e-92c5-6c5db294f255" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8fb311e8-db3a-45a9-9f6c-3cf29ddef9fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_5b22c8b0-0483-4581-93f3-7146433a8e25" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8fb311e8-db3a-45a9-9f6c-3cf29ddef9fc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8fb311e8-db3a-45a9-9f6c-3cf29ddef9fc_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8fb311e8-db3a-45a9-9f6c-3cf29ddef9fc" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8fb311e8-db3a-45a9-9f6c-3cf29ddef9fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_01e727df-393c-49bd-a40d-880f3bed0881" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8fb311e8-db3a-45a9-9f6c-3cf29ddef9fc" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_01e727df-393c-49bd-a40d-880f3bed0881" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompassionateCareHospiceMember_77f9437f-9d43-49e4-ae29-950bea21be83" xlink:href="amed-20200331.xsd#amed_CompassionateCareHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_01e727df-393c-49bd-a40d-880f3bed0881" xlink:to="loc_amed_CompassionateCareHospiceMember_77f9437f-9d43-49e4-ae29-950bea21be83" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="amed-20200331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails" xlink:type="extended" id="ie4eaa9b950ad44f09466f741143cfc3a_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_79980c2d-dd1d-4e04-9420-2ff5b72cd15d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases_64e09313-d7b3-4581-b4eb-da407656305e" xlink:href="amed-20200331.xsd#amed_DebtInstrumentCarryingAmountExcludingFinanceLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_79980c2d-dd1d-4e04-9420-2ff5b72cd15d" xlink:to="loc_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases_64e09313-d7b3-4581-b4eb-da407656305e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_b65626db-0b46-4459-a96e-113981f48751" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_79980c2d-dd1d-4e04-9420-2ff5b72cd15d" xlink:to="loc_us-gaap_LongTermDebtFairValue_b65626db-0b46-4459-a96e-113981f48751" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ffcaaf2e-69d2-4556-a875-66512f0e44ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_79980c2d-dd1d-4e04-9420-2ff5b72cd15d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ffcaaf2e-69d2-4556-a875-66512f0e44ea" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_da31888c-8bc8-4228-a631-42b8f16d4dd2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ffcaaf2e-69d2-4556-a875-66512f0e44ea" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_da31888c-8bc8-4228-a631-42b8f16d4dd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_da31888c-8bc8-4228-a631-42b8f16d4dd2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_da31888c-8bc8-4228-a631-42b8f16d4dd2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_da31888c-8bc8-4228-a631-42b8f16d4dd2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_957fa086-21a4-49bf-9684-d0a52ca33431" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_da31888c-8bc8-4228-a631-42b8f16d4dd2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_957fa086-21a4-49bf-9684-d0a52ca33431" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_05790a8e-4eba-4ba5-9033-1e728e9e0158" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_957fa086-21a4-49bf-9684-d0a52ca33431" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_05790a8e-4eba-4ba5-9033-1e728e9e0158" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_06d53729-7511-4f35-8ba4-411abb2c9cd2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_957fa086-21a4-49bf-9684-d0a52ca33431" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_06d53729-7511-4f35-8ba4-411abb2c9cd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_584cb2b6-92dd-4ab0-a923-f95457b106fa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_957fa086-21a4-49bf-9684-d0a52ca33431" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_584cb2b6-92dd-4ab0-a923-f95457b106fa" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails" xlink:type="simple" xlink:href="amed-20200331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails" xlink:type="extended" id="i5f0949f99126499e9f5d3ed3a1c845c1_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/ACQUISITIONS" xlink:type="simple" xlink:href="amed-20200331.xsd#ACQUISITIONS"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/ACQUISITIONS" xlink:type="extended" id="i72475b1fcce4455291dad73e00882152_ACQUISITIONS"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/ACQUISITIONSTables" xlink:type="simple" xlink:href="amed-20200331.xsd#ACQUISITIONSTables"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/ACQUISITIONSTables" xlink:type="extended" id="i52a69ec97ca942678ebbff09d7e85f90_ACQUISITIONSTables"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails" xlink:type="simple" xlink:href="amed-20200331.xsd#ACQUISITIONSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails" xlink:type="extended" id="i19a58d3b8bdc46409ad5d23cfcf584be_ACQUISITIONSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_83ce7e79-be74-4fb7-ba76-fdf6698cac05" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageofSharesOutstanding_6356890d-37a2-4c80-9f85-4c94c1958f7d" xlink:href="amed-20200331.xsd#amed_PercentageofSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83ce7e79-be74-4fb7-ba76-fdf6698cac05" xlink:to="loc_amed_PercentageofSharesOutstanding_6356890d-37a2-4c80-9f85-4c94c1958f7d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_886ae87e-35e4-43d7-af74-3c65b85e8c2c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83ce7e79-be74-4fb7-ba76-fdf6698cac05" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_886ae87e-35e4-43d7-af74-3c65b85e8c2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_81077f61-1c30-4ffc-b9ab-ce7ea27350ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83ce7e79-be74-4fb7-ba76-fdf6698cac05" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_81077f61-1c30-4ffc-b9ab-ce7ea27350ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired_5f91accc-0295-4914-848e-3d3a6c5774b3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfBusinessesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83ce7e79-be74-4fb7-ba76-fdf6698cac05" xlink:to="loc_us-gaap_NumberOfBusinessesAcquired_5f91accc-0295-4914-848e-3d3a6c5774b3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_0d0a407b-044f-4444-b6bc-90af7a5d784b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83ce7e79-be74-4fb7-ba76-fdf6698cac05" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_0d0a407b-044f-4444-b6bc-90af7a5d784b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Paymentsrelatedtotaxassetandworkingcapital_111bb1cc-b320-4943-bab5-8bc47ab206a2" xlink:href="amed-20200331.xsd#amed_Paymentsrelatedtotaxassetandworkingcapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83ce7e79-be74-4fb7-ba76-fdf6698cac05" xlink:to="loc_amed_Paymentsrelatedtotaxassetandworkingcapital_111bb1cc-b320-4943-bab5-8bc47ab206a2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_63038ed6-be1d-4c91-9cce-07e72171d364" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83ce7e79-be74-4fb7-ba76-fdf6698cac05" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_63038ed6-be1d-4c91-9cce-07e72171d364" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense_5541e867-ae17-49d2-98ed-bfb2242108ce" xlink:href="amed-20200331.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83ce7e79-be74-4fb7-ba76-fdf6698cac05" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense_5541e867-ae17-49d2-98ed-bfb2242108ce" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset_da21204b-4913-4549-b597-c00a873e719c" xlink:href="amed-20200331.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83ce7e79-be74-4fb7-ba76-fdf6698cac05" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset_da21204b-4913-4549-b597-c00a873e719c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_15347859-b358-477e-8e9f-b974908e54be" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83ce7e79-be74-4fb7-ba76-fdf6698cac05" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_15347859-b358-477e-8e9f-b974908e54be" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets_b5c8d462-fb7d-4187-9331-ad08b7313240" xlink:href="amed-20200331.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83ce7e79-be74-4fb7-ba76-fdf6698cac05" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets_b5c8d462-fb7d-4187-9331-ad08b7313240" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_04f215cb-9b5e-400d-ba5c-09278b767177" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83ce7e79-be74-4fb7-ba76-fdf6698cac05" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_04f215cb-9b5e-400d-ba5c-09278b767177" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_925ff8ed-6575-4b9e-8a30-20b496ffe30c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83ce7e79-be74-4fb7-ba76-fdf6698cac05" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_925ff8ed-6575-4b9e-8a30-20b496ffe30c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_be8739fc-e477-4289-846d-074bcbd623f8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83ce7e79-be74-4fb7-ba76-fdf6698cac05" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_be8739fc-e477-4289-846d-074bcbd623f8" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits_e7bebad5-5c97-4eab-8bb5-f822fae03904" xlink:href="amed-20200331.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83ce7e79-be74-4fb7-ba76-fdf6698cac05" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits_e7bebad5-5c97-4eab-8bb5-f822fae03904" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_ad7f7ec4-68ec-4d85-9cdc-8fc69be54db8" xlink:href="amed-20200331.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83ce7e79-be74-4fb7-ba76-fdf6698cac05" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_ad7f7ec4-68ec-4d85-9cdc-8fc69be54db8" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_35197b8b-3901-4f06-9258-1541c87d7636" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83ce7e79-be74-4fb7-ba76-fdf6698cac05" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_35197b8b-3901-4f06-9258-1541c87d7636" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities_6f2f7d90-ffca-4103-93e4-bf292f01c105" xlink:href="amed-20200331.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83ce7e79-be74-4fb7-ba76-fdf6698cac05" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities_6f2f7d90-ffca-4103-93e4-bf292f01c105" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_ecd2eb33-c829-4d33-8e08-39d666f0e325" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83ce7e79-be74-4fb7-ba76-fdf6698cac05" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_ecd2eb33-c829-4d33-8e08-39d666f0e325" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_50f38397-292a-4fa7-b363-97d2c910d923" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83ce7e79-be74-4fb7-ba76-fdf6698cac05" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_50f38397-292a-4fa7-b363-97d2c910d923" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_907a7bac-65c1-4d34-9096-73fe49a51046" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83ce7e79-be74-4fb7-ba76-fdf6698cac05" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_907a7bac-65c1-4d34-9096-73fe49a51046" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_fe3512f8-baa9-42b6-979c-e592e7d8e038" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83ce7e79-be74-4fb7-ba76-fdf6698cac05" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_fe3512f8-baa9-42b6-979c-e592e7d8e038" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_f8244dc0-c261-4ad6-8281-f25dac51571e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83ce7e79-be74-4fb7-ba76-fdf6698cac05" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_f8244dc0-c261-4ad6-8281-f25dac51571e" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c402f5c2-41b3-41c7-a5db-13ec5578fe15" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83ce7e79-be74-4fb7-ba76-fdf6698cac05" xlink:to="loc_us-gaap_OperatingIncomeLoss_c402f5c2-41b3-41c7-a5db-13ec5578fe15" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_025e9c91-6d97-4274-a74d-39890badde27" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83ce7e79-be74-4fb7-ba76-fdf6698cac05" xlink:to="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_025e9c91-6d97-4274-a74d-39890badde27" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_cfb70f78-b86e-4c32-954d-dde4c1c660d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83ce7e79-be74-4fb7-ba76-fdf6698cac05" xlink:to="loc_us-gaap_DepreciationAndAmortization_cfb70f78-b86e-4c32-954d-dde4c1c660d5" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c3b1643a-3a83-4f66-8713-6c86d12284b7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83ce7e79-be74-4fb7-ba76-fdf6698cac05" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c3b1643a-3a83-4f66-8713-6c86d12284b7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_abaaab6c-35a9-458d-ba4e-4cfabaa64521" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c3b1643a-3a83-4f66-8713-6c86d12284b7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_abaaab6c-35a9-458d-ba4e-4cfabaa64521" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_abaaab6c-35a9-458d-ba4e-4cfabaa64521_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_abaaab6c-35a9-458d-ba4e-4cfabaa64521" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_abaaab6c-35a9-458d-ba4e-4cfabaa64521_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_016c868c-fd7f-4b9c-a0c9-d8063c54a6ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_abaaab6c-35a9-458d-ba4e-4cfabaa64521" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_016c868c-fd7f-4b9c-a0c9-d8063c54a6ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_e68afde7-f6eb-4627-822b-a4431991653f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_016c868c-fd7f-4b9c-a0c9-d8063c54a6ee" xlink:to="loc_us-gaap_TradeNamesMember_e68afde7-f6eb-4627-822b-a4431991653f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_f5264f47-e9dd-49f6-a9e3-fcf2645db9cf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_016c868c-fd7f-4b9c-a0c9-d8063c54a6ee" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_f5264f47-e9dd-49f6-a9e3-fcf2645db9cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AcquiredNamesOfBusinessMember_cc6fe1c5-0a2f-43da-bf5a-6a7a60c3aecf" xlink:href="amed-20200331.xsd#amed_AcquiredNamesOfBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_016c868c-fd7f-4b9c-a0c9-d8063c54a6ee" xlink:to="loc_amed_AcquiredNamesOfBusinessMember_cc6fe1c5-0a2f-43da-bf5a-6a7a60c3aecf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_5cf9e563-a229-4e20-a9e4-a188fba2cea9" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c3b1643a-3a83-4f66-8713-6c86d12284b7" xlink:to="loc_srt_StatementGeographicalAxis_5cf9e563-a229-4e20-a9e4-a188fba2cea9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_5cf9e563-a229-4e20-a9e4-a188fba2cea9_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_5cf9e563-a229-4e20-a9e4-a188fba2cea9" xlink:to="loc_srt_SegmentGeographicalDomain_5cf9e563-a229-4e20-a9e4-a188fba2cea9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_47f04f6b-775d-4681-96ec-2061d8fce841" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_5cf9e563-a229-4e20-a9e4-a188fba2cea9" xlink:to="loc_srt_SegmentGeographicalDomain_47f04f6b-775d-4681-96ec-2061d8fce841" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_TN_86a57cd1-c68c-4ad8-b38c-533ac47d036d" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_TN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_47f04f6b-775d-4681-96ec-2061d8fce841" xlink:to="loc_stpr_TN_86a57cd1-c68c-4ad8-b38c-533ac47d036d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_693091e9-7e68-4b9f-8920-0f4e3ea5ccb9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c3b1643a-3a83-4f66-8713-6c86d12284b7" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_693091e9-7e68-4b9f-8920-0f4e3ea5ccb9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_693091e9-7e68-4b9f-8920-0f4e3ea5ccb9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_693091e9-7e68-4b9f-8920-0f4e3ea5ccb9" xlink:to="loc_us-gaap_SegmentDomain_693091e9-7e68-4b9f-8920-0f4e3ea5ccb9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_a2333559-85ef-4256-bdbe-3d977789fbd8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_693091e9-7e68-4b9f-8920-0f4e3ea5ccb9" xlink:to="loc_us-gaap_SegmentDomain_a2333559-85ef-4256-bdbe-3d977789fbd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_9b55a964-ed9a-4cf5-9182-3c75a46bca98" xlink:href="amed-20200331.xsd#amed_HospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_a2333559-85ef-4256-bdbe-3d977789fbd8" xlink:to="loc_amed_HospiceMember_9b55a964-ed9a-4cf5-9182-3c75a46bca98" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_b616d3b7-3921-4300-a665-09541d158fc2" xlink:href="amed-20200331.xsd#amed_HomeHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_a2333559-85ef-4256-bdbe-3d977789fbd8" xlink:to="loc_amed_HomeHealthMember_b616d3b7-3921-4300-a665-09541d158fc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e003894d-08b3-477a-b958-c43653122678" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c3b1643a-3a83-4f66-8713-6c86d12284b7" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e003894d-08b3-477a-b958-c43653122678" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e003894d-08b3-477a-b958-c43653122678_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e003894d-08b3-477a-b958-c43653122678" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e003894d-08b3-477a-b958-c43653122678_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_75ec9d17-07e1-407a-92ee-3b1a7c754175" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e003894d-08b3-477a-b958-c43653122678" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_75ec9d17-07e1-407a-92ee-3b1a7c754175" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompassionateCareHospiceMember_f764bc41-b612-49cf-993f-a997cc7c7b32" xlink:href="amed-20200331.xsd#amed_CompassionateCareHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_75ec9d17-07e1-407a-92ee-3b1a7c754175" xlink:to="loc_amed_CompassionateCareHospiceMember_f764bc41-b612-49cf-993f-a997cc7c7b32" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ChristianCareatHomeMember_34ffb0f3-10e5-4f17-a72a-5af6f98f83f0" xlink:href="amed-20200331.xsd#amed_ChristianCareatHomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_75ec9d17-07e1-407a-92ee-3b1a7c754175" xlink:to="loc_amed_ChristianCareatHomeMember_34ffb0f3-10e5-4f17-a72a-5af6f98f83f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EastTennesseePersonalCareServicesMember_7161e3ab-8ba4-4908-899e-91960eb7a261" xlink:href="amed-20200331.xsd#amed_EastTennesseePersonalCareServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_75ec9d17-07e1-407a-92ee-3b1a7c754175" xlink:to="loc_amed_EastTennesseePersonalCareServicesMember_7161e3ab-8ba4-4908-899e-91960eb7a261" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RoseRockHealthcareMember_32a94394-e8f3-4ded-8dd6-6271e4759ead" xlink:href="amed-20200331.xsd#amed_RoseRockHealthcareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_75ec9d17-07e1-407a-92ee-3b1a7c754175" xlink:to="loc_amed_RoseRockHealthcareMember_32a94394-e8f3-4ded-8dd6-6271e4759ead" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AsanaHospiceMember_87baafdb-d39b-4978-a50b-2411de776919" xlink:href="amed-20200331.xsd#amed_AsanaHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_75ec9d17-07e1-407a-92ee-3b1a7c754175" xlink:to="loc_amed_AsanaHospiceMember_87baafdb-d39b-4978-a50b-2411de776919" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8edcebf7-3ca1-4f1a-8c89-0fe083ed9345" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c3b1643a-3a83-4f66-8713-6c86d12284b7" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8edcebf7-3ca1-4f1a-8c89-0fe083ed9345" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8edcebf7-3ca1-4f1a-8c89-0fe083ed9345_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8edcebf7-3ca1-4f1a-8c89-0fe083ed9345" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8edcebf7-3ca1-4f1a-8c89-0fe083ed9345_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_514af4db-44d5-47d6-9946-668a6c2ad16c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8edcebf7-3ca1-4f1a-8c89-0fe083ed9345" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_514af4db-44d5-47d6-9946-668a6c2ad16c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificateOfNeedMember_02a65052-b687-4c22-bf57-b92a52c2e64e" xlink:href="amed-20200331.xsd#amed_CertificateOfNeedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_514af4db-44d5-47d6-9946-668a6c2ad16c" xlink:to="loc_amed_CertificateOfNeedMember_02a65052-b687-4c22-bf57-b92a52c2e64e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareLicenseMember_2243377e-0530-43e7-ab98-47895ee5733c" xlink:href="amed-20200331.xsd#amed_MedicareLicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_514af4db-44d5-47d6-9946-668a6c2ad16c" xlink:to="loc_amed_MedicareLicenseMember_2243377e-0530-43e7-ab98-47895ee5733c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/ACQUISITIONSProFormaDetails" xlink:type="simple" xlink:href="amed-20200331.xsd#ACQUISITIONSProFormaDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/ACQUISITIONSProFormaDetails" xlink:type="extended" id="idf211d2d5dcf4280964077c874b6c540_ACQUISITIONSProFormaDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_b3071dde-5874-4ee5-9580-0b03241ecaa4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_59047c80-9b82-42b4-997e-aa8c30ee9517" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b3071dde-5874-4ee5-9580-0b03241ecaa4" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_59047c80-9b82-42b4-997e-aa8c30ee9517" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Businessacquisitionproformaoperatingincomeloss_19c759ea-ad83-4811-afab-1dd45e820cd4" xlink:href="amed-20200331.xsd#amed_Businessacquisitionproformaoperatingincomeloss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b3071dde-5874-4ee5-9580-0b03241ecaa4" xlink:to="loc_amed_Businessacquisitionproformaoperatingincomeloss_19c759ea-ad83-4811-afab-1dd45e820cd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_09f7b11b-a5d5-4bf6-b002-2b0782fac683" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b3071dde-5874-4ee5-9580-0b03241ecaa4" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_09f7b11b-a5d5-4bf6-b002-2b0782fac683" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_f5f4759b-d170-4f2e-82b8-4cb166b7f968" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b3071dde-5874-4ee5-9580-0b03241ecaa4" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_f5f4759b-d170-4f2e-82b8-4cb166b7f968" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_fa4a8786-ddd9-4919-b917-7720fe5369df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b3071dde-5874-4ee5-9580-0b03241ecaa4" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_fa4a8786-ddd9-4919-b917-7720fe5369df" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_066c5399-14d8-47a8-92fd-d697ff60cf21" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b3071dde-5874-4ee5-9580-0b03241ecaa4" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_066c5399-14d8-47a8-92fd-d697ff60cf21" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_7cbe4de0-dd46-46e3-a44d-28efb72ff980" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_066c5399-14d8-47a8-92fd-d697ff60cf21" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_7cbe4de0-dd46-46e3-a44d-28efb72ff980" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_7cbe4de0-dd46-46e3-a44d-28efb72ff980_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7cbe4de0-dd46-46e3-a44d-28efb72ff980" xlink:to="loc_us-gaap_SegmentDomain_7cbe4de0-dd46-46e3-a44d-28efb72ff980_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8dfd41e3-5f34-420f-abc8-be1f337f40d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7cbe4de0-dd46-46e3-a44d-28efb72ff980" xlink:to="loc_us-gaap_SegmentDomain_8dfd41e3-5f34-420f-abc8-be1f337f40d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_e4ded6d8-96d4-4e4a-9761-8c7e5b01250f" xlink:href="amed-20200331.xsd#amed_HospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_8dfd41e3-5f34-420f-abc8-be1f337f40d0" xlink:to="loc_amed_HospiceMember_e4ded6d8-96d4-4e4a-9761-8c7e5b01250f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_a5575bc7-391f-44ff-a5bd-184f671c77b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_066c5399-14d8-47a8-92fd-d697ff60cf21" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_a5575bc7-391f-44ff-a5bd-184f671c77b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a5575bc7-391f-44ff-a5bd-184f671c77b4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a5575bc7-391f-44ff-a5bd-184f671c77b4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a5575bc7-391f-44ff-a5bd-184f671c77b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2c7392b6-cb7a-47b0-8626-13ce580ec9dc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a5575bc7-391f-44ff-a5bd-184f671c77b4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2c7392b6-cb7a-47b0-8626-13ce580ec9dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompassionateCareHospiceMember_cd6a1e4f-2da2-4795-9e27-0cbdae4248fd" xlink:href="amed-20200331.xsd#amed_CompassionateCareHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2c7392b6-cb7a-47b0-8626-13ce580ec9dc" xlink:to="loc_amed_CompassionateCareHospiceMember_cd6a1e4f-2da2-4795-9e27-0cbdae4248fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_c3e2992e-6ac6-408e-8abc-38cfabf60901" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_066c5399-14d8-47a8-92fd-d697ff60cf21" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_c3e2992e-6ac6-408e-8abc-38cfabf60901" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c3e2992e-6ac6-408e-8abc-38cfabf60901_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c3e2992e-6ac6-408e-8abc-38cfabf60901" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c3e2992e-6ac6-408e-8abc-38cfabf60901_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a862fa42-3fa5-4e9e-9025-ef1946e5d5d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c3e2992e-6ac6-408e-8abc-38cfabf60901" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a862fa42-3fa5-4e9e-9025-ef1946e5d5d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_4d7bb324-2497-4e88-b9c5-aba4876dd2c1" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_066c5399-14d8-47a8-92fd-d697ff60cf21" xlink:to="loc_srt_OwnershipAxis_4d7bb324-2497-4e88-b9c5-aba4876dd2c1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_4d7bb324-2497-4e88-b9c5-aba4876dd2c1_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_4d7bb324-2497-4e88-b9c5-aba4876dd2c1" xlink:to="loc_srt_OwnershipDomain_4d7bb324-2497-4e88-b9c5-aba4876dd2c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_486174a8-414f-42db-8ee4-e00c83f31c18" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_4d7bb324-2497-4e88-b9c5-aba4876dd2c1" xlink:to="loc_srt_OwnershipDomain_486174a8-414f-42db-8ee4-e00c83f31c18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3d67ff53-8de6-4fde-b644-bf9d1af46432" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_066c5399-14d8-47a8-92fd-d697ff60cf21" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3d67ff53-8de6-4fde-b644-bf9d1af46432" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3d67ff53-8de6-4fde-b644-bf9d1af46432_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3d67ff53-8de6-4fde-b644-bf9d1af46432" xlink:to="loc_us-gaap_ClassOfStockDomain_3d67ff53-8de6-4fde-b644-bf9d1af46432_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7e442ac5-ee17-41ad-b281-aec7ddd63c83" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3d67ff53-8de6-4fde-b644-bf9d1af46432" xlink:to="loc_us-gaap_ClassOfStockDomain_7e442ac5-ee17-41ad-b281-aec7ddd63c83" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONS" xlink:type="simple" xlink:href="amed-20200331.xsd#LONGTERMOBLIGATIONS"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONS" xlink:type="extended" id="i73fa49d46c0c456794db8541a528069e_LONGTERMOBLIGATIONS"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSLONGTERMOBLIGATIONSTables" xlink:type="simple" xlink:href="amed-20200331.xsd#LONGTERMOBLIGATIONSLONGTERMOBLIGATIONSTables"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSLONGTERMOBLIGATIONSTables" xlink:type="extended" id="i4092b11b94fb4913a72c21dd06df0ba4_LONGTERMOBLIGATIONSLONGTERMOBLIGATIONSTables"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails" xlink:type="simple" xlink:href="amed-20200331.xsd#LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails" xlink:type="extended" id="i97babb5fb95f4340bd8fc5874a8b5fea_LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_7db91735-e57b-430e-86d7-122d2971ca28" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_6a2dc957-4a1e-4178-a13e-46aa10284d3e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7db91735-e57b-430e-86d7-122d2971ca28" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_6a2dc957-4a1e-4178-a13e-46aa10284d3e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_cf511175-a301-4e1e-baf8-1d3c4d77e4ff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7db91735-e57b-430e-86d7-122d2971ca28" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_cf511175-a301-4e1e-baf8-1d3c4d77e4ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_2ad5ca06-e863-4e33-948d-6fd6e3ed2fbb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7db91735-e57b-430e-86d7-122d2971ca28" xlink:to="loc_us-gaap_LongTermDebt_2ad5ca06-e863-4e33-948d-6fd6e3ed2fbb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_a63f75b1-2d19-4ab1-ada6-142e0e6f95f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7db91735-e57b-430e-86d7-122d2971ca28" xlink:to="loc_us-gaap_LongTermDebtCurrent_a63f75b1-2d19-4ab1-ada6-142e0e6f95f4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_8ac997b6-3a13-41f3-8be8-ba46d078500f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7db91735-e57b-430e-86d7-122d2971ca28" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_8ac997b6-3a13-41f3-8be8-ba46d078500f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_c12127b8-0570-4f48-89d2-2eca79ebaabe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7db91735-e57b-430e-86d7-122d2971ca28" xlink:to="loc_us-gaap_DebtInstrumentTable_c12127b8-0570-4f48-89d2-2eca79ebaabe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_152f0a49-cde7-43d5-adbf-64523868abe8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c12127b8-0570-4f48-89d2-2eca79ebaabe" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_152f0a49-cde7-43d5-adbf-64523868abe8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_152f0a49-cde7-43d5-adbf-64523868abe8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_152f0a49-cde7-43d5-adbf-64523868abe8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_152f0a49-cde7-43d5-adbf-64523868abe8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7efaface-7ca9-4de0-8059-19d5c389ec02" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_152f0a49-cde7-43d5-adbf-64523868abe8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7efaface-7ca9-4de0-8059-19d5c389ec02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_c9aab7f7-97b6-42b1-aa17-f7d034ad2a29" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7efaface-7ca9-4de0-8059-19d5c389ec02" xlink:to="loc_us-gaap_LoansPayableMember_c9aab7f7-97b6-42b1-aa17-f7d034ad2a29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_41247680-a2bb-4a10-975a-7792f3b775c5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7efaface-7ca9-4de0-8059-19d5c389ec02" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_41247680-a2bb-4a10-975a-7792f3b775c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PromissoryNotesMember_d9e54cda-d421-496c-9f63-ca6915601e51" xlink:href="amed-20200331.xsd#amed_PromissoryNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7efaface-7ca9-4de0-8059-19d5c389ec02" xlink:to="loc_amed_PromissoryNotesMember_d9e54cda-d421-496c-9f63-ca6915601e51" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsMember_3b0e7025-9cef-4d3a-859b-9ded3eaf17c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalLeaseObligationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7efaface-7ca9-4de0-8059-19d5c389ec02" xlink:to="loc_us-gaap_CapitalLeaseObligationsMember_3b0e7025-9cef-4d3a-859b-9ded3eaf17c0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f5f1bf93-e111-4728-a229-6f9fa10a68ae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c12127b8-0570-4f48-89d2-2eca79ebaabe" xlink:to="loc_us-gaap_DebtInstrumentAxis_f5f1bf93-e111-4728-a229-6f9fa10a68ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f5f1bf93-e111-4728-a229-6f9fa10a68ae_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_f5f1bf93-e111-4728-a229-6f9fa10a68ae" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f5f1bf93-e111-4728-a229-6f9fa10a68ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ff100b05-f3bd-4fba-a82e-76635036361d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_f5f1bf93-e111-4728-a229-6f9fa10a68ae" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ff100b05-f3bd-4fba-a82e-76635036361d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_382c85df-a425-4e99-af0f-9aa7c4825426" xlink:href="amed-20200331.xsd#amed_OneHundredSeventyFiveMillionTermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ff100b05-f3bd-4fba-a82e-76635036361d" xlink:to="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_382c85df-a425-4e99-af0f-9aa7c4825426" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OneHundredMillionTermLoanMember_87fc4f4e-407a-4724-afe5-8e0a2ce21522" xlink:href="amed-20200331.xsd#amed_OneHundredMillionTermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ff100b05-f3bd-4fba-a82e-76635036361d" xlink:to="loc_amed_OneHundredMillionTermLoanMember_87fc4f4e-407a-4724-afe5-8e0a2ce21522" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember_41c71a59-b15f-4b28-b20c-5bb7281ba6b8" xlink:href="amed-20200331.xsd#amed_TwoHundredMillionRevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ff100b05-f3bd-4fba-a82e-76635036361d" xlink:to="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember_41c71a59-b15f-4b28-b20c-5bb7281ba6b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_528a15a5-ccb3-48c0-a91f-b80d91c52c09" xlink:href="amed-20200331.xsd#amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ff100b05-f3bd-4fba-a82e-76635036361d" xlink:to="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_528a15a5-ccb3-48c0-a91f-b80d91c52c09" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_d5bc6670-f32a-48d3-8de0-562db5da4e20" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c12127b8-0570-4f48-89d2-2eca79ebaabe" xlink:to="loc_us-gaap_VariableRateAxis_d5bc6670-f32a-48d3-8de0-562db5da4e20" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_d5bc6670-f32a-48d3-8de0-562db5da4e20_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_d5bc6670-f32a-48d3-8de0-562db5da4e20" xlink:to="loc_us-gaap_VariableRateDomain_d5bc6670-f32a-48d3-8de0-562db5da4e20_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_4b2ad36a-0c5d-4ff0-9346-8aafde64d12e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_d5bc6670-f32a-48d3-8de0-562db5da4e20" xlink:to="loc_us-gaap_VariableRateDomain_4b2ad36a-0c5d-4ff0-9346-8aafde64d12e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_17696381-c7d3-4522-b875-7519ac454763" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_4b2ad36a-0c5d-4ff0-9346-8aafde64d12e" xlink:to="loc_us-gaap_EurodollarMember_17696381-c7d3-4522-b875-7519ac454763" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails" xlink:type="simple" xlink:href="amed-20200331.xsd#LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails" xlink:type="extended" id="i7f31943f692044ca849a79f47e3ea3de_LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_1f14e8b1-2ad8-44a3-ae62-b677f1f35aa6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_8ee93fe4-f80d-4cbf-815c-31b8a1beb42d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1f14e8b1-2ad8-44a3-ae62-b677f1f35aa6" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_8ee93fe4-f80d-4cbf-815c-31b8a1beb42d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestRateatPeriodEnd_408b22af-ee92-4268-8e49-4fcbf16d7bfe" xlink:href="amed-20200331.xsd#amed_DebtInstrumentInterestRateatPeriodEnd"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1f14e8b1-2ad8-44a3-ae62-b677f1f35aa6" xlink:to="loc_amed_DebtInstrumentInterestRateatPeriodEnd_408b22af-ee92-4268-8e49-4fcbf16d7bfe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_afdad1d4-8a01-4592-a4ef-9043f97d352d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1f14e8b1-2ad8-44a3-ae62-b677f1f35aa6" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_afdad1d4-8a01-4592-a4ef-9043f97d352d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_11f5c9c0-fd6e-4b8d-90ce-2691b1134e5d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1f14e8b1-2ad8-44a3-ae62-b677f1f35aa6" xlink:to="loc_us-gaap_DebtInstrumentTable_11f5c9c0-fd6e-4b8d-90ce-2691b1134e5d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_fef00e5a-847a-44f1-b3ba-5424beb4728d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_11f5c9c0-fd6e-4b8d-90ce-2691b1134e5d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_fef00e5a-847a-44f1-b3ba-5424beb4728d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_fef00e5a-847a-44f1-b3ba-5424beb4728d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_fef00e5a-847a-44f1-b3ba-5424beb4728d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_fef00e5a-847a-44f1-b3ba-5424beb4728d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_bfaa0d1d-814d-4a9f-a436-a881e3ed3bc7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_fef00e5a-847a-44f1-b3ba-5424beb4728d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_bfaa0d1d-814d-4a9f-a436-a881e3ed3bc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_c7411efd-0d01-402f-8c70-54b30c6c2247" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_bfaa0d1d-814d-4a9f-a436-a881e3ed3bc7" xlink:to="loc_us-gaap_LoansPayableMember_c7411efd-0d01-402f-8c70-54b30c6c2247" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_035b9f5a-61fa-4550-ac09-dc2708bd9abb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_bfaa0d1d-814d-4a9f-a436-a881e3ed3bc7" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_035b9f5a-61fa-4550-ac09-dc2708bd9abb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_6e3aa542-58ab-42a3-ba3b-511d40ac0549" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_11f5c9c0-fd6e-4b8d-90ce-2691b1134e5d" xlink:to="loc_us-gaap_DebtInstrumentAxis_6e3aa542-58ab-42a3-ba3b-511d40ac0549" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6e3aa542-58ab-42a3-ba3b-511d40ac0549_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_6e3aa542-58ab-42a3-ba3b-511d40ac0549" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6e3aa542-58ab-42a3-ba3b-511d40ac0549_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2b7e41d1-5b66-4156-8a86-00b03d6a6b96" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_6e3aa542-58ab-42a3-ba3b-511d40ac0549" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2b7e41d1-5b66-4156-8a86-00b03d6a6b96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_130e4b47-2eb8-4272-9e05-b107ff7294d7" xlink:href="amed-20200331.xsd#amed_OneHundredSeventyFiveMillionTermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2b7e41d1-5b66-4156-8a86-00b03d6a6b96" xlink:to="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_130e4b47-2eb8-4272-9e05-b107ff7294d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember_78a473cc-744d-4927-bf1f-ee114a2b8e9b" xlink:href="amed-20200331.xsd#amed_TwoHundredMillionRevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2b7e41d1-5b66-4156-8a86-00b03d6a6b96" xlink:to="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember_78a473cc-744d-4927-bf1f-ee114a2b8e9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_a02f8403-6fe3-40f6-ad73-8b17f0797b2c" xlink:href="amed-20200331.xsd#amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2b7e41d1-5b66-4156-8a86-00b03d6a6b96" xlink:to="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_a02f8403-6fe3-40f6-ad73-8b17f0797b2c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_285bdddb-75d7-4cf7-b564-3b84eeb0eb4b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_11f5c9c0-fd6e-4b8d-90ce-2691b1134e5d" xlink:to="loc_us-gaap_VariableRateAxis_285bdddb-75d7-4cf7-b564-3b84eeb0eb4b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_285bdddb-75d7-4cf7-b564-3b84eeb0eb4b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_285bdddb-75d7-4cf7-b564-3b84eeb0eb4b" xlink:to="loc_us-gaap_VariableRateDomain_285bdddb-75d7-4cf7-b564-3b84eeb0eb4b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_4841b607-d2df-4da4-a2dd-175064bbcb47" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_285bdddb-75d7-4cf7-b564-3b84eeb0eb4b" xlink:to="loc_us-gaap_VariableRateDomain_4841b607-d2df-4da4-a2dd-175064bbcb47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_0bfa4e24-3688-446d-89e7-6013404af439" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_4841b607-d2df-4da4-a2dd-175064bbcb47" xlink:to="loc_us-gaap_EurodollarMember_0bfa4e24-3688-446d-89e7-6013404af439" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails" xlink:type="simple" xlink:href="amed-20200331.xsd#LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails" xlink:type="extended" id="id68fa8037fbd470a972bb0159d5b81c6_LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_3d364978-d21f-4f69-83c2-3838af58c6c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ConsolidatedLeverageRatio_f0dd4b1b-ca20-4d1e-a29f-c8a9c1e8f456" xlink:href="amed-20200331.xsd#amed_ConsolidatedLeverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_3d364978-d21f-4f69-83c2-3838af58c6c4" xlink:to="loc_amed_ConsolidatedLeverageRatio_f0dd4b1b-ca20-4d1e-a29f-c8a9c1e8f456" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_49ff804e-57f6-4b54-9333-03a261ffee74" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_3d364978-d21f-4f69-83c2-3838af58c6c4" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_49ff804e-57f6-4b54-9333-03a261ffee74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LetterOfCreditFee_2f5a708b-5bf9-4f38-ad95-c082e86acafb" xlink:href="amed-20200331.xsd#amed_LetterOfCreditFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_3d364978-d21f-4f69-83c2-3838af58c6c4" xlink:to="loc_amed_LetterOfCreditFee_2f5a708b-5bf9-4f38-ad95-c082e86acafb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_18944dbb-930c-493e-8973-b0a3a95ff366" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_3d364978-d21f-4f69-83c2-3838af58c6c4" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_18944dbb-930c-493e-8973-b0a3a95ff366" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_848d7594-5db2-4b7b-9611-4d3b288f167d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_3d364978-d21f-4f69-83c2-3838af58c6c4" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_848d7594-5db2-4b7b-9611-4d3b288f167d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8d2bb1f5-adc6-4ab5-a138-c0455335b0e7" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_848d7594-5db2-4b7b-9611-4d3b288f167d" xlink:to="loc_srt_RangeAxis_8d2bb1f5-adc6-4ab5-a138-c0455335b0e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8d2bb1f5-adc6-4ab5-a138-c0455335b0e7_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_8d2bb1f5-adc6-4ab5-a138-c0455335b0e7" xlink:to="loc_srt_RangeMember_8d2bb1f5-adc6-4ab5-a138-c0455335b0e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_30df2077-65db-4675-bd40-c3bd1f4ba3e5" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_8d2bb1f5-adc6-4ab5-a138-c0455335b0e7" xlink:to="loc_srt_RangeMember_30df2077-65db-4675-bd40-c3bd1f4ba3e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_cdbb2989-a031-4cd8-ac7e-e563948a06e7" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_30df2077-65db-4675-bd40-c3bd1f4ba3e5" xlink:to="loc_srt_MinimumMember_cdbb2989-a031-4cd8-ac7e-e563948a06e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c84626a2-d151-4a30-8580-2518712f9c7e" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_30df2077-65db-4675-bd40-c3bd1f4ba3e5" xlink:to="loc_srt_MaximumMember_c84626a2-d151-4a30-8580-2518712f9c7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_0b4eacd9-85d0-47f7-a293-4ff602ff0496" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_848d7594-5db2-4b7b-9611-4d3b288f167d" xlink:to="loc_us-gaap_DebtInstrumentAxis_0b4eacd9-85d0-47f7-a293-4ff602ff0496" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0b4eacd9-85d0-47f7-a293-4ff602ff0496_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_0b4eacd9-85d0-47f7-a293-4ff602ff0496" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0b4eacd9-85d0-47f7-a293-4ff602ff0496_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1cf8db8a-456a-4226-b622-4eb288bc2baf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_0b4eacd9-85d0-47f7-a293-4ff602ff0496" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1cf8db8a-456a-4226-b622-4eb288bc2baf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentByLeverageRatioTrancheOneMember_95943bfd-ec02-49d6-ad3e-3bf2c0286326" xlink:href="amed-20200331.xsd#amed_DebtInstrumentByLeverageRatioTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1cf8db8a-456a-4226-b622-4eb288bc2baf" xlink:to="loc_amed_DebtInstrumentByLeverageRatioTrancheOneMember_95943bfd-ec02-49d6-ad3e-3bf2c0286326" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentByLeverageRatioTrancheTwoMember_23427133-4565-47d8-be9d-0db5675ae314" xlink:href="amed-20200331.xsd#amed_DebtInstrumentByLeverageRatioTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1cf8db8a-456a-4226-b622-4eb288bc2baf" xlink:to="loc_amed_DebtInstrumentByLeverageRatioTrancheTwoMember_23427133-4565-47d8-be9d-0db5675ae314" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentByLeverageRatioTrancheThreeMember_f2611ee3-ea8b-4b4f-8772-1e37f4f43998" xlink:href="amed-20200331.xsd#amed_DebtInstrumentByLeverageRatioTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1cf8db8a-456a-4226-b622-4eb288bc2baf" xlink:to="loc_amed_DebtInstrumentByLeverageRatioTrancheThreeMember_f2611ee3-ea8b-4b4f-8772-1e37f4f43998" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentByLeverageRatioTrancheFourMember_6850c13b-7a18-4f88-8b03-3426710d89fa" xlink:href="amed-20200331.xsd#amed_DebtInstrumentByLeverageRatioTrancheFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1cf8db8a-456a-4226-b622-4eb288bc2baf" xlink:to="loc_amed_DebtInstrumentByLeverageRatioTrancheFourMember_6850c13b-7a18-4f88-8b03-3426710d89fa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_180596ab-97cc-453b-a3d2-bcd26162517d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_848d7594-5db2-4b7b-9611-4d3b288f167d" xlink:to="loc_us-gaap_VariableRateAxis_180596ab-97cc-453b-a3d2-bcd26162517d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_180596ab-97cc-453b-a3d2-bcd26162517d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_180596ab-97cc-453b-a3d2-bcd26162517d" xlink:to="loc_us-gaap_VariableRateDomain_180596ab-97cc-453b-a3d2-bcd26162517d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_f15bbec0-8e50-4bfa-a69a-a083b5943433" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_180596ab-97cc-453b-a3d2-bcd26162517d" xlink:to="loc_us-gaap_VariableRateDomain_f15bbec0-8e50-4bfa-a69a-a083b5943433" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_bb267afd-dc9a-4e71-ae1c-8f9165d857bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_f15bbec0-8e50-4bfa-a69a-a083b5943433" xlink:to="loc_us-gaap_EurodollarMember_bb267afd-dc9a-4e71-ae1c-8f9165d857bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_15098981-4759-4035-a164-efa58d22b37a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_f15bbec0-8e50-4bfa-a69a-a083b5943433" xlink:to="loc_us-gaap_BaseRateMember_15098981-4759-4035-a164-efa58d22b37a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_efdc06cb-7a58-4d45-9343-1126defb82aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_848d7594-5db2-4b7b-9611-4d3b288f167d" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_efdc06cb-7a58-4d45-9343-1126defb82aa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_efdc06cb-7a58-4d45-9343-1126defb82aa_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_efdc06cb-7a58-4d45-9343-1126defb82aa" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_efdc06cb-7a58-4d45-9343-1126defb82aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_c45637bc-581f-491f-81cd-c1322333f82d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_efdc06cb-7a58-4d45-9343-1126defb82aa" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_c45637bc-581f-491f-81cd-c1322333f82d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_1b16d848-38c9-40b8-83fe-0f81b19d89e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_848d7594-5db2-4b7b-9611-4d3b288f167d" xlink:to="loc_us-gaap_CreditFacilityAxis_1b16d848-38c9-40b8-83fe-0f81b19d89e4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_1b16d848-38c9-40b8-83fe-0f81b19d89e4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_1b16d848-38c9-40b8-83fe-0f81b19d89e4" xlink:to="loc_us-gaap_CreditFacilityDomain_1b16d848-38c9-40b8-83fe-0f81b19d89e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_3cda6dc2-2108-4fb6-b70b-925e8590af55" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_1b16d848-38c9-40b8-83fe-0f81b19d89e4" xlink:to="loc_us-gaap_CreditFacilityDomain_3cda6dc2-2108-4fb6-b70b-925e8590af55" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails" xlink:type="simple" xlink:href="amed-20200331.xsd#LONGTERMOBLIGATIONSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails" xlink:type="extended" id="ifd458ff7bc00447cb9b9331c23fa86ca_LONGTERMOBLIGATIONSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_cb2ce1da-cdca-4bbb-a604-42cd1d03f5d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentPeriodicPaymentPercentage_e9e53cb6-1ff7-4562-8ebf-13a8f5899a02" xlink:href="amed-20200331.xsd#amed_DebtInstrumentPeriodicPaymentPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb2ce1da-cdca-4bbb-a604-42cd1d03f5d2" xlink:to="loc_amed_DebtInstrumentPeriodicPaymentPercentage_e9e53cb6-1ff7-4562-8ebf-13a8f5899a02" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_d5ec4e41-60ff-40d4-bea0-cffbaa8b8b7f" xlink:href="amed-20200331.xsd#amed_ProceedsReceivedFromLoanPartyOfSubsidiary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb2ce1da-cdca-4bbb-a604-42cd1d03f5d2" xlink:to="loc_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_d5ec4e41-60ff-40d4-bea0-cffbaa8b8b7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_aa4c46e6-1e81-42c4-af81-a6ac6d0ce75f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb2ce1da-cdca-4bbb-a604-42cd1d03f5d2" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_aa4c46e6-1e81-42c4-af81-a6ac6d0ce75f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_5db914a7-f60d-4d18-84e3-c4b0636ae933" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb2ce1da-cdca-4bbb-a604-42cd1d03f5d2" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_5db914a7-f60d-4d18-84e3-c4b0636ae933" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_2d4b5ae5-7c1e-46bc-bed6-83f95a502a6b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtWeightedAverageInterestRateOverTime"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb2ce1da-cdca-4bbb-a604-42cd1d03f5d2" xlink:to="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_2d4b5ae5-7c1e-46bc-bed6-83f95a502a6b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TotalLeverageRatio_6bd5bcc1-e558-427d-8658-3076d0479502" xlink:href="amed-20200331.xsd#amed_TotalLeverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb2ce1da-cdca-4bbb-a604-42cd1d03f5d2" xlink:to="loc_amed_TotalLeverageRatio_6bd5bcc1-e558-427d-8658-3076d0479502" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ConsolidatedInterestCoverageRatio_dd877a8b-58ac-4687-adad-39cc719e1a0a" xlink:href="amed-20200331.xsd#amed_ConsolidatedInterestCoverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb2ce1da-cdca-4bbb-a604-42cd1d03f5d2" xlink:to="loc_amed_ConsolidatedInterestCoverageRatio_dd877a8b-58ac-4687-adad-39cc719e1a0a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_cfa91056-14bd-407e-8cd3-1e492f45e54d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb2ce1da-cdca-4bbb-a604-42cd1d03f5d2" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_cfa91056-14bd-407e-8cd3-1e492f45e54d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RevolvingCreditFacilityTotal_d64519c5-6bee-48a3-929d-0f008d6b17ab" xlink:href="amed-20200331.xsd#amed_RevolvingCreditFacilityTotal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb2ce1da-cdca-4bbb-a604-42cd1d03f5d2" xlink:to="loc_amed_RevolvingCreditFacilityTotal_d64519c5-6bee-48a3-929d-0f008d6b17ab" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_7f167aa7-8bcc-4690-9f7b-c7e72adba2f5" xlink:href="amed-20200331.xsd#amed_LineOfCreditFacilityAdditionalBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb2ce1da-cdca-4bbb-a604-42cd1d03f5d2" xlink:to="loc_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_7f167aa7-8bcc-4690-9f7b-c7e72adba2f5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple_8ceef61f-93b6-4550-9fdb-6d9490c7a7a9" xlink:href="amed-20200331.xsd#amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb2ce1da-cdca-4bbb-a604-42cd1d03f5d2" xlink:to="loc_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple_8ceef61f-93b6-4550-9fdb-6d9490c7a7a9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Creditfacilitymaximumallowableconsolidatedleverageratio_3848c023-262c-43cf-949e-3397df256243" xlink:href="amed-20200331.xsd#amed_Creditfacilitymaximumallowableconsolidatedleverageratio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb2ce1da-cdca-4bbb-a604-42cd1d03f5d2" xlink:to="loc_amed_Creditfacilitymaximumallowableconsolidatedleverageratio_3848c023-262c-43cf-949e-3397df256243" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_21bba4be-662f-42c3-af02-78fe277b267a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb2ce1da-cdca-4bbb-a604-42cd1d03f5d2" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_21bba4be-662f-42c3-af02-78fe277b267a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_b47cd879-52d1-4618-8823-1d21c469cac4" xlink:href="amed-20200331.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb2ce1da-cdca-4bbb-a604-42cd1d03f5d2" xlink:to="loc_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_b47cd879-52d1-4618-8823-1d21c469cac4" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_c8214f5f-6588-43fc-8b11-e41ff3fe86b7" xlink:href="amed-20200331.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb2ce1da-cdca-4bbb-a604-42cd1d03f5d2" xlink:to="loc_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_c8214f5f-6588-43fc-8b11-e41ff3fe86b7" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_5fa13a0c-feea-439c-b95f-95dfc967542a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb2ce1da-cdca-4bbb-a604-42cd1d03f5d2" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_5fa13a0c-feea-439c-b95f-95dfc967542a" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_45d1851d-0e81-4d51-8eec-d423e8dd6d13" xlink:href="amed-20200331.xsd#amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb2ce1da-cdca-4bbb-a604-42cd1d03f5d2" xlink:to="loc_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_45d1851d-0e81-4d51-8eec-d423e8dd6d13" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_f7671fbb-d012-4834-a245-82f63c31af79" xlink:href="amed-20200331.xsd#amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb2ce1da-cdca-4bbb-a604-42cd1d03f5d2" xlink:to="loc_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_f7671fbb-d012-4834-a245-82f63c31af79" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_911d5b4c-eaff-4aaf-855d-beca4940d989" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb2ce1da-cdca-4bbb-a604-42cd1d03f5d2" xlink:to="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_911d5b4c-eaff-4aaf-855d-beca4940d989" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_f0d1a959-95f6-48b1-9659-79f82391d7a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb2ce1da-cdca-4bbb-a604-42cd1d03f5d2" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_f0d1a959-95f6-48b1-9659-79f82391d7a0" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_9b135fbe-99e9-40f8-8228-45b3e8396f60" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb2ce1da-cdca-4bbb-a604-42cd1d03f5d2" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_9b135fbe-99e9-40f8-8228-45b3e8396f60" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_0becf2e6-b533-43bc-bf32-3393c6e333b0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb2ce1da-cdca-4bbb-a604-42cd1d03f5d2" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_0becf2e6-b533-43bc-bf32-3393c6e333b0" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_0fd6ad2c-d81d-4206-8abd-c126d3023794" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb2ce1da-cdca-4bbb-a604-42cd1d03f5d2" xlink:to="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_0fd6ad2c-d81d-4206-8abd-c126d3023794" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestRateatPeriodEnd_91f311cf-6d05-4eec-8638-c9dc43ff7531" xlink:href="amed-20200331.xsd#amed_DebtInstrumentInterestRateatPeriodEnd"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb2ce1da-cdca-4bbb-a604-42cd1d03f5d2" xlink:to="loc_amed_DebtInstrumentInterestRateatPeriodEnd_91f311cf-6d05-4eec-8638-c9dc43ff7531" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_39cc3b89-521b-4a07-8a31-f616aae29874" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb2ce1da-cdca-4bbb-a604-42cd1d03f5d2" xlink:to="loc_us-gaap_DebtInstrumentTable_39cc3b89-521b-4a07-8a31-f616aae29874" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_39ff5940-cf44-497c-b624-43c144c19be7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_39cc3b89-521b-4a07-8a31-f616aae29874" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_39ff5940-cf44-497c-b624-43c144c19be7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_39ff5940-cf44-497c-b624-43c144c19be7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_39ff5940-cf44-497c-b624-43c144c19be7" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_39ff5940-cf44-497c-b624-43c144c19be7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_339aa66a-047e-4317-b3c0-adf815bfc3bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_39ff5940-cf44-497c-b624-43c144c19be7" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_339aa66a-047e-4317-b3c0-adf815bfc3bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_66abf394-0ec1-461c-a343-cb2e276dc123" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_339aa66a-047e-4317-b3c0-adf815bfc3bf" xlink:to="loc_us-gaap_SubsequentEventMember_66abf394-0ec1-461c-a343-cb2e276dc123" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_33e8c9c1-450c-4b53-b1d4-f3af0726edee" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_39cc3b89-521b-4a07-8a31-f616aae29874" xlink:to="loc_srt_RangeAxis_33e8c9c1-450c-4b53-b1d4-f3af0726edee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_33e8c9c1-450c-4b53-b1d4-f3af0726edee_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_33e8c9c1-450c-4b53-b1d4-f3af0726edee" xlink:to="loc_srt_RangeMember_33e8c9c1-450c-4b53-b1d4-f3af0726edee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7488547d-41f6-49a3-9fbd-b2befb6b5b30" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_33e8c9c1-450c-4b53-b1d4-f3af0726edee" xlink:to="loc_srt_RangeMember_7488547d-41f6-49a3-9fbd-b2befb6b5b30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1009ed23-d055-4b7e-8f29-ff231db553c5" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7488547d-41f6-49a3-9fbd-b2befb6b5b30" xlink:to="loc_srt_MinimumMember_1009ed23-d055-4b7e-8f29-ff231db553c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_8c359130-5450-4046-9351-ecf50b800bd7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_39cc3b89-521b-4a07-8a31-f616aae29874" xlink:to="loc_us-gaap_VariableRateAxis_8c359130-5450-4046-9351-ecf50b800bd7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_8c359130-5450-4046-9351-ecf50b800bd7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_8c359130-5450-4046-9351-ecf50b800bd7" xlink:to="loc_us-gaap_VariableRateDomain_8c359130-5450-4046-9351-ecf50b800bd7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_f92175f2-1464-45e1-905e-c99873a18789" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_8c359130-5450-4046-9351-ecf50b800bd7" xlink:to="loc_us-gaap_VariableRateDomain_f92175f2-1464-45e1-905e-c99873a18789" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_85e38542-db3b-4197-b984-a775e15eb65f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_f92175f2-1464-45e1-905e-c99873a18789" xlink:to="loc_us-gaap_BaseRateMember_85e38542-db3b-4197-b984-a775e15eb65f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_57c4b1ad-52fc-4f02-a40f-64bb70da2a10" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_f92175f2-1464-45e1-905e-c99873a18789" xlink:to="loc_us-gaap_EurodollarMember_57c4b1ad-52fc-4f02-a40f-64bb70da2a10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_325289a7-873e-41ac-9fc2-a74226686987" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_39cc3b89-521b-4a07-8a31-f616aae29874" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_325289a7-873e-41ac-9fc2-a74226686987" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_325289a7-873e-41ac-9fc2-a74226686987_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_325289a7-873e-41ac-9fc2-a74226686987" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_325289a7-873e-41ac-9fc2-a74226686987_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1e69d29f-2962-42dc-915e-e5a3730f72da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_325289a7-873e-41ac-9fc2-a74226686987" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1e69d29f-2962-42dc-915e-e5a3730f72da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SwingLineLoanMember_3caa6fbd-3edf-4f81-bc13-1addf82f68a4" xlink:href="amed-20200331.xsd#amed_SwingLineLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1e69d29f-2962-42dc-915e-e5a3730f72da" xlink:to="loc_amed_SwingLineLoanMember_3caa6fbd-3edf-4f81-bc13-1addf82f68a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_f149471c-8950-4eb7-aa24-7873e7b39ce4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1e69d29f-2962-42dc-915e-e5a3730f72da" xlink:to="loc_us-gaap_LetterOfCreditMember_f149471c-8950-4eb7-aa24-7873e7b39ce4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_974fb58d-f396-4dd8-89e4-8c2f93bf4777" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1e69d29f-2962-42dc-915e-e5a3730f72da" xlink:to="loc_us-gaap_LoansPayableMember_974fb58d-f396-4dd8-89e4-8c2f93bf4777" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_a702971b-329f-4a55-8934-b3e9a532f2bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1e69d29f-2962-42dc-915e-e5a3730f72da" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_a702971b-329f-4a55-8934-b3e9a532f2bd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PriorCreditAgreementMember_8ad45671-df11-45f7-ab21-e4bf5445cef7" xlink:href="amed-20200331.xsd#amed_PriorCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1e69d29f-2962-42dc-915e-e5a3730f72da" xlink:to="loc_amed_PriorCreditAgreementMember_8ad45671-df11-45f7-ab21-e4bf5445cef7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_64b2499a-730a-4417-89e6-ac77704df210" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1e69d29f-2962-42dc-915e-e5a3730f72da" xlink:to="loc_us-gaap_LineOfCreditMember_64b2499a-730a-4417-89e6-ac77704df210" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedCreditAgreementMember_52133bf8-845d-452d-81ce-10a4a2de6d7d" xlink:href="amed-20200331.xsd#amed_AmendedCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1e69d29f-2962-42dc-915e-e5a3730f72da" xlink:to="loc_amed_AmendedCreditAgreementMember_52133bf8-845d-452d-81ce-10a4a2de6d7d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_3a226620-ed04-4338-9aa2-ccdf62eb4f9e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_39cc3b89-521b-4a07-8a31-f616aae29874" xlink:to="loc_us-gaap_DebtInstrumentAxis_3a226620-ed04-4338-9aa2-ccdf62eb4f9e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3a226620-ed04-4338-9aa2-ccdf62eb4f9e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_3a226620-ed04-4338-9aa2-ccdf62eb4f9e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3a226620-ed04-4338-9aa2-ccdf62eb4f9e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_13fb73a6-cb9b-4f28-992a-adeab7e42115" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_3a226620-ed04-4338-9aa2-ccdf62eb4f9e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_13fb73a6-cb9b-4f28-992a-adeab7e42115" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedCreditAgreementMember_40e6e6f2-283b-40e0-884f-244d8dcfea0b" xlink:href="amed-20200331.xsd#amed_AmendedCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_13fb73a6-cb9b-4f28-992a-adeab7e42115" xlink:to="loc_amed_AmendedCreditAgreementMember_40e6e6f2-283b-40e0-884f-244d8dcfea0b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OneHundredMillionTermLoanMember_157b9cd5-ee7f-40aa-af4b-7acb5f8165b0" xlink:href="amed-20200331.xsd#amed_OneHundredMillionTermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_13fb73a6-cb9b-4f28-992a-adeab7e42115" xlink:to="loc_amed_OneHundredMillionTermLoanMember_157b9cd5-ee7f-40aa-af4b-7acb5f8165b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember_f955747d-a815-4bd9-a4d5-214640173ed9" xlink:href="amed-20200331.xsd#amed_TwoHundredMillionRevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_13fb73a6-cb9b-4f28-992a-adeab7e42115" xlink:to="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember_f955747d-a815-4bd9-a4d5-214640173ed9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_88c0d871-4877-4500-bedd-45379fc121c2" xlink:href="amed-20200331.xsd#amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_13fb73a6-cb9b-4f28-992a-adeab7e42115" xlink:to="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_88c0d871-4877-4500-bedd-45379fc121c2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_a0570905-de8c-43fd-99fa-2a701c46d11b" xlink:href="amed-20200331.xsd#amed_OneHundredSeventyFiveMillionTermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_13fb73a6-cb9b-4f28-992a-adeab7e42115" xlink:to="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_a0570905-de8c-43fd-99fa-2a701c46d11b" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="amed-20200331.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended" id="i39b582aae0894d57baa901651a2eb2d2_COMMITMENTSANDCONTINGENCIES"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="simple" xlink:href="amed-20200331.xsd#COMMITMENTSANDCONTINGENCIESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="extended" id="i414c98777fb04f79ad3ea454aa729bff_COMMITMENTSANDCONTINGENCIESNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_55fde598-5446-48d3-acff-79895c0ee4fb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_9ff415b9-d735-4456-a804-3b6c48c6796e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_55fde598-5446-48d3-acff-79895c0ee4fb" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_9ff415b9-d735-4456-a804-3b6c48c6796e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Numberofpatients_700d92c0-48fa-4cb2-9f43-5432304cce76" xlink:href="amed-20200331.xsd#amed_Numberofpatients"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_55fde598-5446-48d3-acff-79895c0ee4fb" xlink:to="loc_amed_Numberofpatients_700d92c0-48fa-4cb2-9f43-5432304cce76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CorporateIntegrityAgreementTerm_8c2fe123-1923-491a-a68b-ba5481bf1646" xlink:href="amed-20200331.xsd#amed_CorporateIntegrityAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_55fde598-5446-48d3-acff-79895c0ee4fb" xlink:to="loc_amed_CorporateIntegrityAgreementTerm_8c2fe123-1923-491a-a68b-ba5481bf1646" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_0f726a90-109c-4a9c-b4de-357d63626d3c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_55fde598-5446-48d3-acff-79895c0ee4fb" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_0f726a90-109c-4a9c-b4de-357d63626d3c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_9b051815-664c-4a57-9a77-aab67b2ac028" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_55fde598-5446-48d3-acff-79895c0ee4fb" xlink:to="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_9b051815-664c-4a57-9a77-aab67b2ac028" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyReceivableCurrent_e3cd26dc-7fe6-40fc-8f2d-059884fb5ae9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_55fde598-5446-48d3-acff-79895c0ee4fb" xlink:to="loc_us-gaap_LossContingencyReceivableCurrent_e3cd26dc-7fe6-40fc-8f2d-059884fb5ae9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecuritiesClassActionLawsuitsettlement_a8d6be3b-224e-4418-8926-d2fd9ac6a725" xlink:href="amed-20200331.xsd#amed_SecuritiesClassActionLawsuitsettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_55fde598-5446-48d3-acff-79895c0ee4fb" xlink:to="loc_amed_SecuritiesClassActionLawsuitsettlement_a8d6be3b-224e-4418-8926-d2fd9ac6a725" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfBeneficiaries_4cc71f6e-3c30-411b-b7bc-d186eac8e26a" xlink:href="amed-20200331.xsd#amed_NumberOfBeneficiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_55fde598-5446-48d3-acff-79895c0ee4fb" xlink:to="loc_amed_NumberOfBeneficiaries_4cc71f6e-3c30-411b-b7bc-d186eac8e26a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_2d04f95f-3ae9-4948-97d2-c61322583597" xlink:href="amed-20200331.xsd#amed_RecoveryAmountOfOverpaymentMadeToSubsidiary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_55fde598-5446-48d3-acff-79895c0ee4fb" xlink:to="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_2d04f95f-3ae9-4948-97d2-c61322583597" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_f9bf305e-bced-44d5-8e84-867b62d4a561" xlink:href="amed-20200331.xsd#amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_55fde598-5446-48d3-acff-79895c0ee4fb" xlink:to="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_f9bf305e-bced-44d5-8e84-867b62d4a561" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfClaimsSubmittedBySubsidiary_f5dcdf72-96ba-4775-9719-b0da38578a46" xlink:href="amed-20200331.xsd#amed_NumberOfClaimsSubmittedBySubsidiary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_55fde598-5446-48d3-acff-79895c0ee4fb" xlink:to="loc_amed_NumberOfClaimsSubmittedBySubsidiary_f5dcdf72-96ba-4775-9719-b0da38578a46" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_5170fbf5-ccaf-4630-ab6e-6f81837fc662" xlink:href="amed-20200331.xsd#amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_55fde598-5446-48d3-acff-79895c0ee4fb" xlink:to="loc_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_5170fbf5-ccaf-4630-ab6e-6f81837fc662" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009_a1e38009-bc05-4de6-b92d-31a2f9809f5c" xlink:href="amed-20200331.xsd#amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_55fde598-5446-48d3-acff-79895c0ee4fb" xlink:to="loc_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009_a1e38009-bc05-4de6-b92d-31a2f9809f5c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyReceivableNoncurrent_d2fe10ad-a560-4ed2-9b61-b15e5eddf6ae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyReceivableNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_55fde598-5446-48d3-acff-79895c0ee4fb" xlink:to="loc_us-gaap_LossContingencyReceivableNoncurrent_d2fe10ad-a560-4ed2-9b61-b15e5eddf6ae" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ActualClaimsPayment_d4f7b7d1-c6de-4e46-9950-fcc9b6cbbd4c" xlink:href="amed-20200331.xsd#amed_ActualClaimsPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_55fde598-5446-48d3-acff-79895c0ee4fb" xlink:to="loc_amed_ActualClaimsPayment_d4f7b7d1-c6de-4e46-9950-fcc9b6cbbd4c" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ErrorRatePercentage_d12aff01-ff01-44d4-a028-a585ae5bb3ea" xlink:href="amed-20200331.xsd#amed_ErrorRatePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_55fde598-5446-48d3-acff-79895c0ee4fb" xlink:to="loc_amed_ErrorRatePercentage_d12aff01-ff01-44d4-a028-a585ae5bb3ea" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IndemnificationAmount_ae337d67-7782-4f62-838f-223fc5f96e4f" xlink:href="amed-20200331.xsd#amed_IndemnificationAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_55fde598-5446-48d3-acff-79895c0ee4fb" xlink:to="loc_amed_IndemnificationAmount_ae337d67-7782-4f62-838f-223fc5f96e4f" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FloridaZpicRevenueReduction_a9742352-c355-4c38-8ce7-8c6765987f30" xlink:href="amed-20200331.xsd#amed_FloridaZpicRevenueReduction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_55fde598-5446-48d3-acff-79895c0ee4fb" xlink:to="loc_amed_FloridaZpicRevenueReduction_a9742352-c355-4c38-8ce7-8c6765987f30" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_944bd105-3885-42d2-8cc0-955b2681a15d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_55fde598-5446-48d3-acff-79895c0ee4fb" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_944bd105-3885-42d2-8cc0-955b2681a15d" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HealthInsuranceRetentionLimit_04bd8187-347f-46e0-9ff0-69409710b6e1" xlink:href="amed-20200331.xsd#amed_HealthInsuranceRetentionLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_55fde598-5446-48d3-acff-79895c0ee4fb" xlink:to="loc_amed_HealthInsuranceRetentionLimit_04bd8187-347f-46e0-9ff0-69409710b6e1" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_WorkersCompensationInsuranceRetentionLimit_92fcc820-b974-4671-99f4-20c2618653f6" xlink:href="amed-20200331.xsd#amed_WorkersCompensationInsuranceRetentionLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_55fde598-5446-48d3-acff-79895c0ee4fb" xlink:to="loc_amed_WorkersCompensationInsuranceRetentionLimit_92fcc820-b974-4671-99f4-20c2618653f6" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProfessionalLiabilityInsuranceRetentionLimit_8a4f522d-ecb4-428c-9503-01ee1f592367" xlink:href="amed-20200331.xsd#amed_ProfessionalLiabilityInsuranceRetentionLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_55fde598-5446-48d3-acff-79895c0ee4fb" xlink:to="loc_amed_ProfessionalLiabilityInsuranceRetentionLimit_8a4f522d-ecb4-428c-9503-01ee1f592367" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_c25c525a-11cd-4c08-85d0-c15723ec52b2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_55fde598-5446-48d3-acff-79895c0ee4fb" xlink:to="loc_us-gaap_LossContingenciesTable_c25c525a-11cd-4c08-85d0-c15723ec52b2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorsAxis_9e7d2133-7b37-425e-9f2d-92b0b6a17600" xlink:href="amed-20200331.xsd#amed_PayorsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_c25c525a-11cd-4c08-85d0-c15723ec52b2" xlink:to="loc_amed_PayorsAxis_9e7d2133-7b37-425e-9f2d-92b0b6a17600" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorsDomain_9e7d2133-7b37-425e-9f2d-92b0b6a17600_default" xlink:href="amed-20200331.xsd#amed_PayorsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_amed_PayorsAxis_9e7d2133-7b37-425e-9f2d-92b0b6a17600" xlink:to="loc_amed_PayorsDomain_9e7d2133-7b37-425e-9f2d-92b0b6a17600_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorsDomain_d37bc242-2680-4b40-8525-bb9fb10f7ecb" xlink:href="amed-20200331.xsd#amed_PayorsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_amed_PayorsAxis_9e7d2133-7b37-425e-9f2d-92b0b6a17600" xlink:to="loc_amed_PayorsDomain_d37bc242-2680-4b40-8525-bb9fb10f7ecb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompanysinsurancecarriersMember_27f07870-e209-4b12-9706-2abb3e64b2a2" xlink:href="amed-20200331.xsd#amed_CompanysinsurancecarriersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_PayorsDomain_d37bc242-2680-4b40-8525-bb9fb10f7ecb" xlink:to="loc_amed_CompanysinsurancecarriersMember_27f07870-e209-4b12-9706-2abb3e64b2a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_62c7d820-b30c-4c17-afe4-b5634f2b9b37" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_c25c525a-11cd-4c08-85d0-c15723ec52b2" xlink:to="loc_srt_LitigationCaseAxis_62c7d820-b30c-4c17-afe4-b5634f2b9b37" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_62c7d820-b30c-4c17-afe4-b5634f2b9b37_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_62c7d820-b30c-4c17-afe4-b5634f2b9b37" xlink:to="loc_srt_LitigationCaseTypeDomain_62c7d820-b30c-4c17-afe4-b5634f2b9b37_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_df717d51-9dd5-4fc5-9f77-dbfe7bd4d72b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_62c7d820-b30c-4c17-afe4-b5634f2b9b37" xlink:to="loc_srt_LitigationCaseTypeDomain_df717d51-9dd5-4fc5-9f77-dbfe7bd4d72b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UsDepartmentOfJusticeMember_a4ddc2ca-3c3d-4785-963e-387546025842" xlink:href="amed-20200331.xsd#amed_UsDepartmentOfJusticeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_df717d51-9dd5-4fc5-9f77-dbfe7bd4d72b" xlink:to="loc_amed_UsDepartmentOfJusticeMember_a4ddc2ca-3c3d-4785-963e-387546025842" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmedisysCIAMember_052ec2bc-7b51-4b4a-9016-e5f65281d5ed" xlink:href="amed-20200331.xsd#amed_AmedisysCIAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_df717d51-9dd5-4fc5-9f77-dbfe7bd4d72b" xlink:to="loc_amed_AmedisysCIAMember_052ec2bc-7b51-4b4a-9016-e5f65281d5ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompassionateCareHospiceCIAMember_30afda4e-0ea6-4abc-89dd-7b1819ff4306" xlink:href="amed-20200331.xsd#amed_CompassionateCareHospiceCIAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_df717d51-9dd5-4fc5-9f77-dbfe7bd4d72b" xlink:to="loc_amed_CompassionateCareHospiceCIAMember_30afda4e-0ea6-4abc-89dd-7b1819ff4306" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecuritiesClassActionLawsuitMember_4c98d9e1-e10d-436a-840d-4668f26d0dc1" xlink:href="amed-20200331.xsd#amed_SecuritiesClassActionLawsuitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_df717d51-9dd5-4fc5-9f77-dbfe7bd4d72b" xlink:to="loc_amed_SecuritiesClassActionLawsuitMember_4c98d9e1-e10d-436a-840d-4668f26d0dc1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SafeguardZoneProgramIntegrityContractorMember_2855f76c-b9fc-4078-a73f-2c86440ef60b" xlink:href="amed-20200331.xsd#amed_SafeguardZoneProgramIntegrityContractorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_df717d51-9dd5-4fc5-9f77-dbfe7bd4d72b" xlink:to="loc_amed_SafeguardZoneProgramIntegrityContractorMember_2855f76c-b9fc-4078-a73f-2c86440ef60b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_InternalAuditComplianceReviewMember_2d878353-cd86-4b4e-9f64-cd8ffce7a4e9" xlink:href="amed-20200331.xsd#amed_InternalAuditComplianceReviewMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_df717d51-9dd5-4fc5-9f77-dbfe7bd4d72b" xlink:to="loc_amed_InternalAuditComplianceReviewMember_2d878353-cd86-4b4e-9f64-cd8ffce7a4e9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_1871cb47-0b23-449f-822d-3dab6ffb2f7b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_c25c525a-11cd-4c08-85d0-c15723ec52b2" xlink:to="loc_srt_StatementGeographicalAxis_1871cb47-0b23-449f-822d-3dab6ffb2f7b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_1871cb47-0b23-449f-822d-3dab6ffb2f7b_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_1871cb47-0b23-449f-822d-3dab6ffb2f7b" xlink:to="loc_srt_SegmentGeographicalDomain_1871cb47-0b23-449f-822d-3dab6ffb2f7b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_223b212c-8fe7-4f6f-971e-fbe75472633f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_1871cb47-0b23-449f-822d-3dab6ffb2f7b" xlink:to="loc_srt_SegmentGeographicalDomain_223b212c-8fe7-4f6f-971e-fbe75472633f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MA_294fc11a-23a7-40a1-add0-660690ec5145" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_MA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_223b212c-8fe7-4f6f-971e-fbe75472633f" xlink:to="loc_stpr_MA_294fc11a-23a7-40a1-add0-660690ec5145" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MorgantownWestVirginiaMember_7997ed24-1763-4d9e-a926-4053d16bc4e5" xlink:href="amed-20200331.xsd#amed_MorgantownWestVirginiaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_223b212c-8fe7-4f6f-971e-fbe75472633f" xlink:to="loc_amed_MorgantownWestVirginiaMember_7997ed24-1763-4d9e-a926-4053d16bc4e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ParkersburgWestVirginiaMember_2139e858-bc20-4707-9e63-e11cc8ec8137" xlink:href="amed-20200331.xsd#amed_ParkersburgWestVirginiaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_223b212c-8fe7-4f6f-971e-fbe75472633f" xlink:to="loc_amed_ParkersburgWestVirginiaMember_2139e858-bc20-4707-9e63-e11cc8ec8137" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_SC_080a215b-553d-4a4d-b126-6abfb8342abe" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_SC"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_223b212c-8fe7-4f6f-971e-fbe75472633f" xlink:to="loc_stpr_SC_080a215b-553d-4a4d-b126-6abfb8342abe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_FL_9f7d1535-921e-4a91-ae1f-7c16a12bb935" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_FL"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_223b212c-8fe7-4f6f-971e-fbe75472633f" xlink:to="loc_stpr_FL_9f7d1535-921e-4a91-ae1f-7c16a12bb935" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LakelandFloridaMember_238fb534-d9ec-46c0-bc00-d5d682d3ebdb" xlink:href="amed-20200331.xsd#amed_LakelandFloridaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_stpr_FL_9f7d1535-921e-4a91-ae1f-7c16a12bb935" xlink:to="loc_amed_LakelandFloridaMember_238fb534-d9ec-46c0-bc00-d5d682d3ebdb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ClearwaterFloridaMember_c827ca38-b051-44d8-a57e-4838a5163167" xlink:href="amed-20200331.xsd#amed_ClearwaterFloridaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_stpr_FL_9f7d1535-921e-4a91-ae1f-7c16a12bb935" xlink:to="loc_amed_ClearwaterFloridaMember_c827ca38-b051-44d8-a57e-4838a5163167" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_b266273b-574a-4e4a-a986-368b655c913b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_c25c525a-11cd-4c08-85d0-c15723ec52b2" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_b266273b-574a-4e4a-a986-368b655c913b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b266273b-574a-4e4a-a986-368b655c913b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_b266273b-574a-4e4a-a986-368b655c913b" xlink:to="loc_us-gaap_SegmentDomain_b266273b-574a-4e4a-a986-368b655c913b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_36513ce8-06af-4880-9785-e6eca1f9bdc6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_b266273b-574a-4e4a-a986-368b655c913b" xlink:to="loc_us-gaap_SegmentDomain_36513ce8-06af-4880-9785-e6eca1f9bdc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_c4db6eab-aca5-4516-9e00-223f121ba38a" xlink:href="amed-20200331.xsd#amed_HospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_36513ce8-06af-4880-9785-e6eca1f9bdc6" xlink:to="loc_amed_HospiceMember_c4db6eab-aca5-4516-9e00-223f121ba38a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_d39e9951-e604-474f-8f68-5aa06d630067" xlink:href="amed-20200331.xsd#amed_HomeHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_36513ce8-06af-4880-9785-e6eca1f9bdc6" xlink:to="loc_amed_HomeHealthMember_d39e9951-e604-474f-8f68-5aa06d630067" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_fe4fe543-e86a-42b4-98bc-4f0e09e0feb1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_c25c525a-11cd-4c08-85d0-c15723ec52b2" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_fe4fe543-e86a-42b4-98bc-4f0e09e0feb1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fe4fe543-e86a-42b4-98bc-4f0e09e0feb1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_fe4fe543-e86a-42b4-98bc-4f0e09e0feb1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fe4fe543-e86a-42b4-98bc-4f0e09e0feb1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_797925aa-4a47-4384-81a9-471e8412b27f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_fe4fe543-e86a-42b4-98bc-4f0e09e0feb1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_797925aa-4a47-4384-81a9-471e8412b27f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_InfinityHomeCareMember_09eee135-340f-45e1-9123-84bc244c71ab" xlink:href="amed-20200331.xsd#amed_InfinityHomeCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_797925aa-4a47-4384-81a9-471e8412b27f" xlink:to="loc_amed_InfinityHomeCareMember_09eee135-340f-45e1-9123-84bc244c71ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_2069a203-e3a6-4c94-b097-99694d41f368" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_c25c525a-11cd-4c08-85d0-c15723ec52b2" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_2069a203-e3a6-4c94-b097-99694d41f368" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_2069a203-e3a6-4c94-b097-99694d41f368_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_2069a203-e3a6-4c94-b097-99694d41f368" xlink:to="loc_us-gaap_LossContingencyNatureDomain_2069a203-e3a6-4c94-b097-99694d41f368_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_41c6c1fe-732a-4e6d-9b44-1d98c320f2f1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_2069a203-e3a6-4c94-b097-99694d41f368" xlink:to="loc_us-gaap_LossContingencyNatureDomain_41c6c1fe-732a-4e6d-9b44-1d98c320f2f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ExtrapolatedMember_e50d038f-fd7e-4529-bd33-d9dff67b8244" xlink:href="amed-20200331.xsd#amed_ExtrapolatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_41c6c1fe-732a-4e6d-9b44-1d98c320f2f1" xlink:to="loc_amed_ExtrapolatedMember_e50d038f-fd7e-4529-bd33-d9dff67b8244" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UnfavorableMember_61913b41-5d1b-44b3-893e-b7771fac42d0" xlink:href="amed-20200331.xsd#amed_UnfavorableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_41c6c1fe-732a-4e6d-9b44-1d98c320f2f1" xlink:to="loc_amed_UnfavorableMember_61913b41-5d1b-44b3-893e-b7771fac42d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2f1b672d-6e02-46c1-92a9-abfc3577b8d2" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_c25c525a-11cd-4c08-85d0-c15723ec52b2" xlink:to="loc_srt_RangeAxis_2f1b672d-6e02-46c1-92a9-abfc3577b8d2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2f1b672d-6e02-46c1-92a9-abfc3577b8d2_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2f1b672d-6e02-46c1-92a9-abfc3577b8d2" xlink:to="loc_srt_RangeMember_2f1b672d-6e02-46c1-92a9-abfc3577b8d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_74c021be-b86d-48e3-a90a-204ed616d67e" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2f1b672d-6e02-46c1-92a9-abfc3577b8d2" xlink:to="loc_srt_RangeMember_74c021be-b86d-48e3-a90a-204ed616d67e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c5ddf2f6-8ef9-44c5-924c-0cc8cf346073" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_74c021be-b86d-48e3-a90a-204ed616d67e" xlink:to="loc_srt_MinimumMember_c5ddf2f6-8ef9-44c5-924c-0cc8cf346073" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a1db9e90-6942-4fc6-b0ac-c9549e063db1" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_74c021be-b86d-48e3-a90a-204ed616d67e" xlink:to="loc_srt_MaximumMember_a1db9e90-6942-4fc6-b0ac-c9549e063db1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SEGMENTINFORMATION" xlink:type="simple" xlink:href="amed-20200331.xsd#SEGMENTINFORMATION"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SEGMENTINFORMATION" xlink:type="extended" id="i5d47c516d169464bbafe458e116a2ae5_SEGMENTINFORMATION"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/SEGMENTINFORMATIONTables" xlink:type="simple" xlink:href="amed-20200331.xsd#SEGMENTINFORMATIONTables"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SEGMENTINFORMATIONTables" xlink:type="extended" id="iecb58484f38844cf9ad3a4afb9dc3b4d_SEGMENTINFORMATIONTables"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="simple" xlink:href="amed-20200331.xsd#SEGMENTINFORMATIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="extended" id="iaf67417ff5e149e69f992815ddb82922_SEGMENTINFORMATIONNarrativeDetails"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails" xlink:type="simple" xlink:href="amed-20200331.xsd#SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails" xlink:type="extended" id="i5cab148014e143e0a09dfa32db68ab3e_SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_2a90a191-8fc8-4af3-8658-5546a0e41f5b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_9ad149e2-bc99-4816-9034-58dfa603e29a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2a90a191-8fc8-4af3-8658-5546a0e41f5b" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_9ad149e2-bc99-4816-9034-58dfa603e29a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_687ec2d2-39d6-4526-b234-b1e5b6dd21f9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2a90a191-8fc8-4af3-8658-5546a0e41f5b" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_687ec2d2-39d6-4526-b234-b1e5b6dd21f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_85942567-3903-470f-9b96-e82e3ec5fe01" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2a90a191-8fc8-4af3-8658-5546a0e41f5b" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_85942567-3903-470f-9b96-e82e3ec5fe01" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_ebb42095-55b5-415f-9e58-162c141d011c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2a90a191-8fc8-4af3-8658-5546a0e41f5b" xlink:to="loc_us-gaap_DepreciationAndAmortization_ebb42095-55b5-415f-9e58-162c141d011c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecuritiesClassActionLawsuitsettlement_eb1b7c36-0dc1-4c93-8788-2fde986c50e1" xlink:href="amed-20200331.xsd#amed_SecuritiesClassActionLawsuitsettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2a90a191-8fc8-4af3-8658-5546a0e41f5b" xlink:to="loc_amed_SecuritiesClassActionLawsuitsettlement_eb1b7c36-0dc1-4c93-8788-2fde986c50e1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_bd0cc8e1-9e99-4251-b742-9e1a22b19617" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2a90a191-8fc8-4af3-8658-5546a0e41f5b" xlink:to="loc_us-gaap_CostsAndExpenses_bd0cc8e1-9e99-4251-b742-9e1a22b19617" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_387331ed-5edf-4794-9f3f-1c47b4eefe6d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2a90a191-8fc8-4af3-8658-5546a0e41f5b" xlink:to="loc_us-gaap_OperatingIncomeLoss_387331ed-5edf-4794-9f3f-1c47b4eefe6d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0416a9eb-a401-44b8-8229-352f947e105e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2a90a191-8fc8-4af3-8658-5546a0e41f5b" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0416a9eb-a401-44b8-8229-352f947e105e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_e6117d5b-4e92-43ab-9d3c-3070f956caf0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0416a9eb-a401-44b8-8229-352f947e105e" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_e6117d5b-4e92-43ab-9d3c-3070f956caf0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_e6117d5b-4e92-43ab-9d3c-3070f956caf0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_e6117d5b-4e92-43ab-9d3c-3070f956caf0" xlink:to="loc_us-gaap_SegmentDomain_e6117d5b-4e92-43ab-9d3c-3070f956caf0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_6a19c208-a52c-476d-a93a-8f175e048267" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_e6117d5b-4e92-43ab-9d3c-3070f956caf0" xlink:to="loc_us-gaap_SegmentDomain_6a19c208-a52c-476d-a93a-8f175e048267" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_ab857627-4398-49df-b8ca-b79e44612bc9" xlink:href="amed-20200331.xsd#amed_HomeHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_6a19c208-a52c-476d-a93a-8f175e048267" xlink:to="loc_amed_HomeHealthMember_ab857627-4398-49df-b8ca-b79e44612bc9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_e950eee7-a235-4c83-b4cd-6741449f4a5c" xlink:href="amed-20200331.xsd#amed_HospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_6a19c208-a52c-476d-a93a-8f175e048267" xlink:to="loc_amed_HospiceMember_e950eee7-a235-4c83-b4cd-6741449f4a5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_a253f1df-65ad-4d8a-9c12-887a09e71606" xlink:href="amed-20200331.xsd#amed_PersonalCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_6a19c208-a52c-476d-a93a-8f175e048267" xlink:to="loc_amed_PersonalCareMember_a253f1df-65ad-4d8a-9c12-887a09e71606" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_a5d015f4-96d3-4544-89ac-554141bb17c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_6a19c208-a52c-476d-a93a-8f175e048267" xlink:to="loc_us-gaap_AllOtherSegmentsMember_a5d015f4-96d3-4544-89ac-554141bb17c3" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SHAREREPURCHASESHAREREPURCHASE" xlink:type="simple" xlink:href="amed-20200331.xsd#SHAREREPURCHASESHAREREPURCHASE"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SHAREREPURCHASESHAREREPURCHASE" xlink:type="extended" id="ia57a7494675a49458653a138c7566b2a_SHAREREPURCHASESHAREREPURCHASE"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails" xlink:type="simple" xlink:href="amed-20200331.xsd#SHAREREPURCHASENarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails" xlink:type="extended" id="i402e21284e494bcf9857d2b6df293a86_SHAREREPURCHASENarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseLineItems_eb2456bc-ae7f-4784-a847-d1c40c7eab8c" xlink:href="amed-20200331.xsd#amed_ShareRepurchaseLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_a56fc88c-09aa-4b70-b4ca-63401f36ef44" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseLineItems_eb2456bc-ae7f-4784-a847-d1c40c7eab8c" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_a56fc88c-09aa-4b70-b4ca-63401f36ef44" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramExpirationDate_70572b2c-ca5f-4714-9576-856ea6dfb09c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramExpirationDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseLineItems_eb2456bc-ae7f-4784-a847-d1c40c7eab8c" xlink:to="loc_us-gaap_StockRepurchaseProgramExpirationDate_70572b2c-ca5f-4714-9576-856ea6dfb09c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_ec2920ce-0657-4109-99da-1b8ccb11e664" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseLineItems_eb2456bc-ae7f-4784-a847-d1c40c7eab8c" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_ec2920ce-0657-4109-99da-1b8ccb11e664" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageofSharesOutstanding_134e47d4-534c-4ead-a861-ff167769ab01" xlink:href="amed-20200331.xsd#amed_PercentageofSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseLineItems_eb2456bc-ae7f-4784-a847-d1c40c7eab8c" xlink:to="loc_amed_PercentageofSharesOutstanding_134e47d4-534c-4ead-a861-ff167769ab01" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_554c2a85-ccf4-4963-8fdc-fdceed81e205" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseLineItems_eb2456bc-ae7f-4784-a847-d1c40c7eab8c" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_554c2a85-ccf4-4963-8fdc-fdceed81e205" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Discountedclosingstockprice_13c840bb-db8b-4563-9ff5-e672a246f700" xlink:href="amed-20200331.xsd#amed_Discountedclosingstockprice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseLineItems_eb2456bc-ae7f-4784-a847-d1c40c7eab8c" xlink:to="loc_amed_Discountedclosingstockprice_13c840bb-db8b-4563-9ff5-e672a246f700" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Percentageofclosingstockprice_dd70862e-93f1-49a1-9c81-b8d9f41185b5" xlink:href="amed-20200331.xsd#amed_Percentageofclosingstockprice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseLineItems_eb2456bc-ae7f-4784-a847-d1c40c7eab8c" xlink:to="loc_amed_Percentageofclosingstockprice_dd70862e-93f1-49a1-9c81-b8d9f41185b5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseTable_35f4f312-a378-4268-9cd1-58d09bb45628" xlink:href="amed-20200331.xsd#amed_ShareRepurchaseTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_amed_ShareRepurchaseLineItems_eb2456bc-ae7f-4784-a847-d1c40c7eab8c" xlink:to="loc_amed_ShareRepurchaseTable_35f4f312-a378-4268-9cd1-58d09bb45628" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseAxis_3642347a-9180-4cb4-9b00-b1511587f07a" xlink:href="amed-20200331.xsd#amed_ShareRepurchaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_amed_ShareRepurchaseTable_35f4f312-a378-4268-9cd1-58d09bb45628" xlink:to="loc_amed_ShareRepurchaseAxis_3642347a-9180-4cb4-9b00-b1511587f07a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseDomain_3642347a-9180-4cb4-9b00-b1511587f07a_default" xlink:href="amed-20200331.xsd#amed_ShareRepurchaseDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_amed_ShareRepurchaseAxis_3642347a-9180-4cb4-9b00-b1511587f07a" xlink:to="loc_amed_ShareRepurchaseDomain_3642347a-9180-4cb4-9b00-b1511587f07a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseDomain_760a5971-6a6d-49f8-be41-c213753a74b9" xlink:href="amed-20200331.xsd#amed_ShareRepurchaseDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_amed_ShareRepurchaseAxis_3642347a-9180-4cb4-9b00-b1511587f07a" xlink:to="loc_amed_ShareRepurchaseDomain_760a5971-6a6d-49f8-be41-c213753a74b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_KKRShareRepurchaseMember_ea25a3d3-b3d8-4500-a008-0a5bb1166aeb" xlink:href="amed-20200331.xsd#amed_KKRShareRepurchaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseDomain_760a5971-6a6d-49f8-be41-c213753a74b9" xlink:to="loc_amed_KKRShareRepurchaseMember_ea25a3d3-b3d8-4500-a008-0a5bb1166aeb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSRELATEDPARTYTRANSACTIONS" xlink:type="simple" xlink:href="amed-20200331.xsd#RELATEDPARTYTRANSACTIONSRELATEDPARTYTRANSACTIONS"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSRELATEDPARTYTRANSACTIONS" xlink:type="extended" id="i7190979b48ee4d41804a5c10bf3a7cf3_RELATEDPARTYTRANSACTIONSRELATEDPARTYTRANSACTIONS"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails" xlink:type="simple" xlink:href="amed-20200331.xsd#RELATEDPARTYTRANSACTIONSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails" xlink:type="extended" id="i44a8c2da68894d9e99e6e5db96a5a76d_RELATEDPARTYTRANSACTIONSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_c4f06176-b220-410e-8686-08376bbe6b24" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_b32a5f9e-caf3-484b-a895-dfa05b653fac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_c4f06176-b220-410e-8686-08376bbe6b24" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_b32a5f9e-caf3-484b-a895-dfa05b653fac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_f2f1a72f-260f-440d-b03d-0e62fd957d0d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_c4f06176-b220-410e-8686-08376bbe6b24" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_f2f1a72f-260f-440d-b03d-0e62fd957d0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f1e8b3ed-1cbd-4326-82fc-9cf52f9e9b87" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_c4f06176-b220-410e-8686-08376bbe6b24" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f1e8b3ed-1cbd-4326-82fc-9cf52f9e9b87" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b589904c-09a4-476b-aa0a-fba3b7f7f867" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f1e8b3ed-1cbd-4326-82fc-9cf52f9e9b87" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b589904c-09a4-476b-aa0a-fba3b7f7f867" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_b589904c-09a4-476b-aa0a-fba3b7f7f867_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b589904c-09a4-476b-aa0a-fba3b7f7f867" xlink:to="loc_us-gaap_RelatedPartyDomain_b589904c-09a4-476b-aa0a-fba3b7f7f867_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_a1551000-1834-4363-b8d2-9abc6202cc1a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b589904c-09a4-476b-aa0a-fba3b7f7f867" xlink:to="loc_us-gaap_RelatedPartyDomain_a1551000-1834-4363-b8d2-9abc6202cc1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedalogixMember_59794209-da22-416c-9c24-183703acc762" xlink:href="amed-20200331.xsd#amed_MedalogixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_a1551000-1834-4363-b8d2-9abc6202cc1a" xlink:to="loc_amed_MedalogixMember_59794209-da22-416c-9c24-183703acc762" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_f29f4561-6f99-46af-9e9d-070b1ea3dc73" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f1e8b3ed-1cbd-4326-82fc-9cf52f9e9b87" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_f29f4561-6f99-46af-9e9d-070b1ea3dc73" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_f29f4561-6f99-46af-9e9d-070b1ea3dc73_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_f29f4561-6f99-46af-9e9d-070b1ea3dc73" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_f29f4561-6f99-46af-9e9d-070b1ea3dc73_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_8c8d4c10-b9a6-45b7-91fa-51017a94a227" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_f29f4561-6f99-46af-9e9d-070b1ea3dc73" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_8c8d4c10-b9a6-45b7-91fa-51017a94a227" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUBSEQUENTEVENT" xlink:type="simple" xlink:href="amed-20200331.xsd#SUBSEQUENTEVENT"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SUBSEQUENTEVENT" xlink:type="extended" id="i500b7366470548c7abf31be2bc4e1c1f_SUBSEQUENTEVENT"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails" xlink:type="simple" xlink:href="amed-20200331.xsd#SUBSEQUENTEVENTNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails" xlink:type="extended" id="i4b9ebea5c0774f0a8aec0dff8754adf3_SUBSEQUENTEVENTNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_a94b8f52-eefa-4362-8ce4-de51463a8837" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingForHealthcareProvidersIncludingHospitals_25060c28-0ce9-4dc2-9a87-df2f380faedc" xlink:href="amed-20200331.xsd#amed_FundingForHealthcareProvidersIncludingHospitals"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_a94b8f52-eefa-4362-8ce4-de51463a8837" xlink:to="loc_amed_FundingForHealthcareProvidersIncludingHospitals_25060c28-0ce9-4dc2-9a87-df2f380faedc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements_87dda927-6da4-4a4e-b6fc-3063c3608bd6" xlink:href="amed-20200331.xsd#amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_a94b8f52-eefa-4362-8ce4-de51463a8837" xlink:to="loc_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements_87dda927-6da4-4a4e-b6fc-3063c3608bd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingReceivedFromCARESAct_126d22b8-a786-476e-8ac4-d80592fc578d" xlink:href="amed-20200331.xsd#amed_FundingReceivedFromCARESAct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_a94b8f52-eefa-4362-8ce4-de51463a8837" xlink:to="loc_amed_FundingReceivedFromCARESAct_126d22b8-a786-476e-8ac4-d80592fc578d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AdditionalFundingDistributedToHealthcareProviders_9fcab4b9-c859-4864-8b4d-989bd2f509c6" xlink:href="amed-20200331.xsd#amed_AdditionalFundingDistributedToHealthcareProviders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_a94b8f52-eefa-4362-8ce4-de51463a8837" xlink:to="loc_amed_AdditionalFundingDistributedToHealthcareProviders_9fcab4b9-c859-4864-8b4d-989bd2f509c6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_66ed0f2f-5af3-4fc1-a280-855d76c3576e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_a94b8f52-eefa-4362-8ce4-de51463a8837" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_66ed0f2f-5af3-4fc1-a280-855d76c3576e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Paymentsrelatedtotaxassetandworkingcapital_bafb8dad-243c-4914-a1e6-97e0217b77c1" xlink:href="amed-20200331.xsd#amed_Paymentsrelatedtotaxassetandworkingcapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_a94b8f52-eefa-4362-8ce4-de51463a8837" xlink:to="loc_amed_Paymentsrelatedtotaxassetandworkingcapital_bafb8dad-243c-4914-a1e6-97e0217b77c1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired_8995458b-c23b-4baa-bcb2-6acfb7f3f580" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfBusinessesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_a94b8f52-eefa-4362-8ce4-de51463a8837" xlink:to="loc_us-gaap_NumberOfBusinessesAcquired_8995458b-c23b-4baa-bcb2-6acfb7f3f580" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_739274bd-97e1-4142-a404-0acf07a304c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_a94b8f52-eefa-4362-8ce4-de51463a8837" xlink:to="loc_us-gaap_SubsequentEventTable_739274bd-97e1-4142-a404-0acf07a304c3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_880061ac-61ba-441e-aafb-a40fb92493e8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_739274bd-97e1-4142-a404-0acf07a304c3" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_880061ac-61ba-441e-aafb-a40fb92493e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_880061ac-61ba-441e-aafb-a40fb92493e8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_880061ac-61ba-441e-aafb-a40fb92493e8" xlink:to="loc_us-gaap_SegmentDomain_880061ac-61ba-441e-aafb-a40fb92493e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_7c827c8c-4751-47a4-8145-2a8734d2385e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_880061ac-61ba-441e-aafb-a40fb92493e8" xlink:to="loc_us-gaap_SegmentDomain_7c827c8c-4751-47a4-8145-2a8734d2385e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_e6ac259e-dc35-4071-9f7d-a1d701b82d30" xlink:href="amed-20200331.xsd#amed_HospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_7c827c8c-4751-47a4-8145-2a8734d2385e" xlink:to="loc_amed_HospiceMember_e6ac259e-dc35-4071-9f7d-a1d701b82d30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_360a43ee-cd94-492c-9f44-a161a9c035a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_739274bd-97e1-4142-a404-0acf07a304c3" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_360a43ee-cd94-492c-9f44-a161a9c035a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_360a43ee-cd94-492c-9f44-a161a9c035a9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_360a43ee-cd94-492c-9f44-a161a9c035a9" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_360a43ee-cd94-492c-9f44-a161a9c035a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_fdc49e7a-5a17-4b1e-bdaa-2f52f6b8925c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_360a43ee-cd94-492c-9f44-a161a9c035a9" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_fdc49e7a-5a17-4b1e-bdaa-2f52f6b8925c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_347edd2b-3815-4a89-ba2d-579b81c51e33" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_fdc49e7a-5a17-4b1e-bdaa-2f52f6b8925c" xlink:to="loc_us-gaap_SubsequentEventMember_347edd2b-3815-4a89-ba2d-579b81c51e33" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_bc4071a3-1e75-4bb5-bd73-1654345a7090" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_739274bd-97e1-4142-a404-0acf07a304c3" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_bc4071a3-1e75-4bb5-bd73-1654345a7090" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bc4071a3-1e75-4bb5-bd73-1654345a7090_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_bc4071a3-1e75-4bb5-bd73-1654345a7090" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bc4071a3-1e75-4bb5-bd73-1654345a7090_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7b1d0a3c-cbb5-44f4-b41e-d22d5504f536" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_bc4071a3-1e75-4bb5-bd73-1654345a7090" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7b1d0a3c-cbb5-44f4-b41e-d22d5504f536" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RoseRockHealthcareMember_057d6bce-0953-4de9-a3d7-27f56100c8e0" xlink:href="amed-20200331.xsd#amed_RoseRockHealthcareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7b1d0a3c-cbb5-44f4-b41e-d22d5504f536" xlink:to="loc_amed_RoseRockHealthcareMember_057d6bce-0953-4de9-a3d7-27f56100c8e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AseraCareHospiceMember_2b6a67f4-f109-41c6-a426-d3b6bad93153" xlink:href="amed-20200331.xsd#amed_AseraCareHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7b1d0a3c-cbb5-44f4-b41e-d22d5504f536" xlink:to="loc_amed_AseraCareHospiceMember_2b6a67f4-f109-41c6-a426-d3b6bad93153" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>amed-20200331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:dde64841-3e1e-49e6-96d6-a911d3f838cb,g:d3a0c63a-9ddc-46a6-b2f9-35d46ac243f3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_4e4a6340-288f-475d-a738-048960001cf8_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_b3bdbebd-feea-4ef6-bdde-4d41dbfa8649_terseLabel_en-US" xlink:label="lab_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net service revenue episode payment rate (days)</link:label>
    <link:label id="lab_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_label_en-US" xlink:label="lab_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Service Revenue, Period of Care Payment Rate Duration</link:label>
    <link:label id="lab_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_documentation_en-US" xlink:label="lab_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration" xlink:href="amed-20200331.xsd#amed_NetServiceRevenuePeriodOfCarePaymentRateDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration" xlink:to="lab_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalLeaseObligationsMember_bf38ea64-f6af-4cf1-a046-e47af9f6d927_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases [Member]</link:label>
    <link:label id="lab_us-gaap_CapitalLeaseObligationsMember_label_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Lease Obligations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalLeaseObligationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeaseObligationsMember" xlink:to="lab_us-gaap_CapitalLeaseObligationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_c49adf2f-279a-4c0a-b258-2109b733e342_terseLabel_en-US" xlink:label="lab_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right of use assets</link:label>
    <link:label id="lab_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Right Of Use Asset</link:label>
    <link:label id="lab_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of increase (decrease) In Operating Lease Right Of Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:href="amed-20200331.xsd#amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:to="lab_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_93706b0a-d308-46e0-bb27-88e757c6131d_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1d13b6b2-5967-4f5e-8847-8376e0eef802_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, Stockholders Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_af8b117f-630d-4fce-b67a-58196aeefe6d_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, Stockholders Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ClearwaterFloridaMember_39d912e2-37d9-40b2-91ee-28563b5a8eef_terseLabel_en-US" xlink:label="lab_amed_ClearwaterFloridaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clearwater, Florida</link:label>
    <link:label id="lab_amed_ClearwaterFloridaMember_label_en-US" xlink:label="lab_amed_ClearwaterFloridaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clearwater, Florida [Member]</link:label>
    <link:label id="lab_amed_ClearwaterFloridaMember_documentation_en-US" xlink:label="lab_amed_ClearwaterFloridaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clearwater, Florida [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ClearwaterFloridaMember" xlink:href="amed-20200331.xsd#amed_ClearwaterFloridaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ClearwaterFloridaMember" xlink:to="lab_amed_ClearwaterFloridaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_SC_3295894e-1b65-4a00-ae4d-7d497446488d_terseLabel_en-US" xlink:label="lab_stpr_SC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">South Carolina</link:label>
    <link:label id="lab_stpr_SC_label_en-US" xlink:label="lab_stpr_SC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SOUTH CAROLINA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_SC" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_SC"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_SC" xlink:to="lab_stpr_SC" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_0847afe7-5e4b-428e-b655-c09399aa526d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1902e8e1-e568-4006-abf1-146f062c9868_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_6d322573-6603-4942-a16b-916ead91c43c_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PeriodOfCareAsEpisodicBasedRevenueDuration_b0318dcf-7091-45ba-91cc-807d21a0e2df_terseLabel_en-US" xlink:label="lab_amed_PeriodOfCareAsEpisodicBasedRevenueDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of care as episodic-based revenue (days)</link:label>
    <link:label id="lab_amed_PeriodOfCareAsEpisodicBasedRevenueDuration_label_en-US" xlink:label="lab_amed_PeriodOfCareAsEpisodicBasedRevenueDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of Care As Episodic Based Revenue Duration</link:label>
    <link:label id="lab_amed_PeriodOfCareAsEpisodicBasedRevenueDuration_documentation_en-US" xlink:label="lab_amed_PeriodOfCareAsEpisodicBasedRevenueDuration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of days in a home health period of care using PDGM</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PeriodOfCareAsEpisodicBasedRevenueDuration" xlink:href="amed-20200331.xsd#amed_PeriodOfCareAsEpisodicBasedRevenueDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PeriodOfCareAsEpisodicBasedRevenueDuration" xlink:to="lab_amed_PeriodOfCareAsEpisodicBasedRevenueDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock_b3e2f5af-51ba-4cc0-bcaa-f13738aebafc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Payor Class</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue Sources, Health Care Organization [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_da5104b9-f2f4-4a0e-9529-976bb1ff4a73_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MorgantownWestVirginiaMember_e105d5f7-aaec-4744-b058-d6fbc815c1e7_terseLabel_en-US" xlink:label="lab_amed_MorgantownWestVirginiaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Morgantown, West Virginia</link:label>
    <link:label id="lab_amed_MorgantownWestVirginiaMember_label_en-US" xlink:label="lab_amed_MorgantownWestVirginiaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Morgantown, West Virginia [Member]</link:label>
    <link:label id="lab_amed_MorgantownWestVirginiaMember_documentation_en-US" xlink:label="lab_amed_MorgantownWestVirginiaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Morgantown, West Virginia [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MorgantownWestVirginiaMember" xlink:href="amed-20200331.xsd#amed_MorgantownWestVirginiaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MorgantownWestVirginiaMember" xlink:to="lab_amed_MorgantownWestVirginiaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_eb33ad2e-7bff-4c46-8b44-e84fe6112589_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill recorded during period</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockShares_73ba8504-020c-47de-9e19-ada2f5aba09a_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock at cost (shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_2f72d21d-84fe-48f1-abcb-5ee00b66dda0_verboseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_2d702ee2-2801-4fba-914b-d12c232e35ef_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_6f77ba2f-b53c-4477-bec9-82fa10536bd3_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_f69a7936-ef50-409e-8263-47d02054f67c_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of service, excluding depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_0db69de4-2d8a-47b2-900e-398ee1cb0f3d_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements_2563f75d-1d99-4612-96f5-5aa5b354c8bf_terseLabel_en-US" xlink:label="lab_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Immediately Distributed to Healthcare Providers Based on Their 2019 Medicare Fee-For-Service Reimbursements</link:label>
    <link:label id="lab_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements_label_en-US" xlink:label="lab_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Immediately Distributed to Healthcare Providers Based on Their 2019 Medicare Fee-For-Service Reimbursements</link:label>
    <link:label id="lab_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements_documentation_en-US" xlink:label="lab_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding immediately distributed to healthcare providers based on their 2019 Medicare Fee-For-Service reimbursements provided by the Coronavirus Aid, Relief and Economic Security (CARES) Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements" xlink:href="amed-20200331.xsd#amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements" xlink:to="lab_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ConsolidatedLeverageRatio_b3687b31-b10b-4241-a060-c3cd188853aa_terseLabel_en-US" xlink:label="lab_amed_ConsolidatedLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Leverage Ratio</link:label>
    <link:label id="lab_amed_ConsolidatedLeverageRatio_label_en-US" xlink:label="lab_amed_ConsolidatedLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Leverage Ratio</link:label>
    <link:label id="lab_amed_ConsolidatedLeverageRatio_documentation_en-US" xlink:label="lab_amed_ConsolidatedLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Leverage Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ConsolidatedLeverageRatio" xlink:href="amed-20200331.xsd#amed_ConsolidatedLeverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ConsolidatedLeverageRatio" xlink:to="lab_amed_ConsolidatedLeverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ac0fe5a1-7af1-4f75-82ba-769ae22a409e_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding, diluted (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_17a708a1-40ee-4694-9698-3727b7e469bd_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of shares outstanding - diluted (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_1dd6bf25-a22d-4a1f-89a5-20dee56ac1d9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_afdcdfb6-cc87-4731-8010-a14296309d38_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance/(cancellation) of non-vested stock (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MajorSinglePayorCustomerMember_7f9d4972-8e74-466d-a552-9839ba4960c4_terseLabel_en-US" xlink:label="lab_amed_MajorSinglePayorCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Single Payor</link:label>
    <link:label id="lab_amed_MajorSinglePayorCustomerMember_label_en-US" xlink:label="lab_amed_MajorSinglePayorCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Single Payor Customer [Member]</link:label>
    <link:label id="lab_amed_MajorSinglePayorCustomerMember_documentation_en-US" xlink:label="lab_amed_MajorSinglePayorCustomerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Single Payor Customer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MajorSinglePayorCustomerMember" xlink:href="amed-20200331.xsd#amed_MajorSinglePayorCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MajorSinglePayorCustomerMember" xlink:to="lab_amed_MajorSinglePayorCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_c57ba40d-8e87-4a79-afa9-9a17008b3143_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PaymentsForRepurchaseOfNoncontrollingInterest_84d1ad9a-b4c0-4b71-9485-da3e75a846e4_negatedLabel_en-US" xlink:label="lab_amed_PaymentsForRepurchaseOfNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of noncontrolling interest</link:label>
    <link:label id="lab_amed_PaymentsForRepurchaseOfNoncontrollingInterest_label_en-US" xlink:label="lab_amed_PaymentsForRepurchaseOfNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Repurchase Of Noncontrolling Interest</link:label>
    <link:label id="lab_amed_PaymentsForRepurchaseOfNoncontrollingInterest_documentation_en-US" xlink:label="lab_amed_PaymentsForRepurchaseOfNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The cash outflow during the period for redemption of noncontrolling interests.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PaymentsForRepurchaseOfNoncontrollingInterest" xlink:href="amed-20200331.xsd#amed_PaymentsForRepurchaseOfNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PaymentsForRepurchaseOfNoncontrollingInterest" xlink:to="lab_amed_PaymentsForRepurchaseOfNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MinimumPercentOwnershipForControllingInterestPercent_355f3f01-7c64-45c8-ab7f-e67953d22efe_terseLabel_en-US" xlink:label="lab_amed_MinimumPercentOwnershipForControllingInterestPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum ownership percentage for controlling interest (percent)</link:label>
    <link:label id="lab_amed_MinimumPercentOwnershipForControllingInterestPercent_label_en-US" xlink:label="lab_amed_MinimumPercentOwnershipForControllingInterestPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Percent Ownership For Controlling Interest Percent</link:label>
    <link:label id="lab_amed_MinimumPercentOwnershipForControllingInterestPercent_documentation_en-US" xlink:label="lab_amed_MinimumPercentOwnershipForControllingInterestPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the percentage ownership required in order for a variable interest entity (VIE) to be consolidated in the entity's financial statements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MinimumPercentOwnershipForControllingInterestPercent" xlink:href="amed-20200331.xsd#amed_MinimumPercentOwnershipForControllingInterestPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MinimumPercentOwnershipForControllingInterestPercent" xlink:to="lab_amed_MinimumPercentOwnershipForControllingInterestPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_35b89823-647c-4c4e-9f73-8c4951525450_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit facility, maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_574cbd5e-df47-4845-81af-bf0dac88cff6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net of accumulated depreciation of $98,472 and $96,137</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_EquityImpactofRepurchaseofNoncontrollingInterest_e099fc23-98fd-4105-bdea-5f6ff966da21_negatedLabel_en-US" xlink:label="lab_amed_EquityImpactofRepurchaseofNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of noncontrolling interest</link:label>
    <link:label id="lab_amed_EquityImpactofRepurchaseofNoncontrollingInterest_label_en-US" xlink:label="lab_amed_EquityImpactofRepurchaseofNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Impact of Repurchase of Noncontrolling Interest</link:label>
    <link:label id="lab_amed_EquityImpactofRepurchaseofNoncontrollingInterest_documentation_en-US" xlink:label="lab_amed_EquityImpactofRepurchaseofNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Impact of Repurchase of Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EquityImpactofRepurchaseofNoncontrollingInterest" xlink:href="amed-20200331.xsd#amed_EquityImpactofRepurchaseofNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EquityImpactofRepurchaseofNoncontrollingInterest" xlink:to="lab_amed_EquityImpactofRepurchaseofNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PercentageOfPatientReceivablesOutstanding_5501f38d-9d92-4f17-880e-1266f11044b5_terseLabel_en-US" xlink:label="lab_amed_PercentageOfPatientReceivablesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of patient receivables outstanding</link:label>
    <link:label id="lab_amed_PercentageOfPatientReceivablesOutstanding_label_en-US" xlink:label="lab_amed_PercentageOfPatientReceivablesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Patient Receivables Outstanding</link:label>
    <link:label id="lab_amed_PercentageOfPatientReceivablesOutstanding_documentation_en-US" xlink:label="lab_amed_PercentageOfPatientReceivablesOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of patient receivables outstanding.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfPatientReceivablesOutstanding" xlink:href="amed-20200331.xsd#amed_PercentageOfPatientReceivablesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PercentageOfPatientReceivablesOutstanding" xlink:to="lab_amed_PercentageOfPatientReceivablesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cff56e84-349b-4121-bbdb-e0c4070915fb_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_e1cc6e4e-cb31-4e13-88f3-9bc19c03f74e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_dd967f82-0a5f-4390-bfc3-dab38ab79cde_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_7cc010c7-a208-4fa5-82d7-0c2986529b76_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_feb1fa1b-3b40-48fe-9869-5e25993b6e62_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_55859d30-41d4-4dc9-80d8-36866275e809_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HistoricalCollectionRateFromMedicare_219c85d6-f3d8-4ad2-8c5a-ce8cce85ab10_terseLabel_en-US" xlink:label="lab_amed_HistoricalCollectionRateFromMedicare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Historical collection rate from Medicare</link:label>
    <link:label id="lab_amed_HistoricalCollectionRateFromMedicare_label_en-US" xlink:label="lab_amed_HistoricalCollectionRateFromMedicare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Historical Collection Rate From Medicare</link:label>
    <link:label id="lab_amed_HistoricalCollectionRateFromMedicare_documentation_en-US" xlink:label="lab_amed_HistoricalCollectionRateFromMedicare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Historical collection rate from Medicare.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HistoricalCollectionRateFromMedicare" xlink:href="amed-20200331.xsd#amed_HistoricalCollectionRateFromMedicare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HistoricalCollectionRateFromMedicare" xlink:to="lab_amed_HistoricalCollectionRateFromMedicare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_eb464bd5-c598-4127-b07e-c02f33079255_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term obligations</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_5392ebef-62fa-4923-be65-f61920afe0d5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_be3f53be-fca2-41ad-952c-b0cc8f5bc247_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_b7b76568-49b4-46fe-9f8c-01c6937a9be1_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition and Deferred Revenue [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition and Deferred Revenue [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration_96300ca6-740a-46f0-9721-f68d13641cfc_terseLabel_en-US" xlink:label="lab_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Episode of care as episodic-based revenue (days)</link:label>
    <link:label id="lab_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration_label_en-US" xlink:label="lab_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Episode Of Care As Episodic Based Revenue Duration</link:label>
    <link:label id="lab_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration_documentation_en-US" xlink:label="lab_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of days in a home health episode of care.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration" xlink:href="amed-20200331.xsd#amed_EpisodeOfCareAsEpisodicBasedRevenueDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration" xlink:to="lab_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_SupplementalDisclosuresOfNonCashActivityAbstract_cd770caa-64b1-42d2-8c8d-5841a2ff2d13_terseLabel_en-US" xlink:label="lab_amed_SupplementalDisclosuresOfNonCashActivityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Disclosures of Non-Cash Activity:</link:label>
    <link:label id="lab_amed_SupplementalDisclosuresOfNonCashActivityAbstract_label_en-US" xlink:label="lab_amed_SupplementalDisclosuresOfNonCashActivityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Disclosures of Non-Cash Activity [Abstract]</link:label>
    <link:label id="lab_amed_SupplementalDisclosuresOfNonCashActivityAbstract_documentation_en-US" xlink:label="lab_amed_SupplementalDisclosuresOfNonCashActivityAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Disclosures of Non-Cash Activity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SupplementalDisclosuresOfNonCashActivityAbstract" xlink:href="amed-20200331.xsd#amed_SupplementalDisclosuresOfNonCashActivityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_SupplementalDisclosuresOfNonCashActivityAbstract" xlink:to="lab_amed_SupplementalDisclosuresOfNonCashActivityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_00dcd497-3f0a-4674-a29a-6826f8181b83_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_b05675f0-e7bd-42c4-a992-d1ebefc292fb_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal payments of long-term obligations</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CashDistributionToNoncontrollingInterest_9ea24fda-4ec8-44b6-850f-b340a50ec747_negatedLabel_en-US" xlink:label="lab_amed_CashDistributionToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest distribution</link:label>
    <link:label id="lab_amed_CashDistributionToNoncontrollingInterest_label_en-US" xlink:label="lab_amed_CashDistributionToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Distribution To Noncontrolling Interest</link:label>
    <link:label id="lab_amed_CashDistributionToNoncontrollingInterest_documentation_en-US" xlink:label="lab_amed_CashDistributionToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of dividends or other distributions to noncontrolling interest holders.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CashDistributionToNoncontrollingInterest" xlink:href="amed-20200331.xsd#amed_CashDistributionToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CashDistributionToNoncontrollingInterest" xlink:to="lab_amed_CashDistributionToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_a7f22210-08ee-4803-9696-0026f46396a8_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares repurchased (shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HomeHealthNonMedicareNonEpisodicBasedMember_fbb1112e-abb8-446c-abdd-cd7450aa53dd_terseLabel_en-US" xlink:label="lab_amed_HomeHealthNonMedicareNonEpisodicBasedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health Non-Medicare - Non-Episodic Based [Member]</link:label>
    <link:label id="lab_amed_HomeHealthNonMedicareNonEpisodicBasedMember_label_en-US" xlink:label="lab_amed_HomeHealthNonMedicareNonEpisodicBasedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health Non-Medicare - Non-Episodic Based [Member]</link:label>
    <link:label id="lab_amed_HomeHealthNonMedicareNonEpisodicBasedMember_documentation_en-US" xlink:label="lab_amed_HomeHealthNonMedicareNonEpisodicBasedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health Non-Medicare - Non-Episodic Based [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthNonMedicareNonEpisodicBasedMember" xlink:href="amed-20200331.xsd#amed_HomeHealthNonMedicareNonEpisodicBasedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HomeHealthNonMedicareNonEpisodicBasedMember" xlink:to="lab_amed_HomeHealthNonMedicareNonEpisodicBasedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments_3423f64c-0c2f-4e5b-93b5-f1fb296f546f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of deferred compensation plan assets</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Restricted Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfRestrictedInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CapYearDomain_3f9eb1dc-49ce-4d7b-99ff-25dba333b779_terseLabel_en-US" xlink:label="lab_amed_CapYearDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year [Domain]</link:label>
    <link:label id="lab_amed_CapYearDomain_label_en-US" xlink:label="lab_amed_CapYearDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year [Domain]</link:label>
    <link:label id="lab_amed_CapYearDomain_documentation_en-US" xlink:label="lab_amed_CapYearDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearDomain" xlink:href="amed-20200331.xsd#amed_CapYearDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CapYearDomain" xlink:to="lab_amed_CapYearDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_4b85b103-98dc-43a4-bd74-acd77d0c8769_terseLabel_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Acquired from Acquisition</link:label>
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_label_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Acquired from Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAcquiredFromAcquisition" xlink:to="lab_us-gaap_CashAcquiredFromAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_bf598780-a1d1-4ded-8fed-4d62140d8a77_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_e0174daf-22dd-4963-ae8a-b00b1ba71d97_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_59a0ee7a-1b7a-4c26-85f9-107ba4378320_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_91a0b5b3-f152-4290-8cf7-86463333f820_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use assets obtained in exchange for operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_28489bb9-d25c-4f39-82ea-e10ca770fe7c_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_47dffd60-e0ef-4d28-bbb5-13be69fdb052_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for legal settlements</link:label>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_label_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Legal Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLegalSettlements" xlink:to="lab_us-gaap_PaymentsForLegalSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_73dd6b04-97c9-4e8c-91ae-18f40e51093c_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEGMENT INFORMATION</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_2ac5e4fa-3f00-449b-bde9-f75c3018864c_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_918c23ff-0f34-494d-a02f-520b4af5dfba_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_ebd71f67-1f64-49b7-8a39-47aee4de4eca_terseLabel_en-US" xlink:label="lab_amed_HospiceMedicareRevenueRateAccountedForRoutineCare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice Medicare revenue rate accounted for routine care</link:label>
    <link:label id="lab_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_label_en-US" xlink:label="lab_amed_HospiceMedicareRevenueRateAccountedForRoutineCare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice Medicare Revenue Rate Accounted For Routine Care</link:label>
    <link:label id="lab_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_documentation_en-US" xlink:label="lab_amed_HospiceMedicareRevenueRateAccountedForRoutineCare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the percentage of the entity's Hospice net Medicare service revenue that is derived from routine care.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMedicareRevenueRateAccountedForRoutineCare" xlink:href="amed-20200331.xsd#amed_HospiceMedicareRevenueRateAccountedForRoutineCare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HospiceMedicareRevenueRateAccountedForRoutineCare" xlink:to="lab_amed_HospiceMedicareRevenueRateAccountedForRoutineCare" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations_cb9e5371-b511-4943-b380-d38c2fe9bb30_terseLabel_en-US" xlink:label="lab_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions to right of use assets resulting from reductions to operating lease liabilities</link:label>
    <link:label id="lab_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations_label_en-US" xlink:label="lab_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating lease, Reductions to ROU assets resulting from reductions to lease obligations</link:label>
    <link:label id="lab_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations_documentation_en-US" xlink:label="lab_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating lease, Reductions to ROU assets resulting from reductions to lease obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations" xlink:href="amed-20200331.xsd#amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations" xlink:to="lab_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_7aed164c-8a10-4a55-8302-b573e44c1190_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_f868045a-4ce6-4141-a3e5-de77747bc923_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining availability under revolving credit facility</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_7f468504-e03e-402b-8aaa-abf03d966ca2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from borrowings under revolving line of credit</link:label>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Short-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromShortTermDebt" xlink:to="lab_us-gaap_ProceedsFromShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_7f7f6400-2ac0-4a1f-b905-b2276b478504_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_41f25aa9-f7ba-44af-8674-a67cb51f5132_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_d5f857af-a9c7-4eb9-9414-646f5d6c6f2e_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies&#8212;Note 5</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_23769919-94a8-4ea6-b082-debf4ba950a5_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cb354743-b572-4a53-a404-89545b007cfb_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c39e4c05-18e8-4957-a2a7-6dbb78b975e0_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_01dccd19-ff74-4be4-b523-6f0f62fd4719_terseLabel_en-US" xlink:label="lab_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">550 Million Revolving Credit Facility [Member]</link:label>
    <link:label id="lab_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_label_en-US" xlink:label="lab_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Hundred Fifty Million Revolving Credit Facility [Member]</link:label>
    <link:label id="lab_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_documentation_en-US" xlink:label="lab_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Hundred Fifty Million Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember" xlink:href="amed-20200331.xsd#amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember" xlink:to="lab_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_03ba6fe2-2c9a-4e21-af47-f3526aafcf60_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentAggregateCost_36f1cc4e-6ba7-45b3-bf5b-5b335e8b4684_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, aggregate cost</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentAggregateCost_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Aggregate Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentAggregateCost" xlink:to="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_52494b03-8331-471b-b26f-70d3c2edba59_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HomeHealthMember_95c28125-d79d-484c-9197-5f0b9fb4fbcb_terseLabel_en-US" xlink:label="lab_amed_HomeHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health [Member]</link:label>
    <link:label id="lab_amed_HomeHealthMember_label_en-US" xlink:label="lab_amed_HomeHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health [Member]</link:label>
    <link:label id="lab_amed_HomeHealthMember_documentation_en-US" xlink:label="lab_amed_HomeHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember" xlink:href="amed-20200331.xsd#amed_HomeHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HomeHealthMember" xlink:to="lab_amed_HomeHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare_99aff05e-7990-4858-be46-295be4803270_terseLabel_en-US" xlink:label="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate of request for anticipated payment submitted for subsequent episodes of care</link:label>
    <link:label id="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare_label_en-US" xlink:label="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate Of Request For Anticipated Payment Submitted For Subsequent Episodes Of Care</link:label>
    <link:label id="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare_documentation_en-US" xlink:label="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the percentage of estimated payment that is requested at the start of care for any subsequent episodes of care.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" xlink:href="amed-20200331.xsd#amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" xlink:to="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_a7e1116a-4fb9-4e0a-9a72-c31e728deb64_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use assets obtained in exchange for finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_8d08f38a-839e-4487-9a01-1312d3fea108_terseLabel_en-US" xlink:label="lab_amed_LowUtilizationPaymentAdjustmentNumberOfVisits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Low utilization payment adjustment, maximum number of visits</link:label>
    <link:label id="lab_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_label_en-US" xlink:label="lab_amed_LowUtilizationPaymentAdjustmentNumberOfVisits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Low Utilization Payment Adjustment Number Of Visits</link:label>
    <link:label id="lab_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_documentation_en-US" xlink:label="lab_amed_LowUtilizationPaymentAdjustmentNumberOfVisits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the visit threshold for a low utilization payment adjustment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LowUtilizationPaymentAdjustmentNumberOfVisits" xlink:href="amed-20200331.xsd#amed_LowUtilizationPaymentAdjustmentNumberOfVisits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LowUtilizationPaymentAdjustmentNumberOfVisits" xlink:to="lab_amed_LowUtilizationPaymentAdjustmentNumberOfVisits" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_ca046977-010c-47bb-b8f8-347e940a9faf_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_6f7dacf5-93ea-49d8-b4cf-f4d297fec1f1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred debt issuance cost</link:label>
    <link:label id="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_label_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Line of Credit Arrangements, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross" xlink:to="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_abd6264d-9a96-437f-b05c-09ee8f3c1848_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_2be67da4-8273-4a3e-a42b-c0e5de6b0d9b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_InfinityHomeCareMember_37d7f779-6dee-46ed-be8b-fbac5250d5d0_terseLabel_en-US" xlink:label="lab_amed_InfinityHomeCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infinity HomeCare</link:label>
    <link:label id="lab_amed_InfinityHomeCareMember_label_en-US" xlink:label="lab_amed_InfinityHomeCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infinity HomeCare [Member]</link:label>
    <link:label id="lab_amed_InfinityHomeCareMember_documentation_en-US" xlink:label="lab_amed_InfinityHomeCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infinity HomeCare [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_InfinityHomeCareMember" xlink:href="amed-20200331.xsd#amed_InfinityHomeCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_InfinityHomeCareMember" xlink:to="lab_amed_InfinityHomeCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_584f3719-9acd-48f2-9f25-d860e754a22c_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValueOutstanding_fbbb9883-6ecf-43a1-8c53-486f8d9286fe_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValueOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValueOutstanding" xlink:to="lab_us-gaap_PreferredStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_cc988756-28c1-4d65-acdb-bb9ad709c7c9_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, at cost 4,376,209 and 4,353,970 shares of common stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_daceb3d3-4d0e-48c0-8865-e716ba653788_terseLabel_en-US" xlink:label="lab_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Hundred Seventy Five Million Term Loan Facility [Member]</link:label>
    <link:label id="lab_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_label_en-US" xlink:label="lab_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Hundred Seventy Five Million Term Loan Facility [Member]</link:label>
    <link:label id="lab_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_documentation_en-US" xlink:label="lab_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Hundred Seventy Five Million Term Loan Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember" xlink:href="amed-20200331.xsd#amed_OneHundredSeventyFiveMillionTermLoanFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember" xlink:to="lab_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ProceedsFromBorrowingsUnderTermLoan_466d707c-46e3-47e4-b9b5-884261f9537c_terseLabel_en-US" xlink:label="lab_amed_ProceedsFromBorrowingsUnderTermLoan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from borrowings under term loan</link:label>
    <link:label id="lab_amed_ProceedsFromBorrowingsUnderTermLoan_label_en-US" xlink:label="lab_amed_ProceedsFromBorrowingsUnderTermLoan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Borrowings Under Term Loan</link:label>
    <link:label id="lab_amed_ProceedsFromBorrowingsUnderTermLoan_documentation_en-US" xlink:label="lab_amed_ProceedsFromBorrowingsUnderTermLoan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The cash inflow from borrowings under the term loan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProceedsFromBorrowingsUnderTermLoan" xlink:href="amed-20200331.xsd#amed_ProceedsFromBorrowingsUnderTermLoan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ProceedsFromBorrowingsUnderTermLoan" xlink:to="lab_amed_ProceedsFromBorrowingsUnderTermLoan" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DebtInstrumentByLeverageRatioTrancheFourMember_f267f858-dd9f-41bc-a86b-2a4afaabb009_terseLabel_en-US" xlink:label="lab_amed_DebtInstrumentByLeverageRatioTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Leverage Ratio: Less Than 0.75 to 1.0</link:label>
    <link:label id="lab_amed_DebtInstrumentByLeverageRatioTrancheFourMember_label_en-US" xlink:label="lab_amed_DebtInstrumentByLeverageRatioTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, By Leverage Ratio, Tranche Four [Member]</link:label>
    <link:label id="lab_amed_DebtInstrumentByLeverageRatioTrancheFourMember_documentation_en-US" xlink:label="lab_amed_DebtInstrumentByLeverageRatioTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, By Leverage Ratio, Tranche Four [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentByLeverageRatioTrancheFourMember" xlink:href="amed-20200331.xsd#amed_DebtInstrumentByLeverageRatioTrancheFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DebtInstrumentByLeverageRatioTrancheFourMember" xlink:to="lab_amed_DebtInstrumentByLeverageRatioTrancheFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_68b12697-ea11-4147-81ec-30631d46a32b_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_48a300af-a4f4-472f-8219-fcec7cbcd191_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted earnings per common share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_8a9a9899-c6ff-4f22-8dd8-29513c69f05d_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_7002f5a9-7c1c-4c4b-9e19-918cd2c1e923_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_19a163e6-96f1-43fd-8bbb-0fbb2ead2638_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income (loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_7968e880-b9cc-470d-85f3-007ec378f323_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents Items [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents Items [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_1830c677-e731-4052-9449-3fb88aeb5b01_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_Numberofpatients_fecfddd5-4e46-4659-93dd-82bf5afe63b2_terseLabel_en-US" xlink:label="lab_amed_Numberofpatients" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patients</link:label>
    <link:label id="lab_amed_Numberofpatients_label_en-US" xlink:label="lab_amed_Numberofpatients" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patients</link:label>
    <link:label id="lab_amed_Numberofpatients_documentation_en-US" xlink:label="lab_amed_Numberofpatients" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patients</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Numberofpatients" xlink:href="amed-20200331.xsd#amed_Numberofpatients"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_Numberofpatients" xlink:to="lab_amed_Numberofpatients" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_5959f916-8033-43ae-ba00-cee28e22c4dc_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_82bc4423-33cd-4cab-b8e1-23e45b7b95a2_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_8b4fa7de-dad7-44cd-ad11-19723f6c1cf8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_44208952-7192-4a99-959c-601236045f89_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Amedisys, Inc. common stockholders, basic (usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_ad053f8f-60bc-40ad-a760-8812a0374afd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of variable rate basis</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Description of Variable Rate Basis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:to="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_07867b3a-5154-4ce8-820a-7ab8022b4e85_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Shares Outstanding</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_7260ad1e-598d-46f5-b4b6-fe21e8203307_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_7c858b9b-0bbf-4bec-859f-80a76f967940_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_9aa1c6c5-9760-4298-977d-94fe0a033a99_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition, other intangibles recorded</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_1074191e-148e-45a7-b042-4717ad109b7c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MedicareRevenueMember_5ed9847e-5352-4e2e-a57f-501755db258b_terseLabel_en-US" xlink:label="lab_amed_MedicareRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Revenue</link:label>
    <link:label id="lab_amed_MedicareRevenueMember_label_en-US" xlink:label="lab_amed_MedicareRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Revenue [Member]</link:label>
    <link:label id="lab_amed_MedicareRevenueMember_documentation_en-US" xlink:label="lab_amed_MedicareRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareRevenueMember" xlink:href="amed-20200331.xsd#amed_MedicareRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MedicareRevenueMember" xlink:to="lab_amed_MedicareRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_34aee0df-e6b0-4225-b745-2ad581ede7c4_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_6928c77a-19dc-452a-bfb3-456d17a3ad79_terseLabel_en-US" xlink:label="lab_amed_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit facility, maximum additional borrowing capacity</link:label>
    <link:label id="lab_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_label_en-US" xlink:label="lab_amed_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility Additional Borrowing Capacity</link:label>
    <link:label id="lab_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_documentation_en-US" xlink:label="lab_amed_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility Additional Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:href="amed-20200331.xsd#amed_LineOfCreditFacilityAdditionalBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:to="lab_amed_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentMaturityDate_4d318737-1f5e-4f58-bf4c-463b3dabdd1e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity Date</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentMaturityDate_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Maturity Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDate" xlink:to="lab_us-gaap_DebtInstrumentMaturityDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9d959b16-d08a-4960-b3bb-12b9dc6f8078_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities, net of impact of acquisitions:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_4bad531f-0189-4c2d-bfc4-55f003ae6f3c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_580ddcc0-22e9-4013-beee-5149e466fb50_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_b81a1832-0755-4737-8ad7-1fd705290567_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_SecuritiesClassActionLawsuitsettlement_8206ed4a-4679-4138-93fe-342aaa39f30a_terseLabel_en-US" xlink:label="lab_amed_SecuritiesClassActionLawsuitsettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Class Action Lawsuit settlement, net</link:label>
    <link:label id="lab_amed_SecuritiesClassActionLawsuitsettlement_label_en-US" xlink:label="lab_amed_SecuritiesClassActionLawsuitsettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Class Action Lawsuit settlement</link:label>
    <link:label id="lab_amed_SecuritiesClassActionLawsuitsettlement_documentation_en-US" xlink:label="lab_amed_SecuritiesClassActionLawsuitsettlement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charge related to Securities Class Action Lawsuit settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecuritiesClassActionLawsuitsettlement" xlink:href="amed-20200331.xsd#amed_SecuritiesClassActionLawsuitsettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_SecuritiesClassActionLawsuitsettlement" xlink:to="lab_amed_SecuritiesClassActionLawsuitsettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_Businessacquisitionproformaoperatingincomeloss_c2118c6e-4063-400a-a65c-fb7c394bbbf2_terseLabel_en-US" xlink:label="lab_amed_Businessacquisitionproformaoperatingincomeloss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income (loss)</link:label>
    <link:label id="lab_amed_Businessacquisitionproformaoperatingincomeloss_label_en-US" xlink:label="lab_amed_Businessacquisitionproformaoperatingincomeloss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition pro forma operating income loss</link:label>
    <link:label id="lab_amed_Businessacquisitionproformaoperatingincomeloss_documentation_en-US" xlink:label="lab_amed_Businessacquisitionproformaoperatingincomeloss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The pro forma operating income (loss) for the period as if the business combination or combinations had been completed at the beginning of a period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Businessacquisitionproformaoperatingincomeloss" xlink:href="amed-20200331.xsd#amed_Businessacquisitionproformaoperatingincomeloss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_Businessacquisitionproformaoperatingincomeloss" xlink:to="lab_amed_Businessacquisitionproformaoperatingincomeloss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_5f16e81b-d62d-402c-8bf0-938ceef3eb04_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_0c2c688b-ddf2-423c-ba0f-09eec08e731c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PayorsDomain_f81cdecb-dcab-41de-ade1-efe6e9638748_terseLabel_en-US" xlink:label="lab_amed_PayorsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payors [Domain]</link:label>
    <link:label id="lab_amed_PayorsDomain_label_en-US" xlink:label="lab_amed_PayorsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payors [Domain]</link:label>
    <link:label id="lab_amed_PayorsDomain_documentation_en-US" xlink:label="lab_amed_PayorsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Payors [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorsDomain" xlink:href="amed-20200331.xsd#amed_PayorsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PayorsDomain" xlink:to="lab_amed_PayorsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_TN_fa68f897-20f0-4ebf-ab64-9338f08865fc_terseLabel_en-US" xlink:label="lab_stpr_TN" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tennessee [Member]</link:label>
    <link:label id="lab_stpr_TN_label_en-US" xlink:label="lab_stpr_TN" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TENNESSEE</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_TN" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_TN"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_TN" xlink:to="lab_stpr_TN" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_95f76f13-6a97-4017-85a5-e437b67b3a48_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_eaea1ff9-3749-4600-b9d8-db13aac48a00_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DebtInstrumentByLeverageRatioTrancheThreeMember_75273526-3304-4869-9f15-03bac38065be_terseLabel_en-US" xlink:label="lab_amed_DebtInstrumentByLeverageRatioTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Leverage Ratio: Less Than 2.00 to 1.0 but Greater Than Equal To 0.75 to 1.0</link:label>
    <link:label id="lab_amed_DebtInstrumentByLeverageRatioTrancheThreeMember_label_en-US" xlink:label="lab_amed_DebtInstrumentByLeverageRatioTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, By Leverage Ratio, Tranche Three [Member]</link:label>
    <link:label id="lab_amed_DebtInstrumentByLeverageRatioTrancheThreeMember_documentation_en-US" xlink:label="lab_amed_DebtInstrumentByLeverageRatioTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, By Leverage Ratio, Tranche Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentByLeverageRatioTrancheThreeMember" xlink:href="amed-20200331.xsd#amed_DebtInstrumentByLeverageRatioTrancheThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DebtInstrumentByLeverageRatioTrancheThreeMember" xlink:to="lab_amed_DebtInstrumentByLeverageRatioTrancheThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_7cade50b-5e06-4a45-9283-19cbd01619d4_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_d5553096-a968-4629-9fe1-faa68a17e647_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity in earnings from equity method investments</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_5df6e710-a2e5-4ce2-a088-c05a48890ce5_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity in earnings from equity method investments</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_7239c2f8-47de-43c6-ba8f-37f50706d302_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_3d6aea16-cfd0-450b-ad3b-62457ba8f19d_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramExpirationDate_89855cdc-d7f9-49b2-a313-2992eefbc0b4_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program Expiration Date</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramExpirationDate_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramExpirationDate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramExpirationDate" xlink:to="lab_us-gaap_StockRepurchaseProgramExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DebtInstrumentInterestRateatPeriodEnd_b7090601-15e0-480d-be64-b6c8ee61988b_terseLabel_en-US" xlink:label="lab_amed_DebtInstrumentInterestRateatPeriodEnd" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Rate at Period End</link:label>
    <link:label id="lab_amed_DebtInstrumentInterestRateatPeriodEnd_label_en-US" xlink:label="lab_amed_DebtInstrumentInterestRateatPeriodEnd" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Rate at Period End</link:label>
    <link:label id="lab_amed_DebtInstrumentInterestRateatPeriodEnd_documentation_en-US" xlink:label="lab_amed_DebtInstrumentInterestRateatPeriodEnd" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Rate at Period End</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestRateatPeriodEnd" xlink:href="amed-20200331.xsd#amed_DebtInstrumentInterestRateatPeriodEnd"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DebtInstrumentInterestRateatPeriodEnd" xlink:to="lab_amed_DebtInstrumentInterestRateatPeriodEnd" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_372d79e5-f728-4f60-afbc-f5442a26275e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare_77ecbd74-25c6-4ef2-bbd6-59640bbd9eb2_terseLabel_en-US" xlink:label="lab_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum days to submit final bill from the start of episode</link:label>
    <link:label id="lab_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare_label_en-US" xlink:label="lab_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Days To Submit Final Bill From Start Of Period of Care</link:label>
    <link:label id="lab_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare_documentation_en-US" xlink:label="lab_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of days from the start of the period of care in which the final bill must be submitted to Medicare.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare" xlink:href="amed-20200331.xsd#amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare" xlink:to="lab_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_8828da3b-d316-42fa-8a13-f435f9aa8282_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_bf9285ec-15cf-4a69-9c01-06e86d16b603_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DebtInstrumentByLeverageRatioTrancheOneMember_33072bb5-36e7-4fb8-a22d-84f9bc068ffe_terseLabel_en-US" xlink:label="lab_amed_DebtInstrumentByLeverageRatioTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Leverage Ratio: Greater Than Equal To 3.00 to 1.0</link:label>
    <link:label id="lab_amed_DebtInstrumentByLeverageRatioTrancheOneMember_label_en-US" xlink:label="lab_amed_DebtInstrumentByLeverageRatioTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, By Leverage Ratio, Tranche One [Member]</link:label>
    <link:label id="lab_amed_DebtInstrumentByLeverageRatioTrancheOneMember_documentation_en-US" xlink:label="lab_amed_DebtInstrumentByLeverageRatioTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, By Leverage Ratio, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentByLeverageRatioTrancheOneMember" xlink:href="amed-20200331.xsd#amed_DebtInstrumentByLeverageRatioTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DebtInstrumentByLeverageRatioTrancheOneMember" xlink:to="lab_amed_DebtInstrumentByLeverageRatioTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_61ce69d3-3d89-4b92-88c5-f6aa424aef79_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other expense, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AmendedCreditAgreementMember_a1315862-0a5a-4033-b5b2-08a45f358131_terseLabel_en-US" xlink:label="lab_amed_AmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Agreement [Member]</link:label>
    <link:label id="lab_amed_AmendedCreditAgreementMember_label_en-US" xlink:label="lab_amed_AmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Agreement [Member]</link:label>
    <link:label id="lab_amed_AmendedCreditAgreementMember_documentation_en-US" xlink:label="lab_amed_AmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedCreditAgreementMember" xlink:href="amed-20200331.xsd#amed_AmendedCreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AmendedCreditAgreementMember" xlink:to="lab_amed_AmendedCreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome_07300c4d-01c6-4706-a645-72a9d3d9a73b_negatedLabel_en-US" xlink:label="lab_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-off of other comprehensive income</link:label>
    <link:label id="lab_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome_label_en-US" xlink:label="lab_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Impact of Write Off of Other Comprehensive Income</link:label>
    <link:label id="lab_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome_documentation_en-US" xlink:label="lab_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Impact of Write Off of Other Comprehensive Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome" xlink:href="amed-20200331.xsd#amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome" xlink:to="lab_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_54ef896f-7d3c-49bb-922a-6025c2f9e7be_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_13c2e821-ff6c-4dd8-a905-614baac4db02_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_0752baee-3a66-45b5-969d-edde35515a47_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding letters of credit</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_e6c3bb1b-26b5-4154-8234-8592664271c6_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of stock to employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_150cd9ef-f190-4a0a-83aa-2a86c22a773f_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_6f244fd7-fa4d-4b9d-a45c-12e55c474676_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense_f91d9979-c06f-4ae6-b88d-8e011714bda5_terseLabel_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense_label_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense_documentation_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, acquired at the acquisition date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense" xlink:href="amed-20200331.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense" xlink:to="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_RoseRockHealthcareMember_89f744bd-7c67-4791-8afb-6bb8a788d895_terseLabel_en-US" xlink:label="lab_amed_RoseRockHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RoseRock Healthcare [Member]</link:label>
    <link:label id="lab_amed_RoseRockHealthcareMember_label_en-US" xlink:label="lab_amed_RoseRockHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RoseRock Healthcare [Member]</link:label>
    <link:label id="lab_amed_RoseRockHealthcareMember_documentation_en-US" xlink:label="lab_amed_RoseRockHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RoseRock Healthcare [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RoseRockHealthcareMember" xlink:href="amed-20200331.xsd#amed_RoseRockHealthcareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_RoseRockHealthcareMember" xlink:to="lab_amed_RoseRockHealthcareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_35e4ff2c-cfae-4cef-a4a4-68715c080153_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Amedisys, Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_633025c7-bbbc-4ef2-aedf-b6cb158c0bf5_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of stock upon exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_18ef116f-ac95-41a0-9ab9-f79b41aee61c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_26b743b7-5890-410d-a391-791c37c834ee_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DebtInstrumentByLeverageRatioTrancheTwoMember_f8c0e515-b301-4fd1-a499-656e212aea1e_terseLabel_en-US" xlink:label="lab_amed_DebtInstrumentByLeverageRatioTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Leverage Ratio: Less Than 3.00 to 1.0 but Greater Than Equal To 2.00 to 1.0</link:label>
    <link:label id="lab_amed_DebtInstrumentByLeverageRatioTrancheTwoMember_label_en-US" xlink:label="lab_amed_DebtInstrumentByLeverageRatioTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, By Leverage Ratio, Tranche Two [Member]</link:label>
    <link:label id="lab_amed_DebtInstrumentByLeverageRatioTrancheTwoMember_documentation_en-US" xlink:label="lab_amed_DebtInstrumentByLeverageRatioTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, By Leverage Ratio, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentByLeverageRatioTrancheTwoMember" xlink:href="amed-20200331.xsd#amed_DebtInstrumentByLeverageRatioTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DebtInstrumentByLeverageRatioTrancheTwoMember" xlink:to="lab_amed_DebtInstrumentByLeverageRatioTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_5e665847-39ba-4e70-b861-41b236d218ec_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_8c12948c-c3bb-4060-b974-8ebf5ed4eab7_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of deferred debt issuance costs/debt discount</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009_b0452eb2-c85f-466e-87d7-3fb04d425eb5_terseLabel_en-US" xlink:label="lab_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnity receivable related to amounts withheld prior to August 2009</link:label>
    <link:label id="lab_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009_label_en-US" xlink:label="lab_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Receivable, Noncurrent, Related To Amounts Withheld Prior To August 2009</link:label>
    <link:label id="lab_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009_documentation_en-US" xlink:label="lab_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Receivable, Noncurrent, Related To Amounts Withheld Prior To August 2009</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009" xlink:href="amed-20200331.xsd#amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009" xlink:to="lab_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FinancialInstrumentDetailsTableTextBlock_9d0cb771-0666-4038-a8fe-2df8f22b95cd_terseLabel_en-US" xlink:label="lab_amed_FinancialInstrumentDetailsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Financial Instruments</link:label>
    <link:label id="lab_amed_FinancialInstrumentDetailsTableTextBlock_label_en-US" xlink:label="lab_amed_FinancialInstrumentDetailsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument Details [Table Text Block]</link:label>
    <link:label id="lab_amed_FinancialInstrumentDetailsTableTextBlock_documentation_en-US" xlink:label="lab_amed_FinancialInstrumentDetailsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial instrument details, table.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FinancialInstrumentDetailsTableTextBlock" xlink:href="amed-20200331.xsd#amed_FinancialInstrumentDetailsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FinancialInstrumentDetailsTableTextBlock" xlink:to="lab_amed_FinancialInstrumentDetailsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_0e76b347-da0d-49d4-a553-39312c90cd97_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_e4ca6a13-6715-4cb0-bbb5-d933eb1a8719_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_34b40cfa-39dc-4db5-be6e-355172e5365d_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_RevolvingCreditFacilityTotal_0ccfef01-fe9a-4e30-879f-b537c0f81e58_terseLabel_en-US" xlink:label="lab_amed_RevolvingCreditFacilityTotal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Total</link:label>
    <link:label id="lab_amed_RevolvingCreditFacilityTotal_label_en-US" xlink:label="lab_amed_RevolvingCreditFacilityTotal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Total</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RevolvingCreditFacilityTotal" xlink:href="amed-20200331.xsd#amed_RevolvingCreditFacilityTotal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_RevolvingCreditFacilityTotal" xlink:to="lab_amed_RevolvingCreditFacilityTotal" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_380ecc2a-7315-4c59-ac5b-4b2336ccc872_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_OneHundredMillionTermLoanMember_fd1116cd-3e79-46c7-8efe-632699cb2dc1_terseLabel_en-US" xlink:label="lab_amed_OneHundredMillionTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">100 Million Term Loan</link:label>
    <link:label id="lab_amed_OneHundredMillionTermLoanMember_label_en-US" xlink:label="lab_amed_OneHundredMillionTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Hundred Million Term Loan [Member]</link:label>
    <link:label id="lab_amed_OneHundredMillionTermLoanMember_documentation_en-US" xlink:label="lab_amed_OneHundredMillionTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">100 Million Term Loan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OneHundredMillionTermLoanMember" xlink:href="amed-20200331.xsd#amed_OneHundredMillionTermLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_OneHundredMillionTermLoanMember" xlink:to="lab_amed_OneHundredMillionTermLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CertificateOfNeedMember_d91c2233-7be4-4c68-9965-29f517068ce9_terseLabel_en-US" xlink:label="lab_amed_CertificateOfNeedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificate of Need [Member]</link:label>
    <link:label id="lab_amed_CertificateOfNeedMember_label_en-US" xlink:label="lab_amed_CertificateOfNeedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificate of Need [Member]</link:label>
    <link:label id="lab_amed_CertificateOfNeedMember_documentation_en-US" xlink:label="lab_amed_CertificateOfNeedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificate of Need</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificateOfNeedMember" xlink:href="amed-20200331.xsd#amed_CertificateOfNeedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CertificateOfNeedMember" xlink:to="lab_amed_CertificateOfNeedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_93005e53-dd64-4035-8b11-27f65076365d_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_7ff1f444-bfbf-44fd-9cdc-6c0b3c023d24_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in equity method investees</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_543f1773-334d-49ec-9ced-04bd197d4f4b_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MedalogixMember_4ca697b7-36a2-488b-a816-7176a368f5b6_terseLabel_en-US" xlink:label="lab_amed_MedalogixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medalogix [Member]</link:label>
    <link:label id="lab_amed_MedalogixMember_label_en-US" xlink:label="lab_amed_MedalogixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medalogix [Member]</link:label>
    <link:label id="lab_amed_MedalogixMember_documentation_en-US" xlink:label="lab_amed_MedalogixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medalogix [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedalogixMember" xlink:href="amed-20200331.xsd#amed_MedalogixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MedalogixMember" xlink:to="lab_amed_MedalogixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_InternalAuditComplianceReviewMember_d667a873-d8fc-4c82-8c1a-10481567577e_terseLabel_en-US" xlink:label="lab_amed_InternalAuditComplianceReviewMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Audit Compliance Review [Member]</link:label>
    <link:label id="lab_amed_InternalAuditComplianceReviewMember_label_en-US" xlink:label="lab_amed_InternalAuditComplianceReviewMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Audit Compliance Review [Member]</link:label>
    <link:label id="lab_amed_InternalAuditComplianceReviewMember_documentation_en-US" xlink:label="lab_amed_InternalAuditComplianceReviewMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Audit Compliance Review [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_InternalAuditComplianceReviewMember" xlink:href="amed-20200331.xsd#amed_InternalAuditComplianceReviewMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_InternalAuditComplianceReviewMember" xlink:to="lab_amed_InternalAuditComplianceReviewMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_b75d9efe-0dad-4d62-8182-be797cc5e501_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AccountsReceivablePortionDerivedFromMedicare_8f1c58c4-c64e-41fb-8faf-6c7a3fcab6b5_terseLabel_en-US" xlink:label="lab_amed_AccountsReceivablePortionDerivedFromMedicare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable derived from Medicare</link:label>
    <link:label id="lab_amed_AccountsReceivablePortionDerivedFromMedicare_label_en-US" xlink:label="lab_amed_AccountsReceivablePortionDerivedFromMedicare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Portion Derived From Medicare</link:label>
    <link:label id="lab_amed_AccountsReceivablePortionDerivedFromMedicare_documentation_en-US" xlink:label="lab_amed_AccountsReceivablePortionDerivedFromMedicare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Portion Derived From Medicare</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AccountsReceivablePortionDerivedFromMedicare" xlink:href="amed-20200331.xsd#amed_AccountsReceivablePortionDerivedFromMedicare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AccountsReceivablePortionDerivedFromMedicare" xlink:to="lab_amed_AccountsReceivablePortionDerivedFromMedicare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_1958f05e-8994-4051-bb1a-0b25a80154bb_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_4bf39316-0f5e-4251-a626-2e7466799aab_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_38aa597d-2a0c-4240-8147-8df06fd630d8_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_6a1d4614-0745-4f06-b4f5-e2c7fe13a4bf_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_34d7024b-b7a7-4334-ab70-47c4126a38a9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_e41e436a-8461-414a-b7e4-30ff7a5b1727_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of net services revenue</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NumberOfClaimsSubmittedBySubsidiary_daa60af3-13c4-45a3-8cf5-03565514aa7a_terseLabel_en-US" xlink:label="lab_amed_NumberOfClaimsSubmittedBySubsidiary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of claims submitted by subsidiary</link:label>
    <link:label id="lab_amed_NumberOfClaimsSubmittedBySubsidiary_label_en-US" xlink:label="lab_amed_NumberOfClaimsSubmittedBySubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Claims Submitted By Subsidiary</link:label>
    <link:label id="lab_amed_NumberOfClaimsSubmittedBySubsidiary_documentation_en-US" xlink:label="lab_amed_NumberOfClaimsSubmittedBySubsidiary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of claims submitted by subsidiary.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfClaimsSubmittedBySubsidiary" xlink:href="amed-20200331.xsd#amed_NumberOfClaimsSubmittedBySubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NumberOfClaimsSubmittedBySubsidiary" xlink:to="lab_amed_NumberOfClaimsSubmittedBySubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_e8197bfb-886c-4ad7-a1df-d289c416a885_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term obligations</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_730d054e-7953-498c-985c-7b3e56e9a7bc_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_0f77d769-da7a-4e35-ab7b-64fa08a487f5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, less current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherGeneralAndAdministrativeExpense_1e14c540-3e5f-4342-ae26-a2f29d3396fa_terseLabel_en-US" xlink:label="lab_us-gaap_OtherGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_OtherGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_OtherGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_KKRShareRepurchaseMember_0b881820-cc4a-48cb-b1f3-5da0ae93f089_terseLabel_en-US" xlink:label="lab_amed_KKRShareRepurchaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KKR Share Repurchase</link:label>
    <link:label id="lab_amed_KKRShareRepurchaseMember_label_en-US" xlink:label="lab_amed_KKRShareRepurchaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KKR Share Repurchase [Member]</link:label>
    <link:label id="lab_amed_KKRShareRepurchaseMember_documentation_en-US" xlink:label="lab_amed_KKRShareRepurchaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KKR Share Repurchase [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_KKRShareRepurchaseMember" xlink:href="amed-20200331.xsd#amed_KKRShareRepurchaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_KKRShareRepurchaseMember" xlink:to="lab_amed_KKRShareRepurchaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_LakelandFloridaMember_e3d15eb0-6921-47b9-a076-fa79e06f9439_terseLabel_en-US" xlink:label="lab_amed_LakelandFloridaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lakeland, Florida</link:label>
    <link:label id="lab_amed_LakelandFloridaMember_label_en-US" xlink:label="lab_amed_LakelandFloridaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lakeland, Florida [Member]</link:label>
    <link:label id="lab_amed_LakelandFloridaMember_documentation_en-US" xlink:label="lab_amed_LakelandFloridaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lakeland, Florida [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LakelandFloridaMember" xlink:href="amed-20200331.xsd#amed_LakelandFloridaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LakelandFloridaMember" xlink:to="lab_amed_LakelandFloridaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_e2301ebd-d9b9-4f44-8d40-5333f710cc47_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_a0fa9c7d-d974-4e07-be1a-f45fd5f1b6d9_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, authorized (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_db6701e2-334a-4867-96ef-953d168f1421_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_755f9ec8-9b3f-4dab-92b5-495c5887646a_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_5c56b15c-5ca3-4bcb-9661-eebe041df27d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_f02474fe-7804-4be6-9fd1-06d49ec9180c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUBSEQUENT EVENT</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_ae55378a-f9f1-4ede-a58a-ad8672ab1cdd_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset_82087195-5b37-4788-bb7a-718dcea5ac67_terseLabel_en-US" xlink:label="lab_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and impairment of operating lease right of use assets</link:label>
    <link:label id="lab_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and Impairment of Operating Lease Right Of Use Asset</link:label>
    <link:label id="lab_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and Impairment of Operating Lease Right Of Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset" xlink:href="amed-20200331.xsd#amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset" xlink:to="lab_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_e04f6dce-d89b-4ba5-b4f8-5d3dfdab8360_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted-Average Shares Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted Average Number of Shares [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_fdbd528f-e535-4188-ac33-9ec5ca21e442_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Miscellaneous, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_852b1566-597c-422a-9051-f486c205dc2e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HospiceMedicareMember_10f2a65d-ff67-46f7-a700-874eed2fd7e4_terseLabel_en-US" xlink:label="lab_amed_HospiceMedicareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice Medicare [Member]</link:label>
    <link:label id="lab_amed_HospiceMedicareMember_label_en-US" xlink:label="lab_amed_HospiceMedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice Medicare [Member]</link:label>
    <link:label id="lab_amed_HospiceMedicareMember_documentation_en-US" xlink:label="lab_amed_HospiceMedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice Medicare [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMedicareMember" xlink:href="amed-20200331.xsd#amed_HospiceMedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HospiceMedicareMember" xlink:to="lab_amed_HospiceMedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NonVestedStockAndStockUnits_d9ab429e-bbae-4d80-a1ae-0bc2eb5c0dcd_terseLabel_en-US" xlink:label="lab_amed_NonVestedStockAndStockUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested stock and stock units (shares)</link:label>
    <link:label id="lab_amed_NonVestedStockAndStockUnits_label_en-US" xlink:label="lab_amed_NonVestedStockAndStockUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Vested Stock And Stock Units</link:label>
    <link:label id="lab_amed_NonVestedStockAndStockUnits_documentation_en-US" xlink:label="lab_amed_NonVestedStockAndStockUnits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non vested stock and stock units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonVestedStockAndStockUnits" xlink:href="amed-20200331.xsd#amed_NonVestedStockAndStockUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NonVestedStockAndStockUnits" xlink:to="lab_amed_NonVestedStockAndStockUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_217b6702-98fa-4a5a-9a65-b54a2d5369a0_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PercentageofSharesOutstanding_7c72453c-92ea-4ba0-bd71-d0b2df0d251c_terseLabel_en-US" xlink:label="lab_amed_PercentageofSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of shares outstanding</link:label>
    <link:label id="lab_amed_PercentageofSharesOutstanding_label_en-US" xlink:label="lab_amed_PercentageofSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Shares Outstanding</link:label>
    <link:label id="lab_amed_PercentageofSharesOutstanding_documentation_en-US" xlink:label="lab_amed_PercentageofSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageofSharesOutstanding" xlink:href="amed-20200331.xsd#amed_PercentageofSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PercentageofSharesOutstanding" xlink:to="lab_amed_PercentageofSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_226318ef-1e22-4d9c-a88d-c53f3c42898d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_65122d9b-596b-46a9-8c2c-d77b000807eb_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_f1889c66-a7b3-4134-b239-fe8d8a26f31b_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term obligations</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AcquiredNamesOfBusinessMember_7f2ff050-ebc3-4cb8-81e5-21f87f7cbe34_terseLabel_en-US" xlink:label="lab_amed_AcquiredNamesOfBusinessMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Names of Business [Member]</link:label>
    <link:label id="lab_amed_AcquiredNamesOfBusinessMember_label_en-US" xlink:label="lab_amed_AcquiredNamesOfBusinessMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Names of Business [Member]</link:label>
    <link:label id="lab_amed_AcquiredNamesOfBusinessMember_documentation_en-US" xlink:label="lab_amed_AcquiredNamesOfBusinessMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Names of Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AcquiredNamesOfBusinessMember" xlink:href="amed-20200331.xsd#amed_AcquiredNamesOfBusinessMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AcquiredNamesOfBusinessMember" xlink:to="lab_amed_AcquiredNamesOfBusinessMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_2d6dc95d-37b0-4396-8f62-43721f592d4c_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_38a2020a-8666-4e7f-83d5-8d4c3747d17a_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_IncreaseDecreaseInOperatingLeaseLiability_053f7089-6a83-4312-ba71-2f852c291ba8_terseLabel_en-US" xlink:label="lab_amed_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_amed_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_amed_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Liability</link:label>
    <link:label id="lab_amed_IncreaseDecreaseInOperatingLeaseLiability_documentation_en-US" xlink:label="lab_amed_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of increase (decrease) in operating lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="amed-20200331.xsd#amed_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_amed_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_c4f956e9-0b26-4fba-bed6-b0a81359111d_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_f4f29380-a3ec-45a7-bad4-1dafd3f5c3cf_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_d9998384-3952-40f8-b47f-dcea3f255676_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_5d7c2400-7e8d-4440-b950-a45bc6850bf3_terseLabel_en-US" xlink:label="lab_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated amounts due back to Medicare</link:label>
    <link:label id="lab_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_label_en-US" xlink:label="lab_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Amount Due Back To Medicare In Other Accrued Liabilities</link:label>
    <link:label id="lab_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_documentation_en-US" xlink:label="lab_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of obligations due Medicare upon demand due to overages for the inpatient cap and/or overall payment cap.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" xlink:href="amed-20200331.xsd#amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" xlink:to="lab_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PersonalCareMember_c44a8376-ead8-47fe-bf2e-1e2c390f475b_terseLabel_en-US" xlink:label="lab_amed_PersonalCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Personal Care</link:label>
    <link:label id="lab_amed_PersonalCareMember_label_en-US" xlink:label="lab_amed_PersonalCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Personal Care [Member]</link:label>
    <link:label id="lab_amed_PersonalCareMember_documentation_en-US" xlink:label="lab_amed_PersonalCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Personal Care [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember" xlink:href="amed-20200331.xsd#amed_PersonalCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PersonalCareMember" xlink:to="lab_amed_PersonalCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_54b92a94-6a05-45bd-a82c-20168da8ba7a_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_33260eab-b3d6-44bd-af50-11f3cd755637_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_65ff125c-d3b2-401e-81bc-ea7b21945f95_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_53f399f9-289a-48fe-8dc1-188f2c305195_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare_adeb6150-e5b3-4ddf-bff3-f8904946a5b9_terseLabel_en-US" xlink:label="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate of request for anticipated payment submitted for the initial episode of care</link:label>
    <link:label id="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare_label_en-US" xlink:label="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate Of Request For Anticipated Payment Submitted For Initial Period Of Care</link:label>
    <link:label id="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare_documentation_en-US" xlink:label="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the percentage of estimated payment that is requested at the start of care for an initial period of care.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare" xlink:href="amed-20200331.xsd#amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare" xlink:to="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_b7f33efa-6145-48b6-8700-5b0e5e9227c4_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_a8b59120-42fd-4172-9bcf-51a7989fc4f0_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted earnings (loss) per share</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ParkersburgWestVirginiaMember_697e0ebd-cf25-4acb-8422-304a2b67b476_terseLabel_en-US" xlink:label="lab_amed_ParkersburgWestVirginiaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parkersburg, West Virginia</link:label>
    <link:label id="lab_amed_ParkersburgWestVirginiaMember_label_en-US" xlink:label="lab_amed_ParkersburgWestVirginiaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parkersburg, West Virginia [Member]</link:label>
    <link:label id="lab_amed_ParkersburgWestVirginiaMember_documentation_en-US" xlink:label="lab_amed_ParkersburgWestVirginiaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parkersburg, West Virginia [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ParkersburgWestVirginiaMember" xlink:href="amed-20200331.xsd#amed_ParkersburgWestVirginiaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ParkersburgWestVirginiaMember" xlink:to="lab_amed_ParkersburgWestVirginiaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FundingReceivedFromCARESAct_1785a1a2-c8c7-4f0a-9d49-4a1cd59d835e_terseLabel_en-US" xlink:label="lab_amed_FundingReceivedFromCARESAct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Received From CARES Act</link:label>
    <link:label id="lab_amed_FundingReceivedFromCARESAct_label_en-US" xlink:label="lab_amed_FundingReceivedFromCARESAct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Received From CARES Act</link:label>
    <link:label id="lab_amed_FundingReceivedFromCARESAct_documentation_en-US" xlink:label="lab_amed_FundingReceivedFromCARESAct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding received by the Company from the Coronavirus Aid Relief and Economic Security (CARES) Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingReceivedFromCARESAct" xlink:href="amed-20200331.xsd#amed_FundingReceivedFromCARESAct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FundingReceivedFromCARESAct" xlink:to="lab_amed_FundingReceivedFromCARESAct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1c12402d-456e-4e9a-8e43-ff3973aa5ca9_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Investing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_ed5aa634-9487-4411-a200-409d031b1efb_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_97952d2c-7170-4b96-b033-410a82b572e4_terseLabel_en-US" xlink:label="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery amount of overpayment made to subsidiary including interest</link:label>
    <link:label id="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_label_en-US" xlink:label="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery Amount of Overpayment Made To Subsidiary Including Interest</link:label>
    <link:label id="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_documentation_en-US" xlink:label="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery amount of overpayment made to subsidiary including interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" xlink:href="amed-20200331.xsd#amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" xlink:to="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits_5c014cdf-024a-4306-9e5a-87a16aab63b5_negatedLabel_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits_label_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits_documentation_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits" xlink:href="amed-20200331.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits" xlink:to="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_ecc79dd2-6049-4615-86ab-fdf7c3364d5a_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets_dc8419f8-67fe-41f6-b2ea-d0c0efd0c9d5_terseLabel_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating lease right of use assets</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets_label_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating lease right of use assets</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets_documentation_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating lease right of use assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets" xlink:href="amed-20200331.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets" xlink:to="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PayorClassDomain_fe04684b-015f-4862-ad64-5f31ecf264c8_terseLabel_en-US" xlink:label="lab_amed_PayorClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor Class [Domain]</link:label>
    <link:label id="lab_amed_PayorClassDomain_label_en-US" xlink:label="lab_amed_PayorClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor Class [Domain]</link:label>
    <link:label id="lab_amed_PayorClassDomain_documentation_en-US" xlink:label="lab_amed_PayorClassDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Payor Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorClassDomain" xlink:href="amed-20200331.xsd#amed_PayorClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PayorClassDomain" xlink:to="lab_amed_PayorClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CashPaidForOperatingLeaseLiabilities_e296731d-8f2b-4e36-9322-339000c96675_terseLabel_en-US" xlink:label="lab_amed_CashPaidForOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for operating lease liabilities</link:label>
    <link:label id="lab_amed_CashPaidForOperatingLeaseLiabilities_label_en-US" xlink:label="lab_amed_CashPaidForOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for operating lease liabilities</link:label>
    <link:label id="lab_amed_CashPaidForOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_amed_CashPaidForOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of cash paid for operating lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CashPaidForOperatingLeaseLiabilities" xlink:href="amed-20200331.xsd#amed_CashPaidForOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CashPaidForOperatingLeaseLiabilities" xlink:to="lab_amed_CashPaidForOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_0fc95ca7-777b-403c-b81f-486badad1195_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_dffa75f3-b432-4ed7-aa0a-08bf7230eca3_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_MA_521c2dc6-0306-4c8a-947c-da0c9ad6ed77_terseLabel_en-US" xlink:label="lab_stpr_MA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Massachusetts</link:label>
    <link:label id="lab_stpr_MA_label_en-US" xlink:label="lab_stpr_MA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MASSACHUSETTS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MA" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_MA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_MA" xlink:to="lab_stpr_MA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_ad712f9d-cf3c-4546-b753-69daa1070327_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of company stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_e7b04e4b-1510-432f-942d-ffd07afcb431_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of company stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_db36dcce-ac83-4e60-98df-10fd7c5b7ef1_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_207f9e42-9483-4ff3-876e-7566a4b532f5_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HospiceMember_bfa6e512-2d78-475d-9538-b966dacd8151_terseLabel_en-US" xlink:label="lab_amed_HospiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice [Member]</link:label>
    <link:label id="lab_amed_HospiceMember_label_en-US" xlink:label="lab_amed_HospiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice [Member]</link:label>
    <link:label id="lab_amed_HospiceMember_documentation_en-US" xlink:label="lab_amed_HospiceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember" xlink:href="amed-20200331.xsd#amed_HospiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HospiceMember" xlink:to="lab_amed_HospiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_a859b398-82ad-419d-9e6e-e66cfcfca78b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_2e8f912d-479d-4657-916f-5f34d325c8ec_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Amedisys, Inc. common stockholders, diluted (usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_95f68114-7c25-44b0-9046-0707f2d2277a_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_0eb8adff-6e4e-4345-958a-21e0ad70d5b5_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable business segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_c8939f6e-2b5f-4693-8f6f-029ae1bc478b_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_a4ede96b-3f0e-4ef1-8565-53fa8dd13a85_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_d8f32dae-0829-4abc-aa12-d5bef49651cf_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_f01585b7-a66a-4d8d-9f63-2b911677597b_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockTextBlock_cd767592-bb4e-4da4-a4df-c571e50c1c49_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SHARE REPURCHASE</link:label>
    <link:label id="lab_us-gaap_TreasuryStockTextBlock_label_en-US" xlink:label="lab_us-gaap_TreasuryStockTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockTextBlock" xlink:to="lab_us-gaap_TreasuryStockTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HealthcareanalyticscompanyMember_f138803a-ae57-41ca-b1ce-9bba5d138bd7_terseLabel_en-US" xlink:label="lab_amed_HealthcareanalyticscompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthcare analytics company [Member]</link:label>
    <link:label id="lab_amed_HealthcareanalyticscompanyMember_label_en-US" xlink:label="lab_amed_HealthcareanalyticscompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthcare analytics company [Member]</link:label>
    <link:label id="lab_amed_HealthcareanalyticscompanyMember_documentation_en-US" xlink:label="lab_amed_HealthcareanalyticscompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthcare analytics company [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HealthcareanalyticscompanyMember" xlink:href="amed-20200331.xsd#amed_HealthcareanalyticscompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HealthcareanalyticscompanyMember" xlink:to="lab_amed_HealthcareanalyticscompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ActualClaimsPayment_c59b6e4e-d756-4e5d-89cd-269ea11df9a9_terseLabel_en-US" xlink:label="lab_amed_ActualClaimsPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actual claims payment</link:label>
    <link:label id="lab_amed_ActualClaimsPayment_label_en-US" xlink:label="lab_amed_ActualClaimsPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actual Claims Payment</link:label>
    <link:label id="lab_amed_ActualClaimsPayment_documentation_en-US" xlink:label="lab_amed_ActualClaimsPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actual Claims Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ActualClaimsPayment" xlink:href="amed-20200331.xsd#amed_ActualClaimsPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ActualClaimsPayment" xlink:to="lab_amed_ActualClaimsPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_d10d2eb8-e80f-4f04-9a06-d5f9d0afaf51_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_d5087df4-7413-4381-8994-90d656216003_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3e7baf86-a120-4ad0-9974-63c92e4400a9_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_7def4201-149f-47d8-921a-6af093ac3e60_terseLabel_en-US" xlink:label="lab_amed_ProceedsReceivedFromLoanPartyOfSubsidiary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds Received From Loan Party Of Subsidiary</link:label>
    <link:label id="lab_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_label_en-US" xlink:label="lab_amed_ProceedsReceivedFromLoanPartyOfSubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds Received From Loan Party Of Subsidiary</link:label>
    <link:label id="lab_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_documentation_en-US" xlink:label="lab_amed_ProceedsReceivedFromLoanPartyOfSubsidiary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds Received From Loan Party Of Subsidiary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProceedsReceivedFromLoanPartyOfSubsidiary" xlink:href="amed-20200331.xsd#amed_ProceedsReceivedFromLoanPartyOfSubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ProceedsReceivedFromLoanPartyOfSubsidiary" xlink:to="lab_amed_ProceedsReceivedFromLoanPartyOfSubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions_e6caee6b-537b-4f05-8817-86dd7f1e3ab7_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Return on equity investment</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Equity Method Investment, Distribution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:to="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_164dec99-eb41-47d0-a3c4-e8982649ddcb_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_7f89c661-0ca3-4ec5-8e62-ea4947d6b8ac_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AdditionalFundingDistributedToHealthcareProviders_92e7fb47-b884-47a7-9ba5-32004cffe182_terseLabel_en-US" xlink:label="lab_amed_AdditionalFundingDistributedToHealthcareProviders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Funding Distributed to Healthcare Providers</link:label>
    <link:label id="lab_amed_AdditionalFundingDistributedToHealthcareProviders_label_en-US" xlink:label="lab_amed_AdditionalFundingDistributedToHealthcareProviders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Funding Distributed to Healthcare Providers</link:label>
    <link:label id="lab_amed_AdditionalFundingDistributedToHealthcareProviders_documentation_en-US" xlink:label="lab_amed_AdditionalFundingDistributedToHealthcareProviders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional funding distributed to healthcare providers provided by the Coronavirus Aid, Relief and Economic Security (CARES) Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AdditionalFundingDistributedToHealthcareProviders" xlink:href="amed-20200331.xsd#amed_AdditionalFundingDistributedToHealthcareProviders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AdditionalFundingDistributedToHealthcareProviders" xlink:to="lab_amed_AdditionalFundingDistributedToHealthcareProviders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_b6580b4a-2bc0-430b-9c79-1c34a734f46d_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NonMedicareRevenueTermRates_9d5e9a5f-71a6-4c38-9af5-4864f10c3a95_terseLabel_en-US" xlink:label="lab_amed_NonMedicareRevenueTermRates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Medicare revenue term rates</link:label>
    <link:label id="lab_amed_NonMedicareRevenueTermRates_label_en-US" xlink:label="lab_amed_NonMedicareRevenueTermRates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Medicare Revenue Term Rates</link:label>
    <link:label id="lab_amed_NonMedicareRevenueTermRates_documentation_en-US" xlink:label="lab_amed_NonMedicareRevenueTermRates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Medicare Revenue Term Rates as a percentage of Medicare Term Rates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonMedicareRevenueTermRates" xlink:href="amed-20200331.xsd#amed_NonMedicareRevenueTermRates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NonMedicareRevenueTermRates" xlink:to="lab_amed_NonMedicareRevenueTermRates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_292ed487-84e8-4807-a53a-3db592464918_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term obligations</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PayorsAxis_f8f25070-a9b1-4657-8a54-a9438295e0b3_terseLabel_en-US" xlink:label="lab_amed_PayorsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payors [Axis]</link:label>
    <link:label id="lab_amed_PayorsAxis_label_en-US" xlink:label="lab_amed_PayorsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payors [Axis]</link:label>
    <link:label id="lab_amed_PayorsAxis_documentation_en-US" xlink:label="lab_amed_PayorsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payors [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorsAxis" xlink:href="amed-20200331.xsd#amed_PayorsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PayorsAxis" xlink:to="lab_amed_PayorsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_Creditfacilitymaximumallowableconsolidatedleverageratio_281085d1-05bd-4844-a949-8337e266084b_terseLabel_en-US" xlink:label="lab_amed_Creditfacilitymaximumallowableconsolidatedleverageratio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit facility, maximum allowable consolidated leverage ratio</link:label>
    <link:label id="lab_amed_Creditfacilitymaximumallowableconsolidatedleverageratio_label_en-US" xlink:label="lab_amed_Creditfacilitymaximumallowableconsolidatedleverageratio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit facility maximum allowable consolidated leverage ratio</link:label>
    <link:label id="lab_amed_Creditfacilitymaximumallowableconsolidatedleverageratio_documentation_en-US" xlink:label="lab_amed_Creditfacilitymaximumallowableconsolidatedleverageratio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit facility maximum allowable consolidated leverage ratio as defined in the Company's Credit Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Creditfacilitymaximumallowableconsolidatedleverageratio" xlink:href="amed-20200331.xsd#amed_Creditfacilitymaximumallowableconsolidatedleverageratio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_Creditfacilitymaximumallowableconsolidatedleverageratio" xlink:to="lab_amed_Creditfacilitymaximumallowableconsolidatedleverageratio" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PromissoryNotesMember_44dae8cc-97ce-4b8d-b2eb-31850fcc7fb4_terseLabel_en-US" xlink:label="lab_amed_PromissoryNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Promissory Notes [Member]</link:label>
    <link:label id="lab_amed_PromissoryNotesMember_label_en-US" xlink:label="lab_amed_PromissoryNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Promissory Notes [Member]</link:label>
    <link:label id="lab_amed_PromissoryNotesMember_documentation_en-US" xlink:label="lab_amed_PromissoryNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Promissory Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PromissoryNotesMember" xlink:href="amed-20200331.xsd#amed_PromissoryNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PromissoryNotesMember" xlink:to="lab_amed_PromissoryNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_12c15f23-dbf3-4e66-989f-03d4cbf0d2bf_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllOtherSegmentsMember_230692ba-e645-41af-a32f-9db0cb9b969d_terseLabel_en-US" xlink:label="lab_us-gaap_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_AllOtherSegmentsMember_label_en-US" xlink:label="lab_us-gaap_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllOtherSegmentsMember" xlink:to="lab_us-gaap_AllOtherSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_34d3d011-d3d4-4e1a-9a87-0dcbd004ab05_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HealthInsuranceRetentionLimit_1fccabaf-c74f-4697-8d02-a9020f125a97_terseLabel_en-US" xlink:label="lab_amed_HealthInsuranceRetentionLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health insurance retention limit</link:label>
    <link:label id="lab_amed_HealthInsuranceRetentionLimit_label_en-US" xlink:label="lab_amed_HealthInsuranceRetentionLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Insurance Retention Limit</link:label>
    <link:label id="lab_amed_HealthInsuranceRetentionLimit_documentation_en-US" xlink:label="lab_amed_HealthInsuranceRetentionLimit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum potential amount of future payments the entity could be required to make related to a specific Health Insurance Claim.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HealthInsuranceRetentionLimit" xlink:href="amed-20200331.xsd#amed_HealthInsuranceRetentionLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HealthInsuranceRetentionLimit" xlink:to="lab_amed_HealthInsuranceRetentionLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeNamesMember_1d62e3dd-f2f1-48a4-838d-cd78a070fa70_terseLabel_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:label id="lab_us-gaap_TradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeNamesMember" xlink:to="lab_us-gaap_TradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_fd37777d-67d6-45b2-8370-527e960bca43_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_916ccc3a-d46e-45b2-a188-afeb3813bc10_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_e039e486-cbfb-4e63-b384-7b7b236722fb_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net of accumulated amortization of $9,341 and $7,044</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_e2abd9a5-a3b2-47b2-8add-f111bdb5dcdc_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of each class</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_141269ac-4700-4eb2-8206-2635cb57e018_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_62225398-3610-474a-872f-dbbb2a0084ee_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock - employee stock purchase plan (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ProfessionalLiabilityInsuranceRetentionLimit_47c63210-447a-4241-9391-131458e9af88_terseLabel_en-US" xlink:label="lab_amed_ProfessionalLiabilityInsuranceRetentionLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional liability insurance retention limit</link:label>
    <link:label id="lab_amed_ProfessionalLiabilityInsuranceRetentionLimit_label_en-US" xlink:label="lab_amed_ProfessionalLiabilityInsuranceRetentionLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional Liability Insurance Retention Limit</link:label>
    <link:label id="lab_amed_ProfessionalLiabilityInsuranceRetentionLimit_documentation_en-US" xlink:label="lab_amed_ProfessionalLiabilityInsuranceRetentionLimit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum potential amount of future payments the entity could be required to make related to a specific Professional Liability Claim.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProfessionalLiabilityInsuranceRetentionLimit" xlink:href="amed-20200331.xsd#amed_ProfessionalLiabilityInsuranceRetentionLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ProfessionalLiabilityInsuranceRetentionLimit" xlink:to="lab_amed_ProfessionalLiabilityInsuranceRetentionLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ChristianCareatHomeMember_c45279ac-2733-4974-a9d5-86a5d2e10d47_terseLabel_en-US" xlink:label="lab_amed_ChristianCareatHomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Christian Care at Home</link:label>
    <link:label id="lab_amed_ChristianCareatHomeMember_label_en-US" xlink:label="lab_amed_ChristianCareatHomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Christian Care at Home [Member]</link:label>
    <link:label id="lab_amed_ChristianCareatHomeMember_documentation_en-US" xlink:label="lab_amed_ChristianCareatHomeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Christian Care at Home [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ChristianCareatHomeMember" xlink:href="amed-20200331.xsd#amed_ChristianCareatHomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ChristianCareatHomeMember" xlink:to="lab_amed_ChristianCareatHomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_e8ac3d40-6822-4560-9ed1-dfc5db2a3909_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_2bb98ce2-8741-4e1a-af5a-f666225d93e8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_9d3719fa-e811-4a49-9a10-792556433b6b_negatedLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest distribution</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ExtrapolatedMember_3bcc4361-a1a9-44b9-ba21-73af73cafc0b_terseLabel_en-US" xlink:label="lab_amed_ExtrapolatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extrapolated</link:label>
    <link:label id="lab_amed_ExtrapolatedMember_label_en-US" xlink:label="lab_amed_ExtrapolatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extrapolated [Member]</link:label>
    <link:label id="lab_amed_ExtrapolatedMember_documentation_en-US" xlink:label="lab_amed_ExtrapolatedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extrapolated [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ExtrapolatedMember" xlink:href="amed-20200331.xsd#amed_ExtrapolatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ExtrapolatedMember" xlink:to="lab_amed_ExtrapolatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ThirdThresholdOfTherapyServicesRequired_38c7f102-bda6-4c12-98a6-321b131f29bd_terseLabel_en-US" xlink:label="lab_amed_ThirdThresholdOfTherapyServicesRequired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third threshold of therapy services required (visits)</link:label>
    <link:label id="lab_amed_ThirdThresholdOfTherapyServicesRequired_label_en-US" xlink:label="lab_amed_ThirdThresholdOfTherapyServicesRequired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third Threshold Of Therapy Services Required</link:label>
    <link:label id="lab_amed_ThirdThresholdOfTherapyServicesRequired_documentation_en-US" xlink:label="lab_amed_ThirdThresholdOfTherapyServicesRequired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of visits related to the third threshold of therapy services required.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ThirdThresholdOfTherapyServicesRequired" xlink:href="amed-20200331.xsd#amed_ThirdThresholdOfTherapyServicesRequired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ThirdThresholdOfTherapyServicesRequired" xlink:to="lab_amed_ThirdThresholdOfTherapyServicesRequired" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_IndemnificationAmount_9f8aab75-0829-4fcc-a33f-00ef0d18f0f4_terseLabel_en-US" xlink:label="lab_amed_IndemnificationAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification amount</link:label>
    <link:label id="lab_amed_IndemnificationAmount_label_en-US" xlink:label="lab_amed_IndemnificationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification Amount</link:label>
    <link:label id="lab_amed_IndemnificationAmount_documentation_en-US" xlink:label="lab_amed_IndemnificationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount to be reimbursed if and when certain assumed liabilities are paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IndemnificationAmount" xlink:href="amed-20200331.xsd#amed_IndemnificationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_IndemnificationAmount" xlink:to="lab_amed_IndemnificationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_5a69eb90-c7c0-4ed6-bd07-c8f422f2c532_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HomeHealthMedicareMember_e9ca2bef-57d3-43c1-8040-ff536527c28d_terseLabel_en-US" xlink:label="lab_amed_HomeHealthMedicareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health Medicare [Member]</link:label>
    <link:label id="lab_amed_HomeHealthMedicareMember_label_en-US" xlink:label="lab_amed_HomeHealthMedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health Medicare [Member]</link:label>
    <link:label id="lab_amed_HomeHealthMedicareMember_documentation_en-US" xlink:label="lab_amed_HomeHealthMedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health Medicare [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMedicareMember" xlink:href="amed-20200331.xsd#amed_HomeHealthMedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HomeHealthMedicareMember" xlink:to="lab_amed_HomeHealthMedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DebtIssuanceCostsPolicyPolicyTextBlock_d8e1ac5b-f3be-430a-b0bd-4fa6f5416570_terseLabel_en-US" xlink:label="lab_amed_DebtIssuanceCostsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs</link:label>
    <link:label id="lab_amed_DebtIssuanceCostsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_amed_DebtIssuanceCostsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs Policy [Policy Text Block]</link:label>
    <link:label id="lab_amed_DebtIssuanceCostsPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_amed_DebtIssuanceCostsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of accounting policy for debt issuance costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtIssuanceCostsPolicyPolicyTextBlock" xlink:href="amed-20200331.xsd#amed_DebtIssuanceCostsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DebtIssuanceCostsPolicyPolicyTextBlock" xlink:to="lab_amed_DebtIssuanceCostsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2963d387-dadc-4c87-8cd5-60eac84417f5_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_0507d220-f820-4708-b8a6-1ac98fb766d8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_67e4f6b4-4084-481e-87b2-b9f477c43d1a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_55ddd7e3-2a17-4fc4-8e5c-846ad838689c_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_8d2258d3-d800-4b22-b6a5-513beb737d49_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_b3e0c0ae-6e67-473a-af1b-db51895f0ff6_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_8189c8c3-f91e-4d04-9f3b-1d112cbe91d0_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ShareRepurchaseDomain_5d2896ff-b713-497e-81e8-05a06eb4001a_terseLabel_en-US" xlink:label="lab_amed_ShareRepurchaseDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase [Domain]</link:label>
    <link:label id="lab_amed_ShareRepurchaseDomain_label_en-US" xlink:label="lab_amed_ShareRepurchaseDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase [Domain]</link:label>
    <link:label id="lab_amed_ShareRepurchaseDomain_documentation_en-US" xlink:label="lab_amed_ShareRepurchaseDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Share Repurchase [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseDomain" xlink:href="amed-20200331.xsd#amed_ShareRepurchaseDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ShareRepurchaseDomain" xlink:to="lab_amed_ShareRepurchaseDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_fa1c3284-e274-4199-bb6f-167bd1690c14_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency accrual</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_85a4b4d0-880c-411c-a562-05046568c1ff_terseLabel_en-US" xlink:label="lab_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional interest rate above Federal Fund rate</link:label>
    <link:label id="lab_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_label_en-US" xlink:label="lab_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Additional Interest Above Federal Fund Rate</link:label>
    <link:label id="lab_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_documentation_en-US" xlink:label="lab_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Additional Interest Above Federal Fund Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" xlink:href="amed-20200331.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" xlink:to="lab_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_c06128de-b6d1-4777-a5b9-aeaa917b227a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic earnings (loss) per share</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PayorClassAxis_02693b09-74a8-4bb0-8693-15b7a1039fe6_terseLabel_en-US" xlink:label="lab_amed_PayorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor Class [Axis]</link:label>
    <link:label id="lab_amed_PayorClassAxis_label_en-US" xlink:label="lab_amed_PayorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor Class [Axis]</link:label>
    <link:label id="lab_amed_PayorClassAxis_documentation_en-US" xlink:label="lab_amed_PayorClassAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorClassAxis" xlink:href="amed-20200331.xsd#amed_PayorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PayorClassAxis" xlink:to="lab_amed_PayorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MaximumPercentOwnershipForEquityMethodPercent_9ce9bace-9dcb-4e5d-aaa7-5051d8e06839_terseLabel_en-US" xlink:label="lab_amed_MaximumPercentOwnershipForEquityMethodPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum ownership percentage for equity method investment (percent)</link:label>
    <link:label id="lab_amed_MaximumPercentOwnershipForEquityMethodPercent_label_en-US" xlink:label="lab_amed_MaximumPercentOwnershipForEquityMethodPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Percent Ownership For Equity Method Percent</link:label>
    <link:label id="lab_amed_MaximumPercentOwnershipForEquityMethodPercent_documentation_en-US" xlink:label="lab_amed_MaximumPercentOwnershipForEquityMethodPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the percentage ownership required in order for an investment to be treated under the equity method of accounting in the entity's financial statements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumPercentOwnershipForEquityMethodPercent" xlink:href="amed-20200331.xsd#amed_MaximumPercentOwnershipForEquityMethodPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MaximumPercentOwnershipForEquityMethodPercent" xlink:to="lab_amed_MaximumPercentOwnershipForEquityMethodPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ccf03ca6-b1c3-4b48-aab2-3e7e1fe6e5c6_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Operating Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HospiceNonMedicareMember_46d2ce06-3240-4e4e-a658-27cef00198ea_terseLabel_en-US" xlink:label="lab_amed_HospiceNonMedicareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice Non-Medicare [Member]</link:label>
    <link:label id="lab_amed_HospiceNonMedicareMember_label_en-US" xlink:label="lab_amed_HospiceNonMedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice Non-Medicare [Member]</link:label>
    <link:label id="lab_amed_HospiceNonMedicareMember_documentation_en-US" xlink:label="lab_amed_HospiceNonMedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice Non-Medicare [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceNonMedicareMember" xlink:href="amed-20200331.xsd#amed_HospiceNonMedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HospiceNonMedicareMember" xlink:to="lab_amed_HospiceNonMedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MedicareLicenseMember_f417d356-8617-4326-8526-1c7c57bfaf54_terseLabel_en-US" xlink:label="lab_amed_MedicareLicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare license [Member]</link:label>
    <link:label id="lab_amed_MedicareLicenseMember_label_en-US" xlink:label="lab_amed_MedicareLicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare license [Member]</link:label>
    <link:label id="lab_amed_MedicareLicenseMember_documentation_en-US" xlink:label="lab_amed_MedicareLicenseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare license</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareLicenseMember" xlink:href="amed-20200331.xsd#amed_MedicareLicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MedicareLicenseMember" xlink:to="lab_amed_MedicareLicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_48ca129e-0c42-45c0-ab5b-e355446b0b27_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AsanaHospiceMember_6dddd866-8ecb-4c65-b8da-143049f18223_terseLabel_en-US" xlink:label="lab_amed_AsanaHospiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asana Hospice [Member]</link:label>
    <link:label id="lab_amed_AsanaHospiceMember_label_en-US" xlink:label="lab_amed_AsanaHospiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asana Hospice [Member]</link:label>
    <link:label id="lab_amed_AsanaHospiceMember_documentation_en-US" xlink:label="lab_amed_AsanaHospiceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asana Hospice</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AsanaHospiceMember" xlink:href="amed-20200331.xsd#amed_AsanaHospiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AsanaHospiceMember" xlink:to="lab_amed_AsanaHospiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_a4aa87e3-d636-4dee-9743-50210889704a_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_3fd32ed8-f264-4666-8190-a5eddbdc3b42_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Income of Reportable Segments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PercentageOfTotalReimbursementOfOutlierPayment_07f42e9f-a951-4b52-b9b2-3a9a27d55538_terseLabel_en-US" xlink:label="lab_amed_PercentageOfTotalReimbursementOfOutlierPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of total reimbursement of outlier payment</link:label>
    <link:label id="lab_amed_PercentageOfTotalReimbursementOfOutlierPayment_label_en-US" xlink:label="lab_amed_PercentageOfTotalReimbursementOfOutlierPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Total Reimbursement Of Outlier Payment</link:label>
    <link:label id="lab_amed_PercentageOfTotalReimbursementOfOutlierPayment_documentation_en-US" xlink:label="lab_amed_PercentageOfTotalReimbursementOfOutlierPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage at which total reimbursement is capped if cost of care is unusually costly.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfTotalReimbursementOfOutlierPayment" xlink:href="amed-20200331.xsd#amed_PercentageOfTotalReimbursementOfOutlierPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PercentageOfTotalReimbursementOfOutlierPayment" xlink:to="lab_amed_PercentageOfTotalReimbursementOfOutlierPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_74fd80c3-b80f-4860-9529-cc6b8a602fa6_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset_b93c5538-435f-41bc-b8be-a22addd744c6_terseLabel_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Current Asset</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset_label_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Current Asset</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset_documentation_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of asset related to consideration amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset" xlink:href="amed-20200331.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset" xlink:to="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_9c4ea508-904a-4407-94fe-0d410ad861c8_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_42ec6a1e-e08c-4a48-ac95-3119d6ea7085_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FundingForHealthcareProvidersIncludingHospitals_1ca949fb-5cd4-486d-bfa0-265ec1a6e763_terseLabel_en-US" xlink:label="lab_amed_FundingForHealthcareProvidersIncludingHospitals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding for Healthcare Providers, Including Hospitals</link:label>
    <link:label id="lab_amed_FundingForHealthcareProvidersIncludingHospitals_label_en-US" xlink:label="lab_amed_FundingForHealthcareProvidersIncludingHospitals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding for Healthcare Providers, Including Hospitals</link:label>
    <link:label id="lab_amed_FundingForHealthcareProvidersIncludingHospitals_documentation_en-US" xlink:label="lab_amed_FundingForHealthcareProvidersIncludingHospitals" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding for healthcare providers, including hospitals provided by the Coronavirus Aid, Relief and Economic Security (CARES) Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingForHealthcareProvidersIncludingHospitals" xlink:href="amed-20200331.xsd#amed_FundingForHealthcareProvidersIncludingHospitals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FundingForHealthcareProvidersIncludingHospitals" xlink:to="lab_amed_FundingForHealthcareProvidersIncludingHospitals" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_04004b8b-7912-4c1b-8c2c-b622141ab9a7_terseLabel_en-US" xlink:label="lab_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of consolidated revenue and adjusted EBITDA that guarantor wholly-owned subsidiaries represent</link:label>
    <link:label id="lab_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_label_en-US" xlink:label="lab_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Revenue And Of Earnings Before Interest Taxes Depreciation And Amortization From Wholly Owned Subsidiaries</link:label>
    <link:label id="lab_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_documentation_en-US" xlink:label="lab_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of consolidated net revenues and adjusted EBITDA that guarantor wholly-owned subsidiaries represent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" xlink:href="amed-20200331.xsd#amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" xlink:to="lab_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_901e898e-4e2b-4236-a865-0cf00992d936_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_7376e0d1-60e1-47a6-b39d-bf460a06bd94_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average interest rate (percent)</link:label>
    <link:label id="lab_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_label_en-US" xlink:label="lab_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Weighted Average Interest Rate, over Time</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtWeightedAverageInterestRateOverTime"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:to="lab_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_515776cf-422b-4a6d-af70-28a002d3fe3f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_0850fb8a-24f2-48fd-b1f4-8619b758296d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CashPaidForFinanceLeaseLiabilities_7cd019ca-4eb8-4bd9-9374-62fd2b0ab46f_terseLabel_en-US" xlink:label="lab_amed_CashPaidForFinanceLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for finance lease liabilities</link:label>
    <link:label id="lab_amed_CashPaidForFinanceLeaseLiabilities_label_en-US" xlink:label="lab_amed_CashPaidForFinanceLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for finance lease liabilities</link:label>
    <link:label id="lab_amed_CashPaidForFinanceLeaseLiabilities_documentation_en-US" xlink:label="lab_amed_CashPaidForFinanceLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of cash paid for finance lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CashPaidForFinanceLeaseLiabilities" xlink:href="amed-20200331.xsd#amed_CashPaidForFinanceLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CashPaidForFinanceLeaseLiabilities" xlink:to="lab_amed_CashPaidForFinanceLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_7ef08532-29f1-49c7-aa8c-ae9aea684c90_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_2d0c6e2f-2412-4e26-98ca-2486d5e9e416_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Disclosures of Cash Flow Information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_1efe19ee-d684-4281-9529-25ef5bc8c3a4_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss (gain) on disposal of property and equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ErrorRatePercentage_e9011bcb-e134-48bc-bba2-5d81c5973742_terseLabel_en-US" xlink:label="lab_amed_ErrorRatePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Error rate (percent)</link:label>
    <link:label id="lab_amed_ErrorRatePercentage_label_en-US" xlink:label="lab_amed_ErrorRatePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Error Rate Percentage</link:label>
    <link:label id="lab_amed_ErrorRatePercentage_documentation_en-US" xlink:label="lab_amed_ErrorRatePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Error Rate Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ErrorRatePercentage" xlink:href="amed-20200331.xsd#amed_ErrorRatePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ErrorRatePercentage" xlink:to="lab_amed_ErrorRatePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_e387daf6-900e-4af8-b8aa-76c7ddc29172_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid_dbc13170-27c1-41c9-824a-186de88eef85_terseLabel_en-US" xlink:label="lab_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum days to submit final bill from the date the request for anticipated payment was paid</link:label>
    <link:label id="lab_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid_label_en-US" xlink:label="lab_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Days To Submit Final Bill From Date Request For Anticipated Payment Was Paid</link:label>
    <link:label id="lab_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid_documentation_en-US" xlink:label="lab_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" xlink:href="amed-20200331.xsd#amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" xlink:to="lab_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_ca9d67e7-ca7c-4e2e-81fd-4be786b328bf_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_SecuritiesClassActionLawsuitMember_69aa1615-6e07-4834-85b6-8a9b271237f0_terseLabel_en-US" xlink:label="lab_amed_SecuritiesClassActionLawsuitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Class Action Lawsuit [Member]</link:label>
    <link:label id="lab_amed_SecuritiesClassActionLawsuitMember_label_en-US" xlink:label="lab_amed_SecuritiesClassActionLawsuitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Class Action Lawsuit [Member]</link:label>
    <link:label id="lab_amed_SecuritiesClassActionLawsuitMember_documentation_en-US" xlink:label="lab_amed_SecuritiesClassActionLawsuitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Class Action Lawsuit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecuritiesClassActionLawsuitMember" xlink:href="amed-20200331.xsd#amed_SecuritiesClassActionLawsuitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_SecuritiesClassActionLawsuitMember" xlink:to="lab_amed_SecuritiesClassActionLawsuitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_3189d07a-3c67-4fb4-b693-24e27b8e0e0c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Information</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_bc8069c6-61e6-4923-9844-0517601b0ec6_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_0f305930-7b7d-43b9-85a8-c24d3e0f4c09_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_85714e26-2527-430a-8155-6c1f31fd0db5_terseLabel_en-US" xlink:label="lab_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery amount of over payment made to subsidiary including interest withheld</link:label>
    <link:label id="lab_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_label_en-US" xlink:label="lab_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery Amount Of Over Payment Made To Subsidiary Including Interest Withheld</link:label>
    <link:label id="lab_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_documentation_en-US" xlink:label="lab_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery amount of over payment made to subsidiary including interest withheld</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" xlink:href="amed-20200331.xsd#amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" xlink:to="lab_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_675d8f74-d815-489b-9375-9fdc61642dd2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for income taxes, net of refunds received</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_65e6d00d-8fcc-4d6c-95c0-aaaf58835202_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic earnings per common share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PriorCreditAgreementMember_2e5ea4f9-bfb7-4293-9adb-b44a8b5b2670_terseLabel_en-US" xlink:label="lab_amed_PriorCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Credit Agreement [Member]</link:label>
    <link:label id="lab_amed_PriorCreditAgreementMember_label_en-US" xlink:label="lab_amed_PriorCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Credit Agreement [Member]</link:label>
    <link:label id="lab_amed_PriorCreditAgreementMember_documentation_en-US" xlink:label="lab_amed_PriorCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Credit Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PriorCreditAgreementMember" xlink:href="amed-20200331.xsd#amed_PriorCreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PriorCreditAgreementMember" xlink:to="lab_amed_PriorCreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_d9515929-3895-4281-b9ab-92937ebb000e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LONG-TERM OBLIGATIONS</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_095f0f60-2fb9-45fc-aaf2-57a9754bd7d7_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_986c486c-845e-4dc9-97df-57f671073e60_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_5bdf0e09-da4a-4575-9e83-491f416ccc26_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, authorized (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_290700e1-fc14-4328-914e-0f90eeeb4c05_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_86004959-5dbb-4b8f-8f1c-088630b6954b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_2f7d5a65-7384-4587-9916-ad6b97f99a6b_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_51f06e4e-e064-4867-9523-1cb50ba58038_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_617cf7c9-1862-4431-8096-61d5f91bdbdc_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_34381365-5866-4729-8971-ae5f8f1a1dd6_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_SafeguardZoneProgramIntegrityContractorMember_a0c2ce81-43fc-41bc-a650-96f5c17c37fa_terseLabel_en-US" xlink:label="lab_amed_SafeguardZoneProgramIntegrityContractorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Safeguard Zone Program Integrity Contractor</link:label>
    <link:label id="lab_amed_SafeguardZoneProgramIntegrityContractorMember_label_en-US" xlink:label="lab_amed_SafeguardZoneProgramIntegrityContractorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Safeguard Zone Program Integrity Contractor [Member]</link:label>
    <link:label id="lab_amed_SafeguardZoneProgramIntegrityContractorMember_documentation_en-US" xlink:label="lab_amed_SafeguardZoneProgramIntegrityContractorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Safeguard Zone Program Integrity Contractor [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SafeguardZoneProgramIntegrityContractorMember" xlink:href="amed-20200331.xsd#amed_SafeguardZoneProgramIntegrityContractorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_SafeguardZoneProgramIntegrityContractorMember" xlink:to="lab_amed_SafeguardZoneProgramIntegrityContractorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts_44b33801-3a2b-4b9d-82d2-296bb18b2654_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Integration Related Costs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Integration Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_FL_d78e4a09-c86e-467e-8221-834dd74f60b7_terseLabel_en-US" xlink:label="lab_stpr_FL" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Florida</link:label>
    <link:label id="lab_stpr_FL_label_en-US" xlink:label="lab_stpr_FL" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FLORIDA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_FL" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_FL"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_FL" xlink:to="lab_stpr_FL" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_df1e047b-4549-4a98-b643-6ea1a55a03b4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_4bdd2868-e3eb-4ef3-b84f-a11435bf0034_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_a669396b-4d9b-40cb-9540-bfb169b1db46_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term obligations, less current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CompassionateCareHospiceMember_27cce609-f65a-498b-9452-1d5c384dd7b3_terseLabel_en-US" xlink:label="lab_amed_CompassionateCareHospiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compassionate Care Hospice [Member]</link:label>
    <link:label id="lab_amed_CompassionateCareHospiceMember_label_en-US" xlink:label="lab_amed_CompassionateCareHospiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compassionate Care Hospice [Member]</link:label>
    <link:label id="lab_amed_CompassionateCareHospiceMember_documentation_en-US" xlink:label="lab_amed_CompassionateCareHospiceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compassionate Care Hospice [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompassionateCareHospiceMember" xlink:href="amed-20200331.xsd#amed_CompassionateCareHospiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CompassionateCareHospiceMember" xlink:to="lab_amed_CompassionateCareHospiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_24c9e1f5-a7b3-4a69-aafe-f6b1155cef62_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AsanaHospiceAquisitionMember_4d73f0a9-ce1e-4bd9-a807-b99cdbbffa5e_terseLabel_en-US" xlink:label="lab_amed_AsanaHospiceAquisitionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asana Hospice Aquisition [Member]</link:label>
    <link:label id="lab_amed_AsanaHospiceAquisitionMember_label_en-US" xlink:label="lab_amed_AsanaHospiceAquisitionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asana Hospice Aquisition [Member]</link:label>
    <link:label id="lab_amed_AsanaHospiceAquisitionMember_documentation_en-US" xlink:label="lab_amed_AsanaHospiceAquisitionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asana Hospice Aquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AsanaHospiceAquisitionMember" xlink:href="amed-20200331.xsd#amed_AsanaHospiceAquisitionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AsanaHospiceAquisitionMember" xlink:to="lab_amed_AsanaHospiceAquisitionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_70fc6ee0-4e23-474e-8222-51a7cc2c0a33_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll and employee benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BaseRateMember_0fc410f6-4334-4273-8b97-6d38839f8d6f_terseLabel_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:label id="lab_us-gaap_BaseRateMember_label_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BaseRateMember" xlink:to="lab_us-gaap_BaseRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_4c6a7d4d-5cb7-4e37-8633-d37278680e3b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_139f7025-19e9-4483-92e5-28eaad9bd71c_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_2d8f8775-d135-4506-bae9-2242fb7eeea2_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment fee percentage</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_f9b64d82-806a-4647-8eca-0b77a51fc832_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, issued (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_5b5363a0-c61d-44ca-bb57-8ae129cded53_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b5d11bed-c40b-48fc-857b-51dd971cfb3b_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_TotalLeverageRatio_536e2011-52c8-4706-8214-696176388307_terseLabel_en-US" xlink:label="lab_amed_TotalLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated leverage ratio</link:label>
    <link:label id="lab_amed_TotalLeverageRatio_label_en-US" xlink:label="lab_amed_TotalLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Leverage Ratio</link:label>
    <link:label id="lab_amed_TotalLeverageRatio_documentation_en-US" xlink:label="lab_amed_TotalLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ratio of debt to earnings before interest, taxes, depreciation and amortization.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TotalLeverageRatio" xlink:href="amed-20200331.xsd#amed_TotalLeverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_TotalLeverageRatio" xlink:to="lab_amed_TotalLeverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_89e24b96-9b76-4f7f-a8e4-ebb395881a2a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_SwingLineLoanMember_c094bd90-2c48-4787-8042-fa3a38a23785_terseLabel_en-US" xlink:label="lab_amed_SwingLineLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swing Line Loan [Member]</link:label>
    <link:label id="lab_amed_SwingLineLoanMember_label_en-US" xlink:label="lab_amed_SwingLineLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swing Line Loan [Member]</link:label>
    <link:label id="lab_amed_SwingLineLoanMember_documentation_en-US" xlink:label="lab_amed_SwingLineLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swing Line Loan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SwingLineLoanMember" xlink:href="amed-20200331.xsd#amed_SwingLineLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_SwingLineLoanMember" xlink:to="lab_amed_SwingLineLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_826491de-9e6e-45f1-af75-41524f01acae_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Financing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_f6e5277a-3ba3-4778-957a-dcfac607425f_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_297b6abd-e36c-4210-be3f-a398b7d6a0f6_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_82db83af-3b57-49a5-b97f-34087731e29c_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_9a129d0e-c589-4c46-810a-c27fc5950712_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term obligations, including current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfStatesInWhichEntityOperates_e80f4223-11f4-4564-a9d3-41dcf553ba3a_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of states with facilities</link:label>
    <link:label id="lab_us-gaap_NumberOfStatesInWhichEntityOperates_label_en-US" xlink:label="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of States in which Entity Operates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:to="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d81a036b-0a8f-4060-b01a-9bbe06b0b046_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_eb9b4f31-3b5b-44c2-89b7-db3f6e6b1cdb_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AmedisysCIAMember_1f56de9a-0db3-46c8-9b87-7073b319e46a_terseLabel_en-US" xlink:label="lab_amed_AmedisysCIAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amedisys CIA</link:label>
    <link:label id="lab_amed_AmedisysCIAMember_label_en-US" xlink:label="lab_amed_AmedisysCIAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amedisys CIA [Member]</link:label>
    <link:label id="lab_amed_AmedisysCIAMember_documentation_en-US" xlink:label="lab_amed_AmedisysCIAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amedisys CIA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmedisysCIAMember" xlink:href="amed-20200331.xsd#amed_AmedisysCIAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AmedisysCIAMember" xlink:to="lab_amed_AmedisysCIAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterestAndDividend_2f3858bd-f13f-4798-b4e2-70523fce3790_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterestAndDividend" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterestAndDividend_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterestAndDividend" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest and Dividend</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterestAndDividend" xlink:to="lab_us-gaap_InvestmentIncomeInterestAndDividend" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CompanysinsurancecarriersMember_d8399e1c-4e70-45aa-8ddf-fb17333f604b_terseLabel_en-US" xlink:label="lab_amed_CompanysinsurancecarriersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company's insurance carriers [Member]</link:label>
    <link:label id="lab_amed_CompanysinsurancecarriersMember_label_en-US" xlink:label="lab_amed_CompanysinsurancecarriersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company's insurance carriers [Member]</link:label>
    <link:label id="lab_amed_CompanysinsurancecarriersMember_documentation_en-US" xlink:label="lab_amed_CompanysinsurancecarriersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company's insurance carriers [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompanysinsurancecarriersMember" xlink:href="amed-20200331.xsd#amed_CompanysinsurancecarriersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CompanysinsurancecarriersMember" xlink:to="lab_amed_CompanysinsurancecarriersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DebtInstrumentPeriodicPaymentPercentage_9fb8b750-bb91-4540-8d13-d7ba5b64b45b_terseLabel_en-US" xlink:label="lab_amed_DebtInstrumentPeriodicPaymentPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Periodic Payment Percentage</link:label>
    <link:label id="lab_amed_DebtInstrumentPeriodicPaymentPercentage_label_en-US" xlink:label="lab_amed_DebtInstrumentPeriodicPaymentPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Periodic Payment Percentage</link:label>
    <link:label id="lab_amed_DebtInstrumentPeriodicPaymentPercentage_documentation_en-US" xlink:label="lab_amed_DebtInstrumentPeriodicPaymentPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The percentage of the Term Loan that is required as periodic payments including both interest and principal payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentPeriodicPaymentPercentage" xlink:href="amed-20200331.xsd#amed_DebtInstrumentPeriodicPaymentPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DebtInstrumentPeriodicPaymentPercentage" xlink:to="lab_amed_DebtInstrumentPeriodicPaymentPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ShareRepurchaseAxis_bcd1f979-abf9-4d58-bc65-ee552332d001_terseLabel_en-US" xlink:label="lab_amed_ShareRepurchaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase [Axis]</link:label>
    <link:label id="lab_amed_ShareRepurchaseAxis_label_en-US" xlink:label="lab_amed_ShareRepurchaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase [Axis]</link:label>
    <link:label id="lab_amed_ShareRepurchaseAxis_documentation_en-US" xlink:label="lab_amed_ShareRepurchaseAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseAxis" xlink:href="amed-20200331.xsd#amed_ShareRepurchaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ShareRepurchaseAxis" xlink:to="lab_amed_ShareRepurchaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_WriteOffOfOtherComprehensiveIncome_83210cb6-0593-4041-94de-74f7ecd9e9e7_negatedLabel_en-US" xlink:label="lab_amed_WriteOffOfOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-off of other comprehensive income</link:label>
    <link:label id="lab_amed_WriteOffOfOtherComprehensiveIncome_label_en-US" xlink:label="lab_amed_WriteOffOfOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write off of Other Comprehensive Income</link:label>
    <link:label id="lab_amed_WriteOffOfOtherComprehensiveIncome_documentation_en-US" xlink:label="lab_amed_WriteOffOfOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write off of Other Comprehensive Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_WriteOffOfOtherComprehensiveIncome" xlink:href="amed-20200331.xsd#amed_WriteOffOfOtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_WriteOffOfOtherComprehensiveIncome" xlink:to="lab_amed_WriteOffOfOtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_Paymentsrelatedtotaxassetandworkingcapital_00c0f9dc-b2e9-401d-8054-be3770723424_terseLabel_en-US" xlink:label="lab_amed_Paymentsrelatedtotaxassetandworkingcapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments related to tax asset and working capital</link:label>
    <link:label id="lab_amed_Paymentsrelatedtotaxassetandworkingcapital_label_en-US" xlink:label="lab_amed_Paymentsrelatedtotaxassetandworkingcapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments related to tax asset and working capital</link:label>
    <link:label id="lab_amed_Paymentsrelatedtotaxassetandworkingcapital_documentation_en-US" xlink:label="lab_amed_Paymentsrelatedtotaxassetandworkingcapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments related to tax asset and working capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Paymentsrelatedtotaxassetandworkingcapital" xlink:href="amed-20200331.xsd#amed_Paymentsrelatedtotaxassetandworkingcapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_Paymentsrelatedtotaxassetandworkingcapital" xlink:to="lab_amed_Paymentsrelatedtotaxassetandworkingcapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_a345fefc-467f-4a55-bb9b-4b1f82cf9632_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_26b07663-f8cf-4db8-8fb5-07fea53f5818_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_792d6ce6-07f8-450c-abbe-afd03257daa0_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_74d83e47-5353-4d10-8885-e183e4a2d7ab_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_f4a61b66-959c-4c70-87c7-25d2e719b313_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases_633a8d1a-05e4-4969-8f52-459fa6e6129f_terseLabel_en-US" xlink:label="lab_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Carrying Amount Excluding Finance Leases</link:label>
    <link:label id="lab_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases_label_en-US" xlink:label="lab_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Carrying Amount Excluding Finance Leases</link:label>
    <link:label id="lab_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases_documentation_en-US" xlink:label="lab_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Carrying Amount Excluding Finance Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases" xlink:href="amed-20200331.xsd#amed_DebtInstrumentCarryingAmountExcludingFinanceLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases" xlink:to="lab_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_9925a1b3-078c-4d20-9d04-363c8ee2f51b_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions of businesses, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_a0de0134-a42b-40c8-80c0-09c32a13e5b2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance/(cancellation) of non-vested stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_afd91dcd-4344-447c-ab05-efeb48565c06_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_9d501203-d7b5-4af5-acdd-744b11146fd3_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Financing Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfFinancingCosts" xlink:to="lab_us-gaap_PaymentsOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_d394ee3f-f2fd-47c1-a4d3-e8ee6a659693_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Street Name</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_0fe19330-998c-4952-87b3-27cded76acfb_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_6b4a2ae9-d247-44cc-800d-2a41a687334a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Suite</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_ad3285e4-f243-4572-80ac-01bc13aba694_terseLabel_en-US" xlink:label="lab_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of adjusted EBITDA that guarantor subsidiaries represent</link:label>
    <link:label id="lab_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_label_en-US" xlink:label="lab_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Earnings Before Interest Taxes Depreciation And Amortization From Subsidiaries</link:label>
    <link:label id="lab_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_documentation_en-US" xlink:label="lab_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of adjusted EBITDA that guarantor subsidiaries represent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" xlink:href="amed-20200331.xsd#amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" xlink:to="lab_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_bd40ac04-0bb9-4ce2-966f-7feef5468601_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_589055b9-fb8a-4af4-8180-7a1221fee88e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_c742ed49-a3ad-4e1f-9037-3794fe47cfc0_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_527e22b0-6098-467e-abe3-6f509e25b560_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire business</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_57ac5f5a-b356-4539-bda0-6195dc85b04c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_76f88bcd-2692-4f09-96c9-ce7722ba2c58_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_c2b586bd-8cf5-406c-9f53-024669974a1a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_94cf911b-9990-425a-a9ba-81ef913bf21c_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_224c276e-4702-4bb7-919c-dfcb4e19ac5c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue Sources, Health Care Organization [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue Sources, Health Care Organization [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xlink:to="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1d4ff293-1015-415a-8897-84fcc8c4f3e8_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_UnfavorableMember_9ec69f9c-74d9-4434-b81c-5254309d1b68_terseLabel_en-US" xlink:label="lab_amed_UnfavorableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfavorable</link:label>
    <link:label id="lab_amed_UnfavorableMember_label_en-US" xlink:label="lab_amed_UnfavorableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfavorable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UnfavorableMember" xlink:href="amed-20200331.xsd#amed_UnfavorableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_UnfavorableMember" xlink:to="lab_amed_UnfavorableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a2e24762-b77e-4ab9-8de6-baf53fef711b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_42dd33e3-1172-4656-a692-d18146438d32_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionExpense_65f15e19-3b48-49c5-b3a9-df188d8c6442_terseLabel_en-US" xlink:label="lab_us-gaap_PensionExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">401(k) employer match</link:label>
    <link:label id="lab_us-gaap_PensionExpense_label_en-US" xlink:label="lab_us-gaap_PensionExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Cost (Reversal of Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionExpense" xlink:to="lab_us-gaap_PensionExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansPayableMember_79201280-ebf4-4f68-b265-0d6442fc975d_terseLabel_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan [Member]</link:label>
    <link:label id="lab_us-gaap_LoansPayableMember_label_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansPayableMember" xlink:to="lab_us-gaap_LoansPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_c5aa8f32-481d-4c12-8129-b0c752242bc4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total purchase price for acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfBusinessesAcquired_20874e50-5002-4ddd-a52c-7121ffe44815_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfBusinessesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition, number of care centers acquired</link:label>
    <link:label id="lab_us-gaap_NumberOfBusinessesAcquired_label_en-US" xlink:label="lab_us-gaap_NumberOfBusinessesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Businesses Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfBusinessesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfBusinessesAcquired" xlink:to="lab_us-gaap_NumberOfBusinessesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_e607987a-33b6-48f8-9b6b-9e328456d2d2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the sale of property and equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost_865a6528-01d5-4b4c-8514-cc3c524efa27_terseLabel_en-US" xlink:label="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write off of deferred debt issuance cost</link:label>
    <link:label id="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost_label_en-US" xlink:label="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write off of Deferred Debt Issuance Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:to="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_67f4779b-c781-44c0-8e62-5701205b70ac_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_da1919c8-c0bb-4bc5-b6b8-d969e844403d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_dfc6efb9-07c8-427c-ab69-161be289f990_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CapYearAxis_49a91937-1e86-4780-8b5b-9775f8386f6e_terseLabel_en-US" xlink:label="lab_amed_CapYearAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year [Axis]</link:label>
    <link:label id="lab_amed_CapYearAxis_label_en-US" xlink:label="lab_amed_CapYearAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year [Axis]</link:label>
    <link:label id="lab_amed_CapYearAxis_documentation_en-US" xlink:label="lab_amed_CapYearAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearAxis" xlink:href="amed-20200331.xsd#amed_CapYearAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CapYearAxis" xlink:to="lab_amed_CapYearAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_fbbfa223-6421-4e84-a1db-70b63c4a2047_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of borrowings under revolving line of credit</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Short-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:to="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_UsDepartmentOfJusticeMember_0a2803c0-91d1-4934-8b3b-bb420a18d72f_terseLabel_en-US" xlink:label="lab_amed_UsDepartmentOfJusticeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Department of Justice</link:label>
    <link:label id="lab_amed_UsDepartmentOfJusticeMember_label_en-US" xlink:label="lab_amed_UsDepartmentOfJusticeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Department of Justice [Member]</link:label>
    <link:label id="lab_amed_UsDepartmentOfJusticeMember_documentation_en-US" xlink:label="lab_amed_UsDepartmentOfJusticeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Department of Justice</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UsDepartmentOfJusticeMember" xlink:href="amed-20200331.xsd#amed_UsDepartmentOfJusticeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_UsDepartmentOfJusticeMember" xlink:to="lab_amed_UsDepartmentOfJusticeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_9858ecbc-c810-4022-b4f6-49865d6b64b8_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ShareRepurchaseTable_d1cf50a9-6a98-435b-b3cb-abf99d1163c6_terseLabel_en-US" xlink:label="lab_amed_ShareRepurchaseTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase [Table]</link:label>
    <link:label id="lab_amed_ShareRepurchaseTable_label_en-US" xlink:label="lab_amed_ShareRepurchaseTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase [Table]</link:label>
    <link:label id="lab_amed_ShareRepurchaseTable_documentation_en-US" xlink:label="lab_amed_ShareRepurchaseTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseTable" xlink:href="amed-20200331.xsd#amed_ShareRepurchaseTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ShareRepurchaseTable" xlink:to="lab_amed_ShareRepurchaseTable" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_RevenueAdjustmentToMedicareRevenue_47023192-58f1-443a-aa85-a30657659d18_terseLabel_en-US" xlink:label="lab_amed_RevenueAdjustmentToMedicareRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue adjustment to Medicare revenue</link:label>
    <link:label id="lab_amed_RevenueAdjustmentToMedicareRevenue_label_en-US" xlink:label="lab_amed_RevenueAdjustmentToMedicareRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Adjustment To Medicare Revenue</link:label>
    <link:label id="lab_amed_RevenueAdjustmentToMedicareRevenue_documentation_en-US" xlink:label="lab_amed_RevenueAdjustmentToMedicareRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of the provisions that reduce the amount of Medicare revenue recognized by the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RevenueAdjustmentToMedicareRevenue" xlink:href="amed-20200331.xsd#amed_RevenueAdjustmentToMedicareRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_RevenueAdjustmentToMedicareRevenue" xlink:to="lab_amed_RevenueAdjustmentToMedicareRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_269288f4-80b7-4943-b356-79c29fb03b37_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_2db71810-a5ac-43e6-929f-5eaea144a4d9_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_34a539be-99ba-4356-87cb-5d36e2eb47f9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, issued (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_d08f0fcf-a899-45d0-8897-cc9125a72786_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_d4f23c20-5220-4bc5-98bb-f89bf83fecdf_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_45d0fe3b-bf7d-4138-93b2-2ea9db89f958_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_53be5e2b-94d7-4059-a29a-94da71fd75b0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ConsolidatedInterestCoverageRatio_0db8e091-f7f5-4f2b-9796-a344a5230ba1_terseLabel_en-US" xlink:label="lab_amed_ConsolidatedInterestCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated interest coverage ratio</link:label>
    <link:label id="lab_amed_ConsolidatedInterestCoverageRatio_label_en-US" xlink:label="lab_amed_ConsolidatedInterestCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Interest Coverage Ratio</link:label>
    <link:label id="lab_amed_ConsolidatedInterestCoverageRatio_documentation_en-US" xlink:label="lab_amed_ConsolidatedInterestCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ratio of adjusted earnings before interest, taxes, depreciation and amortization to cash interest charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ConsolidatedInterestCoverageRatio" xlink:href="amed-20200331.xsd#amed_ConsolidatedInterestCoverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ConsolidatedInterestCoverageRatio" xlink:to="lab_amed_ConsolidatedInterestCoverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HomeHealthNonMedicareEpisodicBasedMember_62d1be79-cc40-4170-8cf3-1b6355997543_terseLabel_en-US" xlink:label="lab_amed_HomeHealthNonMedicareEpisodicBasedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health Non-Medicare - Episodic Based [Member]</link:label>
    <link:label id="lab_amed_HomeHealthNonMedicareEpisodicBasedMember_label_en-US" xlink:label="lab_amed_HomeHealthNonMedicareEpisodicBasedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health Non-Medicare - Episodic Based [Member]</link:label>
    <link:label id="lab_amed_HomeHealthNonMedicareEpisodicBasedMember_documentation_en-US" xlink:label="lab_amed_HomeHealthNonMedicareEpisodicBasedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health Non-Medicare - Episodic Based [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthNonMedicareEpisodicBasedMember" xlink:href="amed-20200331.xsd#amed_HomeHealthNonMedicareEpisodicBasedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HomeHealthNonMedicareEpisodicBasedMember" xlink:to="lab_amed_HomeHealthNonMedicareEpisodicBasedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FloridaZpicRevenueReduction_2024afc4-1546-4aa2-a27a-b26a5a8fbace_terseLabel_en-US" xlink:label="lab_amed_FloridaZpicRevenueReduction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Florida ZPIC revenue reduction</link:label>
    <link:label id="lab_amed_FloridaZpicRevenueReduction_label_en-US" xlink:label="lab_amed_FloridaZpicRevenueReduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Florida Zpic Revenue Reduction</link:label>
    <link:label id="lab_amed_FloridaZpicRevenueReduction_documentation_en-US" xlink:label="lab_amed_FloridaZpicRevenueReduction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in revenue as a result of the Florida ZPIC audit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FloridaZpicRevenueReduction" xlink:href="amed-20200331.xsd#amed_FloridaZpicRevenueReduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FloridaZpicRevenueReduction" xlink:to="lab_amed_FloridaZpicRevenueReduction" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AseraCareHospiceMember_292b08dc-906d-4eeb-8854-1ca1364e581a_terseLabel_en-US" xlink:label="lab_amed_AseraCareHospiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AseraCare Hospice [Member]</link:label>
    <link:label id="lab_amed_AseraCareHospiceMember_label_en-US" xlink:label="lab_amed_AseraCareHospiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AseraCare Hospice [Member]</link:label>
    <link:label id="lab_amed_AseraCareHospiceMember_documentation_en-US" xlink:label="lab_amed_AseraCareHospiceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AseraCare Hospice</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AseraCareHospiceMember" xlink:href="amed-20200331.xsd#amed_AseraCareHospiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AseraCareHospiceMember" xlink:to="lab_amed_AseraCareHospiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_TwoHundredMillionRevolvingCreditFacilityMember_d5fd1ced-5f71-4959-9259-b900704e59ce_terseLabel_en-US" xlink:label="lab_amed_TwoHundredMillionRevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">200 Million Revolving Credit Facility</link:label>
    <link:label id="lab_amed_TwoHundredMillionRevolvingCreditFacilityMember_label_en-US" xlink:label="lab_amed_TwoHundredMillionRevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Hundred Million Revolving Credit Facility [Member]</link:label>
    <link:label id="lab_amed_TwoHundredMillionRevolvingCreditFacilityMember_documentation_en-US" xlink:label="lab_amed_TwoHundredMillionRevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Hundred Million Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember" xlink:href="amed-20200331.xsd#amed_TwoHundredMillionRevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember" xlink:to="lab_amed_TwoHundredMillionRevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_4761bdbd-33ed-4e41-a3e1-884dd4672284_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term obligations, less current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_70a2bf0b-6f5a-451c-9452-157e34be8a96_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares withheld upon stock vesting</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6fae73d2-8aa5-40de-9f56-f248d64476a4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_dd3da7af-68cf-4293-8297-089ce63a0253_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_e1bead42-715d-41e2-9a51-7efbc0c73d99_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Commitment Fee Under Credit Facilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Line of Credit Facilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:to="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract_0d74d993-e21b-47cd-9849-0415043ce0d2_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expenses:</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_c8c5b1fc-35c1-4226-a168-09e40073145d_terseLabel_en-US" xlink:label="lab_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock - 401(k) plan (shares)</link:label>
    <link:label id="lab_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_label_en-US" xlink:label="lab_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Shares Four Zero One K Employer Match</link:label>
    <link:label id="lab_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_documentation_en-US" xlink:label="lab_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued during the period to employees as employer's matching contribution to the company's 401(K) plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" xlink:href="amed-20200331.xsd#amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" xlink:to="lab_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ShareRepurchaseLineItems_689d65dd-7683-48f0-9d04-e258381c24fe_terseLabel_en-US" xlink:label="lab_amed_ShareRepurchaseLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase [Line Items]</link:label>
    <link:label id="lab_amed_ShareRepurchaseLineItems_label_en-US" xlink:label="lab_amed_ShareRepurchaseLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase [Line Items]</link:label>
    <link:label id="lab_amed_ShareRepurchaseLineItems_documentation_en-US" xlink:label="lab_amed_ShareRepurchaseLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Share Repurchase [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseLineItems" xlink:href="amed-20200331.xsd#amed_ShareRepurchaseLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ShareRepurchaseLineItems" xlink:to="lab_amed_ShareRepurchaseLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_OperatingCareCenters_7f09c9a2-8f84-4292-acbb-690a85e591f8_terseLabel_en-US" xlink:label="lab_amed_OperatingCareCenters" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of owned and operated care centers</link:label>
    <link:label id="lab_amed_OperatingCareCenters_label_en-US" xlink:label="lab_amed_OperatingCareCenters" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Care Centers</link:label>
    <link:label id="lab_amed_OperatingCareCenters_documentation_en-US" xlink:label="lab_amed_OperatingCareCenters" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of care centers owned by the entity as of the balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OperatingCareCenters" xlink:href="amed-20200331.xsd#amed_OperatingCareCenters"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_OperatingCareCenters" xlink:to="lab_amed_OperatingCareCenters" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_e28d607a-34e0-4728-9826-9f9421021bc5_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_Discountedclosingstockprice_9512e47e-a938-401e-a600-d94ccb49b4c5_terseLabel_en-US" xlink:label="lab_amed_Discountedclosingstockprice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounted closing stock price</link:label>
    <link:label id="lab_amed_Discountedclosingstockprice_label_en-US" xlink:label="lab_amed_Discountedclosingstockprice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounted closing stock price</link:label>
    <link:label id="lab_amed_Discountedclosingstockprice_documentation_en-US" xlink:label="lab_amed_Discountedclosingstockprice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounted closing stock price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Discountedclosingstockprice" xlink:href="amed-20200331.xsd#amed_Discountedclosingstockprice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_Discountedclosingstockprice" xlink:to="lab_amed_Discountedclosingstockprice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_bdaebe10-b28f-45eb-b429-ebb7b4a5b3a3_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_LetterOfCreditFee_f7cc1f6f-8c07-4868-9b7f-96a1a208c06c_terseLabel_en-US" xlink:label="lab_amed_LetterOfCreditFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter Of Credit Fee</link:label>
    <link:label id="lab_amed_LetterOfCreditFee_label_en-US" xlink:label="lab_amed_LetterOfCreditFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter Of Credit Fee</link:label>
    <link:label id="lab_amed_LetterOfCreditFee_documentation_en-US" xlink:label="lab_amed_LetterOfCreditFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The fee, expressed as a percentage of the letters of credit, for the letters of credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LetterOfCreditFee" xlink:href="amed-20200331.xsd#amed_LetterOfCreditFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LetterOfCreditFee" xlink:to="lab_amed_LetterOfCreditFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_cb6460ea-4ace-4072-9437-6427d71ee0f1_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1f7099df-ed80-47f1-a05f-d8a5fe762b83_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LaborAndRelatedExpense_45be7d9b-63ba-47fb-a70c-a23ffdffc536_terseLabel_en-US" xlink:label="lab_us-gaap_LaborAndRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salaries and benefits</link:label>
    <link:label id="lab_us-gaap_LaborAndRelatedExpense_label_en-US" xlink:label="lab_us-gaap_LaborAndRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Labor and Related Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LaborAndRelatedExpense" xlink:to="lab_us-gaap_LaborAndRelatedExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_c0cf305d-fc92-4e95-8e59-3d7a8b5ea0d2_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_5c803d04-6c98-478e-922d-9afbbf3cbe85_terseLabel_en-US" xlink:label="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery amount of overpayment made to subsidiary</link:label>
    <link:label id="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_label_en-US" xlink:label="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery Amount Of Overpayment Made To Subsidiary</link:label>
    <link:label id="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_documentation_en-US" xlink:label="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery amount of the overpayment made to the subsidiary.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary" xlink:href="amed-20200331.xsd#amed_RecoveryAmountOfOverpaymentMadeToSubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary" xlink:to="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_f6310e11-0ddc-431b-9481-d901f8b238e7_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_ecf70861-b29c-4f2b-80a1-feeb48506f98_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock - employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_SurrenderedShares_415ea660-b8ff-46a1-80a1-7b639608afe8_negatedLabel_en-US" xlink:label="lab_amed_SurrenderedShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surrendered Shares</link:label>
    <link:label id="lab_amed_SurrenderedShares_label_en-US" xlink:label="lab_amed_SurrenderedShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surrendered Shares</link:label>
    <link:label id="lab_amed_SurrenderedShares_documentation_en-US" xlink:label="lab_amed_SurrenderedShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock surrendered by certain employees to satisfy obligations in connection with the vesting of stock. Shares held in Treasury Stock at cost.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SurrenderedShares" xlink:href="amed-20200331.xsd#amed_SurrenderedShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_SurrenderedShares" xlink:to="lab_amed_SurrenderedShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_9a809f4e-204d-4126-a884-ff8dd947512f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_3966c689-5ba9-491d-8c3d-c5caa11a12a7_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_62d72100-0677-4e94-8586-a007a581abb8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_da28d682-6946-4106-9644-8f61cd32daa0_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NumberOfBeneficiaries_827d4b15-720d-4f07-bb9c-7cd066704100_terseLabel_en-US" xlink:label="lab_amed_NumberOfBeneficiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of beneficiaries</link:label>
    <link:label id="lab_amed_NumberOfBeneficiaries_label_en-US" xlink:label="lab_amed_NumberOfBeneficiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of beneficiaries</link:label>
    <link:label id="lab_amed_NumberOfBeneficiaries_documentation_en-US" xlink:label="lab_amed_NumberOfBeneficiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of beneficiaries who received services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfBeneficiaries" xlink:href="amed-20200331.xsd#amed_NumberOfBeneficiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NumberOfBeneficiaries" xlink:to="lab_amed_NumberOfBeneficiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue_0f8eb807-dec8-4b52-b1b0-c24b3f6f201d_terseLabel_en-US" xlink:label="lab_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue by payor class as a percentage of total net service revenue</link:label>
    <link:label id="lab_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue_label_en-US" xlink:label="lab_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue by payor class as a percentage of total net service revenue</link:label>
    <link:label id="lab_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue_documentation_en-US" xlink:label="lab_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue by payor class as a percentage of total net service revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue" xlink:href="amed-20200331.xsd#amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue" xlink:to="lab_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_49790f8e-9f81-4d94-804f-429c0dc655b8_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Fair Value</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fc4aa4f9-1f58-492d-a932-bbabaca4c4e7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_eb809bd8-db2f-410c-bca5-b53e8f3298ff_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_EastTennesseePersonalCareServicesMember_1a15aedc-ee47-44ba-aea1-05c07b19be9d_terseLabel_en-US" xlink:label="lab_amed_EastTennesseePersonalCareServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">East Tennessee Personal Care Services</link:label>
    <link:label id="lab_amed_EastTennesseePersonalCareServicesMember_label_en-US" xlink:label="lab_amed_EastTennesseePersonalCareServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">East Tennessee Personal Care Services [Member]</link:label>
    <link:label id="lab_amed_EastTennesseePersonalCareServicesMember_documentation_en-US" xlink:label="lab_amed_EastTennesseePersonalCareServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">East Tennessee Personal Care Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EastTennesseePersonalCareServicesMember" xlink:href="amed-20200331.xsd#amed_EastTennesseePersonalCareServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EastTennesseePersonalCareServicesMember" xlink:to="lab_amed_EastTennesseePersonalCareServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_8abbb002-a01c-43ee-955a-8cd485a2bd0c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACQUISITIONS</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_TypeofEquityMethodInvestmentAxis_03f82e56-1074-4c96-97ea-e7daa19becde_terseLabel_en-US" xlink:label="lab_amed_TypeofEquityMethodInvestmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Equity Method Investment [Axis]</link:label>
    <link:label id="lab_amed_TypeofEquityMethodInvestmentAxis_label_en-US" xlink:label="lab_amed_TypeofEquityMethodInvestmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Equity Method Investment [Axis]</link:label>
    <link:label id="lab_amed_TypeofEquityMethodInvestmentAxis_documentation_en-US" xlink:label="lab_amed_TypeofEquityMethodInvestmentAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Equity Method Investment [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TypeofEquityMethodInvestmentAxis" xlink:href="amed-20200331.xsd#amed_TypeofEquityMethodInvestmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_TypeofEquityMethodInvestmentAxis" xlink:to="lab_amed_TypeofEquityMethodInvestmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_b3be0737-1758-407b-a4b9-c87e6d96cd9f_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CompassionateCareHospiceCIAMember_45be3198-bce9-47bd-ac97-5bed0aad6e70_terseLabel_en-US" xlink:label="lab_amed_CompassionateCareHospiceCIAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compassionate Care Hospice CIA</link:label>
    <link:label id="lab_amed_CompassionateCareHospiceCIAMember_label_en-US" xlink:label="lab_amed_CompassionateCareHospiceCIAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compassionate Care Hospice CIA [Member]</link:label>
    <link:label id="lab_amed_CompassionateCareHospiceCIAMember_documentation_en-US" xlink:label="lab_amed_CompassionateCareHospiceCIAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compassionate Care Hospice CIA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompassionateCareHospiceCIAMember" xlink:href="amed-20200331.xsd#amed_CompassionateCareHospiceCIAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CompassionateCareHospiceCIAMember" xlink:to="lab_amed_CompassionateCareHospiceCIAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncompeteAgreementsMember_56692a5b-f85d-47ce-854e-607caaff0bd3_terseLabel_en-US" xlink:label="lab_us-gaap_NoncompeteAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncompete Agreements [Member]</link:label>
    <link:label id="lab_us-gaap_NoncompeteAgreementsMember_label_en-US" xlink:label="lab_us-gaap_NoncompeteAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncompete Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncompeteAgreementsMember" xlink:to="lab_us-gaap_NoncompeteAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_e398c84b-0870-4168-8903-e908bcee0223_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency accrual, period increase (decrease)</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:to="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities_0a95007d-6a9d-4d88-b5fb-208d12717764_negatedLabel_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities_label_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities" xlink:href="amed-20200331.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities" xlink:to="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CapYearTwoThousandThirteenThroughTwoThousandTwentyMember_7d98659d-e6f8-4bdd-b4c5-f844c305bdd0_terseLabel_en-US" xlink:label="lab_amed_CapYearTwoThousandThirteenThroughTwoThousandTwentyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year 2013 Through 2020</link:label>
    <link:label id="lab_amed_CapYearTwoThousandThirteenThroughTwoThousandTwentyMember_label_en-US" xlink:label="lab_amed_CapYearTwoThousandThirteenThroughTwoThousandTwentyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year Two Thousand Thirteen Through Two Thousand Twenty [Member]</link:label>
    <link:label id="lab_amed_CapYearTwoThousandThirteenThroughTwoThousandTwentyMember_documentation_en-US" xlink:label="lab_amed_CapYearTwoThousandThirteenThroughTwoThousandTwentyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year Two Thousand Thirteen Through Two Thousand Twenty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearTwoThousandThirteenThroughTwoThousandTwentyMember" xlink:href="amed-20200331.xsd#amed_CapYearTwoThousandThirteenThroughTwoThousandTwentyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CapYearTwoThousandThirteenThroughTwoThousandTwentyMember" xlink:to="lab_amed_CapYearTwoThousandThirteenThroughTwoThousandTwentyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_d703665f-d604-4829-a0c2-e03e676b2246_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CorporateIntegrityAgreementTerm_8e905a2c-416c-4193-b05a-07985fd1b3de_terseLabel_en-US" xlink:label="lab_amed_CorporateIntegrityAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate integrity agreement term (years)</link:label>
    <link:label id="lab_amed_CorporateIntegrityAgreementTerm_label_en-US" xlink:label="lab_amed_CorporateIntegrityAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Integrity Agreement Term</link:label>
    <link:label id="lab_amed_CorporateIntegrityAgreementTerm_documentation_en-US" xlink:label="lab_amed_CorporateIntegrityAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Integrity Agreement Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CorporateIntegrityAgreementTerm" xlink:href="amed-20200331.xsd#amed_CorporateIntegrityAgreementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CorporateIntegrityAgreementTerm" xlink:to="lab_amed_CorporateIntegrityAgreementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_26a730bb-1b14-4ffb-846d-eb496575493b_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_cef99d5b-57f5-4bbf-a089-e8fc125a25f4_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options (shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_078c1ad8-59a3-43d8-a22a-1492502675c6_terseLabel_en-US" xlink:label="lab_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional interest rate above Eurodollar rate</link:label>
    <link:label id="lab_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_label_en-US" xlink:label="lab_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Additional Interest Above Eurodollar Rate</link:label>
    <link:label id="lab_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_documentation_en-US" xlink:label="lab_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Additional Interest Above Eurodollar Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" xlink:href="amed-20200331.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" xlink:to="lab_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_9112930a-e34f-4c0a-ac7d-f498e7e26ebe_terseLabel_en-US" xlink:label="lab_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock - 401(k) plan</link:label>
    <link:label id="lab_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_label_en-US" xlink:label="lab_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Value Four Zero One K Employer Match</link:label>
    <link:label id="lab_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_documentation_en-US" xlink:label="lab_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of stock issued during the period to employees as employer's matching contribution to the company's 401(K) plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" xlink:href="amed-20200331.xsd#amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" xlink:to="lab_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f5c218eb-de9d-43d8-b70e-465201d35d09_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding, basic (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e712ba9e-df60-4c28-9cd2-9ec3a5a7fcb8_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of shares outstanding - basic (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_3fa39bc6-971e-480d-839d-dfbc28010145_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right of use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MaximumPercentOwnershipForCostMethodPercent_bb69821e-03ea-42df-9daa-08a8e153614a_terseLabel_en-US" xlink:label="lab_amed_MaximumPercentOwnershipForCostMethodPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum ownership percentage for cost method investment (percent)</link:label>
    <link:label id="lab_amed_MaximumPercentOwnershipForCostMethodPercent_label_en-US" xlink:label="lab_amed_MaximumPercentOwnershipForCostMethodPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Percent Ownership For Cost Method Percent</link:label>
    <link:label id="lab_amed_MaximumPercentOwnershipForCostMethodPercent_documentation_en-US" xlink:label="lab_amed_MaximumPercentOwnershipForCostMethodPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the percentage ownership required in order for an investment to be treated under the cost method of accounting in the entity's financial statements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumPercentOwnershipForCostMethodPercent" xlink:href="amed-20200331.xsd#amed_MaximumPercentOwnershipForCostMethodPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MaximumPercentOwnershipForCostMethodPercent" xlink:to="lab_amed_MaximumPercentOwnershipForCostMethodPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_2e009b7a-d5f1-4f49-aea3-49169670585e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_COVID19PPEMember_94966b2b-f865-44b6-834f-66d18426b88a_terseLabel_en-US" xlink:label="lab_amed_COVID19PPEMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 PPE [Member]</link:label>
    <link:label id="lab_amed_COVID19PPEMember_label_en-US" xlink:label="lab_amed_COVID19PPEMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 PPE [Member]</link:label>
    <link:label id="lab_amed_COVID19PPEMember_documentation_en-US" xlink:label="lab_amed_COVID19PPEMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 PPE</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_COVID19PPEMember" xlink:href="amed-20200331.xsd#amed_COVID19PPEMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_COVID19PPEMember" xlink:to="lab_amed_COVID19PPEMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_92804d33-5148-4b92-ba4d-b6868e284a0b_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_b547a264-3f2f-4325-a183-4d9c8155a5a8_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_78e72258-cb16-4056-8fd6-5e5d7bacb3d2_negatedLabel_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_label_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_documentation_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:href="amed-20200331.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:to="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_23b86808-bc3a-4b25-9434-ddaaeebf0d34_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Amedisys, Inc. stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8256c2bd-2850-48f8-aed5-99b48fb5d16a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_74fc30a7-ee90-499c-9388-5eb36eac27dc_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_8f962d25-7c3f-4e1d-a873-a47f7b747720_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6061725f-cba4-403e-934d-c45a15b0e4b7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_d5d527e7-7468-4036-8aba-ae6198fc7787_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_81132ebd-7a16-4468-9281-c7400f8a613c_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_86f4ff10-958b-4b87-bd56-689217903934_terseLabel_en-US" xlink:label="lab_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net service revenue</link:label>
    <link:label id="lab_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_label_en-US" xlink:label="lab_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Organization, Revenue Net of Patient Service Revenue Provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" xlink:to="lab_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_WorkersCompensationInsuranceRetentionLimit_644d1235-dc08-43e0-96b1-075e55b84d6f_terseLabel_en-US" xlink:label="lab_amed_WorkersCompensationInsuranceRetentionLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workers compensation insurance retention limit</link:label>
    <link:label id="lab_amed_WorkersCompensationInsuranceRetentionLimit_label_en-US" xlink:label="lab_amed_WorkersCompensationInsuranceRetentionLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workers Compensation Insurance Retention Limit</link:label>
    <link:label id="lab_amed_WorkersCompensationInsuranceRetentionLimit_documentation_en-US" xlink:label="lab_amed_WorkersCompensationInsuranceRetentionLimit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum potential amount of future payments the entity could be required to make related to a specific Workers' Compensation Insurance Claim.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_WorkersCompensationInsuranceRetentionLimit" xlink:href="amed-20200331.xsd#amed_WorkersCompensationInsuranceRetentionLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_WorkersCompensationInsuranceRetentionLimit" xlink:to="lab_amed_WorkersCompensationInsuranceRetentionLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_0996a5d7-7e8e-4525-b3de-02b5960c1b23_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EurodollarMember_11f68d14-314f-4834-a01d-a8e108a20bed_terseLabel_en-US" xlink:label="lab_us-gaap_EurodollarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eurodollar [Member]</link:label>
    <link:label id="lab_us-gaap_EurodollarMember_label_en-US" xlink:label="lab_us-gaap_EurodollarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eurodollar [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EurodollarMember" xlink:to="lab_us-gaap_EurodollarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_9cfd3d52-341b-4bc8-b851-5e83fb1dbacc_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_SecondThresholdOfServicesRequired_94a64477-32ba-48ee-b6d9-9bb7465a44bc_terseLabel_en-US" xlink:label="lab_amed_SecondThresholdOfServicesRequired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second threshold of therapy services required (visits)</link:label>
    <link:label id="lab_amed_SecondThresholdOfServicesRequired_label_en-US" xlink:label="lab_amed_SecondThresholdOfServicesRequired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Threshold Of Services Required</link:label>
    <link:label id="lab_amed_SecondThresholdOfServicesRequired_documentation_en-US" xlink:label="lab_amed_SecondThresholdOfServicesRequired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of visits related to the second threshold of therapy services required.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecondThresholdOfServicesRequired" xlink:href="amed-20200331.xsd#amed_SecondThresholdOfServicesRequired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_SecondThresholdOfServicesRequired" xlink:to="lab_amed_SecondThresholdOfServicesRequired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_6fb1d356-e57a-4302-8305-a14d625980e8_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares repurchased</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_31a840e1-6825-4609-9fc8-8b6eec42cfde_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of each exchange on which registered</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_de884c9f-f341-4241-a0f3-188715ed4982_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_870013bc-b092-48da-b4b0-0b067bd0ed69_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyReceivableCurrent_e837bca6-8b6b-4716-afdf-09eda2f1f5fc_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement amount to be paid by company's insurance carriers</link:label>
    <link:label id="lab_us-gaap_LossContingencyReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_LossContingencyReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyReceivableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyReceivableCurrent" xlink:to="lab_us-gaap_LossContingencyReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_93b9686f-87ed-469b-bd49-88527a4b10d2_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive securities (shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_TypeofEquityMethodInvestmentDomain_abf8d2f2-1ec4-4572-b946-4cf5691f2e7c_terseLabel_en-US" xlink:label="lab_amed_TypeofEquityMethodInvestmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Equity Method Investment [Domain]</link:label>
    <link:label id="lab_amed_TypeofEquityMethodInvestmentDomain_label_en-US" xlink:label="lab_amed_TypeofEquityMethodInvestmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Equity Method Investment [Domain]</link:label>
    <link:label id="lab_amed_TypeofEquityMethodInvestmentDomain_documentation_en-US" xlink:label="lab_amed_TypeofEquityMethodInvestmentDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Type of Equity Method Investment [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TypeofEquityMethodInvestmentDomain" xlink:href="amed-20200331.xsd#amed_TypeofEquityMethodInvestmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_TypeofEquityMethodInvestmentDomain" xlink:to="lab_amed_TypeofEquityMethodInvestmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_91b069fc-d4d1-4bdf-aadd-134437634b18_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_80c6f889-a1ee-4669-9977-854c3a26dafc_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FirstThresholdOfTherapyServicesRequired_8aa2ad56-c02c-4636-9552-e1802734610f_terseLabel_en-US" xlink:label="lab_amed_FirstThresholdOfTherapyServicesRequired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First threshold of therapy services required (visits)</link:label>
    <link:label id="lab_amed_FirstThresholdOfTherapyServicesRequired_label_en-US" xlink:label="lab_amed_FirstThresholdOfTherapyServicesRequired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Threshold Of Therapy Services Required</link:label>
    <link:label id="lab_amed_FirstThresholdOfTherapyServicesRequired_documentation_en-US" xlink:label="lab_amed_FirstThresholdOfTherapyServicesRequired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of visits related to the first threshold of therapy services required.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FirstThresholdOfTherapyServicesRequired" xlink:href="amed-20200331.xsd#amed_FirstThresholdOfTherapyServicesRequired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FirstThresholdOfTherapyServicesRequired" xlink:to="lab_amed_FirstThresholdOfTherapyServicesRequired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_fc58dc0a-f289-419c-85ec-f08f35173879_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_f983912a-5f31-4e9f-af20-7c2668c73715_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_81ae7a6b-7535-4097-9728-e393422ec12f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_f1ea18db-0861-4eed-b0e3-b7186dfaf335_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_82505bf0-a210-4870-80e3-827b1edf2f7d_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_fe245557-c659-4ba4-a851-129f269ee02b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value, 60,000,000 shares authorized; 36,746,554 and 36,638,021 shares issued; and 32,370,345 and 32,284,051 shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding" xlink:to="lab_us-gaap_CommonStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_fd7a2305-3d91-40f2-ade3-6d0f21c51293_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_5bb29d60-0cca-4777-9b1c-5f8c73a2fd63_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple_367e7a5f-d428-4a84-9621-e5b8573a9790_terseLabel_en-US" xlink:label="lab_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility Maximum Allowable Consolidated Leverage Ratio Multiple</link:label>
    <link:label id="lab_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple_label_en-US" xlink:label="lab_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility Maximum Allowable Consolidated Leverage Ratio Multiple</link:label>
    <link:label id="lab_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple_documentation_en-US" xlink:label="lab_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility, Maximum Allowable Consolidated Leverage Ratio Multiple</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple" xlink:href="amed-20200331.xsd#amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple" xlink:to="lab_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_6ad2d163-ad33-4d2e-9c0c-269b3128a7bd_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_Percentageofclosingstockprice_305d854d-ac7b-46ec-994c-5a849773c7dc_terseLabel_en-US" xlink:label="lab_amed_Percentageofclosingstockprice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of closing stock price</link:label>
    <link:label id="lab_amed_Percentageofclosingstockprice_label_en-US" xlink:label="lab_amed_Percentageofclosingstockprice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of closing stock price</link:label>
    <link:label id="lab_amed_Percentageofclosingstockprice_documentation_en-US" xlink:label="lab_amed_Percentageofclosingstockprice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of closing stock price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Percentageofclosingstockprice" xlink:href="amed-20200331.xsd#amed_Percentageofclosingstockprice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_Percentageofclosingstockprice" xlink:to="lab_amed_Percentageofclosingstockprice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_1013eadd-1137-49d9-8abd-38e4bdcc381c_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average amortization period</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_778968ca-f518-4cc8-b57d-e77d85005f38_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net service revenue</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyReceivableNoncurrent_28e34f84-62b5-4421-96bf-dc3b2667690d_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyReceivableNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnity receivable</link:label>
    <link:label id="lab_us-gaap_LossContingencyReceivableNoncurrent_label_en-US" xlink:label="lab_us-gaap_LossContingencyReceivableNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Receivable, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyReceivableNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyReceivableNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyReceivableNoncurrent" xlink:to="lab_us-gaap_LossContingencyReceivableNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_4c466400-2ae5-41a0-883c-dd0185553bf7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAndCostMethodInvestmentsPolicy_c0401da2-17e8-4f3c-aa46-8c9b429b1270_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAndCostMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_EquityAndCostMethodInvestmentsPolicy_label_en-US" xlink:label="lab_us-gaap_EquityAndCostMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity and Cost Method Investments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAndCostMethodInvestmentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAndCostMethodInvestmentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAndCostMethodInvestmentsPolicy" xlink:to="lab_us-gaap_EquityAndCostMethodInvestmentsPolicy" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>amed-20200331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:dde64841-3e1e-49e6-96d6-a911d3f838cb,g:d3a0c63a-9ddc-46a6-b2f9-35d46ac243f3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.amedisys.com/role/Cover" xlink:type="simple" xlink:href="amed-20200331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_b690b77f-9f0c-4730-b778-e61e0f97f538" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_ff1c278a-aa15-4233-8a3f-b47383e5d6ed" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b690b77f-9f0c-4730-b778-e61e0f97f538" xlink:to="loc_dei_DocumentType_ff1c278a-aa15-4233-8a3f-b47383e5d6ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_457191c2-2f19-44cb-85cf-22dea185fa59" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b690b77f-9f0c-4730-b778-e61e0f97f538" xlink:to="loc_dei_DocumentQuarterlyReport_457191c2-2f19-44cb-85cf-22dea185fa59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_3ea8c46f-8301-4515-902c-774f39970815" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b690b77f-9f0c-4730-b778-e61e0f97f538" xlink:to="loc_dei_DocumentPeriodEndDate_3ea8c46f-8301-4515-902c-774f39970815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_d74d53b8-aadd-4aab-8fa9-c221f33af520" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b690b77f-9f0c-4730-b778-e61e0f97f538" xlink:to="loc_dei_DocumentTransitionReport_d74d53b8-aadd-4aab-8fa9-c221f33af520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_683b1727-c72a-4ea5-8bf9-18ff07775fc6" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b690b77f-9f0c-4730-b778-e61e0f97f538" xlink:to="loc_dei_EntityFileNumber_683b1727-c72a-4ea5-8bf9-18ff07775fc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_64974184-df01-4308-8433-87770173559e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b690b77f-9f0c-4730-b778-e61e0f97f538" xlink:to="loc_dei_EntityRegistrantName_64974184-df01-4308-8433-87770173559e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_147b673d-e54b-4b2e-9d25-c98933eb11dd" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b690b77f-9f0c-4730-b778-e61e0f97f538" xlink:to="loc_dei_EntityIncorporationStateCountryCode_147b673d-e54b-4b2e-9d25-c98933eb11dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_c18a1038-63d5-4aa0-9d2a-fa354273725d" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b690b77f-9f0c-4730-b778-e61e0f97f538" xlink:to="loc_dei_EntityTaxIdentificationNumber_c18a1038-63d5-4aa0-9d2a-fa354273725d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_7e2c49dd-4c9c-4263-865e-6f7ccb0ff374" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b690b77f-9f0c-4730-b778-e61e0f97f538" xlink:to="loc_dei_EntityAddressAddressLine1_7e2c49dd-4c9c-4263-865e-6f7ccb0ff374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_a5c7c9b6-346c-4272-ad88-a881586869ed" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b690b77f-9f0c-4730-b778-e61e0f97f538" xlink:to="loc_dei_EntityAddressAddressLine2_a5c7c9b6-346c-4272-ad88-a881586869ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_30412348-f63f-4b40-a632-b7577a078769" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b690b77f-9f0c-4730-b778-e61e0f97f538" xlink:to="loc_dei_EntityAddressCityOrTown_30412348-f63f-4b40-a632-b7577a078769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_956ae194-dbd0-4010-aec2-b0d1281694d1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b690b77f-9f0c-4730-b778-e61e0f97f538" xlink:to="loc_dei_EntityAddressStateOrProvince_956ae194-dbd0-4010-aec2-b0d1281694d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_d7b82b1d-d6ff-4275-aa52-e05cec97ed78" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b690b77f-9f0c-4730-b778-e61e0f97f538" xlink:to="loc_dei_EntityAddressPostalZipCode_d7b82b1d-d6ff-4275-aa52-e05cec97ed78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_67e3eba1-6586-4a7a-9343-7bb53f3bebff" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b690b77f-9f0c-4730-b778-e61e0f97f538" xlink:to="loc_dei_CityAreaCode_67e3eba1-6586-4a7a-9343-7bb53f3bebff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_292c7a8e-7551-4187-bf9e-4d2c3facac9b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b690b77f-9f0c-4730-b778-e61e0f97f538" xlink:to="loc_dei_LocalPhoneNumber_292c7a8e-7551-4187-bf9e-4d2c3facac9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_c4231ea5-82be-470c-be67-e24832daa60a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b690b77f-9f0c-4730-b778-e61e0f97f538" xlink:to="loc_dei_Security12bTitle_c4231ea5-82be-470c-be67-e24832daa60a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_cdc3dcff-a6f3-4bac-a4a2-80e8d6fea79e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b690b77f-9f0c-4730-b778-e61e0f97f538" xlink:to="loc_dei_TradingSymbol_cdc3dcff-a6f3-4bac-a4a2-80e8d6fea79e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_ac5fcaeb-1181-4901-9d45-2aeef5acf906" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b690b77f-9f0c-4730-b778-e61e0f97f538" xlink:to="loc_dei_SecurityExchangeName_ac5fcaeb-1181-4901-9d45-2aeef5acf906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_f12b76e5-9cc6-4d26-a3cc-d9cb511576d6" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b690b77f-9f0c-4730-b778-e61e0f97f538" xlink:to="loc_dei_EntityCurrentReportingStatus_f12b76e5-9cc6-4d26-a3cc-d9cb511576d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_24519781-4bbd-479a-9e66-eec5a8ecfc0e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b690b77f-9f0c-4730-b778-e61e0f97f538" xlink:to="loc_dei_EntityInteractiveDataCurrent_24519781-4bbd-479a-9e66-eec5a8ecfc0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_1738ade3-39fc-4fb3-95e4-bf61a87429f9" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b690b77f-9f0c-4730-b778-e61e0f97f538" xlink:to="loc_dei_EntityFilerCategory_1738ade3-39fc-4fb3-95e4-bf61a87429f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_fb703f78-7e0d-4d73-bbb1-7d20750f6e44" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b690b77f-9f0c-4730-b778-e61e0f97f538" xlink:to="loc_dei_EntityEmergingGrowthCompany_fb703f78-7e0d-4d73-bbb1-7d20750f6e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_94e2b12b-4c92-4c43-9c31-3cdb5802f023" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b690b77f-9f0c-4730-b778-e61e0f97f538" xlink:to="loc_dei_EntitySmallBusiness_94e2b12b-4c92-4c43-9c31-3cdb5802f023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_7f391b59-2cf1-4ee3-bb52-6467cc52cff1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b690b77f-9f0c-4730-b778-e61e0f97f538" xlink:to="loc_dei_EntityShellCompany_7f391b59-2cf1-4ee3-bb52-6467cc52cff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_97de84e0-49d3-4530-ae75-a22f799bda60" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b690b77f-9f0c-4730-b778-e61e0f97f538" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_97de84e0-49d3-4530-ae75-a22f799bda60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_91ca7201-f896-4f6b-bfda-b473c5faed69" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b690b77f-9f0c-4730-b778-e61e0f97f538" xlink:to="loc_dei_AmendmentFlag_91ca7201-f896-4f6b-bfda-b473c5faed69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_f2565b54-6953-4017-a00a-67e9aae19004" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b690b77f-9f0c-4730-b778-e61e0f97f538" xlink:to="loc_dei_DocumentFiscalYearFocus_f2565b54-6953-4017-a00a-67e9aae19004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_852d5759-da6b-4680-823e-f0dde7debcf4" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b690b77f-9f0c-4730-b778-e61e0f97f538" xlink:to="loc_dei_DocumentFiscalPeriodFocus_852d5759-da6b-4680-823e-f0dde7debcf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_bbf7c360-5da3-4b93-9236-70966305c748" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b690b77f-9f0c-4730-b778-e61e0f97f538" xlink:to="loc_dei_EntityCentralIndexKey_bbf7c360-5da3-4b93-9236-70966305c748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_2d58cf5b-7749-44d2-9efd-656bfe42bc7e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b690b77f-9f0c-4730-b778-e61e0f97f538" xlink:to="loc_dei_CurrentFiscalYearEndDate_2d58cf5b-7749-44d2-9efd-656bfe42bc7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_333ae881-ee39-42b3-aa0c-e4173d0a368a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b690b77f-9f0c-4730-b778-e61e0f97f538" xlink:to="loc_dei_EntityVoluntaryFilers_333ae881-ee39-42b3-aa0c-e4173d0a368a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_cb0e9524-d8d1-4fff-b5eb-5af3919cbab4" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b690b77f-9f0c-4730-b778-e61e0f97f538" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_cb0e9524-d8d1-4fff-b5eb-5af3919cbab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="amed-20200331.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_207da6ea-598e-47c1-8715-d9ba332fbdd8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_118bc752-e506-46cb-82b7-09b4ee68ff09" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_207da6ea-598e-47c1-8715-d9ba332fbdd8" xlink:to="loc_us-gaap_AssetsAbstract_118bc752-e506-46cb-82b7-09b4ee68ff09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_8fbd88ef-baec-401a-acfd-19318a8af326" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_118bc752-e506-46cb-82b7-09b4ee68ff09" xlink:to="loc_us-gaap_AssetsCurrentAbstract_8fbd88ef-baec-401a-acfd-19318a8af326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_92ddcfe4-eba8-478c-b8bf-6700a6338973" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8fbd88ef-baec-401a-acfd-19318a8af326" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_92ddcfe4-eba8-478c-b8bf-6700a6338973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_59f76c69-dfb0-4324-b9ea-479d1a0f8936" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8fbd88ef-baec-401a-acfd-19318a8af326" xlink:to="loc_us-gaap_RestrictedCash_59f76c69-dfb0-4324-b9ea-479d1a0f8936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_56d2ed1e-cdbb-41ad-8f12-b5fc36b9a0c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8fbd88ef-baec-401a-acfd-19318a8af326" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_56d2ed1e-cdbb-41ad-8f12-b5fc36b9a0c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_bc05d799-50b0-4214-ab51-104ed3ffef2d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8fbd88ef-baec-401a-acfd-19318a8af326" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_bc05d799-50b0-4214-ab51-104ed3ffef2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_dc085757-ba0e-49e8-9987-4f2751df4e5f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8fbd88ef-baec-401a-acfd-19318a8af326" xlink:to="loc_us-gaap_OtherAssetsCurrent_dc085757-ba0e-49e8-9987-4f2751df4e5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1fa39718-7804-403c-ab1f-c1a96aa56537" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8fbd88ef-baec-401a-acfd-19318a8af326" xlink:to="loc_us-gaap_AssetsCurrent_1fa39718-7804-403c-ab1f-c1a96aa56537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e7e06f77-9e46-484e-a30f-a3b1bace6b6a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_118bc752-e506-46cb-82b7-09b4ee68ff09" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_e7e06f77-9e46-484e-a30f-a3b1bace6b6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_6b8b9364-e47d-413b-aa38-8bbf65e6648f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_118bc752-e506-46cb-82b7-09b4ee68ff09" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_6b8b9364-e47d-413b-aa38-8bbf65e6648f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_349a18fe-6cd3-4aea-9a17-9f91c3a5d570" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_118bc752-e506-46cb-82b7-09b4ee68ff09" xlink:to="loc_us-gaap_Goodwill_349a18fe-6cd3-4aea-9a17-9f91c3a5d570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_4fc4affe-9bf6-45da-b179-4c95d4870bbb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_118bc752-e506-46cb-82b7-09b4ee68ff09" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_4fc4affe-9bf6-45da-b179-4c95d4870bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_5abc3a0c-bd47-406b-b6ec-96d1acb1570b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_118bc752-e506-46cb-82b7-09b4ee68ff09" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_5abc3a0c-bd47-406b-b6ec-96d1acb1570b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_80d16af9-09ad-4b12-840d-85aa4edd2197" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_118bc752-e506-46cb-82b7-09b4ee68ff09" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_80d16af9-09ad-4b12-840d-85aa4edd2197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_4c3006de-75b3-4a7c-aeb0-fbdfec7d080f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_118bc752-e506-46cb-82b7-09b4ee68ff09" xlink:to="loc_us-gaap_Assets_4c3006de-75b3-4a7c-aeb0-fbdfec7d080f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_edc85e4c-bb0f-4969-92c5-9a26f2a81f07" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_207da6ea-598e-47c1-8715-d9ba332fbdd8" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_edc85e4c-bb0f-4969-92c5-9a26f2a81f07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_519a898a-dbaa-4fb2-824a-0b3cbc94d08c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_edc85e4c-bb0f-4969-92c5-9a26f2a81f07" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_519a898a-dbaa-4fb2-824a-0b3cbc94d08c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_b0b850ea-eb51-4ac5-98b0-a625c5344d43" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_519a898a-dbaa-4fb2-824a-0b3cbc94d08c" xlink:to="loc_us-gaap_AccountsPayableCurrent_b0b850ea-eb51-4ac5-98b0-a625c5344d43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_9da2a674-d5d5-45ee-aee2-248b3cc94d72" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_519a898a-dbaa-4fb2-824a-0b3cbc94d08c" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_9da2a674-d5d5-45ee-aee2-248b3cc94d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_5f4e47ba-819b-45e9-9317-a629acae7164" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_519a898a-dbaa-4fb2-824a-0b3cbc94d08c" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_5f4e47ba-819b-45e9-9317-a629acae7164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_76a6e946-9d5e-4254-9e93-ad19367012ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_519a898a-dbaa-4fb2-824a-0b3cbc94d08c" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_76a6e946-9d5e-4254-9e93-ad19367012ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_39539bef-a7d3-4f4e-8e10-e8d03c4e5134" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_519a898a-dbaa-4fb2-824a-0b3cbc94d08c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_39539bef-a7d3-4f4e-8e10-e8d03c4e5134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_94eac5fe-20b2-4c3b-8d84-fdaf30cb2eac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_519a898a-dbaa-4fb2-824a-0b3cbc94d08c" xlink:to="loc_us-gaap_LiabilitiesCurrent_94eac5fe-20b2-4c3b-8d84-fdaf30cb2eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_872c5084-7c4f-4687-84c4-80a80a441119" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_edc85e4c-bb0f-4969-92c5-9a26f2a81f07" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_872c5084-7c4f-4687-84c4-80a80a441119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e65c37c5-ced0-471b-93c5-d18558fad4ec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_edc85e4c-bb0f-4969-92c5-9a26f2a81f07" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e65c37c5-ced0-471b-93c5-d18558fad4ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_fbd3e06b-4b75-4e5d-b389-ad3da1c44f3e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_edc85e4c-bb0f-4969-92c5-9a26f2a81f07" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_fbd3e06b-4b75-4e5d-b389-ad3da1c44f3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_b88c6f91-d1cc-426a-b1c0-d77c231127cc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_edc85e4c-bb0f-4969-92c5-9a26f2a81f07" xlink:to="loc_us-gaap_Liabilities_b88c6f91-d1cc-426a-b1c0-d77c231127cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_6f01842d-d27b-4964-9f78-19640767c723" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_edc85e4c-bb0f-4969-92c5-9a26f2a81f07" xlink:to="loc_us-gaap_CommitmentsAndContingencies_6f01842d-d27b-4964-9f78-19640767c723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a8fcf0b3-e1d4-4504-93ff-04bcd73a1eda" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_edc85e4c-bb0f-4969-92c5-9a26f2a81f07" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a8fcf0b3-e1d4-4504-93ff-04bcd73a1eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValueOutstanding_0b22ccdd-1312-403e-995b-5360a5793829" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValueOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a8fcf0b3-e1d4-4504-93ff-04bcd73a1eda" xlink:to="loc_us-gaap_PreferredStockValueOutstanding_0b22ccdd-1312-403e-995b-5360a5793829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_d35b1661-240a-42fc-a986-901b53757845" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a8fcf0b3-e1d4-4504-93ff-04bcd73a1eda" xlink:to="loc_us-gaap_CommonStockValueOutstanding_d35b1661-240a-42fc-a986-901b53757845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_5f161e5f-c800-4fe4-8f78-5cb42d7a9088" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a8fcf0b3-e1d4-4504-93ff-04bcd73a1eda" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_5f161e5f-c800-4fe4-8f78-5cb42d7a9088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_fe94f162-fd77-4a5a-bf95-3d80ae3ae3c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a8fcf0b3-e1d4-4504-93ff-04bcd73a1eda" xlink:to="loc_us-gaap_TreasuryStockValue_fe94f162-fd77-4a5a-bf95-3d80ae3ae3c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5dd3576d-654d-4369-ab27-8f36ce890cc5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a8fcf0b3-e1d4-4504-93ff-04bcd73a1eda" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5dd3576d-654d-4369-ab27-8f36ce890cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_368aff22-cdee-4b06-a034-1e44d1d20af3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a8fcf0b3-e1d4-4504-93ff-04bcd73a1eda" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_368aff22-cdee-4b06-a034-1e44d1d20af3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a7b529fe-6741-410e-9964-8d8115f7ca54" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a8fcf0b3-e1d4-4504-93ff-04bcd73a1eda" xlink:to="loc_us-gaap_StockholdersEquity_a7b529fe-6741-410e-9964-8d8115f7ca54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_70d3c453-2fd0-4951-ba86-94156bd0f6d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a8fcf0b3-e1d4-4504-93ff-04bcd73a1eda" xlink:to="loc_us-gaap_MinorityInterest_70d3c453-2fd0-4951-ba86-94156bd0f6d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_27be087e-26e1-4c98-bef6-35a6ae89dd7f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a8fcf0b3-e1d4-4504-93ff-04bcd73a1eda" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_27be087e-26e1-4c98-bef6-35a6ae89dd7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_395b1912-ad88-4428-bc93-1a4f2ebb8f1d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_edc85e4c-bb0f-4969-92c5-9a26f2a81f07" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_395b1912-ad88-4428-bc93-1a4f2ebb8f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="amed-20200331.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_b61897eb-dab4-4e05-b389-3231b013024e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_353b28ed-0fd0-4235-9e53-3794c853c0ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b61897eb-dab4-4e05-b389-3231b013024e" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_353b28ed-0fd0-4235-9e53-3794c853c0ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_b7a28ceb-10e7-49eb-a2bf-6fca183a3a06" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b61897eb-dab4-4e05-b389-3231b013024e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_b7a28ceb-10e7-49eb-a2bf-6fca183a3a06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_c1c59005-fd46-481c-b845-609620d55093" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b61897eb-dab4-4e05-b389-3231b013024e" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_c1c59005-fd46-481c-b845-609620d55093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_0aa1be72-1135-480f-a159-550071ceb5a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b61897eb-dab4-4e05-b389-3231b013024e" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_0aa1be72-1135-480f-a159-550071ceb5a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_3cbd1570-d1f6-4a07-9f85-10b64ce5bece" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b61897eb-dab4-4e05-b389-3231b013024e" xlink:to="loc_us-gaap_PreferredStockSharesIssued_3cbd1570-d1f6-4a07-9f85-10b64ce5bece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_b5f3783f-e22a-4487-a4ab-3b05db2a2623" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b61897eb-dab4-4e05-b389-3231b013024e" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_b5f3783f-e22a-4487-a4ab-3b05db2a2623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_155e16b3-0f8b-429d-87d1-df2981c612c9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b61897eb-dab4-4e05-b389-3231b013024e" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_155e16b3-0f8b-429d-87d1-df2981c612c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_21528744-a758-4585-90b2-b18efce67263" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b61897eb-dab4-4e05-b389-3231b013024e" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_21528744-a758-4585-90b2-b18efce67263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_252e9c62-2248-4966-a128-7366e0912451" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b61897eb-dab4-4e05-b389-3231b013024e" xlink:to="loc_us-gaap_CommonStockSharesIssued_252e9c62-2248-4966-a128-7366e0912451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_6128a717-8fbf-4b80-ae7a-87295eb1aae7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b61897eb-dab4-4e05-b389-3231b013024e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_6128a717-8fbf-4b80-ae7a-87295eb1aae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_56b5cb59-b6d7-4644-89af-88058d0f9384" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b61897eb-dab4-4e05-b389-3231b013024e" xlink:to="loc_us-gaap_TreasuryStockShares_56b5cb59-b6d7-4644-89af-88058d0f9384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="amed-20200331.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_63f9349c-649e-43aa-bc24-085419ed320a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_c12f7a1d-9aa1-49f0-9d20-d0ce457bbc93" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_63f9349c-649e-43aa-bc24-085419ed320a" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_c12f7a1d-9aa1-49f0-9d20-d0ce457bbc93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_a45ea76d-e1c3-4057-993c-dcb398ee5b4d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_63f9349c-649e-43aa-bc24-085419ed320a" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_a45ea76d-e1c3-4057-993c-dcb398ee5b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_5bc14c2d-7e16-4784-b7ee-2e1807faf576" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_63f9349c-649e-43aa-bc24-085419ed320a" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_5bc14c2d-7e16-4784-b7ee-2e1807faf576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_5d3f8f5f-fe41-428c-bbc7-5c00578ecd0b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_5bc14c2d-7e16-4784-b7ee-2e1807faf576" xlink:to="loc_us-gaap_LaborAndRelatedExpense_5d3f8f5f-fe41-428c-bbc7-5c00578ecd0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_9a30f5a8-7548-4a11-af50-02a5d42227d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_5bc14c2d-7e16-4784-b7ee-2e1807faf576" xlink:to="loc_us-gaap_ShareBasedCompensation_9a30f5a8-7548-4a11-af50-02a5d42227d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense_b902dff3-7e1d-492a-a6ba-69274bf6650e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_5bc14c2d-7e16-4784-b7ee-2e1807faf576" xlink:to="loc_us-gaap_OtherGeneralAndAdministrativeExpense_b902dff3-7e1d-492a-a6ba-69274bf6650e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_3e584287-d42c-435f-873a-a47c9c66e06a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_63f9349c-649e-43aa-bc24-085419ed320a" xlink:to="loc_us-gaap_DepreciationAndAmortization_3e584287-d42c-435f-873a-a47c9c66e06a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_34194999-64c7-4f22-a383-a9c622373985" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_63f9349c-649e-43aa-bc24-085419ed320a" xlink:to="loc_us-gaap_CostsAndExpenses_34194999-64c7-4f22-a383-a9c622373985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_dd307342-e0d0-4f28-b5d8-94d844f184f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_63f9349c-649e-43aa-bc24-085419ed320a" xlink:to="loc_us-gaap_OperatingIncomeLoss_dd307342-e0d0-4f28-b5d8-94d844f184f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e03a3f29-a461-43e4-9fd6-3d30786dcff5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_63f9349c-649e-43aa-bc24-085419ed320a" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e03a3f29-a461-43e4-9fd6-3d30786dcff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend_b14d21ef-7f13-47d4-b469-a9dcbf0dde43" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e03a3f29-a461-43e4-9fd6-3d30786dcff5" xlink:to="loc_us-gaap_InvestmentIncomeInterestAndDividend_b14d21ef-7f13-47d4-b469-a9dcbf0dde43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_b693d1f9-ba92-4fe1-b1e7-7c4f592638e3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e03a3f29-a461-43e4-9fd6-3d30786dcff5" xlink:to="loc_us-gaap_InterestExpense_b693d1f9-ba92-4fe1-b1e7-7c4f592638e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_e5ea6c9d-d33d-4e24-88d8-1c4095e56418" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e03a3f29-a461-43e4-9fd6-3d30786dcff5" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_e5ea6c9d-d33d-4e24-88d8-1c4095e56418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_fda91c11-e42b-4487-9ff8-6973ae64c03e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e03a3f29-a461-43e4-9fd6-3d30786dcff5" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_fda91c11-e42b-4487-9ff8-6973ae64c03e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_174c1828-b36a-445d-b94e-8c9ab45d6810" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e03a3f29-a461-43e4-9fd6-3d30786dcff5" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_174c1828-b36a-445d-b94e-8c9ab45d6810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_13a17b25-6744-4053-9975-b9118e73b3d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_63f9349c-649e-43aa-bc24-085419ed320a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_13a17b25-6744-4053-9975-b9118e73b3d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_60f149cc-eb3c-4e7f-8799-cf6e943e5c06" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_63f9349c-649e-43aa-bc24-085419ed320a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_60f149cc-eb3c-4e7f-8799-cf6e943e5c06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_4b970e3e-6cd3-464a-a8c4-4ceffc79c064" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_63f9349c-649e-43aa-bc24-085419ed320a" xlink:to="loc_us-gaap_ProfitLoss_4b970e3e-6cd3-464a-a8c4-4ceffc79c064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_2de8b830-d0cd-45fa-8361-611ec60aa1c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_63f9349c-649e-43aa-bc24-085419ed320a" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_2de8b830-d0cd-45fa-8361-611ec60aa1c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_db6288c7-5c6a-4cf4-b027-36e1d526a6f1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_63f9349c-649e-43aa-bc24-085419ed320a" xlink:to="loc_us-gaap_NetIncomeLoss_db6288c7-5c6a-4cf4-b027-36e1d526a6f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_4985cf5d-ee50-4fca-9a93-69ec99abd53d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_63f9349c-649e-43aa-bc24-085419ed320a" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_4985cf5d-ee50-4fca-9a93-69ec99abd53d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_2ffc25ec-d546-4923-9f10-25304d373471" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_4985cf5d-ee50-4fca-9a93-69ec99abd53d" xlink:to="loc_us-gaap_EarningsPerShareBasic_2ffc25ec-d546-4923-9f10-25304d373471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0dbf0dfc-5bd2-43da-841b-fa9a96c9e089" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_4985cf5d-ee50-4fca-9a93-69ec99abd53d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0dbf0dfc-5bd2-43da-841b-fa9a96c9e089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_15e63d5e-3a44-4747-8fc6-0a0be38f9562" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_63f9349c-649e-43aa-bc24-085419ed320a" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_15e63d5e-3a44-4747-8fc6-0a0be38f9562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_9d5531dc-2e96-4839-bef0-e94eb4d2b83d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_15e63d5e-3a44-4747-8fc6-0a0be38f9562" xlink:to="loc_us-gaap_EarningsPerShareDiluted_9d5531dc-2e96-4839-bef0-e94eb4d2b83d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0f797ba6-398b-4e6c-96d0-64b3e95d975b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_15e63d5e-3a44-4747-8fc6-0a0be38f9562" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0f797ba6-398b-4e6c-96d0-64b3e95d975b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement" xlink:type="simple" xlink:href="amed-20200331.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_23c993f2-872f-44c8-a6d4-cd087527f747" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0b183d6f-8ea0-40cb-b152-e5a82424e33b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_23c993f2-872f-44c8-a6d4-cd087527f747" xlink:to="loc_us-gaap_StatementTable_0b183d6f-8ea0-40cb-b152-e5a82424e33b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_51866a3e-785a-40a0-97c2-4488479905aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0b183d6f-8ea0-40cb-b152-e5a82424e33b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_51866a3e-785a-40a0-97c2-4488479905aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e92fad79-9fb6-48ad-8a78-b4b48a7dc6da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_51866a3e-785a-40a0-97c2-4488479905aa" xlink:to="loc_us-gaap_EquityComponentDomain_e92fad79-9fb6-48ad-8a78-b4b48a7dc6da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f92a4c5f-624a-424f-8e58-d42909a3a96c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e92fad79-9fb6-48ad-8a78-b4b48a7dc6da" xlink:to="loc_us-gaap_CommonStockMember_f92a4c5f-624a-424f-8e58-d42909a3a96c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6f68ab27-a8b3-4207-9fb2-8d16babf65ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e92fad79-9fb6-48ad-8a78-b4b48a7dc6da" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_6f68ab27-a8b3-4207-9fb2-8d16babf65ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_3ee44518-4a90-4dbd-ba4c-5b869d284b14" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e92fad79-9fb6-48ad-8a78-b4b48a7dc6da" xlink:to="loc_us-gaap_TreasuryStockMember_3ee44518-4a90-4dbd-ba4c-5b869d284b14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_547c6322-a062-4087-8496-be5a154f3833" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e92fad79-9fb6-48ad-8a78-b4b48a7dc6da" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_547c6322-a062-4087-8496-be5a154f3833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ad2f1121-0a6f-48a2-889a-b5c049764360" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e92fad79-9fb6-48ad-8a78-b4b48a7dc6da" xlink:to="loc_us-gaap_RetainedEarningsMember_ad2f1121-0a6f-48a2-889a-b5c049764360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_c0a6b568-fd94-465d-a4ec-b5214db69194" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e92fad79-9fb6-48ad-8a78-b4b48a7dc6da" xlink:to="loc_us-gaap_NoncontrollingInterestMember_c0a6b568-fd94-465d-a4ec-b5214db69194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_77970f72-5aef-4f5b-9deb-959dfcd4e224" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0b183d6f-8ea0-40cb-b152-e5a82424e33b" xlink:to="loc_us-gaap_StatementLineItems_77970f72-5aef-4f5b-9deb-959dfcd4e224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_04656be8-b02c-4b36-b106-709d03bb6ad9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_77970f72-5aef-4f5b-9deb-959dfcd4e224" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_04656be8-b02c-4b36-b106-709d03bb6ad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_0abdb79c-1636-4e25-9987-a994044590fb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_77970f72-5aef-4f5b-9deb-959dfcd4e224" xlink:to="loc_us-gaap_SharesOutstanding_0abdb79c-1636-4e25-9987-a994044590fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_2d2a41c1-b5b9-4049-bb3e-9f88e66acb97" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_77970f72-5aef-4f5b-9deb-959dfcd4e224" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_2d2a41c1-b5b9-4049-bb3e-9f88e66acb97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_10795db2-084e-4114-9c46-21830fb3dacb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_77970f72-5aef-4f5b-9deb-959dfcd4e224" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_10795db2-084e-4114-9c46-21830fb3dacb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_0ddde317-d379-4b06-8209-4065ee9cf7d7" xlink:href="amed-20200331.xsd#amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_77970f72-5aef-4f5b-9deb-959dfcd4e224" xlink:to="loc_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_0ddde317-d379-4b06-8209-4065ee9cf7d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_ba56d976-68a3-49d0-9c6f-01d44881658a" xlink:href="amed-20200331.xsd#amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_77970f72-5aef-4f5b-9deb-959dfcd4e224" xlink:to="loc_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_ba56d976-68a3-49d0-9c6f-01d44881658a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_5101a886-91fa-499e-acfb-da29069f2e77" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_77970f72-5aef-4f5b-9deb-959dfcd4e224" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_5101a886-91fa-499e-acfb-da29069f2e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_9c14e591-10d0-44be-9eca-e64d31960190" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_77970f72-5aef-4f5b-9deb-959dfcd4e224" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_9c14e591-10d0-44be-9eca-e64d31960190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_a184f3f8-fbc6-4c56-93ac-bb740582c114" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_77970f72-5aef-4f5b-9deb-959dfcd4e224" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_a184f3f8-fbc6-4c56-93ac-bb740582c114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_63bf4f51-9c2b-4cfc-a537-f9fa88548e3d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_77970f72-5aef-4f5b-9deb-959dfcd4e224" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_63bf4f51-9c2b-4cfc-a537-f9fa88548e3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0702124a-f65f-4d64-81dc-2df8b2585403" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_77970f72-5aef-4f5b-9deb-959dfcd4e224" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0702124a-f65f-4d64-81dc-2df8b2585403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SurrenderedShares_aaae0202-eb3f-4aff-9436-eb0013fe661a" xlink:href="amed-20200331.xsd#amed_SurrenderedShares"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_77970f72-5aef-4f5b-9deb-959dfcd4e224" xlink:to="loc_amed_SurrenderedShares_aaae0202-eb3f-4aff-9436-eb0013fe661a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_2d1e2d91-f13f-496d-8e69-ceca84ddf344" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_77970f72-5aef-4f5b-9deb-959dfcd4e224" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_2d1e2d91-f13f-496d-8e69-ceca84ddf344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_a764f90b-d3cd-4a0a-a770-24b4c1510523" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_77970f72-5aef-4f5b-9deb-959dfcd4e224" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_a764f90b-d3cd-4a0a-a770-24b4c1510523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EquityImpactofRepurchaseofNoncontrollingInterest_8a7915c0-4940-421a-8e81-8981c8cd09c9" xlink:href="amed-20200331.xsd#amed_EquityImpactofRepurchaseofNoncontrollingInterest"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_77970f72-5aef-4f5b-9deb-959dfcd4e224" xlink:to="loc_amed_EquityImpactofRepurchaseofNoncontrollingInterest_8a7915c0-4940-421a-8e81-8981c8cd09c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome_1e7a5931-7c3c-4676-bded-9581c8069205" xlink:href="amed-20200331.xsd#amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_77970f72-5aef-4f5b-9deb-959dfcd4e224" xlink:to="loc_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome_1e7a5931-7c3c-4676-bded-9581c8069205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_0b795668-8a80-4b22-90aa-2308e9e30e37" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_77970f72-5aef-4f5b-9deb-959dfcd4e224" xlink:to="loc_us-gaap_ProfitLoss_0b795668-8a80-4b22-90aa-2308e9e30e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7b2cf370-ee9a-4a50-aa28-3fcb73beff57" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_77970f72-5aef-4f5b-9deb-959dfcd4e224" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7b2cf370-ee9a-4a50-aa28-3fcb73beff57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_66c8f4f9-a8ff-4cea-a030-cd719cc9b122" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_77970f72-5aef-4f5b-9deb-959dfcd4e224" xlink:to="loc_us-gaap_SharesOutstanding_66c8f4f9-a8ff-4cea-a030-cd719cc9b122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="amed-20200331.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_64e4e9c3-bdc2-465c-9eb3-a45ef2c884e1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4958e267-89ef-4062-87e4-701649c62066" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_64e4e9c3-bdc2-465c-9eb3-a45ef2c884e1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4958e267-89ef-4062-87e4-701649c62066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_5375ef4d-83e7-4a64-afd9-baa55ad96f14" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4958e267-89ef-4062-87e4-701649c62066" xlink:to="loc_us-gaap_ProfitLoss_5375ef4d-83e7-4a64-afd9-baa55ad96f14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0d2fcd6e-9940-4eba-9106-779b19f47262" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4958e267-89ef-4062-87e4-701649c62066" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0d2fcd6e-9940-4eba-9106-779b19f47262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_14760b04-8afc-45e9-8af7-9e80ff655bb9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0d2fcd6e-9940-4eba-9106-779b19f47262" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_14760b04-8afc-45e9-8af7-9e80ff655bb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_c1fba500-5b18-49fc-b18a-a31f49f9264e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0d2fcd6e-9940-4eba-9106-779b19f47262" xlink:to="loc_us-gaap_ShareBasedCompensation_c1fba500-5b18-49fc-b18a-a31f49f9264e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionExpense_eba4a7ee-c749-46bf-8868-f5c238ed303c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0d2fcd6e-9940-4eba-9106-779b19f47262" xlink:to="loc_us-gaap_PensionExpense_eba4a7ee-c749-46bf-8868-f5c238ed303c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset_c5f4d0de-325c-4dfd-b406-7c40b81f227b" xlink:href="amed-20200331.xsd#amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0d2fcd6e-9940-4eba-9106-779b19f47262" xlink:to="loc_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset_c5f4d0de-325c-4dfd-b406-7c40b81f227b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_d0af1e52-8bec-42ff-a5de-6e5dbb2128e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0d2fcd6e-9940-4eba-9106-779b19f47262" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_d0af1e52-8bec-42ff-a5de-6e5dbb2128e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_WriteOffOfOtherComprehensiveIncome_d156cb36-c4e2-4f5c-8688-1c10da81135d" xlink:href="amed-20200331.xsd#amed_WriteOffOfOtherComprehensiveIncome"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0d2fcd6e-9940-4eba-9106-779b19f47262" xlink:to="loc_amed_WriteOffOfOtherComprehensiveIncome_d156cb36-c4e2-4f5c-8688-1c10da81135d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_67ede16c-e0ce-4b5d-94bb-02ee0151cbc0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0d2fcd6e-9940-4eba-9106-779b19f47262" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_67ede16c-e0ce-4b5d-94bb-02ee0151cbc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_4f035912-f5cc-4181-b1f7-3e5352d294e8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0d2fcd6e-9940-4eba-9106-779b19f47262" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_4f035912-f5cc-4181-b1f7-3e5352d294e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_d00ffcdd-1707-4daa-b6a1-056939fb4eb8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0d2fcd6e-9940-4eba-9106-779b19f47262" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_d00ffcdd-1707-4daa-b6a1-056939fb4eb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_26950529-8ac2-4490-a465-c3d5185a8c01" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0d2fcd6e-9940-4eba-9106-779b19f47262" xlink:to="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_26950529-8ac2-4490-a465-c3d5185a8c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_3881a911-6a46-4379-aff5-2d2c4277b332" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0d2fcd6e-9940-4eba-9106-779b19f47262" xlink:to="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_3881a911-6a46-4379-aff5-2d2c4277b332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_09f77ffa-94ac-420f-9dc9-6fe4f8670bbf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0d2fcd6e-9940-4eba-9106-779b19f47262" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_09f77ffa-94ac-420f-9dc9-6fe4f8670bbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_858c47b9-e75d-4ed1-9a92-836f3fdcd035" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_09f77ffa-94ac-420f-9dc9-6fe4f8670bbf" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_858c47b9-e75d-4ed1-9a92-836f3fdcd035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_be3572cd-319b-42f6-a7bf-d852ed22dc6d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_09f77ffa-94ac-420f-9dc9-6fe4f8670bbf" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_be3572cd-319b-42f6-a7bf-d852ed22dc6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_a4fd9235-58b5-4bad-8be8-5e7a913d6a5d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_09f77ffa-94ac-420f-9dc9-6fe4f8670bbf" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_a4fd9235-58b5-4bad-8be8-5e7a913d6a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_fe26548b-0eac-462b-a84e-71433a56dddf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_09f77ffa-94ac-420f-9dc9-6fe4f8670bbf" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_fe26548b-0eac-462b-a84e-71433a56dddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_97795599-3368-4866-aed8-68dcac63835f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_09f77ffa-94ac-420f-9dc9-6fe4f8670bbf" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_97795599-3368-4866-aed8-68dcac63835f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_96ac7d2f-9673-45c8-982a-19236aa08f2b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_09f77ffa-94ac-420f-9dc9-6fe4f8670bbf" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_96ac7d2f-9673-45c8-982a-19236aa08f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncreaseDecreaseInOperatingLeaseLiability_70c2d351-beb6-4287-b290-83487541a119" xlink:href="amed-20200331.xsd#amed_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_09f77ffa-94ac-420f-9dc9-6fe4f8670bbf" xlink:to="loc_amed_IncreaseDecreaseInOperatingLeaseLiability_70c2d351-beb6-4287-b290-83487541a119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_c4b927f2-6858-40c0-9104-81536ed57a61" xlink:href="amed-20200331.xsd#amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_09f77ffa-94ac-420f-9dc9-6fe4f8670bbf" xlink:to="loc_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_c4b927f2-6858-40c0-9104-81536ed57a61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_15b2c517-ff3f-4218-a067-99b665ce54a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4958e267-89ef-4062-87e4-701649c62066" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_15b2c517-ff3f-4218-a067-99b665ce54a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d05ee7bb-20d4-4254-8caa-427d9ce7727b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_64e4e9c3-bdc2-465c-9eb3-a45ef2c884e1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d05ee7bb-20d4-4254-8caa-427d9ce7727b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments_084694ea-73ab-45d0-b29e-bad908b0f65b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfRestrictedInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d05ee7bb-20d4-4254-8caa-427d9ce7727b" xlink:to="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments_084694ea-73ab-45d0-b29e-bad908b0f65b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_56fbbbf4-b982-4177-9011-a5d5028e63ad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d05ee7bb-20d4-4254-8caa-427d9ce7727b" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_56fbbbf4-b982-4177-9011-a5d5028e63ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_952acad8-22db-4996-b9c3-6ee42903cc0f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d05ee7bb-20d4-4254-8caa-427d9ce7727b" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_952acad8-22db-4996-b9c3-6ee42903cc0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_507f19a4-98d9-4684-9ae5-78114119387a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d05ee7bb-20d4-4254-8caa-427d9ce7727b" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_507f19a4-98d9-4684-9ae5-78114119387a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_09e6b9a7-9aa6-49da-8b5a-0d4b09af553e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d05ee7bb-20d4-4254-8caa-427d9ce7727b" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_09e6b9a7-9aa6-49da-8b5a-0d4b09af553e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2e358bb2-b380-4b67-a614-158f4a5c479e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d05ee7bb-20d4-4254-8caa-427d9ce7727b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2e358bb2-b380-4b67-a614-158f4a5c479e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2aae800f-516e-4510-9c33-095bb449aef9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_64e4e9c3-bdc2-465c-9eb3-a45ef2c884e1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2aae800f-516e-4510-9c33-095bb449aef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_33c63758-36cb-435c-8c6a-25ef441b2bf6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2aae800f-516e-4510-9c33-095bb449aef9" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_33c63758-36cb-435c-8c6a-25ef441b2bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_10e22943-5d06-421c-b351-585c2657e50a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2aae800f-516e-4510-9c33-095bb449aef9" xlink:to="loc_us-gaap_ProceedsFromStockPlans_10e22943-5d06-421c-b351-585c2657e50a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_6bce4629-4fa7-4590-b40f-1ee25507cde4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2aae800f-516e-4510-9c33-095bb449aef9" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_6bce4629-4fa7-4590-b40f-1ee25507cde4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CashDistributionToNoncontrollingInterest_26edc21d-ff55-462e-9afd-70352f6ae087" xlink:href="amed-20200331.xsd#amed_CashDistributionToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2aae800f-516e-4510-9c33-095bb449aef9" xlink:to="loc_amed_CashDistributionToNoncontrollingInterest_26edc21d-ff55-462e-9afd-70352f6ae087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProceedsFromBorrowingsUnderTermLoan_bf8e54f7-b14f-4384-abc0-0ea211124c74" xlink:href="amed-20200331.xsd#amed_ProceedsFromBorrowingsUnderTermLoan"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2aae800f-516e-4510-9c33-095bb449aef9" xlink:to="loc_amed_ProceedsFromBorrowingsUnderTermLoan_bf8e54f7-b14f-4384-abc0-0ea211124c74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_08712ea0-8168-46e2-b645-df8a55baf754" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2aae800f-516e-4510-9c33-095bb449aef9" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_08712ea0-8168-46e2-b645-df8a55baf754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_4e3e3833-9376-4c1f-af83-ad2d95cdd619" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2aae800f-516e-4510-9c33-095bb449aef9" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_4e3e3833-9376-4c1f-af83-ad2d95cdd619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_4f3572a8-7d32-4dae-a563-f3d9a28c1b16" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2aae800f-516e-4510-9c33-095bb449aef9" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_4f3572a8-7d32-4dae-a563-f3d9a28c1b16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_9b29795d-1483-4e82-9e3a-ba726f03da1b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2aae800f-516e-4510-9c33-095bb449aef9" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_9b29795d-1483-4e82-9e3a-ba726f03da1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_4cd48fa3-8236-4e44-81c5-2496cbfff28f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2aae800f-516e-4510-9c33-095bb449aef9" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_4cd48fa3-8236-4e44-81c5-2496cbfff28f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PaymentsForRepurchaseOfNoncontrollingInterest_d1df8a2b-1740-445c-aeb2-80e1f088feed" xlink:href="amed-20200331.xsd#amed_PaymentsForRepurchaseOfNoncontrollingInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2aae800f-516e-4510-9c33-095bb449aef9" xlink:to="loc_amed_PaymentsForRepurchaseOfNoncontrollingInterest_d1df8a2b-1740-445c-aeb2-80e1f088feed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_81365c28-9ff6-454c-b4a5-c51efa8123fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2aae800f-516e-4510-9c33-095bb449aef9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_81365c28-9ff6-454c-b4a5-c51efa8123fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_cf6fb7de-7553-416b-ad6f-0983b58ed21a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_64e4e9c3-bdc2-465c-9eb3-a45ef2c884e1" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_cf6fb7de-7553-416b-ad6f-0983b58ed21a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bfdccf23-cdae-4689-9af1-5bef4fe2935d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_64e4e9c3-bdc2-465c-9eb3-a45ef2c884e1" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bfdccf23-cdae-4689-9af1-5bef4fe2935d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d4edd449-27c7-45b3-ad8c-27d0d2ca14d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_64e4e9c3-bdc2-465c-9eb3-a45ef2c884e1" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d4edd449-27c7-45b3-ad8c-27d0d2ca14d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_9f3cd790-3295-4fdb-b9d0-34a11554f5b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_64e4e9c3-bdc2-465c-9eb3-a45ef2c884e1" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_9f3cd790-3295-4fdb-b9d0-34a11554f5b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_de1b014a-5fb2-4d3d-afc7-30664ae9b002" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_9f3cd790-3295-4fdb-b9d0-34a11554f5b5" xlink:to="loc_us-gaap_InterestPaidNet_de1b014a-5fb2-4d3d-afc7-30664ae9b002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_fed12227-593c-4c2b-8593-0d4b74642959" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_9f3cd790-3295-4fdb-b9d0-34a11554f5b5" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_fed12227-593c-4c2b-8593-0d4b74642959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CashPaidForOperatingLeaseLiabilities_0cad7ed8-4f89-4d1a-b7fb-4e115813c314" xlink:href="amed-20200331.xsd#amed_CashPaidForOperatingLeaseLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_9f3cd790-3295-4fdb-b9d0-34a11554f5b5" xlink:to="loc_amed_CashPaidForOperatingLeaseLiabilities_0cad7ed8-4f89-4d1a-b7fb-4e115813c314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CashPaidForFinanceLeaseLiabilities_d044f1c6-6db7-4bd5-bbd6-3fde74a07ac3" xlink:href="amed-20200331.xsd#amed_CashPaidForFinanceLeaseLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_9f3cd790-3295-4fdb-b9d0-34a11554f5b5" xlink:to="loc_amed_CashPaidForFinanceLeaseLiabilities_d044f1c6-6db7-4bd5-bbd6-3fde74a07ac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SupplementalDisclosuresOfNonCashActivityAbstract_9b4c7fda-b6cc-4269-b6ea-891f141842c8" xlink:href="amed-20200331.xsd#amed_SupplementalDisclosuresOfNonCashActivityAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_64e4e9c3-bdc2-465c-9eb3-a45ef2c884e1" xlink:to="loc_amed_SupplementalDisclosuresOfNonCashActivityAbstract_9b4c7fda-b6cc-4269-b6ea-891f141842c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_58e1f690-08e8-4abd-8535-073bdd6079e1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_SupplementalDisclosuresOfNonCashActivityAbstract_9b4c7fda-b6cc-4269-b6ea-891f141842c8" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_58e1f690-08e8-4abd-8535-073bdd6079e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_f16cfda0-37b4-4920-b466-f5eca659c9ce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_SupplementalDisclosuresOfNonCashActivityAbstract_9b4c7fda-b6cc-4269-b6ea-891f141842c8" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_f16cfda0-37b4-4920-b466-f5eca659c9ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations_c78c9abf-1507-4421-9126-5260a411fa3e" xlink:href="amed-20200331.xsd#amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_SupplementalDisclosuresOfNonCashActivityAbstract_9b4c7fda-b6cc-4269-b6ea-891f141842c8" xlink:to="loc_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations_c78c9abf-1507-4421-9126-5260a411fa3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS" xlink:type="simple" xlink:href="amed-20200331.xsd#NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2b707473-3e3c-4d17-9307-7699cf4c018f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_9b483f7c-80ca-43f2-940e-12e8afc01050" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2b707473-3e3c-4d17-9307-7699cf4c018f" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_9b483f7c-80ca-43f2-940e-12e8afc01050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails" xlink:type="simple" xlink:href="amed-20200331.xsd#NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f0dee150-43b9-4c50-95ea-e9aa9f92c2bb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_ea90521f-1777-4463-a672-be39eeeb3f94" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f0dee150-43b9-4c50-95ea-e9aa9f92c2bb" xlink:to="loc_us-gaap_ConcentrationRiskTable_ea90521f-1777-4463-a672-be39eeeb3f94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_4c3347a2-f93c-47e5-9a93-aae171d20f30" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_ea90521f-1777-4463-a672-be39eeeb3f94" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_4c3347a2-f93c-47e5-9a93-aae171d20f30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_60dec81f-3495-4a18-aa79-923cc06e4f91" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_4c3347a2-f93c-47e5-9a93-aae171d20f30" xlink:to="loc_us-gaap_TypeOfAdoptionMember_60dec81f-3495-4a18-aa79-923cc06e4f91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_45abc9ee-35b4-4449-b34a-fd305818f163" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_60dec81f-3495-4a18-aa79-923cc06e4f91" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_45abc9ee-35b4-4449-b34a-fd305818f163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TypeofEquityMethodInvestmentAxis_dfcf5edf-44c4-4cb2-8254-12a4548031f2" xlink:href="amed-20200331.xsd#amed_TypeofEquityMethodInvestmentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_ea90521f-1777-4463-a672-be39eeeb3f94" xlink:to="loc_amed_TypeofEquityMethodInvestmentAxis_dfcf5edf-44c4-4cb2-8254-12a4548031f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TypeofEquityMethodInvestmentDomain_3d67e6fa-d1a7-4f17-b4af-8aeab3b86e53" xlink:href="amed-20200331.xsd#amed_TypeofEquityMethodInvestmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_TypeofEquityMethodInvestmentAxis_dfcf5edf-44c4-4cb2-8254-12a4548031f2" xlink:to="loc_amed_TypeofEquityMethodInvestmentDomain_3d67e6fa-d1a7-4f17-b4af-8aeab3b86e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HealthcareanalyticscompanyMember_c38d2798-babc-496e-8300-bde78a0b2e2f" xlink:href="amed-20200331.xsd#amed_HealthcareanalyticscompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_TypeofEquityMethodInvestmentDomain_3d67e6fa-d1a7-4f17-b4af-8aeab3b86e53" xlink:to="loc_amed_HealthcareanalyticscompanyMember_c38d2798-babc-496e-8300-bde78a0b2e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a9e393d7-0778-46fa-ac19-b9f6a8fb4080" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_ea90521f-1777-4463-a672-be39eeeb3f94" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a9e393d7-0778-46fa-ac19-b9f6a8fb4080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_914d1926-54e3-431f-b1c8-98a08ca9cfd9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a9e393d7-0778-46fa-ac19-b9f6a8fb4080" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_914d1926-54e3-431f-b1c8-98a08ca9cfd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_7bad22a1-f9b2-43be-8ac2-df0c6102a93c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_914d1926-54e3-431f-b1c8-98a08ca9cfd9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_7bad22a1-f9b2-43be-8ac2-df0c6102a93c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_8f984057-6a4c-426c-b6df-e7b1b2f3772e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_ea90521f-1777-4463-a672-be39eeeb3f94" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_8f984057-6a4c-426c-b6df-e7b1b2f3772e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_6f1eff7c-73c1-4da1-b926-e2bf7b2f545b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_8f984057-6a4c-426c-b6df-e7b1b2f3772e" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_6f1eff7c-73c1-4da1-b926-e2bf7b2f545b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareRevenueMember_b6bb20b9-8aa8-4b52-b64f-92f050babe38" xlink:href="amed-20200331.xsd#amed_MedicareRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_6f1eff7c-73c1-4da1-b926-e2bf7b2f545b" xlink:to="loc_amed_MedicareRevenueMember_b6bb20b9-8aa8-4b52-b64f-92f050babe38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_d1084460-f630-4864-8711-b901470a88c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_ea90521f-1777-4463-a672-be39eeeb3f94" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_d1084460-f630-4864-8711-b901470a88c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_6e294063-5b31-4f54-8579-5d6ee566053d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d1084460-f630-4864-8711-b901470a88c0" xlink:to="loc_us-gaap_SegmentDomain_6e294063-5b31-4f54-8579-5d6ee566053d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_95b4ee13-63e1-4207-a075-6ff60ab857ef" xlink:href="amed-20200331.xsd#amed_HomeHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_6e294063-5b31-4f54-8579-5d6ee566053d" xlink:to="loc_amed_HomeHealthMember_95b4ee13-63e1-4207-a075-6ff60ab857ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_f940d7c9-546f-49c4-b5ee-086fa782d401" xlink:href="amed-20200331.xsd#amed_HospiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_6e294063-5b31-4f54-8579-5d6ee566053d" xlink:to="loc_amed_HospiceMember_f940d7c9-546f-49c4-b5ee-086fa782d401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_5584e534-4789-48bc-a000-39922cd19da5" xlink:href="amed-20200331.xsd#amed_PersonalCareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_6e294063-5b31-4f54-8579-5d6ee566053d" xlink:to="loc_amed_PersonalCareMember_5584e534-4789-48bc-a000-39922cd19da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_b90a3323-2057-45b4-90f8-3dd025e5f6fe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_ea90521f-1777-4463-a672-be39eeeb3f94" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_b90a3323-2057-45b4-90f8-3dd025e5f6fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_8c907bd8-ad67-4035-947b-34960728b5e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_b90a3323-2057-45b4-90f8-3dd025e5f6fe" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_8c907bd8-ad67-4035-947b-34960728b5e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OperatingCareCenters_db27d672-9a9b-4fe8-b574-678c1ca0f4f1" xlink:href="amed-20200331.xsd#amed_OperatingCareCenters"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_b90a3323-2057-45b4-90f8-3dd025e5f6fe" xlink:to="loc_amed_OperatingCareCenters_db27d672-9a9b-4fe8-b574-678c1ca0f4f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates_533d6270-5ede-4ac8-94d4-e01bb010929e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_b90a3323-2057-45b4-90f8-3dd025e5f6fe" xlink:to="loc_us-gaap_NumberOfStatesInWhichEntityOperates_533d6270-5ede-4ac8-94d4-e01bb010929e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MinimumPercentOwnershipForControllingInterestPercent_f09c01ab-6bee-4e81-8f84-b5a8c59d15f2" xlink:href="amed-20200331.xsd#amed_MinimumPercentOwnershipForControllingInterestPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_b90a3323-2057-45b4-90f8-3dd025e5f6fe" xlink:to="loc_amed_MinimumPercentOwnershipForControllingInterestPercent_f09c01ab-6bee-4e81-8f84-b5a8c59d15f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumPercentOwnershipForEquityMethodPercent_05ccc7ed-e2a1-4521-b161-b0448a235f7b" xlink:href="amed-20200331.xsd#amed_MaximumPercentOwnershipForEquityMethodPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_b90a3323-2057-45b4-90f8-3dd025e5f6fe" xlink:to="loc_amed_MaximumPercentOwnershipForEquityMethodPercent_05ccc7ed-e2a1-4521-b161-b0448a235f7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_65ae5e22-186f-45b0-aa15-6e7011720ce7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_b90a3323-2057-45b4-90f8-3dd025e5f6fe" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_65ae5e22-186f-45b0-aa15-6e7011720ce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumPercentOwnershipForCostMethodPercent_1a1f49e9-7deb-4661-a6d9-cdc16fb34430" xlink:href="amed-20200331.xsd#amed_MaximumPercentOwnershipForCostMethodPercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_b90a3323-2057-45b4-90f8-3dd025e5f6fe" xlink:to="loc_amed_MaximumPercentOwnershipForCostMethodPercent_1a1f49e9-7deb-4661-a6d9-cdc16fb34430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="amed-20200331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4bfe6a12-d6de-4c59-b7dc-a84e7bdd9381" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_fbf1fa29-6db8-4919-a01f-0629b8718c4f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4bfe6a12-d6de-4c59-b7dc-a84e7bdd9381" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_fbf1fa29-6db8-4919-a01f-0629b8718c4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="amed-20200331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c72f4c02-b32c-4955-b995-c1a3326d4e04" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_7173bbf6-6ed9-4943-aa59-4672f36d6986" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c72f4c02-b32c-4955-b995-c1a3326d4e04" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_7173bbf6-6ed9-4943-aa59-4672f36d6986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_50f8ff88-ce98-4157-9d6d-de196fc9d1b7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c72f4c02-b32c-4955-b995-c1a3326d4e04" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_50f8ff88-ce98-4157-9d6d-de196fc9d1b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_2a0569cb-f5d2-41f6-8aa0-db28e41c99d7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c72f4c02-b32c-4955-b995-c1a3326d4e04" xlink:to="loc_us-gaap_UseOfEstimates_2a0569cb-f5d2-41f6-8aa0-db28e41c99d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_f73a56aa-727a-4ac5-a7f0-bbd0569431d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c72f4c02-b32c-4955-b995-c1a3326d4e04" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_f73a56aa-727a-4ac5-a7f0-bbd0569431d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAndCostMethodInvestmentsPolicy_9b709fb8-1b4c-42a7-ba8e-a5176ad40387" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAndCostMethodInvestmentsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c72f4c02-b32c-4955-b995-c1a3326d4e04" xlink:to="loc_us-gaap_EquityAndCostMethodInvestmentsPolicy_9b709fb8-1b4c-42a7-ba8e-a5176ad40387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_def0aa0a-a6cd-4c75-a17f-a128f4118837" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c72f4c02-b32c-4955-b995-c1a3326d4e04" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_def0aa0a-a6cd-4c75-a17f-a128f4118837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_861ec4be-6ccc-4eee-b363-4afa426023fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c72f4c02-b32c-4955-b995-c1a3326d4e04" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_861ec4be-6ccc-4eee-b363-4afa426023fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_20dc6a91-acc4-483f-8b50-2e124b400533" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c72f4c02-b32c-4955-b995-c1a3326d4e04" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_20dc6a91-acc4-483f-8b50-2e124b400533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtIssuanceCostsPolicyPolicyTextBlock_bb3b83d8-a392-4dea-91fe-02d681d60ea3" xlink:href="amed-20200331.xsd#amed_DebtIssuanceCostsPolicyPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c72f4c02-b32c-4955-b995-c1a3326d4e04" xlink:to="loc_amed_DebtIssuanceCostsPolicyPolicyTextBlock_bb3b83d8-a392-4dea-91fe-02d681d60ea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_eb24283c-2090-4d90-985e-b2069bad71ec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c72f4c02-b32c-4955-b995-c1a3326d4e04" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_eb24283c-2090-4d90-985e-b2069bad71ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_2e9e9b85-d799-4153-8413-4ab156cf73e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c72f4c02-b32c-4955-b995-c1a3326d4e04" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_2e9e9b85-d799-4153-8413-4ab156cf73e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_d633216c-72b3-4dd4-a468-5d9439bf1a12" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c72f4c02-b32c-4955-b995-c1a3326d4e04" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_d633216c-72b3-4dd4-a468-5d9439bf1a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="simple" xlink:href="amed-20200331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_aa5a7702-5476-4746-949e-3ca84d75f10d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock_384e4b80-83e2-4842-b20d-b2413b2325df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aa5a7702-5476-4746-949e-3ca84d75f10d" xlink:to="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock_384e4b80-83e2-4842-b20d-b2413b2325df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FinancialInstrumentDetailsTableTextBlock_b131ed21-a83b-497e-9856-2e384970ef13" xlink:href="amed-20200331.xsd#amed_FinancialInstrumentDetailsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aa5a7702-5476-4746-949e-3ca84d75f10d" xlink:to="loc_amed_FinancialInstrumentDetailsTableTextBlock_b131ed21-a83b-497e-9856-2e384970ef13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_9222bbf5-65f9-4cca-afd9-82d1562d8210" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aa5a7702-5476-4746-949e-3ca84d75f10d" xlink:to="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_9222bbf5-65f9-4cca-afd9-82d1562d8210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" xlink:type="simple" xlink:href="amed-20200331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_90c96b76-c591-43c8-9779-5376d9a52a07" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_82487f1b-14ce-496b-b340-ff1c7877c068" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_90c96b76-c591-43c8-9779-5376d9a52a07" xlink:to="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_82487f1b-14ce-496b-b340-ff1c7877c068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_727f579d-c539-42ae-b228-a9c07f16c9d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_82487f1b-14ce-496b-b340-ff1c7877c068" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_727f579d-c539-42ae-b228-a9c07f16c9d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_17362bd1-96a3-4c84-96ef-30f03a5278d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_727f579d-c539-42ae-b228-a9c07f16c9d0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_17362bd1-96a3-4c84-96ef-30f03a5278d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompassionateCareHospiceMember_78cde2cc-8018-4218-ba2b-26334bb8f1d9" xlink:href="amed-20200331.xsd#amed_CompassionateCareHospiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_17362bd1-96a3-4c84-96ef-30f03a5278d3" xlink:to="loc_amed_CompassionateCareHospiceMember_78cde2cc-8018-4218-ba2b-26334bb8f1d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_c092e137-e086-4b5b-bbe5-d08697687a38" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_82487f1b-14ce-496b-b340-ff1c7877c068" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_c092e137-e086-4b5b-bbe5-d08697687a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_70c5e50e-7b68-4c03-a057-353c958e46da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_c092e137-e086-4b5b-bbe5-d08697687a38" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_70c5e50e-7b68-4c03-a057-353c958e46da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareRevenueMember_07d95de9-94da-490a-90a7-ed69fc9c6dce" xlink:href="amed-20200331.xsd#amed_MedicareRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_70c5e50e-7b68-4c03-a057-353c958e46da" xlink:to="loc_amed_MedicareRevenueMember_07d95de9-94da-490a-90a7-ed69fc9c6dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7ff4c4ab-01a5-4329-84ce-b837d880f382" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_82487f1b-14ce-496b-b340-ff1c7877c068" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7ff4c4ab-01a5-4329-84ce-b837d880f382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8c328af8-bbfa-4acf-bc76-9b91549770ef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7ff4c4ab-01a5-4329-84ce-b837d880f382" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8c328af8-bbfa-4acf-bc76-9b91549770ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_cd2057af-65ac-4b3f-82fd-10affabba281" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8c328af8-bbfa-4acf-bc76-9b91549770ef" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_cd2057af-65ac-4b3f-82fd-10affabba281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearAxis_579620d3-26ae-460f-8049-4956fa14a162" xlink:href="amed-20200331.xsd#amed_CapYearAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_82487f1b-14ce-496b-b340-ff1c7877c068" xlink:to="loc_amed_CapYearAxis_579620d3-26ae-460f-8049-4956fa14a162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearDomain_033bf732-8bee-4870-af96-032ee282722d" xlink:href="amed-20200331.xsd#amed_CapYearDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_CapYearAxis_579620d3-26ae-460f-8049-4956fa14a162" xlink:to="loc_amed_CapYearDomain_033bf732-8bee-4870-af96-032ee282722d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearTwoThousandThirteenThroughTwoThousandTwentyMember_8152b8cc-0931-4e51-bc03-8fb8c736fb3e" xlink:href="amed-20200331.xsd#amed_CapYearTwoThousandThirteenThroughTwoThousandTwentyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_CapYearDomain_033bf732-8bee-4870-af96-032ee282722d" xlink:to="loc_amed_CapYearTwoThousandThirteenThroughTwoThousandTwentyMember_8152b8cc-0931-4e51-bc03-8fb8c736fb3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_cb9beed4-c2e0-413b-9352-c1d08409879d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_82487f1b-14ce-496b-b340-ff1c7877c068" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_cb9beed4-c2e0-413b-9352-c1d08409879d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_0cfae0eb-8b10-40b6-bf4b-19928909d068" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_cb9beed4-c2e0-413b-9352-c1d08409879d" xlink:to="loc_us-gaap_SegmentDomain_0cfae0eb-8b10-40b6-bf4b-19928909d068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_6bdc4e52-a4ac-49b1-9684-d44bb28eff48" xlink:href="amed-20200331.xsd#amed_HomeHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_0cfae0eb-8b10-40b6-bf4b-19928909d068" xlink:to="loc_amed_HomeHealthMember_6bdc4e52-a4ac-49b1-9684-d44bb28eff48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_6455b270-9d55-475d-8159-9d7c45de46bd" xlink:href="amed-20200331.xsd#amed_HospiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_0cfae0eb-8b10-40b6-bf4b-19928909d068" xlink:to="loc_amed_HospiceMember_6455b270-9d55-475d-8159-9d7c45de46bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_04b9d437-711e-410a-98f2-11cfefa995ff" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_82487f1b-14ce-496b-b340-ff1c7877c068" xlink:to="loc_srt_RangeAxis_04b9d437-711e-410a-98f2-11cfefa995ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_992a84af-dc68-4b23-bb94-edb5681e23c6" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_04b9d437-711e-410a-98f2-11cfefa995ff" xlink:to="loc_srt_RangeMember_992a84af-dc68-4b23-bb94-edb5681e23c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_782946b6-89c7-4011-81dc-7450eb67e5c3" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_992a84af-dc68-4b23-bb94-edb5681e23c6" xlink:to="loc_srt_MinimumMember_782946b6-89c7-4011-81dc-7450eb67e5c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e58cbb7c-da88-404c-8263-c0b2f4d45d3a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_992a84af-dc68-4b23-bb94-edb5681e23c6" xlink:to="loc_srt_MaximumMember_e58cbb7c-da88-404c-8263-c0b2f4d45d3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_bc8b7045-452f-411c-a66a-9a5f39aaec6e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_82487f1b-14ce-496b-b340-ff1c7877c068" xlink:to="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_bc8b7045-452f-411c-a66a-9a5f39aaec6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_6f2e3eb9-347a-476e-837c-31dd04afea16" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_bc8b7045-452f-411c-a66a-9a5f39aaec6e" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_6f2e3eb9-347a-476e-837c-31dd04afea16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration_c9148145-8a92-4b9b-a874-862a0f76778e" xlink:href="amed-20200331.xsd#amed_EpisodeOfCareAsEpisodicBasedRevenueDuration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_bc8b7045-452f-411c-a66a-9a5f39aaec6e" xlink:to="loc_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration_c9148145-8a92-4b9b-a874-862a0f76778e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_66711c13-bded-4b50-9d07-9fe08f4f8ccc" xlink:href="amed-20200331.xsd#amed_NetServiceRevenuePeriodOfCarePaymentRateDuration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_bc8b7045-452f-411c-a66a-9a5f39aaec6e" xlink:to="loc_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_66711c13-bded-4b50-9d07-9fe08f4f8ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PeriodOfCareAsEpisodicBasedRevenueDuration_43a5e323-562f-48d1-b795-0f5a3aad798b" xlink:href="amed-20200331.xsd#amed_PeriodOfCareAsEpisodicBasedRevenueDuration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_bc8b7045-452f-411c-a66a-9a5f39aaec6e" xlink:to="loc_amed_PeriodOfCareAsEpisodicBasedRevenueDuration_43a5e323-562f-48d1-b795-0f5a3aad798b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfTotalReimbursementOfOutlierPayment_5c4ddb6c-cd57-42c7-aafa-fce34ff55d03" xlink:href="amed-20200331.xsd#amed_PercentageOfTotalReimbursementOfOutlierPayment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_bc8b7045-452f-411c-a66a-9a5f39aaec6e" xlink:to="loc_amed_PercentageOfTotalReimbursementOfOutlierPayment_5c4ddb6c-cd57-42c7-aafa-fce34ff55d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_1081a6cf-30de-4b07-a373-81c337048561" xlink:href="amed-20200331.xsd#amed_LowUtilizationPaymentAdjustmentNumberOfVisits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_bc8b7045-452f-411c-a66a-9a5f39aaec6e" xlink:to="loc_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_1081a6cf-30de-4b07-a373-81c337048561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FirstThresholdOfTherapyServicesRequired_9d77af5a-6ca6-4fbc-b18f-f0cc998ba967" xlink:href="amed-20200331.xsd#amed_FirstThresholdOfTherapyServicesRequired"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_bc8b7045-452f-411c-a66a-9a5f39aaec6e" xlink:to="loc_amed_FirstThresholdOfTherapyServicesRequired_9d77af5a-6ca6-4fbc-b18f-f0cc998ba967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecondThresholdOfServicesRequired_51062a56-a146-4fd5-878e-c4d981ae7d21" xlink:href="amed-20200331.xsd#amed_SecondThresholdOfServicesRequired"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_bc8b7045-452f-411c-a66a-9a5f39aaec6e" xlink:to="loc_amed_SecondThresholdOfServicesRequired_51062a56-a146-4fd5-878e-c4d981ae7d21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ThirdThresholdOfTherapyServicesRequired_90fa010d-16a3-443d-89ab-1b18e660b89d" xlink:href="amed-20200331.xsd#amed_ThirdThresholdOfTherapyServicesRequired"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_bc8b7045-452f-411c-a66a-9a5f39aaec6e" xlink:to="loc_amed_ThirdThresholdOfTherapyServicesRequired_90fa010d-16a3-443d-89ab-1b18e660b89d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HistoricalCollectionRateFromMedicare_876ba7ba-20ac-4b80-8684-c136f9285919" xlink:href="amed-20200331.xsd#amed_HistoricalCollectionRateFromMedicare"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_bc8b7045-452f-411c-a66a-9a5f39aaec6e" xlink:to="loc_amed_HistoricalCollectionRateFromMedicare_876ba7ba-20ac-4b80-8684-c136f9285919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonMedicareRevenueTermRates_1b048d27-c5a6-4717-b8e1-25b6d22d5a46" xlink:href="amed-20200331.xsd#amed_NonMedicareRevenueTermRates"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_bc8b7045-452f-411c-a66a-9a5f39aaec6e" xlink:to="loc_amed_NonMedicareRevenueTermRates_1b048d27-c5a6-4717-b8e1-25b6d22d5a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_d9ac1c12-8e94-4411-83bf-4508622fa571" xlink:href="amed-20200331.xsd#amed_HospiceMedicareRevenueRateAccountedForRoutineCare"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_bc8b7045-452f-411c-a66a-9a5f39aaec6e" xlink:to="loc_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_d9ac1c12-8e94-4411-83bf-4508622fa571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_5026f9be-1140-44b3-a68a-8b68669788e9" xlink:href="amed-20200331.xsd#amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_bc8b7045-452f-411c-a66a-9a5f39aaec6e" xlink:to="loc_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_5026f9be-1140-44b3-a68a-8b68669788e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails" xlink:type="simple" xlink:href="amed-20200331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_1646df7e-e4c8-4269-a86e-b7bc511e9fb5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_8115d5d8-e655-4171-b7bd-6c6880573951" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_1646df7e-e4c8-4269-a86e-b7bc511e9fb5" xlink:to="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_8115d5d8-e655-4171-b7bd-6c6880573951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorClassAxis_fccc1ad0-9c6e-4b51-be1f-7274c832cf5f" xlink:href="amed-20200331.xsd#amed_PayorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_8115d5d8-e655-4171-b7bd-6c6880573951" xlink:to="loc_amed_PayorClassAxis_fccc1ad0-9c6e-4b51-be1f-7274c832cf5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorClassDomain_85c8612f-b962-4287-838e-21708003cd50" xlink:href="amed-20200331.xsd#amed_PayorClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorClassAxis_fccc1ad0-9c6e-4b51-be1f-7274c832cf5f" xlink:to="loc_amed_PayorClassDomain_85c8612f-b962-4287-838e-21708003cd50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMedicareMember_9e690ad6-f91e-4ce1-b75c-4534dc0f7d8e" xlink:href="amed-20200331.xsd#amed_HomeHealthMedicareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorClassDomain_85c8612f-b962-4287-838e-21708003cd50" xlink:to="loc_amed_HomeHealthMedicareMember_9e690ad6-f91e-4ce1-b75c-4534dc0f7d8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthNonMedicareEpisodicBasedMember_64f001ab-f80e-47a9-8dad-f6f2d689876a" xlink:href="amed-20200331.xsd#amed_HomeHealthNonMedicareEpisodicBasedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorClassDomain_85c8612f-b962-4287-838e-21708003cd50" xlink:to="loc_amed_HomeHealthNonMedicareEpisodicBasedMember_64f001ab-f80e-47a9-8dad-f6f2d689876a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthNonMedicareNonEpisodicBasedMember_9f834efd-387d-4daf-be0a-a05f4ee01da7" xlink:href="amed-20200331.xsd#amed_HomeHealthNonMedicareNonEpisodicBasedMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorClassDomain_85c8612f-b962-4287-838e-21708003cd50" xlink:to="loc_amed_HomeHealthNonMedicareNonEpisodicBasedMember_9f834efd-387d-4daf-be0a-a05f4ee01da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMedicareMember_1702b1dc-46ca-47de-8d28-e1e5c78957f3" xlink:href="amed-20200331.xsd#amed_HospiceMedicareMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorClassDomain_85c8612f-b962-4287-838e-21708003cd50" xlink:to="loc_amed_HospiceMedicareMember_1702b1dc-46ca-47de-8d28-e1e5c78957f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceNonMedicareMember_70cb587e-9593-4210-8416-d058b05b93f0" xlink:href="amed-20200331.xsd#amed_HospiceNonMedicareMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorClassDomain_85c8612f-b962-4287-838e-21708003cd50" xlink:to="loc_amed_HospiceNonMedicareMember_70cb587e-9593-4210-8416-d058b05b93f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_35ec1827-4d45-4557-a702-741a85f46e3a" xlink:href="amed-20200331.xsd#amed_PersonalCareMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorClassDomain_85c8612f-b962-4287-838e-21708003cd50" xlink:to="loc_amed_PersonalCareMember_35ec1827-4d45-4557-a702-741a85f46e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_29f461ee-783d-482b-9daf-aa719862882c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_8115d5d8-e655-4171-b7bd-6c6880573951" xlink:to="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_29f461ee-783d-482b-9daf-aa719862882c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue_4b14acef-d0bd-4531-9cc7-4b41868c2075" xlink:href="amed-20200331.xsd#amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_29f461ee-783d-482b-9daf-aa719862882c" xlink:to="loc_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue_4b14acef-d0bd-4531-9cc7-4b41868c2075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails" xlink:type="simple" xlink:href="amed-20200331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3a514c59-ea1c-43d0-8657-c947e6789d9d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_475a40cd-f5c3-4b7a-8100-dfab2d10cebd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3a514c59-ea1c-43d0-8657-c947e6789d9d" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_475a40cd-f5c3-4b7a-8100-dfab2d10cebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_148b1abe-bc50-4ff5-9f5a-d33fdc91f243" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_475a40cd-f5c3-4b7a-8100-dfab2d10cebd" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_148b1abe-bc50-4ff5-9f5a-d33fdc91f243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c3b3523e-7322-4f13-858a-370e405496d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_148b1abe-bc50-4ff5-9f5a-d33fdc91f243" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c3b3523e-7322-4f13-858a-370e405496d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AsanaHospiceAquisitionMember_69969b3c-c213-4cd8-9dca-e0346923b3ce" xlink:href="amed-20200331.xsd#amed_AsanaHospiceAquisitionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c3b3523e-7322-4f13-858a-370e405496d2" xlink:to="loc_amed_AsanaHospiceAquisitionMember_69969b3c-c213-4cd8-9dca-e0346923b3ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_COVID19PPEMember_33914e05-c74e-4d0c-87e3-ac1590a73f30" xlink:href="amed-20200331.xsd#amed_COVID19PPEMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c3b3523e-7322-4f13-858a-370e405496d2" xlink:to="loc_amed_COVID19PPEMember_33914e05-c74e-4d0c-87e3-ac1590a73f30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_29951e92-dec9-4817-91c2-e231f0e70534" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_475a40cd-f5c3-4b7a-8100-dfab2d10cebd" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_29951e92-dec9-4817-91c2-e231f0e70534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_21c9fef3-25d3-4c50-9aa6-68ff38b3075a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_29951e92-dec9-4817-91c2-e231f0e70534" xlink:to="loc_us-gaap_RestrictedCash_21c9fef3-25d3-4c50-9aa6-68ff38b3075a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails" xlink:type="simple" xlink:href="amed-20200331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_69d97d0f-e077-470c-b77f-92d3fcbe45a7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_5b22c8b0-0483-4581-93f3-7146433a8e25" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_69d97d0f-e077-470c-b77f-92d3fcbe45a7" xlink:to="loc_us-gaap_ConcentrationRiskTable_5b22c8b0-0483-4581-93f3-7146433a8e25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_368cc8af-1ec2-486a-a247-876252f5d0e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_5b22c8b0-0483-4581-93f3-7146433a8e25" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_368cc8af-1ec2-486a-a247-876252f5d0e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_857f260a-505e-44cb-8c60-100d5562b062" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_368cc8af-1ec2-486a-a247-876252f5d0e2" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_857f260a-505e-44cb-8c60-100d5562b062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_919e531b-26f0-4579-bc70-1e39cbdf35ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_857f260a-505e-44cb-8c60-100d5562b062" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_919e531b-26f0-4579-bc70-1e39cbdf35ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_59a99c4d-29c9-4ed4-8189-8421f68acbcd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_5b22c8b0-0483-4581-93f3-7146433a8e25" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_59a99c4d-29c9-4ed4-8189-8421f68acbcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6a392f91-a973-4890-8df3-b84e6338a953" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_59a99c4d-29c9-4ed4-8189-8421f68acbcd" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6a392f91-a973-4890-8df3-b84e6338a953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_0e84b157-b5fa-4528-a3b0-1f52be0aca62" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6a392f91-a973-4890-8df3-b84e6338a953" xlink:to="loc_us-gaap_AccountsReceivableMember_0e84b157-b5fa-4528-a3b0-1f52be0aca62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_1a891239-9457-41b9-b585-bb4a028b8a0c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_5b22c8b0-0483-4581-93f3-7146433a8e25" xlink:to="loc_srt_MajorCustomersAxis_1a891239-9457-41b9-b585-bb4a028b8a0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_06a58b73-67d4-4883-bca9-b58f368c67d5" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_1a891239-9457-41b9-b585-bb4a028b8a0c" xlink:to="loc_srt_NameOfMajorCustomerDomain_06a58b73-67d4-4883-bca9-b58f368c67d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MajorSinglePayorCustomerMember_53fc71f8-4900-4c8e-92c5-6c5db294f255" xlink:href="amed-20200331.xsd#amed_MajorSinglePayorCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_06a58b73-67d4-4883-bca9-b58f368c67d5" xlink:to="loc_amed_MajorSinglePayorCustomerMember_53fc71f8-4900-4c8e-92c5-6c5db294f255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8fb311e8-db3a-45a9-9f6c-3cf29ddef9fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_5b22c8b0-0483-4581-93f3-7146433a8e25" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8fb311e8-db3a-45a9-9f6c-3cf29ddef9fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_01e727df-393c-49bd-a40d-880f3bed0881" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8fb311e8-db3a-45a9-9f6c-3cf29ddef9fc" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_01e727df-393c-49bd-a40d-880f3bed0881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompassionateCareHospiceMember_77f9437f-9d43-49e4-ae29-950bea21be83" xlink:href="amed-20200331.xsd#amed_CompassionateCareHospiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_01e727df-393c-49bd-a40d-880f3bed0881" xlink:to="loc_amed_CompassionateCareHospiceMember_77f9437f-9d43-49e4-ae29-950bea21be83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_b6b3aa23-c7e7-4e8b-806d-7d87eb4a9ca1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_5b22c8b0-0483-4581-93f3-7146433a8e25" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_b6b3aa23-c7e7-4e8b-806d-7d87eb4a9ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfPatientReceivablesOutstanding_f0fe0611-3253-40eb-b395-b783ff4fa7f7" xlink:href="amed-20200331.xsd#amed_PercentageOfPatientReceivablesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_69d97d0f-e077-470c-b77f-92d3fcbe45a7" xlink:to="loc_amed_PercentageOfPatientReceivablesOutstanding_f0fe0611-3253-40eb-b395-b783ff4fa7f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AccountsReceivablePortionDerivedFromMedicare_d30018d0-7c12-4250-b328-4548fe370bd2" xlink:href="amed-20200331.xsd#amed_AccountsReceivablePortionDerivedFromMedicare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_69d97d0f-e077-470c-b77f-92d3fcbe45a7" xlink:to="loc_amed_AccountsReceivablePortionDerivedFromMedicare_d30018d0-7c12-4250-b328-4548fe370bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HistoricalCollectionRateFromMedicare_853de819-68af-4ef0-acf4-abcbc74f889d" xlink:href="amed-20200331.xsd#amed_HistoricalCollectionRateFromMedicare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_69d97d0f-e077-470c-b77f-92d3fcbe45a7" xlink:to="loc_amed_HistoricalCollectionRateFromMedicare_853de819-68af-4ef0-acf4-abcbc74f889d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RevenueAdjustmentToMedicareRevenue_85781e33-5d9c-4dba-b05a-b545763d6d77" xlink:href="amed-20200331.xsd#amed_RevenueAdjustmentToMedicareRevenue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_69d97d0f-e077-470c-b77f-92d3fcbe45a7" xlink:to="loc_amed_RevenueAdjustmentToMedicareRevenue_85781e33-5d9c-4dba-b05a-b545763d6d77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare_ad9ab494-f343-4b86-aef1-7e6742b1e3e9" xlink:href="amed-20200331.xsd#amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_69d97d0f-e077-470c-b77f-92d3fcbe45a7" xlink:to="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare_ad9ab494-f343-4b86-aef1-7e6742b1e3e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare_d7d51e36-271f-4d0c-a1e1-1ee237d88822" xlink:href="amed-20200331.xsd#amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_69d97d0f-e077-470c-b77f-92d3fcbe45a7" xlink:to="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare_d7d51e36-271f-4d0c-a1e1-1ee237d88822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare_e995f7b8-ccc1-413a-bd05-c3d674b5569f" xlink:href="amed-20200331.xsd#amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_69d97d0f-e077-470c-b77f-92d3fcbe45a7" xlink:to="loc_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare_e995f7b8-ccc1-413a-bd05-c3d674b5569f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid_dab2ed73-2261-4c65-b173-355eca7b7671" xlink:href="amed-20200331.xsd#amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_69d97d0f-e077-470c-b77f-92d3fcbe45a7" xlink:to="loc_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid_dab2ed73-2261-4c65-b173-355eca7b7671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="amed-20200331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f15d2c9e-47b5-406a-b75b-b87b7dfaf89b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ffcaaf2e-69d2-4556-a875-66512f0e44ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f15d2c9e-47b5-406a-b75b-b87b7dfaf89b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ffcaaf2e-69d2-4556-a875-66512f0e44ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_da31888c-8bc8-4228-a631-42b8f16d4dd2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ffcaaf2e-69d2-4556-a875-66512f0e44ea" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_da31888c-8bc8-4228-a631-42b8f16d4dd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_957fa086-21a4-49bf-9684-d0a52ca33431" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_da31888c-8bc8-4228-a631-42b8f16d4dd2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_957fa086-21a4-49bf-9684-d0a52ca33431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_05790a8e-4eba-4ba5-9033-1e728e9e0158" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_957fa086-21a4-49bf-9684-d0a52ca33431" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_05790a8e-4eba-4ba5-9033-1e728e9e0158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_06d53729-7511-4f35-8ba4-411abb2c9cd2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_957fa086-21a4-49bf-9684-d0a52ca33431" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_06d53729-7511-4f35-8ba4-411abb2c9cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_584cb2b6-92dd-4ab0-a923-f95457b106fa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_957fa086-21a4-49bf-9684-d0a52ca33431" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_584cb2b6-92dd-4ab0-a923-f95457b106fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_79980c2d-dd1d-4e04-9420-2ff5b72cd15d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ffcaaf2e-69d2-4556-a875-66512f0e44ea" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_79980c2d-dd1d-4e04-9420-2ff5b72cd15d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases_64e09313-d7b3-4581-b4eb-da407656305e" xlink:href="amed-20200331.xsd#amed_DebtInstrumentCarryingAmountExcludingFinanceLeases"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_79980c2d-dd1d-4e04-9420-2ff5b72cd15d" xlink:to="loc_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases_64e09313-d7b3-4581-b4eb-da407656305e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_b65626db-0b46-4459-a96e-113981f48751" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_79980c2d-dd1d-4e04-9420-2ff5b72cd15d" xlink:to="loc_us-gaap_LongTermDebtFairValue_b65626db-0b46-4459-a96e-113981f48751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails" xlink:type="simple" xlink:href="amed-20200331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6a47a24e-129c-45d3-8132-074109cbc4ce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5652d344-c093-4d5b-86c9-ffc52e9f9d1f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6a47a24e-129c-45d3-8132-074109cbc4ce" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5652d344-c093-4d5b-86c9-ffc52e9f9d1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_e9610543-e3cb-47b5-bc21-939294ddf2db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6a47a24e-129c-45d3-8132-074109cbc4ce" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_e9610543-e3cb-47b5-bc21-939294ddf2db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_6a5c369a-1134-4701-b35e-d571d1745b47" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_e9610543-e3cb-47b5-bc21-939294ddf2db" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_6a5c369a-1134-4701-b35e-d571d1745b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonVestedStockAndStockUnits_90dc6abd-20ca-48a5-9ab4-15d66fb7c8b3" xlink:href="amed-20200331.xsd#amed_NonVestedStockAndStockUnits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_e9610543-e3cb-47b5-bc21-939294ddf2db" xlink:to="loc_amed_NonVestedStockAndStockUnits_90dc6abd-20ca-48a5-9ab4-15d66fb7c8b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7b6e7570-f352-41d0-9fdd-ca80b0701864" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6a47a24e-129c-45d3-8132-074109cbc4ce" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7b6e7570-f352-41d0-9fdd-ca80b0701864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d2575811-0208-4429-9e1a-0583738e3797" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6a47a24e-129c-45d3-8132-074109cbc4ce" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d2575811-0208-4429-9e1a-0583738e3797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/ACQUISITIONS" xlink:type="simple" xlink:href="amed-20200331.xsd#ACQUISITIONS"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/ACQUISITIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_7fe357c0-0788-45a3-952d-70fe27254cc7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_17043b66-7e4c-470c-9ac6-f98f4e29b89b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_7fe357c0-0788-45a3-952d-70fe27254cc7" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_17043b66-7e4c-470c-9ac6-f98f4e29b89b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/ACQUISITIONSTables" xlink:type="simple" xlink:href="amed-20200331.xsd#ACQUISITIONSTables"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/ACQUISITIONSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_ad79f856-38b7-4e68-b5cb-33cec02801aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_d405fe0c-6899-49d2-92e5-f30dc07d5873" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_ad79f856-38b7-4e68-b5cb-33cec02801aa" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_d405fe0c-6899-49d2-92e5-f30dc07d5873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_9ca6bd39-7e0a-4500-907c-2502bce82338" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_ad79f856-38b7-4e68-b5cb-33cec02801aa" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_9ca6bd39-7e0a-4500-907c-2502bce82338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails" xlink:type="simple" xlink:href="amed-20200331.xsd#ACQUISITIONSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_68f7bf77-1992-4c9b-9af1-d327ecfbbe50" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c3b1643a-3a83-4f66-8713-6c86d12284b7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_68f7bf77-1992-4c9b-9af1-d327ecfbbe50" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c3b1643a-3a83-4f66-8713-6c86d12284b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_abaaab6c-35a9-458d-ba4e-4cfabaa64521" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c3b1643a-3a83-4f66-8713-6c86d12284b7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_abaaab6c-35a9-458d-ba4e-4cfabaa64521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_016c868c-fd7f-4b9c-a0c9-d8063c54a6ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_abaaab6c-35a9-458d-ba4e-4cfabaa64521" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_016c868c-fd7f-4b9c-a0c9-d8063c54a6ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_e68afde7-f6eb-4627-822b-a4431991653f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_016c868c-fd7f-4b9c-a0c9-d8063c54a6ee" xlink:to="loc_us-gaap_TradeNamesMember_e68afde7-f6eb-4627-822b-a4431991653f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_f5264f47-e9dd-49f6-a9e3-fcf2645db9cf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_016c868c-fd7f-4b9c-a0c9-d8063c54a6ee" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_f5264f47-e9dd-49f6-a9e3-fcf2645db9cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AcquiredNamesOfBusinessMember_cc6fe1c5-0a2f-43da-bf5a-6a7a60c3aecf" xlink:href="amed-20200331.xsd#amed_AcquiredNamesOfBusinessMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_016c868c-fd7f-4b9c-a0c9-d8063c54a6ee" xlink:to="loc_amed_AcquiredNamesOfBusinessMember_cc6fe1c5-0a2f-43da-bf5a-6a7a60c3aecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_5cf9e563-a229-4e20-a9e4-a188fba2cea9" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c3b1643a-3a83-4f66-8713-6c86d12284b7" xlink:to="loc_srt_StatementGeographicalAxis_5cf9e563-a229-4e20-a9e4-a188fba2cea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_47f04f6b-775d-4681-96ec-2061d8fce841" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_5cf9e563-a229-4e20-a9e4-a188fba2cea9" xlink:to="loc_srt_SegmentGeographicalDomain_47f04f6b-775d-4681-96ec-2061d8fce841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_TN_86a57cd1-c68c-4ad8-b38c-533ac47d036d" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_TN"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_47f04f6b-775d-4681-96ec-2061d8fce841" xlink:to="loc_stpr_TN_86a57cd1-c68c-4ad8-b38c-533ac47d036d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_693091e9-7e68-4b9f-8920-0f4e3ea5ccb9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c3b1643a-3a83-4f66-8713-6c86d12284b7" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_693091e9-7e68-4b9f-8920-0f4e3ea5ccb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_a2333559-85ef-4256-bdbe-3d977789fbd8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_693091e9-7e68-4b9f-8920-0f4e3ea5ccb9" xlink:to="loc_us-gaap_SegmentDomain_a2333559-85ef-4256-bdbe-3d977789fbd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_9b55a964-ed9a-4cf5-9182-3c75a46bca98" xlink:href="amed-20200331.xsd#amed_HospiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_a2333559-85ef-4256-bdbe-3d977789fbd8" xlink:to="loc_amed_HospiceMember_9b55a964-ed9a-4cf5-9182-3c75a46bca98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_b616d3b7-3921-4300-a665-09541d158fc2" xlink:href="amed-20200331.xsd#amed_HomeHealthMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_a2333559-85ef-4256-bdbe-3d977789fbd8" xlink:to="loc_amed_HomeHealthMember_b616d3b7-3921-4300-a665-09541d158fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e003894d-08b3-477a-b958-c43653122678" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c3b1643a-3a83-4f66-8713-6c86d12284b7" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e003894d-08b3-477a-b958-c43653122678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_75ec9d17-07e1-407a-92ee-3b1a7c754175" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e003894d-08b3-477a-b958-c43653122678" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_75ec9d17-07e1-407a-92ee-3b1a7c754175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompassionateCareHospiceMember_f764bc41-b612-49cf-993f-a997cc7c7b32" xlink:href="amed-20200331.xsd#amed_CompassionateCareHospiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_75ec9d17-07e1-407a-92ee-3b1a7c754175" xlink:to="loc_amed_CompassionateCareHospiceMember_f764bc41-b612-49cf-993f-a997cc7c7b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ChristianCareatHomeMember_34ffb0f3-10e5-4f17-a72a-5af6f98f83f0" xlink:href="amed-20200331.xsd#amed_ChristianCareatHomeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_75ec9d17-07e1-407a-92ee-3b1a7c754175" xlink:to="loc_amed_ChristianCareatHomeMember_34ffb0f3-10e5-4f17-a72a-5af6f98f83f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EastTennesseePersonalCareServicesMember_7161e3ab-8ba4-4908-899e-91960eb7a261" xlink:href="amed-20200331.xsd#amed_EastTennesseePersonalCareServicesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_75ec9d17-07e1-407a-92ee-3b1a7c754175" xlink:to="loc_amed_EastTennesseePersonalCareServicesMember_7161e3ab-8ba4-4908-899e-91960eb7a261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RoseRockHealthcareMember_32a94394-e8f3-4ded-8dd6-6271e4759ead" xlink:href="amed-20200331.xsd#amed_RoseRockHealthcareMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_75ec9d17-07e1-407a-92ee-3b1a7c754175" xlink:to="loc_amed_RoseRockHealthcareMember_32a94394-e8f3-4ded-8dd6-6271e4759ead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AsanaHospiceMember_87baafdb-d39b-4978-a50b-2411de776919" xlink:href="amed-20200331.xsd#amed_AsanaHospiceMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_75ec9d17-07e1-407a-92ee-3b1a7c754175" xlink:to="loc_amed_AsanaHospiceMember_87baafdb-d39b-4978-a50b-2411de776919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8edcebf7-3ca1-4f1a-8c89-0fe083ed9345" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c3b1643a-3a83-4f66-8713-6c86d12284b7" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8edcebf7-3ca1-4f1a-8c89-0fe083ed9345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_514af4db-44d5-47d6-9946-668a6c2ad16c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8edcebf7-3ca1-4f1a-8c89-0fe083ed9345" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_514af4db-44d5-47d6-9946-668a6c2ad16c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificateOfNeedMember_02a65052-b687-4c22-bf57-b92a52c2e64e" xlink:href="amed-20200331.xsd#amed_CertificateOfNeedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_514af4db-44d5-47d6-9946-668a6c2ad16c" xlink:to="loc_amed_CertificateOfNeedMember_02a65052-b687-4c22-bf57-b92a52c2e64e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareLicenseMember_2243377e-0530-43e7-ab98-47895ee5733c" xlink:href="amed-20200331.xsd#amed_MedicareLicenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_514af4db-44d5-47d6-9946-668a6c2ad16c" xlink:to="loc_amed_MedicareLicenseMember_2243377e-0530-43e7-ab98-47895ee5733c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_83ce7e79-be74-4fb7-ba76-fdf6698cac05" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c3b1643a-3a83-4f66-8713-6c86d12284b7" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_83ce7e79-be74-4fb7-ba76-fdf6698cac05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageofSharesOutstanding_6356890d-37a2-4c80-9f85-4c94c1958f7d" xlink:href="amed-20200331.xsd#amed_PercentageofSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83ce7e79-be74-4fb7-ba76-fdf6698cac05" xlink:to="loc_amed_PercentageofSharesOutstanding_6356890d-37a2-4c80-9f85-4c94c1958f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_886ae87e-35e4-43d7-af74-3c65b85e8c2c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83ce7e79-be74-4fb7-ba76-fdf6698cac05" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_886ae87e-35e4-43d7-af74-3c65b85e8c2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_81077f61-1c30-4ffc-b9ab-ce7ea27350ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83ce7e79-be74-4fb7-ba76-fdf6698cac05" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_81077f61-1c30-4ffc-b9ab-ce7ea27350ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired_5f91accc-0295-4914-848e-3d3a6c5774b3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfBusinessesAcquired"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83ce7e79-be74-4fb7-ba76-fdf6698cac05" xlink:to="loc_us-gaap_NumberOfBusinessesAcquired_5f91accc-0295-4914-848e-3d3a6c5774b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_0d0a407b-044f-4444-b6bc-90af7a5d784b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83ce7e79-be74-4fb7-ba76-fdf6698cac05" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_0d0a407b-044f-4444-b6bc-90af7a5d784b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Paymentsrelatedtotaxassetandworkingcapital_111bb1cc-b320-4943-bab5-8bc47ab206a2" xlink:href="amed-20200331.xsd#amed_Paymentsrelatedtotaxassetandworkingcapital"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83ce7e79-be74-4fb7-ba76-fdf6698cac05" xlink:to="loc_amed_Paymentsrelatedtotaxassetandworkingcapital_111bb1cc-b320-4943-bab5-8bc47ab206a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_63038ed6-be1d-4c91-9cce-07e72171d364" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83ce7e79-be74-4fb7-ba76-fdf6698cac05" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_63038ed6-be1d-4c91-9cce-07e72171d364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense_5541e867-ae17-49d2-98ed-bfb2242108ce" xlink:href="amed-20200331.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83ce7e79-be74-4fb7-ba76-fdf6698cac05" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense_5541e867-ae17-49d2-98ed-bfb2242108ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset_da21204b-4913-4549-b597-c00a873e719c" xlink:href="amed-20200331.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83ce7e79-be74-4fb7-ba76-fdf6698cac05" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset_da21204b-4913-4549-b597-c00a873e719c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_15347859-b358-477e-8e9f-b974908e54be" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83ce7e79-be74-4fb7-ba76-fdf6698cac05" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_15347859-b358-477e-8e9f-b974908e54be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets_b5c8d462-fb7d-4187-9331-ad08b7313240" xlink:href="amed-20200331.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83ce7e79-be74-4fb7-ba76-fdf6698cac05" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets_b5c8d462-fb7d-4187-9331-ad08b7313240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_04f215cb-9b5e-400d-ba5c-09278b767177" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83ce7e79-be74-4fb7-ba76-fdf6698cac05" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_04f215cb-9b5e-400d-ba5c-09278b767177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_925ff8ed-6575-4b9e-8a30-20b496ffe30c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83ce7e79-be74-4fb7-ba76-fdf6698cac05" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_925ff8ed-6575-4b9e-8a30-20b496ffe30c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_be8739fc-e477-4289-846d-074bcbd623f8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83ce7e79-be74-4fb7-ba76-fdf6698cac05" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_be8739fc-e477-4289-846d-074bcbd623f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits_e7bebad5-5c97-4eab-8bb5-f822fae03904" xlink:href="amed-20200331.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83ce7e79-be74-4fb7-ba76-fdf6698cac05" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits_e7bebad5-5c97-4eab-8bb5-f822fae03904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_ad7f7ec4-68ec-4d85-9cdc-8fc69be54db8" xlink:href="amed-20200331.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83ce7e79-be74-4fb7-ba76-fdf6698cac05" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_ad7f7ec4-68ec-4d85-9cdc-8fc69be54db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_35197b8b-3901-4f06-9258-1541c87d7636" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83ce7e79-be74-4fb7-ba76-fdf6698cac05" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_35197b8b-3901-4f06-9258-1541c87d7636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities_6f2f7d90-ffca-4103-93e4-bf292f01c105" xlink:href="amed-20200331.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83ce7e79-be74-4fb7-ba76-fdf6698cac05" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities_6f2f7d90-ffca-4103-93e4-bf292f01c105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_ecd2eb33-c829-4d33-8e08-39d666f0e325" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83ce7e79-be74-4fb7-ba76-fdf6698cac05" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_ecd2eb33-c829-4d33-8e08-39d666f0e325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_50f38397-292a-4fa7-b363-97d2c910d923" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83ce7e79-be74-4fb7-ba76-fdf6698cac05" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_50f38397-292a-4fa7-b363-97d2c910d923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_907a7bac-65c1-4d34-9096-73fe49a51046" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83ce7e79-be74-4fb7-ba76-fdf6698cac05" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_907a7bac-65c1-4d34-9096-73fe49a51046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_fe3512f8-baa9-42b6-979c-e592e7d8e038" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83ce7e79-be74-4fb7-ba76-fdf6698cac05" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_fe3512f8-baa9-42b6-979c-e592e7d8e038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_f8244dc0-c261-4ad6-8281-f25dac51571e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83ce7e79-be74-4fb7-ba76-fdf6698cac05" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_f8244dc0-c261-4ad6-8281-f25dac51571e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c402f5c2-41b3-41c7-a5db-13ec5578fe15" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83ce7e79-be74-4fb7-ba76-fdf6698cac05" xlink:to="loc_us-gaap_OperatingIncomeLoss_c402f5c2-41b3-41c7-a5db-13ec5578fe15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_025e9c91-6d97-4274-a74d-39890badde27" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83ce7e79-be74-4fb7-ba76-fdf6698cac05" xlink:to="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_025e9c91-6d97-4274-a74d-39890badde27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_cfb70f78-b86e-4c32-954d-dde4c1c660d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_83ce7e79-be74-4fb7-ba76-fdf6698cac05" xlink:to="loc_us-gaap_DepreciationAndAmortization_cfb70f78-b86e-4c32-954d-dde4c1c660d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/ACQUISITIONSProFormaDetails" xlink:type="simple" xlink:href="amed-20200331.xsd#ACQUISITIONSProFormaDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/ACQUISITIONSProFormaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_4d26a0ae-1934-4a3d-afff-fc14ebd23790" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_066c5399-14d8-47a8-92fd-d697ff60cf21" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_4d26a0ae-1934-4a3d-afff-fc14ebd23790" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_066c5399-14d8-47a8-92fd-d697ff60cf21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_7cbe4de0-dd46-46e3-a44d-28efb72ff980" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_066c5399-14d8-47a8-92fd-d697ff60cf21" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_7cbe4de0-dd46-46e3-a44d-28efb72ff980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8dfd41e3-5f34-420f-abc8-be1f337f40d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7cbe4de0-dd46-46e3-a44d-28efb72ff980" xlink:to="loc_us-gaap_SegmentDomain_8dfd41e3-5f34-420f-abc8-be1f337f40d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_e4ded6d8-96d4-4e4a-9761-8c7e5b01250f" xlink:href="amed-20200331.xsd#amed_HospiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_8dfd41e3-5f34-420f-abc8-be1f337f40d0" xlink:to="loc_amed_HospiceMember_e4ded6d8-96d4-4e4a-9761-8c7e5b01250f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_a5575bc7-391f-44ff-a5bd-184f671c77b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_066c5399-14d8-47a8-92fd-d697ff60cf21" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_a5575bc7-391f-44ff-a5bd-184f671c77b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2c7392b6-cb7a-47b0-8626-13ce580ec9dc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a5575bc7-391f-44ff-a5bd-184f671c77b4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2c7392b6-cb7a-47b0-8626-13ce580ec9dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompassionateCareHospiceMember_cd6a1e4f-2da2-4795-9e27-0cbdae4248fd" xlink:href="amed-20200331.xsd#amed_CompassionateCareHospiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2c7392b6-cb7a-47b0-8626-13ce580ec9dc" xlink:to="loc_amed_CompassionateCareHospiceMember_cd6a1e4f-2da2-4795-9e27-0cbdae4248fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_c3e2992e-6ac6-408e-8abc-38cfabf60901" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_066c5399-14d8-47a8-92fd-d697ff60cf21" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_c3e2992e-6ac6-408e-8abc-38cfabf60901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a862fa42-3fa5-4e9e-9025-ef1946e5d5d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c3e2992e-6ac6-408e-8abc-38cfabf60901" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a862fa42-3fa5-4e9e-9025-ef1946e5d5d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_4d7bb324-2497-4e88-b9c5-aba4876dd2c1" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_066c5399-14d8-47a8-92fd-d697ff60cf21" xlink:to="loc_srt_OwnershipAxis_4d7bb324-2497-4e88-b9c5-aba4876dd2c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_486174a8-414f-42db-8ee4-e00c83f31c18" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_4d7bb324-2497-4e88-b9c5-aba4876dd2c1" xlink:to="loc_srt_OwnershipDomain_486174a8-414f-42db-8ee4-e00c83f31c18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3d67ff53-8de6-4fde-b644-bf9d1af46432" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_066c5399-14d8-47a8-92fd-d697ff60cf21" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3d67ff53-8de6-4fde-b644-bf9d1af46432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7e442ac5-ee17-41ad-b281-aec7ddd63c83" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3d67ff53-8de6-4fde-b644-bf9d1af46432" xlink:to="loc_us-gaap_ClassOfStockDomain_7e442ac5-ee17-41ad-b281-aec7ddd63c83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_b3071dde-5874-4ee5-9580-0b03241ecaa4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_066c5399-14d8-47a8-92fd-d697ff60cf21" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_b3071dde-5874-4ee5-9580-0b03241ecaa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_59047c80-9b82-42b4-997e-aa8c30ee9517" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b3071dde-5874-4ee5-9580-0b03241ecaa4" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_59047c80-9b82-42b4-997e-aa8c30ee9517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Businessacquisitionproformaoperatingincomeloss_19c759ea-ad83-4811-afab-1dd45e820cd4" xlink:href="amed-20200331.xsd#amed_Businessacquisitionproformaoperatingincomeloss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b3071dde-5874-4ee5-9580-0b03241ecaa4" xlink:to="loc_amed_Businessacquisitionproformaoperatingincomeloss_19c759ea-ad83-4811-afab-1dd45e820cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_09f7b11b-a5d5-4bf6-b002-2b0782fac683" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b3071dde-5874-4ee5-9580-0b03241ecaa4" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_09f7b11b-a5d5-4bf6-b002-2b0782fac683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_f5f4759b-d170-4f2e-82b8-4cb166b7f968" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b3071dde-5874-4ee5-9580-0b03241ecaa4" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_f5f4759b-d170-4f2e-82b8-4cb166b7f968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_fa4a8786-ddd9-4919-b917-7720fe5369df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b3071dde-5874-4ee5-9580-0b03241ecaa4" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_fa4a8786-ddd9-4919-b917-7720fe5369df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONS" xlink:type="simple" xlink:href="amed-20200331.xsd#LONGTERMOBLIGATIONS"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_395680e4-6c7a-4e68-bae2-995a92f0363a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_96c50f3e-95f1-427a-bef7-b03e046766ce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_395680e4-6c7a-4e68-bae2-995a92f0363a" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_96c50f3e-95f1-427a-bef7-b03e046766ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSLONGTERMOBLIGATIONSTables" xlink:type="simple" xlink:href="amed-20200331.xsd#LONGTERMOBLIGATIONSLONGTERMOBLIGATIONSTables"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSLONGTERMOBLIGATIONSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_a889df73-b405-4690-ad2e-611bb85a0d26" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_20477ce3-7f0a-4475-a51b-e68e7ee81b91" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a889df73-b405-4690-ad2e-611bb85a0d26" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_20477ce3-7f0a-4475-a51b-e68e7ee81b91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_afba20e7-4563-455e-897a-53ea7a820d92" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a889df73-b405-4690-ad2e-611bb85a0d26" xlink:to="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_afba20e7-4563-455e-897a-53ea7a820d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails" xlink:type="simple" xlink:href="amed-20200331.xsd#LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_572076dd-b433-4482-9fb9-348e54b36fa4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_c12127b8-0570-4f48-89d2-2eca79ebaabe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_572076dd-b433-4482-9fb9-348e54b36fa4" xlink:to="loc_us-gaap_DebtInstrumentTable_c12127b8-0570-4f48-89d2-2eca79ebaabe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_152f0a49-cde7-43d5-adbf-64523868abe8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c12127b8-0570-4f48-89d2-2eca79ebaabe" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_152f0a49-cde7-43d5-adbf-64523868abe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7efaface-7ca9-4de0-8059-19d5c389ec02" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_152f0a49-cde7-43d5-adbf-64523868abe8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7efaface-7ca9-4de0-8059-19d5c389ec02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_c9aab7f7-97b6-42b1-aa17-f7d034ad2a29" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7efaface-7ca9-4de0-8059-19d5c389ec02" xlink:to="loc_us-gaap_LoansPayableMember_c9aab7f7-97b6-42b1-aa17-f7d034ad2a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_41247680-a2bb-4a10-975a-7792f3b775c5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7efaface-7ca9-4de0-8059-19d5c389ec02" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_41247680-a2bb-4a10-975a-7792f3b775c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PromissoryNotesMember_d9e54cda-d421-496c-9f63-ca6915601e51" xlink:href="amed-20200331.xsd#amed_PromissoryNotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7efaface-7ca9-4de0-8059-19d5c389ec02" xlink:to="loc_amed_PromissoryNotesMember_d9e54cda-d421-496c-9f63-ca6915601e51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsMember_3b0e7025-9cef-4d3a-859b-9ded3eaf17c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalLeaseObligationsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7efaface-7ca9-4de0-8059-19d5c389ec02" xlink:to="loc_us-gaap_CapitalLeaseObligationsMember_3b0e7025-9cef-4d3a-859b-9ded3eaf17c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f5f1bf93-e111-4728-a229-6f9fa10a68ae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c12127b8-0570-4f48-89d2-2eca79ebaabe" xlink:to="loc_us-gaap_DebtInstrumentAxis_f5f1bf93-e111-4728-a229-6f9fa10a68ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ff100b05-f3bd-4fba-a82e-76635036361d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_f5f1bf93-e111-4728-a229-6f9fa10a68ae" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ff100b05-f3bd-4fba-a82e-76635036361d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_382c85df-a425-4e99-af0f-9aa7c4825426" xlink:href="amed-20200331.xsd#amed_OneHundredSeventyFiveMillionTermLoanFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ff100b05-f3bd-4fba-a82e-76635036361d" xlink:to="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_382c85df-a425-4e99-af0f-9aa7c4825426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OneHundredMillionTermLoanMember_87fc4f4e-407a-4724-afe5-8e0a2ce21522" xlink:href="amed-20200331.xsd#amed_OneHundredMillionTermLoanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ff100b05-f3bd-4fba-a82e-76635036361d" xlink:to="loc_amed_OneHundredMillionTermLoanMember_87fc4f4e-407a-4724-afe5-8e0a2ce21522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember_41c71a59-b15f-4b28-b20c-5bb7281ba6b8" xlink:href="amed-20200331.xsd#amed_TwoHundredMillionRevolvingCreditFacilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ff100b05-f3bd-4fba-a82e-76635036361d" xlink:to="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember_41c71a59-b15f-4b28-b20c-5bb7281ba6b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_528a15a5-ccb3-48c0-a91f-b80d91c52c09" xlink:href="amed-20200331.xsd#amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ff100b05-f3bd-4fba-a82e-76635036361d" xlink:to="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_528a15a5-ccb3-48c0-a91f-b80d91c52c09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_d5bc6670-f32a-48d3-8de0-562db5da4e20" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c12127b8-0570-4f48-89d2-2eca79ebaabe" xlink:to="loc_us-gaap_VariableRateAxis_d5bc6670-f32a-48d3-8de0-562db5da4e20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_4b2ad36a-0c5d-4ff0-9346-8aafde64d12e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_d5bc6670-f32a-48d3-8de0-562db5da4e20" xlink:to="loc_us-gaap_VariableRateDomain_4b2ad36a-0c5d-4ff0-9346-8aafde64d12e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_17696381-c7d3-4522-b875-7519ac454763" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_4b2ad36a-0c5d-4ff0-9346-8aafde64d12e" xlink:to="loc_us-gaap_EurodollarMember_17696381-c7d3-4522-b875-7519ac454763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_7db91735-e57b-430e-86d7-122d2971ca28" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c12127b8-0570-4f48-89d2-2eca79ebaabe" xlink:to="loc_us-gaap_DebtInstrumentLineItems_7db91735-e57b-430e-86d7-122d2971ca28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_6a2dc957-4a1e-4178-a13e-46aa10284d3e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7db91735-e57b-430e-86d7-122d2971ca28" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_6a2dc957-4a1e-4178-a13e-46aa10284d3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_cf511175-a301-4e1e-baf8-1d3c4d77e4ff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7db91735-e57b-430e-86d7-122d2971ca28" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_cf511175-a301-4e1e-baf8-1d3c4d77e4ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_2ad5ca06-e863-4e33-948d-6fd6e3ed2fbb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7db91735-e57b-430e-86d7-122d2971ca28" xlink:to="loc_us-gaap_LongTermDebt_2ad5ca06-e863-4e33-948d-6fd6e3ed2fbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_a63f75b1-2d19-4ab1-ada6-142e0e6f95f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7db91735-e57b-430e-86d7-122d2971ca28" xlink:to="loc_us-gaap_LongTermDebtCurrent_a63f75b1-2d19-4ab1-ada6-142e0e6f95f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_8ac997b6-3a13-41f3-8be8-ba46d078500f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7db91735-e57b-430e-86d7-122d2971ca28" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_8ac997b6-3a13-41f3-8be8-ba46d078500f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails_1" xlink:type="simple" xlink:href="amed-20200331.xsd#LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails_1"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails" xlink:type="simple" xlink:href="amed-20200331.xsd#LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1055296f-1fe4-47d3-8cb1-c24246553093" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_11f5c9c0-fd6e-4b8d-90ce-2691b1134e5d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1055296f-1fe4-47d3-8cb1-c24246553093" xlink:to="loc_us-gaap_DebtInstrumentTable_11f5c9c0-fd6e-4b8d-90ce-2691b1134e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_fef00e5a-847a-44f1-b3ba-5424beb4728d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_11f5c9c0-fd6e-4b8d-90ce-2691b1134e5d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_fef00e5a-847a-44f1-b3ba-5424beb4728d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_bfaa0d1d-814d-4a9f-a436-a881e3ed3bc7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_fef00e5a-847a-44f1-b3ba-5424beb4728d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_bfaa0d1d-814d-4a9f-a436-a881e3ed3bc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_c7411efd-0d01-402f-8c70-54b30c6c2247" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_bfaa0d1d-814d-4a9f-a436-a881e3ed3bc7" xlink:to="loc_us-gaap_LoansPayableMember_c7411efd-0d01-402f-8c70-54b30c6c2247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_035b9f5a-61fa-4550-ac09-dc2708bd9abb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_bfaa0d1d-814d-4a9f-a436-a881e3ed3bc7" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_035b9f5a-61fa-4550-ac09-dc2708bd9abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_6e3aa542-58ab-42a3-ba3b-511d40ac0549" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_11f5c9c0-fd6e-4b8d-90ce-2691b1134e5d" xlink:to="loc_us-gaap_DebtInstrumentAxis_6e3aa542-58ab-42a3-ba3b-511d40ac0549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2b7e41d1-5b66-4156-8a86-00b03d6a6b96" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_6e3aa542-58ab-42a3-ba3b-511d40ac0549" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2b7e41d1-5b66-4156-8a86-00b03d6a6b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_130e4b47-2eb8-4272-9e05-b107ff7294d7" xlink:href="amed-20200331.xsd#amed_OneHundredSeventyFiveMillionTermLoanFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2b7e41d1-5b66-4156-8a86-00b03d6a6b96" xlink:to="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_130e4b47-2eb8-4272-9e05-b107ff7294d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember_78a473cc-744d-4927-bf1f-ee114a2b8e9b" xlink:href="amed-20200331.xsd#amed_TwoHundredMillionRevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2b7e41d1-5b66-4156-8a86-00b03d6a6b96" xlink:to="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember_78a473cc-744d-4927-bf1f-ee114a2b8e9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_a02f8403-6fe3-40f6-ad73-8b17f0797b2c" xlink:href="amed-20200331.xsd#amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2b7e41d1-5b66-4156-8a86-00b03d6a6b96" xlink:to="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_a02f8403-6fe3-40f6-ad73-8b17f0797b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_285bdddb-75d7-4cf7-b564-3b84eeb0eb4b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_11f5c9c0-fd6e-4b8d-90ce-2691b1134e5d" xlink:to="loc_us-gaap_VariableRateAxis_285bdddb-75d7-4cf7-b564-3b84eeb0eb4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_4841b607-d2df-4da4-a2dd-175064bbcb47" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_285bdddb-75d7-4cf7-b564-3b84eeb0eb4b" xlink:to="loc_us-gaap_VariableRateDomain_4841b607-d2df-4da4-a2dd-175064bbcb47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_0bfa4e24-3688-446d-89e7-6013404af439" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_4841b607-d2df-4da4-a2dd-175064bbcb47" xlink:to="loc_us-gaap_EurodollarMember_0bfa4e24-3688-446d-89e7-6013404af439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_1f14e8b1-2ad8-44a3-ae62-b677f1f35aa6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_11f5c9c0-fd6e-4b8d-90ce-2691b1134e5d" xlink:to="loc_us-gaap_DebtInstrumentLineItems_1f14e8b1-2ad8-44a3-ae62-b677f1f35aa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_8ee93fe4-f80d-4cbf-815c-31b8a1beb42d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1f14e8b1-2ad8-44a3-ae62-b677f1f35aa6" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_8ee93fe4-f80d-4cbf-815c-31b8a1beb42d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestRateatPeriodEnd_408b22af-ee92-4268-8e49-4fcbf16d7bfe" xlink:href="amed-20200331.xsd#amed_DebtInstrumentInterestRateatPeriodEnd"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1f14e8b1-2ad8-44a3-ae62-b677f1f35aa6" xlink:to="loc_amed_DebtInstrumentInterestRateatPeriodEnd_408b22af-ee92-4268-8e49-4fcbf16d7bfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_afdad1d4-8a01-4592-a4ef-9043f97d352d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1f14e8b1-2ad8-44a3-ae62-b677f1f35aa6" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_afdad1d4-8a01-4592-a4ef-9043f97d352d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails" xlink:type="simple" xlink:href="amed-20200331.xsd#LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_315f77f6-9d9b-40e9-b56b-625af0f9c97b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_848d7594-5db2-4b7b-9611-4d3b288f167d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_315f77f6-9d9b-40e9-b56b-625af0f9c97b" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_848d7594-5db2-4b7b-9611-4d3b288f167d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8d2bb1f5-adc6-4ab5-a138-c0455335b0e7" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_848d7594-5db2-4b7b-9611-4d3b288f167d" xlink:to="loc_srt_RangeAxis_8d2bb1f5-adc6-4ab5-a138-c0455335b0e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_30df2077-65db-4675-bd40-c3bd1f4ba3e5" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_8d2bb1f5-adc6-4ab5-a138-c0455335b0e7" xlink:to="loc_srt_RangeMember_30df2077-65db-4675-bd40-c3bd1f4ba3e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_cdbb2989-a031-4cd8-ac7e-e563948a06e7" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_30df2077-65db-4675-bd40-c3bd1f4ba3e5" xlink:to="loc_srt_MinimumMember_cdbb2989-a031-4cd8-ac7e-e563948a06e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c84626a2-d151-4a30-8580-2518712f9c7e" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_30df2077-65db-4675-bd40-c3bd1f4ba3e5" xlink:to="loc_srt_MaximumMember_c84626a2-d151-4a30-8580-2518712f9c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_0b4eacd9-85d0-47f7-a293-4ff602ff0496" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_848d7594-5db2-4b7b-9611-4d3b288f167d" xlink:to="loc_us-gaap_DebtInstrumentAxis_0b4eacd9-85d0-47f7-a293-4ff602ff0496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1cf8db8a-456a-4226-b622-4eb288bc2baf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_0b4eacd9-85d0-47f7-a293-4ff602ff0496" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1cf8db8a-456a-4226-b622-4eb288bc2baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentByLeverageRatioTrancheOneMember_95943bfd-ec02-49d6-ad3e-3bf2c0286326" xlink:href="amed-20200331.xsd#amed_DebtInstrumentByLeverageRatioTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1cf8db8a-456a-4226-b622-4eb288bc2baf" xlink:to="loc_amed_DebtInstrumentByLeverageRatioTrancheOneMember_95943bfd-ec02-49d6-ad3e-3bf2c0286326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentByLeverageRatioTrancheTwoMember_23427133-4565-47d8-be9d-0db5675ae314" xlink:href="amed-20200331.xsd#amed_DebtInstrumentByLeverageRatioTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1cf8db8a-456a-4226-b622-4eb288bc2baf" xlink:to="loc_amed_DebtInstrumentByLeverageRatioTrancheTwoMember_23427133-4565-47d8-be9d-0db5675ae314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentByLeverageRatioTrancheThreeMember_f2611ee3-ea8b-4b4f-8772-1e37f4f43998" xlink:href="amed-20200331.xsd#amed_DebtInstrumentByLeverageRatioTrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1cf8db8a-456a-4226-b622-4eb288bc2baf" xlink:to="loc_amed_DebtInstrumentByLeverageRatioTrancheThreeMember_f2611ee3-ea8b-4b4f-8772-1e37f4f43998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentByLeverageRatioTrancheFourMember_6850c13b-7a18-4f88-8b03-3426710d89fa" xlink:href="amed-20200331.xsd#amed_DebtInstrumentByLeverageRatioTrancheFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1cf8db8a-456a-4226-b622-4eb288bc2baf" xlink:to="loc_amed_DebtInstrumentByLeverageRatioTrancheFourMember_6850c13b-7a18-4f88-8b03-3426710d89fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_180596ab-97cc-453b-a3d2-bcd26162517d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_848d7594-5db2-4b7b-9611-4d3b288f167d" xlink:to="loc_us-gaap_VariableRateAxis_180596ab-97cc-453b-a3d2-bcd26162517d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_f15bbec0-8e50-4bfa-a69a-a083b5943433" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_180596ab-97cc-453b-a3d2-bcd26162517d" xlink:to="loc_us-gaap_VariableRateDomain_f15bbec0-8e50-4bfa-a69a-a083b5943433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_bb267afd-dc9a-4e71-ae1c-8f9165d857bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_f15bbec0-8e50-4bfa-a69a-a083b5943433" xlink:to="loc_us-gaap_EurodollarMember_bb267afd-dc9a-4e71-ae1c-8f9165d857bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_15098981-4759-4035-a164-efa58d22b37a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_f15bbec0-8e50-4bfa-a69a-a083b5943433" xlink:to="loc_us-gaap_BaseRateMember_15098981-4759-4035-a164-efa58d22b37a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_efdc06cb-7a58-4d45-9343-1126defb82aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_848d7594-5db2-4b7b-9611-4d3b288f167d" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_efdc06cb-7a58-4d45-9343-1126defb82aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_c45637bc-581f-491f-81cd-c1322333f82d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_efdc06cb-7a58-4d45-9343-1126defb82aa" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_c45637bc-581f-491f-81cd-c1322333f82d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_1b16d848-38c9-40b8-83fe-0f81b19d89e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_848d7594-5db2-4b7b-9611-4d3b288f167d" xlink:to="loc_us-gaap_CreditFacilityAxis_1b16d848-38c9-40b8-83fe-0f81b19d89e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_3cda6dc2-2108-4fb6-b70b-925e8590af55" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_1b16d848-38c9-40b8-83fe-0f81b19d89e4" xlink:to="loc_us-gaap_CreditFacilityDomain_3cda6dc2-2108-4fb6-b70b-925e8590af55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_3d364978-d21f-4f69-83c2-3838af58c6c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_848d7594-5db2-4b7b-9611-4d3b288f167d" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_3d364978-d21f-4f69-83c2-3838af58c6c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ConsolidatedLeverageRatio_f0dd4b1b-ca20-4d1e-a29f-c8a9c1e8f456" xlink:href="amed-20200331.xsd#amed_ConsolidatedLeverageRatio"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_3d364978-d21f-4f69-83c2-3838af58c6c4" xlink:to="loc_amed_ConsolidatedLeverageRatio_f0dd4b1b-ca20-4d1e-a29f-c8a9c1e8f456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_49ff804e-57f6-4b54-9333-03a261ffee74" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_3d364978-d21f-4f69-83c2-3838af58c6c4" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_49ff804e-57f6-4b54-9333-03a261ffee74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LetterOfCreditFee_2f5a708b-5bf9-4f38-ad95-c082e86acafb" xlink:href="amed-20200331.xsd#amed_LetterOfCreditFee"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_3d364978-d21f-4f69-83c2-3838af58c6c4" xlink:to="loc_amed_LetterOfCreditFee_2f5a708b-5bf9-4f38-ad95-c082e86acafb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_18944dbb-930c-493e-8973-b0a3a95ff366" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_3d364978-d21f-4f69-83c2-3838af58c6c4" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_18944dbb-930c-493e-8973-b0a3a95ff366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails" xlink:type="simple" xlink:href="amed-20200331.xsd#LONGTERMOBLIGATIONSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_59a5d749-4766-4f86-bb23-48627ca0ae64" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_39cc3b89-521b-4a07-8a31-f616aae29874" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_59a5d749-4766-4f86-bb23-48627ca0ae64" xlink:to="loc_us-gaap_DebtInstrumentTable_39cc3b89-521b-4a07-8a31-f616aae29874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_39ff5940-cf44-497c-b624-43c144c19be7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_39cc3b89-521b-4a07-8a31-f616aae29874" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_39ff5940-cf44-497c-b624-43c144c19be7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_339aa66a-047e-4317-b3c0-adf815bfc3bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_39ff5940-cf44-497c-b624-43c144c19be7" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_339aa66a-047e-4317-b3c0-adf815bfc3bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_66abf394-0ec1-461c-a343-cb2e276dc123" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_339aa66a-047e-4317-b3c0-adf815bfc3bf" xlink:to="loc_us-gaap_SubsequentEventMember_66abf394-0ec1-461c-a343-cb2e276dc123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_33e8c9c1-450c-4b53-b1d4-f3af0726edee" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_39cc3b89-521b-4a07-8a31-f616aae29874" xlink:to="loc_srt_RangeAxis_33e8c9c1-450c-4b53-b1d4-f3af0726edee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7488547d-41f6-49a3-9fbd-b2befb6b5b30" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_33e8c9c1-450c-4b53-b1d4-f3af0726edee" xlink:to="loc_srt_RangeMember_7488547d-41f6-49a3-9fbd-b2befb6b5b30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1009ed23-d055-4b7e-8f29-ff231db553c5" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7488547d-41f6-49a3-9fbd-b2befb6b5b30" xlink:to="loc_srt_MinimumMember_1009ed23-d055-4b7e-8f29-ff231db553c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_8c359130-5450-4046-9351-ecf50b800bd7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_39cc3b89-521b-4a07-8a31-f616aae29874" xlink:to="loc_us-gaap_VariableRateAxis_8c359130-5450-4046-9351-ecf50b800bd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_f92175f2-1464-45e1-905e-c99873a18789" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_8c359130-5450-4046-9351-ecf50b800bd7" xlink:to="loc_us-gaap_VariableRateDomain_f92175f2-1464-45e1-905e-c99873a18789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_85e38542-db3b-4197-b984-a775e15eb65f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_f92175f2-1464-45e1-905e-c99873a18789" xlink:to="loc_us-gaap_BaseRateMember_85e38542-db3b-4197-b984-a775e15eb65f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_57c4b1ad-52fc-4f02-a40f-64bb70da2a10" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_f92175f2-1464-45e1-905e-c99873a18789" xlink:to="loc_us-gaap_EurodollarMember_57c4b1ad-52fc-4f02-a40f-64bb70da2a10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_325289a7-873e-41ac-9fc2-a74226686987" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_39cc3b89-521b-4a07-8a31-f616aae29874" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_325289a7-873e-41ac-9fc2-a74226686987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1e69d29f-2962-42dc-915e-e5a3730f72da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_325289a7-873e-41ac-9fc2-a74226686987" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1e69d29f-2962-42dc-915e-e5a3730f72da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SwingLineLoanMember_3caa6fbd-3edf-4f81-bc13-1addf82f68a4" xlink:href="amed-20200331.xsd#amed_SwingLineLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1e69d29f-2962-42dc-915e-e5a3730f72da" xlink:to="loc_amed_SwingLineLoanMember_3caa6fbd-3edf-4f81-bc13-1addf82f68a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_f149471c-8950-4eb7-aa24-7873e7b39ce4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1e69d29f-2962-42dc-915e-e5a3730f72da" xlink:to="loc_us-gaap_LetterOfCreditMember_f149471c-8950-4eb7-aa24-7873e7b39ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_974fb58d-f396-4dd8-89e4-8c2f93bf4777" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1e69d29f-2962-42dc-915e-e5a3730f72da" xlink:to="loc_us-gaap_LoansPayableMember_974fb58d-f396-4dd8-89e4-8c2f93bf4777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_a702971b-329f-4a55-8934-b3e9a532f2bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1e69d29f-2962-42dc-915e-e5a3730f72da" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_a702971b-329f-4a55-8934-b3e9a532f2bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PriorCreditAgreementMember_8ad45671-df11-45f7-ab21-e4bf5445cef7" xlink:href="amed-20200331.xsd#amed_PriorCreditAgreementMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1e69d29f-2962-42dc-915e-e5a3730f72da" xlink:to="loc_amed_PriorCreditAgreementMember_8ad45671-df11-45f7-ab21-e4bf5445cef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_64b2499a-730a-4417-89e6-ac77704df210" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1e69d29f-2962-42dc-915e-e5a3730f72da" xlink:to="loc_us-gaap_LineOfCreditMember_64b2499a-730a-4417-89e6-ac77704df210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedCreditAgreementMember_52133bf8-845d-452d-81ce-10a4a2de6d7d" xlink:href="amed-20200331.xsd#amed_AmendedCreditAgreementMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1e69d29f-2962-42dc-915e-e5a3730f72da" xlink:to="loc_amed_AmendedCreditAgreementMember_52133bf8-845d-452d-81ce-10a4a2de6d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_3a226620-ed04-4338-9aa2-ccdf62eb4f9e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_39cc3b89-521b-4a07-8a31-f616aae29874" xlink:to="loc_us-gaap_DebtInstrumentAxis_3a226620-ed04-4338-9aa2-ccdf62eb4f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_13fb73a6-cb9b-4f28-992a-adeab7e42115" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_3a226620-ed04-4338-9aa2-ccdf62eb4f9e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_13fb73a6-cb9b-4f28-992a-adeab7e42115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedCreditAgreementMember_40e6e6f2-283b-40e0-884f-244d8dcfea0b" xlink:href="amed-20200331.xsd#amed_AmendedCreditAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_13fb73a6-cb9b-4f28-992a-adeab7e42115" xlink:to="loc_amed_AmendedCreditAgreementMember_40e6e6f2-283b-40e0-884f-244d8dcfea0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OneHundredMillionTermLoanMember_157b9cd5-ee7f-40aa-af4b-7acb5f8165b0" xlink:href="amed-20200331.xsd#amed_OneHundredMillionTermLoanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_13fb73a6-cb9b-4f28-992a-adeab7e42115" xlink:to="loc_amed_OneHundredMillionTermLoanMember_157b9cd5-ee7f-40aa-af4b-7acb5f8165b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember_f955747d-a815-4bd9-a4d5-214640173ed9" xlink:href="amed-20200331.xsd#amed_TwoHundredMillionRevolvingCreditFacilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_13fb73a6-cb9b-4f28-992a-adeab7e42115" xlink:to="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember_f955747d-a815-4bd9-a4d5-214640173ed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_88c0d871-4877-4500-bedd-45379fc121c2" xlink:href="amed-20200331.xsd#amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_13fb73a6-cb9b-4f28-992a-adeab7e42115" xlink:to="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_88c0d871-4877-4500-bedd-45379fc121c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_a0570905-de8c-43fd-99fa-2a701c46d11b" xlink:href="amed-20200331.xsd#amed_OneHundredSeventyFiveMillionTermLoanFacilityMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_13fb73a6-cb9b-4f28-992a-adeab7e42115" xlink:to="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_a0570905-de8c-43fd-99fa-2a701c46d11b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_cb2ce1da-cdca-4bbb-a604-42cd1d03f5d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_39cc3b89-521b-4a07-8a31-f616aae29874" xlink:to="loc_us-gaap_DebtInstrumentLineItems_cb2ce1da-cdca-4bbb-a604-42cd1d03f5d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentPeriodicPaymentPercentage_e9e53cb6-1ff7-4562-8ebf-13a8f5899a02" xlink:href="amed-20200331.xsd#amed_DebtInstrumentPeriodicPaymentPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb2ce1da-cdca-4bbb-a604-42cd1d03f5d2" xlink:to="loc_amed_DebtInstrumentPeriodicPaymentPercentage_e9e53cb6-1ff7-4562-8ebf-13a8f5899a02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_d5ec4e41-60ff-40d4-bea0-cffbaa8b8b7f" xlink:href="amed-20200331.xsd#amed_ProceedsReceivedFromLoanPartyOfSubsidiary"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb2ce1da-cdca-4bbb-a604-42cd1d03f5d2" xlink:to="loc_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_d5ec4e41-60ff-40d4-bea0-cffbaa8b8b7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_aa4c46e6-1e81-42c4-af81-a6ac6d0ce75f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb2ce1da-cdca-4bbb-a604-42cd1d03f5d2" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_aa4c46e6-1e81-42c4-af81-a6ac6d0ce75f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_5db914a7-f60d-4d18-84e3-c4b0636ae933" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb2ce1da-cdca-4bbb-a604-42cd1d03f5d2" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_5db914a7-f60d-4d18-84e3-c4b0636ae933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_2d4b5ae5-7c1e-46bc-bed6-83f95a502a6b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtWeightedAverageInterestRateOverTime"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb2ce1da-cdca-4bbb-a604-42cd1d03f5d2" xlink:to="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_2d4b5ae5-7c1e-46bc-bed6-83f95a502a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TotalLeverageRatio_6bd5bcc1-e558-427d-8658-3076d0479502" xlink:href="amed-20200331.xsd#amed_TotalLeverageRatio"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb2ce1da-cdca-4bbb-a604-42cd1d03f5d2" xlink:to="loc_amed_TotalLeverageRatio_6bd5bcc1-e558-427d-8658-3076d0479502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ConsolidatedInterestCoverageRatio_dd877a8b-58ac-4687-adad-39cc719e1a0a" xlink:href="amed-20200331.xsd#amed_ConsolidatedInterestCoverageRatio"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb2ce1da-cdca-4bbb-a604-42cd1d03f5d2" xlink:to="loc_amed_ConsolidatedInterestCoverageRatio_dd877a8b-58ac-4687-adad-39cc719e1a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_cfa91056-14bd-407e-8cd3-1e492f45e54d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb2ce1da-cdca-4bbb-a604-42cd1d03f5d2" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_cfa91056-14bd-407e-8cd3-1e492f45e54d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RevolvingCreditFacilityTotal_d64519c5-6bee-48a3-929d-0f008d6b17ab" xlink:href="amed-20200331.xsd#amed_RevolvingCreditFacilityTotal"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb2ce1da-cdca-4bbb-a604-42cd1d03f5d2" xlink:to="loc_amed_RevolvingCreditFacilityTotal_d64519c5-6bee-48a3-929d-0f008d6b17ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_7f167aa7-8bcc-4690-9f7b-c7e72adba2f5" xlink:href="amed-20200331.xsd#amed_LineOfCreditFacilityAdditionalBorrowingCapacity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb2ce1da-cdca-4bbb-a604-42cd1d03f5d2" xlink:to="loc_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_7f167aa7-8bcc-4690-9f7b-c7e72adba2f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple_8ceef61f-93b6-4550-9fdb-6d9490c7a7a9" xlink:href="amed-20200331.xsd#amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb2ce1da-cdca-4bbb-a604-42cd1d03f5d2" xlink:to="loc_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple_8ceef61f-93b6-4550-9fdb-6d9490c7a7a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Creditfacilitymaximumallowableconsolidatedleverageratio_3848c023-262c-43cf-949e-3397df256243" xlink:href="amed-20200331.xsd#amed_Creditfacilitymaximumallowableconsolidatedleverageratio"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb2ce1da-cdca-4bbb-a604-42cd1d03f5d2" xlink:to="loc_amed_Creditfacilitymaximumallowableconsolidatedleverageratio_3848c023-262c-43cf-949e-3397df256243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_21bba4be-662f-42c3-af02-78fe277b267a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb2ce1da-cdca-4bbb-a604-42cd1d03f5d2" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_21bba4be-662f-42c3-af02-78fe277b267a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_b47cd879-52d1-4618-8823-1d21c469cac4" xlink:href="amed-20200331.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb2ce1da-cdca-4bbb-a604-42cd1d03f5d2" xlink:to="loc_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_b47cd879-52d1-4618-8823-1d21c469cac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_c8214f5f-6588-43fc-8b11-e41ff3fe86b7" xlink:href="amed-20200331.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb2ce1da-cdca-4bbb-a604-42cd1d03f5d2" xlink:to="loc_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_c8214f5f-6588-43fc-8b11-e41ff3fe86b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_5fa13a0c-feea-439c-b95f-95dfc967542a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb2ce1da-cdca-4bbb-a604-42cd1d03f5d2" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_5fa13a0c-feea-439c-b95f-95dfc967542a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_45d1851d-0e81-4d51-8eec-d423e8dd6d13" xlink:href="amed-20200331.xsd#amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb2ce1da-cdca-4bbb-a604-42cd1d03f5d2" xlink:to="loc_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_45d1851d-0e81-4d51-8eec-d423e8dd6d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_f7671fbb-d012-4834-a245-82f63c31af79" xlink:href="amed-20200331.xsd#amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb2ce1da-cdca-4bbb-a604-42cd1d03f5d2" xlink:to="loc_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_f7671fbb-d012-4834-a245-82f63c31af79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_911d5b4c-eaff-4aaf-855d-beca4940d989" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb2ce1da-cdca-4bbb-a604-42cd1d03f5d2" xlink:to="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_911d5b4c-eaff-4aaf-855d-beca4940d989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_f0d1a959-95f6-48b1-9659-79f82391d7a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb2ce1da-cdca-4bbb-a604-42cd1d03f5d2" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_f0d1a959-95f6-48b1-9659-79f82391d7a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_9b135fbe-99e9-40f8-8228-45b3e8396f60" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb2ce1da-cdca-4bbb-a604-42cd1d03f5d2" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_9b135fbe-99e9-40f8-8228-45b3e8396f60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_0becf2e6-b533-43bc-bf32-3393c6e333b0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb2ce1da-cdca-4bbb-a604-42cd1d03f5d2" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_0becf2e6-b533-43bc-bf32-3393c6e333b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_0fd6ad2c-d81d-4206-8abd-c126d3023794" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb2ce1da-cdca-4bbb-a604-42cd1d03f5d2" xlink:to="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_0fd6ad2c-d81d-4206-8abd-c126d3023794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestRateatPeriodEnd_91f311cf-6d05-4eec-8638-c9dc43ff7531" xlink:href="amed-20200331.xsd#amed_DebtInstrumentInterestRateatPeriodEnd"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb2ce1da-cdca-4bbb-a604-42cd1d03f5d2" xlink:to="loc_amed_DebtInstrumentInterestRateatPeriodEnd_91f311cf-6d05-4eec-8638-c9dc43ff7531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="amed-20200331.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d12e7d5b-77cf-445a-8f1a-b577c0d423a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1cf21d65-1628-4fef-8288-98a8ae754716" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d12e7d5b-77cf-445a-8f1a-b577c0d423a0" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1cf21d65-1628-4fef-8288-98a8ae754716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="simple" xlink:href="amed-20200331.xsd#COMMITMENTSANDCONTINGENCIESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0d45fb09-a335-45d4-9570-f8cb025378fb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_c25c525a-11cd-4c08-85d0-c15723ec52b2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0d45fb09-a335-45d4-9570-f8cb025378fb" xlink:to="loc_us-gaap_LossContingenciesTable_c25c525a-11cd-4c08-85d0-c15723ec52b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorsAxis_9e7d2133-7b37-425e-9f2d-92b0b6a17600" xlink:href="amed-20200331.xsd#amed_PayorsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_c25c525a-11cd-4c08-85d0-c15723ec52b2" xlink:to="loc_amed_PayorsAxis_9e7d2133-7b37-425e-9f2d-92b0b6a17600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorsDomain_d37bc242-2680-4b40-8525-bb9fb10f7ecb" xlink:href="amed-20200331.xsd#amed_PayorsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorsAxis_9e7d2133-7b37-425e-9f2d-92b0b6a17600" xlink:to="loc_amed_PayorsDomain_d37bc242-2680-4b40-8525-bb9fb10f7ecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompanysinsurancecarriersMember_27f07870-e209-4b12-9706-2abb3e64b2a2" xlink:href="amed-20200331.xsd#amed_CompanysinsurancecarriersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorsDomain_d37bc242-2680-4b40-8525-bb9fb10f7ecb" xlink:to="loc_amed_CompanysinsurancecarriersMember_27f07870-e209-4b12-9706-2abb3e64b2a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_62c7d820-b30c-4c17-afe4-b5634f2b9b37" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_c25c525a-11cd-4c08-85d0-c15723ec52b2" xlink:to="loc_srt_LitigationCaseAxis_62c7d820-b30c-4c17-afe4-b5634f2b9b37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_df717d51-9dd5-4fc5-9f77-dbfe7bd4d72b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_62c7d820-b30c-4c17-afe4-b5634f2b9b37" xlink:to="loc_srt_LitigationCaseTypeDomain_df717d51-9dd5-4fc5-9f77-dbfe7bd4d72b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UsDepartmentOfJusticeMember_a4ddc2ca-3c3d-4785-963e-387546025842" xlink:href="amed-20200331.xsd#amed_UsDepartmentOfJusticeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_df717d51-9dd5-4fc5-9f77-dbfe7bd4d72b" xlink:to="loc_amed_UsDepartmentOfJusticeMember_a4ddc2ca-3c3d-4785-963e-387546025842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmedisysCIAMember_052ec2bc-7b51-4b4a-9016-e5f65281d5ed" xlink:href="amed-20200331.xsd#amed_AmedisysCIAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_df717d51-9dd5-4fc5-9f77-dbfe7bd4d72b" xlink:to="loc_amed_AmedisysCIAMember_052ec2bc-7b51-4b4a-9016-e5f65281d5ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompassionateCareHospiceCIAMember_30afda4e-0ea6-4abc-89dd-7b1819ff4306" xlink:href="amed-20200331.xsd#amed_CompassionateCareHospiceCIAMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_df717d51-9dd5-4fc5-9f77-dbfe7bd4d72b" xlink:to="loc_amed_CompassionateCareHospiceCIAMember_30afda4e-0ea6-4abc-89dd-7b1819ff4306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecuritiesClassActionLawsuitMember_4c98d9e1-e10d-436a-840d-4668f26d0dc1" xlink:href="amed-20200331.xsd#amed_SecuritiesClassActionLawsuitMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_df717d51-9dd5-4fc5-9f77-dbfe7bd4d72b" xlink:to="loc_amed_SecuritiesClassActionLawsuitMember_4c98d9e1-e10d-436a-840d-4668f26d0dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SafeguardZoneProgramIntegrityContractorMember_2855f76c-b9fc-4078-a73f-2c86440ef60b" xlink:href="amed-20200331.xsd#amed_SafeguardZoneProgramIntegrityContractorMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_df717d51-9dd5-4fc5-9f77-dbfe7bd4d72b" xlink:to="loc_amed_SafeguardZoneProgramIntegrityContractorMember_2855f76c-b9fc-4078-a73f-2c86440ef60b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_InternalAuditComplianceReviewMember_2d878353-cd86-4b4e-9f64-cd8ffce7a4e9" xlink:href="amed-20200331.xsd#amed_InternalAuditComplianceReviewMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_df717d51-9dd5-4fc5-9f77-dbfe7bd4d72b" xlink:to="loc_amed_InternalAuditComplianceReviewMember_2d878353-cd86-4b4e-9f64-cd8ffce7a4e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_1871cb47-0b23-449f-822d-3dab6ffb2f7b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_c25c525a-11cd-4c08-85d0-c15723ec52b2" xlink:to="loc_srt_StatementGeographicalAxis_1871cb47-0b23-449f-822d-3dab6ffb2f7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_223b212c-8fe7-4f6f-971e-fbe75472633f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_1871cb47-0b23-449f-822d-3dab6ffb2f7b" xlink:to="loc_srt_SegmentGeographicalDomain_223b212c-8fe7-4f6f-971e-fbe75472633f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MA_294fc11a-23a7-40a1-add0-660690ec5145" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_MA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_223b212c-8fe7-4f6f-971e-fbe75472633f" xlink:to="loc_stpr_MA_294fc11a-23a7-40a1-add0-660690ec5145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MorgantownWestVirginiaMember_7997ed24-1763-4d9e-a926-4053d16bc4e5" xlink:href="amed-20200331.xsd#amed_MorgantownWestVirginiaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_223b212c-8fe7-4f6f-971e-fbe75472633f" xlink:to="loc_amed_MorgantownWestVirginiaMember_7997ed24-1763-4d9e-a926-4053d16bc4e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ParkersburgWestVirginiaMember_2139e858-bc20-4707-9e63-e11cc8ec8137" xlink:href="amed-20200331.xsd#amed_ParkersburgWestVirginiaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_223b212c-8fe7-4f6f-971e-fbe75472633f" xlink:to="loc_amed_ParkersburgWestVirginiaMember_2139e858-bc20-4707-9e63-e11cc8ec8137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_SC_080a215b-553d-4a4d-b126-6abfb8342abe" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_SC"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_223b212c-8fe7-4f6f-971e-fbe75472633f" xlink:to="loc_stpr_SC_080a215b-553d-4a4d-b126-6abfb8342abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_FL_9f7d1535-921e-4a91-ae1f-7c16a12bb935" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_FL"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_223b212c-8fe7-4f6f-971e-fbe75472633f" xlink:to="loc_stpr_FL_9f7d1535-921e-4a91-ae1f-7c16a12bb935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LakelandFloridaMember_238fb534-d9ec-46c0-bc00-d5d682d3ebdb" xlink:href="amed-20200331.xsd#amed_LakelandFloridaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_stpr_FL_9f7d1535-921e-4a91-ae1f-7c16a12bb935" xlink:to="loc_amed_LakelandFloridaMember_238fb534-d9ec-46c0-bc00-d5d682d3ebdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ClearwaterFloridaMember_c827ca38-b051-44d8-a57e-4838a5163167" xlink:href="amed-20200331.xsd#amed_ClearwaterFloridaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_stpr_FL_9f7d1535-921e-4a91-ae1f-7c16a12bb935" xlink:to="loc_amed_ClearwaterFloridaMember_c827ca38-b051-44d8-a57e-4838a5163167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_b266273b-574a-4e4a-a986-368b655c913b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_c25c525a-11cd-4c08-85d0-c15723ec52b2" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_b266273b-574a-4e4a-a986-368b655c913b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_36513ce8-06af-4880-9785-e6eca1f9bdc6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_b266273b-574a-4e4a-a986-368b655c913b" xlink:to="loc_us-gaap_SegmentDomain_36513ce8-06af-4880-9785-e6eca1f9bdc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_c4db6eab-aca5-4516-9e00-223f121ba38a" xlink:href="amed-20200331.xsd#amed_HospiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_36513ce8-06af-4880-9785-e6eca1f9bdc6" xlink:to="loc_amed_HospiceMember_c4db6eab-aca5-4516-9e00-223f121ba38a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_d39e9951-e604-474f-8f68-5aa06d630067" xlink:href="amed-20200331.xsd#amed_HomeHealthMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_36513ce8-06af-4880-9785-e6eca1f9bdc6" xlink:to="loc_amed_HomeHealthMember_d39e9951-e604-474f-8f68-5aa06d630067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_fe4fe543-e86a-42b4-98bc-4f0e09e0feb1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_c25c525a-11cd-4c08-85d0-c15723ec52b2" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_fe4fe543-e86a-42b4-98bc-4f0e09e0feb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_797925aa-4a47-4384-81a9-471e8412b27f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_fe4fe543-e86a-42b4-98bc-4f0e09e0feb1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_797925aa-4a47-4384-81a9-471e8412b27f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_InfinityHomeCareMember_09eee135-340f-45e1-9123-84bc244c71ab" xlink:href="amed-20200331.xsd#amed_InfinityHomeCareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_797925aa-4a47-4384-81a9-471e8412b27f" xlink:to="loc_amed_InfinityHomeCareMember_09eee135-340f-45e1-9123-84bc244c71ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_2069a203-e3a6-4c94-b097-99694d41f368" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_c25c525a-11cd-4c08-85d0-c15723ec52b2" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_2069a203-e3a6-4c94-b097-99694d41f368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_41c6c1fe-732a-4e6d-9b44-1d98c320f2f1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_2069a203-e3a6-4c94-b097-99694d41f368" xlink:to="loc_us-gaap_LossContingencyNatureDomain_41c6c1fe-732a-4e6d-9b44-1d98c320f2f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ExtrapolatedMember_e50d038f-fd7e-4529-bd33-d9dff67b8244" xlink:href="amed-20200331.xsd#amed_ExtrapolatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_41c6c1fe-732a-4e6d-9b44-1d98c320f2f1" xlink:to="loc_amed_ExtrapolatedMember_e50d038f-fd7e-4529-bd33-d9dff67b8244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UnfavorableMember_61913b41-5d1b-44b3-893e-b7771fac42d0" xlink:href="amed-20200331.xsd#amed_UnfavorableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_41c6c1fe-732a-4e6d-9b44-1d98c320f2f1" xlink:to="loc_amed_UnfavorableMember_61913b41-5d1b-44b3-893e-b7771fac42d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2f1b672d-6e02-46c1-92a9-abfc3577b8d2" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_c25c525a-11cd-4c08-85d0-c15723ec52b2" xlink:to="loc_srt_RangeAxis_2f1b672d-6e02-46c1-92a9-abfc3577b8d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_74c021be-b86d-48e3-a90a-204ed616d67e" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2f1b672d-6e02-46c1-92a9-abfc3577b8d2" xlink:to="loc_srt_RangeMember_74c021be-b86d-48e3-a90a-204ed616d67e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c5ddf2f6-8ef9-44c5-924c-0cc8cf346073" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_74c021be-b86d-48e3-a90a-204ed616d67e" xlink:to="loc_srt_MinimumMember_c5ddf2f6-8ef9-44c5-924c-0cc8cf346073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a1db9e90-6942-4fc6-b0ac-c9549e063db1" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_74c021be-b86d-48e3-a90a-204ed616d67e" xlink:to="loc_srt_MaximumMember_a1db9e90-6942-4fc6-b0ac-c9549e063db1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_55fde598-5446-48d3-acff-79895c0ee4fb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_c25c525a-11cd-4c08-85d0-c15723ec52b2" xlink:to="loc_us-gaap_LossContingenciesLineItems_55fde598-5446-48d3-acff-79895c0ee4fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_9ff415b9-d735-4456-a804-3b6c48c6796e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_55fde598-5446-48d3-acff-79895c0ee4fb" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_9ff415b9-d735-4456-a804-3b6c48c6796e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Numberofpatients_700d92c0-48fa-4cb2-9f43-5432304cce76" xlink:href="amed-20200331.xsd#amed_Numberofpatients"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_55fde598-5446-48d3-acff-79895c0ee4fb" xlink:to="loc_amed_Numberofpatients_700d92c0-48fa-4cb2-9f43-5432304cce76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CorporateIntegrityAgreementTerm_8c2fe123-1923-491a-a68b-ba5481bf1646" xlink:href="amed-20200331.xsd#amed_CorporateIntegrityAgreementTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_55fde598-5446-48d3-acff-79895c0ee4fb" xlink:to="loc_amed_CorporateIntegrityAgreementTerm_8c2fe123-1923-491a-a68b-ba5481bf1646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_0f726a90-109c-4a9c-b4de-357d63626d3c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_55fde598-5446-48d3-acff-79895c0ee4fb" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_0f726a90-109c-4a9c-b4de-357d63626d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_9b051815-664c-4a57-9a77-aab67b2ac028" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_55fde598-5446-48d3-acff-79895c0ee4fb" xlink:to="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_9b051815-664c-4a57-9a77-aab67b2ac028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyReceivableCurrent_e3cd26dc-7fe6-40fc-8f2d-059884fb5ae9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyReceivableCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_55fde598-5446-48d3-acff-79895c0ee4fb" xlink:to="loc_us-gaap_LossContingencyReceivableCurrent_e3cd26dc-7fe6-40fc-8f2d-059884fb5ae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecuritiesClassActionLawsuitsettlement_a8d6be3b-224e-4418-8926-d2fd9ac6a725" xlink:href="amed-20200331.xsd#amed_SecuritiesClassActionLawsuitsettlement"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_55fde598-5446-48d3-acff-79895c0ee4fb" xlink:to="loc_amed_SecuritiesClassActionLawsuitsettlement_a8d6be3b-224e-4418-8926-d2fd9ac6a725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfBeneficiaries_4cc71f6e-3c30-411b-b7bc-d186eac8e26a" xlink:href="amed-20200331.xsd#amed_NumberOfBeneficiaries"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_55fde598-5446-48d3-acff-79895c0ee4fb" xlink:to="loc_amed_NumberOfBeneficiaries_4cc71f6e-3c30-411b-b7bc-d186eac8e26a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_2d04f95f-3ae9-4948-97d2-c61322583597" xlink:href="amed-20200331.xsd#amed_RecoveryAmountOfOverpaymentMadeToSubsidiary"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_55fde598-5446-48d3-acff-79895c0ee4fb" xlink:to="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_2d04f95f-3ae9-4948-97d2-c61322583597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_f9bf305e-bced-44d5-8e84-867b62d4a561" xlink:href="amed-20200331.xsd#amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_55fde598-5446-48d3-acff-79895c0ee4fb" xlink:to="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_f9bf305e-bced-44d5-8e84-867b62d4a561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfClaimsSubmittedBySubsidiary_f5dcdf72-96ba-4775-9719-b0da38578a46" xlink:href="amed-20200331.xsd#amed_NumberOfClaimsSubmittedBySubsidiary"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_55fde598-5446-48d3-acff-79895c0ee4fb" xlink:to="loc_amed_NumberOfClaimsSubmittedBySubsidiary_f5dcdf72-96ba-4775-9719-b0da38578a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_5170fbf5-ccaf-4630-ab6e-6f81837fc662" xlink:href="amed-20200331.xsd#amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_55fde598-5446-48d3-acff-79895c0ee4fb" xlink:to="loc_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_5170fbf5-ccaf-4630-ab6e-6f81837fc662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009_a1e38009-bc05-4de6-b92d-31a2f9809f5c" xlink:href="amed-20200331.xsd#amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_55fde598-5446-48d3-acff-79895c0ee4fb" xlink:to="loc_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009_a1e38009-bc05-4de6-b92d-31a2f9809f5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyReceivableNoncurrent_d2fe10ad-a560-4ed2-9b61-b15e5eddf6ae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyReceivableNoncurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_55fde598-5446-48d3-acff-79895c0ee4fb" xlink:to="loc_us-gaap_LossContingencyReceivableNoncurrent_d2fe10ad-a560-4ed2-9b61-b15e5eddf6ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ActualClaimsPayment_d4f7b7d1-c6de-4e46-9950-fcc9b6cbbd4c" xlink:href="amed-20200331.xsd#amed_ActualClaimsPayment"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_55fde598-5446-48d3-acff-79895c0ee4fb" xlink:to="loc_amed_ActualClaimsPayment_d4f7b7d1-c6de-4e46-9950-fcc9b6cbbd4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ErrorRatePercentage_d12aff01-ff01-44d4-a028-a585ae5bb3ea" xlink:href="amed-20200331.xsd#amed_ErrorRatePercentage"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_55fde598-5446-48d3-acff-79895c0ee4fb" xlink:to="loc_amed_ErrorRatePercentage_d12aff01-ff01-44d4-a028-a585ae5bb3ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IndemnificationAmount_ae337d67-7782-4f62-838f-223fc5f96e4f" xlink:href="amed-20200331.xsd#amed_IndemnificationAmount"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_55fde598-5446-48d3-acff-79895c0ee4fb" xlink:to="loc_amed_IndemnificationAmount_ae337d67-7782-4f62-838f-223fc5f96e4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FloridaZpicRevenueReduction_a9742352-c355-4c38-8ce7-8c6765987f30" xlink:href="amed-20200331.xsd#amed_FloridaZpicRevenueReduction"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_55fde598-5446-48d3-acff-79895c0ee4fb" xlink:to="loc_amed_FloridaZpicRevenueReduction_a9742352-c355-4c38-8ce7-8c6765987f30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_944bd105-3885-42d2-8cc0-955b2681a15d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_55fde598-5446-48d3-acff-79895c0ee4fb" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_944bd105-3885-42d2-8cc0-955b2681a15d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HealthInsuranceRetentionLimit_04bd8187-347f-46e0-9ff0-69409710b6e1" xlink:href="amed-20200331.xsd#amed_HealthInsuranceRetentionLimit"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_55fde598-5446-48d3-acff-79895c0ee4fb" xlink:to="loc_amed_HealthInsuranceRetentionLimit_04bd8187-347f-46e0-9ff0-69409710b6e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_WorkersCompensationInsuranceRetentionLimit_92fcc820-b974-4671-99f4-20c2618653f6" xlink:href="amed-20200331.xsd#amed_WorkersCompensationInsuranceRetentionLimit"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_55fde598-5446-48d3-acff-79895c0ee4fb" xlink:to="loc_amed_WorkersCompensationInsuranceRetentionLimit_92fcc820-b974-4671-99f4-20c2618653f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProfessionalLiabilityInsuranceRetentionLimit_8a4f522d-ecb4-428c-9503-01ee1f592367" xlink:href="amed-20200331.xsd#amed_ProfessionalLiabilityInsuranceRetentionLimit"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_55fde598-5446-48d3-acff-79895c0ee4fb" xlink:to="loc_amed_ProfessionalLiabilityInsuranceRetentionLimit_8a4f522d-ecb4-428c-9503-01ee1f592367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SEGMENTINFORMATION" xlink:type="simple" xlink:href="amed-20200331.xsd#SEGMENTINFORMATION"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SEGMENTINFORMATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_5b04fdac-5552-42b8-a0e0-7304559718b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_6e39cf63-4674-44ed-b22e-b84bee915344" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_5b04fdac-5552-42b8-a0e0-7304559718b6" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_6e39cf63-4674-44ed-b22e-b84bee915344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SEGMENTINFORMATIONTables" xlink:type="simple" xlink:href="amed-20200331.xsd#SEGMENTINFORMATIONTables"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SEGMENTINFORMATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_1c85489b-8cf1-413f-85b8-6d62c51c0c1d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_6921f556-4609-488c-9124-2b8467f84b21" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_1c85489b-8cf1-413f-85b8-6d62c51c0c1d" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_6921f556-4609-488c-9124-2b8467f84b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="simple" xlink:href="amed-20200331.xsd#SEGMENTINFORMATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_2c36d5d6-41f8-4b05-876e-94a88921728a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_5034cab8-3ece-4f14-b032-e66ac909b863" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_2c36d5d6-41f8-4b05-876e-94a88921728a" xlink:to="loc_us-gaap_NumberOfReportableSegments_5034cab8-3ece-4f14-b032-e66ac909b863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails" xlink:type="simple" xlink:href="amed-20200331.xsd#SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_c1f65a85-7bcd-456d-b951-290afe9bad08" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0416a9eb-a401-44b8-8229-352f947e105e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c1f65a85-7bcd-456d-b951-290afe9bad08" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0416a9eb-a401-44b8-8229-352f947e105e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_e6117d5b-4e92-43ab-9d3c-3070f956caf0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0416a9eb-a401-44b8-8229-352f947e105e" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_e6117d5b-4e92-43ab-9d3c-3070f956caf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_6a19c208-a52c-476d-a93a-8f175e048267" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_e6117d5b-4e92-43ab-9d3c-3070f956caf0" xlink:to="loc_us-gaap_SegmentDomain_6a19c208-a52c-476d-a93a-8f175e048267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_ab857627-4398-49df-b8ca-b79e44612bc9" xlink:href="amed-20200331.xsd#amed_HomeHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_6a19c208-a52c-476d-a93a-8f175e048267" xlink:to="loc_amed_HomeHealthMember_ab857627-4398-49df-b8ca-b79e44612bc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_e950eee7-a235-4c83-b4cd-6741449f4a5c" xlink:href="amed-20200331.xsd#amed_HospiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_6a19c208-a52c-476d-a93a-8f175e048267" xlink:to="loc_amed_HospiceMember_e950eee7-a235-4c83-b4cd-6741449f4a5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_a253f1df-65ad-4d8a-9c12-887a09e71606" xlink:href="amed-20200331.xsd#amed_PersonalCareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_6a19c208-a52c-476d-a93a-8f175e048267" xlink:to="loc_amed_PersonalCareMember_a253f1df-65ad-4d8a-9c12-887a09e71606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_a5d015f4-96d3-4544-89ac-554141bb17c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_6a19c208-a52c-476d-a93a-8f175e048267" xlink:to="loc_us-gaap_AllOtherSegmentsMember_a5d015f4-96d3-4544-89ac-554141bb17c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_2a90a191-8fc8-4af3-8658-5546a0e41f5b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0416a9eb-a401-44b8-8229-352f947e105e" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_2a90a191-8fc8-4af3-8658-5546a0e41f5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_9ad149e2-bc99-4816-9034-58dfa603e29a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2a90a191-8fc8-4af3-8658-5546a0e41f5b" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_9ad149e2-bc99-4816-9034-58dfa603e29a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_687ec2d2-39d6-4526-b234-b1e5b6dd21f9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2a90a191-8fc8-4af3-8658-5546a0e41f5b" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_687ec2d2-39d6-4526-b234-b1e5b6dd21f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_85942567-3903-470f-9b96-e82e3ec5fe01" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2a90a191-8fc8-4af3-8658-5546a0e41f5b" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_85942567-3903-470f-9b96-e82e3ec5fe01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_ebb42095-55b5-415f-9e58-162c141d011c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2a90a191-8fc8-4af3-8658-5546a0e41f5b" xlink:to="loc_us-gaap_DepreciationAndAmortization_ebb42095-55b5-415f-9e58-162c141d011c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecuritiesClassActionLawsuitsettlement_eb1b7c36-0dc1-4c93-8788-2fde986c50e1" xlink:href="amed-20200331.xsd#amed_SecuritiesClassActionLawsuitsettlement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2a90a191-8fc8-4af3-8658-5546a0e41f5b" xlink:to="loc_amed_SecuritiesClassActionLawsuitsettlement_eb1b7c36-0dc1-4c93-8788-2fde986c50e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_bd0cc8e1-9e99-4251-b742-9e1a22b19617" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2a90a191-8fc8-4af3-8658-5546a0e41f5b" xlink:to="loc_us-gaap_CostsAndExpenses_bd0cc8e1-9e99-4251-b742-9e1a22b19617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_387331ed-5edf-4794-9f3f-1c47b4eefe6d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2a90a191-8fc8-4af3-8658-5546a0e41f5b" xlink:to="loc_us-gaap_OperatingIncomeLoss_387331ed-5edf-4794-9f3f-1c47b4eefe6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SHAREREPURCHASESHAREREPURCHASE" xlink:type="simple" xlink:href="amed-20200331.xsd#SHAREREPURCHASESHAREREPURCHASE"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SHAREREPURCHASESHAREREPURCHASE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_13c30c8d-5d4a-4663-a1ac-c579e6012333" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockTextBlock_4c0f181f-3630-4b6c-9945-b2ecd5bc45e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_13c30c8d-5d4a-4663-a1ac-c579e6012333" xlink:to="loc_us-gaap_TreasuryStockTextBlock_4c0f181f-3630-4b6c-9945-b2ecd5bc45e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails" xlink:type="simple" xlink:href="amed-20200331.xsd#SHAREREPURCHASENarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_19860462-662f-481b-93fc-1f8a2e2f9645" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseTable_35f4f312-a378-4268-9cd1-58d09bb45628" xlink:href="amed-20200331.xsd#amed_ShareRepurchaseTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_19860462-662f-481b-93fc-1f8a2e2f9645" xlink:to="loc_amed_ShareRepurchaseTable_35f4f312-a378-4268-9cd1-58d09bb45628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseAxis_3642347a-9180-4cb4-9b00-b1511587f07a" xlink:href="amed-20200331.xsd#amed_ShareRepurchaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseTable_35f4f312-a378-4268-9cd1-58d09bb45628" xlink:to="loc_amed_ShareRepurchaseAxis_3642347a-9180-4cb4-9b00-b1511587f07a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseDomain_760a5971-6a6d-49f8-be41-c213753a74b9" xlink:href="amed-20200331.xsd#amed_ShareRepurchaseDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseAxis_3642347a-9180-4cb4-9b00-b1511587f07a" xlink:to="loc_amed_ShareRepurchaseDomain_760a5971-6a6d-49f8-be41-c213753a74b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_KKRShareRepurchaseMember_ea25a3d3-b3d8-4500-a008-0a5bb1166aeb" xlink:href="amed-20200331.xsd#amed_KKRShareRepurchaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseDomain_760a5971-6a6d-49f8-be41-c213753a74b9" xlink:to="loc_amed_KKRShareRepurchaseMember_ea25a3d3-b3d8-4500-a008-0a5bb1166aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseLineItems_eb2456bc-ae7f-4784-a847-d1c40c7eab8c" xlink:href="amed-20200331.xsd#amed_ShareRepurchaseLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseTable_35f4f312-a378-4268-9cd1-58d09bb45628" xlink:to="loc_amed_ShareRepurchaseLineItems_eb2456bc-ae7f-4784-a847-d1c40c7eab8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_a56fc88c-09aa-4b70-b4ca-63401f36ef44" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseLineItems_eb2456bc-ae7f-4784-a847-d1c40c7eab8c" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_a56fc88c-09aa-4b70-b4ca-63401f36ef44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramExpirationDate_70572b2c-ca5f-4714-9576-856ea6dfb09c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramExpirationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseLineItems_eb2456bc-ae7f-4784-a847-d1c40c7eab8c" xlink:to="loc_us-gaap_StockRepurchaseProgramExpirationDate_70572b2c-ca5f-4714-9576-856ea6dfb09c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_ec2920ce-0657-4109-99da-1b8ccb11e664" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseLineItems_eb2456bc-ae7f-4784-a847-d1c40c7eab8c" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_ec2920ce-0657-4109-99da-1b8ccb11e664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageofSharesOutstanding_134e47d4-534c-4ead-a861-ff167769ab01" xlink:href="amed-20200331.xsd#amed_PercentageofSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseLineItems_eb2456bc-ae7f-4784-a847-d1c40c7eab8c" xlink:to="loc_amed_PercentageofSharesOutstanding_134e47d4-534c-4ead-a861-ff167769ab01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_554c2a85-ccf4-4963-8fdc-fdceed81e205" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseLineItems_eb2456bc-ae7f-4784-a847-d1c40c7eab8c" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_554c2a85-ccf4-4963-8fdc-fdceed81e205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Discountedclosingstockprice_13c840bb-db8b-4563-9ff5-e672a246f700" xlink:href="amed-20200331.xsd#amed_Discountedclosingstockprice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseLineItems_eb2456bc-ae7f-4784-a847-d1c40c7eab8c" xlink:to="loc_amed_Discountedclosingstockprice_13c840bb-db8b-4563-9ff5-e672a246f700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Percentageofclosingstockprice_dd70862e-93f1-49a1-9c81-b8d9f41185b5" xlink:href="amed-20200331.xsd#amed_Percentageofclosingstockprice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseLineItems_eb2456bc-ae7f-4784-a847-d1c40c7eab8c" xlink:to="loc_amed_Percentageofclosingstockprice_dd70862e-93f1-49a1-9c81-b8d9f41185b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSRELATEDPARTYTRANSACTIONS" xlink:type="simple" xlink:href="amed-20200331.xsd#RELATEDPARTYTRANSACTIONSRELATEDPARTYTRANSACTIONS"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSRELATEDPARTYTRANSACTIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_1199e787-8c3b-434b-aa91-c21ea420906d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_bef21178-89f2-4bde-afbb-415acce3b06b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_1199e787-8c3b-434b-aa91-c21ea420906d" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_bef21178-89f2-4bde-afbb-415acce3b06b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails" xlink:type="simple" xlink:href="amed-20200331.xsd#RELATEDPARTYTRANSACTIONSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_d51f4465-c46d-4d88-81f9-d3d2f8afa619" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f1e8b3ed-1cbd-4326-82fc-9cf52f9e9b87" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_d51f4465-c46d-4d88-81f9-d3d2f8afa619" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f1e8b3ed-1cbd-4326-82fc-9cf52f9e9b87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b589904c-09a4-476b-aa0a-fba3b7f7f867" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f1e8b3ed-1cbd-4326-82fc-9cf52f9e9b87" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b589904c-09a4-476b-aa0a-fba3b7f7f867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_a1551000-1834-4363-b8d2-9abc6202cc1a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b589904c-09a4-476b-aa0a-fba3b7f7f867" xlink:to="loc_us-gaap_RelatedPartyDomain_a1551000-1834-4363-b8d2-9abc6202cc1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedalogixMember_59794209-da22-416c-9c24-183703acc762" xlink:href="amed-20200331.xsd#amed_MedalogixMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_a1551000-1834-4363-b8d2-9abc6202cc1a" xlink:to="loc_amed_MedalogixMember_59794209-da22-416c-9c24-183703acc762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_f29f4561-6f99-46af-9e9d-070b1ea3dc73" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f1e8b3ed-1cbd-4326-82fc-9cf52f9e9b87" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_f29f4561-6f99-46af-9e9d-070b1ea3dc73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_8c8d4c10-b9a6-45b7-91fa-51017a94a227" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_f29f4561-6f99-46af-9e9d-070b1ea3dc73" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_8c8d4c10-b9a6-45b7-91fa-51017a94a227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_c4f06176-b220-410e-8686-08376bbe6b24" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f1e8b3ed-1cbd-4326-82fc-9cf52f9e9b87" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_c4f06176-b220-410e-8686-08376bbe6b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_b32a5f9e-caf3-484b-a895-dfa05b653fac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_c4f06176-b220-410e-8686-08376bbe6b24" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_b32a5f9e-caf3-484b-a895-dfa05b653fac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_f2f1a72f-260f-440d-b03d-0e62fd957d0d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_c4f06176-b220-410e-8686-08376bbe6b24" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_f2f1a72f-260f-440d-b03d-0e62fd957d0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUBSEQUENTEVENT" xlink:type="simple" xlink:href="amed-20200331.xsd#SUBSEQUENTEVENT"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUBSEQUENTEVENT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_1735a563-6e47-44b4-af7d-fd1579130b17" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_c966b1ca-cf1d-453f-8ce6-1070aacc6914" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_1735a563-6e47-44b4-af7d-fd1579130b17" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_c966b1ca-cf1d-453f-8ce6-1070aacc6914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails" xlink:type="simple" xlink:href="amed-20200331.xsd#SUBSEQUENTEVENTNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_2fbf59e5-841f-4ec5-9cc9-d0e1c5da4fa9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_739274bd-97e1-4142-a404-0acf07a304c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_2fbf59e5-841f-4ec5-9cc9-d0e1c5da4fa9" xlink:to="loc_us-gaap_SubsequentEventTable_739274bd-97e1-4142-a404-0acf07a304c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_880061ac-61ba-441e-aafb-a40fb92493e8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_739274bd-97e1-4142-a404-0acf07a304c3" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_880061ac-61ba-441e-aafb-a40fb92493e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_7c827c8c-4751-47a4-8145-2a8734d2385e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_880061ac-61ba-441e-aafb-a40fb92493e8" xlink:to="loc_us-gaap_SegmentDomain_7c827c8c-4751-47a4-8145-2a8734d2385e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_e6ac259e-dc35-4071-9f7d-a1d701b82d30" xlink:href="amed-20200331.xsd#amed_HospiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_7c827c8c-4751-47a4-8145-2a8734d2385e" xlink:to="loc_amed_HospiceMember_e6ac259e-dc35-4071-9f7d-a1d701b82d30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_360a43ee-cd94-492c-9f44-a161a9c035a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_739274bd-97e1-4142-a404-0acf07a304c3" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_360a43ee-cd94-492c-9f44-a161a9c035a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_fdc49e7a-5a17-4b1e-bdaa-2f52f6b8925c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_360a43ee-cd94-492c-9f44-a161a9c035a9" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_fdc49e7a-5a17-4b1e-bdaa-2f52f6b8925c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_347edd2b-3815-4a89-ba2d-579b81c51e33" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_fdc49e7a-5a17-4b1e-bdaa-2f52f6b8925c" xlink:to="loc_us-gaap_SubsequentEventMember_347edd2b-3815-4a89-ba2d-579b81c51e33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_bc4071a3-1e75-4bb5-bd73-1654345a7090" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_739274bd-97e1-4142-a404-0acf07a304c3" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_bc4071a3-1e75-4bb5-bd73-1654345a7090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7b1d0a3c-cbb5-44f4-b41e-d22d5504f536" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_bc4071a3-1e75-4bb5-bd73-1654345a7090" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7b1d0a3c-cbb5-44f4-b41e-d22d5504f536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RoseRockHealthcareMember_057d6bce-0953-4de9-a3d7-27f56100c8e0" xlink:href="amed-20200331.xsd#amed_RoseRockHealthcareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7b1d0a3c-cbb5-44f4-b41e-d22d5504f536" xlink:to="loc_amed_RoseRockHealthcareMember_057d6bce-0953-4de9-a3d7-27f56100c8e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AseraCareHospiceMember_2b6a67f4-f109-41c6-a426-d3b6bad93153" xlink:href="amed-20200331.xsd#amed_AseraCareHospiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7b1d0a3c-cbb5-44f4-b41e-d22d5504f536" xlink:to="loc_amed_AseraCareHospiceMember_2b6a67f4-f109-41c6-a426-d3b6bad93153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_a94b8f52-eefa-4362-8ce4-de51463a8837" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_739274bd-97e1-4142-a404-0acf07a304c3" xlink:to="loc_us-gaap_SubsequentEventLineItems_a94b8f52-eefa-4362-8ce4-de51463a8837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingForHealthcareProvidersIncludingHospitals_25060c28-0ce9-4dc2-9a87-df2f380faedc" xlink:href="amed-20200331.xsd#amed_FundingForHealthcareProvidersIncludingHospitals"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_a94b8f52-eefa-4362-8ce4-de51463a8837" xlink:to="loc_amed_FundingForHealthcareProvidersIncludingHospitals_25060c28-0ce9-4dc2-9a87-df2f380faedc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements_87dda927-6da4-4a4e-b6fc-3063c3608bd6" xlink:href="amed-20200331.xsd#amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_a94b8f52-eefa-4362-8ce4-de51463a8837" xlink:to="loc_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements_87dda927-6da4-4a4e-b6fc-3063c3608bd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingReceivedFromCARESAct_126d22b8-a786-476e-8ac4-d80592fc578d" xlink:href="amed-20200331.xsd#amed_FundingReceivedFromCARESAct"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_a94b8f52-eefa-4362-8ce4-de51463a8837" xlink:to="loc_amed_FundingReceivedFromCARESAct_126d22b8-a786-476e-8ac4-d80592fc578d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AdditionalFundingDistributedToHealthcareProviders_9fcab4b9-c859-4864-8b4d-989bd2f509c6" xlink:href="amed-20200331.xsd#amed_AdditionalFundingDistributedToHealthcareProviders"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_a94b8f52-eefa-4362-8ce4-de51463a8837" xlink:to="loc_amed_AdditionalFundingDistributedToHealthcareProviders_9fcab4b9-c859-4864-8b4d-989bd2f509c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_66ed0f2f-5af3-4fc1-a280-855d76c3576e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_a94b8f52-eefa-4362-8ce4-de51463a8837" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_66ed0f2f-5af3-4fc1-a280-855d76c3576e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Paymentsrelatedtotaxassetandworkingcapital_bafb8dad-243c-4914-a1e6-97e0217b77c1" xlink:href="amed-20200331.xsd#amed_Paymentsrelatedtotaxassetandworkingcapital"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_a94b8f52-eefa-4362-8ce4-de51463a8837" xlink:to="loc_amed_Paymentsrelatedtotaxassetandworkingcapital_bafb8dad-243c-4914-a1e6-97e0217b77c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired_8995458b-c23b-4baa-bcb2-6acfb7f3f580" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfBusinessesAcquired"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_a94b8f52-eefa-4362-8ce4-de51463a8837" xlink:to="loc_us-gaap_NumberOfBusinessesAcquired_8995458b-c23b-4baa-bcb2-6acfb7f3f580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>amed-20200331_g1.jpg
<TEXT>
begin 644 amed-20200331_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1"@17AI9@  34T *@    @ ! $[  (
M   /   (2H=I  0    !   (6IR=  $    >   0>NH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $ME96=A;BY+
M=VER86YT     >H<  <   @,   (;      <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                        2P!E &4 9P!A &X +@!+ '< :0!R &$ ;@!T
M    _^$*9VAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X<&%C:V5T
M(&)E9VEN/2?ON[\G(&ED/2=7-4TP37!#96AI2'IR95-Z3E1C>FMC.60G/SX-
M"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B/CQR9&8Z4D1&
M('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M
M<WEN=&%X+6YS(R(^/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](G5U:60Z
M9F%F-6)D9#4M8F$S9"TQ,61A+6%D,S$M9#,S9#<U,3@R9C%B(B!X;6QN<SID
M8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B+SX\<F1F.D1E
M<V-R:7!T:6]N(')D9CIA8F]U=#TB=75I9#IF868U8F1D-2UB83-D+3$Q9&$M
M860S,2UD,S-D-S4Q.#)F,6(B('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O
M9&,O96QE;65N=',O,2XQ+R(^/&1C.F-R96%T;W(^/')D9CI397$@>&UL;G,Z
M<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M
M;G,C(CX\<F1F.FQI/DME96=A;BY+=VER86YT/"]R9&8Z;&D^/"]R9&8Z4V5Q
M/@T*"0D)/"]D8SIC<F5A=&]R/CPO<F1F.D1E<V-R:7!T:6]N/CPO<F1F.E)$
M1CX\+W@Z>&UP;65T83X-"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @/#]X<&%C
M:V5T(&5N9#TG=R<_/O_; $, !P4%!@4$!P8%!@@'!P@*$0L*"0D*%0\0#!$8
M%1H9&!48%QL>)R$;'24=%Q@B+B(E*"DK+"L:("\S+RHR)RHK*O_; $,!!P@(
M"@D*% L+%"H<&!PJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ
M*BHJ*BHJ*BHJ*BHJ*BHJ*O_  !$( F\$M ,!(@ "$0$#$0'_Q  ?   !!0$!
M 0$! 0           0(#! 4&!P@)"@O_Q "U$  " 0,# @0#!04$!    7T!
M @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F
M)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?PGXM36(Q:7Q5+Y1P>@E'J/?U'^1U%>G&2DKH[XR4E=!1115%!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 !(4$DX Y)/:O,/&'BHZM.;*Q<BRC/+#_ );$=_IZ
M?G6OX[\2>4C:19/\[#_2'!Z#^[^/?V^M>?5PXBK]A''6J?904445QG*%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #HY'AE62)F1T
M.593@@^M>J^$_$Z:Y:^3<D+?1+\XZ>8/[P_K7E%3V5Y/I]Y%=6KE)8FRI_I]
M*UI5'3?D:TZC@SW*BL[0]8AUO2X[N'Y6^[(F?N-W%:->HFFKH]!--704444Q
MA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** ,3Q;JO]D^'IG1L33?NHO4$]3^ R:\AKK?B%J7V
MK6TLT.4M4Y_WVY/Z8_6N2KS,1/FG;L<%:7-+T"BBBL# **** "BBB@ HHHH
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M'J1=U<****H84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %-DD6&)Y)#A$4LQ] *=6+XNN_L?A6]8'#2)Y0]]
MQP?T)J9/E38I.RN>3WUTU]J$]U)]Z:1G/MDYJ"BBO'W/+"BBB@04444 %%%%
M !1110 5Z!X/\'^5Y>I:M'^\^]# P^[_ +3#U]!V_D>#_!_E>7J6K1_O/O0P
M,/N_[3#U]!V_EW-=M&C]J1V4J7VI!3)IH[>%YIW6.-!N9F. !1--';PO-.ZQ
MQH-S,QP *\M\5>*I-;F-O:EH[%#PO0R'^\?Z"NBI45-&U2HH(/%7BJ36YC;V
MI:.Q0\+T,A_O'^@KGH9I+>9)H':.1#N5E."#3**\R4G)W9Y\I.3NSU7PKXJC
MUN$6]T5COD'(Z"0?WA_45TE>$PS26\R30.T<B'<K*<$&O4O"OBJ/6X1;W16.
M^0<CH)!_>']17=1K<WNRW.RE5YO=EN:FM:+:ZY8&WNEP1S'(!\T9]1_A7DFK
M:3=:-?M:WB8(Y5Q]UQZBO:ZS]:T6UURP-O=#!',<@'S1GU'^%56HJ:NMRJM)
M35UN>6>%_P#D:=/_ .NPKV.O*=-TFZT;QQ8VMXF&$P*N/NN/45ZM4X9-1:9-
M!-)IF'XS_P"10OOHG_H:UY%7KOC/_D4+[Z)_Z&M>15CBOC1EB/B"BBBN4Y@H
MHHH **** .V^&]]LOKNQ8\2H)%^HX/Z']*]#KQWPK=_8_%%C(3@-)Y9_X%\O
M]:]BKT<-*\+=COH.\+!11172;A1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(4444 %%=KX9\&Z?K.AQWEU-<I(S,"(V4#@X[J:U_P#A7&D?\_-[_P!]I_\
M$UNJ$VKHV5&;5T>9T5J^)-+AT?7);*U:1XT52#(03R >P%958M-.S,FFG9A1
M112$%/AFDMYDF@=HY$.Y64X(-,HH ]5\*>*X];A%O=%8[Y!R.@E'J/?U%=)7
MA,,TEO,DL#M'(AW*RG!!KU+PIXKCUN$6]T5COD'(Z"4>H]_45Z%&MS>[+<[J
M57F]V6YJ:SHUKKE@UM=+@]8Y /F0^H_PKR35](NM%OVM;Q<$<HX^ZX]17M=9
M^LZ-:ZY8&VNUP1S'(!\T9]1_A55J*FKK<JK24U=;GBU%7M7TBZT6_:UO%P1R
MCC[KCU%4:\UIIV9P--.S"BBB@05[9HL7DZ#81]UMXP?KM%>+P1-/<1PI]Z1P
MH^I.*]S1!'&J+PJ@ ?2NS"K5LZ\.M6QU%%%=QUA1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3\/?^1F;_KW;^8KEJZ?P#+'#XD9I76-?(898X'45I2^-&E/XT>I457^WV?\
MS]0?]_!1]OL_^?J#_OX*]6Z/1NBQ138Y$E3?$ZNOJIR*=3&%%127=O$Y26>)
M&'56< TS[?9_\_4'_?P4KH5T-U3_ ) ]Y_UP?_T$UXA7M&IWUHVDW86ZA),#
M@ 2#GY37B]<.*W1R8C=!1117(<H4444 %/BED@F66%VCD0Y5E."#3** -/\
MX236?^@I=?\ ?TT?\))K/_04NO\ OZ:S**KFEW*YI=RW>:I?:@BK>W<LZJ<J
M)&SBJE%;GA'2?[6\00JZY@@_>R^X'0?B<?K0DYRL"3D['H_AC3/[*\/6UNPQ
M*R^9)_O-SC\.GX5K445ZZ22LCTTK*R"BBBF,**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KRWQSHO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5%%>FE961Z.P4444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)8L&%KY[C^*<[_TZ?I6]16D:4([(T5."V0B(L:!(U"J. JC %+116IH%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\2/^0':_]?(_]!:O-J\W$?Q#@K_&%>R>&/\ D5]/_P"N(KQNO9/#'_(KZ?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%-=TCC+R,J(HR68X %<SJ?CW2K%F2UW7L@
M_P">?"?]]'^@-3*<8[LF4E'<ZBBO+[SX@:Q<9%OY-JO;8FYOS.?Y5AW6L:C>
MY^U7UQ*#_"TAQ^72N>6*BMD8O$16Q[-+>6T'^NN(H_\ ?<"J[:WI2_>U.S'U
MN%_QKQ2BL_K3[&?UA]CVQ-9TN1ML>I6CGT6=3_6K:2)(NZ-U<>JG->$4Y':-
MMR,5/J#BA8I]4-8A]4>[T5X[9>*=9L,"&_E91_!*=X_7I^%=/I7Q&#,(]8M@
M@/\ RV@S@?53_0_A6L<1![Z&D:\7N=W14%I>VU_;B>SF2:,]&0Y__54]=.YN
M%%%% !1110 4444 %%>6ZOXLUJ'6;R*&]:...=T555> &('453_X3#7O^@B_
M_?"_X5RO$P3M8YWB(IGKU%<!X-\1ZIJ.O"VOKHS1-&S890,$?05W];TYJ:NC
M6$U-7044R:>*WA:6>18XT&69C@"N,UCXAPPLT6CQ>>PX\Z3A?P'4_I1.<8+4
M)3C'<[:JMQJ=C:?\?-Y!$?1Y *\CO_$6JZEN%U>RE&_Y9J=J_D*S*Y98KLC!
MXCLCVE=?TAF 74K4D]!YHJY%/#.N894D'JC UX52H[1L&1BK#H0<&DL4^J)6
M(?5'O%%>0:?XMUG3V&R[:9!_RSG.\?XUW&A^.+'5&2"['V2Y8X 8Y1S['M]#
M6\*\):;&T:T9:'3T445N;!1110 45FZQK]AH<(:]E^=AE(DY9OP_K7":G\0-
M2NV9;!5LXNQ'S.?QK*=6$-S.=2,-STQF5%RY"@=23BJ<VLZ9 V)K^V0^AE%>
M-7-[<WLF^[N)9V]9'+?SJ"N9XKLC!XCLCVR/6M,FXBU"V;Z2BK4<T4W^JD1_
M]U@:\)IR2/$X>-F1AT*G!%"Q3ZH7UA]4>[T5Y%8^,-:L6&+MIT'\$_SC\^M=
MCH_CZQOF6+4$^QRG@,3E#^/;\?SK>&(A+38VC6C(ZRBD!#*"I!!&01WI:W-@
MHHHH **** "BBB@ HHHH ***S]4US3]'CW7]RJ-C(C'+M] *3:2NQ-I:LT**
M\]U#XD3OE=+M%B7M),=Q_(<#\S7.7GB76+[/VC4)MIZJC;!^2XKGEB8+;4QE
M7BMCV":ZM[89N)XXAZNX7^=5CK>E+][4[,?6X3_&O%2Q9B6))/4FDK+ZT^B,
MOK#['MR:MITAQ'?VKGT693_6K2LKKE&##U!S7@]20W$UN^ZWFDB;U1BI_2A8
MKNAK$=T>ZT5Y+8>-=:L< W/VE/[MP-WZ]?UKK=+^(.GW;+'J$;6<AXWYW)^?
M4?E^-;QQ$)>1K&M"1UM%-CD2:-9(G61&&593D$?6G5N;!1110 4444 %%%%
M!1110 4456O]2M-,MS-?3I"G;<>3]!WI-VW#8LT5P.J?$9BS1Z1; +T$LW4_
M11_C7*WGB#5;_/VF^F93_"&VK^0KGEB8+;4PE7BMM3V&XOK2T_X^KJ&'_KI(
M%_G51O$6C+UU2U_"4&O&"2>IS163Q3Z(R^L/L>T+XAT=NFJ6GXS*/ZU=AN(;
ME-]O-'*OJC!A^E>%4Y)'B8-&[(PZ%3BA8I]4"Q#ZH]WHKR.Q\8ZU8D8NS.@_
M@G&[]>OZUV.C^/;"_*Q7ZFSF/&2<H?Q[?C^=;PKPEY&T:T9'5T4 A@"IR#T(
MHK<V./\ B1_R [7_ *^1_P"@M7FU>D_$C_D!VO\ U\C_ -!:O-J\W$?Q#@K_
M !A7LGAC_D5]/_ZXBO&Z]D\,?\BOI_\ UQ%7A?B96'^)FK1117>=H4444 %%
M4]7N)+31KRXA.)(H'=#C." <5Y=_PF6O?]!!O^_:_P"%8U*T:;LS*=10>IZ[
M17D7_"9:]_T$&_[X7_"NV\#ZM>ZMIUR^H3><T<H56*@<8]J4*\9RLA0K1F[(
MZ>BBBMS8**** "BBB@ HIDTT5O"\T\BQQH,L['  KA]8^(H5VBT6 .!QY\PX
M/T7_ !_*HG4C#<B4XPW.[JO+J%E <37<$?\ ORJ/ZUX[?ZYJ>I,3>7LL@/\
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M ,L;W3XY,K<?D*TE\.:,GW=,M?QC!KH6%GU9NL/+J>,45[0WA_2'^]IMJ?\
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MSB-_G'JIX/Z5C2GR33,J<N629[5134=9(U>,AE8 J1W%.KUCT@HHHH ****
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MU*/,MT85H<T;]3S.I+>XDM;J.>%MLD;!E([$5'17G' >X:=>IJ.FV]W%]V9
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M\,?\BOI__7$5XW7LGAC_ )%?3_\ KB*Z\+\3.C#_ !,U:***[SM"BBB@#/\
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MFHEQMC*QA4W<GJ?RS^=<44G))G)%)NS/4[*SBT^QAM;==L<*A5_Q^M3US/\
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MTUU._P#'&K6&I^'+<V%W'/BY4E5/S ;6ZCJ*X"BBHJ3<W=D3DYN["O6_!/\
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MGI;,\*&[MQTDB'('NO4?J*\ZI0E#5:HX:E%QU6QSM6;+4;S3I-]C<RP'OL;
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ML9T'5HV'Z4GL!X:S%F+,<DG)/K2445XQY)V_PUM5>]O;IAS&BQK_ ,"))_\
M017H5<!\-)E$VH0D_,RQN![#<#_,5W]>GA_X:/0H_ @HHHK<V"BBB@ HHHH
M**** .;\>_\ (J2_]=$_G7E5=;XW\2KJ5Q_9]D^;6%LNX/$C_P" _P ]JY*O
M,KR4IZ'GUI*4] KUOP3_ ,B=9?\ ;3_T8U>25ZWX)_Y$ZR_[:?\ HQJO"_&_
M0K#_ !F]1117H'<%%%% 'BFM_P#(?U#_ *^9/_0C5&KVM_\ (?U#_KYD_P#0
MC5&O&ENSRGN=-X _Y&I/^N+UZG7EG@#_ )&I/^N+UZG7H8;X#NP_P!11172;
MA1110 4444 %%%% 'C'B'_D9-0_Z^'_G6;6EXA_Y&34/^OA_YUFUX\OB9Y<M
MV=%X%_Y&VV_W'_\ 037J]>4>!?\ D;;;_<?_ -!->KUWX;X#LP_P!11172=
M4444 %%%% !1110!X_XN_P"1KOO]_P#H*QJV?%W_ "-=]_O_ -!6-7D5/C9Y
MD_B9O>"?^1PLO^!_^@-7K=>2>"?^1PLO^!_^@-7K==N%^#YG7A_@"BBBNHZ
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M10^,[2BBBO3.\**** "BBD9U12SL%4=23@"@!:*BM[JWNT9[6>.95;:6C<,
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M<QJGQ!T^U!334:\D_O'Y4'Y\G\OQJ)3C'=DRG&.[.KFFCMX6EGD6.-!EG8X
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M#Q_Q=_R-=]_O_P!!6-6SXN_Y&N^_ZZ?T%8U>14^-GF3^)F]X)_Y'"R_X'_Z
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M@**T=;G6&6XE'*PKRBGW_O?R^M=F!@8%=M'#N_-,ZJ5%WO(****[3K"BBB@
MHHHH **** "F2Q1SQF.:-9$/577(/X4^B@# O/!6AW9+?9/(8]X6*_IT_2LN
M7X;6+?ZB^N$_WPK?X5V=%9NE![HS=.#Z'"'X9KNXU4X]/L__ -E4T7PUM P\
M[4)G'<(@7_&NUHJ?84^PO8P[&!9^"M#L\'[*;AA_%.V[].GZ5N10Q01B."-(
MT'144 #\!3Z*TC&,=D6HI;(****HHCGMX;J%HKF))HVZI(H93^!JI_86D?\
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MB7>3+IT2D]X\I_Z#BM>BDXI[B:3W.2N/AUI4F3!-<PGTW!A^HS^M4F^&<?\
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M6D8QCLC112V044450PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ KSKXBZIYU]#IT;96 ;Y!_M'I^0_G7H
M%U<QV=I+<S'$<2%V/L!7B5[=R7]]-=3??F<N?;/:N7$SM'E[G/7E:-B"GP0O
M<7$<,*[I)&"*/4DX%,KK/A_I7VO66O9%S':C*Y'5ST_+D_E7#"/-)(XXQYI6
M/0],L4TS3(+.+I$@4GU/<_G5JBBO72LK'J+30****8!1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% ''_$/5/L^F1Z?&V)+D[GQV0?XG^5>;5W'B7PUKNLZ[/<I;H81A(LRK
M]T?CZY/XUE?\()KW_/M'_P!_E_QKSJL9SFW8X:BG*5['.5[!X4TO^RO#T$3+
MB60>;+]3V_ 8'X5Q^C^!=275[=]2A1;9&W/^\#9QVP/6O2:UP]-Q;E)&E"FU
MJPHHHKL.H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6875382272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text">RELATED PARTY TRANSACTIONSDuring 2018, we made a $7.0 million investment in Medalogix, a healthcare predictive data and analytics company; this investment is accounted for under the equity method. During the three-month period ended March 31, 2020, we incurred costs of approximately $0.6 million  in connection with the usage of Medalogix's analytics platforms. We believe that the terms of these transactions are consistent with those negotiated at arm's length.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>amed-20200331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:amed="http://www.amedisys.com/20200331"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2019-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="amed-20200331.xsd" xlink:type="simple"/>
    <context id="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ie94809e1cf0d453a8421029757c0fff8_I20200501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2020-05-01</instant>
        </period>
    </context>
    <context id="i886ddae2179d4ed793345586cc440c4e_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i014c385050454730837d592e15bca5e0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i379583ecb9374798b4c230bb394c2c67_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6a5040a26fb048c0a87bf6f051f93896_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3febdb7171a24ee1801a9231cc9591f3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i74e0f28f8b654d48a67abd821a86e3c4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iae980ac5b3a541419edf1dafb6f4c6f5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iea78279e652f4d91ae574d24a6286705_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic64b3c79c65143a4a4af6c36f8b99fcf_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ife895f7907c04cc1809e6c1fec83c56f_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i24fbf8ed4ce94e058258628cf71035a5_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i3897e7c6671f45b2a1b361f76b28fea4_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i766b3828bac34e55bd02b261a75f847a_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib4ce05f08cf04e5691c12539b7c46390_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i0a470325c5bc4889b266f68e9544d3e5_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="iac55dce70a374679bd199e04eaa5b649_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i4ab26af603e844e9b6bdda46662485c3_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i1593f26e241b483ebd91cefceb35d199_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="idf11627cc0b7467f85b1368394bb2664_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i30654d85149642fdae1198cad652319f_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i5070e06e0c374add9463ca31e59e3d55_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i89a07a7310c54227add149c2b0b87ee3_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ib79791d3ae294c48a6a6f3b9d4237287_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i2973a18d82d64089981faf633016e337_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ib6e258d79aa94c7b85ea31dd68768540_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i90b913e7ac1542e6928ba4790c344cb1_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ibd20ee3ceb1b468ca3e169ae4b78ec43_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i24ae5ea6239844c1943ccc8250cf4d3e_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ie8ccec4951d54e429f9b0776571c27c8_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="iae6e37863ef2446982ab4508cb5c6a4a_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ia2a1f77af6c6468e80794d3e6619da24_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ia3dbbd4d693549d08a550ff85e19d07e_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i3202099b2aaf4cc88461f7725441d5a3_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="ie390be034b284f5082baf3f2f9d8d312_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="if286a7fc2ab5482e927587b135cac060_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i0a118ef4adc642169df30733695018e7_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i07447f32d01d4b719bba4d5394e101f1_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i9aced020e10e41469ac1511a249cd44a_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="ie495d4805b994e769059ce32d0936a6c_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i58e124b0d6b94d7c921cc9069e91b8ba_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">amed:MedicareRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i0836ed4fa3b14e54895551f7cea7ebcf_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="iedecd98e5aa64817971cc51d13696c31_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i7c4c8579b54540d3958eb43f0bb5f417_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i1b4727e37ed3465f9d534f1fb6bb413c_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">amed:MedicareRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i08f8228195d4482abb1638f4aff3246a_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i4775f859e4944ad78c696d06861399db_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i1585d446638b4ebaaafeda3e997809c6_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareEpisodicBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i023ad62f89a640b9bafc773ed8834c5c_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareEpisodicBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i504907be1af1401896b436e9f31ef9b2_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareNonEpisodicBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i6c0374d568c345b1895f99bc4c5da6a1_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareNonEpisodicBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i012f167f36504108a1f5b3c3b8746634_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="idbce36e4c2a04a1ab922f6c09ff1bf77_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i9379225a4bef4cf6a6dc439d3252aa78_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceNonMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib45c518834644bd5a393af3f5453153c_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceNonMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i244a79cf50e84b398521caa51f9417a5_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="id20d8630a41943e5824e25095e23ca89_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i91721ec84cfa456ea3fe8a1300bb24f5_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib06523f2884143ccb65798237a08ecee_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i1803f21995a846beaf2e5491abdaa75f_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ie2a5b1046a72421f919b53e916e3b7b9_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iecd85c6103824b598da9159d305f569b_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:CapYearAxis">amed:CapYearTwoThousandThirteenThroughTwoThousandTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i7ff59164cb40413fac8d060bc05c3403_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:CapYearAxis">amed:CapYearTwoThousandThirteenThroughTwoThousandTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i94c155e0b36a4453979995375a4118aa_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">amed:AsanaHospiceAquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="id6a265dc3d6143ed962cec7a4019507c_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">amed:COVID19PPEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i0c3c88d49d1d4d8a95daf44cd924af53_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i7815a32e7798440abd6d377ab708f8e5_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i72f233d9e2f84fa7a940e82385eff8a4_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ia13fdf76a2e04a3f85e27598086705bf_D20200301-20200301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-01</endDate>
        </period>
    </context>
    <context id="if1a12a5a1ad7439bb6eb83289bc57f39_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:CertificateOfNeedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ic7171631cf3944959da9674b593c9910_D20200101-20200101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AsanaHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-01</endDate>
        </period>
    </context>
    <context id="i9c5dbb2e85d34e54b0517980e6f8d0eb_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AsanaHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i75590cbf7a2a42d792be47ee29fed5a2_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AsanaHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i758d8a3c5dd14c668b6a8284e987ffea_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AsanaHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:MedicareLicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="iaeb6ae8b7d9c4d529b6d4a55a4212894_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AsanaHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AcquiredNamesOfBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i19dd87f55ab74480af0f28e529fe3174_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AsanaHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i966c726cb1b24dc69084cdec997e95f6_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AsanaHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AcquiredNamesOfBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i63c633d2b51b42baa61a11b822bb68a4_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AsanaHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic735d35014784f0395b22a1d4852e2bb_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i9683f40a00e94c1abb96d732c3041061_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i8ba21eb95e2e43d1b0a24756aec8f4e8_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i62c497259b644d859d8f0eea7f3e524e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0ff90663d1684cb09b78cf9c7fde47b7_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i9224a41a12a14375adaf6a341b29f6fb_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="if270e80806534123864832e895591246_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i2057b301fd0c4cd39ca4cc85da07a5f6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i645e5d94ba734fb2a80140b926935a3d_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:PromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i72eea6f293c44f77b3987d12a9412f37_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:PromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2ef172d1bcd342b98c9cdb09d302dc65_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i3608bfa9782e4bac938cc97a5f45bbc6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia6972271e2cb4f179a778bd579050d45_I20190204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2019-02-04</instant>
        </period>
    </context>
    <context id="i686590f797e04c189494ff3b9677db0c_I20190204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-04</instant>
        </period>
    </context>
    <context id="iffa33294d8f04f04b0db89e59138db4a_I20190204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-04</instant>
        </period>
    </context>
    <context id="i71126d46462944a9aee1ee7aef720bee_D20190204-20190204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-04</startDate>
            <endDate>2019-02-04</endDate>
        </period>
    </context>
    <context id="ie8766fbac86e4b5a80af143791d0f409_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i6d6002c5f99d4721838ee0060efd407b_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i116335fec8a8410395d5970ead81815b_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i4d3ef9b25fd64694a1f379a432f9bb62_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i03234fef29e642489ae4417c7674ca60_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i2c19ce09b115491883ac15a09c9fce6d_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i262c9a55a12d4a2e82c1e6f3a19cf70f_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ie32195fe339a4436b4904c56998424fb_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ie3e4c94018794c938917b5e4762bb3a3_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="id274d4e6f62045c8b0313e71c808f7a0_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib3424d73450945acbfb6662c2947d02c_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i587391f59a70479592d057ca4817c53d_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i10e7017e38964ada930ea223919b92d6_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i40aeb3bc9f044ec2948f550127151c2f_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i12d7c31ad0e442449db03a43e8ee94b2_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i88e1a49559cf4832bf8d22eb47cac167_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic343676840f04990b1419f15ad513197_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i01dd577fcaf548d1bf70b0a704312472_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i01f445fe93c14d05abd4461abdf8ac06_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i2aa959b6fa504afaa53549e81bde7718_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i52efcfba53a641308fa077db50f1031f_D20190204-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-04</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i0ee8f60caeec4edeb0fa06f3891d0fcf_D20200401-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i9c02e2cca97c41ee89b6417d85253d91_D20230401-20240204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-02-04</endDate>
        </period>
    </context>
    <context id="ia85dd0cda56f46d88648f67dd3c62846_D20190204-20190204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-04</startDate>
            <endDate>2019-02-04</endDate>
        </period>
    </context>
    <context id="ia9def8d782364ec6a243d4e1839a987f_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ia378c7f5c8aa4e24951f6ef187aefeb4_D20190204-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-04</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ib409845529d94d28bc9b375ca272bc7d_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ib06e3eda34d04dff97bdcb1a32a5c655_D20190204-20190204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-04</startDate>
            <endDate>2019-02-04</endDate>
        </period>
    </context>
    <context id="iabee2409c21d4a51ab396e763ff8944e_D20190204-20190204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-04</startDate>
            <endDate>2019-02-04</endDate>
        </period>
    </context>
    <context id="i11afc1711d40400ab2e0bf09b8a0bda6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3a33f09f3173490fa79c2009fa38ee93_D20150521-20150521">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-05-21</startDate>
            <endDate>2015-05-21</endDate>
        </period>
    </context>
    <context id="idb70013011f74758ae2ef2a1a0de32c1_D20151103-20151103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:MorgantownWestVirginiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-11-03</startDate>
            <endDate>2015-11-03</endDate>
        </period>
    </context>
    <context id="i301ee02ef1954d139674e96cc1e9ee1b_D20160627-20160627">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ParkersburgWestVirginiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-06-27</startDate>
            <endDate>2016-06-27</endDate>
        </period>
    </context>
    <context id="ia37b8daa112347b8876c86941748cb37_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i039c0407f0b846cab386767ba04caf96_D20150130-20150130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:CompassionateCareHospiceCIAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-30</startDate>
            <endDate>2015-01-30</endDate>
        </period>
    </context>
    <context id="ibfe6dd3be0b34aeba5d1341e4d23edbe_D20140423-20140423">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:AmedisysCIAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-04-23</startDate>
            <endDate>2014-04-23</endDate>
        </period>
    </context>
    <context id="i563cd3af8c9d4df58214f2a851b9496f_D20080101-20100331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2008-01-01</startDate>
            <endDate>2010-03-31</endDate>
        </period>
    </context>
    <context id="i276fbb8a5a1041bba0699b8eaa7d329d_D20110606-20110606">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:ExtrapolatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2011-06-06</startDate>
            <endDate>2011-06-06</endDate>
        </period>
    </context>
    <context id="i2d397d49a7654cbabf31f8c0d4d869b8_I20160118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:UnfavorableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-01-18</instant>
        </period>
    </context>
    <context id="i2968328e88e748f192feb97bbe016702_D20160118-20160118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:UnfavorableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-18</startDate>
            <endDate>2016-01-18</endDate>
        </period>
    </context>
    <context id="i7b1a1c40b9524b08903a47b4db462e1e_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:UnfavorableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="iaedb1c7adfc24c0e9954154d61af1ff0_I20190110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-10</instant>
        </period>
    </context>
    <context id="ifb12069843564cf694b4e3999c45bb5a_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ia425738a537b4545a17322f5f6160d33_I20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:LakelandFloridaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-31</instant>
        </period>
    </context>
    <context id="ie0c2bead86ad4679b8c4aaddd217dfd0_D20170801-20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:LakelandFloridaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-01</startDate>
            <endDate>2017-08-31</endDate>
        </period>
    </context>
    <context id="i7fc8fa757ad24f1c8f989fa9c81c260f_I20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ClearwaterFloridaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-31</instant>
        </period>
    </context>
    <context id="ibc4bbdf502e3446cbb7600c7178a92c3_D20170801-20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ClearwaterFloridaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-01</startDate>
            <endDate>2017-08-31</endDate>
        </period>
    </context>
    <context id="i98f80d9f97ca4a82bc3965056f5fa3f3_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:LakelandFloridaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ie2fd0246a3884dbd98fb1fee55bbb120_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ClearwaterFloridaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i935299f8f69f411d82a301973293010c_I20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:InfinityHomeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-31</instant>
        </period>
    </context>
    <context id="i4c556fa53fa14b20ae65e1dc18d8bc25_I20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-31</instant>
        </period>
    </context>
    <context id="i727d1a03a2854f0a8ab0f8f940d78506_I20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-31</instant>
        </period>
    </context>
    <context id="icc208c6318744c7da8b8a731efe00cdf_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ic8bb62c8d3f64b36aef46b46e53aa57a_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i749346d879b94b75885c06bedb422e0f_I20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-31</instant>
        </period>
    </context>
    <context id="i94fb4c71db4b4aec948a8a7a52e540a1_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i87ea094035bb4053a1610c6754611f97_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:InfinityHomeCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i6a2423ba41a14b54bbfa09ffcbf822de_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i0fca8bc8c2274f6fadc2205b072e559c_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i0ea4477e2b7e45148118c36d32e8f280_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i2a6321b07a44425ca22c6f9c6f1f5d8b_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ica2ca9848a114f40a419416038f9d299_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ifd5794f300984d0ebb27f829a61f2449_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i156f24d3122641318de844c5586c409a_I20190225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2019-02-25</instant>
        </period>
    </context>
    <context id="i61c83eb39bd448178123272ce803cd04_D20190225-20190225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <startDate>2019-02-25</startDate>
            <endDate>2019-02-25</endDate>
        </period>
    </context>
    <context id="iba4950c59f204d1fadc805bed37fde70_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">amed:MedalogixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i814b93d2c0884001a010153e4ffc90ec_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">amed:MedalogixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i8b9efcf5de4c480e81af5d9bd1cdb30e_I20200327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2020-03-27</instant>
        </period>
    </context>
    <context id="i64e606224ada41f7b469907990f9cbec_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="ie825c970c94741d3bc87bb70762f3d6b_I20200424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-24</instant>
        </period>
    </context>
    <context id="i231cc4c6c6914005bf14c4a47eaefddd_D20200423-20200423">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-23</startDate>
            <endDate>2020-04-23</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="care_center">
        <measure>amed:care_center</measure>
    </unit>
    <unit id="state">
        <measure>amed:state</measure>
    </unit>
    <unit id="visit">
        <measure>amed:visit</measure>
    </unit>
    <unit id="day">
        <measure>amed:day</measure>
    </unit>
    <unit id="patient">
        <measure>amed:patient</measure>
    </unit>
    <unit id="beneficiary">
        <measure>amed:beneficiary</measure>
    </unit>
    <unit id="claim">
        <measure>amed:claim</measure>
    </unit>
    <unit id="segments">
        <measure>amed:Segments</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80L2ZyYWc6YmZlODQ0NjRkZmVkNDIxZjk4Njc0MTA4ZmFiYTkzZWUvdGFibGU6M2YxZDZkMjFiY2M5NDA1MjhmNzdhMzE5NWEzNGZmZTUvdGFibGVyYW5nZTozZjFkNmQyMWJjYzk0MDUyOGY3N2EzMTk1YTM0ZmZlNV80LTEtMS0xLTA_b9b236a3-014e-4ea8-b687-338262d45bbe">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80L2ZyYWc6YmZlODQ0NjRkZmVkNDIxZjk4Njc0MTA4ZmFiYTkzZWUvdGFibGU6M2YxZDZkMjFiY2M5NDA1MjhmNzdhMzE5NWEzNGZmZTUvdGFibGVyYW5nZTozZjFkNmQyMWJjYzk0MDUyOGY3N2EzMTk1YTM0ZmZlNV82LTEtMS0xLTA_5f6f8d42-92ca-44a3-b3e6-0f2f4f3fac91">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80L2ZyYWc6YmZlODQ0NjRkZmVkNDIxZjk4Njc0MTA4ZmFiYTkzZWUvdGFibGU6M2YxZDZkMjFiY2M5NDA1MjhmNzdhMzE5NWEzNGZmZTUvdGFibGVyYW5nZTozZjFkNmQyMWJjYzk0MDUyOGY3N2EzMTk1YTM0ZmZlNV83LTEtMS0xLTA_07a06634-a139-47ed-b00b-af5ea75ca680">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityRegistrantName
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80L2ZyYWc6YmZlODQ0NjRkZmVkNDIxZjk4Njc0MTA4ZmFiYTkzZWUvdGFibGU6M2YxZDZkMjFiY2M5NDA1MjhmNzdhMzE5NWEzNGZmZTUvdGFibGVyYW5nZTozZjFkNmQyMWJjYzk0MDUyOGY3N2EzMTk1YTM0ZmZlNV85LTEtMS0xLTA_c047e51d-5245-463d-aace-6109ba6bc74f">AMEDISYS INC</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80L2ZyYWc6YmZlODQ0NjRkZmVkNDIxZjk4Njc0MTA4ZmFiYTkzZWUvdGFibGU6M2YxZDZkMjFiY2M5NDA1MjhmNzdhMzE5NWEzNGZmZTUvdGFibGVyYW5nZTozZjFkNmQyMWJjYzk0MDUyOGY3N2EzMTk1YTM0ZmZlNV8xMC0xLTEtMS0w_8de8000a-fe5b-4439-84f2-d2672b4cb8ef">0000896262</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80L2ZyYWc6YmZlODQ0NjRkZmVkNDIxZjk4Njc0MTA4ZmFiYTkzZWUvdGFibGU6M2YxZDZkMjFiY2M5NDA1MjhmNzdhMzE5NWEzNGZmZTUvdGFibGVyYW5nZTozZjFkNmQyMWJjYzk0MDUyOGY3N2EzMTk1YTM0ZmZlNV8xMS0xLTEtMS0w_deef310e-f49f-4903-ae4e-961bfe08a0ef">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i014c385050454730837d592e15bca5e0_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yMi9mcmFnOjRmMjcyZDI2ODc4ZjRkZjc4YzA3ODA5OWQ5ZDY5Y2NiL3RhYmxlOjg3MGQ5YTcyYWU5ZjQxMDBhZTZkMmEzYTU1ZDA1OTU4L3RhYmxlcmFuZ2U6ODcwZDlhNzJhZTlmNDEwMGFlNmQyYTNhNTVkMDU5NThfMy0yLTEtMS0w_6c0e7389-8090-48da-831a-be6d56b5b066"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i014c385050454730837d592e15bca5e0_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yMi9mcmFnOjRmMjcyZDI2ODc4ZjRkZjc4YzA3ODA5OWQ5ZDY5Y2NiL3RhYmxlOjg3MGQ5YTcyYWU5ZjQxMDBhZTZkMmEzYTU1ZDA1OTU4L3RhYmxlcmFuZ2U6ODcwZDlhNzJhZTlmNDEwMGFlNmQyYTNhNTVkMDU5NThfNC0yLTEtMS0w_da0d385f-d88b-4ad1-9bb6-a5a88ab15e82"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yMi9mcmFnOjRmMjcyZDI2ODc4ZjRkZjc4YzA3ODA5OWQ5ZDY5Y2NiL3RhYmxlOjg3MGQ5YTcyYWU5ZjQxMDBhZTZkMmEzYTU1ZDA1OTU4L3RhYmxlcmFuZ2U6ODcwZDlhNzJhZTlmNDEwMGFlNmQyYTNhNTVkMDU5NThfNS0xLTEtMS0w_c0e99f91-a6ab-4dbf-80b9-ca6a873b7fc7"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i014c385050454730837d592e15bca5e0_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yMi9mcmFnOjRmMjcyZDI2ODc4ZjRkZjc4YzA3ODA5OWQ5ZDY5Y2NiL3RhYmxlOjg3MGQ5YTcyYWU5ZjQxMDBhZTZkMmEzYTU1ZDA1OTU4L3RhYmxlcmFuZ2U6ODcwZDlhNzJhZTlmNDEwMGFlNmQyYTNhNTVkMDU5NThfNS0yLTEtMS0w_f5144afa-7687-434b-8157-27012ca9591d"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yMi9mcmFnOjRmMjcyZDI2ODc4ZjRkZjc4YzA3ODA5OWQ5ZDY5Y2NiL3RhYmxlOjg3MGQ5YTcyYWU5ZjQxMDBhZTZkMmEzYTU1ZDA1OTU4L3RhYmxlcmFuZ2U6ODcwZDlhNzJhZTlmNDEwMGFlNmQyYTNhNTVkMDU5NThfNi0xLTEtMS0w_1b3574ec-ea14-47f5-b44b-6fb28d350721"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i014c385050454730837d592e15bca5e0_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yMi9mcmFnOjRmMjcyZDI2ODc4ZjRkZjc4YzA3ODA5OWQ5ZDY5Y2NiL3RhYmxlOjg3MGQ5YTcyYWU5ZjQxMDBhZTZkMmEzYTU1ZDA1OTU4L3RhYmxlcmFuZ2U6ODcwZDlhNzJhZTlmNDEwMGFlNmQyYTNhNTVkMDU5NThfNi0yLTEtMS0w_4747b684-d60b-4662-90bc-8172a9e093af"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i014c385050454730837d592e15bca5e0_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yMi9mcmFnOjRmMjcyZDI2ODc4ZjRkZjc4YzA3ODA5OWQ5ZDY5Y2NiL3RhYmxlOjg3MGQ5YTcyYWU5ZjQxMDBhZTZkMmEzYTU1ZDA1OTU4L3RhYmxlcmFuZ2U6ODcwZDlhNzJhZTlmNDEwMGFlNmQyYTNhNTVkMDU5NThfNy0yLTEtMS0w_23f3db62-fe60-4684-9b3c-26bb0d106db8"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i014c385050454730837d592e15bca5e0_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yMi9mcmFnOjRmMjcyZDI2ODc4ZjRkZjc4YzA3ODA5OWQ5ZDY5Y2NiL3RhYmxlOjg3MGQ5YTcyYWU5ZjQxMDBhZTZkMmEzYTU1ZDA1OTU4L3RhYmxlcmFuZ2U6ODcwZDlhNzJhZTlmNDEwMGFlNmQyYTNhNTVkMDU5NThfOC0yLTEtMS0w_da7b4776-2788-43d8-be89-9a50e1abfd3f"
      unitRef="shares">60000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i1b4727e37ed3465f9d534f1fb6bb413c_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80MC9mcmFnOjQ4Mjg0YzcxODc4YTQyZDk5YzRlNDJiNTE5ZWUxNGY3L3RhYmxlOjNkNGM5YTcxNGYwNDQ1MDU4ZTg2NDAzN2Y2MGY1MGU0L3RhYmxlcmFuZ2U6M2Q0YzlhNzE0ZjA0NDUwNThlODY0MDM3ZjYwZjUwZTRfMy0xLTEtMS0w_72ded738-a504-4b59-b6fd-3d7c76dd013d"
      unitRef="number">0.74</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i1b4727e37ed3465f9d534f1fb6bb413c_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80Ni9mcmFnOjU5MjlkNjhkZjM0MDQzZmQ5Y2RkZWUyNzc5NjQ5NmQ3L3RleHRyZWdpb246NTkyOWQ2OGRmMzQwNDNmZDljZGRlZTI3Nzk2NDk2ZDdfNDM_a2aeb4dc-dea7-4a83-97c7-1a972cd5e84e"
      unitRef="number">0.74</us-gaap:ConcentrationRiskPercentage1>
    <amed:EpisodeOfCareAsEpisodicBasedRevenueDuration
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80Ni9mcmFnOjU5MjlkNjhkZjM0MDQzZmQ5Y2RkZWUyNzc5NjQ5NmQ3L3RleHRyZWdpb246NTkyOWQ2OGRmMzQwNDNmZDljZGRlZTI3Nzk2NDk2ZDdfNTEz_64a8dd3b-63e8-4a29-9270-8bfc85896305">P60D</amed:EpisodeOfCareAsEpisodicBasedRevenueDuration>
    <amed:PeriodOfCareAsEpisodicBasedRevenueDuration
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80Ni9mcmFnOjU5MjlkNjhkZjM0MDQzZmQ5Y2RkZWUyNzc5NjQ5NmQ3L3RleHRyZWdpb246NTkyOWQ2OGRmMzQwNDNmZDljZGRlZTI3Nzk2NDk2ZDdfMzI5ODUzNDg4NDczOQ_ae579688-9cae-4c1d-916c-4ebafc377d7c">P30D</amed:PeriodOfCareAsEpisodicBasedRevenueDuration>
    <amed:NetServiceRevenuePeriodOfCarePaymentRateDuration
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80Ni9mcmFnOjU5MjlkNjhkZjM0MDQzZmQ5Y2RkZWUyNzc5NjQ5NmQ3L3RleHRyZWdpb246NTkyOWQ2OGRmMzQwNDNmZDljZGRlZTI3Nzk2NDk2ZDdfNjY0_e527415a-e6e5-42d8-9c74-f36622edcb95">P30D</amed:NetServiceRevenuePeriodOfCarePaymentRateDuration>
    <amed:AccountsReceivablePortionDerivedFromMedicare
      contextRef="i014c385050454730837d592e15bca5e0_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80Ni9mcmFnOjU5MjlkNjhkZjM0MDQzZmQ5Y2RkZWUyNzc5NjQ5NmQ3L3RleHRyZWdpb246NTkyOWQ2OGRmMzQwNDNmZDljZGRlZTI3Nzk2NDk2ZDdfMTY0OTI2NzQ0MzAzOQ_a89e8bc9-1ca2-4292-931e-aee5e4311819"
      unitRef="number">0.58</amed:AccountsReceivablePortionDerivedFromMedicare>
    <us-gaap:OperatingIncomeLoss
      contextRef="i75590cbf7a2a42d792be47ee29fed5a2_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl81Mi9mcmFnOjkxMWZmY2IzMWRjNTQ4OTNhZjQwMTliODU1ODgxMDRmL3RhYmxlOjJjZDI1ZTI0MjA0ZjRmODZiYWFjYTNhYmQwZTMzZTc1L3RhYmxlcmFuZ2U6MmNkMjVlMjQyMDRmNGY4NmJhYWNhM2FiZDBlMzNlNzVfMS0xLTEtMS0w_8e421f79-5a89-42b9-b9ad-b4e63c115ded"
      unitRef="usd">-1300000</us-gaap:OperatingIncomeLoss>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i63c633d2b51b42baa61a11b822bb68a4_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl81Mi9mcmFnOjkxMWZmY2IzMWRjNTQ4OTNhZjQwMTliODU1ODgxMDRmL3RleHRyZWdpb246OTExZmZjYjMxZGM1NDg5M2FmNDAxOWI4NTU4ODEwNGZfMTY0OTI2NzQ0MTc3NQ_48c32b0c-1a79-4072-94cc-e8edac41b1b9">P2Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis
      contextRef="ib06e3eda34d04dff97bdcb1a32a5c655_D20190204-20190204"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82NC9mcmFnOmIyZDQzYTFhZjQzZjQxN2U5NGVlM2ZiNmY4MTA0MTkzL3RleHRyZWdpb246YjJkNDNhMWFmNDNmNDE3ZTk0ZWUzZmI2ZjgxMDQxOTNfODEw_7ccdf412-d56e-41f2-ad2f-c74879f9c305">Fluctuating rate per annum equal to the highest of (a)&#160;the federal funds rate plus 0.50% per annum, (b)&#160;the prime rate of interest established by the Administrative Agent, and (c)&#160;the Eurodollar Rate for an interest period of one month plus 1% per annum.</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
    <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis
      contextRef="iabee2409c21d4a51ab396e763ff8944e_D20190204-20190204"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82NC9mcmFnOmIyZDQzYTFhZjQzZjQxN2U5NGVlM2ZiNmY4MTA0MTkzL3RleHRyZWdpb246YjJkNDNhMWFmNDNmNDE3ZTk0ZWUzZmI2ZjgxMDQxOTNfODEx_ec6cc796-6c0e-48a3-a3da-bf882f318184">Rate at which Eurodollar deposits in the London interbank market for an interest period of one, two, three or six months</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="i11afc1711d40400ab2e0bf09b8a0bda6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82NC9mcmFnOmIyZDQzYTFhZjQzZjQxN2U5NGVlM2ZiNmY4MTA0MTkzL3RleHRyZWdpb246YjJkNDNhMWFmNDNmNDE3ZTk0ZWUzZmI2ZjgxMDQxOTNfNjI2_b2ab0d7f-34cc-421d-9da5-eb3a1426db07"
      unitRef="usd">800000</us-gaap:PaymentsOfFinancingCosts>
    <dei:DocumentType
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xL2ZyYWc6ZTM1NThjNTE5NTgyNGJhYmFlYzYwYjYxMGIxZTRhYWEvdGV4dHJlZ2lvbjplMzU1OGM1MTk1ODI0YmFiYWVjNjBiNjEwYjFlNGFhYV8yMjQ2_49b62220-90e2-437c-a4f1-005d89582739">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xL2ZyYWc6ZTM1NThjNTE5NTgyNGJhYmFlYzYwYjYxMGIxZTRhYWEvdGFibGU6NTc1ODcwN2IzMmFiNDllOWE4ZTkwZTdjMzJlNmQ1NDcvdGFibGVyYW5nZTo1NzU4NzA3YjMyYWI0OWU5YThlOTBlN2MzMmU2ZDU0N18wLTAtMS0xLTA_a2061896-4059-41ae-a402-ed3480c793ae">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xL2ZyYWc6ZTM1NThjNTE5NTgyNGJhYmFlYzYwYjYxMGIxZTRhYWEvdGV4dHJlZ2lvbjplMzU1OGM1MTk1ODI0YmFiYWVjNjBiNjEwYjFlNGFhYV8xNDA_09811299-1518-4689-8aa7-64bce643ab2e">2020-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xL2ZyYWc6ZTM1NThjNTE5NTgyNGJhYmFlYzYwYjYxMGIxZTRhYWEvdGFibGU6MzEyMzVjMWY0ZTQ2NGJjOWJiN2U4ZjAxZWQ4MGI0NTMvdGFibGVyYW5nZTozMTIzNWMxZjRlNDY0YmM5YmI3ZThmMDFlZDgwYjQ1M18wLTAtMS0xLTA_25823660-552d-4c5f-a4bb-358f4c3465dd">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xL2ZyYWc6ZTM1NThjNTE5NTgyNGJhYmFlYzYwYjYxMGIxZTRhYWEvdGV4dHJlZ2lvbjplMzU1OGM1MTk1ODI0YmFiYWVjNjBiNjEwYjFlNGFhYV8yMjQx_f9d3a612-d23b-47e0-b4e4-d61d8152cc7b">0-24260</dei:EntityFileNumber>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xL2ZyYWc6ZTM1NThjNTE5NTgyNGJhYmFlYzYwYjYxMGIxZTRhYWEvdGFibGU6NDQ5ZTVjZmQzYTFkNGNmNDg4ZjUzYTczOTUzMTRjY2MvdGFibGVyYW5nZTo0NDllNWNmZDNhMWQ0Y2Y0ODhmNTNhNzM5NTMxNGNjY18xLTAtMS0xLTA_c275c07c-3dc2-4982-a529-1d5d5a583956">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xL2ZyYWc6ZTM1NThjNTE5NTgyNGJhYmFlYzYwYjYxMGIxZTRhYWEvdGFibGU6NDQ5ZTVjZmQzYTFkNGNmNDg4ZjUzYTczOTUzMTRjY2MvdGFibGVyYW5nZTo0NDllNWNmZDNhMWQ0Y2Y0ODhmNTNhNzM5NTMxNGNjY18xLTItMS0xLTA_d86edf01-ed70-4a71-9631-286ecff476ae">11-3131700</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xL2ZyYWc6ZTM1NThjNTE5NTgyNGJhYmFlYzYwYjYxMGIxZTRhYWEvdGV4dHJlZ2lvbjplMzU1OGM1MTk1ODI0YmFiYWVjNjBiNjEwYjFlNGFhYV8yMjQ3_a4bfb04b-7de8-4b3d-a6b7-a8ed2eb90572">3854 American Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xL2ZyYWc6ZTM1NThjNTE5NTgyNGJhYmFlYzYwYjYxMGIxZTRhYWEvdGV4dHJlZ2lvbjplMzU1OGM1MTk1ODI0YmFiYWVjNjBiNjEwYjFlNGFhYV8yMjQ4_6a7ec2fa-dc1b-4ddd-b89d-545f89f5f142">Suite A</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xL2ZyYWc6ZTM1NThjNTE5NTgyNGJhYmFlYzYwYjYxMGIxZTRhYWEvdGV4dHJlZ2lvbjplMzU1OGM1MTk1ODI0YmFiYWVjNjBiNjEwYjFlNGFhYV8yMjQy_f10e90c2-237a-4aa1-b3ff-f5898c7dbdf1">Baton Rouge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xL2ZyYWc6ZTM1NThjNTE5NTgyNGJhYmFlYzYwYjYxMGIxZTRhYWEvdGV4dHJlZ2lvbjplMzU1OGM1MTk1ODI0YmFiYWVjNjBiNjEwYjFlNGFhYV8yMjQ5_7a86daa7-5482-4beb-b78f-23f46f6c2d2d">LA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xL2ZyYWc6ZTM1NThjNTE5NTgyNGJhYmFlYzYwYjYxMGIxZTRhYWEvdGV4dHJlZ2lvbjplMzU1OGM1MTk1ODI0YmFiYWVjNjBiNjEwYjFlNGFhYV8yMjUw_36a9a6d9-fd86-492d-bb1e-c7220a4d5f6c">70816</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xL2ZyYWc6ZTM1NThjNTE5NTgyNGJhYmFlYzYwYjYxMGIxZTRhYWEvdGV4dHJlZ2lvbjplMzU1OGM1MTk1ODI0YmFiYWVjNjBiNjEwYjFlNGFhYV8yMjUx_3343e9b8-1677-4723-8b0d-6c7dd12e2348">225</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xL2ZyYWc6ZTM1NThjNTE5NTgyNGJhYmFlYzYwYjYxMGIxZTRhYWEvdGV4dHJlZ2lvbjplMzU1OGM1MTk1ODI0YmFiYWVjNjBiNjEwYjFlNGFhYV8yMjQ0_ca0cb3ac-ce2d-4a94-b7e4-bb914ff229fb">292-2031</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xL2ZyYWc6ZTM1NThjNTE5NTgyNGJhYmFlYzYwYjYxMGIxZTRhYWEvdGFibGU6ZGM5ZWQ1YjU2ZjQ2NDMzYWEzNzI3YWU5YWJkN2FiYjYvdGFibGVyYW5nZTpkYzllZDViNTZmNDY0MzNhYTM3MjdhZTlhYmQ3YWJiNl8xLTAtMS0xLTA_2b6d4ca5-5fff-4fe3-ad2c-1df737a96f17">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xL2ZyYWc6ZTM1NThjNTE5NTgyNGJhYmFlYzYwYjYxMGIxZTRhYWEvdGFibGU6ZGM5ZWQ1YjU2ZjQ2NDMzYWEzNzI3YWU5YWJkN2FiYjYvdGFibGVyYW5nZTpkYzllZDViNTZmNDY0MzNhYTM3MjdhZTlhYmQ3YWJiNl8xLTItMS0xLTA_885644ab-6915-43b9-a5a4-ddda06a41d15">AMED</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xL2ZyYWc6ZTM1NThjNTE5NTgyNGJhYmFlYzYwYjYxMGIxZTRhYWEvdGFibGU6ZGM5ZWQ1YjU2ZjQ2NDMzYWEzNzI3YWU5YWJkN2FiYjYvdGFibGVyYW5nZTpkYzllZDViNTZmNDY0MzNhYTM3MjdhZTlhYmQ3YWJiNl8xLTQtMS0xLTA_15ccd024-faed-4021-b758-4dcc4887eacd">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xL2ZyYWc6ZTM1NThjNTE5NTgyNGJhYmFlYzYwYjYxMGIxZTRhYWEvdGV4dHJlZ2lvbjplMzU1OGM1MTk1ODI0YmFiYWVjNjBiNjEwYjFlNGFhYV8yMjQ1_101c9871-b74f-4248-b09f-13c5565e4281">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xL2ZyYWc6ZTM1NThjNTE5NTgyNGJhYmFlYzYwYjYxMGIxZTRhYWEvdGV4dHJlZ2lvbjplMzU1OGM1MTk1ODI0YmFiYWVjNjBiNjEwYjFlNGFhYV8yMjUy_32d85425-510d-4bac-a479-68264a6f07f8">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xL2ZyYWc6ZTM1NThjNTE5NTgyNGJhYmFlYzYwYjYxMGIxZTRhYWEvdGFibGU6NjBlN2MwNWQ3ZWQyNDI3MWIxNzE0ZTdlM2Q3N2VjNDEvdGFibGVyYW5nZTo2MGU3YzA1ZDdlZDI0MjcxYjE3MTRlN2UzZDc3ZWM0MV8xLTAtMS0xLTA_b222ef99-091c-4dac-a3dc-d33feb875913">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xL2ZyYWc6ZTM1NThjNTE5NTgyNGJhYmFlYzYwYjYxMGIxZTRhYWEvdGFibGU6NjBlN2MwNWQ3ZWQyNDI3MWIxNzE0ZTdlM2Q3N2VjNDEvdGFibGVyYW5nZTo2MGU3YzA1ZDdlZDI0MjcxYjE3MTRlN2UzZDc3ZWM0MV8zLTYtMS0xLTA_8635d344-3db7-4d7c-a079-a0659f6814ae">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xL2ZyYWc6ZTM1NThjNTE5NTgyNGJhYmFlYzYwYjYxMGIxZTRhYWEvdGFibGU6NjBlN2MwNWQ3ZWQyNDI3MWIxNzE0ZTdlM2Q3N2VjNDEvdGFibGVyYW5nZTo2MGU3YzA1ZDdlZDI0MjcxYjE3MTRlN2UzZDc3ZWM0MV81LTItMS0xLTA_348f86c9-128e-4a01-a6ff-6336d66e566a">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xL2ZyYWc6ZTM1NThjNTE5NTgyNGJhYmFlYzYwYjYxMGIxZTRhYWEvdGV4dHJlZ2lvbjplMzU1OGM1MTk1ODI0YmFiYWVjNjBiNjEwYjFlNGFhYV8yMjQz_ea236f24-0a9e-4303-ae7c-240160ad4aa1">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ie94809e1cf0d453a8421029757c0fff8_I20200501"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xL2ZyYWc6ZTM1NThjNTE5NTgyNGJhYmFlYzYwYjYxMGIxZTRhYWEvdGV4dHJlZ2lvbjplMzU1OGM1MTk1ODI0YmFiYWVjNjBiNjEwYjFlNGFhYV8yMjA4_40c9298f-a64c-42d6-9e6e-d358e0a3f36a"
      unitRef="shares">32379165</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMy0xLTEtMS0w_bdbb7362-2beb-40ec-a046-8fdbe6f7a68e"
      unitRef="usd">174756000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i014c385050454730837d592e15bca5e0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMy0zLTEtMS0w_dab6dfff-2759-4b83-8a90-f29c98bcddcc"
      unitRef="usd">30294000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfNC0xLTEtMS0zMw_311a7ef2-b9ff-4b98-9bf2-ebe2d7c92638"
      unitRef="usd">3056000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i014c385050454730837d592e15bca5e0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfNC0zLTEtMS0zMA_f0255c26-a546-42df-a235-6ed46f4c3ebd"
      unitRef="usd">66196000</us-gaap:RestrictedCash>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfNC0xLTEtMS0w_7da6ebc6-6022-4589-ad5d-5d2c8ba703ad"
      unitRef="usd">268551000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i014c385050454730837d592e15bca5e0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfNC0zLTEtMS0w_008b2f6d-22d9-4185-9616-965dae67387b"
      unitRef="usd">237596000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfNS0xLTEtMS0w_d9d95af0-d8b5-4208-90e1-462902030946"
      unitRef="usd">12487000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i014c385050454730837d592e15bca5e0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfNS0zLTEtMS0w_36836d27-3bdf-4131-a282-e99e14742a2f"
      unitRef="usd">8243000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfNi0xLTEtMS0w_9b8eb868-593a-4a8b-868f-2aabdf6bed54"
      unitRef="usd">9278000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i014c385050454730837d592e15bca5e0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfNi0zLTEtMS0w_fef5d5cd-8ea5-49b3-a99e-1e3533d216a4"
      unitRef="usd">8225000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfNy0xLTEtMS0w_49ec0bd1-8f2e-4d88-afae-8b907d8b2318"
      unitRef="usd">468128000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i014c385050454730837d592e15bca5e0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfNy0zLTEtMS0w_07383549-7f45-40d0-acbe-c8db12a265d6"
      unitRef="usd">350554000</us-gaap:AssetsCurrent>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfOC0wLTEtMS0wL3RleHRyZWdpb246Nzc4N2ZlZWVmMDQ0NGI5YTkxYTZjYjIzMDRlNjA2NDdfMTY0OTI2NzQ0MTc2Mw_85d4997d-1893-4e75-8f39-793fa38c5dbe"
      unitRef="usd">98472000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i014c385050454730837d592e15bca5e0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfOC0wLTEtMS0wL3RleHRyZWdpb246Nzc4N2ZlZWVmMDQ0NGI5YTkxYTZjYjIzMDRlNjA2NDdfMTY0OTI2NzQ0MTc1Mw_3d5974b0-e9be-41ec-807b-d7e993565293"
      unitRef="usd">96137000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfOC0xLTEtMS0w_6ab4d132-0d0e-4dd9-9bfe-1936da31a5e7"
      unitRef="usd">26477000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i014c385050454730837d592e15bca5e0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfOC0zLTEtMS0w_38ee4144-2f26-4ca5-8eb6-ab6ea15d1faf"
      unitRef="usd">28113000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfOS0xLTEtMS0w_b43f2936-7d87-4b93-9cd4-42a057388fb6"
      unitRef="usd">83693000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i014c385050454730837d592e15bca5e0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfOS0zLTEtMS0w_b3f5cd14-1588-4fcc-9038-ef24e3291175"
      unitRef="usd">84791000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill
      contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMTAtMS0xLTEtMA_cfde875f-52cc-4ae1-9c24-b72b1b6a3c59"
      unitRef="usd">721049000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i014c385050454730837d592e15bca5e0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMTAtMy0xLTEtMA_022f796a-07f5-4566-8447-6ff1748a1b35"
      unitRef="usd">658500000</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMTEtMC0xLTEtMC90ZXh0cmVnaW9uOjE3MTA5M2Q3ODM0ODQ3MTliNTEyOTdkYWUwNjNkY2QzXzE2NDkyNjc0NDE3NDc_4ccc0543-1bf9-4fb5-975b-980c6234f714"
      unitRef="usd">9341000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i014c385050454730837d592e15bca5e0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMTEtMC0xLTEtMC90ZXh0cmVnaW9uOjE3MTA5M2Q3ODM0ODQ3MTliNTEyOTdkYWUwNjNkY2QzXzE2NDkyNjc0NDE3NTc_fe0786e5-f3cf-4bea-8548-91d93b22eef2"
      unitRef="usd">7044000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMTEtMS0xLTEtMA_48f9c2d9-539b-4d9b-a7b6-7cc7deaf8046"
      unitRef="usd">68251000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i014c385050454730837d592e15bca5e0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMTEtMy0xLTEtMA_16100f3c-cab9-4d9c-b4a8-da106361e52b"
      unitRef="usd">64748000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMTItMS0xLTEtMA_d124ca42-f7bd-43a8-b3b6-631c6e45ada3"
      unitRef="usd">20199000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i014c385050454730837d592e15bca5e0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMTItMy0xLTEtMA_d841d204-a41f-45ff-9b66-d58f0a917d74"
      unitRef="usd">21427000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMTMtMS0xLTEtMA_2b81b338-4a78-4d08-8cad-e7af13b8ede9"
      unitRef="usd">52287000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i014c385050454730837d592e15bca5e0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMTMtMy0xLTEtMA_115de8c6-10b4-4b2f-856b-dc1f23a2ed64"
      unitRef="usd">54612000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMTQtMS0xLTEtMA_b839c514-b1e7-4848-beb4-596116260cfb"
      unitRef="usd">1440084000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i014c385050454730837d592e15bca5e0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMTQtMy0xLTEtMA_44db823c-f663-4693-bbed-f44e3f3d9487"
      unitRef="usd">1262745000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMTctMS0xLTEtMA_e8edd55e-3609-4a4b-8ada-c7a6219737f1"
      unitRef="usd">31147000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i014c385050454730837d592e15bca5e0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMTctMy0xLTEtMA_3ef3f1eb-5064-4138-8dab-72d115c1d991"
      unitRef="usd">31259000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMTgtMS0xLTEtMA_2f2b554a-f67e-4be2-85ba-fdbade897916"
      unitRef="usd">109713000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i014c385050454730837d592e15bca5e0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMTgtMy0xLTEtMA_f3faa828-eb6d-4255-b870-4acd54b39d9d"
      unitRef="usd">120877000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMTktMS0xLTEtMA_b892f384-bb19-40c6-b456-e94ed8b19f5d"
      unitRef="usd">136659000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i014c385050454730837d592e15bca5e0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMTktMy0xLTEtMA_0221039c-4757-48df-a8cb-ed79fcfbb1f9"
      unitRef="usd">137111000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMjAtMS0xLTEtMA_ef352ce9-39ee-45c0-8931-a8d736121e6d"
      unitRef="usd">11122000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="i014c385050454730837d592e15bca5e0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMjAtMy0xLTEtMA_f5954305-906d-4aa1-8b62-bf38d660e1aa"
      unitRef="usd">9927000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMjEtMS0xLTEtMA_ad31173c-0447-4763-b5b8-b20e0bad4d2e"
      unitRef="usd">27465000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i014c385050454730837d592e15bca5e0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMjEtMy0xLTEtMA_f2d87782-55b4-4d78-91e2-07cd671d97d5"
      unitRef="usd">27769000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMjItMS0xLTEtMA_196fec40-321d-4485-9070-4670e1ca172f"
      unitRef="usd">316106000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i014c385050454730837d592e15bca5e0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMjItMy0xLTEtMA_a8a168a9-681b-4285-a689-8e9cf997d82f"
      unitRef="usd">326943000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMjMtMS0xLTEtMA_d70a1715-8719-4fa8-bd7a-c973851a6209"
      unitRef="usd">379942000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="i014c385050454730837d592e15bca5e0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMjMtMy0xLTEtMA_e0dc9aa1-562a-4a05-b164-12923d9e8cc9"
      unitRef="usd">232256000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMjQtMS0xLTEtMA_5f253900-a5a4-4e96-9b07-b7d3452b0e1f"
      unitRef="usd">54926000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i014c385050454730837d592e15bca5e0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMjQtMy0xLTEtMA_b9ac735e-ecfd-4249-8325-dbdddfd9ec0c"
      unitRef="usd">56128000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMjUtMS0xLTEtMA_ab59c3e2-0b0d-4467-9212-dcb0d0d596c6"
      unitRef="usd">8966000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i014c385050454730837d592e15bca5e0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMjUtMy0xLTEtMA_16fbba52-8025-4e4a-907b-b0e6bee431dc"
      unitRef="usd">5905000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMjYtMS0xLTEtMA_9ba3cff2-79d6-485a-ab5e-b058db6f192a"
      unitRef="usd">759940000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i014c385050454730837d592e15bca5e0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMjYtMy0xLTEtMA_ebf8edb8-464b-42d0-891e-6f904a10a119"
      unitRef="usd">621232000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMjctMS0xLTEtMA_cdfda4df-4aa2-4264-9889-d14ad017e84c"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmMxMjJmZmYzNjQzNzQyOGU4YTRlZTY5OGFkMzVlN2ZhXzE2NDkyNjc0NDE3NjQ_3dd4f1e2-646e-4482-91ce-8b44478d89a1"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmMxMjJmZmYzNjQzNzQyOGU4YTRlZTY5OGFkMzVlN2ZhXzE2NDkyNjc0NDE3NzU_6dcaf4b0-6272-4c91-93c5-9d21f19101e5"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockValueOutstanding
      contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMjktMS0xLTEtMA_a74f75e2-d33b-4bb3-9c5f-ee8c34255159"
      unitRef="usd">0</us-gaap:PreferredStockValueOutstanding>
    <us-gaap:PreferredStockValueOutstanding
      contextRef="i014c385050454730837d592e15bca5e0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMjktMy0xLTEtMA_eb58362a-5082-471f-ae97-4354fa042c11"
      unitRef="usd">0</us-gaap:PreferredStockValueOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmYwYTlhM2Q0YmU3MjQwY2ZhZjcxMTdjNTQ5OGYwODk2XzE2NDkyNjc0NDE4MjY_61194800-c7a2-4ea7-af63-b3641af56eac"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmYwYTlhM2Q0YmU3MjQwY2ZhZjcxMTdjNTQ5OGYwODk2XzE2NDkyNjc0NDE4Mzk_1cedb7b5-b681-4605-9b07-c053e8b02dd8"
      unitRef="shares">60000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmYwYTlhM2Q0YmU3MjQwY2ZhZjcxMTdjNTQ5OGYwODk2XzE2NDkyNjc0NDE4NTE_abd3cf5e-2acc-4c8a-a324-604090f78b2a"
      unitRef="shares">36746554</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i014c385050454730837d592e15bca5e0_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmYwYTlhM2Q0YmU3MjQwY2ZhZjcxMTdjNTQ5OGYwODk2XzE2NDkyNjc0NDE4NjM_7753cb12-cac0-4c17-87bc-ac853e5ac2f0"
      unitRef="shares">36638021</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmYwYTlhM2Q0YmU3MjQwY2ZhZjcxMTdjNTQ5OGYwODk2XzE2NDkyNjc0NDE4NzU_e1ed1fba-8021-4f88-aaf7-b004223cdf52"
      unitRef="shares">32370345</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i014c385050454730837d592e15bca5e0_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmYwYTlhM2Q0YmU3MjQwY2ZhZjcxMTdjNTQ5OGYwODk2XzE2NDkyNjc0NDE4OTA_77ff90ed-b6c0-4ed8-ba85-558733c4eda1"
      unitRef="shares">32284051</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMzAtMS0xLTEtMA_dfb6be1f-4162-47c2-9659-b7fc224c9263"
      unitRef="usd">37000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="i014c385050454730837d592e15bca5e0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMzAtMy0xLTEtMA_1fdd763a-df88-4630-8719-064aa430b188"
      unitRef="usd">37000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMzEtMS0xLTEtMA_632b83f3-e7b4-4709-8415-3ada4e274fca"
      unitRef="usd">656266000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i014c385050454730837d592e15bca5e0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMzEtMy0xLTEtMA_fcd927ec-c2a6-460f-8265-403340f9aaba"
      unitRef="usd">645256000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:TreasuryStockShares
      contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmNkYWM2ZTBiNWMzOTQzNDZiYTQ5YTcyMDkxMzliZTM2XzE2NDkyNjc0NDE3NDc_85b8f11e-4fc1-44a4-8669-8a7b7c352e18"
      unitRef="shares">4376209</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="i014c385050454730837d592e15bca5e0_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmNkYWM2ZTBiNWMzOTQzNDZiYTQ5YTcyMDkxMzliZTM2XzE2NDkyNjc0NDE3NTg_f5acec34-d05a-41a5-a5b0-884efa3f251a"
      unitRef="shares">4353970</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMzItMS0xLTEtMA_5d46b371-c506-4c9f-b01b-6c7006d36938"
      unitRef="usd">255291000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="i014c385050454730837d592e15bca5e0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMzItMy0xLTEtMA_7f4250fd-94eb-4a2b-9a1b-1e44247dc6e8"
      unitRef="usd">251241000</us-gaap:TreasuryStockValue>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMzMtMS0xLTEtMA_5f5888dc-06d4-4af3-bc5d-a1c415d1cd09"
      unitRef="usd">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i014c385050454730837d592e15bca5e0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMzMtMy0xLTEtMA_74c2b50e-ed24-4d3c-8b4b-00a5891e3443"
      unitRef="usd">15000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMzQtMS0xLTEtMA_c150979f-a3b2-4fc1-a23d-2196ac15ce6d"
      unitRef="usd">278185000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i014c385050454730837d592e15bca5e0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMzQtMy0xLTEtMA_2c4b428f-b95e-4476-b083-7093db11b373"
      unitRef="usd">246383000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMzUtMS0xLTEtMA_adadf53b-a6a9-4b48-907c-731caae70cf1"
      unitRef="usd">679197000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i014c385050454730837d592e15bca5e0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMzUtMy0xLTEtMA_508d4c12-4674-4290-9873-661a7c11a106"
      unitRef="usd">640450000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMzYtMS0xLTEtMA_2a1930d1-065b-48a2-8ec7-ed99879260c7"
      unitRef="usd">947000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i014c385050454730837d592e15bca5e0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMzYtMy0xLTEtMA_d705520d-31e8-4e45-9c6e-c12947ba7228"
      unitRef="usd">1063000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMzctMS0xLTEtMA_59ca4920-c3ce-41df-a154-c7f15798f6da"
      unitRef="usd">680144000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i014c385050454730837d592e15bca5e0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMzctMy0xLTEtMA_f3cd80a0-49a8-45df-851c-34d58fbb3c5a"
      unitRef="usd">641513000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMzgtMS0xLTEtMA_63cd6e1f-6897-432d-add7-ab283e0860db"
      unitRef="usd">1440084000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i014c385050454730837d592e15bca5e0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8xOS9mcmFnOjgyMjBjOWMzZDM1NDRkNDQ4MGUzOTA0YmE5YjhiNjcyL3RhYmxlOjlmYmQ3N2U3OTc3MzQxOTE4NDBmZGE1NzAxYzhhMTJkL3RhYmxlcmFuZ2U6OWZiZDc3ZTc5NzczNDE5MTg0MGZkYTU3MDFjOGExMmRfMzgtMy0xLTEtMA_99d78495-d764-403a-a35e-989f49078164"
      unitRef="usd">1262745000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMi0xLTEtMS0w_29c2c494-87aa-4583-a1c1-8e0cb4a1c40b"
      unitRef="usd">491685000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMi0zLTEtMS0w_bfe1f36e-8651-4457-9fc7-88a33020a90c"
      unitRef="usd">467340000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMy0xLTEtMS0w_5934d60a-1541-4dbf-84f1-dc3c15861388"
      unitRef="usd">285737000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMy0zLTEtMS0w_da37b35b-3328-4186-8b35-98b38e0afdf3"
      unitRef="usd">275274000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:LaborAndRelatedExpense
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfNS0xLTEtMS0w_8ee3a7d9-6d76-406f-b3b5-e506eafcde0b"
      unitRef="usd">101566000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfNS0zLTEtMS0w_d5f50a86-aaa5-449e-9bb1-e18975f86ef5"
      unitRef="usd">94830000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfNi0xLTEtMS0w_92aaf2df-4bfb-408c-95bc-ac6d6c108571"
      unitRef="usd">5909000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfNi0zLTEtMS0w_efc3a938-12cd-4ff8-a714-366e1942070e"
      unitRef="usd">6615000</us-gaap:ShareBasedCompensation>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfNy0xLTEtMS0w_accdd821-3f11-481d-844e-438c357d2990"
      unitRef="usd">49265000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfNy0zLTEtMS0w_fb2017dd-bb96-46e3-b90e-a4961936c5e6"
      unitRef="usd">43402000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfOC0xLTEtMS0w_f80dd8fe-f136-4754-8a5d-dee0d3c5d386"
      unitRef="usd">5338000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfOC0zLTEtMS0w_93a112ea-c9c5-4d9f-9cf6-77c332db0459"
      unitRef="usd">2895000</us-gaap:DepreciationAndAmortization>
    <us-gaap:CostsAndExpenses
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfOS0xLTEtMS0w_46652bdc-7bee-4a4c-aec4-526b76456889"
      unitRef="usd">447815000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfOS0zLTEtMS0w_00e94191-a1c2-4d32-a2d7-7e95c3cef369"
      unitRef="usd">423016000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMTAtMS0xLTEtMA_2b5f24f8-7159-41b0-9e13-fc9d71eb320a"
      unitRef="usd">43870000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMTAtMy0xLTEtMA_24d88988-14f1-4697-9194-e294ca553242"
      unitRef="usd">44324000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMTItMS0xLTEtMA_6dbd92f9-5479-4d16-9ff4-dd83ed1f8004"
      unitRef="usd">13000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMTItMy0xLTEtMA_4459e784-02a4-426e-a064-62bad916e1e7"
      unitRef="usd">24000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InterestExpense
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMTMtMS0xLTEtMA_a972c8ac-1142-436f-a8f3-b6f07fc7ebd8"
      unitRef="usd">3231000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMTMtMy0xLTEtMA_c0a5929b-e3d4-4162-acc8-f1b8368410c3"
      unitRef="usd">3349000</us-gaap:InterestExpense>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMTQtMS0xLTEtMA_1afac7cc-5945-470a-a059-fcb6c97cda3c"
      unitRef="usd">477000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMTQtMy0xLTEtMA_e3b75ea1-a2f0-49a8-b948-410eb3526ae1"
      unitRef="usd">1216000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMTUtMS0xLTEtMA_424eef7a-8ef9-4acc-9f73-6ce1bd0e3bb2"
      unitRef="usd">263000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMTUtMy0xLTEtMA_5f825db8-cee3-4875-bf2b-98f4cb8dcfd6"
      unitRef="usd">236000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMTYtMS0xLTEtMA_0714eba1-6201-4a55-ad4b-f652964ac5b0"
      unitRef="usd">-2478000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMTYtMy0xLTEtMA_79670c26-5284-4532-bb52-ac5ff29cfcf5"
      unitRef="usd">-1873000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMTctMS0xLTEtMA_a1e49ebb-045f-46cb-aeb7-ae3e2dd733bf"
      unitRef="usd">41392000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMTctMy0xLTEtMA_c5efec3e-db22-4f16-a707-c628832966f4"
      unitRef="usd">42451000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMTgtMS0xLTEtMA_1fff05e0-bf0e-4b44-a020-6f4b4c4d121f"
      unitRef="usd">9346000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMTgtMy0xLTEtMA_76c6f8bb-4ecc-4e63-afb0-2d0b05c1f6dd"
      unitRef="usd">10878000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMTktMS0xLTEtMA_a2b677f9-3530-46f0-bf31-0112d759b71f"
      unitRef="usd">32046000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMTktMy0xLTEtMA_9208aa22-fda8-4845-894c-c7e87dfd0f52"
      unitRef="usd">31573000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMjAtMS0xLTEtMA_73e89f53-745b-4ca3-b059-82df005d8c22"
      unitRef="usd">244000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMjAtMy0xLTEtMA_69543b07-9845-47cf-955c-cf413a2a2e7b"
      unitRef="usd">269000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMjEtMS0xLTEtMA_9adc08bb-0053-4f64-9fe4-76779876ed85"
      unitRef="usd">31802000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMjEtMy0xLTEtMA_0e0495a0-5f84-4a53-b669-44f59c2987fa"
      unitRef="usd">31304000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMjMtMS0xLTEtMA_c6fbb07d-ce40-4aa6-a260-a0c868de0050"
      unitRef="usdPerShare">0.98</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMjMtMy0xLTEtMA_69489146-f5a7-43e6-8d8e-7327329b5a2f"
      unitRef="usdPerShare">0.98</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMjQtMS0xLTEtMA_1c8e0782-8951-4fdf-9d89-8de9577cdb9a"
      unitRef="shares">32331000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMjQtMy0xLTEtMA_7484f902-a029-48d1-ad64-5621f3ca7e92"
      unitRef="shares">32001000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMjYtMS0xLTEtMA_34eab55a-6462-4f92-aeb7-43d39cb45467"
      unitRef="usdPerShare">0.96</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMjYtMy0xLTEtMA_a9fd4e2f-d72e-41a2-8db9-80b77e0fbe04"
      unitRef="usdPerShare">0.95</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMjctMS0xLTEtMA_c5b7220e-b56f-43be-bbe4-5593e14b304e"
      unitRef="shares">33234000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yNS9mcmFnOjQ5ODYzZmIyOGJkYTRkZDY4MzdiNmUwYTM5ODRmMmU1L3RhYmxlOjI3ZDQ4YTk4ZDZlNjQ1Mzc5ZjM1NDAyYWRmNDVmM2YwL3RhYmxlcmFuZ2U6MjdkNDhhOThkNmU2NDUzNzlmMzU0MDJhZGY0NWYzZjBfMjctMy0xLTEtMA_61be274d-ab6e-4961-841c-509febb6a9c7"
      unitRef="shares">32893000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i014c385050454730837d592e15bca5e0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMy0xLTEtMS0w_6b4bf251-5220-4ec0-a60e-7d85ffc311f3"
      unitRef="usd">641513000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i379583ecb9374798b4c230bb394c2c67_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMy0zLTEtMS0w_e86ea137-6cf8-4d9c-ad89-797c545ebb1b"
      unitRef="shares">36638021</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i379583ecb9374798b4c230bb394c2c67_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMy01LTEtMS0w_ea1e59ec-f051-4f7d-a4f5-d49c11e1ce76"
      unitRef="usd">37000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6a5040a26fb048c0a87bf6f051f93896_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMy03LTEtMS0w_4dca8c99-d644-4b2d-8d0d-6e1625b7258a"
      unitRef="usd">645256000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3febdb7171a24ee1801a9231cc9591f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMy05LTEtMS0w_7e3e0689-027b-4530-91e7-7f176d656d22"
      unitRef="usd">-251241000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i74e0f28f8b654d48a67abd821a86e3c4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMy0xMS0xLTEtMA_fdaf3b93-446b-461e-8e72-c0aab61d4341"
      unitRef="usd">15000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iae980ac5b3a541419edf1dafb6f4c6f5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMy0xMy0xLTEtMA_6b7ac594-7788-430f-a471-49a1f7309318"
      unitRef="usd">246383000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iea78279e652f4d91ae574d24a6286705_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMy0xNS0xLTEtMA_386234b8-007d-4787-9ca0-404768a31fc7"
      unitRef="usd">1063000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfNC0xLTEtMS0w_1d9dde6d-e285-4c5f-9309-760ced45228e"
      unitRef="usd">860000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ic64b3c79c65143a4a4af6c36f8b99fcf_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfNC0zLTEtMS0w_d3aa4715-218d-4672-8ae0-171898b8637b"
      unitRef="shares">6063</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ife895f7907c04cc1809e6c1fec83c56f_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfNC03LTEtMS0w_f9c25b4d-f545-4424-91d2-e06995600049"
      unitRef="usd">860000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfNS0xLTEtMS0w_9d95314a-2a0c-477b-bfcb-e0643acffca3"
      unitRef="usd">3057000</amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch>
    <amed:StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch
      contextRef="ic64b3c79c65143a4a4af6c36f8b99fcf_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfNS0zLTEtMS0w_9f1d4dc6-fc56-49a6-b90f-a0c88aaf4536"
      unitRef="shares">18312</amed:StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch>
    <amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch
      contextRef="ife895f7907c04cc1809e6c1fec83c56f_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfNS03LTEtMS0w_88ae8b7e-4117-4e5c-b2a1-447cc2c95724"
      unitRef="usd">3057000</amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfNi0xLTEtMS0w_251850d2-e1ba-454a-8a12-330ec352ed9e"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="ic64b3c79c65143a4a4af6c36f8b99fcf_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfNi0zLTEtMS0w_4b293d7a-8596-4dc0-88fe-c951bd0573c5"
      unitRef="shares">55423</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="ic64b3c79c65143a4a4af6c36f8b99fcf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfNi01LTEtMS0w_a296ff57-b955-435f-9168-fd7b165f8194"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="ife895f7907c04cc1809e6c1fec83c56f_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfNi03LTEtMS0w_4e4f75ce-4795-48c0-b5d1-d6cdc6a388bc"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfNy0xLTEtMS0w_4f70ed14-ccd9-408a-977d-8a5b009b0cdd"
      unitRef="usd">1184000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ic64b3c79c65143a4a4af6c36f8b99fcf_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfNy0zLTEtMS0w_2baf77ff-f2c4-4dd8-9f6a-cf4799473201"
      unitRef="shares">28735</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ife895f7907c04cc1809e6c1fec83c56f_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfNy03LTEtMS0w_67b4c242-e253-41d5-a71e-4f141d820a7c"
      unitRef="usd">1184000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfOC0xLTEtMS0w_468b063d-8587-465e-937c-2104fb1f8e4b"
      unitRef="usd">5909000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ife895f7907c04cc1809e6c1fec83c56f_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfOC03LTEtMS0w_52daeb12-eb67-4a0d-a38e-8ffa1e0af9d5"
      unitRef="usd">5909000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <amed:SurrenderedShares
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfOS0xLTEtMS0w_e4c0d854-e86d-49bf-a017-46d746474614"
      unitRef="usd">4050000</amed:SurrenderedShares>
    <amed:SurrenderedShares
      contextRef="i24fbf8ed4ce94e058258628cf71035a5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfOS05LTEtMS0w_9f729dd7-0bd6-4a8f-9cb3-fcedceda90ee"
      unitRef="usd">4050000</amed:SurrenderedShares>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMTAtMS0xLTEtMA_ed762b39-558a-42c7-a47f-d1f7c6942c4e"
      unitRef="usd">360000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i3897e7c6671f45b2a1b361f76b28fea4_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMTAtMTUtMS0xLTA_fd086ab2-877c-4dc2-be93-abcd2e299c3e"
      unitRef="usd">360000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <amed:EquityImpactOfWriteOffOfOtherComprehensiveIncome
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMTEtMS0xLTEtMTU5Mw_ce3e6d41-2305-4e8b-bcf1-a640500e63c2"
      unitRef="usd">15000</amed:EquityImpactOfWriteOffOfOtherComprehensiveIncome>
    <amed:EquityImpactOfWriteOffOfOtherComprehensiveIncome
      contextRef="i766b3828bac34e55bd02b261a75f847a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMTEtMTEtMS0xLTE1OTM_f12d5dfc-69b0-4eef-b4d9-c0bd690dcda9"
      unitRef="usd">15000</amed:EquityImpactOfWriteOffOfOtherComprehensiveIncome>
    <us-gaap:ProfitLoss
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMTEtMS0xLTEtMA_18d0b2a8-e76d-4e88-ad67-952f571d9aed"
      unitRef="usd">32046000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ib4ce05f08cf04e5691c12539b7c46390_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMTEtMTMtMS0xLTA_cdcd3460-d27f-4d74-9b9c-db8d0076763d"
      unitRef="usd">31802000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i3897e7c6671f45b2a1b361f76b28fea4_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMTEtMTUtMS0xLTA_2eaa0309-070b-4887-a4c0-710c73f70288"
      unitRef="usd">244000</us-gaap:ProfitLoss>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMTItMS0xLTEtMA_25ade516-3a21-4093-b47d-cd4e3160ff59"
      unitRef="usd">680144000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i0a470325c5bc4889b266f68e9544d3e5_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMTItMy0xLTEtMA_ccac0c1b-02c7-42c8-b782-78dc01cf68c5"
      unitRef="shares">36746554</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0a470325c5bc4889b266f68e9544d3e5_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMTItNS0xLTEtMA_047b92a2-4b5f-464a-982a-0f55e31a2c26"
      unitRef="usd">37000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iac55dce70a374679bd199e04eaa5b649_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMTItNy0xLTEtMA_a2a81ecc-77a4-4377-9867-6aa8283f164d"
      unitRef="usd">656266000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4ab26af603e844e9b6bdda46662485c3_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMTItOS0xLTEtMA_96b934fd-a752-432c-9549-71cb53c81bab"
      unitRef="usd">-255291000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1593f26e241b483ebd91cefceb35d199_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMTItMTEtMS0xLTA_24817f95-df94-4fe9-b86b-8cd4e43175e8"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idf11627cc0b7467f85b1368394bb2664_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMTItMTMtMS0xLTA_c45d0d7f-d40c-43f7-ae51-ecb6f4f13b2c"
      unitRef="usd">278185000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i30654d85149642fdae1198cad652319f_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMTItMTUtMS0xLTA_7f00ffee-e5a5-4a29-b798-08ed714630fe"
      unitRef="usd">947000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5070e06e0c374add9463ca31e59e3d55_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMTctMS0xLTEtMA_6dda3e4c-c8d1-4f19-bcea-e81986dbbe01"
      unitRef="usd">482633000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i89a07a7310c54227add149c2b0b87ee3_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMTctMy0xLTEtMA_b4ba4a44-1e4e-4118-ba31-22fe780a1540"
      unitRef="shares">36252280</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i89a07a7310c54227add149c2b0b87ee3_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMTctNS0xLTEtMA_a48d77cb-5eaf-478a-89af-3308895f7b0f"
      unitRef="usd">36000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib79791d3ae294c48a6a6f3b9d4237287_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMTctNy0xLTEtMA_c534c85f-54b1-4850-8ff7-67da30ae6173"
      unitRef="usd">603666000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2973a18d82d64089981faf633016e337_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMTctOS0xLTEtMA_bb0624da-dd09-4de3-859e-8721f7f14f3b"
      unitRef="usd">-241685000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib6e258d79aa94c7b85ea31dd68768540_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMTctMTEtMS0xLTA_a4fd8835-7cdb-4d44-ab84-4971530e4f5b"
      unitRef="usd">15000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i90b913e7ac1542e6928ba4790c344cb1_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMTctMTMtMS0xLTA_9e6ddd15-9787-42a2-a59b-660768ca9e4f"
      unitRef="usd">119550000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibd20ee3ceb1b468ca3e169ae4b78ec43_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMTctMTUtMS0xLTA_2ca29af7-ef9e-4cb0-9a64-ac96d81ddade"
      unitRef="usd">1051000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMTgtMS0xLTEtMA_63d2030e-705e-4df5-b7b8-c0c2c3cfd13e"
      unitRef="usd">782000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i24ae5ea6239844c1943ccc8250cf4d3e_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMTgtMy0xLTEtMA_6e15cccc-41f2-4a22-a202-f5a46b8db9f5"
      unitRef="shares">7856</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ie8ccec4951d54e429f9b0776571c27c8_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMTgtNy0xLTEtMA_68ae70c9-0020-4188-948c-1fe6e47940fb"
      unitRef="usd">782000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMTktMS0xLTEtMA_7e557e31-01e9-4869-a912-27c344b06e10"
      unitRef="usd">2295000</amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch>
    <amed:StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch
      contextRef="i24ae5ea6239844c1943ccc8250cf4d3e_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMTktMy0xLTEtMA_fdb0c951-4d31-4f15-a88f-890577e42912"
      unitRef="shares">19591</amed:StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch>
    <amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch
      contextRef="ie8ccec4951d54e429f9b0776571c27c8_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMTktNy0xLTEtMA_821f366b-39b3-4498-bb81-c05434d47f2e"
      unitRef="usd">2295000</amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMjAtMS0xLTEtMA_47c7d951-6a57-4469-970c-d509f95f666b"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i24ae5ea6239844c1943ccc8250cf4d3e_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMjAtMy0xLTEtMA_16d32944-9a8c-49c6-afc1-19011535365f"
      unitRef="shares">51162</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i24ae5ea6239844c1943ccc8250cf4d3e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMjAtNS0xLTEtMA_73ab1f3b-7ee7-4ef8-a9a5-ce9df2f6a68c"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="ie8ccec4951d54e429f9b0776571c27c8_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMjAtNy0xLTEtMA_4f4e294d-6075-4ee7-afad-564011390487"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMjEtMS0xLTEtMA_e86eb856-d77d-402c-9ceb-9fe9cd65261a"
      unitRef="usd">356000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i24ae5ea6239844c1943ccc8250cf4d3e_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMjEtMy0xLTEtMA_41830510-5a31-41ac-bf11-f8a6b08fa82c"
      unitRef="shares">6854</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ie8ccec4951d54e429f9b0776571c27c8_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMjEtNy0xLTEtMA_6cac0a6a-e976-4246-8496-55468009b6df"
      unitRef="usd">356000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMjItMS0xLTEtMA_80bcd415-2671-4fb7-bbde-c95c85841e27"
      unitRef="usd">6615000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie8ccec4951d54e429f9b0776571c27c8_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMjItNy0xLTEtMA_c418576f-8152-44cd-9909-640a0c9ec2fd"
      unitRef="usd">6615000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <amed:SurrenderedShares
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMjMtMS0xLTEtMA_d4b3a1b4-01f0-4b28-854b-44ce3e6173d0"
      unitRef="usd">2688000</amed:SurrenderedShares>
    <amed:SurrenderedShares
      contextRef="iae6e37863ef2446982ab4508cb5c6a4a_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMjMtOS0xLTEtMA_218ec680-2829-4194-b04d-de2a5066894b"
      unitRef="usd">2688000</amed:SurrenderedShares>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMjQtMS0xLTEtMA_6cc70ef1-9f8b-4044-aa8d-d6560fe9ddfd"
      unitRef="usd">366000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ia2a1f77af6c6468e80794d3e6619da24_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMjQtMTUtMS0xLTA_a43e656b-31d0-4682-a87d-4601cf9f45f8"
      unitRef="usd">366000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:ProfitLoss
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMjYtMS0xLTEtMA_768616ad-2c23-4f82-884f-30528d14c63d"
      unitRef="usd">31573000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ia3dbbd4d693549d08a550ff85e19d07e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMjYtMTMtMS0xLTA_31bbe0b3-ca4d-4629-b8b7-ed749e14d17e"
      unitRef="usd">31304000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ia2a1f77af6c6468e80794d3e6619da24_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMjYtMTUtMS0xLTA_281a8111-cb93-4399-bfc1-977156628a06"
      unitRef="usd">269000</us-gaap:ProfitLoss>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3202099b2aaf4cc88461f7725441d5a3_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMjctMS0xLTEtMA_c7f8b475-a40d-4dfc-880b-8b83468a7872"
      unitRef="usd">521200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="ie390be034b284f5082baf3f2f9d8d312_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMjctMy0xLTEtMA_87c7cb59-7022-4fcf-ac4b-ed022fae499e"
      unitRef="shares">36337743</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie390be034b284f5082baf3f2f9d8d312_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMjctNS0xLTEtMA_794bec10-f262-4804-85fa-4cf9424bd02f"
      unitRef="usd">36000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if286a7fc2ab5482e927587b135cac060_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMjctNy0xLTEtMA_2f353712-24c1-437e-9b6d-9ee45b620e11"
      unitRef="usd">613714000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0a118ef4adc642169df30733695018e7_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMjctOS0xLTEtMA_5defd606-23ef-41bc-9090-7e555826e29d"
      unitRef="usd">-244373000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i07447f32d01d4b719bba4d5394e101f1_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMjctMTEtMS0xLTA_91641b5c-11de-42c3-b170-46318f7b8c57"
      unitRef="usd">15000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9aced020e10e41469ac1511a249cd44a_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMjctMTMtMS0xLTA_2d21fa98-572c-4081-853d-bd53356ac8ec"
      unitRef="usd">150854000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie495d4805b994e769059ce32d0936a6c_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8yOC9mcmFnOjFhNWQ2YzNkNGI4YTRjNzQ5YTE0OWRhMjI3MzNlNjViL3RhYmxlOjljODUxOWUyNTNlYTQ1YzU5YzdjYzhjZWUzYWIwYTNlL3RhYmxlcmFuZ2U6OWM4NTE5ZTI1M2VhNDVjNTljN2NjOGNlZTNhYjBhM2VfMjctMTUtMS0xLTA_dd45aafc-ec68-4170-bf06-94bf71ff37df"
      unitRef="usd">954000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMy0xLTEtMS0w_7c7c55fe-ff7f-4425-b379-d334f53bd943"
      unitRef="usd">32046000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMy0zLTEtMS0w_c1d3331d-06fc-44f0-9973-ad7288af6738"
      unitRef="usd">31573000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfNS0xLTEtMS0w_cfe2879f-4e5d-4ec5-8798-f093da4f2781"
      unitRef="usd">5338000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfNS0zLTEtMS0w_a56a91c5-f6d3-4890-abdd-4c57ed5bf432"
      unitRef="usd">2895000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfNi0xLTEtMS0w_fe814b10-b879-49d9-9387-2a156fb7b00d"
      unitRef="usd">5909000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfNi0zLTEtMS0w_88565dd3-88c1-4898-92b8-f07e31702e5d"
      unitRef="usd">6615000</us-gaap:ShareBasedCompensation>
    <us-gaap:PensionExpense
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfNy0xLTEtMS0w_560ce0eb-9c29-4f7d-8c77-707cb0371fd9"
      unitRef="usd">3291000</us-gaap:PensionExpense>
    <us-gaap:PensionExpense
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfNy0zLTEtMS0w_4f0a1b49-2b15-45d9-812f-0ba5f60ee463"
      unitRef="usd">2379000</us-gaap:PensionExpense>
    <amed:AmortizationandImpairmentofOperatingLeaseRightOfUseAsset
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfOC0xLTEtMS0w_57f4463b-aed4-497a-96f4-1353086b80b8"
      unitRef="usd">9058000</amed:AmortizationandImpairmentofOperatingLeaseRightOfUseAsset>
    <amed:AmortizationandImpairmentofOperatingLeaseRightOfUseAsset
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfOC0zLTEtMS0w_a07970da-29ce-4b55-862b-80eb847832c2"
      unitRef="usd">8345000</amed:AmortizationandImpairmentofOperatingLeaseRightOfUseAsset>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfOS0xLTEtMS0w_c2fd7686-1b0b-4956-8e8a-c5bc2706f3c1"
      unitRef="usd">-55000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfOS0zLTEtMS0w_50ff3fea-ab3c-49d5-8675-79bc1220df53"
      unitRef="usd">4000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <amed:WriteOffOfOtherComprehensiveIncome
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMTAtMS0xLTEtMTc4Ng_e49da80c-d061-44c5-a978-d68b2ebce750"
      unitRef="usd">15000</amed:WriteOffOfOtherComprehensiveIncome>
    <amed:WriteOffOfOtherComprehensiveIncome
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMTAtMy0xLTEtMTc4Ng_53615347-1ef2-46f5-a14d-9946d8390e8d"
      unitRef="usd">0</amed:WriteOffOfOtherComprehensiveIncome>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMTAtMS0xLTEtMA_77e1fd52-1c34-4ee3-be66-8931f02fd2dd"
      unitRef="usd">1228000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMTAtMy0xLTEtMA_b48815c9-119a-46cd-b8ea-39bed4299cad"
      unitRef="usd">3269000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMTEtMS0xLTEtMA_1cf4aab1-afff-4ff0-9ab2-365768ff33c0"
      unitRef="usd">477000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMTEtMy0xLTEtMA_48630a4b-e342-4cdb-8ed2-d9af1fd6b433"
      unitRef="usd">1216000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMTItMS0xLTEtMA_5e552c12-439b-4869-ba3b-843e459fd890"
      unitRef="usd">220000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMTItMy0xLTEtMA_ab8e67ef-6abf-4b6e-9b19-dbedf18688d1"
      unitRef="usd">213000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMTMtMS0xLTEtMA_d2bc89dd-c1f3-4530-a5b7-395825b81cdb"
      unitRef="usd">2369000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMTMtMy0xLTEtMA_ec9102d3-4088-4894-8159-d141a1dd59cf"
      unitRef="usd">725000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMTUtMS0xLTEtMA_aac5eee4-10a3-4d4c-bde8-1f32fe83afb9"
      unitRef="usd">25459000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMTUtMy0xLTEtMA_e2ec9239-f6c6-4fa5-bcbe-d8b0f12be017"
      unitRef="usd">22333000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMTYtMS0xLTEtMA_98c73e65-cb08-459d-b592-01a50b95ed4a"
      unitRef="usd">5756000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMTYtMy0xLTEtMA_c1a8d14d-a161-475a-b655-ef372a35bcd2"
      unitRef="usd">10635000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMTctMS0xLTEtMA_ded1276a-3c05-4711-a156-af4c1389a7a0"
      unitRef="usd">-417000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMTctMy0xLTEtMA_e24e6687-597c-4315-b800-7be4e6981098"
      unitRef="usd">338000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMTgtMS0xLTEtMA_b6d8ab81-9378-45e5-8c17-67e3c448672f"
      unitRef="usd">-2673000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMTgtMy0xLTEtMA_5aae7927-fd4d-42e1-b601-66b3a640fd88"
      unitRef="usd">-11140000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMTktMS0xLTEtMA_620e097c-c25f-49ae-aeda-1fab635b9fd7"
      unitRef="usd">-13627000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMTktMy0xLTEtMA_b1622c95-774c-44c3-a5af-130c1c3130fe"
      unitRef="usd">18838000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMjAtMS0xLTEtMA_056efae0-ee16-4d26-b523-95e415a782dc"
      unitRef="usd">3060000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMjAtMy0xLTEtMA_5f470225-038e-4591-8f74-ed50414b8b84"
      unitRef="usd">-144000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <amed:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMjEtMS0xLTEtMA_513a781b-9f05-4fa7-bd62-071879711524"
      unitRef="usd">-8132000</amed:IncreaseDecreaseInOperatingLeaseLiability>
    <amed:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMjEtMy0xLTEtMA_490ff027-5946-4994-b69c-489eadb819da"
      unitRef="usd">-8139000</amed:IncreaseDecreaseInOperatingLeaseLiability>
    <amed:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMjItMS0xLTEtMA_b928d5cb-12b5-4620-9771-7312b17568d4"
      unitRef="usd">-817000</amed:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <amed:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMjItMy0xLTEtMA_20fbc656-fbaf-44da-9798-78268699ee12"
      unitRef="usd">-844000</amed:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMjMtMS0xLTEtMA_7f52e5eb-0d3a-4efb-99f4-6c9fe6820ff3"
      unitRef="usd">6035000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMjMtMy0xLTEtMA_83247f61-7538-4907-b4e7-31a8aed7495d"
      unitRef="usd">20059000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleOfRestrictedInvestments
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMjUtMS0xLTEtMA_226a0f26-1c2a-4eb9-bf74-79a46e9b9378"
      unitRef="usd">16000</us-gaap:ProceedsFromSaleOfRestrictedInvestments>
    <us-gaap:ProceedsFromSaleOfRestrictedInvestments
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMjUtMy0xLTEtMA_0ca0f4fd-31bd-4c40-80e8-554db09b3944"
      unitRef="usd">208000</us-gaap:ProceedsFromSaleOfRestrictedInvestments>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMjYtMS0xLTEtMA_331166ee-7110-439d-b53d-b9a808b47bba"
      unitRef="usd">12000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMjYtMy0xLTEtMA_f0f0cf40-bb43-4809-868e-2b7b27996dbe"
      unitRef="usd">65000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMjctMS0xLTEtOTYz_deddf060-d7e3-4319-95b3-410b25417de7"
      unitRef="usd">1434000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMjctMy0xLTEtOTYz_02ef7902-ccd7-479b-a392-31b37c2db12b"
      unitRef="usd">1198000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMjctMS0xLTEtMA_7fdbe7a8-9c49-4e45-8418-2175f1b3ee90"
      unitRef="usd">0</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMjctMy0xLTEtMA_a9b43013-e170-43fe-b2eb-fdffa8ea6b72"
      unitRef="usd">120000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMjktMS0xLTEtMA_1a8fb39d-a012-425c-b927-991f1d0c3c78"
      unitRef="usd">69349000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMjktMy0xLTEtMA_fbbc45af-3d94-47ee-b7f6-957608501cf1"
      unitRef="usd">327867000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMzAtMS0xLTEtMA_254179b8-fb1d-48e2-a63c-249da8425274"
      unitRef="usd">-70755000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMzAtMy0xLTEtMA_30d9decb-a8ae-4efb-a32b-f96a7017436e"
      unitRef="usd">-328912000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMzItMS0xLTEtMA_51e7bdc6-192a-4fa9-9573-121717beef96"
      unitRef="usd">1184000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMzItMy0xLTEtMA_7236caea-82f8-4eb1-84fd-1cf3f03aff31"
      unitRef="usd">356000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMzMtMS0xLTEtMA_be5b8967-a57f-46ef-8d58-e1e5c64c4f69"
      unitRef="usd">860000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMzMtMy0xLTEtMA_67221160-ebae-468b-a984-58c9b35f342c"
      unitRef="usd">782000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMzQtMS0xLTEtMA_fecb6997-0131-46b5-aa7f-35a59c74f08e"
      unitRef="usd">4050000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMzQtMy0xLTEtMA_2331e86d-6600-4b0d-b788-2b6cc6e06e96"
      unitRef="usd">2688000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <amed:CashDistributionToNoncontrollingInterest
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMzUtMS0xLTEtMA_34b5e529-3e5c-4f92-ac5f-71cd3de44f50"
      unitRef="usd">360000</amed:CashDistributionToNoncontrollingInterest>
    <amed:CashDistributionToNoncontrollingInterest
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMzUtMy0xLTEtMA_02d6825a-8b14-4a9a-9d53-0ce3c4a5b910"
      unitRef="usd">366000</amed:CashDistributionToNoncontrollingInterest>
    <amed:ProceedsFromBorrowingsUnderTermLoan
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMzYtMS0xLTEtMA_c2bf72da-5f4e-4e4c-9f4e-7051cc65eaa4"
      unitRef="usd">0</amed:ProceedsFromBorrowingsUnderTermLoan>
    <amed:ProceedsFromBorrowingsUnderTermLoan
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMzYtMy0xLTEtMA_e51cf059-2026-40d0-b6d9-6fab952cfa83"
      unitRef="usd">175000000</amed:ProceedsFromBorrowingsUnderTermLoan>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMzctMS0xLTEtMA_06c9e6f4-8ef4-474a-a666-3eb33af8776a"
      unitRef="usd">187500000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMzctMy0xLTEtMA_29fa6d46-9c35-4161-9f98-17fd384c473a"
      unitRef="usd">161500000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMzgtMS0xLTEtMA_da9f6042-c49d-48ae-bea9-db6b6c76c9e5"
      unitRef="usd">37500000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMzgtMy0xLTEtMA_d865823e-12ce-4900-9259-7ca5374cdc81"
      unitRef="usd">34000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMzktMS0xLTEtMA_5b7aa5ba-9751-49ca-97b8-ce06ab285a4c"
      unitRef="usd">1592000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfMzktMy0xLTEtMA_3d1ce3a5-d58a-4e56-9bc9-e04350b0cb9d"
      unitRef="usd">559000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfNDAtMS0xLTEtMA_cac370ec-e583-45e8-b1d7-ce674b3e6493"
      unitRef="usd">0</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfNDAtMy0xLTEtMA_cd2d5fec-56af-4adc-8d14-ff2e54642ad4"
      unitRef="usd">847000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfNDMtMS0xLTEtMA_716772b3-7630-442b-9d92-8cda0a5dea03"
      unitRef="usd">146042000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfNDMtMy0xLTEtMA_27508da1-efe2-439a-a928-06a6668bd87c"
      unitRef="usd">299178000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfNDQtMS0xLTEtMA_14bac2b1-4e3e-4da5-b855-64c173bba728"
      unitRef="usd">81322000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfNDQtMy0xLTEtMA_0f7f63c8-20de-4da8-b595-65e4ea5bd174"
      unitRef="usd">-9675000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i014c385050454730837d592e15bca5e0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfNDUtMS0xLTEtMA_a1c1da4d-d03b-4ca9-ae96-4363f742d184"
      unitRef="usd">96490000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5070e06e0c374add9463ca31e59e3d55_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfNDUtMy0xLTEtMA_0900596a-14da-457f-b578-d5f2882ffef9"
      unitRef="usd">20229000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfNDYtMS0xLTEtMA_61f24e20-9162-4070-ab6c-4134ee5dd662"
      unitRef="usd">177812000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3202099b2aaf4cc88461f7725441d5a3_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfNDYtMy0xLTEtMA_0b96509e-66fb-4cc6-bfcc-22fc0d2eedf7"
      unitRef="usd">10554000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfNDgtMS0xLTEtMA_fedebe7d-e167-4a7b-9411-2e9480c713d8"
      unitRef="usd">1755000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfNDgtMy0xLTEtMA_a0c0aa1b-5c6f-43f2-952d-38140399eaf9"
      unitRef="usd">725000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfNDktMS0xLTEtMA_5a48839f-7a1b-432f-87d6-8fbafc99542b"
      unitRef="usd">5272000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfNDktMy0xLTEtMA_5a22cb84-040c-40dc-842b-092c77e9e3a5"
      unitRef="usd">404000</us-gaap:IncomeTaxesPaidNet>
    <amed:CashPaidForOperatingLeaseLiabilities
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfNDktMS0xLTEtNDAyNA_49a87f49-0d93-4581-ab48-8d5428488890"
      unitRef="usd">8949000</amed:CashPaidForOperatingLeaseLiabilities>
    <amed:CashPaidForOperatingLeaseLiabilities
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfNDktMy0xLTEtNDAyNA_41922544-914c-4566-b0b8-7159007f8c88"
      unitRef="usd">8983000</amed:CashPaidForOperatingLeaseLiabilities>
    <amed:CashPaidForFinanceLeaseLiabilities
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfNTAtMS0xLTEtNDAyNA_c5139ffa-5f05-47b6-a878-964c5402ca78"
      unitRef="usd">499000</amed:CashPaidForFinanceLeaseLiabilities>
    <amed:CashPaidForFinanceLeaseLiabilities
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfNTAtMy0xLTEtNDAyNA_13bd4bc8-b79c-48a8-b29c-24b409515056"
      unitRef="usd">384000</amed:CashPaidForFinanceLeaseLiabilities>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfNTItMS0xLTEtNDAyMQ_be5aaf54-2e04-42f2-95d0-697213712c80"
      unitRef="usd">6437000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfNTItMy0xLTEtNDAyMQ_96f6855e-eb9d-47e2-bed1-f62336e97add"
      unitRef="usd">91743000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfNTMtMS0xLTEtNDAyMQ_9bde0ef5-4653-4ff2-96b7-2b41c646e706"
      unitRef="usd">254000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfNTMtMy0xLTEtNDAyMQ_e2d33e33-a0d7-4a3c-b0fc-b3ec65aa2be4"
      unitRef="usd">808000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <amed:LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfNTQtMS0xLTEtNDAyMQ_179e42d2-6e7f-43a3-8b72-fbab969a91f5"
      unitRef="usd">159000</amed:LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations>
    <amed:LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zMS9mcmFnOjMwZGJjYjg1MGQ0YTRjNTk4ZWZiNWNhZDFlMDM1YzgyL3RhYmxlOmI4OGI2NGRjZTcxNjQyMWI4OGRmZjk3YTNlMjAwNTU1L3RhYmxlcmFuZ2U6Yjg4YjY0ZGNlNzE2NDIxYjg4ZGZmOTdhM2UyMDA1NTVfNTQtMy0xLTEtNDAyMQ_414e9ca5-36c7-4c2c-99a9-c56d0742d584"
      unitRef="usd">625000</amed:LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zNy9mcmFnOmE3ZGQzNTc4OWI5YjQxMTBhODBmMWMxNzEwYWYwYWQzL3RleHRyZWdpb246YTdkZDM1Nzg5YjliNDExMGE4MGYxYzE3MTBhZjBhZDNfNjM5NA_de6f7c1f-397b-472d-91c4-62859ee5f8e4">NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Amedisys, Inc., a Delaware corporation, (together with its consolidated subsidiaries, referred to herein as &#x201c;Amedisys,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; or &#x201c;our&#x201d;) is a multi-state provider of home health, hospice and personal care services with approximately 74% of our revenue derived from Medicare for the three-month periods ended March&#160;31, 2020 and 2019. As of March&#160;31, 2020, we owned and operated 322 Medicare-certified home health care centers, 146 Medicare-certified hospice care centers and 12 personal-care care centers in 38 states within the United States and the District of Columbia.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In our opinion, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly our financial position, our results of operations, and our cash flows in accordance with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) for interim financial reporting. Our results of operations for the interim periods presented are not necessarily indicative of the results of our operations for the entire year and have not been audited by our independent auditors.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;This report should be read in conjunction with our consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December&#160;31, 2019, as filed with the Securities and Exchange Commission (&#x201c;SEC&#x201d;) on February 19, 2020 (the &#x201c;Form 10-K&#x201d;), which includes information and disclosures not included herein. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from the interim financial information presented, as allowed by SEC rules and regulations. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In December 2019, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2019-12, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Income Taxes (Topic 740) - Simplifying the Accounting for Income Taxes,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; which simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and improves consistent application by clarifying and amending existing guidance. The ASU is effective for annual and interim periods beginning after December 15, 2020. Early adoption is permitted. While the Company does not expect a material impact upon adoption of ASU 2019-12, we are still evaluating the effect the standard will have on our consolidated financial statements and related disclosures and ongoing financial reporting.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Our accounting and reporting policies conform with U.S. GAAP. In preparing the unaudited condensed consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;These unaudited condensed consolidated financial statements include the accounts of Amedisys, Inc. and our wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in our accompanying unaudited condensed consolidated financial statements, and business combinations accounted for as purchases have been included in our unaudited condensed consolidated financial statements from their respective dates of acquisition. In addition to our wholly owned subsidiaries, we also have certain equity investments that are accounted for as set forth below.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We consolidate investments when the entity is a variable interest entity and we are the primary beneficiary or if we have controlling interests in the entity, which is generally ownership in excess of 50%. Third party equity interests in our consolidated joint ventures are reflected as noncontrolling interests in our condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We account for investments in entities in which we have the ability to exercise significant influence under the equity method if we hold 50% or less of the voting stock and the entity is not a variable interest entity in which we are the primary beneficiary. &lt;/span&gt;&lt;/div&gt;The book value of investments that we account for under the equity method of accounting was $33.8 million and $35.7 million as of March&#160;31, 2020 and December&#160;31, 2019, respectively, and is reflected in other assets within our condensed consolidated balance sheets.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i58e124b0d6b94d7c921cc9069e91b8ba_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zNy9mcmFnOmE3ZGQzNTc4OWI5YjQxMTBhODBmMWMxNzEwYWYwYWQzL3RleHRyZWdpb246YTdkZDM1Nzg5YjliNDExMGE4MGYxYzE3MTBhZjBhZDNfMzIz_c7d6ac56-7cc5-4ea6-b6a0-15503d6fb420"
      unitRef="number">0.74</us-gaap:ConcentrationRiskPercentage1>
    <amed:OperatingCareCenters
      contextRef="i0836ed4fa3b14e54895551f7cea7ebcf_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zNy9mcmFnOmE3ZGQzNTc4OWI5YjQxMTBhODBmMWMxNzEwYWYwYWQzL3RleHRyZWdpb246YTdkZDM1Nzg5YjliNDExMGE4MGYxYzE3MTBhZjBhZDNfNTY5_93c8026e-7d18-44df-812a-3046454828b2"
      unitRef="care_center">322</amed:OperatingCareCenters>
    <amed:OperatingCareCenters
      contextRef="iedecd98e5aa64817971cc51d13696c31_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zNy9mcmFnOmE3ZGQzNTc4OWI5YjQxMTBhODBmMWMxNzEwYWYwYWQzL3RleHRyZWdpb246YTdkZDM1Nzg5YjliNDExMGE4MGYxYzE3MTBhZjBhZDNfNjE3_76e52285-afe8-4eb6-8301-57b11c0c883a"
      unitRef="care_center">146</amed:OperatingCareCenters>
    <amed:OperatingCareCenters
      contextRef="i7c4c8579b54540d3958eb43f0bb5f417_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zNy9mcmFnOmE3ZGQzNTc4OWI5YjQxMTBhODBmMWMxNzEwYWYwYWQzL3RleHRyZWdpb246YTdkZDM1Nzg5YjliNDExMGE4MGYxYzE3MTBhZjBhZDNfNjY0_1729d34f-c817-403d-accf-099e9b352446"
      unitRef="care_center">12</amed:OperatingCareCenters>
    <us-gaap:NumberOfStatesInWhichEntityOperates
      contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zNy9mcmFnOmE3ZGQzNTc4OWI5YjQxMTBhODBmMWMxNzEwYWYwYWQzL3RleHRyZWdpb246YTdkZDM1Nzg5YjliNDExMGE4MGYxYzE3MTBhZjBhZDNfNjk3_b7e677d0-15fe-4a5e-8c3f-ce010c85e21f"
      unitRef="state">38</us-gaap:NumberOfStatesInWhichEntityOperates>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zNy9mcmFnOmE3ZGQzNTc4OWI5YjQxMTBhODBmMWMxNzEwYWYwYWQzL3RleHRyZWdpb246YTdkZDM1Nzg5YjliNDExMGE4MGYxYzE3MTBhZjBhZDNfNjQxMw_366df52e-6e00-4d30-ad7a-374c986bc42a">&lt;div style="text-align:justify;margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In our opinion, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly our financial position, our results of operations, and our cash flows in accordance with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) for interim financial reporting. Our results of operations for the interim periods presented are not necessarily indicative of the results of our operations for the entire year and have not been audited by our independent auditors.&lt;/span&gt;&lt;/div&gt;This report should be read in conjunction with our consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December&#160;31, 2019, as filed with the Securities and Exchange Commission (&#x201c;SEC&#x201d;) on February 19, 2020 (the &#x201c;Form 10-K&#x201d;), which includes information and disclosures not included herein.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zNy9mcmFnOmE3ZGQzNTc4OWI5YjQxMTBhODBmMWMxNzEwYWYwYWQzL3RleHRyZWdpb246YTdkZDM1Nzg5YjliNDExMGE4MGYxYzE3MTBhZjBhZDNfMTY0OTI2NzQ1MTgzNQ_4eccd904-a497-4aa0-8638-21d65ad827b7">&lt;div style="text-align:justify;margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In December 2019, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2019-12, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Income Taxes (Topic 740) - Simplifying the Accounting for Income Taxes,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; which simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and improves consistent application by clarifying and amending existing guidance. The ASU is effective for annual and interim periods beginning after December 15, 2020. Early adoption is permitted. While the Company does not expect a material impact upon adoption of ASU 2019-12, we are still evaluating the effect the standard will have on our consolidated financial statements and related disclosures and ongoing financial reporting.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zNy9mcmFnOmE3ZGQzNTc4OWI5YjQxMTBhODBmMWMxNzEwYWYwYWQzL3RleHRyZWdpb246YTdkZDM1Nzg5YjliNDExMGE4MGYxYzE3MTBhZjBhZDNfNjM5OA_c623f5e1-6705-4585-93e8-3f0ee2b338b9">&lt;div style="text-align:justify;margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Our accounting and reporting policies conform with U.S. GAAP. In preparing the unaudited condensed consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zNy9mcmFnOmE3ZGQzNTc4OWI5YjQxMTBhODBmMWMxNzEwYWYwYWQzL3RleHRyZWdpb246YTdkZDM1Nzg5YjliNDExMGE4MGYxYzE3MTBhZjBhZDNfNjQwMA_f82ff82f-0fd4-408f-bedf-e1767c729d4c">&lt;div style="text-align:justify;margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;These unaudited condensed consolidated financial statements include the accounts of Amedisys, Inc. and our wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in our accompanying unaudited condensed consolidated financial statements, and business combinations accounted for as purchases have been included in our unaudited condensed consolidated financial statements from their respective dates of acquisition. In addition to our wholly owned subsidiaries, we also have certain equity investments that are accounted for as set forth below.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:EquityAndCostMethodInvestmentsPolicy
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zNy9mcmFnOmE3ZGQzNTc4OWI5YjQxMTBhODBmMWMxNzEwYWYwYWQzL3RleHRyZWdpb246YTdkZDM1Nzg5YjliNDExMGE4MGYxYzE3MTBhZjBhZDNfNjQxNA_52073958-5dda-4cf4-a1ed-6275a48f7a3d">&lt;div style="text-align:justify;margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We consolidate investments when the entity is a variable interest entity and we are the primary beneficiary or if we have controlling interests in the entity, which is generally ownership in excess of 50%. Third party equity interests in our consolidated joint ventures are reflected as noncontrolling interests in our condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We account for investments in entities in which we have the ability to exercise significant influence under the equity method if we hold 50% or less of the voting stock and the entity is not a variable interest entity in which we are the primary beneficiary. &lt;/span&gt;&lt;/div&gt;The book value of investments that we account for under the equity method of accounting was $33.8 million and $35.7 million as of March&#160;31, 2020 and December&#160;31, 2019, respectively, and is reflected in other assets within our condensed consolidated balance sheets.</us-gaap:EquityAndCostMethodInvestmentsPolicy>
    <amed:MinimumPercentOwnershipForControllingInterestPercent
      contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zNy9mcmFnOmE3ZGQzNTc4OWI5YjQxMTBhODBmMWMxNzEwYWYwYWQzL3RleHRyZWdpb246YTdkZDM1Nzg5YjliNDExMGE4MGYxYzE3MTBhZjBhZDNfNTU0OA_2973d197-f5a2-43d8-8b5d-d6d3e736f94c"
      unitRef="number">0.50</amed:MinimumPercentOwnershipForControllingInterestPercent>
    <amed:MaximumPercentOwnershipForEquityMethodPercent
      contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zNy9mcmFnOmE3ZGQzNTc4OWI5YjQxMTBhODBmMWMxNzEwYWYwYWQzL3RleHRyZWdpb246YTdkZDM1Nzg5YjliNDExMGE4MGYxYzE3MTBhZjBhZDNfNTg0Nw_44a57c6e-12c2-439a-98b8-cc090bd85fa5"
      unitRef="number">0.50</amed:MaximumPercentOwnershipForEquityMethodPercent>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zNy9mcmFnOmE3ZGQzNTc4OWI5YjQxMTBhODBmMWMxNzEwYWYwYWQzL3RleHRyZWdpb246YTdkZDM1Nzg5YjliNDExMGE4MGYxYzE3MTBhZjBhZDNfNjA2MA_5670c69b-7d72-4246-90f0-0bcf923942b8"
      unitRef="usd">33800000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="i014c385050454730837d592e15bca5e0_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl8zNy9mcmFnOmE3ZGQzNTc4OWI5YjQxMTBhODBmMWMxNzEwYWYwYWQzL3RleHRyZWdpb246YTdkZDM1Nzg5YjliNDExMGE4MGYxYzE3MTBhZjBhZDNfNjA2Nw_e9463e33-eb5f-4b4a-9109-fc195dfb80e3"
      unitRef="usd">35700000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RleHRyZWdpb246ODc3MjBkMjEyMGFkNGY4NWIxZDk3NzQyNGNhYzBmYjVfMjA3MzE_89992ba8-b092-4d9c-898b-94b608fc3c4c">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We account for revenue from contracts with customers in accordance with ASU 2014-09, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Revenue from Contracts with Customers (Topic 606)&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; and ASU 2015-14, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; (collectively, "ASC 606"), and as such, we recognize revenue in the period in which we satisfy our performance obligations under our contracts by transferring our promised services to our customers in amounts that reflect the consideration to which we expect to be entitled in exchange for providing patient care, which are the transaction prices allocated to the distinct services. The Company's cost of obtaining contracts is not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenues are recognized as performance obligations are satisfied, which varies based on the nature of the services provided. Our performance obligation is the delivery of patient care services in accordance with the nature and frequency of services outlined in physicians' orders, which are determined by a physician based on a patient's specific goals.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company's performance obligations relate to contracts with a duration of less than one year; therefore, the Company has elected to apply the optional exemption provided by ASC 606 and is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We determine the transaction price based on gross charges for services provided, reduced by estimates for contractual and non-contractual revenue adjustments. Contractual revenue adjustments include adjustments provided to patients and third-party payors. Non-contractual revenue adjustments include discounts provided to self-pay, uninsured patients or other payors, adjustments resulting from payment reviews and adjustments arising from our inability to obtain appropriate billing documentation, authorizations or face-to-face documentation. Subsequent changes to the estimate of the transaction price are recorded as adjustments to net service revenue in the period of change. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third party payors and others for services provided. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Non-contractual revenue adjustments are recorded for self-pay, uninsured patients and other payors by major payor class based on our historical collection experience, aged accounts receivable by payor and current economic conditions. The non-contractual revenue adjustments represent the difference between amounts billed and amounts we expect to collect based on our collection history with similar payors. The Company assesses its ability to collect for the healthcare services provided at the time of patient admission based on the Company's verification of the patient's insurance coverage under Medicare, Medicaid, and other commercial or managed care insurance programs. Medicare represents approximately 74% of the Company's consolidated net service revenue for the three-month periods ended March&#160;31, 2020 and 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Amounts due from third-party payors, primarily commercial health insurers and government programs (Medicare and Medicaid), include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to payment reviews based on our historical experience and success rates in the claim appeals and adjudication process.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We determine our estimates for non-contractual revenue adjustments related to our inability to obtain appropriate billing documentation, authorizations, or face-to-face documentation based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims. Revenue is recorded at amounts we estimate to be realizable for services provided.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenue by payor class as a percentage of total net service revenue is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:92.690%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.659%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.618%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.904%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Three-Month Periods Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;Home Health:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Non-Medicare - Episodic-based&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Non-Medicare - Non-episodic based&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;Hospice (1):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Non-Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;Personal Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="11" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1) Acquired Compassionate Care Hospice on February 1, 2019, RoseRock Healthcare on April 1, 2019 and Asana Hospice on January 1, 2020.&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Home Health Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Medicare Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Effective January 1, 2020, the Centers for Medicare and Medicaid Services ("CMS") implemented a revised case-mix adjustment methodology, the Patient-Driven Groupings Model ("PDGM"), to better align payment with patient care needs and ensure that clinically complex and ill beneficiaries have adequate access to home health care. PDGM uses 30-day periods of care rather than 60-day episodes of care as the unit of payment, eliminates the use of the number of therapy visits provided in determining payment and relies more heavily on clinical characteristics and other patient information.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Net service revenue is recorded based on the established Federal Medicare home health payment rate for a 30-day period of care ("billing period"). PDGM uses timing, admission source, functional impairment levels and principal and other diagnoses to case-mix adjust payments. The case-mix adjusted payment for a 30-day period of care is subject to additional adjustments based on certain variables, including, but not limited to (a) an outlier payment if our patient's care was unusually costly (capped at 10% of total reimbursement per provider number); (b)&#160;a low utilization payment adjustment (&#x201c;LUPA&#x201d;) if the number of visits provided was less than the established threshold, which ranges from two to six visits and varies for every case-mix group under PDGM; (c)&#160;a partial payment if a patient transferred to another provider or from another provider before completing the 30-day period of care; and (d) the applicable geographic wage index. Payment for non-routine supplies are now included in the 30-day payment rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Medicare can also make various adjustments to payments received if we are unable to produce appropriate billing documentation or acceptable authorizations. We estimate the impact of such adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record this estimate during the period in which services are rendered as a reduction to revenue and a corresponding reduction to patient accounts receivable. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Amounts due from Medicare include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to payment reviews based on our historical experience and success rates in the claim appeals and adjudication process.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Medicare home health benefit requires that beneficiaries be homebound (meaning that the beneficiary is unable to leave their home without a considerable and taxing effort), require intermittent skilled nursing, physical therapy or speech therapy services, and receive treatment under a plan of care established and periodically reviewed by a physician. In order to provide greater flexibility during the novel coronavirus pandemic ("COVID-19"), CMS has relaxed the definition of homebound status. During the pandemic, a beneficiary is considered homebound if they have been instructed by a physician not to leave their home because of a confirmed or suspected COVID-19 diagnosis or if the patient has a condition that makes them more susceptible to contracting COVID-19. Therefore, if a beneficiary is homebound due to COVID-19 and requires skilled services, the services will be covered under the Medicare home health benefit.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;All Medicare contracts are required to have a signed plan of care which represents a single performance obligation, comprising of the delivery of a series of distinct services that are substantially similar and have a similar pattern of transfer to the customer. Accordingly, the Company accounts for the series of services ("episode") as a single performance obligation satisfied over time, as the customer simultaneously receives and consumes the benefits of the goods and services provided. An episode starts the first day a billable visit is performed and ends 60 days later or upon discharge, if earlier, with multiple continuous episodes allowed.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As noted above, under PDGM, we are now reimbursed for 30-day periods of care rather than 60-day episodes of care. ASC 606 notes that if an entity has a right to consideration from a customer in an amount that corresponds directly with the value of the entity&#x2019;s performance completed to date, the entity may recognize revenue in the amount to which the entity has a right to invoice. We have elected to apply the "right to invoice&#x201d; practical expedient utilizing our historical average length of stay for each 30-day payment period as the measure of progress towards the satisfaction of our performance obligation.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;A portion of reimbursement from each Medicare episode is billed near the start of each 30-day period of care, and cash is typically received before all services are rendered. The amount of revenue recognized for periods of care which are incomplete at period end is based on the company's historical average percentage of days complete on each 30-day period of care. Any cash received from Medicare for a request for anticipated payment (&#x201c;RAP&#x201d;) for a 30-day period of care that exceeds the associated revenue earned is recorded to accrued expenses within our condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Non-Medicare Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Episodic-based Revenue.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; We recognize revenue in a similar manner as we recognize Medicare revenue for amounts that are paid by other insurance carriers, including Medicare Advantage programs; however, these amounts can vary based upon the negotiated terms which generally range from 90% to 100% of Medicare rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Non-episodic based Revenue.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third parties and others for services provided and are deducted from gross revenue to determine net service revenue. We also make non-contractual revenue adjustments to non-episodic revenue based on historical experience, to reflect the estimated transaction price. We receive a minimal amount of our net service revenue from patients who are either self-insured or are obligated for an insurance co-payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Hospice Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Hospice Medicare Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are predetermined daily or hourly rates for each of the four levels of care we deliver. The four levels of care are routine care, general inpatient care, continuous home care and respite care. Routine care accounted for 97%  and 98% of our total net Medicare hospice service revenue for each of the three-month periods ended March&#160;31, 2020 and March&#160;31, 2019, respectively. There are two separate payment rates for routine care: payments for the first 60 days of care and care beyond 60 days. In addition to the two routine rates, we may also receive a service intensity add-on (&#x201c;SIA&#x201d;). The SIA is based on visits made in the last seven days of life by a registered nurse (&#x201c;RN&#x201d;) or medical social worker (&#x201c;MSW&#x201d;) for patients in a routine level of care.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The performance obligation is the delivery of hospice services to the patient, as determined by a physician, each day the patient is on hospice care.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We make adjustments to Medicare revenue for non-contractual revenue adjustments, which include our inability to obtain appropriate billing documentation or acceptable authorizations and other reasons unrelated to credit risk. We estimate the impact of these non-contractual revenue adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record it during the period services are rendered.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Additionally, our hospice service revenue is subject to certain limitations on payments from Medicare which are considered variable consideration. We are subject to an inpatient cap limit and an overall Medicare payment cap for each provider number. We monitor these caps on a provider-by-provider basis and estimate amounts due back to Medicare if we estimate a cap has been exceeded.&#160;We record these adjustments as a reduction to revenue and an increase in accrued expenses within our condensed consolidated balance sheet. Beginning for the cap year ending October&#160;31, 2017, providers are required to self-report &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;and pay their estimated cap liability by February 28&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"&gt;th&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; of the following year. As of March&#160;31, 2020, we have recorded $5.5 million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2013 through September 30, 2020. As of December&#160;31, 2019, we had recorded $5.7 million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2013 through September 30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Hospice Non-Medicare Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per day rates, as applicable. Contractual revenue adjustments are recorded for the difference between our standard rates and the contractual rates to be realized from patients, third party payors and others for services provided and are deducted from gross revenue to determine our net service revenue. We also make non-contractual adjustments to non-Medicare revenue based on historical experience, to reflect the estimated transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Personal Care Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Personal Care Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We generate net service revenues by providing our services directly to patients based on authorized hours, visits or units determined by the relevant agency, at a rate that is either contractual or fixed by legislation. Net service revenue is recognized at the time services are rendered based on gross charges for the services provided, reduced by estimates for contractual and non-contractual revenue adjustments. We receive payment for providing such services from payors, including state and local governmental agencies, managed care organizations, commercial insurers and private consumers. Payors include the following elder service agencies: Aging Services Access Points (ASAPs), Senior Care Options (SCOs), Program of All-Inclusive Care for the Elderly (PACE) and the Veterans Administration (VA). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Cash, Cash Equivalents and Restricted Cash &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Cash and cash equivalents include certificates of deposit and all highly liquid debt instruments with maturities of three months or less when purchased. Restricted cash includes cash that is not available for ordinary business use. As of March 31, 2020, we had $3.1&#160;million of restricted cash that was placed into escrow accounts related to the potential indemnity and working capital adjustment provisions within the Asana Hospice purchase agreement ($2.3&#160;million) and to secure the purchase of personal protective equipment from new suppliers in response to COVID-19 ($0.8&#160;million).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Patient Accounts Receivable &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We report accounts receivable from services rendered at their estimated transaction price, which includes contractual and non-contractual revenue adjustments based on the amounts expected to be due from payors. Our patient accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other third-party payors and patients. As of March&#160;31, 2020, there is no single payor, other than Medicare, that accounts for more than 10% of our total outstanding patient receivables. Thus, we believe there are no other significant concentrations of receivables that would subject us to any significant credit risk in the collection of our patient accounts receivable. We write off accounts on a monthly basis once we have exhausted our collection efforts and deem an account to be uncollectible. We believe the collectibility risk associated with our Medicare accounts, which represent 58% of our patient accounts receivable at March&#160;31, 2020 and December&#160;31, 2019 is limited due to our historical collection rate of over 99% from Medicare and the fact that Medicare is a U.S. government payor. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We do not believe there are any significant concentrations of revenues from any payor that would subject us to any significant credit risk in the collection of our accounts receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Medicare Home Health&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For our home health patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We submit a RAP for 20% of our estimated payment for each 30-day period of care. The full amount of the payment for each 30-day period of care is billed after the period of care has been completed (&#x201c;final billed&#x201d;). The RAP received for that billing period is then deducted from our final payment. If a final bill is not submitted within the greater of 90 days from the start of the 30-day period of care, or 60 days from the date the RAP was paid, &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;any RAPs received for that billing period will be recouped by Medicare from any other claims in process for that particular provider number. The RAP claim must then be resubmitted. CMS has mandated the full elimination of RAPs in 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Medicare Hospice&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For our hospice patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We bill Medicare on a monthly basis for the services provided to the patient.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Non-Medicare Home Health, Hospice and Personal Care&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For our non-Medicare patients, our pre-billing process primarily begins with verifying a patient&#x2019;s eligibility for services with the applicable payor. Once the patient has been confirmed for eligibility, we will provide services to the patient and bill the applicable payor. Our review and evaluation of non-Medicare accounts receivable includes a detailed review of outstanding balances and special consideration to concentrations of receivables from particular payors or groups of payors with similar characteristics that would subject us to any significant credit risk.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:16pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.076%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:24.054%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.921%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.553%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.921%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.553%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.921%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.553%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.924%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value at Reporting Date Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;Financial Instrument&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Carrying Value as of March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Quoted&#160;Prices&#160;in&#160;Active&lt;br/&gt;Markets for Identical&lt;br/&gt;Items&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Significant&lt;br/&gt;Unobservable&#160;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;391.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;383.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The three levels of inputs are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"&gt;Level&#160;1 &#x2013; Quoted prices in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"&gt;Level&#160;2 &#x2013; Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"&gt;Level&#160;3 &#x2013; Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Our deferred compensation plan assets are recorded at fair value and are considered a level 2 measurement. For our other financial instruments, including our cash and cash equivalents, patient accounts receivable, accounts payable, payroll and employee benefits and accrued expenses, we estimate the carrying amounts approximate fair value. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:16pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Weighted-Average Shares Outstanding&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Net income per share attributable to Amedisys, Inc. common stockholders, calculated on the treasury stock method, is based on the weighted average number of shares outstanding during the period. The following table sets forth, for the periods indicated, shares used in our computation of the weighted-average shares outstanding, which are used to calculate our basic and diluted net income attributable to Amedisys, Inc. common stockholders (amounts in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:90.497%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:69.082%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.054%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.607%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.057%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Three-&lt;br/&gt;Month Periods&lt;br/&gt;Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted average number of shares outstanding - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;32,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;32,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:20.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Non-vested stock and stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted average number of shares outstanding - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;32,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Anti-dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:16pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We account for acquisitions using the acquisition method of accounting in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) 805, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Business Combinations&lt;/span&gt;. Acquisitions are accounted for as purchases and are included in our condensed consolidated financial statements from their respective acquisition dates. Assets acquired and liabilities assumed, if any, are measured at fair value on the acquisition date using the appropriate valuation method. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RleHRyZWdpb246ODc3MjBkMjEyMGFkNGY4NWIxZDk3NzQyNGNhYzBmYjVfMjA3Mzg_fa7c2b2f-1a8f-4ba8-934f-235b9b64ee25">&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We account for revenue from contracts with customers in accordance with ASU 2014-09, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Revenue from Contracts with Customers (Topic 606)&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; and ASU 2015-14, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; (collectively, "ASC 606"), and as such, we recognize revenue in the period in which we satisfy our performance obligations under our contracts by transferring our promised services to our customers in amounts that reflect the consideration to which we expect to be entitled in exchange for providing patient care, which are the transaction prices allocated to the distinct services. The Company's cost of obtaining contracts is not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenues are recognized as performance obligations are satisfied, which varies based on the nature of the services provided. Our performance obligation is the delivery of patient care services in accordance with the nature and frequency of services outlined in physicians' orders, which are determined by a physician based on a patient's specific goals.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company's performance obligations relate to contracts with a duration of less than one year; therefore, the Company has elected to apply the optional exemption provided by ASC 606 and is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We determine the transaction price based on gross charges for services provided, reduced by estimates for contractual and non-contractual revenue adjustments. Contractual revenue adjustments include adjustments provided to patients and third-party payors. Non-contractual revenue adjustments include discounts provided to self-pay, uninsured patients or other payors, adjustments resulting from payment reviews and adjustments arising from our inability to obtain appropriate billing documentation, authorizations or face-to-face documentation. Subsequent changes to the estimate of the transaction price are recorded as adjustments to net service revenue in the period of change. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third party payors and others for services provided. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Non-contractual revenue adjustments are recorded for self-pay, uninsured patients and other payors by major payor class based on our historical collection experience, aged accounts receivable by payor and current economic conditions. The non-contractual revenue adjustments represent the difference between amounts billed and amounts we expect to collect based on our collection history with similar payors. The Company assesses its ability to collect for the healthcare services provided at the time of patient admission based on the Company's verification of the patient's insurance coverage under Medicare, Medicaid, and other commercial or managed care insurance programs. Medicare represents approximately 74% of the Company's consolidated net service revenue for the three-month periods ended March&#160;31, 2020 and 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Amounts due from third-party payors, primarily commercial health insurers and government programs (Medicare and Medicaid), include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to payment reviews based on our historical experience and success rates in the claim appeals and adjudication process.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We determine our estimates for non-contractual revenue adjustments related to our inability to obtain appropriate billing documentation, authorizations, or face-to-face documentation based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims. Revenue is recorded at amounts we estimate to be realizable for services provided.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenue by payor class as a percentage of total net service revenue is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:92.690%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.659%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.618%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.904%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Three-Month Periods Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;Home Health:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Non-Medicare - Episodic-based&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Non-Medicare - Non-episodic based&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;Hospice (1):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Non-Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;Personal Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="11" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1) Acquired Compassionate Care Hospice on February 1, 2019, RoseRock Healthcare on April 1, 2019 and Asana Hospice on January 1, 2020.&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Home Health Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Medicare Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Effective January 1, 2020, the Centers for Medicare and Medicaid Services ("CMS") implemented a revised case-mix adjustment methodology, the Patient-Driven Groupings Model ("PDGM"), to better align payment with patient care needs and ensure that clinically complex and ill beneficiaries have adequate access to home health care. PDGM uses 30-day periods of care rather than 60-day episodes of care as the unit of payment, eliminates the use of the number of therapy visits provided in determining payment and relies more heavily on clinical characteristics and other patient information.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Net service revenue is recorded based on the established Federal Medicare home health payment rate for a 30-day period of care ("billing period"). PDGM uses timing, admission source, functional impairment levels and principal and other diagnoses to case-mix adjust payments. The case-mix adjusted payment for a 30-day period of care is subject to additional adjustments based on certain variables, including, but not limited to (a) an outlier payment if our patient's care was unusually costly (capped at 10% of total reimbursement per provider number); (b)&#160;a low utilization payment adjustment (&#x201c;LUPA&#x201d;) if the number of visits provided was less than the established threshold, which ranges from two to six visits and varies for every case-mix group under PDGM; (c)&#160;a partial payment if a patient transferred to another provider or from another provider before completing the 30-day period of care; and (d) the applicable geographic wage index. Payment for non-routine supplies are now included in the 30-day payment rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Medicare can also make various adjustments to payments received if we are unable to produce appropriate billing documentation or acceptable authorizations. We estimate the impact of such adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record this estimate during the period in which services are rendered as a reduction to revenue and a corresponding reduction to patient accounts receivable. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Amounts due from Medicare include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to payment reviews based on our historical experience and success rates in the claim appeals and adjudication process.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Medicare home health benefit requires that beneficiaries be homebound (meaning that the beneficiary is unable to leave their home without a considerable and taxing effort), require intermittent skilled nursing, physical therapy or speech therapy services, and receive treatment under a plan of care established and periodically reviewed by a physician. In order to provide greater flexibility during the novel coronavirus pandemic ("COVID-19"), CMS has relaxed the definition of homebound status. During the pandemic, a beneficiary is considered homebound if they have been instructed by a physician not to leave their home because of a confirmed or suspected COVID-19 diagnosis or if the patient has a condition that makes them more susceptible to contracting COVID-19. Therefore, if a beneficiary is homebound due to COVID-19 and requires skilled services, the services will be covered under the Medicare home health benefit.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;All Medicare contracts are required to have a signed plan of care which represents a single performance obligation, comprising of the delivery of a series of distinct services that are substantially similar and have a similar pattern of transfer to the customer. Accordingly, the Company accounts for the series of services ("episode") as a single performance obligation satisfied over time, as the customer simultaneously receives and consumes the benefits of the goods and services provided. An episode starts the first day a billable visit is performed and ends 60 days later or upon discharge, if earlier, with multiple continuous episodes allowed.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As noted above, under PDGM, we are now reimbursed for 30-day periods of care rather than 60-day episodes of care. ASC 606 notes that if an entity has a right to consideration from a customer in an amount that corresponds directly with the value of the entity&#x2019;s performance completed to date, the entity may recognize revenue in the amount to which the entity has a right to invoice. We have elected to apply the "right to invoice&#x201d; practical expedient utilizing our historical average length of stay for each 30-day payment period as the measure of progress towards the satisfaction of our performance obligation.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;A portion of reimbursement from each Medicare episode is billed near the start of each 30-day period of care, and cash is typically received before all services are rendered. The amount of revenue recognized for periods of care which are incomplete at period end is based on the company's historical average percentage of days complete on each 30-day period of care. Any cash received from Medicare for a request for anticipated payment (&#x201c;RAP&#x201d;) for a 30-day period of care that exceeds the associated revenue earned is recorded to accrued expenses within our condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Non-Medicare Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Episodic-based Revenue.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; We recognize revenue in a similar manner as we recognize Medicare revenue for amounts that are paid by other insurance carriers, including Medicare Advantage programs; however, these amounts can vary based upon the negotiated terms which generally range from 90% to 100% of Medicare rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Non-episodic based Revenue.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third parties and others for services provided and are deducted from gross revenue to determine net service revenue. We also make non-contractual revenue adjustments to non-episodic revenue based on historical experience, to reflect the estimated transaction price. We receive a minimal amount of our net service revenue from patients who are either self-insured or are obligated for an insurance co-payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Hospice Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Hospice Medicare Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are predetermined daily or hourly rates for each of the four levels of care we deliver. The four levels of care are routine care, general inpatient care, continuous home care and respite care. Routine care accounted for 97%  and 98% of our total net Medicare hospice service revenue for each of the three-month periods ended March&#160;31, 2020 and March&#160;31, 2019, respectively. There are two separate payment rates for routine care: payments for the first 60 days of care and care beyond 60 days. In addition to the two routine rates, we may also receive a service intensity add-on (&#x201c;SIA&#x201d;). The SIA is based on visits made in the last seven days of life by a registered nurse (&#x201c;RN&#x201d;) or medical social worker (&#x201c;MSW&#x201d;) for patients in a routine level of care.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The performance obligation is the delivery of hospice services to the patient, as determined by a physician, each day the patient is on hospice care.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We make adjustments to Medicare revenue for non-contractual revenue adjustments, which include our inability to obtain appropriate billing documentation or acceptable authorizations and other reasons unrelated to credit risk. We estimate the impact of these non-contractual revenue adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record it during the period services are rendered.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Additionally, our hospice service revenue is subject to certain limitations on payments from Medicare which are considered variable consideration. We are subject to an inpatient cap limit and an overall Medicare payment cap for each provider number. We monitor these caps on a provider-by-provider basis and estimate amounts due back to Medicare if we estimate a cap has been exceeded.&#160;We record these adjustments as a reduction to revenue and an increase in accrued expenses within our condensed consolidated balance sheet. Beginning for the cap year ending October&#160;31, 2017, providers are required to self-report &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;and pay their estimated cap liability by February 28&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"&gt;th&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; of the following year. As of March&#160;31, 2020, we have recorded $5.5 million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2013 through September 30, 2020. As of December&#160;31, 2019, we had recorded $5.7 million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2013 through September 30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Hospice Non-Medicare Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per day rates, as applicable. Contractual revenue adjustments are recorded for the difference between our standard rates and the contractual rates to be realized from patients, third party payors and others for services provided and are deducted from gross revenue to determine our net service revenue. We also make non-contractual adjustments to non-Medicare revenue based on historical experience, to reflect the estimated transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Personal Care Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Personal Care Revenue&lt;/span&gt;&lt;/div&gt;We generate net service revenues by providing our services directly to patients based on authorized hours, visits or units determined by the relevant agency, at a rate that is either contractual or fixed by legislation. Net service revenue is recognized at the time services are rendered based on gross charges for the services provided, reduced by estimates for contractual and non-contractual revenue adjustments. We receive payment for providing such services from payors, including state and local governmental agencies, managed care organizations, commercial insurers and private consumers. Payors include the following elder service agencies: Aging Services Access Points (ASAPs), Senior Care Options (SCOs), Program of All-Inclusive Care for the Elderly (PACE) and the Veterans Administration (VA).</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i58e124b0d6b94d7c921cc9069e91b8ba_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RleHRyZWdpb246ODc3MjBkMjEyMGFkNGY4NWIxZDk3NzQyNGNhYzBmYjVfMzI1MA_c7d6ac56-7cc5-4ea6-b6a0-15503d6fb420"
      unitRef="number">0.74</us-gaap:ConcentrationRiskPercentage1>
    <amed:HistoricalCollectionRateFromMedicare
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RleHRyZWdpb246ODc3MjBkMjEyMGFkNGY4NWIxZDk3NzQyNGNhYzBmYjVfNDI2OA_83fbdfca-300b-4e08-913b-126d0c1ba721"
      unitRef="number">0.99</amed:HistoricalCollectionRateFromMedicare>
    <us-gaap:ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RleHRyZWdpb246ODc3MjBkMjEyMGFkNGY4NWIxZDk3NzQyNGNhYzBmYjVfMjA3NDY_ceb61c4a-7f70-4489-b16d-d65fc0e5238d">&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenue by payor class as a percentage of total net service revenue is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:92.690%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.659%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.618%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.904%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Three-Month Periods Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;Home Health:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Non-Medicare - Episodic-based&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Non-Medicare - Non-episodic based&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;Hospice (1):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Non-Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;Personal Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="11" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1) Acquired Compassionate Care Hospice on February 1, 2019, RoseRock Healthcare on April 1, 2019 and Asana Hospice on January 1, 2020.&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i08f8228195d4482abb1638f4aff3246a_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RhYmxlOmQ3MDM2NTFkOWRjOTRiYmFiMWMyOWQyNjYyYTY1NGZhL3RhYmxlcmFuZ2U6ZDcwMzY1MWQ5ZGM5NGJiYWIxYzI5ZDI2NjJhNjU0ZmFfMy0xLTEtMS0w_326ce964-a678-437f-8a51-2f18cf3afc02"
      unitRef="number">0.41</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i4775f859e4944ad78c696d06861399db_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RhYmxlOmQ3MDM2NTFkOWRjOTRiYmFiMWMyOWQyNjYyYTY1NGZhL3RhYmxlcmFuZ2U6ZDcwMzY1MWQ5ZGM5NGJiYWIxYzI5ZDI2NjJhNjU0ZmFfMy0zLTEtMS0w_9f42626b-6ff7-4817-93b5-9635cda6baa1"
      unitRef="number">0.46</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i1585d446638b4ebaaafeda3e997809c6_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RhYmxlOmQ3MDM2NTFkOWRjOTRiYmFiMWMyOWQyNjYyYTY1NGZhL3RhYmxlcmFuZ2U6ZDcwMzY1MWQ5ZGM5NGJiYWIxYzI5ZDI2NjJhNjU0ZmFfNC0xLTEtMS0w_b967595e-a831-4e37-afdf-a31e112a5abb"
      unitRef="number">0.06</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i023ad62f89a640b9bafc773ed8834c5c_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RhYmxlOmQ3MDM2NTFkOWRjOTRiYmFiMWMyOWQyNjYyYTY1NGZhL3RhYmxlcmFuZ2U6ZDcwMzY1MWQ5ZGM5NGJiYWIxYzI5ZDI2NjJhNjU0ZmFfNC0zLTEtMS0w_86ab9669-ec09-4cc0-a59b-69a44195ba64"
      unitRef="number">0.09</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i504907be1af1401896b436e9f31ef9b2_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RhYmxlOmQ3MDM2NTFkOWRjOTRiYmFiMWMyOWQyNjYyYTY1NGZhL3RhYmxlcmFuZ2U6ZDcwMzY1MWQ5ZGM5NGJiYWIxYzI5ZDI2NjJhNjU0ZmFfNS0xLTEtMS0w_b05b1780-50fd-426b-bfbf-28d934701346"
      unitRef="number">0.14</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i6c0374d568c345b1895f99bc4c5da6a1_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RhYmxlOmQ3MDM2NTFkOWRjOTRiYmFiMWMyOWQyNjYyYTY1NGZhL3RhYmxlcmFuZ2U6ZDcwMzY1MWQ5ZGM5NGJiYWIxYzI5ZDI2NjJhNjU0ZmFfNS0zLTEtMS0w_596dc75e-2030-45fb-be16-9b5dccb77232"
      unitRef="number">0.12</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i012f167f36504108a1f5b3c3b8746634_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RhYmxlOmQ3MDM2NTFkOWRjOTRiYmFiMWMyOWQyNjYyYTY1NGZhL3RhYmxlcmFuZ2U6ZDcwMzY1MWQ5ZGM5NGJiYWIxYzI5ZDI2NjJhNjU0ZmFfNy0xLTEtMS0w_a98617fd-8260-4f3d-855b-b8b039ae5513"
      unitRef="number">0.33</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="idbce36e4c2a04a1ab922f6c09ff1bf77_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RhYmxlOmQ3MDM2NTFkOWRjOTRiYmFiMWMyOWQyNjYyYTY1NGZhL3RhYmxlcmFuZ2U6ZDcwMzY1MWQ5ZGM5NGJiYWIxYzI5ZDI2NjJhNjU0ZmFfNy0zLTEtMS0w_e4aee3d8-82a0-4eeb-bbd9-209007bbedbc"
      unitRef="number">0.28</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i9379225a4bef4cf6a6dc439d3252aa78_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RhYmxlOmQ3MDM2NTFkOWRjOTRiYmFiMWMyOWQyNjYyYTY1NGZhL3RhYmxlcmFuZ2U6ZDcwMzY1MWQ5ZGM5NGJiYWIxYzI5ZDI2NjJhNjU0ZmFfOC0xLTEtMS0w_0cd7fb44-1a36-4806-8638-c9c39e9994d3"
      unitRef="number">0.02</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="ib45c518834644bd5a393af3f5453153c_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RhYmxlOmQ3MDM2NTFkOWRjOTRiYmFiMWMyOWQyNjYyYTY1NGZhL3RhYmxlcmFuZ2U6ZDcwMzY1MWQ5ZGM5NGJiYWIxYzI5ZDI2NjJhNjU0ZmFfOC0zLTEtMS0w_edf520df-4ebd-41af-9f0a-41e361eba577"
      unitRef="number">0.01</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i244a79cf50e84b398521caa51f9417a5_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RhYmxlOmQ3MDM2NTFkOWRjOTRiYmFiMWMyOWQyNjYyYTY1NGZhL3RhYmxlcmFuZ2U6ZDcwMzY1MWQ5ZGM5NGJiYWIxYzI5ZDI2NjJhNjU0ZmFfOS0xLTEtMS0w_4c2eecd1-d321-4fbb-a8ae-119c6d0d111c"
      unitRef="number">0.04</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="id20d8630a41943e5824e25095e23ca89_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RhYmxlOmQ3MDM2NTFkOWRjOTRiYmFiMWMyOWQyNjYyYTY1NGZhL3RhYmxlcmFuZ2U6ZDcwMzY1MWQ5ZGM5NGJiYWIxYzI5ZDI2NjJhNjU0ZmFfOS0zLTEtMS0w_e7dcdbc8-5722-4459-90c3-6cd02a8dd950"
      unitRef="number">0.04</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RhYmxlOmQ3MDM2NTFkOWRjOTRiYmFiMWMyOWQyNjYyYTY1NGZhL3RhYmxlcmFuZ2U6ZDcwMzY1MWQ5ZGM5NGJiYWIxYzI5ZDI2NjJhNjU0ZmFfMTAtMS0xLTEtMA_efbef354-f185-43c1-8d9c-3e193cef77a5"
      unitRef="number">1</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RhYmxlOmQ3MDM2NTFkOWRjOTRiYmFiMWMyOWQyNjYyYTY1NGZhL3RhYmxlcmFuZ2U6ZDcwMzY1MWQ5ZGM5NGJiYWIxYzI5ZDI2NjJhNjU0ZmFfMTAtMy0xLTEtMA_be317d2b-1236-4d8d-a2ba-d0a0aee1ecd8"
      unitRef="number">1</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:PercentageOfTotalReimbursementOfOutlierPayment
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RleHRyZWdpb246ODc3MjBkMjEyMGFkNGY4NWIxZDk3NzQyNGNhYzBmYjVfNDc1NQ_ce5a17b8-2af9-4006-8a24-589cdb028c02"
      unitRef="number">0.10</amed:PercentageOfTotalReimbursementOfOutlierPayment>
    <amed:LowUtilizationPaymentAdjustmentNumberOfVisits
      contextRef="i91721ec84cfa456ea3fe8a1300bb24f5_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RleHRyZWdpb246ODc3MjBkMjEyMGFkNGY4NWIxZDk3NzQyNGNhYzBmYjVfMTY0OTI2NzQ4NDcwMQ_51dd26b6-ba02-4c0d-99eb-c6751c2d013d"
      unitRef="visit">2</amed:LowUtilizationPaymentAdjustmentNumberOfVisits>
    <amed:LowUtilizationPaymentAdjustmentNumberOfVisits
      contextRef="ib06523f2884143ccb65798237a08ecee_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RleHRyZWdpb246ODc3MjBkMjEyMGFkNGY4NWIxZDk3NzQyNGNhYzBmYjVfMTY0OTI2NzQ4NDcxMA_758b501b-f271-4a99-812c-312a90519c7a"
      unitRef="visit">6</amed:LowUtilizationPaymentAdjustmentNumberOfVisits>
    <amed:HistoricalCollectionRateFromMedicare
      contextRef="i1803f21995a846beaf2e5491abdaa75f_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RleHRyZWdpb246ODc3MjBkMjEyMGFkNGY4NWIxZDk3NzQyNGNhYzBmYjVfNzgyOQ_9b322763-30e5-435f-a65a-a3d66771279e"
      unitRef="number">0.99</amed:HistoricalCollectionRateFromMedicare>
    <amed:NonMedicareRevenueTermRates
      contextRef="i91721ec84cfa456ea3fe8a1300bb24f5_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RleHRyZWdpb246ODc3MjBkMjEyMGFkNGY4NWIxZDk3NzQyNGNhYzBmYjVfODk0Mw_a065316f-8485-415f-8951-1f25d077670a"
      unitRef="number">0.90</amed:NonMedicareRevenueTermRates>
    <amed:NonMedicareRevenueTermRates
      contextRef="ib06523f2884143ccb65798237a08ecee_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RleHRyZWdpb246ODc3MjBkMjEyMGFkNGY4NWIxZDk3NzQyNGNhYzBmYjVfODk0OQ_ce4df2be-4f40-4d40-bf88-99d7c931f7f8"
      unitRef="number">1</amed:NonMedicareRevenueTermRates>
    <amed:HospiceMedicareRevenueRateAccountedForRoutineCare
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RleHRyZWdpb246ODc3MjBkMjEyMGFkNGY4NWIxZDk3NzQyNGNhYzBmYjVfMTAxMzE_8d6483d8-512d-454d-a554-022603ecf112"
      unitRef="number">0.97</amed:HospiceMedicareRevenueRateAccountedForRoutineCare>
    <amed:HospiceMedicareRevenueRateAccountedForRoutineCare
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RleHRyZWdpb246ODc3MjBkMjEyMGFkNGY4NWIxZDk3NzQyNGNhYzBmYjVfMTAyNTI_498cb30c-4b1f-4fbd-ac2e-3aa2d3adaeb9"
      unitRef="number">0.98</amed:HospiceMedicareRevenueRateAccountedForRoutineCare>
    <amed:HistoricalCollectionRateFromMedicare
      contextRef="ie2a5b1046a72421f919b53e916e3b7b9_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RleHRyZWdpb246ODc3MjBkMjEyMGFkNGY4NWIxZDk3NzQyNGNhYzBmYjVfMTEyNTU_82f7d3c3-878a-4022-b2e2-7775cb282307"
      unitRef="number">0.99</amed:HistoricalCollectionRateFromMedicare>
    <amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities
      contextRef="iecd85c6103824b598da9159d305f569b_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RleHRyZWdpb246ODc3MjBkMjEyMGFkNGY4NWIxZDk3NzQyNGNhYzBmYjVfMTIwNTM_d3fa4712-66b9-47a8-a3ba-e9d4bd9f4802"
      unitRef="usd">5500000</amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities>
    <amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities
      contextRef="i7ff59164cb40413fac8d060bc05c3403_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RleHRyZWdpb246ODc3MjBkMjEyMGFkNGY4NWIxZDk3NzQyNGNhYzBmYjVfMTIzNTg_faf03678-09c3-4c13-a4c7-572e12d9df58"
      unitRef="usd">5700000</amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RleHRyZWdpb246ODc3MjBkMjEyMGFkNGY4NWIxZDk3NzQyNGNhYzBmYjVfMjc0ODc3OTExMjYwNg_f7af46a0-b91d-4813-bccf-afef4ba668c7">&lt;div style="text-align:justify;margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Cash, Cash Equivalents and Restricted Cash &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Cash and cash equivalents include certificates of deposit and all highly liquid debt instruments with maturities of three months or less when purchased. Restricted cash includes cash that is not available for ordinary business use. As of March 31, 2020, we had $3.1&#160;million of restricted cash that was placed into escrow accounts related to the potential indemnity and working capital adjustment provisions within the Asana Hospice purchase agreement ($2.3&#160;million) and to secure the purchase of personal protective equipment from new suppliers in response to COVID-19 ($0.8&#160;million).&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RestrictedCash
      contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RleHRyZWdpb246ODc3MjBkMjEyMGFkNGY4NWIxZDk3NzQyNGNhYzBmYjVfMTY0OTI2NzQ4NDc4OQ_070e5ab6-e756-4e88-8ad9-002ef2808f34"
      unitRef="usd">3100000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i94c155e0b36a4453979995375a4118aa_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RleHRyZWdpb246ODc3MjBkMjEyMGFkNGY4NWIxZDk3NzQyNGNhYzBmYjVfMTY0OTI2NzQ4NDgwMw_688444a3-c3ac-42c4-980e-b15fff182730"
      unitRef="usd">2300000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="id6a265dc3d6143ed962cec7a4019507c_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RleHRyZWdpb246ODc3MjBkMjEyMGFkNGY4NWIxZDk3NzQyNGNhYzBmYjVfMTY0OTI2NzQ4NDgxNw_219289b4-90a6-45ca-a3fd-fc682ea769dd"
      unitRef="usd">800000</us-gaap:RestrictedCash>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RleHRyZWdpb246ODc3MjBkMjEyMGFkNGY4NWIxZDk3NzQyNGNhYzBmYjVfMjA3MjM_a47682a6-1ec8-4db9-9dba-90ea82da12cd">&lt;div style="text-align:justify;margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Patient Accounts Receivable &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We report accounts receivable from services rendered at their estimated transaction price, which includes contractual and non-contractual revenue adjustments based on the amounts expected to be due from payors. Our patient accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other third-party payors and patients. As of March&#160;31, 2020, there is no single payor, other than Medicare, that accounts for more than 10% of our total outstanding patient receivables. Thus, we believe there are no other significant concentrations of receivables that would subject us to any significant credit risk in the collection of our patient accounts receivable. We write off accounts on a monthly basis once we have exhausted our collection efforts and deem an account to be uncollectible. We believe the collectibility risk associated with our Medicare accounts, which represent 58% of our patient accounts receivable at March&#160;31, 2020 and December&#160;31, 2019 is limited due to our historical collection rate of over 99% from Medicare and the fact that Medicare is a U.S. government payor. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We do not believe there are any significant concentrations of revenues from any payor that would subject us to any significant credit risk in the collection of our accounts receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Medicare Home Health&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For our home health patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We submit a RAP for 20% of our estimated payment for each 30-day period of care. The full amount of the payment for each 30-day period of care is billed after the period of care has been completed (&#x201c;final billed&#x201d;). The RAP received for that billing period is then deducted from our final payment. If a final bill is not submitted within the greater of 90 days from the start of the 30-day period of care, or 60 days from the date the RAP was paid, &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;any RAPs received for that billing period will be recouped by Medicare from any other claims in process for that particular provider number. The RAP claim must then be resubmitted. CMS has mandated the full elimination of RAPs in 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Medicare Hospice&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For our hospice patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We bill Medicare on a monthly basis for the services provided to the patient.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Non-Medicare Home Health, Hospice and Personal Care&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For our non-Medicare patients, our pre-billing process primarily begins with verifying a patient&#x2019;s eligibility for services with the applicable payor. Once the patient has been confirmed for eligibility, we will provide services to the patient and bill the applicable payor. Our review and evaluation of non-Medicare accounts receivable includes a detailed review of outstanding balances and special consideration to concentrations of receivables from particular payors or groups of payors with similar characteristics that would subject us to any significant credit risk.&lt;/span&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <amed:PercentageOfPatientReceivablesOutstanding
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RleHRyZWdpb246ODc3MjBkMjEyMGFkNGY4NWIxZDk3NzQyNGNhYzBmYjVfMTQzODU_aea125b0-f170-4f1b-9217-bf363b13ec9e"
      unitRef="number">0.10</amed:PercentageOfPatientReceivablesOutstanding>
    <amed:AccountsReceivablePortionDerivedFromMedicare
      contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RleHRyZWdpb246ODc3MjBkMjEyMGFkNGY4NWIxZDk3NzQyNGNhYzBmYjVfMTQ4NDQ_7607040c-26ac-4bee-bf01-b546a5a8efbc"
      unitRef="number">0.58</amed:AccountsReceivablePortionDerivedFromMedicare>
    <amed:HistoricalCollectionRateFromMedicare
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RleHRyZWdpb246ODc3MjBkMjEyMGFkNGY4NWIxZDk3NzQyNGNhYzBmYjVfMTQ5Njc_b6d1bd40-b965-4e5e-9553-a483a7be513e"
      unitRef="number">0.99</amed:HistoricalCollectionRateFromMedicare>
    <amed:RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RleHRyZWdpb246ODc3MjBkMjEyMGFkNGY4NWIxZDk3NzQyNGNhYzBmYjVfMTU1ODQ_f24cbd0d-bc22-436e-862f-0f91129964c5"
      unitRef="number">0.20</amed:RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare>
    <amed:MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RleHRyZWdpb246ODc3MjBkMjEyMGFkNGY4NWIxZDk3NzQyNGNhYzBmYjVfMTYwMjE_5bf5053a-fef3-492c-9086-626613d1992d"
      unitRef="day">90</amed:MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare>
    <amed:MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RleHRyZWdpb246ODc3MjBkMjEyMGFkNGY4NWIxZDk3NzQyNGNhYzBmYjVfMTYwNjM_17956edb-850b-4398-9bad-a0cb8e97654e"
      unitRef="day">60</amed:MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RleHRyZWdpb246ODc3MjBkMjEyMGFkNGY4NWIxZDk3NzQyNGNhYzBmYjVfMjA3MjQ_eac9360f-b82a-4d1b-af96-19a6ab6eb89d">&lt;div style="text-align:justify;margin-top:16pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.076%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:24.054%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.921%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.553%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.921%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.553%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.921%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.553%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.924%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value at Reporting Date Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;Financial Instrument&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Carrying Value as of March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Quoted&#160;Prices&#160;in&#160;Active&lt;br/&gt;Markets for Identical&lt;br/&gt;Items&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Significant&lt;br/&gt;Unobservable&#160;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;391.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;383.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The three levels of inputs are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"&gt;Level&#160;1 &#x2013; Quoted prices in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"&gt;Level&#160;2 &#x2013; Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"&gt;Level&#160;3 &#x2013; Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;Our deferred compensation plan assets are recorded at fair value and are considered a level 2 measurement. For our other financial instruments, including our cash and cash equivalents, patient accounts receivable, accounts payable, payroll and employee benefits and accrued expenses, we estimate the carrying amounts approximate fair value.</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <amed:FinancialInstrumentDetailsTableTextBlock
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RleHRyZWdpb246ODc3MjBkMjEyMGFkNGY4NWIxZDk3NzQyNGNhYzBmYjVfMjA3NDM_d56fa97f-ec49-420e-a1f5-69041285e810">&lt;div style="text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.076%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:24.054%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.921%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.553%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.921%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.553%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.921%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.553%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.924%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value at Reporting Date Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;Financial Instrument&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Carrying Value as of March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Quoted&#160;Prices&#160;in&#160;Active&lt;br/&gt;Markets for Identical&lt;br/&gt;Items&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Significant&lt;br/&gt;Unobservable&#160;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;391.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;383.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</amed:FinancialInstrumentDetailsTableTextBlock>
    <amed:DebtInstrumentCarryingAmountExcludingFinanceLeases
      contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RhYmxlOmJhOTM5NWI0ODA0ZDRlYWViOTI2NDFkNTg1MGQzNDRkL3RhYmxlcmFuZ2U6YmE5Mzk1YjQ4MDRkNGVhZWI5MjY0MWQ1ODUwZDM0NGRfMi0xLTEtMS0w_ae010d80-3faa-4d86-a4d1-371bbb18b2e1"
      unitRef="usd">391200000</amed:DebtInstrumentCarryingAmountExcludingFinanceLeases>
    <us-gaap:LongTermDebtFairValue
      contextRef="i0c3c88d49d1d4d8a95daf44cd924af53_I20200331"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RhYmxlOmJhOTM5NWI0ODA0ZDRlYWViOTI2NDFkNTg1MGQzNDRkL3RhYmxlcmFuZ2U6YmE5Mzk1YjQ4MDRkNGVhZWI5MjY0MWQ1ODUwZDM0NGRfMi0zLTEtMS0w_2ce305ca-4f9c-4af7-96a0-1bfb4dec9e0d"
      unitRef="usd">0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i7815a32e7798440abd6d377ab708f8e5_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RhYmxlOmJhOTM5NWI0ODA0ZDRlYWViOTI2NDFkNTg1MGQzNDRkL3RhYmxlcmFuZ2U6YmE5Mzk1YjQ4MDRkNGVhZWI5MjY0MWQ1ODUwZDM0NGRfMi01LTEtMS0w_d8742ddd-8734-43b5-9079-7997ae4e4c64"
      unitRef="usd">383600000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i72f233d9e2f84fa7a940e82385eff8a4_I20200331"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RhYmxlOmJhOTM5NWI0ODA0ZDRlYWViOTI2NDFkNTg1MGQzNDRkL3RhYmxlcmFuZ2U6YmE5Mzk1YjQ4MDRkNGVhZWI5MjY0MWQ1ODUwZDM0NGRfMi03LTEtMS0w_95efb9e9-de4e-4fb0-a4ad-b958a867526a"
      unitRef="usd">0</us-gaap:LongTermDebtFairValue>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RleHRyZWdpb246ODc3MjBkMjEyMGFkNGY4NWIxZDk3NzQyNGNhYzBmYjVfMjA3MzQ_7fffc18d-32eb-4339-9c0f-1c3199600a6e">Weighted-Average Shares OutstandingNet income per share attributable to Amedisys, Inc. common stockholders, calculated on the treasury stock method, is based on the weighted average number of shares outstanding during the period.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RleHRyZWdpb246ODc3MjBkMjEyMGFkNGY4NWIxZDk3NzQyNGNhYzBmYjVfMjA3MzY_ef78005d-35ee-45fe-a043-345628d8cb8f">The following table sets forth, for the periods indicated, shares used in our computation of the weighted-average shares outstanding, which are used to calculate our basic and diluted net income attributable to Amedisys, Inc. common stockholders (amounts in thousands):&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:90.497%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:69.082%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.054%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.607%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.057%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Three-&lt;br/&gt;Month Periods&lt;br/&gt;Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted average number of shares outstanding - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;32,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;32,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:20.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Non-vested stock and stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted average number of shares outstanding - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;32,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Anti-dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RhYmxlOjBmODA0MWY1ZjAyMTQ3ZWJhNDUzMWRiOWUwMjc1MDIxL3RhYmxlcmFuZ2U6MGY4MDQxZjVmMDIxNDdlYmE0NTMxZGI5ZTAyNzUwMjFfMi0xLTEtMS0w_20ff6ba8-f0d9-46e5-8f49-fceff46527cb"
      unitRef="shares">32331000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RhYmxlOjBmODA0MWY1ZjAyMTQ3ZWJhNDUzMWRiOWUwMjc1MDIxL3RhYmxlcmFuZ2U6MGY4MDQxZjVmMDIxNDdlYmE0NTMxZGI5ZTAyNzUwMjFfMi0zLTEtMS0w_65875890-45ae-42e8-8ff0-155669bd9794"
      unitRef="shares">32001000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RhYmxlOjBmODA0MWY1ZjAyMTQ3ZWJhNDUzMWRiOWUwMjc1MDIxL3RhYmxlcmFuZ2U6MGY4MDQxZjVmMDIxNDdlYmE0NTMxZGI5ZTAyNzUwMjFfNC0xLTEtMS0w_d0cf322b-789a-4187-bdf6-0bfc9bae0db0"
      unitRef="shares">594000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RhYmxlOjBmODA0MWY1ZjAyMTQ3ZWJhNDUzMWRiOWUwMjc1MDIxL3RhYmxlcmFuZ2U6MGY4MDQxZjVmMDIxNDdlYmE0NTMxZGI5ZTAyNzUwMjFfNC0zLTEtMS0w_e2f9835b-6362-4cbe-9fa9-68523ed05aa3"
      unitRef="shares">559000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <amed:NonVestedStockAndStockUnits
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RhYmxlOjBmODA0MWY1ZjAyMTQ3ZWJhNDUzMWRiOWUwMjc1MDIxL3RhYmxlcmFuZ2U6MGY4MDQxZjVmMDIxNDdlYmE0NTMxZGI5ZTAyNzUwMjFfNS0xLTEtMS0w_b6caee0d-9665-464e-ab6e-c3ae592bed63"
      unitRef="shares">309000</amed:NonVestedStockAndStockUnits>
    <amed:NonVestedStockAndStockUnits
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RhYmxlOjBmODA0MWY1ZjAyMTQ3ZWJhNDUzMWRiOWUwMjc1MDIxL3RhYmxlcmFuZ2U6MGY4MDQxZjVmMDIxNDdlYmE0NTMxZGI5ZTAyNzUwMjFfNS0zLTEtMS0w_0f04ce76-c76c-4b64-851b-5d94fb280817"
      unitRef="shares">333000</amed:NonVestedStockAndStockUnits>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RhYmxlOjBmODA0MWY1ZjAyMTQ3ZWJhNDUzMWRiOWUwMjc1MDIxL3RhYmxlcmFuZ2U6MGY4MDQxZjVmMDIxNDdlYmE0NTMxZGI5ZTAyNzUwMjFfNi0xLTEtMS0w_8ff411b3-ef27-46b1-a26e-9be6acaae5a0"
      unitRef="shares">33234000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RhYmxlOjBmODA0MWY1ZjAyMTQ3ZWJhNDUzMWRiOWUwMjc1MDIxL3RhYmxlcmFuZ2U6MGY4MDQxZjVmMDIxNDdlYmE0NTMxZGI5ZTAyNzUwMjFfNi0zLTEtMS0w_958962bc-ea33-4c75-b539-027f09107a50"
      unitRef="shares">32893000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RhYmxlOjBmODA0MWY1ZjAyMTQ3ZWJhNDUzMWRiOWUwMjc1MDIxL3RhYmxlcmFuZ2U6MGY4MDQxZjVmMDIxNDdlYmE0NTMxZGI5ZTAyNzUwMjFfNy0xLTEtMS0w_0845658b-24ee-40b1-a8b8-2aefa6a28b1d"
      unitRef="shares">57000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RhYmxlOjBmODA0MWY1ZjAyMTQ3ZWJhNDUzMWRiOWUwMjc1MDIxL3RhYmxlcmFuZ2U6MGY4MDQxZjVmMDIxNDdlYmE0NTMxZGI5ZTAyNzUwMjFfNy0zLTEtMS0w_2fa3dfad-9db0-4a32-8dd0-16c0db22cd72"
      unitRef="shares">148000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80My9mcmFnOjg3NzIwZDIxMjBhZDRmODViMWQ5Nzc0MjRjYWMwZmI1L3RleHRyZWdpb246ODc3MjBkMjEyMGFkNGY4NWIxZDk3NzQyNGNhYzBmYjVfMjA3NTY_49266ee4-6bbb-4607-b055-a03fdccb6b23">Business Combinations&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We account for acquisitions using the acquisition method of accounting in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) 805, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Business Combinations&lt;/span&gt;. Acquisitions are accounted for as purchases and are included in our condensed consolidated financial statements from their respective acquisition dates. Assets acquired and liabilities assumed, if any, are measured at fair value on the acquisition date using the appropriate valuation method. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets.</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80OS9mcmFnOjdjOThkNmQ0ZTFlODRmNjA4OGNiYjg2OGY2M2JhZWEzL3RleHRyZWdpb246N2M5OGQ2ZDRlMWU4NGY2MDg4Y2JiODY4ZjYzYmFlYTNfMTY0OTI2NzQ1NDczNw_08bdc3d9-6356-44a1-8ba0-e13d046b6009">ACQUISITIONS&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We complete acquisitions from time to time in order to pursue our strategy of increasing our market presence by expanding our service base and enhancing our position in certain geographic areas as a leading provider of home health, hospice and personal care services. The purchase price paid for acquisitions is negotiated through arm&#x2019;s length transactions, with consideration based on our analysis of, among other things, comparable acquisitions and expected cash flows. Acquisitions are accounted for as purchases and are included in our condensed consolidated financial statements from their respective acquisition dates. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets because of the expected contributions of the acquisitions to our overall corporate strategy. We typically engage outside appraisal firms to assist in the fair value determination of identifiable intangible assets for significant acquisitions. The preliminary purchase price allocation is adjusted, as necessary, up to one year after the acquisition closing date if management obtains more information regarding asset valuations and liabilities assumed.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:16pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Home Health Division&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On March 1, 2020, we acquired the regulatory assets of a home health provider in Washington for a purchase price of $3.0&#160;million. The purchase price was paid with cash on hand on the date of the transaction. Based on the Company's preliminary valuation, we recorded goodwill of $2.8&#160;million and other intangibles (certificate of need) of $0.2&#160;million in connection with the acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:16pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Hospice Division&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On January 1, 2020, we acquired Asana Hospice ("Asana"), a hospice provider with locations in Pennsylvania, Ohio, Texas, Missouri and Kansas for a purchase price of $66.3&#160;million, net of cash acquired of $0.7&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company is in the process of finalizing its valuation of the assets acquired and liabilities assumed. Based on the Company's preliminary valuation, the total estimated consideration of $66.3&#160;million has been allocated to assets acquired and liabilities assumed as of the acquisition date as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:79.970%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:73.137%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:22.863%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Patient accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease right of use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Total assets acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Payroll and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Total liabilities assumed&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(5.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net identifiable assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;59.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total estimated consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;66.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Intangible assets acquired include licenses ($2.0&#160;million), acquired names ($1.3&#160;million) and non-compete agreements ($2.3&#160;million). The acquired names and non-compete agreements will be amortized over a weighted-average period of 2.0 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Asana contributed approximately $7.4&#160;million in net service revenue and an operating loss of $1.3&#160;million (inclusive of acquisition and integration costs totaling $1.1&#160;million and intangibles amortization totaling $0.5&#160;million) during the three-month period ended March 31, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="ia13fdf76a2e04a3f85e27598086705bf_D20200301-20200301"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80OS9mcmFnOjdjOThkNmQ0ZTFlODRmNjA4OGNiYjg2OGY2M2JhZWEzL3RleHRyZWdpb246N2M5OGQ2ZDRlMWU4NGY2MDg4Y2JiODY4ZjYzYmFlYTNfMTY0OTI2NzQ1MzU5Nw_e8906adf-2fc9-4f67-9f4a-e73a55beebb7"
      unitRef="usd">3000000.0</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i1803f21995a846beaf2e5491abdaa75f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80OS9mcmFnOjdjOThkNmQ0ZTFlODRmNjA4OGNiYjg2OGY2M2JhZWEzL3RleHRyZWdpb246N2M5OGQ2ZDRlMWU4NGY2MDg4Y2JiODY4ZjYzYmFlYTNfMTY0OTI2NzQ1MzYxMQ_8b0d5ab9-280b-47bb-956f-44445fc6c974"
      unitRef="usd">2800000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="if1a12a5a1ad7439bb6eb83289bc57f39_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80OS9mcmFnOjdjOThkNmQ0ZTFlODRmNjA4OGNiYjg2OGY2M2JhZWEzL3RleHRyZWdpb246N2M5OGQ2ZDRlMWU4NGY2MDg4Y2JiODY4ZjYzYmFlYTNfMTY0OTI2NzQ1MzYyNQ_7bbcf11f-c169-4b22-b467-94343d0f5654"
      unitRef="usd">200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="ic7171631cf3944959da9674b593c9910_D20200101-20200101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80OS9mcmFnOjdjOThkNmQ0ZTFlODRmNjA4OGNiYjg2OGY2M2JhZWEzL3RleHRyZWdpb246N2M5OGQ2ZDRlMWU4NGY2MDg4Y2JiODY4ZjYzYmFlYTNfMTY0OTI2NzQ1NDU0OQ_919770a7-eec0-4094-afb6-2bf2c89a12fa"
      unitRef="usd">66300000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="ic7171631cf3944959da9674b593c9910_D20200101-20200101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80OS9mcmFnOjdjOThkNmQ0ZTFlODRmNjA4OGNiYjg2OGY2M2JhZWEzL3RleHRyZWdpb246N2M5OGQ2ZDRlMWU4NGY2MDg4Y2JiODY4ZjYzYmFlYTNfMTY0OTI2NzQ1MzY1NA_b846e4eb-5a4a-4a5f-84a6-f49faf22d9d7"
      unitRef="usd">700000</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80OS9mcmFnOjdjOThkNmQ0ZTFlODRmNjA4OGNiYjg2OGY2M2JhZWEzL3RleHRyZWdpb246N2M5OGQ2ZDRlMWU4NGY2MDg4Y2JiODY4ZjYzYmFlYTNfMTY0OTI2NzQ1NDczOA_0475dc18-9ee6-4ddc-ad36-5e729b8d87e3">The Company is in the process of finalizing its valuation of the assets acquired and liabilities assumed. Based on the Company's preliminary valuation, the total estimated consideration of $66.3&#160;million has been allocated to assets acquired and liabilities assumed as of the acquisition date as follows (amounts in millions):&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:79.970%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:73.137%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:22.863%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Patient accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease right of use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Total assets acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Payroll and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Total liabilities assumed&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(5.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net identifiable assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;59.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total estimated consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;66.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="ic7171631cf3944959da9674b593c9910_D20200101-20200101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80OS9mcmFnOjdjOThkNmQ0ZTFlODRmNjA4OGNiYjg2OGY2M2JhZWEzL3RleHRyZWdpb246N2M5OGQ2ZDRlMWU4NGY2MDg4Y2JiODY4ZjYzYmFlYTNfMTY0OTI2NzQ1MzY2OA_2ea12b45-84b0-4242-b415-f18c440c5f5d"
      unitRef="usd">66300000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="i9c5dbb2e85d34e54b0517980e6f8d0eb_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80OS9mcmFnOjdjOThkNmQ0ZTFlODRmNjA4OGNiYjg2OGY2M2JhZWEzL3RhYmxlOmIyYmJiMWU1ZDZjZjRkYmNiNDExZWQ1NDA0YzA0YmJhL3RhYmxlcmFuZ2U6YjJiYmIxZTVkNmNmNGRiY2I0MTFlZDU0MDRjMDRiYmFfMS0xLTEtMS0zMzky_b2a1cd67-58e5-4e85-9bbf-154a8ebcae87"
      unitRef="usd">5500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="i9c5dbb2e85d34e54b0517980e6f8d0eb_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80OS9mcmFnOjdjOThkNmQ0ZTFlODRmNjA4OGNiYjg2OGY2M2JhZWEzL3RhYmxlOmIyYmJiMWU1ZDZjZjRkYmNiNDExZWQ1NDA0YzA0YmJhL3RhYmxlcmFuZ2U6YjJiYmIxZTVkNmNmNGRiY2I0MTFlZDU0MDRjMDRiYmFfMi0xLTEtMS0zMzk1_05c2271a-943c-4b1f-874c-56be6f69f04c"
      unitRef="usd">200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets
      contextRef="i9c5dbb2e85d34e54b0517980e6f8d0eb_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80OS9mcmFnOjdjOThkNmQ0ZTFlODRmNjA4OGNiYjg2OGY2M2JhZWEzL3RhYmxlOmIyYmJiMWU1ZDZjZjRkYmNiNDExZWQ1NDA0YzA0YmJhL3RhYmxlcmFuZ2U6YjJiYmIxZTVkNmNmNGRiY2I0MTFlZDU0MDRjMDRiYmFfMy0xLTEtMS0zMzk3_45c19359-0aba-4a49-a87c-5672bd507c4f"
      unitRef="usd">900000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i9c5dbb2e85d34e54b0517980e6f8d0eb_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80OS9mcmFnOjdjOThkNmQ0ZTFlODRmNjA4OGNiYjg2OGY2M2JhZWEzL3RhYmxlOmIyYmJiMWU1ZDZjZjRkYmNiNDExZWQ1NDA0YzA0YmJhL3RhYmxlcmFuZ2U6YjJiYmIxZTVkNmNmNGRiY2I0MTFlZDU0MDRjMDRiYmFfNC0xLTEtMS0zMzk5_9591035d-7847-491e-bd1a-10fe485c9a9b"
      unitRef="usd">5600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="i9c5dbb2e85d34e54b0517980e6f8d0eb_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80OS9mcmFnOjdjOThkNmQ0ZTFlODRmNjA4OGNiYjg2OGY2M2JhZWEzL3RhYmxlOmIyYmJiMWU1ZDZjZjRkYmNiNDExZWQ1NDA0YzA0YmJhL3RhYmxlcmFuZ2U6YjJiYmIxZTVkNmNmNGRiY2I0MTFlZDU0MDRjMDRiYmFfNS0xLTEtMS0zNDAx_89275a09-98c2-4d10-a868-19dd01332cbe"
      unitRef="usd">12200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="i9c5dbb2e85d34e54b0517980e6f8d0eb_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80OS9mcmFnOjdjOThkNmQ0ZTFlODRmNjA4OGNiYjg2OGY2M2JhZWEzL3RhYmxlOmIyYmJiMWU1ZDZjZjRkYmNiNDExZWQ1NDA0YzA0YmJhL3RhYmxlcmFuZ2U6YjJiYmIxZTVkNmNmNGRiY2I0MTFlZDU0MDRjMDRiYmFfNi0xLTEtMS0zNDAz_e7e0b9bf-c846-411c-899f-ccc2a787e6f9"
      unitRef="usd">3000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits
      contextRef="i9c5dbb2e85d34e54b0517980e6f8d0eb_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80OS9mcmFnOjdjOThkNmQ0ZTFlODRmNjA4OGNiYjg2OGY2M2JhZWEzL3RhYmxlOmIyYmJiMWU1ZDZjZjRkYmNiNDExZWQ1NDA0YzA0YmJhL3RhYmxlcmFuZ2U6YjJiYmIxZTVkNmNmNGRiY2I0MTFlZDU0MDRjMDRiYmFfNy0xLTEtMS0zNDA1_282b7bee-59cb-4a98-840b-fdd3e4b8f23d"
      unitRef="usd">1500000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses
      contextRef="i9c5dbb2e85d34e54b0517980e6f8d0eb_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80OS9mcmFnOjdjOThkNmQ0ZTFlODRmNjA4OGNiYjg2OGY2M2JhZWEzL3RhYmxlOmIyYmJiMWU1ZDZjZjRkYmNiNDExZWQ1NDA0YzA0YmJhL3RhYmxlcmFuZ2U6YjJiYmIxZTVkNmNmNGRiY2I0MTFlZDU0MDRjMDRiYmFfOC0xLTEtMS0zNDA3_f7b900ff-6eda-4141-b0ab-233e19a5fcdc"
      unitRef="usd">200000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities
      contextRef="i9c5dbb2e85d34e54b0517980e6f8d0eb_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80OS9mcmFnOjdjOThkNmQ0ZTFlODRmNjA4OGNiYjg2OGY2M2JhZWEzL3RhYmxlOmIyYmJiMWU1ZDZjZjRkYmNiNDExZWQ1NDA0YzA0YmJhL3RhYmxlcmFuZ2U6YjJiYmIxZTVkNmNmNGRiY2I0MTFlZDU0MDRjMDRiYmFfOS0xLTEtMS0zNDA5_8aea8024-3615-4e6c-8b01-54573548c7ff"
      unitRef="usd">900000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="i9c5dbb2e85d34e54b0517980e6f8d0eb_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80OS9mcmFnOjdjOThkNmQ0ZTFlODRmNjA4OGNiYjg2OGY2M2JhZWEzL3RhYmxlOmIyYmJiMWU1ZDZjZjRkYmNiNDExZWQ1NDA0YzA0YmJhL3RhYmxlcmFuZ2U6YjJiYmIxZTVkNmNmNGRiY2I0MTFlZDU0MDRjMDRiYmFfMTAtMS0xLTEtMzQxMQ_45e2d20d-4769-4b22-8612-0c8852e4041f"
      unitRef="usd">5600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="i9c5dbb2e85d34e54b0517980e6f8d0eb_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80OS9mcmFnOjdjOThkNmQ0ZTFlODRmNjA4OGNiYjg2OGY2M2JhZWEzL3RhYmxlOmIyYmJiMWU1ZDZjZjRkYmNiNDExZWQ1NDA0YzA0YmJhL3RhYmxlcmFuZ2U6YjJiYmIxZTVkNmNmNGRiY2I0MTFlZDU0MDRjMDRiYmFfMTEtMS0xLTEtMzQxNA_9a7216a9-978e-4959-89e3-643f37827d2e"
      unitRef="usd">6600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i75590cbf7a2a42d792be47ee29fed5a2_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80OS9mcmFnOjdjOThkNmQ0ZTFlODRmNjA4OGNiYjg2OGY2M2JhZWEzL3RhYmxlOmIyYmJiMWU1ZDZjZjRkYmNiNDExZWQ1NDA0YzA0YmJhL3RhYmxlcmFuZ2U6YjJiYmIxZTVkNmNmNGRiY2I0MTFlZDU0MDRjMDRiYmFfMTItMS0xLTEtMzQxNg_b4b00c63-e28b-41f1-81b6-d52bb63d3761"
      unitRef="usd">59700000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i75590cbf7a2a42d792be47ee29fed5a2_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80OS9mcmFnOjdjOThkNmQ0ZTFlODRmNjA4OGNiYjg2OGY2M2JhZWEzL3RhYmxlOmIyYmJiMWU1ZDZjZjRkYmNiNDExZWQ1NDA0YzA0YmJhL3RhYmxlcmFuZ2U6YjJiYmIxZTVkNmNmNGRiY2I0MTFlZDU0MDRjMDRiYmFfMTMtMS0xLTEtMzQxOA_32ee5340-325f-42c1-8086-655ce8e41950"
      unitRef="usd">66300000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i758d8a3c5dd14c668b6a8284e987ffea_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80OS9mcmFnOjdjOThkNmQ0ZTFlODRmNjA4OGNiYjg2OGY2M2JhZWEzL3RleHRyZWdpb246N2M5OGQ2ZDRlMWU4NGY2MDg4Y2JiODY4ZjYzYmFlYTNfMTY0OTI2NzQ1NDY4NA_c2952906-c7fa-45a1-b03a-0644dbe7269b"
      unitRef="usd">2000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="iaeb6ae8b7d9c4d529b6d4a55a4212894_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80OS9mcmFnOjdjOThkNmQ0ZTFlODRmNjA4OGNiYjg2OGY2M2JhZWEzL3RleHRyZWdpb246N2M5OGQ2ZDRlMWU4NGY2MDg4Y2JiODY4ZjYzYmFlYTNfMTY0OTI2NzQ1NDY5OA_16dcdbff-4bcb-4fa9-b03f-00080564aab2"
      unitRef="usd">1300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i19dd87f55ab74480af0f28e529fe3174_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80OS9mcmFnOjdjOThkNmQ0ZTFlODRmNjA4OGNiYjg2OGY2M2JhZWEzL3RleHRyZWdpb246N2M5OGQ2ZDRlMWU4NGY2MDg4Y2JiODY4ZjYzYmFlYTNfMTY0OTI2NzQ1NDcxMg_b31aba9d-5c63-4f37-825c-03c1516f6d8f"
      unitRef="usd">2300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i966c726cb1b24dc69084cdec997e95f6_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80OS9mcmFnOjdjOThkNmQ0ZTFlODRmNjA4OGNiYjg2OGY2M2JhZWEzL3RleHRyZWdpb246N2M5OGQ2ZDRlMWU4NGY2MDg4Y2JiODY4ZjYzYmFlYTNfMTY0OTI2NzQ1MTY0OQ_1277f1f5-06af-44cb-9c1a-e72d73fbc7ca">P2Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i75590cbf7a2a42d792be47ee29fed5a2_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80OS9mcmFnOjdjOThkNmQ0ZTFlODRmNjA4OGNiYjg2OGY2M2JhZWEzL3RleHRyZWdpb246N2M5OGQ2ZDRlMWU4NGY2MDg4Y2JiODY4ZjYzYmFlYTNfMTY0OTI2NzQ1NDU2NQ_f0f77b2e-fe0f-4b94-a8dd-d5b0ae631eaf"
      unitRef="usd">7400000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:BusinessCombinationIntegrationRelatedCosts
      contextRef="i75590cbf7a2a42d792be47ee29fed5a2_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80OS9mcmFnOjdjOThkNmQ0ZTFlODRmNjA4OGNiYjg2OGY2M2JhZWEzL3RleHRyZWdpb246N2M5OGQ2ZDRlMWU4NGY2MDg4Y2JiODY4ZjYzYmFlYTNfMTY0OTI2NzQ1NDYwOQ_fc04b832-146a-4bf9-b61c-107d7d65061a"
      unitRef="usd">1100000</us-gaap:BusinessCombinationIntegrationRelatedCosts>
    <us-gaap:DepreciationAndAmortization
      contextRef="i75590cbf7a2a42d792be47ee29fed5a2_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl80OS9mcmFnOjdjOThkNmQ0ZTFlODRmNjA4OGNiYjg2OGY2M2JhZWEzL3RleHRyZWdpb246N2M5OGQ2ZDRlMWU4NGY2MDg4Y2JiODY4ZjYzYmFlYTNfMTY0OTI2NzQ1NDU5NA_2d1f0d7a-a773-4bf6-bb56-480ccb4c984f"
      unitRef="usd">500000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RleHRyZWdpb246MGRkY2MwZmFlMjM3NGNmNTljNWM4MzA4Y2NkYWIyMjhfNjgxNQ_9587148d-fb1a-4724-a911-d33aa0f2e452">LONG-TERM OBLIGATIONS&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Long-term debt consisted of the following for the periods indicated (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:91.812%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:65.356%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.923%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.596%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.925%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;$175.0 million Term Loan; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate (2.5% at March 31, 2020); due February&#160;4, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;170.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;171.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;$550.0 million Revolving Credit Facility; interest only payments; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate (2.4% at March 31, 2020); due February&#160;4, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;220.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;70.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Promissory notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Principal amount of long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;394.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;245.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;391.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;242.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current portion of long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(11.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(9.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;379.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;232.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;First Amendment to Amended and Restated Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On February 4, 2019, we entered into the First Amendment to our Credit Agreement (as amended by the First Amendment, the "Amended Credit Agreement"). The Amended Credit Agreement provides for a senior secured credit facility in an initial aggregate principal amount of up to $725.0 million, which includes a $550.0 million Revolving Credit Facility under the Credit Agreement and a term loan facility with a principal amount of up to $175.0 million (the "Term Loan Facility" and collectively with the Revolving Credit Facility, the "Credit Facility"), which was added by the First Amendment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We borrowed the entire principal amount of the Term Loan Facility on February&#160;4, 2019 in order to fund a portion of the purchase price of the Compassionate Care Hospice ("CCH") acquisition, with the remainder of the purchase price and associated transactional fees and expenses funded by proceeds from the Revolving Credit Facility. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The loans issued under the Credit Facility bear interest on a per annum basis, at our election, at either: (i) the Base Rate plus the Applicable Rate or (ii) the Eurodollar Rate plus the Applicable Rate. The &#x201c;Base Rate&#x201d; means a fluctuating rate per annum equal to the highest of (a) the federal funds rate plus 0.50% per annum, (b) the prime rate of interest established by the Administrative Agent, and (c) the Eurodollar Rate plus 1% per annum. The &#x201c;Eurodollar Rate&#x201d; means the quoted rate per annum equal to the London Interbank Offered Rate (&#x201c;LIBOR&#x201d;) or a comparable successor rate approved by the Administrative Agent for an interest period of one, two, three or six months (as selected by us). The &#x201c;Applicable Rate&#x201d; is based on the consolidated leverage ratio and is presented in the table below. As of March&#160;31, 2020, the Applicable Rate is 0.50% per annum for Base Rate loans and 1.50% per annum for Eurodollar Rate loans. We are also subject to a commitment fee and letter of credit fee under the terms of the Amended Credit Agreement, as presented in the table below.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:92.251%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.251%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:25.258%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.908%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.836%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.908%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.839%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Pricing Tier&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Consolidated Leverage Ratio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commitment Fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Letter of Credit Fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Eurodollar Rate Loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Base Rate Loans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;I&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;&#x2265; 3.00 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.35%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;II&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;&amp;lt; 3.00 to 1.0 but &#x2265; 2.00 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.30%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.75%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;III&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;&amp;lt; 2.00 to 1.0 but &#x2265; 0.75 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.50%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;IV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;&amp;lt; 0.75 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.20%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.25%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The final maturity date of the Credit Facility is February 4, 2024. The Revolving Credit Facility will terminate and be due and payable as of the final maturity date. The Term Loan Facility, however, is subject to quarterly amortization of principal in the amount of (i) 0.625% for the period commencing on February 4, 2019 and ending on March 31, 2020, (ii) 1.250% for the period commencing on April 1, 2020 and ending on March 31, 2023, and (iii) 1.875% for the period commencing on April 1, 2023 and ending on February 4, 2024. The remaining balance of the Term Loan Facility must be paid upon the final maturity date. In addition to the scheduled amortization of the Term Loan Facility, and subject to customary exceptions and reinvestment rights, we are required to prepay the Term Loan Facility, first, and the Revolving Credit Facility, second, with 100% of all net cash proceeds received by any loan party or any subsidiary thereof in connection with (a) any asset sale or disposition where such loan party receives net cash proceeds in excess of $5 million or (b) any debt issuance that is not permitted under the Amended Credit Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Amended Credit Agreement requires maintenance of two financial covenants: (i) a consolidated leverage ratio of funded indebtedness to Earnings Before Interest, Taxes, Depreciation and Amortization ("EBITDA"), as defined in the Amended Credit Agreement, and (ii) a consolidated interest coverage ratio of EBITDA to cash interest charges, as defined in the Amended Credit Agreement. Each of these covenants is calculated over rolling four-quarter periods and also is subject to certain exceptions and baskets. The Amended Credit Agreement also contains customary covenants, including, but not limited to, restrictions on: incurrence of liens, incurrence of additional debt, sales of assets and other fundamental corporate changes, investments, and declarations of dividends. These covenants contain customary exclusions and baskets as detailed in the Amended Credit Agreement. In connection with our entry into the Amended Credit Agreement, we recorded $0.8 million in deferred debt issuance costs as long-term obligations, less current portion within our condensed consolidated balance sheet during the year ended December 31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Revolving Credit Facility is guaranteed by substantially all of our wholly-owned direct and indirect subsidiaries. The Amended Credit Agreement requires at all times that we (i) provide guarantees from wholly-owned subsidiaries that in the &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;aggregate represent not less than 95% of our consolidated net revenues and adjusted EBITDA from all wholly-owned subsidiaries and (ii) provide guarantees from subsidiaries that in the aggregate represent not less than 70% of consolidated adjusted EBITDA, subject to certain exceptions.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Our weighted average interest rate for borrowings under our $550.0 million Revolving Credit Facility was 3.2% and 4.2% for the three-month periods ended March&#160;31, 2020 and March 31, 2019, respectively. Our weighted average interest rate for borrowings under our $175.0 million Term Loan Facility was 3.2% for the three-month period ended March&#160;31, 2020 and 4.2% for the period February 4, 2019 to March 31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of March&#160;31, 2020, our consolidated leverage ratio was 1.5, our consolidated interest coverage ratio was 16.6 and we are in compliance with our covenants under the Amended Credit Agreement. In the event we are not in compliance with our debt covenants in the future, we would pursue various alternatives in an attempt to successfully resolve the non-compliance, which might include, among other things, seeking debt covenant waivers or amendments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of March&#160;31, 2020, our availability under our $550.0 million Revolving Credit Facility was $299.8 million as we have $220.0 million outstanding in borrowings and $30.2 million outstanding in letters of credit.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Joinder Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In connection with the CCH acquisition, we entered into a Joinder Agreement, dated as of February 4, 2019, pursuant to which CCH and its subsidiaries were made parties to, and became subject to the terms and conditions of, the Amended Credit Agreement, the Amended and Restated Security Agreement, dated as of June 29, 2018, and the Amended and Restated Pledge Agreement, dated as of June 29, 2018. Pursuant to the Joinder, the Amended and Restated Security Agreement and the Amended and Restated Pledge Agreement, CCH and its subsidiaries granted in favor of the Administrative Agent a first lien security interest in substantially all of their personal property assets and pledged to the Administrative Agent each of their respective subsidiaries' issued and outstanding equity interests. CCH and its subsidiaries also guaranteed our obligations, whether now existing or arising after the effective date of the Joinder, under the Amended Credit Agreement pursuant to the terms of the Joinder and the Amended Credit Agreement.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RleHRyZWdpb246MGRkY2MwZmFlMjM3NGNmNTljNWM4MzA4Y2NkYWIyMjhfNjgxMQ_a32da9be-9708-467b-a9b0-542a5db33363">&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Long-term debt consisted of the following for the periods indicated (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:91.812%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:65.356%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.923%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.596%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.925%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;$175.0 million Term Loan; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate (2.5% at March 31, 2020); due February&#160;4, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;170.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;171.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;$550.0 million Revolving Credit Facility; interest only payments; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate (2.4% at March 31, 2020); due February&#160;4, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;220.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;70.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Promissory notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Principal amount of long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;394.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;245.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;391.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;242.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current portion of long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(11.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(9.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;379.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;232.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ic735d35014784f0395b22a1d4852e2bb_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjcyZjBlYThiNGMxZTRlYmY5ZWVhMTAyZmU3MjYxZmEzL3RhYmxlcmFuZ2U6NzJmMGVhOGI0YzFlNGViZjllZWExMDJmZTcyNjFmYTNfMS0wLTEtMS0zODk0L3RleHRyZWdpb246ZWExOTBiMzVjNzdhNDkzYWJiZDhhYzZmZGYwOTE0MmVfMTY0OTI2NzQ0MTg4Mg_bb8b6fe0-5af0-482a-9bd5-151a433aaaff"
      unitRef="usd">175000000.0</us-gaap:DebtInstrumentFaceAmount>
    <amed:DebtInstrumentInterestRateatPeriodEnd
      contextRef="i9683f40a00e94c1abb96d732c3041061_I20200331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjcyZjBlYThiNGMxZTRlYmY5ZWVhMTAyZmU3MjYxZmEzL3RhYmxlcmFuZ2U6NzJmMGVhOGI0YzFlNGViZjllZWExMDJmZTcyNjFmYTNfMS0wLTEtMS0zODk0L3RleHRyZWdpb246ZWExOTBiMzVjNzdhNDkzYWJiZDhhYzZmZGYwOTE0MmVfMTY0OTI2NzQ0MTg4OA_1a1af7ec-316e-4a0b-9f1a-659e4130cd1f"
      unitRef="number">0.025</amed:DebtInstrumentInterestRateatPeriodEnd>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="i8ba21eb95e2e43d1b0a24756aec8f4e8_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjcyZjBlYThiNGMxZTRlYmY5ZWVhMTAyZmU3MjYxZmEzL3RhYmxlcmFuZ2U6NzJmMGVhOGI0YzFlNGViZjllZWExMDJmZTcyNjFmYTNfMS0wLTEtMS0zODk0L3RleHRyZWdpb246ZWExOTBiMzVjNzdhNDkzYWJiZDhhYzZmZGYwOTE0MmVfMTY0OTI2NzQ0MTkwNg_321999b2-13b1-4760-92c5-6a12914a4b37">2024-02-04</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ic735d35014784f0395b22a1d4852e2bb_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjcyZjBlYThiNGMxZTRlYmY5ZWVhMTAyZmU3MjYxZmEzL3RhYmxlcmFuZ2U6NzJmMGVhOGI0YzFlNGViZjllZWExMDJmZTcyNjFmYTNfMS0xLTEtMS0w_1c868cc0-4eee-491a-8dca-13663a6aff9f"
      unitRef="usd">170600000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i62c497259b644d859d8f0eea7f3e524e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjcyZjBlYThiNGMxZTRlYmY5ZWVhMTAyZmU3MjYxZmEzL3RhYmxlcmFuZ2U6NzJmMGVhOGI0YzFlNGViZjllZWExMDJmZTcyNjFmYTNfMS0zLTEtMS0w_35eb1696-725c-4bf3-be4a-420241187bc2"
      unitRef="usd">171700000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i0ff90663d1684cb09b78cf9c7fde47b7_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjcyZjBlYThiNGMxZTRlYmY5ZWVhMTAyZmU3MjYxZmEzL3RhYmxlcmFuZ2U6NzJmMGVhOGI0YzFlNGViZjllZWExMDJmZTcyNjFmYTNfMi0wLTEtMS0zOTI3L3RleHRyZWdpb246YzI0ZTAyOWZjMGU5NDBiNTkzYTYxNjRjZGM4NTRjN2RfMTY0OTI2NzQ0MTkzMA_c105751e-7fbe-4e47-b9ac-437faf3ce922"
      unitRef="usd">550000000.0</us-gaap:DebtInstrumentFaceAmount>
    <amed:DebtInstrumentInterestRateatPeriodEnd
      contextRef="i9224a41a12a14375adaf6a341b29f6fb_I20200331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjcyZjBlYThiNGMxZTRlYmY5ZWVhMTAyZmU3MjYxZmEzL3RhYmxlcmFuZ2U6NzJmMGVhOGI0YzFlNGViZjllZWExMDJmZTcyNjFmYTNfMi0wLTEtMS0zOTI3L3RleHRyZWdpb246YzI0ZTAyOWZjMGU5NDBiNTkzYTYxNjRjZGM4NTRjN2RfMTY0OTI2NzQ0MTkzNw_a4aebaa2-ca0a-4d3f-94f0-a847c4a76449"
      unitRef="number">0.024</amed:DebtInstrumentInterestRateatPeriodEnd>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="if270e80806534123864832e895591246_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjcyZjBlYThiNGMxZTRlYmY5ZWVhMTAyZmU3MjYxZmEzL3RhYmxlcmFuZ2U6NzJmMGVhOGI0YzFlNGViZjllZWExMDJmZTcyNjFmYTNfMi0wLTEtMS0zOTI3L3RleHRyZWdpb246YzI0ZTAyOWZjMGU5NDBiNTkzYTYxNjRjZGM4NTRjN2RfMTY0OTI2NzQ0MTk1Ng_191eeaa6-877e-40f2-8ba0-d34b89fbc602">2024-02-04</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i0ff90663d1684cb09b78cf9c7fde47b7_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjcyZjBlYThiNGMxZTRlYmY5ZWVhMTAyZmU3MjYxZmEzL3RhYmxlcmFuZ2U6NzJmMGVhOGI0YzFlNGViZjllZWExMDJmZTcyNjFmYTNfMi0xLTEtMS0w_72c2717b-0644-445d-98c3-1e70a733c84e"
      unitRef="usd">220000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i2057b301fd0c4cd39ca4cc85da07a5f6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjcyZjBlYThiNGMxZTRlYmY5ZWVhMTAyZmU3MjYxZmEzL3RhYmxlcmFuZ2U6NzJmMGVhOGI0YzFlNGViZjllZWExMDJmZTcyNjFmYTNfMi0zLTEtMS0w_e15bacd0-bde5-490e-b83b-abbc9c6edc84"
      unitRef="usd">70000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i645e5d94ba734fb2a80140b926935a3d_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjcyZjBlYThiNGMxZTRlYmY5ZWVhMTAyZmU3MjYxZmEzL3RhYmxlcmFuZ2U6NzJmMGVhOGI0YzFlNGViZjllZWExMDJmZTcyNjFmYTNfMy0xLTEtMS0w_6e2645bb-3c1c-4d90-9990-6baa98d7c0ec"
      unitRef="usd">600000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i72eea6f293c44f77b3987d12a9412f37_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjcyZjBlYThiNGMxZTRlYmY5ZWVhMTAyZmU3MjYxZmEzL3RhYmxlcmFuZ2U6NzJmMGVhOGI0YzFlNGViZjllZWExMDJmZTcyNjFmYTNfMy0zLTEtMS0w_1effc58f-2470-4005-b3e9-0f616558da81"
      unitRef="usd">600000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i2ef172d1bcd342b98c9cdb09d302dc65_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjcyZjBlYThiNGMxZTRlYmY5ZWVhMTAyZmU3MjYxZmEzL3RhYmxlcmFuZ2U6NzJmMGVhOGI0YzFlNGViZjllZWExMDJmZTcyNjFmYTNfNC0xLTEtMS0w_9a492be3-93ee-4d5e-a4da-9541d4789d94"
      unitRef="usd">3100000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i3608bfa9782e4bac938cc97a5f45bbc6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjcyZjBlYThiNGMxZTRlYmY5ZWVhMTAyZmU3MjYxZmEzL3RhYmxlcmFuZ2U6NzJmMGVhOGI0YzFlNGViZjllZWExMDJmZTcyNjFmYTNfNC0zLTEtMS0w_6e8ea1d5-b0d8-4d44-9390-0e8ddd529231"
      unitRef="usd">3400000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjcyZjBlYThiNGMxZTRlYmY5ZWVhMTAyZmU3MjYxZmEzL3RhYmxlcmFuZ2U6NzJmMGVhOGI0YzFlNGViZjllZWExMDJmZTcyNjFmYTNfNS0xLTEtMS0w_726354c7-7abd-4798-ae44-8af094c58e11"
      unitRef="usd">394300000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i014c385050454730837d592e15bca5e0_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjcyZjBlYThiNGMxZTRlYmY5ZWVhMTAyZmU3MjYxZmEzL3RhYmxlcmFuZ2U6NzJmMGVhOGI0YzFlNGViZjllZWExMDJmZTcyNjFmYTNfNS0zLTEtMS0w_d30415c0-afb0-42b8-a9b1-8b1b99e067cd"
      unitRef="usd">245700000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjcyZjBlYThiNGMxZTRlYmY5ZWVhMTAyZmU3MjYxZmEzL3RhYmxlcmFuZ2U6NzJmMGVhOGI0YzFlNGViZjllZWExMDJmZTcyNjFmYTNfNi0xLTEtMS0w_cb7d5abe-76c6-4afd-82c6-75d970b9d1ae"
      unitRef="usd">3300000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i014c385050454730837d592e15bca5e0_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjcyZjBlYThiNGMxZTRlYmY5ZWVhMTAyZmU3MjYxZmEzL3RhYmxlcmFuZ2U6NzJmMGVhOGI0YzFlNGViZjllZWExMDJmZTcyNjFmYTNfNi0zLTEtMS0w_72453f57-f947-4408-b0b0-aafd9ac7ad41"
      unitRef="usd">3500000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjcyZjBlYThiNGMxZTRlYmY5ZWVhMTAyZmU3MjYxZmEzL3RhYmxlcmFuZ2U6NzJmMGVhOGI0YzFlNGViZjllZWExMDJmZTcyNjFmYTNfNy0xLTEtMS0w_fc9a8aa5-dc5e-4d58-a015-7f6943220c70"
      unitRef="usd">391000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i014c385050454730837d592e15bca5e0_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjcyZjBlYThiNGMxZTRlYmY5ZWVhMTAyZmU3MjYxZmEzL3RhYmxlcmFuZ2U6NzJmMGVhOGI0YzFlNGViZjllZWExMDJmZTcyNjFmYTNfNy0zLTEtMS0w_07bdf2fb-8008-4b04-b8d2-3929a8c3d686"
      unitRef="usd">242200000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjcyZjBlYThiNGMxZTRlYmY5ZWVhMTAyZmU3MjYxZmEzL3RhYmxlcmFuZ2U6NzJmMGVhOGI0YzFlNGViZjllZWExMDJmZTcyNjFmYTNfOC0xLTEtMS0w_dd6e62c1-7828-4fc9-a12f-ea943fa356b7"
      unitRef="usd">11100000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i014c385050454730837d592e15bca5e0_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjcyZjBlYThiNGMxZTRlYmY5ZWVhMTAyZmU3MjYxZmEzL3RhYmxlcmFuZ2U6NzJmMGVhOGI0YzFlNGViZjllZWExMDJmZTcyNjFmYTNfOC0zLTEtMS0w_93ec5f7c-385d-47a2-ba5b-7c5d50c91ef4"
      unitRef="usd">9900000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjcyZjBlYThiNGMxZTRlYmY5ZWVhMTAyZmU3MjYxZmEzL3RhYmxlcmFuZ2U6NzJmMGVhOGI0YzFlNGViZjllZWExMDJmZTcyNjFmYTNfOS0xLTEtMS0w_eeef020e-f9b9-4173-ac09-48b5af61f48d"
      unitRef="usd">379900000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i014c385050454730837d592e15bca5e0_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjcyZjBlYThiNGMxZTRlYmY5ZWVhMTAyZmU3MjYxZmEzL3RhYmxlcmFuZ2U6NzJmMGVhOGI0YzFlNGViZjllZWExMDJmZTcyNjFmYTNfOS0zLTEtMS0w_4b4ccd96-b4c4-4416-a6f7-9716635d91f3"
      unitRef="usd">232300000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ia6972271e2cb4f179a778bd579050d45_I20190204"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RleHRyZWdpb246MGRkY2MwZmFlMjM3NGNmNTljNWM4MzA4Y2NkYWIyMjhfNDU3_e1dbbd12-f962-4d08-bf27-8eebf906dd5e"
      unitRef="usd">725000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i686590f797e04c189494ff3b9677db0c_I20190204"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RleHRyZWdpb246MGRkY2MwZmFlMjM3NGNmNTljNWM4MzA4Y2NkYWIyMjhfNDc4_bcecf6e0-cfb7-4e8f-9ae4-2188147716c1"
      unitRef="usd">550000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="iffa33294d8f04f04b0db89e59138db4a_I20190204"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RleHRyZWdpb246MGRkY2MwZmFlMjM3NGNmNTljNWM4MzA4Y2NkYWIyMjhfNTky_b5962d0e-b335-49d8-9d1f-2406e022078b"
      unitRef="usd">175000000.0</us-gaap:DebtInstrumentFaceAmount>
    <amed:DebtInstrumentInterestAdditionalInterestAboveFederalFundRate
      contextRef="i71126d46462944a9aee1ee7aef720bee_D20190204-20190204"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RleHRyZWdpb246MGRkY2MwZmFlMjM3NGNmNTljNWM4MzA4Y2NkYWIyMjhfMTM1NA_ff5244c5-d1ff-4174-ab00-5b62b93fd6f4"
      unitRef="number">0.0050</amed:DebtInstrumentInterestAdditionalInterestAboveFederalFundRate>
    <amed:DebtInstrumentInterestAdditionalInterestAboveEurodollarRate
      contextRef="i71126d46462944a9aee1ee7aef720bee_D20190204-20190204"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RleHRyZWdpb246MGRkY2MwZmFlMjM3NGNmNTljNWM4MzA4Y2NkYWIyMjhfMTQ3Mw_0ea23ee2-eb5d-497d-b59d-196f9c0d966c"
      unitRef="number">0.01</amed:DebtInstrumentInterestAdditionalInterestAboveEurodollarRate>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ie8766fbac86e4b5a80af143791d0f409_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RleHRyZWdpb246MGRkY2MwZmFlMjM3NGNmNTljNWM4MzA4Y2NkYWIyMjhfMTg3NQ_615ae31b-9f20-4a0a-86a2-9743d400b76d"
      unitRef="number">0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i6d6002c5f99d4721838ee0060efd407b_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RleHRyZWdpb246MGRkY2MwZmFlMjM3NGNmNTljNWM4MzA4Y2NkYWIyMjhfMTkxMg_660f9962-1c0e-4601-8029-b61e5aa0f4bb"
      unitRef="number">0.0150</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RleHRyZWdpb246MGRkY2MwZmFlMjM3NGNmNTljNWM4MzA4Y2NkYWIyMjhfNjgxOQ_029d796f-0569-4235-bed0-4fc5b3a8f1de">We are also subject to a commitment fee and letter of credit fee under the terms of the Amended Credit Agreement, as presented in the table below.&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:92.251%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.251%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:25.258%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.908%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.836%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.908%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.839%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Pricing Tier&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Consolidated Leverage Ratio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commitment Fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Letter of Credit Fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Eurodollar Rate Loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Base Rate Loans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;I&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;&#x2265; 3.00 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.35%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;II&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;&amp;lt; 3.00 to 1.0 but &#x2265; 2.00 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.30%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.75%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;III&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;&amp;lt; 2.00 to 1.0 but &#x2265; 0.75 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.50%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;IV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;&amp;lt; 0.75 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.20%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.25%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock>
    <amed:ConsolidatedLeverageRatio
      contextRef="i116335fec8a8410395d5970ead81815b_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjgzMjA1ZTZkOGQ3ZDRiYjY4ZTAxODU0ZjJkZGIzYWViL3RhYmxlcmFuZ2U6ODMyMDVlNmQ4ZDdkNGJiNjhlMDE4NTRmMmRkYjNhZWJfMS0xLTEtMS0zOTY2L3RleHRyZWdpb246NTMzOTAwZTYwZjRhNGY2NmJkNjNlODczODZkOTcwNDRfMTY0OTI2NzQ0MTY4NQ_02a9f915-14be-4af8-b34e-ee9470b43790"
      unitRef="number">3.00</amed:ConsolidatedLeverageRatio>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i4d3ef9b25fd64694a1f379a432f9bb62_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjgzMjA1ZTZkOGQ3ZDRiYjY4ZTAxODU0ZjJkZGIzYWViL3RhYmxlcmFuZ2U6ODMyMDVlNmQ4ZDdkNGJiNjhlMDE4NTRmMmRkYjNhZWJfMS0yLTEtMS0w_629f3c09-5c84-472c-b161-d419b111f7af"
      unitRef="number">0.0035</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <amed:LetterOfCreditFee
      contextRef="i4d3ef9b25fd64694a1f379a432f9bb62_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjgzMjA1ZTZkOGQ3ZDRiYjY4ZTAxODU0ZjJkZGIzYWViL3RhYmxlcmFuZ2U6ODMyMDVlNmQ4ZDdkNGJiNjhlMDE4NTRmMmRkYjNhZWJfMS0zLTEtMS0w_089171a9-a73c-46d3-888a-6d67e2ba47a7"
      unitRef="number">0.0175</amed:LetterOfCreditFee>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i03234fef29e642489ae4417c7674ca60_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjgzMjA1ZTZkOGQ3ZDRiYjY4ZTAxODU0ZjJkZGIzYWViL3RhYmxlcmFuZ2U6ODMyMDVlNmQ4ZDdkNGJiNjhlMDE4NTRmMmRkYjNhZWJfMS00LTEtMS0w_344d43eb-e77e-41ed-9656-9c47c20006af"
      unitRef="number">0.0200</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i2c19ce09b115491883ac15a09c9fce6d_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjgzMjA1ZTZkOGQ3ZDRiYjY4ZTAxODU0ZjJkZGIzYWViL3RhYmxlcmFuZ2U6ODMyMDVlNmQ4ZDdkNGJiNjhlMDE4NTRmMmRkYjNhZWJfMS01LTEtMS0w_c6d9a229-7a7b-4c78-a48a-f3662310b1c0"
      unitRef="number">0.0100</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <amed:ConsolidatedLeverageRatio
      contextRef="i262c9a55a12d4a2e82c1e6f3a19cf70f_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjgzMjA1ZTZkOGQ3ZDRiYjY4ZTAxODU0ZjJkZGIzYWViL3RhYmxlcmFuZ2U6ODMyMDVlNmQ4ZDdkNGJiNjhlMDE4NTRmMmRkYjNhZWJfMi0xLTEtMS0zOTcwL3RleHRyZWdpb246MTM3OTRiMzg2YWE4NDA0MjkyMDY1MjZhZmQ2MzI3OTVfMTY0OTI2NzQ0MTcwMw_0bd68f00-8089-4139-9faa-e3ec63b3c90b"
      unitRef="number">3.00</amed:ConsolidatedLeverageRatio>
    <amed:ConsolidatedLeverageRatio
      contextRef="ie32195fe339a4436b4904c56998424fb_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjgzMjA1ZTZkOGQ3ZDRiYjY4ZTAxODU0ZjJkZGIzYWViL3RhYmxlcmFuZ2U6ODMyMDVlNmQ4ZDdkNGJiNjhlMDE4NTRmMmRkYjNhZWJfMi0xLTEtMS0zOTcwL3RleHRyZWdpb246MTM3OTRiMzg2YWE4NDA0MjkyMDY1MjZhZmQ2MzI3OTVfMTY0OTI2NzQ0MTcwOQ_7965318b-4b57-410e-b084-1e5748138cad"
      unitRef="number">2.00</amed:ConsolidatedLeverageRatio>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="ie3e4c94018794c938917b5e4762bb3a3_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjgzMjA1ZTZkOGQ3ZDRiYjY4ZTAxODU0ZjJkZGIzYWViL3RhYmxlcmFuZ2U6ODMyMDVlNmQ4ZDdkNGJiNjhlMDE4NTRmMmRkYjNhZWJfMi0yLTEtMS0w_a992615f-3e2d-4c37-b3b6-df5ea71bb4e3"
      unitRef="number">0.0030</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <amed:LetterOfCreditFee
      contextRef="ie3e4c94018794c938917b5e4762bb3a3_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjgzMjA1ZTZkOGQ3ZDRiYjY4ZTAxODU0ZjJkZGIzYWViL3RhYmxlcmFuZ2U6ODMyMDVlNmQ4ZDdkNGJiNjhlMDE4NTRmMmRkYjNhZWJfMi0zLTEtMS0w_c9da63fe-4952-4b68-a5c7-db35901b554b"
      unitRef="number">0.0150</amed:LetterOfCreditFee>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="id274d4e6f62045c8b0313e71c808f7a0_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjgzMjA1ZTZkOGQ3ZDRiYjY4ZTAxODU0ZjJkZGIzYWViL3RhYmxlcmFuZ2U6ODMyMDVlNmQ4ZDdkNGJiNjhlMDE4NTRmMmRkYjNhZWJfMi00LTEtMS0w_ac0a3835-d2a9-4c16-8128-675ccf131347"
      unitRef="number">0.0175</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ib3424d73450945acbfb6662c2947d02c_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjgzMjA1ZTZkOGQ3ZDRiYjY4ZTAxODU0ZjJkZGIzYWViL3RhYmxlcmFuZ2U6ODMyMDVlNmQ4ZDdkNGJiNjhlMDE4NTRmMmRkYjNhZWJfMi01LTEtMS0w_3b6375fc-bb42-4866-ba4f-5d51a0544e24"
      unitRef="number">0.0075</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <amed:ConsolidatedLeverageRatio
      contextRef="i587391f59a70479592d057ca4817c53d_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjgzMjA1ZTZkOGQ3ZDRiYjY4ZTAxODU0ZjJkZGIzYWViL3RhYmxlcmFuZ2U6ODMyMDVlNmQ4ZDdkNGJiNjhlMDE4NTRmMmRkYjNhZWJfMy0xLTEtMS0zOTczL3RleHRyZWdpb246YTcxNTZhZjgwNDIwNDc2MmE4M2FlN2FjMTYxZjkyODRfMTY0OTI2NzQ0MTcwMw_64b76683-9c41-443f-a6e1-d1b02bd6dbcd"
      unitRef="number">2.00</amed:ConsolidatedLeverageRatio>
    <amed:ConsolidatedLeverageRatio
      contextRef="i10e7017e38964ada930ea223919b92d6_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjgzMjA1ZTZkOGQ3ZDRiYjY4ZTAxODU0ZjJkZGIzYWViL3RhYmxlcmFuZ2U6ODMyMDVlNmQ4ZDdkNGJiNjhlMDE4NTRmMmRkYjNhZWJfMy0xLTEtMS0zOTczL3RleHRyZWdpb246YTcxNTZhZjgwNDIwNDc2MmE4M2FlN2FjMTYxZjkyODRfMTY0OTI2NzQ0MTcwOQ_91204738-93df-46fb-8d6a-b8d48702691c"
      unitRef="number">0.75</amed:ConsolidatedLeverageRatio>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i40aeb3bc9f044ec2948f550127151c2f_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjgzMjA1ZTZkOGQ3ZDRiYjY4ZTAxODU0ZjJkZGIzYWViL3RhYmxlcmFuZ2U6ODMyMDVlNmQ4ZDdkNGJiNjhlMDE4NTRmMmRkYjNhZWJfMy0yLTEtMS0w_652215b5-2c4f-4b10-810e-f6fc465ec536"
      unitRef="number">0.0025</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <amed:LetterOfCreditFee
      contextRef="i40aeb3bc9f044ec2948f550127151c2f_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjgzMjA1ZTZkOGQ3ZDRiYjY4ZTAxODU0ZjJkZGIzYWViL3RhYmxlcmFuZ2U6ODMyMDVlNmQ4ZDdkNGJiNjhlMDE4NTRmMmRkYjNhZWJfMy0zLTEtMS0w_cda98606-c4ea-4b9e-bfca-8c9323265352"
      unitRef="number">0.0125</amed:LetterOfCreditFee>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i12d7c31ad0e442449db03a43e8ee94b2_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjgzMjA1ZTZkOGQ3ZDRiYjY4ZTAxODU0ZjJkZGIzYWViL3RhYmxlcmFuZ2U6ODMyMDVlNmQ4ZDdkNGJiNjhlMDE4NTRmMmRkYjNhZWJfMy00LTEtMS0w_ed733292-6b48-4b34-bf50-7e4a1007a4bf"
      unitRef="number">0.0150</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i88e1a49559cf4832bf8d22eb47cac167_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjgzMjA1ZTZkOGQ3ZDRiYjY4ZTAxODU0ZjJkZGIzYWViL3RhYmxlcmFuZ2U6ODMyMDVlNmQ4ZDdkNGJiNjhlMDE4NTRmMmRkYjNhZWJfMy01LTEtMS0w_14bba858-f0a4-4ad4-b0ae-bf01181080dd"
      unitRef="number">0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <amed:ConsolidatedLeverageRatio
      contextRef="ic343676840f04990b1419f15ad513197_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjgzMjA1ZTZkOGQ3ZDRiYjY4ZTAxODU0ZjJkZGIzYWViL3RhYmxlcmFuZ2U6ODMyMDVlNmQ4ZDdkNGJiNjhlMDE4NTRmMmRkYjNhZWJfNC0xLTEtMS0zOTc2L3RleHRyZWdpb246ODBkMDc0YTQzNTM0NDhlNzk4ODlmMzYxZWY1YTMzMzRfMTY0OTI2NzQ0MTY4NQ_879b181d-f215-4e86-9745-b26351588768"
      unitRef="number">0.75</amed:ConsolidatedLeverageRatio>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i01dd577fcaf548d1bf70b0a704312472_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjgzMjA1ZTZkOGQ3ZDRiYjY4ZTAxODU0ZjJkZGIzYWViL3RhYmxlcmFuZ2U6ODMyMDVlNmQ4ZDdkNGJiNjhlMDE4NTRmMmRkYjNhZWJfNC0yLTEtMS0w_3ad53fbf-3159-4c71-9d39-19916a0b5be4"
      unitRef="number">0.0020</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <amed:LetterOfCreditFee
      contextRef="i01dd577fcaf548d1bf70b0a704312472_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjgzMjA1ZTZkOGQ3ZDRiYjY4ZTAxODU0ZjJkZGIzYWViL3RhYmxlcmFuZ2U6ODMyMDVlNmQ4ZDdkNGJiNjhlMDE4NTRmMmRkYjNhZWJfNC0zLTEtMS0w_5450493f-f1ee-4b80-bcc8-199b097f286d"
      unitRef="number">0.0100</amed:LetterOfCreditFee>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i01f445fe93c14d05abd4461abdf8ac06_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjgzMjA1ZTZkOGQ3ZDRiYjY4ZTAxODU0ZjJkZGIzYWViL3RhYmxlcmFuZ2U6ODMyMDVlNmQ4ZDdkNGJiNjhlMDE4NTRmMmRkYjNhZWJfNC00LTEtMS0w_6ff4612d-65d3-4039-8341-aec207f68c90"
      unitRef="number">0.0125</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i2aa959b6fa504afaa53549e81bde7718_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RhYmxlOjgzMjA1ZTZkOGQ3ZDRiYjY4ZTAxODU0ZjJkZGIzYWViL3RhYmxlcmFuZ2U6ODMyMDVlNmQ4ZDdkNGJiNjhlMDE4NTRmMmRkYjNhZWJfNC01LTEtMS0w_fc25e76f-0df0-4eec-b854-b6ee025f0e10"
      unitRef="number">0.0025</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="i71126d46462944a9aee1ee7aef720bee_D20190204-20190204"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RleHRyZWdpb246MGRkY2MwZmFlMjM3NGNmNTljNWM4MzA4Y2NkYWIyMjhfMjE1Mw_f7b60ca4-220b-4081-8bc9-18d77fe37edc">2024-02-04</us-gaap:DebtInstrumentMaturityDate>
    <amed:DebtInstrumentPeriodicPaymentPercentage
      contextRef="i52efcfba53a641308fa077db50f1031f_D20190204-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RleHRyZWdpb246MGRkY2MwZmFlMjM3NGNmNTljNWM4MzA4Y2NkYWIyMjhfMjM2MA_30efe89f-9293-4c69-b384-0f11551f761e"
      unitRef="number">0.00625</amed:DebtInstrumentPeriodicPaymentPercentage>
    <amed:DebtInstrumentPeriodicPaymentPercentage
      contextRef="i0ee8f60caeec4edeb0fa06f3891d0fcf_D20200401-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RleHRyZWdpb246MGRkY2MwZmFlMjM3NGNmNTljNWM4MzA4Y2NkYWIyMjhfMjQ0NA_b0d8a79f-e974-4ff3-bf54-8954c94567e6"
      unitRef="number">0.01250</amed:DebtInstrumentPeriodicPaymentPercentage>
    <amed:DebtInstrumentPeriodicPaymentPercentage
      contextRef="i9c02e2cca97c41ee89b6417d85253d91_D20230401-20240204"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RleHRyZWdpb246MGRkY2MwZmFlMjM3NGNmNTljNWM4MzA4Y2NkYWIyMjhfMjUzMA_935c5584-c399-4ba7-9e07-de79d3b1c017"
      unitRef="number">0.01875</amed:DebtInstrumentPeriodicPaymentPercentage>
    <amed:ProceedsReceivedFromLoanPartyOfSubsidiary
      contextRef="ia85dd0cda56f46d88648f67dd3c62846_D20190204-20190204"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RleHRyZWdpb246MGRkY2MwZmFlMjM3NGNmNTljNWM4MzA4Y2NkYWIyMjhfMzEzMg_1d71b609-469a-4c78-9876-1d61ea6f7b55"
      unitRef="usd">5000000</amed:ProceedsReceivedFromLoanPartyOfSubsidiary>
    <amed:PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries
      contextRef="i71126d46462944a9aee1ee7aef720bee_D20190204-20190204"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RleHRyZWdpb246MGRkY2MwZmFlMjM3NGNmNTljNWM4MzA4Y2NkYWIyMjhfNDU3MQ_6b0790c8-49cd-4e0a-8e75-8fa6071ad95e"
      unitRef="number">0.95</amed:PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries>
    <amed:PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries
      contextRef="i71126d46462944a9aee1ee7aef720bee_D20190204-20190204"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RleHRyZWdpb246MGRkY2MwZmFlMjM3NGNmNTljNWM4MzA4Y2NkYWIyMjhfNDc1NA_927f41b7-01f1-4a69-b6a6-317b5727fab7"
      unitRef="number">0.70</amed:PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i0ff90663d1684cb09b78cf9c7fde47b7_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RleHRyZWdpb246MGRkY2MwZmFlMjM3NGNmNTljNWM4MzA4Y2NkYWIyMjhfNDg4Mg_8b6e0c34-c598-4aa3-a9b9-56598fafad65"
      unitRef="usd">550000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongTermDebtWeightedAverageInterestRateOverTime
      contextRef="if270e80806534123864832e895591246_D20200101-20200331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RleHRyZWdpb246MGRkY2MwZmFlMjM3NGNmNTljNWM4MzA4Y2NkYWIyMjhfNDkxNQ_07ef981d-8a38-428d-a0b8-d7e1cedeaa29"
      unitRef="number">0.032</us-gaap:LongTermDebtWeightedAverageInterestRateOverTime>
    <us-gaap:LongTermDebtWeightedAverageInterestRateOverTime
      contextRef="ia9def8d782364ec6a243d4e1839a987f_D20190101-20190331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RleHRyZWdpb246MGRkY2MwZmFlMjM3NGNmNTljNWM4MzA4Y2NkYWIyMjhfNDkyMg_995c7cb9-1048-4cc1-a515-f793811eee6d"
      unitRef="number">0.042</us-gaap:LongTermDebtWeightedAverageInterestRateOverTime>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ic735d35014784f0395b22a1d4852e2bb_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RleHRyZWdpb246MGRkY2MwZmFlMjM3NGNmNTljNWM4MzA4Y2NkYWIyMjhfNTA0Ng_a407b8f9-d550-4f9f-b5ab-9115acfa0461"
      unitRef="usd">175000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongTermDebtWeightedAverageInterestRateOverTime
      contextRef="i8ba21eb95e2e43d1b0a24756aec8f4e8_D20200101-20200331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RleHRyZWdpb246MGRkY2MwZmFlMjM3NGNmNTljNWM4MzA4Y2NkYWIyMjhfNTA3Mg_bce5a4eb-324d-4353-b1e7-476a2107dfca"
      unitRef="number">0.032</us-gaap:LongTermDebtWeightedAverageInterestRateOverTime>
    <us-gaap:LongTermDebtWeightedAverageInterestRateOverTime
      contextRef="ia378c7f5c8aa4e24951f6ef187aefeb4_D20190204-20190331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RleHRyZWdpb246MGRkY2MwZmFlMjM3NGNmNTljNWM4MzA4Y2NkYWIyMjhfNTA3OQ_366ac8e5-78e9-47ba-8490-f863b0292e23"
      unitRef="number">0.042</us-gaap:LongTermDebtWeightedAverageInterestRateOverTime>
    <amed:TotalLeverageRatio
      contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RleHRyZWdpb246MGRkY2MwZmFlMjM3NGNmNTljNWM4MzA4Y2NkYWIyMjhfNTIyMQ_8be456cb-e7a6-43a3-938f-3f422252ed9b"
      unitRef="number">1.5</amed:TotalLeverageRatio>
    <amed:ConsolidatedInterestCoverageRatio
      contextRef="i886ddae2179d4ed793345586cc440c4e_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RleHRyZWdpb246MGRkY2MwZmFlMjM3NGNmNTljNWM4MzA4Y2NkYWIyMjhfNTI3MA_02efa594-5766-40c6-a888-c88ef50d8945"
      unitRef="number">16.6</amed:ConsolidatedInterestCoverageRatio>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i0ff90663d1684cb09b78cf9c7fde47b7_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RleHRyZWdpb246MGRkY2MwZmFlMjM3NGNmNTljNWM4MzA4Y2NkYWIyMjhfNTY0OA_0a608e90-1a71-44c1-8a3a-16d371d62c47"
      unitRef="usd">550000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="i0ff90663d1684cb09b78cf9c7fde47b7_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RleHRyZWdpb246MGRkY2MwZmFlMjM3NGNmNTljNWM4MzA4Y2NkYWIyMjhfNTY4MQ_19558b16-035b-4839-989a-cf07110d238e"
      unitRef="usd">299800000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i0ff90663d1684cb09b78cf9c7fde47b7_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RleHRyZWdpb246MGRkY2MwZmFlMjM3NGNmNTljNWM4MzA4Y2NkYWIyMjhfNTY5NQ_3b931d69-aebb-4eb7-a933-e13090da2e33"
      unitRef="usd">220000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="ib409845529d94d28bc9b375ca272bc7d_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82MS9mcmFnOjBkZGNjMGZhZTIzNzRjZjU5YzVjODMwOGNjZGFiMjI4L3RleHRyZWdpb246MGRkY2MwZmFlMjM3NGNmNTljNWM4MzA4Y2NkYWIyMjhfNTcyOA_e37339ab-8a0a-48f1-a2c8-34e8ec65601c"
      unitRef="usd">30200000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfMTM3NDU_9420758b-d494-40ba-870e-7c2693c8f656">COMMITMENTS AND CONTINGENCIES&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Legal Proceedings - Ongoing&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We are involved in the following legal actions:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Subpoena Duces Tecum and Civil Investigative Demands Issued by the U.S. Department of Justice&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On May&#160;21, 2015, we received a Subpoena Duces Tecum (&#x201c;Subpoena&#x201d;) issued by the U.S. Department of Justice. The Subpoena requests the delivery of information regarding 53 identified hospice patients to the United States Attorney&#x2019;s Office for the District of Massachusetts. It also requests the delivery of documents relating to our hospice clinical and business operations and related compliance activities. The Subpoena generally covers the period from January&#160;1, 2011 through May&#160;21, 2015. We are fully cooperating with the U.S. Department of Justice with respect to this investigation. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On November&#160;3, 2015, we received a civil investigative demand (&#x201c;CID&#x201d;) issued by the U.S. Department of Justice pursuant to the federal False Claims Act relating to claims submitted to Medicare and/or Medicaid for hospice services provided through designated facilities in the Morgantown, West Virginia area. The CID requests the delivery of information to the United States Attorney&#x2019;s Office for the Northern District of West Virginia regarding 66 identified hospice patients, as well as documents relating to our hospice clinical and business operations in the Morgantown area. The CID generally covers the period from January&#160;1, 2009 through August 31, 2015. We are fully cooperating with the U.S. Department of Justice with respect to this investigation. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On June&#160;27, 2016, we received a CID issued by the U.S. Department of Justice pursuant to the federal False Claims Act relating to claims submitted to Medicare and/or Medicaid for hospice services provided through designated facilities in the Parkersburg, West Virginia area. The CID requests the delivery of information to the United States Attorney&#x2019;s Office for the Southern District of West Virginia regarding 68 identified hospice patients, as well as documents relating to our hospice clinical and business operations in the Parkersburg area. The CID generally covers the period from January&#160;1, 2011 through June&#160;20, 2016. We are fully cooperating with the U.S. Department of Justice with respect to this investigation. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Based on our analysis of sample claims data in connection with preliminary settlement discussions with the U.S. Department of Justice regarding the above matters, we have recorded a total of $6.5 million to accrued expenses in our condensed consolidated balance sheet related to this matter. Due to the ongoing nature of the investigations and current stage of the settlement discussions, we are unable to estimate a range of potential loss at this time, and we cannot predict the timing or outcome of these investigations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In addition to the matters referenced in this note, we are involved in legal actions in the normal course of business, some of which seek monetary damages, including claims for punitive damages. We do not believe that these normal course actions, when finally concluded and determined, will have a material impact on our consolidated financial condition, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Legal fees related to all legal matters are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:16pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Other Investigative Matters - Ongoing&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Compassionate Care Hospice Corporate Integrity Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On January 30, 2015, CCH entered into a corporate integrity agreement ("CIA") with the Office of Inspector General-HHS (&#x201c;OIG&#x201d;). The CIA required that CCH provide annual on-site compliance training; develop and implement policies to ensure compliance with federal health care program requirements; screen new and current employees to ensure that they are eligible to participate in federal health care programs;&#160;establish a compliance committee that contains both a Compliance Officer and a&#160;Chief Quality Officer; retain a Governing Authority expert who will periodically complete a compliance program review; and retain an independent review organization ("IRO") to complete claims reviews for hospice services rendered in New York. The OIG waived the claims review for the final year of the CCH CIA based on the closure of the New York operations. Additionally, the CIA required that CCH report substantial overpayments that CCH discovered it had received from federal health care programs, as well as probable violations of federal criminal, civil or administrative health care laws. Upon breach of the CIA, CCH could have become liable for payment of certain stipulated penalties, or could have been excluded from participation in federal health care programs. The CIA had a term of five years that ended on January 30, 2020. We filed our final annual report on March 25, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:16pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Other Investigative Matters - Completed&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Corporate Integrity Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On April&#160;23, 2014, with no admissions of liability on our part, we entered into a settlement agreement with the U.S. Department of Justice relating to certain of our clinical and business operations. Concurrently with our entry into this agreement, we entered into a CIA with the OIG. The CIA formalized various aspects of our already existing ethics and compliance programs and contained other requirements designed to help ensure our ongoing compliance with federal health care program requirements. Among other things, the CIA required us to maintain our existing compliance program, executive compliance committee and compliance committee of the Board of Directors; provide certain compliance training; continue screening new and current employees to ensure they are eligible to participate in federal health care programs; engage an IRO to perform certain auditing and reviews and prepare certain reports regarding our compliance with federal health care programs, our billing submissions to federal health care programs and our compliance and risk mitigation programs; and provide certain reports and management certifications to the OIG. Additionally, the CIA specifically required that we report substantial overpayments that we discovered we had received from federal health care programs, as well as probable violations of federal health care laws. The corporate integrity agreement had a term of five years that ended on April 21, 2019. We filed our final annual report on July 19, 2019. On May 5, 2020, the Company received notice from the OIG that the Company's five-year CIA with the OIG has been completed. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:16pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Third Party Audits - Ongoing&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;From time to time, in the ordinary course of business, we are subject to audits under various governmental programs including Recovery Audit Contractors (&#x201c;RACs&#x201d;), Zone Program Integrity Contractors (&#x201c;ZPICs&#x201d;), Uniform Program Integrity Contractors ("UPICs"), Program Safeguard Contractors (&#x201c;PSCs&#x201d;) and Medicaid Integrity Contributors (&#x201c;MICs&#x201d;) in which third party firms engaged by CMS conduct extensive reviews of claims data to identify potential improper payments. We cannot predict the ultimate outcome of any regulatory reviews or other governmental audits and investigations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In July 2010, our subsidiary that provides hospice services in Florence, South Carolina received from a ZPIC a request for records regarding a sample of 30 beneficiaries who received services from the subsidiary during the period of January&#160;1, 2008 through March&#160;31, 2010 (the &#x201c;Review Period&#x201d;) to determine whether the underlying services met pertinent Medicare payment requirements.&#160;We acquired the hospice operations subject to this review on August&#160;1, 2009; the Review Period covers time periods both before and after our ownership of these hospice operations.&#160;Based on the ZPIC&#x2019;s findings for 16 beneficiaries, which were extrapolated to all claims for hospice services provided by the Florence subsidiary billed during the Review Period, on June&#160;6, 2011, the Medicare Administrative Contractor (&#x201c;MAC&#x201d;) for the subsidiary issued a notice of overpayment seeking recovery from our subsidiary of an alleged overpayment. We dispute these findings, and our Florence subsidiary has filed appeals through the Original Medicare Standard Appeals Process, in which we are seeking to have those findings overturned. An administrative law judge ("ALJ") hearing was held in early January 2015. On January&#160;18, 2016, we received a letter dated January&#160;6, 2016 referencing the ALJ hearing decision for the overpayment issued on June&#160;6, 2011. The decision was partially favorable with a new overpayment amount of $3.7 million with a balance owed of $5.6 million, including interest, based on 9 disputed claims (originally 16). We filed an appeal to the Medicare Appeals Council on the remaining 9 disputed claims and also argued that the statistical method used to select the sample was not valid.&#160;No assurances can be given as to the timing or outcome of the Medicare Appeals Council decision. As of March&#160;31, 2020, Medicare has withheld payments of $5.7 million (including additional interest) as part of their standard procedures once this level of the appeal process has been reached. In the event we are not able to recoup this alleged overpayment, we are entitled to be indemnified by the prior owners of the hospice operations for amounts relating to the period prior to August&#160;1, 2009. On January 10, 2019, an arbitration panel from the American Health Lawyers Association determined that the prior owners' liability for their indemnification obligation was $2.8 million. Accordingly, the Company reduced its indemnity receivable from $4.9 million to $2.8 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In July 2016, the Company received a request for medical records from SafeGuard Services, L.L.C (&#x201c;SafeGuard&#x201d;), a ZPIC, related to services provided by some of the care centers that the Company acquired from Infinity Home Care, L.L.C. The review period covers time periods both before and after our ownership of the care centers, which were acquired on December&#160;31, 2015. In August 2017, the Company received Requests for Repayment from Palmetto GBA, LLC ("Palmetto") regarding Infinity Home Care of Lakeland, LLC ("Lakeland Care Centers") and Infinity Home Care of Pinellas, LLC ("Clearwater Care Center"). The Palmetto letters are based on a statistical extrapolation performed by SafeGuard which alleged an overpayment of $34.0 million for the Lakeland Care Centers on a universe of 72 Medicare claims totaling $0.2 million in actual claims payments using a 100% error rate and an overpayment of $4.8 million for the Clearwater Care Center on a universe of 70 Medicare claims totaling $0.2 million in actual claims payments using a 100% error rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Lakeland Request for Repayment covers claims between January 2, 2014 and September 13, 2016. The Clearwater Request for Repayment covers claims between January 2, 2015 and December 9, 2016. As a result of partially successful Level I and Level II Administrative Appeals, the alleged overpayment for the Lakeland Care Centers has been reduced to $26.0 million and the alleged overpayment for the Clearwater Care Center has been reduced to $3.3 million. The Company has now filed Level III Administrative Appeals, and will continue to vigorously pursue its appeal rights, which include contesting the methodology used by the ZPIC contractor to perform statistical extrapolation. The Company is contractually entitled to indemnification by the prior owners for all claims prior to December 31, 2015, for up to $12.6 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;At this stage of the review, based on the information currently available to the Company, the Company cannot predict the timing or outcome of this review. The Company estimates a low-end potential range of loss related to this review of $6.5 million (assuming the Company is successful in seeking indemnity from the prior owners and unsuccessful in demonstrating that the extrapolation method used by SafeGuard was erroneous). The Company has reduced its high-end potential range of loss from $38.8 million (the maximum amount Palmetto claims has been overpaid for both the Lakeland Care Centers and the Clearwater Care Center, of which amount $12.6 million is subject to indemnification by the prior owners) to $29.3 million based on the partial success achieved by the Company in prosecuting its Level I and II Administrative Appeals.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of March&#160;31, 2020, we have an accrued liability of approximately $17.4 million related to this matter. We expect to be indemnified by the prior owners for approximately $10.9 million of the total $12.6 million available indemnification related to this matter and have recorded this amount within other assets in our condensed consolidated balance sheet as of March&#160;31, 2020. The net of these two amounts, $6.5 million, was recorded as a reduction in revenue in our condensed consolidated statements of operations during 2017. As of March&#160;31, 2020, $1.5 million of receivables have been impacted by this payment suspension.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:14pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Insurance&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We are obligated for certain costs associated with our insurance programs, including employee health, workers&#x2019; compensation and professional liability. While we maintain various insurance programs to cover these risks, we are self-insured for a substantial portion of our potential claims. We recognize our obligations associated with these costs, up to specified deductible limits in the period in which a claim is incurred, including with respect to both reported claims and claims incurred but not reported. These costs have generally been estimated based on historical data of our claims experience. Such estimates, and the resulting reserves, are reviewed and updated by us on a quarterly basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Our health insurance has an exposure limit of $1.3 million for any individual covered life. Our workers&#x2019; compensation insurance has a retention limit of $1.0 million per incident and our professional liability insurance has a retention limit of $0.3 million per incident.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <amed:Numberofpatients
      contextRef="i3a33f09f3173490fa79c2009fa38ee93_D20150521-20150521"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfMzc2_0e741bf0-6f82-48d2-838c-8a7217e696b5"
      unitRef="patient">53</amed:Numberofpatients>
    <amed:Numberofpatients
      contextRef="idb70013011f74758ae2ef2a1a0de32c1_D20151103-20151103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfMTI0Mw_f244caf3-fe46-4cce-ac33-a6eeb9035323"
      unitRef="patient">66</amed:Numberofpatients>
    <amed:Numberofpatients
      contextRef="i301ee02ef1954d139674e96cc1e9ee1b_D20160627-20160627"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfMTk3MQ_26118482-64b3-47ea-bdca-36d66a2f4e50"
      unitRef="patient">68</amed:Numberofpatients>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="ia37b8daa112347b8876c86941748cb37_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfMjQ3NQ_8f650946-7322-4add-ab62-3190aec06d30"
      unitRef="usd">6500000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <amed:CorporateIntegrityAgreementTerm
      contextRef="i039c0407f0b846cab386767ba04caf96_D20150130-20150130"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfNjIxNw_35288dc5-2915-496e-b5f0-8e631e2649f3">P5Y</amed:CorporateIntegrityAgreementTerm>
    <amed:CorporateIntegrityAgreementTerm
      contextRef="ibfe6dd3be0b34aeba5d1341e4d23edbe_D20140423-20140423"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfMTY0OTI2NzQ2NjExNw_b2a19f5d-8504-454b-8297-62acb8877806">P5Y</amed:CorporateIntegrityAgreementTerm>
    <amed:NumberOfBeneficiaries
      contextRef="i563cd3af8c9d4df58214f2a851b9496f_D20080101-20100331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfNzA2OQ_df4c2522-c7dc-4132-bfe6-edae503377ea"
      unitRef="beneficiary">30</amed:NumberOfBeneficiaries>
    <amed:NumberOfBeneficiaries
      contextRef="i276fbb8a5a1041bba0699b8eaa7d329d_D20110606-20110606"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfNzUxMw_7cc323ce-c1e8-430d-851b-523b11c22c6a"
      unitRef="beneficiary">16</amed:NumberOfBeneficiaries>
    <amed:RecoveryAmountOfOverpaymentMadeToSubsidiary
      contextRef="i2d397d49a7654cbabf31f8c0d4d869b8_I20160118"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfODMxNg_e2ed2fb5-3537-4687-ab80-9d6514d9fee0"
      unitRef="usd">3700000</amed:RecoveryAmountOfOverpaymentMadeToSubsidiary>
    <amed:RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest
      contextRef="i2d397d49a7654cbabf31f8c0d4d869b8_I20160118"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfODM0Mg_4c4e1fbc-505d-4b72-9861-beb21bbd101d"
      unitRef="usd">5600000</amed:RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest>
    <amed:NumberOfClaimsSubmittedBySubsidiary
      contextRef="i2968328e88e748f192feb97bbe016702_D20160118-20160118"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfODM3NQ_6f81ab25-e4ed-4121-97e1-4f2cd664cc42"
      unitRef="claim">9</amed:NumberOfClaimsSubmittedBySubsidiary>
    <amed:NumberOfBeneficiaries
      contextRef="i276fbb8a5a1041bba0699b8eaa7d329d_D20110606-20110606"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfODQwNg_fd473ca8-75f5-451b-bd28-0899cb1304e8"
      unitRef="beneficiary">16</amed:NumberOfBeneficiaries>
    <amed:NumberOfClaimsSubmittedBySubsidiary
      contextRef="i2968328e88e748f192feb97bbe016702_D20160118-20160118"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfODQ3OQ_b8f7d958-ffda-45d6-93f4-5e36ed17a9de"
      unitRef="claim">9</amed:NumberOfClaimsSubmittedBySubsidiary>
    <amed:Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld
      contextRef="i7b1a1c40b9524b08903a47b4db462e1e_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfODcyNA_9fdc09cd-5b84-46c1-9f69-957b52da4afd"
      unitRef="usd">5700000</amed:Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld>
    <amed:IndemnificationAmount
      contextRef="iaedb1c7adfc24c0e9954154d61af1ff0_I20190110"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfOTIyOQ_52dde620-1379-4e1a-bc44-edad584d2057"
      unitRef="usd">2800000</amed:IndemnificationAmount>
    <us-gaap:LossContingencyReceivableNoncurrent
      contextRef="ifb12069843564cf694b4e3999c45bb5a_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfOTI5Ng_91cfa138-0721-4f1c-9c43-771c54b7420d"
      unitRef="usd">4900000</us-gaap:LossContingencyReceivableNoncurrent>
    <us-gaap:LossContingencyReceivableNoncurrent
      contextRef="iaedb1c7adfc24c0e9954154d61af1ff0_I20190110"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfOTMwMg_9dcbbe88-d8a5-48d3-a825-d6d4c2043c0d"
      unitRef="usd">2800000</us-gaap:LossContingencyReceivableNoncurrent>
    <amed:RecoveryAmountOfOverpaymentMadeToSubsidiary
      contextRef="ia425738a537b4545a17322f5f6160d33_I20170831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfMTAzNDE_1b7995c1-cc55-4c44-b018-1f3342b2c84a"
      unitRef="usd">34000000.0</amed:RecoveryAmountOfOverpaymentMadeToSubsidiary>
    <amed:NumberOfClaimsSubmittedBySubsidiary
      contextRef="ie0c2bead86ad4679b8c4aaddd217dfd0_D20170801-20170831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfMTAzOTE_73f6d541-e214-41bd-b97b-3aaa1081ea96"
      unitRef="claim">72</amed:NumberOfClaimsSubmittedBySubsidiary>
    <amed:ActualClaimsPayment
      contextRef="ia425738a537b4545a17322f5f6160d33_I20170831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfMTA0MTk_14d70929-b683-4574-a1f7-c43e9540a2cb"
      unitRef="usd">200000</amed:ActualClaimsPayment>
    <amed:ErrorRatePercentage
      contextRef="ia425738a537b4545a17322f5f6160d33_I20170831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfMTA0NTY_31319b08-e711-40a8-99ba-247d11cd65ac"
      unitRef="number">1</amed:ErrorRatePercentage>
    <amed:RecoveryAmountOfOverpaymentMadeToSubsidiary
      contextRef="i7fc8fa757ad24f1c8f989fa9c81c260f_I20170831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfMTA0OTI_4c00c500-3e98-4744-b1b2-bc958aa863c6"
      unitRef="usd">4800000</amed:RecoveryAmountOfOverpaymentMadeToSubsidiary>
    <amed:NumberOfClaimsSubmittedBySubsidiary
      contextRef="ibc4bbdf502e3446cbb7600c7178a92c3_D20170801-20170831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfMTA1NDM_22c5dc57-2a59-4b62-a72e-7d7823a80707"
      unitRef="claim">70</amed:NumberOfClaimsSubmittedBySubsidiary>
    <amed:ActualClaimsPayment
      contextRef="i7fc8fa757ad24f1c8f989fa9c81c260f_I20170831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfMTA1NzE_742367f7-e4e1-45dc-a4d9-62fac1567634"
      unitRef="usd">200000</amed:ActualClaimsPayment>
    <amed:ErrorRatePercentage
      contextRef="i7fc8fa757ad24f1c8f989fa9c81c260f_I20170831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfMTA2MDg_e8b64add-9c75-450c-8974-6568645515bd"
      unitRef="number">1</amed:ErrorRatePercentage>
    <amed:RecoveryAmountOfOverpaymentMadeToSubsidiary
      contextRef="i98f80d9f97ca4a82bc3965056f5fa3f3_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfMTA5NzI_67110ed4-c5ae-4b45-b63e-3535655f095b"
      unitRef="usd">26000000.0</amed:RecoveryAmountOfOverpaymentMadeToSubsidiary>
    <amed:RecoveryAmountOfOverpaymentMadeToSubsidiary
      contextRef="ie2fd0246a3884dbd98fb1fee55bbb120_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfMTEwNTQ_72a70048-570b-4eeb-a78c-7d538ec54500"
      unitRef="usd">3300000</amed:RecoveryAmountOfOverpaymentMadeToSubsidiary>
    <amed:IndemnificationAmount
      contextRef="i935299f8f69f411d82a301973293010c_I20170831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfMTE0MTM_3d43b6b3-fe8f-4791-94ad-8c1dd62a1a94"
      unitRef="usd">12600000</amed:IndemnificationAmount>
    <amed:RecoveryAmountOfOverpaymentMadeToSubsidiary
      contextRef="i4c556fa53fa14b20ae65e1dc18d8bc25_I20170831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfMTE2NTQ_b72d78a4-252d-4fb5-9747-165653363e93"
      unitRef="usd">6500000</amed:RecoveryAmountOfOverpaymentMadeToSubsidiary>
    <amed:RecoveryAmountOfOverpaymentMadeToSubsidiary
      contextRef="i727d1a03a2854f0a8ab0f8f940d78506_I20170831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfMTE5MDA_9ee4dd35-1a76-4dbd-97b3-bc2aebd2a9d6"
      unitRef="usd">38800000</amed:RecoveryAmountOfOverpaymentMadeToSubsidiary>
    <amed:IndemnificationAmount
      contextRef="i935299f8f69f411d82a301973293010c_I20170831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfMTIwNDA_0026cdb9-abdf-49ba-b407-8aa3c39de8a8"
      unitRef="usd">12600000</amed:IndemnificationAmount>
    <amed:RecoveryAmountOfOverpaymentMadeToSubsidiary
      contextRef="icc208c6318744c7da8b8a731efe00cdf_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfMTIwOTc_bd0bc584-b89d-491c-9638-d36ede03c7bd"
      unitRef="usd">29300000</amed:RecoveryAmountOfOverpaymentMadeToSubsidiary>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="ic8bb62c8d3f64b36aef46b46e53aa57a_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfMTIyNjc_cd81250b-9fda-439a-9e63-28237eaa9de3"
      unitRef="usd">17400000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyReceivableNoncurrent
      contextRef="ic8bb62c8d3f64b36aef46b46e53aa57a_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfMTIzNjA_e0ee217c-33ba-45a5-acf9-c475626ed4df"
      unitRef="usd">10900000</us-gaap:LossContingencyReceivableNoncurrent>
    <amed:IndemnificationAmount
      contextRef="i749346d879b94b75885c06bedb422e0f_I20170831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfMTIzNzY_a04653ef-a152-4314-9bd9-ace2d3fc0835"
      unitRef="usd">12600000</amed:IndemnificationAmount>
    <amed:FloridaZpicRevenueReduction
      contextRef="i94fb4c71db4b4aec948a8a7a52e540a1_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfMTI1NjI_af0d6023-922d-4038-b963-abe480dde74c"
      unitRef="usd">6500000</amed:FloridaZpicRevenueReduction>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i87ea094035bb4053a1610c6754611f97_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfMTI3MjY_6a45f351-24fe-4c66-85e3-d0d620ecbbe7"
      unitRef="usd">1500000</us-gaap:AccountsReceivableNetCurrent>
    <amed:HealthInsuranceRetentionLimit
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfMTM1NDg_caa54951-45c0-43d2-adf2-0571cc270e38"
      unitRef="usd">1300000</amed:HealthInsuranceRetentionLimit>
    <amed:WorkersCompensationInsuranceRetentionLimit
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfMTM2NDU_a41107da-3d61-40c4-a574-9ad0543a9eca"
      unitRef="usd">1000000.0</amed:WorkersCompensationInsuranceRetentionLimit>
    <amed:ProfessionalLiabilityInsuranceRetentionLimit
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl82Ny9mcmFnOjdmODZlZjI0ZDhmZTRiZjI5YjMyZjhmYmE1OTI0MTU4L3RleHRyZWdpb246N2Y4NmVmMjRkOGZlNGJmMjliMzJmOGZiYTU5MjQxNThfMTM3Mjc_ca93a447-1029-438e-8268-d8bca2194487"
      unitRef="usd">300000</amed:ProfessionalLiabilityInsuranceRetentionLimit>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RleHRyZWdpb246NjY5N2JhZGFiNjhiNGZiNGI2ZWU1Zjc4MDFjYjE0YjFfMTM4MQ_bd977b2e-edb7-4d53-8fc3-2ef7afb3eca7">SEGMENT INFORMATION&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Our operations involve servicing patients through our three reportable business segments: home health, hospice and personal care. Our home health segment delivers a wide range of services in the homes of individuals who may be recovering from surgery, have a chronic disability or terminal illness or need assistance with completing important personal tasks. Our hospice segment provides palliative care and comfort to terminally ill patients and their families. Our personal care segment provides patients with assistance with the essential activities of daily living. The &#x201c;other&#x201d; column in the following tables consists of costs relating to executive management and administrative support functions, primarily information services, accounting, finance, billing and collections, legal, compliance, risk management, procurement, marketing, clinical administration, training, human resources and administration.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Management evaluates performance and allocates resources based on the operating income of the reportable segments, which includes an allocation of corporate expenses directly attributable to the specific segment and includes revenues and all other costs directly attributable to the specific segment. Segment assets are not reviewed by the company&#x2019;s chief operating decision maker and therefore are not disclosed below (amounts in millions).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:46.023%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.809%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.809%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.809%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.809%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.813%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Three-Month Period Ended March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Home&lt;br/&gt;Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Personal&lt;br/&gt;Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net service revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;303.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;169.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;491.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cost of service, excluding depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;179.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;91.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;285.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;75.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;38.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;39.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;156.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;256.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;131.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;42.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;447.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;47.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;38.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(42.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;43.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Three-Month Period Ended March 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Home&lt;br/&gt;Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Personal&lt;br/&gt;Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net service revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;310.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;137.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;467.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cost of service, excluding depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;185.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;74.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;275.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;71.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;29.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;41.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;144.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;258.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;103.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;42.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;423.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;52.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(42.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;44.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RleHRyZWdpb246NjY5N2JhZGFiNjhiNGZiNGI2ZWU1Zjc4MDFjYjE0YjFfODI_44304806-0ba8-4b8e-863d-cbb559720c17"
      unitRef="segments">3</us-gaap:NumberOfReportableSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RleHRyZWdpb246NjY5N2JhZGFiNjhiNGZiNGI2ZWU1Zjc4MDFjYjE0YjFfMTM4NQ_aa664355-aa61-4aa6-832b-bcbdf0776607">&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:46.023%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.809%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.809%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.809%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.809%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.813%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Three-Month Period Ended March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Home&lt;br/&gt;Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Personal&lt;br/&gt;Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net service revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;303.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;169.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;491.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cost of service, excluding depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;179.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;91.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;285.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;75.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;38.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;39.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;156.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;256.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;131.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;42.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;447.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;47.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;38.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(42.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;43.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Three-Month Period Ended March 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Home&lt;br/&gt;Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Personal&lt;br/&gt;Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net service revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;310.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;137.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;467.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cost of service, excluding depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;185.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;74.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;275.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;71.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;29.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;41.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;144.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;258.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;103.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;42.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;423.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;52.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(42.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;44.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i1803f21995a846beaf2e5491abdaa75f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMi0xLTEtMS0w_383932d0-9280-41f9-88e4-1e0be34fdeae"
      unitRef="usd">303600000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="ie2a5b1046a72421f919b53e916e3b7b9_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMi0zLTEtMS0w_6be45331-622e-4280-8f58-3d0026bbd2b3"
      unitRef="usd">169400000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i6a2423ba41a14b54bbfa09ffcbf822de_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMi01LTEtMS0w_a53c72cd-a22c-4479-be7d-8cb263097129"
      unitRef="usd">18700000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i0fca8bc8c2274f6fadc2205b072e559c_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMi03LTEtMS0w_0e2154cc-624a-4206-b0da-e4c15e60a6fb"
      unitRef="usd">0</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMi05LTEtMS0w_ecab8d3a-0eea-46c0-b2c1-3dc52cd45a61"
      unitRef="usd">491700000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i1803f21995a846beaf2e5491abdaa75f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMy0xLTEtMS0w_26ac3872-2741-42ed-9330-5d013261ff82"
      unitRef="usd">179800000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ie2a5b1046a72421f919b53e916e3b7b9_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMy0zLTEtMS0w_d0ddd456-7e91-4dda-9ede-1b63cf082d43"
      unitRef="usd">91800000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i6a2423ba41a14b54bbfa09ffcbf822de_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMy01LTEtMS0w_460c1825-6d57-4ec9-a52e-8a23c5cd8d44"
      unitRef="usd">14100000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i0fca8bc8c2274f6fadc2205b072e559c_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMy03LTEtMS0w_ffec4212-7407-4129-b75b-b3212af5c592"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMy05LTEtMS0w_be00c156-a7fa-483c-be6b-0bcca219c6e0"
      unitRef="usd">285700000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i1803f21995a846beaf2e5491abdaa75f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfNC0xLTEtMS0w_8e5821d2-ebf8-4965-894e-8aa5d1e9db1e"
      unitRef="usd">75700000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ie2a5b1046a72421f919b53e916e3b7b9_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfNC0zLTEtMS0w_a4dc887d-8ee2-46bf-86c4-14a6b70d1fdc"
      unitRef="usd">38700000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i6a2423ba41a14b54bbfa09ffcbf822de_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfNC01LTEtMS0w_67a8cfc2-04b0-441c-b022-f31693acd2fa"
      unitRef="usd">3400000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i0fca8bc8c2274f6fadc2205b072e559c_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfNC03LTEtMS0w_5ac0568a-cd81-4b90-bd99-ea81821adc9a"
      unitRef="usd">39000000.0</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfNC05LTEtMS0w_81736bc9-9e06-4c72-8dc1-c973b90c8d91"
      unitRef="usd">156800000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="i1803f21995a846beaf2e5491abdaa75f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfNS0xLTEtMS0w_1820f514-1fa1-48f3-b553-0d843f072c8a"
      unitRef="usd">1000000.0</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="ie2a5b1046a72421f919b53e916e3b7b9_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfNS0zLTEtMS0w_27df84e5-7ac7-4414-a03b-3c2b85e2fddb"
      unitRef="usd">600000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i6a2423ba41a14b54bbfa09ffcbf822de_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfNS01LTEtMS0w_a692e190-98f3-4ead-8f50-78d1f57e8d8c"
      unitRef="usd">0</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i0fca8bc8c2274f6fadc2205b072e559c_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfNS03LTEtMS0w_75ef94dd-2db9-41f3-8473-092b4d197a7f"
      unitRef="usd">3700000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfNS05LTEtMS0w_915c5c88-2c1f-4158-a7f8-3bd0b428cba4"
      unitRef="usd">5300000</us-gaap:DepreciationAndAmortization>
    <us-gaap:CostsAndExpenses
      contextRef="i1803f21995a846beaf2e5491abdaa75f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfNi0xLTEtMS0w_b6dc7ded-35bd-466f-9747-eccbda546dfd"
      unitRef="usd">256500000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ie2a5b1046a72421f919b53e916e3b7b9_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfNi0zLTEtMS0w_4bc78afb-ccb0-408b-8f4b-d198a80fa2f3"
      unitRef="usd">131100000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i6a2423ba41a14b54bbfa09ffcbf822de_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfNi01LTEtMS0w_1a871ed5-283a-4a15-8cd3-d425a9a3c4b2"
      unitRef="usd">17500000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i0fca8bc8c2274f6fadc2205b072e559c_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfNi03LTEtMS0w_aef5164b-73f9-473d-8edf-7fce02570ace"
      unitRef="usd">42700000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfNi05LTEtMS0w_01559de0-4bf6-4a48-9f52-ea2515973240"
      unitRef="usd">447800000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i1803f21995a846beaf2e5491abdaa75f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfNy0xLTEtMS0w_ae1b382d-3d06-40c8-8fb6-474f07cf99d2"
      unitRef="usd">47100000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie2a5b1046a72421f919b53e916e3b7b9_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfNy0zLTEtMS0w_7660283b-2fbb-4aab-b355-7b47ce2bd64c"
      unitRef="usd">38300000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6a2423ba41a14b54bbfa09ffcbf822de_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfNy01LTEtMS0w_362506f8-b18e-458b-a07b-80e85f2e2a80"
      unitRef="usd">1200000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0fca8bc8c2274f6fadc2205b072e559c_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfNy03LTEtMS0w_efa05c46-511e-4c33-999c-9c3eb453e47e"
      unitRef="usd">-42700000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfNy05LTEtMS0w_3357b809-c9d8-4c53-8639-68dba25db9ea"
      unitRef="usd">43900000</us-gaap:OperatingIncomeLoss>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i0ea4477e2b7e45148118c36d32e8f280_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMTEtMS0xLTEtMA_2a9c921f-6bbb-4c01-8465-fc1762dee8ac"
      unitRef="usd">310100000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i2a6321b07a44425ca22c6f9c6f1f5d8b_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMTEtMy0xLTEtMA_0511854b-4596-4aec-9b08-34c3c44a276b"
      unitRef="usd">137000000.0</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="ica2ca9848a114f40a419416038f9d299_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMTEtNS0xLTEtMA_552afab9-b49e-42d5-9947-1378c30b7871"
      unitRef="usd">20200000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="ifd5794f300984d0ebb27f829a61f2449_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMTEtNy0xLTEtMA_f356996e-df96-4abd-8000-ae2d7ab8130e"
      unitRef="usd">0</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMTEtOS0xLTEtMA_e0f0813e-81ff-4523-b7aa-b966381d780e"
      unitRef="usd">467300000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i0ea4477e2b7e45148118c36d32e8f280_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMTItMS0xLTEtMA_3babc357-ea4a-403a-9a80-c584bd30ab1b"
      unitRef="usd">185700000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i2a6321b07a44425ca22c6f9c6f1f5d8b_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMTItMy0xLTEtMA_d3783ab3-c957-4166-89ce-9936fac73162"
      unitRef="usd">74100000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ica2ca9848a114f40a419416038f9d299_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMTItNS0xLTEtMA_bed68e44-e77e-4675-8ba2-f1fbe800f07f"
      unitRef="usd">15500000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ifd5794f300984d0ebb27f829a61f2449_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMTItNy0xLTEtMA_20050f32-9ed1-4cd5-a523-95d42635aabd"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMTItOS0xLTEtMA_1be25ca4-2e90-4891-8099-3e26e7883e43"
      unitRef="usd">275300000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i0ea4477e2b7e45148118c36d32e8f280_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMTMtMS0xLTEtMA_bd0465ed-21fe-40ea-ba80-814ece667f0a"
      unitRef="usd">71400000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i2a6321b07a44425ca22c6f9c6f1f5d8b_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMTMtMy0xLTEtMA_08b8acce-acba-4417-a6f4-2a542d2ca1bd"
      unitRef="usd">29000000.0</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ica2ca9848a114f40a419416038f9d299_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMTMtNS0xLTEtMA_178ed4bd-440e-4562-b72c-cb1a0b574b11"
      unitRef="usd">3100000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ifd5794f300984d0ebb27f829a61f2449_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMTMtNy0xLTEtMA_f4c83fbf-cd70-4de8-afd0-eb88cabe35b6"
      unitRef="usd">41300000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMTMtOS0xLTEtMA_f8861e58-ab68-48b1-8ca4-55d32a1e8727"
      unitRef="usd">144800000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="i0ea4477e2b7e45148118c36d32e8f280_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMTQtMS0xLTEtMA_cc5c6d3c-a3c9-43e4-b47a-c26880e298d5"
      unitRef="usd">1000000.0</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i2a6321b07a44425ca22c6f9c6f1f5d8b_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMTQtMy0xLTEtMA_d814ff51-a445-4d95-b54f-415075e418eb"
      unitRef="usd">400000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="ica2ca9848a114f40a419416038f9d299_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMTQtNS0xLTEtMA_2a2d4e48-f605-4961-b596-e086d05a62ba"
      unitRef="usd">100000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="ifd5794f300984d0ebb27f829a61f2449_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMTQtNy0xLTEtMA_606f286e-41c0-437d-b4cc-7f5374ef83be"
      unitRef="usd">1400000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMTQtOS0xLTEtMA_71303c66-6daf-46ca-9af5-62d38a1cfeda"
      unitRef="usd">2900000</us-gaap:DepreciationAndAmortization>
    <us-gaap:CostsAndExpenses
      contextRef="i0ea4477e2b7e45148118c36d32e8f280_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMTUtMS0xLTEtMA_5a810f82-5800-462a-a64e-d9deca1f8c0c"
      unitRef="usd">258100000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i2a6321b07a44425ca22c6f9c6f1f5d8b_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMTUtMy0xLTEtMA_903263cf-da31-40f1-a6ac-0768d9ea9a5c"
      unitRef="usd">103500000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ica2ca9848a114f40a419416038f9d299_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMTUtNS0xLTEtMA_8f31c1a1-038c-474e-a401-e28c011019ff"
      unitRef="usd">18700000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ifd5794f300984d0ebb27f829a61f2449_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMTUtNy0xLTEtMA_2565a766-54f4-469a-8a69-27ac50530f51"
      unitRef="usd">42700000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMTUtOS0xLTEtMA_6beaf016-d361-4fee-97cd-e255b4dcd03a"
      unitRef="usd">423000000.0</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0ea4477e2b7e45148118c36d32e8f280_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMTYtMS0xLTEtMA_6dcb06e2-3181-43eb-8413-a10e0646fcd0"
      unitRef="usd">52000000.0</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i2a6321b07a44425ca22c6f9c6f1f5d8b_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMTYtMy0xLTEtMA_d195d600-0ce8-4792-9009-a68368bf3e54"
      unitRef="usd">33500000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ica2ca9848a114f40a419416038f9d299_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMTYtNS0xLTEtMA_14a726a1-7231-4c17-aa5c-64473ff312b9"
      unitRef="usd">1500000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ifd5794f300984d0ebb27f829a61f2449_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMTYtNy0xLTEtMA_94fad0ba-99a9-41bc-bf85-03ded274079b"
      unitRef="usd">-42700000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i3ad832f305e5446fa9bf1c6c91ca5c2e_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83My9mcmFnOjY2OTdiYWRhYjY4YjRmYjRiNmVlNWY3ODAxY2IxNGIxL3RhYmxlOmE5ZTM0N2M1ZWIzYTQwNWJiZDNlMzc1NjU4OTg3MmM4L3RhYmxlcmFuZ2U6YTllMzQ3YzVlYjNhNDA1YmJkM2UzNzU2NTg5ODcyYzhfMTYtOS0xLTEtMA_3e166053-1b56-44f1-af8c-11aa05c06d96"
      unitRef="usd">44300000</us-gaap:OperatingIncomeLoss>
    <us-gaap:TreasuryStockTextBlock
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83OS9mcmFnOmJkZmVhOGJkMTUzMjQ4NGFhMzE5YTdjZTg0Njc1NzZlL3RleHRyZWdpb246YmRmZWE4YmQxNTMyNDg0YWEzMTlhN2NlODQ2NzU3NmVfMTUxNQ_e8154b7f-5b2c-4e79-a242-fd0285f29894">SHARE REPURCHASE &lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;2019 Stock Repurchase Program&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On February 25, 2019, we announced that our Board of Directors authorized a stock repurchase program, under which we may repurchase up to $100 million of our outstanding common stock through March 1, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Under the terms of the program, we were allowed to repurchase shares from time to time in open market transactions, block purchases or in private transactions in accordance with applicable federal securities laws and other legal requirements. We were allowed to enter into Rule 10b5-1 plans to effect some or all of the repurchases. The timing and the amount of the repurchases would be determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We did not repurchase any shares pursuant to this stock repurchase program during the three-month periods ended March&#160;31, 2020 or March 31, 2019. The stock repurchase program expired on March 1, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:TreasuryStockTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i156f24d3122641318de844c5586c409a_I20190225"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83OS9mcmFnOmJkZmVhOGJkMTUzMjQ4NGFhMzE5YTdjZTg0Njc1NzZlL3RleHRyZWdpb246YmRmZWE4YmQxNTMyNDg0YWEzMTlhN2NlODQ2NzU3NmVfMTk0_aa28749c-b89e-425e-82b5-ce6a7c47d4ea"
      unitRef="usd">100000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramExpirationDate
      contextRef="i61c83eb39bd448178123272ce803cd04_D20190225-20190225"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl83OS9mcmFnOmJkZmVhOGJkMTUzMjQ4NGFhMzE5YTdjZTg0Njc1NzZlL3RleHRyZWdpb246YmRmZWE4YmQxNTMyNDg0YWEzMTlhN2NlODQ2NzU3NmVfMjM3_76cbdf54-d495-4944-a182-041efdabc32a">2020-03-01</us-gaap:StockRepurchaseProgramExpirationDate>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl84Mi9mcmFnOjEwYWE4ZTNkM2M2MzQ2MDg4MjJlOGYyODdmNjNiODY1L3RleHRyZWdpb246MTBhYThlM2QzYzYzNDYwODgyMmU4ZjI4N2Y2M2I4NjVfMzg2_803c70bf-e64a-4cda-9749-64d78345c0e6">RELATED PARTY TRANSACTIONSDuring 2018, we made a $7.0 million investment in Medalogix, a healthcare predictive data and analytics company; this investment is accounted for under the equity method. During the three-month period ended March 31, 2020, we incurred costs of approximately $0.6 million  in connection with the usage of Medalogix's analytics platforms. We believe that the terms of these transactions are consistent with those negotiated at arm's length.</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="iba4950c59f204d1fadc805bed37fde70_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl84Mi9mcmFnOjEwYWE4ZTNkM2M2MzQ2MDg4MjJlOGYyODdmNjNiODY1L3RleHRyZWdpb246MTBhYThlM2QzYzYzNDYwODgyMmU4ZjI4N2Y2M2I4NjVfNTg_7228a7cb-c963-45a6-81aa-aa15bf304232"
      unitRef="usd">7000000.0</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="i814b93d2c0884001a010153e4ffc90ec_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl84Mi9mcmFnOjEwYWE4ZTNkM2M2MzQ2MDg4MjJlOGYyODdmNjNiODY1L3RleHRyZWdpb246MTBhYThlM2QzYzYzNDYwODgyMmU4ZjI4N2Y2M2I4NjVfMjk3_860d602e-e18d-4c50-91eb-2d88b98be757"
      unitRef="usd">600000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i444a95b00413472087a2a74f3d0ed812_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl84NS9mcmFnOjkzMWNjMDFjZDAyNDQzY2NiYjVjMzExODI5NWJjOTM1L3RleHRyZWdpb246OTMxY2MwMWNkMDI0NDNjY2JiNWMzMTE4Mjk1YmM5MzVfMTY0OTI2NzQ0MzIzMg_932b6ed1-f9c4-4592-b314-3ba85995a883">SUBSEQUENT EVENTS&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Novel Coronavirus Pandemic ("COVID-19")&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In March 2020, the World Health Organization declared COVID-19 a pandemic. As a healthcare at home company, we have been and will continue to be impacted by the effects of COVID-19; however, we remain committed to carrying out our mission of caring for our patients. We will continue to closely monitor the impact of COVID-19 on all aspects of our business, including the impacts to our employees, patients and suppliers; however, at this time, we are unable to estimate the ultimate impact the pandemic will have on our consolidated financial condition, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On March 27, 2020, the bipartisan Coronavirus Aid, Relief, and Economic Security Act ("CARES Act") was signed into legislation. The CARES Act provides for $100&#160;billion to healthcare providers, including hospitals on the front lines of the COVID-19 pandemic. Of this total allocated amount, $30&#160;billion was distributed immediately to providers based on their proportionate share of Medicare fee-for-service reimbursements in 2019. Healthcare providers must sign an attestation confirming receipt of the funds and agree to the terms and conditions of payment. We received approximately $100&#160;million from the first $30&#160;billion of funds distributed to healthcare providers in April 2020. Consistent with the terms and conditions for receipt of the payment, we will utilize the funds to cover lost revenue and health care costs related to COVID-19, and we will properly and fully document the use of these funds in required quarterly reports to the U.S. Department of Health and Human Services ("HHS").&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In order to properly attest to receipt of our payment, we are seeking clarity from HHS regarding the formula utilized to determine our receipt of funds and the total amount of funds available to us to be used towards lost revenue and health care expenses related to COVID-19. At this time, we have fully separated these funds into their own account and will not be utilizing any of them until additional clarity is received from HHS.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On April 24, 2020, HHS distributed an additional $20&#160;billion in funds to healthcare providers. We did not receive, nor apply, for any additional funds from this second distribution.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On April 23, 2020, we signed a definitive agreement to acquire Homecare Preferred Choice, Inc., doing business as AseraCare Hospice ("AseraCare Hospice"), a national hospice care provider with 44 locations, for a purchase price of $235&#160;million in cash, inclusive of $32&#160;million in payments related to the present value of the tax benefits created through the transaction (subject to customary adjustments at closing for working capital, cash indebtedness and transaction expenses). We will not use any of the funds we received from the CARES Act to fund the acquisition.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <amed:FundingForHealthcareProvidersIncludingHospitals
      contextRef="i8b9efcf5de4c480e81af5d9bd1cdb30e_I20200327"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl84NS9mcmFnOjkzMWNjMDFjZDAyNDQzY2NiYjVjMzExODI5NWJjOTM1L3RleHRyZWdpb246OTMxY2MwMWNkMDI0NDNjY2JiNWMzMTE4Mjk1YmM5MzVfMTY0OTI2NzQ0Mzc4MQ_0216b23c-c6f7-4b9e-b274-13b0f6279a93"
      unitRef="usd">100000000000</amed:FundingForHealthcareProvidersIncludingHospitals>
    <amed:FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements
      contextRef="i8b9efcf5de4c480e81af5d9bd1cdb30e_I20200327"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl84NS9mcmFnOjkzMWNjMDFjZDAyNDQzY2NiYjVjMzExODI5NWJjOTM1L3RleHRyZWdpb246OTMxY2MwMWNkMDI0NDNjY2JiNWMzMTE4Mjk1YmM5MzVfMTY0OTI2NzQ0Mzc5NQ_8ff23cf9-45e4-40be-b66d-e0c18e3b1263"
      unitRef="usd">30000000000</amed:FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements>
    <amed:FundingReceivedFromCARESAct
      contextRef="i64e606224ada41f7b469907990f9cbec_D20200401-20200430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl84NS9mcmFnOjkzMWNjMDFjZDAyNDQzY2NiYjVjMzExODI5NWJjOTM1L3RleHRyZWdpb246OTMxY2MwMWNkMDI0NDNjY2JiNWMzMTE4Mjk1YmM5MzVfMTY0OTI2NzQ0MzgwOA_4eda8c5e-09c2-4859-83ac-b86dc70e7a6c"
      unitRef="usd">100000000</amed:FundingReceivedFromCARESAct>
    <amed:FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements
      contextRef="i8b9efcf5de4c480e81af5d9bd1cdb30e_I20200327"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl84NS9mcmFnOjkzMWNjMDFjZDAyNDQzY2NiYjVjMzExODI5NWJjOTM1L3RleHRyZWdpb246OTMxY2MwMWNkMDI0NDNjY2JiNWMzMTE4Mjk1YmM5MzVfMTY0OTI2NzQ1NTM0MA_4e168f1c-b112-415d-9549-bc2fcf442059"
      unitRef="usd">30000000000</amed:FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements>
    <amed:AdditionalFundingDistributedToHealthcareProviders
      contextRef="ie825c970c94741d3bc87bb70762f3d6b_I20200424"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl84NS9mcmFnOjkzMWNjMDFjZDAyNDQzY2NiYjVjMzExODI5NWJjOTM1L3RleHRyZWdpb246OTMxY2MwMWNkMDI0NDNjY2JiNWMzMTE4Mjk1YmM5MzVfMTY0OTI2NzQ1NTMyNw_03768a8d-3624-4ac5-a132-89295e24d29d"
      unitRef="usd">20000000000</amed:AdditionalFundingDistributedToHealthcareProviders>
    <us-gaap:NumberOfBusinessesAcquired
      contextRef="i231cc4c6c6914005bf14c4a47eaefddd_D20200423-20200423"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl84NS9mcmFnOjkzMWNjMDFjZDAyNDQzY2NiYjVjMzExODI5NWJjOTM1L3RleHRyZWdpb246OTMxY2MwMWNkMDI0NDNjY2JiNWMzMTE4Mjk1YmM5MzVfMTY0OTI2NzQ0Mzg3MA_76dd973b-2a03-4e2a-9ade-e89d494b5c1a"
      unitRef="care_center">44</us-gaap:NumberOfBusinessesAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i231cc4c6c6914005bf14c4a47eaefddd_D20200423-20200423"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl84NS9mcmFnOjkzMWNjMDFjZDAyNDQzY2NiYjVjMzExODI5NWJjOTM1L3RleHRyZWdpb246OTMxY2MwMWNkMDI0NDNjY2JiNWMzMTE4Mjk1YmM5MzVfMTY0OTI2NzQ0MzgyMg_32c6502e-1f4f-4709-b8a3-bdbdefa785ca"
      unitRef="usd">235000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <amed:Paymentsrelatedtotaxassetandworkingcapital
      contextRef="i231cc4c6c6914005bf14c4a47eaefddd_D20200423-20200423"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5M2U2OGNkY2NiNDRiOThhNzNhZWY2ZTMzZjQ5N2JmL3NlYzo3OTNlNjhjZGNjYjQ0Yjk4YTczYWVmNmUzM2Y0OTdiZl84NS9mcmFnOjkzMWNjMDFjZDAyNDQzY2NiYjVjMzExODI5NWJjOTM1L3RleHRyZWdpb246OTMxY2MwMWNkMDI0NDNjY2JiNWMzMTE4Mjk1YmM5MzVfMTY0OTI2NzQ0MzgzNg_5bbdda7e-d084-4db9-a116-cd640fb90941"
      unitRef="usd">32000000</amed:Paymentsrelatedtotaxassetandworkingcapital>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6871993232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM OBLIGATIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">LONG-TERM OBLIGATIONS</a></td>
<td class="text">LONG-TERM OBLIGATIONS<div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Long-term debt consisted of the following for the periods indicated (amounts in millions):</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:91.812%;"><tr><td style="width:1.0%;"/><td style="width:65.356%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:13.923%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.596%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.925%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">$175.0 million Term Loan; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate (2.5% at March 31, 2020); due February&#160;4, 2024</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">170.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">171.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">$550.0 million Revolving Credit Facility; interest only payments; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate (2.4% at March 31, 2020); due February&#160;4, 2024</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">220.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">70.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Promissory notes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finance leases</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Principal amount of long-term obligations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">394.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">245.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred debt issuance costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">391.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">242.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current portion of long-term obligations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">379.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">232.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">First Amendment to Amended and Restated Credit Agreement</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On February 4, 2019, we entered into the First Amendment to our Credit Agreement (as amended by the First Amendment, the "Amended Credit Agreement"). The Amended Credit Agreement provides for a senior secured credit facility in an initial aggregate principal amount of up to $725.0 million, which includes a $550.0 million Revolving Credit Facility under the Credit Agreement and a term loan facility with a principal amount of up to $175.0 million (the "Term Loan Facility" and collectively with the Revolving Credit Facility, the "Credit Facility"), which was added by the First Amendment.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We borrowed the entire principal amount of the Term Loan Facility on February&#160;4, 2019 in order to fund a portion of the purchase price of the Compassionate Care Hospice ("CCH") acquisition, with the remainder of the purchase price and associated transactional fees and expenses funded by proceeds from the Revolving Credit Facility. </span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The loans issued under the Credit Facility bear interest on a per annum basis, at our election, at either: (i) the Base Rate plus the Applicable Rate or (ii) the Eurodollar Rate plus the Applicable Rate. The &#8220;Base Rate&#8221; means a fluctuating rate per annum equal to the highest of (a) the federal funds rate plus 0.50% per annum, (b) the prime rate of interest established by the Administrative Agent, and (c) the Eurodollar Rate plus 1% per annum. The &#8220;Eurodollar Rate&#8221; means the quoted rate per annum equal to the London Interbank Offered Rate (&#8220;LIBOR&#8221;) or a comparable successor rate approved by the Administrative Agent for an interest period of one, two, three or six months (as selected by us). The &#8220;Applicable Rate&#8221; is based on the consolidated leverage ratio and is presented in the table below. As of March&#160;31, 2020, the Applicable Rate is 0.50% per annum for Base Rate loans and 1.50% per annum for Eurodollar Rate loans. We are also subject to a commitment fee and letter of credit fee under the terms of the Amended Credit Agreement, as presented in the table below.</span></div><div><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:92.251%;"><tr><td style="width:1.0%;"/><td style="width:9.251%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:25.258%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.908%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.836%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.908%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.839%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pricing Tier</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Consolidated Leverage Ratio</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commitment Fee</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Letter of Credit Fee</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Eurodollar Rate Loans</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Base Rate Loans</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">I</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#8805; 3.00 to 1.0</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.35%</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.75%</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.00%</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.00%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">II</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&lt; 3.00 to 1.0 but &#8805; 2.00 to 1.0</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.30%</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.50%</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.75%</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.75%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">III</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&lt; 2.00 to 1.0 but &#8805; 0.75 to 1.0</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.25%</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.25%</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.50%</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.50%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">IV</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&lt; 0.75 to 1.0</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.20%</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.00%</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.25%</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.25%</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The final maturity date of the Credit Facility is February 4, 2024. The Revolving Credit Facility will terminate and be due and payable as of the final maturity date. The Term Loan Facility, however, is subject to quarterly amortization of principal in the amount of (i) 0.625% for the period commencing on February 4, 2019 and ending on March 31, 2020, (ii) 1.250% for the period commencing on April 1, 2020 and ending on March 31, 2023, and (iii) 1.875% for the period commencing on April 1, 2023 and ending on February 4, 2024. The remaining balance of the Term Loan Facility must be paid upon the final maturity date. In addition to the scheduled amortization of the Term Loan Facility, and subject to customary exceptions and reinvestment rights, we are required to prepay the Term Loan Facility, first, and the Revolving Credit Facility, second, with 100% of all net cash proceeds received by any loan party or any subsidiary thereof in connection with (a) any asset sale or disposition where such loan party receives net cash proceeds in excess of $5 million or (b) any debt issuance that is not permitted under the Amended Credit Agreement.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Amended Credit Agreement requires maintenance of two financial covenants: (i) a consolidated leverage ratio of funded indebtedness to Earnings Before Interest, Taxes, Depreciation and Amortization ("EBITDA"), as defined in the Amended Credit Agreement, and (ii) a consolidated interest coverage ratio of EBITDA to cash interest charges, as defined in the Amended Credit Agreement. Each of these covenants is calculated over rolling four-quarter periods and also is subject to certain exceptions and baskets. The Amended Credit Agreement also contains customary covenants, including, but not limited to, restrictions on: incurrence of liens, incurrence of additional debt, sales of assets and other fundamental corporate changes, investments, and declarations of dividends. These covenants contain customary exclusions and baskets as detailed in the Amended Credit Agreement. In connection with our entry into the Amended Credit Agreement, we recorded $0.8 million in deferred debt issuance costs as long-term obligations, less current portion within our condensed consolidated balance sheet during the year ended December 31, 2019.</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Revolving Credit Facility is guaranteed by substantially all of our wholly-owned direct and indirect subsidiaries. The Amended Credit Agreement requires at all times that we (i) provide guarantees from wholly-owned subsidiaries that in the </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">aggregate represent not less than 95% of our consolidated net revenues and adjusted EBITDA from all wholly-owned subsidiaries and (ii) provide guarantees from subsidiaries that in the aggregate represent not less than 70% of consolidated adjusted EBITDA, subject to certain exceptions.</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our weighted average interest rate for borrowings under our $550.0 million Revolving Credit Facility was 3.2% and 4.2% for the three-month periods ended March&#160;31, 2020 and March 31, 2019, respectively. Our weighted average interest rate for borrowings under our $175.0 million Term Loan Facility was 3.2% for the three-month period ended March&#160;31, 2020 and 4.2% for the period February 4, 2019 to March 31, 2019.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March&#160;31, 2020, our consolidated leverage ratio was 1.5, our consolidated interest coverage ratio was 16.6 and we are in compliance with our covenants under the Amended Credit Agreement. In the event we are not in compliance with our debt covenants in the future, we would pursue various alternatives in an attempt to successfully resolve the non-compliance, which might include, among other things, seeking debt covenant waivers or amendments.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March&#160;31, 2020, our availability under our $550.0 million Revolving Credit Facility was $299.8 million as we have $220.0 million outstanding in borrowings and $30.2 million outstanding in letters of credit.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Joinder Agreement</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the CCH acquisition, we entered into a Joinder Agreement, dated as of February 4, 2019, pursuant to which CCH and its subsidiaries were made parties to, and became subject to the terms and conditions of, the Amended Credit Agreement, the Amended and Restated Security Agreement, dated as of June 29, 2018, and the Amended and Restated Pledge Agreement, dated as of June 29, 2018. Pursuant to the Joinder, the Amended and Restated Security Agreement and the Amended and Restated Pledge Agreement, CCH and its subsidiaries granted in favor of the Administrative Agent a first lien security interest in substantially all of their personal property assets and pledged to the Administrative Agent each of their respective subsidiaries' issued and outstanding equity interests. CCH and its subsidiaries also guaranteed our obligations, whether now existing or arising after the effective date of the Joinder, under the Amended Credit Agreement pursuant to the terms of the Joinder and the Amended Credit Agreement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6871967520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Schedule of Business Acquisitions</a></td>
<td class="text">The Company is in the process of finalizing its valuation of the assets acquired and liabilities assumed. Based on the Company's preliminary valuation, the total estimated consideration of $66.3&#160;million has been allocated to assets acquired and liabilities assumed as of the acquisition date as follows (amounts in millions):<table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:79.970%;"><tr><td style="width:1.0%;"/><td style="width:73.137%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:22.863%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Patient accounts receivable</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease right of use assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Intangible assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Total assets acquired</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payroll and employee benefits</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Total liabilities assumed</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net identifiable assets acquired</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">59.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total estimated consideration</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">66.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1486-128463<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6891140000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">27 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 27, 2016 </div>
<div>patient</div>
</th>
<th class="th">
<div>Jan. 18, 2016 </div>
<div>USD ($) </div>
<div>claim</div>
</th>
<th class="th">
<div>Nov. 03, 2015 </div>
<div>patient</div>
</th>
<th class="th">
<div>May 21, 2015 </div>
<div>patient</div>
</th>
<th class="th"><div>Jan. 30, 2015</div></th>
<th class="th"><div>Apr. 23, 2014</div></th>
<th class="th">
<div>Jun. 06, 2011 </div>
<div>beneficiary</div>
</th>
<th class="th">
<div>Aug. 31, 2017 </div>
<div>USD ($) </div>
<div>claim</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2010 </div>
<div>beneficiary</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 10, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Patient accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 268,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 237,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_HealthInsuranceRetentionLimit', window );">Health insurance retention limit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_WorkersCompensationInsuranceRetentionLimit', window );">Workers compensation insurance retention limit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ProfessionalLiabilityInsuranceRetentionLimit', window );">Professional liability insurance retention limit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_SC', window );">South Carolina | Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfBeneficiaries', window );">Number of beneficiaries | beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyReceivableNoncurrent', window );">Indemnity receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="nump">$ 4,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_IndemnificationAmount', window );">Indemnification amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_SC', window );">South Carolina | Hospice [Member] | Extrapolated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfBeneficiaries', window );">Number of beneficiaries | beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_SC', window );">South Carolina | Hospice [Member] | Unfavorable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary', window );">Recovery amount of overpayment made to subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest', window );">Recovery amount of overpayment made to subsidiary including interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfClaimsSubmittedBySubsidiary', window );">Number of claims submitted by subsidiary | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld', window );">Recovery amount of over payment made to subsidiary including interest withheld</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_UsDepartmentOfJusticeMember', window );">US Department of Justice | Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_UsDepartmentOfJusticeMember', window );">US Department of Justice | Massachusetts | Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Numberofpatients', window );">Number of patients | patient</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_UsDepartmentOfJusticeMember', window );">US Department of Justice | Morgantown, West Virginia | Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Numberofpatients', window );">Number of patients | patient</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_UsDepartmentOfJusticeMember', window );">US Department of Justice | Parkersburg, West Virginia | Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Numberofpatients', window );">Number of patients | patient</a></td>
<td class="nump">68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_AmedisysCIAMember', window );">Amedisys CIA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CorporateIntegrityAgreementTerm', window );">Corporate integrity agreement term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_CompassionateCareHospiceCIAMember', window );">Compassionate Care Hospice CIA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CorporateIntegrityAgreementTerm', window );">Corporate integrity agreement term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember', window );">Safeguard Zone Program Integrity Contractor | Florida</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyReceivableNoncurrent', window );">Indemnity receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_IndemnificationAmount', window );">Indemnification amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember', window );">Safeguard Zone Program Integrity Contractor | Florida | Infinity HomeCare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_IndemnificationAmount', window );">Indemnification amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember', window );">Safeguard Zone Program Integrity Contractor | Florida | Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_FloridaZpicRevenueReduction', window );">Florida ZPIC revenue reduction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember', window );">Safeguard Zone Program Integrity Contractor | Florida | Home Health [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary', window );">Recovery amount of overpayment made to subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember', window );">Safeguard Zone Program Integrity Contractor | Florida | Home Health [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary', window );">Recovery amount of overpayment made to subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,800<span></span>
</td>
<td class="nump">29,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember', window );">Safeguard Zone Program Integrity Contractor | Florida | Home Health [Member] | Infinity HomeCare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Patient accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember', window );">Safeguard Zone Program Integrity Contractor | Lakeland, Florida | Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary', window );">Recovery amount of overpayment made to subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,000<span></span>
</td>
<td class="nump">26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfClaimsSubmittedBySubsidiary', window );">Number of claims submitted by subsidiary | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ActualClaimsPayment', window );">Actual claims payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ErrorRatePercentage', window );">Error rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember', window );">Safeguard Zone Program Integrity Contractor | Clearwater, Florida | Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary', window );">Recovery amount of overpayment made to subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,800<span></span>
</td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfClaimsSubmittedBySubsidiary', window );">Number of claims submitted by subsidiary | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ActualClaimsPayment', window );">Actual claims payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ErrorRatePercentage', window );">Error rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ActualClaimsPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Actual Claims Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ActualClaimsPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CorporateIntegrityAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Corporate Integrity Agreement Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CorporateIntegrityAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ErrorRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Error Rate Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ErrorRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_FloridaZpicRevenueReduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in revenue as a result of the Florida ZPIC audit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_FloridaZpicRevenueReduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_HealthInsuranceRetentionLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum potential amount of future payments the entity could be required to make related to a specific Health Insurance Claim.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_HealthInsuranceRetentionLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_IndemnificationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount to be reimbursed if and when certain assumed liabilities are paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_IndemnificationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NumberOfBeneficiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of beneficiaries who received services</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NumberOfBeneficiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NumberOfClaimsSubmittedBySubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of claims submitted by subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NumberOfClaimsSubmittedBySubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_Numberofpatients">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of patients</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_Numberofpatients</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ProfessionalLiabilityInsuranceRetentionLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum potential amount of future payments the entity could be required to make related to a specific Professional Liability Claim.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ProfessionalLiabilityInsuranceRetentionLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recovery amount of the overpayment made to the subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_RecoveryAmountOfOverpaymentMadeToSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recovery amount of overpayment made to subsidiary including interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recovery amount of over payment made to subsidiary including interest withheld</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_WorkersCompensationInsuranceRetentionLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum potential amount of future payments the entity could be required to make related to a specific Workers' Compensation Insurance Claim.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_WorkersCompensationInsuranceRetentionLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyReceivableNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivable related to a loss contingency accrual that is expected to be collected after one year or beyond the normal operating cycle, if longer. For example, an insurance recovery receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118943654&amp;loc=d3e12053-110248<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyReceivableNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_SC">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_SC</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=amed_ExtrapolatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=amed_ExtrapolatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=amed_UnfavorableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=amed_UnfavorableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=amed_UsDepartmentOfJusticeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=amed_UsDepartmentOfJusticeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_MA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_MA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=amed_MorgantownWestVirginiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=amed_MorgantownWestVirginiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=amed_ParkersburgWestVirginiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=amed_ParkersburgWestVirginiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=amed_AmedisysCIAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=amed_AmedisysCIAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=amed_CompassionateCareHospiceCIAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=amed_CompassionateCareHospiceCIAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_FL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_FL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amed_InfinityHomeCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amed_InfinityHomeCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=amed_LakelandFloridaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=amed_LakelandFloridaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=amed_ClearwaterFloridaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=amed_ClearwaterFloridaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6874746848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Payments to Acquire Investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=amed_MedalogixMember', window );">Medalogix [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Payments to Acquire Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related Party Transaction, Amounts of Transaction</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=amed_MedalogixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=amed_MedalogixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "amed-20200331.htm": {
   "axisCustom": 2,
   "axisStandard": 18,
   "contextCount": 167,
   "dts": {
    "calculationLink": {
     "local": [
      "amed-20200331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "amed-20200331_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "amed-20200331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "amed-20200331_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "amed-20200331_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "amed-20200331.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 514,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2019-01-31": 15,
    "http://www.amedisys.com/20200331": 4,
    "http://xbrl.sec.gov/dei/2019-01-31": 6,
    "total": 25
   },
   "keyCustom": 68,
   "keyStandard": 271,
   "memberCustom": 37,
   "memberStandard": 24,
   "nsprefix": "amed",
   "nsuri": "http://www.amedisys.com/20200331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i444a95b00413472087a2a74f3d0ed812_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.amedisys.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i444a95b00413472087a2a74f3d0ed812_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i444a95b00413472087a2a74f3d0ed812_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116104 - Disclosure - LONG-TERM OBLIGATIONS",
     "role": "http://www.amedisys.com/role/LONGTERMOBLIGATIONS",
     "shortName": "LONG-TERM OBLIGATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i444a95b00413472087a2a74f3d0ed812_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i444a95b00413472087a2a74f3d0ed812_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2122105 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "role": "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i444a95b00413472087a2a74f3d0ed812_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i444a95b00413472087a2a74f3d0ed812_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124106 - Disclosure - SEGMENT INFORMATION",
     "role": "http://www.amedisys.com/role/SEGMENTINFORMATION",
     "shortName": "SEGMENT INFORMATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i444a95b00413472087a2a74f3d0ed812_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i444a95b00413472087a2a74f3d0ed812_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128107 - Disclosure - SHARE REPURCHASE SHARE REPURCHASE",
     "role": "http://www.amedisys.com/role/SHAREREPURCHASESHAREREPURCHASE",
     "shortName": "SHARE REPURCHASE SHARE REPURCHASE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i444a95b00413472087a2a74f3d0ed812_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i444a95b00413472087a2a74f3d0ed812_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130108 - Disclosure - RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONS",
     "role": "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSRELATEDPARTYTRANSACTIONS",
     "shortName": "RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i444a95b00413472087a2a74f3d0ed812_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i444a95b00413472087a2a74f3d0ed812_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2132109 - Disclosure - SUBSEQUENT EVENT",
     "role": "http://www.amedisys.com/role/SUBSEQUENTEVENT",
     "shortName": "SUBSEQUENT EVENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i444a95b00413472087a2a74f3d0ed812_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i444a95b00413472087a2a74f3d0ed812_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i444a95b00413472087a2a74f3d0ed812_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i444a95b00413472087a2a74f3d0ed812_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i444a95b00413472087a2a74f3d0ed812_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i444a95b00413472087a2a74f3d0ed812_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313302 - Disclosure - ACQUISITIONS (Tables)",
     "role": "http://www.amedisys.com/role/ACQUISITIONSTables",
     "shortName": "ACQUISITIONS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i444a95b00413472087a2a74f3d0ed812_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i444a95b00413472087a2a74f3d0ed812_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2317303 - Disclosure - LONG-TERM OBLIGATIONS LONG-TERM OBLIGATIONS (Tables)",
     "role": "http://www.amedisys.com/role/LONGTERMOBLIGATIONSLONGTERMOBLIGATIONSTables",
     "shortName": "LONG-TERM OBLIGATIONS LONG-TERM OBLIGATIONS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i444a95b00413472087a2a74f3d0ed812_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i886ddae2179d4ed793345586cc440c4e_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i886ddae2179d4ed793345586cc440c4e_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i444a95b00413472087a2a74f3d0ed812_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2325304 - Disclosure - SEGMENT INFORMATION (Tables)",
     "role": "http://www.amedisys.com/role/SEGMENTINFORMATIONTables",
     "shortName": "SEGMENT INFORMATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i444a95b00413472087a2a74f3d0ed812_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i886ddae2179d4ed793345586cc440c4e_I20200331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfStatesInWhichEntityOperates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "state",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - Narrative (Details)",
     "role": "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
     "shortName": "NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i886ddae2179d4ed793345586cc440c4e_I20200331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfStatesInWhichEntityOperates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "state",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i444a95b00413472087a2a74f3d0ed812_D20200101-20200331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "amed:PercentageOfTotalReimbursementOfOutlierPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition Narrative (Details)",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i444a95b00413472087a2a74f3d0ed812_D20200101-20200331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "amed:PercentageOfTotalReimbursementOfOutlierPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i444a95b00413472087a2a74f3d0ed812_D20200101-20200331",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue by Payor Class (Details)",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue by Payor Class (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i444a95b00413472087a2a74f3d0ed812_D20200101-20200331",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i886ddae2179d4ed793345586cc440c4e_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestrictedCash",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash and Cash Equivalents (Details)",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash and Cash Equivalents (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i94c155e0b36a4453979995375a4118aa_I20200331",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:RestrictedCash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i444a95b00413472087a2a74f3d0ed812_D20200101-20200331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "amed:PercentageOfPatientReceivablesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409405 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Patient Accounts Receivable Narrative (Details)",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Patient Accounts Receivable Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i444a95b00413472087a2a74f3d0ed812_D20200101-20200331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "amed:PercentageOfPatientReceivablesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amed:FinancialInstrumentDetailsTableTextBlock",
       "us-gaap:FairValueOfFinancialInstrumentsPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i886ddae2179d4ed793345586cc440c4e_I20200331",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "amed:DebtInstrumentCarryingAmountExcludingFinanceLeases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410406 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value of Financial Instruments (Details)",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value of Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amed:FinancialInstrumentDetailsTableTextBlock",
       "us-gaap:FairValueOfFinancialInstrumentsPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i886ddae2179d4ed793345586cc440c4e_I20200331",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "amed:DebtInstrumentCarryingAmountExcludingFinanceLeases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i444a95b00413472087a2a74f3d0ed812_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411407 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Weighted-Average Shares Outstanding (Details)",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Weighted-Average Shares Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i444a95b00413472087a2a74f3d0ed812_D20200101-20200331",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i444a95b00413472087a2a74f3d0ed812_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414408 - Disclosure - ACQUISITIONS - Narrative (Details)",
     "role": "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
     "shortName": "ACQUISITIONS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "ic7171631cf3944959da9674b593c9910_D20200101-20200101",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i886ddae2179d4ed793345586cc440c4e_I20200331",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418410 - Disclosure - LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt (Details)",
     "role": "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails",
     "shortName": "LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i886ddae2179d4ed793345586cc440c4e_I20200331",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:DeferredFinanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i886ddae2179d4ed793345586cc440c4e_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i886ddae2179d4ed793345586cc440c4e_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "ic735d35014784f0395b22a1d4852e2bb_I20200331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419411 - Disclosure - LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt Additional Information (Details)",
     "role": "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
     "shortName": "LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i4d3ef9b25fd64694a1f379a432f9bb62_D20200101-20200331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:LineOfCreditFacilityCommitmentFeePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420412 - Disclosure - LONG-TERM OBLIGATIONS - Fees and Rates Under Credit Facilities (Details)",
     "role": "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
     "shortName": "LONG-TERM OBLIGATIONS - Fees and Rates Under Credit Facilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i4d3ef9b25fd64694a1f379a432f9bb62_D20200101-20200331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:LineOfCreditFacilityCommitmentFeePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i444a95b00413472087a2a74f3d0ed812_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsOfFinancingCosts",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421413 - Disclosure - LONG-TERM OBLIGATIONS - Narrative (Details)",
     "role": "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
     "shortName": "LONG-TERM OBLIGATIONS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "ia6972271e2cb4f179a778bd579050d45_I20190204",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i886ddae2179d4ed793345586cc440c4e_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423414 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)",
     "role": "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i444a95b00413472087a2a74f3d0ed812_D20200101-20200331",
      "decimals": "-5",
      "lang": null,
      "name": "amed:HealthInsuranceRetentionLimit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i444a95b00413472087a2a74f3d0ed812_D20200101-20200331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segments",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426415 - Disclosure - SEGMENT INFORMATION - Narrative (Details)",
     "role": "http://www.amedisys.com/role/SEGMENTINFORMATIONNarrativeDetails",
     "shortName": "SEGMENT INFORMATION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i444a95b00413472087a2a74f3d0ed812_D20200101-20200331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segments",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i444a95b00413472087a2a74f3d0ed812_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427416 - Disclosure - SEGMENT INFORMATION - Operating Income of Reportable Segments (Details)",
     "role": "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails",
     "shortName": "SEGMENT INFORMATION - Operating Income of Reportable Segments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i444a95b00413472087a2a74f3d0ed812_D20200101-20200331",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i156f24d3122641318de844c5586c409a_I20190225",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429417 - Disclosure - SHARE REPURCHASE Narrative (Details)",
     "role": "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails",
     "shortName": "SHARE REPURCHASE Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i156f24d3122641318de844c5586c409a_I20190225",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i444a95b00413472087a2a74f3d0ed812_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsToAcquireInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431418 - Disclosure - RELATED PARTY TRANSACTIONS Narrative (Details)",
     "role": "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails",
     "shortName": "RELATED PARTY TRANSACTIONS Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "iba4950c59f204d1fadc805bed37fde70_D20180101-20181231",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:PaymentsToAcquireInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i8b9efcf5de4c480e81af5d9bd1cdb30e_I20200327",
      "decimals": "-9",
      "first": true,
      "lang": null,
      "name": "amed:FundingForHealthcareProvidersIncludingHospitals",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433419 - Disclosure - SUBSEQUENT EVENT - Narrative (Details)",
     "role": "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails",
     "shortName": "SUBSEQUENT EVENT - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i8b9efcf5de4c480e81af5d9bd1cdb30e_I20200327",
      "decimals": "-9",
      "first": true,
      "lang": null,
      "name": "amed:FundingForHealthcareProvidersIncludingHospitals",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i444a95b00413472087a2a74f3d0ed812_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i444a95b00413472087a2a74f3d0ed812_D20200101-20200331",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:LaborAndRelatedExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i5070e06e0c374add9463ca31e59e3d55_I20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statement",
     "role": "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i5070e06e0c374add9463ca31e59e3d55_I20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i444a95b00413472087a2a74f3d0ed812_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i444a95b00413472087a2a74f3d0ed812_D20200101-20200331",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i444a95b00413472087a2a74f3d0ed812_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS",
     "role": "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS",
     "shortName": "NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i444a95b00413472087a2a74f3d0ed812_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i444a95b00413472087a2a74f3d0ed812_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i444a95b00413472087a2a74f3d0ed812_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i444a95b00413472087a2a74f3d0ed812_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112103 - Disclosure - ACQUISITIONS",
     "role": "http://www.amedisys.com/role/ACQUISITIONS",
     "shortName": "ACQUISITIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20200331.htm",
      "contextRef": "i444a95b00413472087a2a74f3d0ed812_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 63,
   "tag": {
    "amed_AccountsReceivablePortionDerivedFromMedicare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounts Receivable, Portion Derived From Medicare",
        "label": "Accounts Receivable, Portion Derived From Medicare",
        "terseLabel": "Accounts receivable derived from Medicare"
       }
      }
     },
     "localname": "AccountsReceivablePortionDerivedFromMedicare",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_AcquiredNamesOfBusinessMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Acquired Names of Business",
        "label": "Acquired Names of Business [Member]",
        "terseLabel": "Acquired Names of Business [Member]"
       }
      }
     },
     "localname": "AcquiredNamesOfBusinessMember",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ActualClaimsPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Actual Claims Payment",
        "label": "Actual Claims Payment",
        "terseLabel": "Actual claims payment"
       }
      }
     },
     "localname": "ActualClaimsPayment",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_AdditionalFundingDistributedToHealthcareProviders": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional funding distributed to healthcare providers provided by the Coronavirus Aid, Relief and Economic Security (CARES) Act",
        "label": "Additional Funding Distributed to Healthcare Providers",
        "terseLabel": "Additional Funding Distributed to Healthcare Providers"
       }
      }
     },
     "localname": "AdditionalFundingDistributedToHealthcareProviders",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_AmedisysCIAMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amedisys CIA [Member]",
        "label": "Amedisys CIA [Member]",
        "terseLabel": "Amedisys CIA"
       }
      }
     },
     "localname": "AmedisysCIAMember",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_AmendedCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amended Credit Agreement [Member]",
        "label": "Amended Credit Agreement [Member]",
        "terseLabel": "Amended Credit Agreement [Member]"
       }
      }
     },
     "localname": "AmendedCreditAgreementMember",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortization and Impairment of Operating Lease Right Of Use Asset",
        "label": "Amortization and Impairment of Operating Lease Right Of Use Asset",
        "terseLabel": "Amortization and impairment of operating lease right of use assets"
       }
      }
     },
     "localname": "AmortizationandImpairmentofOperatingLeaseRightOfUseAsset",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_AsanaHospiceAquisitionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asana Hospice Aquisition",
        "label": "Asana Hospice Aquisition [Member]",
        "terseLabel": "Asana Hospice Aquisition [Member]"
       }
      }
     },
     "localname": "AsanaHospiceAquisitionMember",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_AsanaHospiceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asana Hospice",
        "label": "Asana Hospice [Member]",
        "terseLabel": "Asana Hospice [Member]"
       }
      }
     },
     "localname": "AsanaHospiceMember",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_AseraCareHospiceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "AseraCare Hospice",
        "label": "AseraCare Hospice [Member]",
        "terseLabel": "AseraCare Hospice [Member]"
       }
      }
     },
     "localname": "AseraCareHospiceMember",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Current Asset",
        "terseLabel": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Current Asset"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses",
        "negatedLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits",
        "negatedLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities",
        "negatedLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating lease right of use assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating lease right of use assets",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating lease right of use assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_Businessacquisitionproformaoperatingincomeloss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The pro forma operating income (loss) for the period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business acquisition pro forma operating income loss",
        "terseLabel": "Operating income (loss)"
       }
      }
     },
     "localname": "Businessacquisitionproformaoperatingincomeloss",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_COVID19PPEMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "COVID-19 PPE",
        "label": "COVID-19 PPE [Member]",
        "terseLabel": "COVID-19 PPE [Member]"
       }
      }
     },
     "localname": "COVID19PPEMember",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_CapYearAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cap Year [Axis]",
        "label": "Cap Year [Axis]",
        "terseLabel": "Cap Year [Axis]"
       }
      }
     },
     "localname": "CapYearAxis",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amed_CapYearDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cap Year [Domain]",
        "label": "Cap Year [Domain]",
        "terseLabel": "Cap Year [Domain]"
       }
      }
     },
     "localname": "CapYearDomain",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_CapYearTwoThousandThirteenThroughTwoThousandTwentyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cap Year Two Thousand Thirteen Through Two Thousand Twenty [Member]",
        "label": "Cap Year Two Thousand Thirteen Through Two Thousand Twenty [Member]",
        "terseLabel": "Cap Year 2013 Through 2020"
       }
      }
     },
     "localname": "CapYearTwoThousandThirteenThroughTwoThousandTwentyMember",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_CashDistributionToNoncontrollingInterest": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payment of dividends or other distributions to noncontrolling interest holders.",
        "label": "Cash Distribution To Noncontrolling Interest",
        "negatedLabel": "Noncontrolling interest distribution"
       }
      }
     },
     "localname": "CashDistributionToNoncontrollingInterest",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_CashPaidForFinanceLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash paid for finance lease liabilities",
        "label": "Cash paid for finance lease liabilities",
        "terseLabel": "Cash paid for finance lease liabilities"
       }
      }
     },
     "localname": "CashPaidForFinanceLeaseLiabilities",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_CashPaidForOperatingLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash paid for operating lease liabilities",
        "label": "Cash paid for operating lease liabilities",
        "terseLabel": "Cash paid for operating lease liabilities"
       }
      }
     },
     "localname": "CashPaidForOperatingLeaseLiabilities",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_CertificateOfNeedMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Certificate of Need",
        "label": "Certificate of Need [Member]",
        "terseLabel": "Certificate of Need [Member]"
       }
      }
     },
     "localname": "CertificateOfNeedMember",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ChristianCareatHomeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Christian Care at Home [Member]",
        "label": "Christian Care at Home [Member]",
        "terseLabel": "Christian Care at Home"
       }
      }
     },
     "localname": "ChristianCareatHomeMember",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ClearwaterFloridaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Clearwater, Florida [Member]",
        "label": "Clearwater, Florida [Member]",
        "terseLabel": "Clearwater, Florida"
       }
      }
     },
     "localname": "ClearwaterFloridaMember",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_CompanysinsurancecarriersMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Company's insurance carriers [Member]",
        "label": "Company's insurance carriers [Member]",
        "terseLabel": "Company's insurance carriers [Member]"
       }
      }
     },
     "localname": "CompanysinsurancecarriersMember",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_CompassionateCareHospiceCIAMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Compassionate Care Hospice CIA [Member]",
        "label": "Compassionate Care Hospice CIA [Member]",
        "terseLabel": "Compassionate Care Hospice CIA"
       }
      }
     },
     "localname": "CompassionateCareHospiceCIAMember",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_CompassionateCareHospiceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Compassionate Care Hospice [Member]",
        "label": "Compassionate Care Hospice [Member]",
        "terseLabel": "Compassionate Care Hospice [Member]"
       }
      }
     },
     "localname": "CompassionateCareHospiceMember",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ConsolidatedInterestCoverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ratio of adjusted earnings before interest, taxes, depreciation and amortization to cash interest charges",
        "label": "Consolidated Interest Coverage Ratio",
        "terseLabel": "Consolidated interest coverage ratio"
       }
      }
     },
     "localname": "ConsolidatedInterestCoverageRatio",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "amed_ConsolidatedLeverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Consolidated Leverage Ratio",
        "label": "Consolidated Leverage Ratio",
        "terseLabel": "Consolidated Leverage Ratio"
       }
      }
     },
     "localname": "ConsolidatedLeverageRatio",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "amed_CorporateIntegrityAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Corporate Integrity Agreement Term",
        "label": "Corporate Integrity Agreement Term",
        "terseLabel": "Corporate integrity agreement term (years)"
       }
      }
     },
     "localname": "CorporateIntegrityAgreementTerm",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Credit Facility, Maximum Allowable Consolidated Leverage Ratio Multiple",
        "label": "Credit Facility Maximum Allowable Consolidated Leverage Ratio Multiple",
        "terseLabel": "Credit Facility Maximum Allowable Consolidated Leverage Ratio Multiple"
       }
      }
     },
     "localname": "CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "amed_Creditfacilitymaximumallowableconsolidatedleverageratio": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Credit facility maximum allowable consolidated leverage ratio as defined in the Company's Credit Agreement",
        "label": "Credit facility maximum allowable consolidated leverage ratio",
        "terseLabel": "Credit facility, maximum allowable consolidated leverage ratio"
       }
      }
     },
     "localname": "Creditfacilitymaximumallowableconsolidatedleverageratio",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "amed_DebtInstrumentByLeverageRatioTrancheFourMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, By Leverage Ratio, Tranche Four [Member]",
        "label": "Debt Instrument, By Leverage Ratio, Tranche Four [Member]",
        "terseLabel": "Consolidated Leverage Ratio: Less Than 0.75 to 1.0"
       }
      }
     },
     "localname": "DebtInstrumentByLeverageRatioTrancheFourMember",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_DebtInstrumentByLeverageRatioTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, By Leverage Ratio, Tranche One [Member]",
        "label": "Debt Instrument, By Leverage Ratio, Tranche One [Member]",
        "terseLabel": "Consolidated Leverage Ratio: Greater Than Equal To 3.00 to 1.0"
       }
      }
     },
     "localname": "DebtInstrumentByLeverageRatioTrancheOneMember",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_DebtInstrumentByLeverageRatioTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, By Leverage Ratio, Tranche Three [Member]",
        "label": "Debt Instrument, By Leverage Ratio, Tranche Three [Member]",
        "terseLabel": "Consolidated Leverage Ratio: Less Than 2.00 to 1.0 but Greater Than Equal To 0.75 to 1.0"
       }
      }
     },
     "localname": "DebtInstrumentByLeverageRatioTrancheThreeMember",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_DebtInstrumentByLeverageRatioTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, By Leverage Ratio, Tranche Two [Member]",
        "label": "Debt Instrument, By Leverage Ratio, Tranche Two [Member]",
        "terseLabel": "Consolidated Leverage Ratio: Less Than 3.00 to 1.0 but Greater Than Equal To 2.00 to 1.0"
       }
      }
     },
     "localname": "DebtInstrumentByLeverageRatioTrancheTwoMember",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_DebtInstrumentCarryingAmountExcludingFinanceLeases": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument Carrying Amount Excluding Finance Leases",
        "label": "Debt Instrument Carrying Amount Excluding Finance Leases",
        "terseLabel": "Debt Instrument Carrying Amount Excluding Finance Leases"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmountExcludingFinanceLeases",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument Interest Additional Interest Above Eurodollar Rate",
        "label": "Debt Instrument Interest Additional Interest Above Eurodollar Rate",
        "terseLabel": "Additional interest rate above Eurodollar rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestAdditionalInterestAboveEurodollarRate",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument Interest Additional Interest Above Federal Fund Rate",
        "label": "Debt Instrument Interest Additional Interest Above Federal Fund Rate",
        "terseLabel": "Additional interest rate above Federal Fund rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestAdditionalInterestAboveFederalFundRate",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_DebtInstrumentInterestRateatPeriodEnd": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument Interest Rate at Period End",
        "label": "Debt Instrument Interest Rate at Period End",
        "terseLabel": "Debt Instrument Interest Rate at Period End"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateatPeriodEnd",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_DebtInstrumentPeriodicPaymentPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The percentage of the Term Loan that is required as periodic payments including both interest and principal payments",
        "label": "Debt Instrument Periodic Payment Percentage",
        "terseLabel": "Debt Instrument Periodic Payment Percentage"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentPercentage",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_DebtIssuanceCostsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for debt issuance costs.",
        "label": "Debt Issuance Costs Policy [Policy Text Block]",
        "terseLabel": "Debt Issuance Costs"
       }
      }
     },
     "localname": "DebtIssuanceCostsPolicyPolicyTextBlock",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_Discountedclosingstockprice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discounted closing stock price",
        "label": "Discounted closing stock price",
        "terseLabel": "Discounted closing stock price"
       }
      }
     },
     "localname": "Discountedclosingstockprice",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "amed_EastTennesseePersonalCareServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "East Tennessee Personal Care Services [Member]",
        "label": "East Tennessee Personal Care Services [Member]",
        "terseLabel": "East Tennessee Personal Care Services"
       }
      }
     },
     "localname": "EastTennesseePersonalCareServicesMember",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_EpisodeOfCareAsEpisodicBasedRevenueDuration": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description containing the number of days in a home health episode of care.",
        "label": "Episode Of Care As Episodic Based Revenue Duration",
        "terseLabel": "Episode of care as episodic-based revenue (days)"
       }
      }
     },
     "localname": "EpisodeOfCareAsEpisodicBasedRevenueDuration",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Impact of Write Off of Other Comprehensive Income",
        "label": "Equity Impact of Write Off of Other Comprehensive Income",
        "negatedLabel": "Write-off of other comprehensive income"
       }
      }
     },
     "localname": "EquityImpactOfWriteOffOfOtherComprehensiveIncome",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_EquityImpactofRepurchaseofNoncontrollingInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Impact of Repurchase of Noncontrolling Interest",
        "label": "Equity Impact of Repurchase of Noncontrolling Interest",
        "negatedLabel": "Repurchase of noncontrolling interest"
       }
      }
     },
     "localname": "EquityImpactofRepurchaseofNoncontrollingInterest",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_ErrorRatePercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Error Rate Percentage",
        "label": "Error Rate Percentage",
        "terseLabel": "Error rate (percent)"
       }
      }
     },
     "localname": "ErrorRatePercentage",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Estimate of obligations due Medicare upon demand due to overages for the inpatient cap and/or overall payment cap.",
        "label": "Estimated Amount Due Back To Medicare In Other Accrued Liabilities",
        "terseLabel": "Estimated amounts due back to Medicare"
       }
      }
     },
     "localname": "EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_ExtrapolatedMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Extrapolated [Member]",
        "label": "Extrapolated [Member]",
        "terseLabel": "Extrapolated"
       }
      }
     },
     "localname": "ExtrapolatedMember",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_FinancialInstrumentDetailsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Financial instrument details, table.",
        "label": "Financial Instrument Details [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FinancialInstrumentDetailsTableTextBlock",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_FirstThresholdOfTherapyServicesRequired": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description containing the number of visits related to the first threshold of therapy services required.",
        "label": "First Threshold Of Therapy Services Required",
        "terseLabel": "First threshold of therapy services required (visits)"
       }
      }
     },
     "localname": "FirstThresholdOfTherapyServicesRequired",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Five Hundred Fifty Million Revolving Credit Facility [Member]",
        "label": "Five Hundred Fifty Million Revolving Credit Facility [Member]",
        "terseLabel": "550 Million Revolving Credit Facility [Member]"
       }
      }
     },
     "localname": "FiveHundredFiftyMillionRevolvingCreditFacilityMember",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_FloridaZpicRevenueReduction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reduction in revenue as a result of the Florida ZPIC audit",
        "label": "Florida Zpic Revenue Reduction",
        "terseLabel": "Florida ZPIC revenue reduction"
       }
      }
     },
     "localname": "FloridaZpicRevenueReduction",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_FundingForHealthcareProvidersIncludingHospitals": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Funding for healthcare providers, including hospitals provided by the Coronavirus Aid, Relief and Economic Security (CARES) Act",
        "label": "Funding for Healthcare Providers, Including Hospitals",
        "terseLabel": "Funding for Healthcare Providers, Including Hospitals"
       }
      }
     },
     "localname": "FundingForHealthcareProvidersIncludingHospitals",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Funding immediately distributed to healthcare providers based on their 2019 Medicare Fee-For-Service reimbursements provided by the Coronavirus Aid, Relief and Economic Security (CARES) Act",
        "label": "Funding Immediately Distributed to Healthcare Providers Based on Their 2019 Medicare Fee-For-Service Reimbursements",
        "terseLabel": "Funding Immediately Distributed to Healthcare Providers Based on Their 2019 Medicare Fee-For-Service Reimbursements"
       }
      }
     },
     "localname": "FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_FundingReceivedFromCARESAct": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Funding received by the Company from the Coronavirus Aid Relief and Economic Security (CARES) Act",
        "label": "Funding Received From CARES Act",
        "terseLabel": "Funding Received From CARES Act"
       }
      }
     },
     "localname": "FundingReceivedFromCARESAct",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_HealthInsuranceRetentionLimit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum potential amount of future payments the entity could be required to make related to a specific Health Insurance Claim.",
        "label": "Health Insurance Retention Limit",
        "terseLabel": "Health insurance retention limit"
       }
      }
     },
     "localname": "HealthInsuranceRetentionLimit",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_HealthcareanalyticscompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Healthcare analytics company [Member]",
        "label": "Healthcare analytics company [Member]",
        "terseLabel": "Healthcare analytics company [Member]"
       }
      }
     },
     "localname": "HealthcareanalyticscompanyMember",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HistoricalCollectionRateFromMedicare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Historical collection rate from Medicare.",
        "label": "Historical Collection Rate From Medicare",
        "terseLabel": "Historical collection rate from Medicare"
       }
      }
     },
     "localname": "HistoricalCollectionRateFromMedicare",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_HomeHealthMedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Home Health Medicare [Member]",
        "label": "Home Health Medicare [Member]",
        "terseLabel": "Home Health Medicare [Member]"
       }
      }
     },
     "localname": "HomeHealthMedicareMember",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HomeHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Home Health [Member]",
        "label": "Home Health [Member]",
        "terseLabel": "Home Health [Member]"
       }
      }
     },
     "localname": "HomeHealthMember",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HomeHealthNonMedicareEpisodicBasedMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Home Health Non-Medicare - Episodic Based [Member]",
        "label": "Home Health Non-Medicare - Episodic Based [Member]",
        "terseLabel": "Home Health Non-Medicare - Episodic Based [Member]"
       }
      }
     },
     "localname": "HomeHealthNonMedicareEpisodicBasedMember",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HomeHealthNonMedicareNonEpisodicBasedMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Home Health Non-Medicare - Non-Episodic Based [Member]",
        "label": "Home Health Non-Medicare - Non-Episodic Based [Member]",
        "terseLabel": "Home Health Non-Medicare - Non-Episodic Based [Member]"
       }
      }
     },
     "localname": "HomeHealthNonMedicareNonEpisodicBasedMember",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HospiceMedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hospice Medicare [Member]",
        "label": "Hospice Medicare [Member]",
        "terseLabel": "Hospice Medicare [Member]"
       }
      }
     },
     "localname": "HospiceMedicareMember",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HospiceMedicareRevenueRateAccountedForRoutineCare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description containing the percentage of the entity's Hospice net Medicare service revenue that is derived from routine care.",
        "label": "Hospice Medicare Revenue Rate Accounted For Routine Care",
        "terseLabel": "Hospice Medicare revenue rate accounted for routine care"
       }
      }
     },
     "localname": "HospiceMedicareRevenueRateAccountedForRoutineCare",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_HospiceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hospice [Member]",
        "label": "Hospice [Member]",
        "terseLabel": "Hospice [Member]"
       }
      }
     },
     "localname": "HospiceMember",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HospiceNonMedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hospice Non-Medicare [Member]",
        "label": "Hospice Non-Medicare [Member]",
        "terseLabel": "Hospice Non-Medicare [Member]"
       }
      }
     },
     "localname": "HospiceNonMedicareMember",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating lease liabilities",
        "label": "Increase (Decrease) In Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of increase (decrease) In Operating Lease Right Of Use Asset",
        "label": "Increase (Decrease) In Operating Lease Right Of Use Asset",
        "terseLabel": "Operating lease right of use assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_IndemnificationAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount to be reimbursed if and when certain assumed liabilities are paid",
        "label": "Indemnification Amount",
        "terseLabel": "Indemnification amount"
       }
      }
     },
     "localname": "IndemnificationAmount",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_InfinityHomeCareMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Infinity HomeCare [Member]",
        "label": "Infinity HomeCare [Member]",
        "terseLabel": "Infinity HomeCare"
       }
      }
     },
     "localname": "InfinityHomeCareMember",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_InternalAuditComplianceReviewMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Internal Audit Compliance Review [Member]",
        "label": "Internal Audit Compliance Review [Member]",
        "terseLabel": "Internal Audit Compliance Review [Member]"
       }
      }
     },
     "localname": "InternalAuditComplianceReviewMember",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_KKRShareRepurchaseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "KKR Share Repurchase [Member]",
        "label": "KKR Share Repurchase [Member]",
        "terseLabel": "KKR Share Repurchase"
       }
      }
     },
     "localname": "KKRShareRepurchaseMember",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_LakelandFloridaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lakeland, Florida [Member]",
        "label": "Lakeland, Florida [Member]",
        "terseLabel": "Lakeland, Florida"
       }
      }
     },
     "localname": "LakelandFloridaMember",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating lease, Reductions to ROU assets resulting from reductions to lease obligations",
        "label": "Lessee, Operating lease, Reductions to ROU assets resulting from reductions to lease obligations",
        "terseLabel": "Reductions to right of use assets resulting from reductions to operating lease liabilities"
       }
      }
     },
     "localname": "LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_LetterOfCreditFee": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the letters of credit, for the letters of credit",
        "label": "Letter Of Credit Fee",
        "terseLabel": "Letter Of Credit Fee"
       }
      }
     },
     "localname": "LetterOfCreditFee",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_LineOfCreditFacilityAdditionalBorrowingCapacity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line Of Credit Facility Additional Borrowing Capacity",
        "label": "Line Of Credit Facility Additional Borrowing Capacity",
        "terseLabel": "Credit facility, maximum additional borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityAdditionalBorrowingCapacity",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Loss Contingency, Receivable, Noncurrent, Related To Amounts Withheld Prior To August 2009",
        "label": "Loss Contingency, Receivable, Noncurrent, Related To Amounts Withheld Prior To August 2009",
        "terseLabel": "Indemnity receivable related to amounts withheld prior to August 2009"
       }
      }
     },
     "localname": "LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_LowUtilizationPaymentAdjustmentNumberOfVisits": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description containing the visit threshold for a low utilization payment adjustment.",
        "label": "Low Utilization Payment Adjustment Number Of Visits",
        "terseLabel": "Low utilization payment adjustment, maximum number of visits"
       }
      }
     },
     "localname": "LowUtilizationPaymentAdjustmentNumberOfVisits",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_MajorSinglePayorCustomerMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Major Single Payor Customer [Member]",
        "label": "Major Single Payor Customer [Member]",
        "terseLabel": "Single Payor"
       }
      }
     },
     "localname": "MajorSinglePayorCustomerMember",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.",
        "label": "Maximum Days To Submit Final Bill From Date Request For Anticipated Payment Was Paid",
        "terseLabel": "Maximum days to submit final bill from the date the request for anticipated payment was paid"
       }
      }
     },
     "localname": "MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description containing the number of days from the start of the period of care in which the final bill must be submitted to Medicare.",
        "label": "Maximum Days To Submit Final Bill From Start Of Period of Care",
        "terseLabel": "Maximum days to submit final bill from the start of episode"
       }
      }
     },
     "localname": "MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_MaximumPercentOwnershipForCostMethodPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description containing the percentage ownership required in order for an investment to be treated under the cost method of accounting in the entity's financial statements.",
        "label": "Maximum Percent Ownership For Cost Method Percent",
        "terseLabel": "Maximum ownership percentage for cost method investment (percent)"
       }
      }
     },
     "localname": "MaximumPercentOwnershipForCostMethodPercent",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_MaximumPercentOwnershipForEquityMethodPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description containing the percentage ownership required in order for an investment to be treated under the equity method of accounting in the entity's financial statements.",
        "label": "Maximum Percent Ownership For Equity Method Percent",
        "terseLabel": "Maximum ownership percentage for equity method investment (percent)"
       }
      }
     },
     "localname": "MaximumPercentOwnershipForEquityMethodPercent",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_MedalogixMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Medalogix [Member]",
        "label": "Medalogix [Member]",
        "terseLabel": "Medalogix [Member]"
       }
      }
     },
     "localname": "MedalogixMember",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_MedicareLicenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Medicare license",
        "label": "Medicare license [Member]",
        "terseLabel": "Medicare license [Member]"
       }
      }
     },
     "localname": "MedicareLicenseMember",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_MedicareRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Medicare Revenue [Member]",
        "label": "Medicare Revenue [Member]",
        "terseLabel": "Medicare Revenue"
       }
      }
     },
     "localname": "MedicareRevenueMember",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_MinimumPercentOwnershipForControllingInterestPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description containing the percentage ownership required in order for a variable interest entity (VIE) to be consolidated in the entity's financial statements.",
        "label": "Minimum Percent Ownership For Controlling Interest Percent",
        "terseLabel": "Minimum ownership percentage for controlling interest (percent)"
       }
      }
     },
     "localname": "MinimumPercentOwnershipForControllingInterestPercent",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_MorgantownWestVirginiaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Morgantown, West Virginia [Member]",
        "label": "Morgantown, West Virginia [Member]",
        "terseLabel": "Morgantown, West Virginia"
       }
      }
     },
     "localname": "MorgantownWestVirginiaMember",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_NetServiceRevenuePeriodOfCarePaymentRateDuration": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.",
        "label": "Net Service Revenue, Period of Care Payment Rate Duration",
        "terseLabel": "Net service revenue episode payment rate (days)"
       }
      }
     },
     "localname": "NetServiceRevenuePeriodOfCarePaymentRateDuration",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amed_NonMedicareRevenueTermRates": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Non-Medicare Revenue Term Rates as a percentage of Medicare Term Rates",
        "label": "Non-Medicare Revenue Term Rates",
        "terseLabel": "Non-Medicare revenue term rates"
       }
      }
     },
     "localname": "NonMedicareRevenueTermRates",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_NonVestedStockAndStockUnits": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Non vested stock and stock units.",
        "label": "Non Vested Stock And Stock Units",
        "terseLabel": "Non-vested stock and stock units (shares)"
       }
      }
     },
     "localname": "NonVestedStockAndStockUnits",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "amed_NumberOfBeneficiaries": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of beneficiaries who received services",
        "label": "Number of beneficiaries",
        "terseLabel": "Number of beneficiaries"
       }
      }
     },
     "localname": "NumberOfBeneficiaries",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_NumberOfClaimsSubmittedBySubsidiary": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of claims submitted by subsidiary.",
        "label": "Number Of Claims Submitted By Subsidiary",
        "terseLabel": "Number of claims submitted by subsidiary"
       }
      }
     },
     "localname": "NumberOfClaimsSubmittedBySubsidiary",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_Numberofpatients": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of patients",
        "label": "Number of patients",
        "terseLabel": "Number of patients"
       }
      }
     },
     "localname": "Numberofpatients",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_OneHundredMillionTermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "100 Million Term Loan [Member]",
        "label": "One Hundred Million Term Loan [Member]",
        "terseLabel": "100 Million Term Loan"
       }
      }
     },
     "localname": "OneHundredMillionTermLoanMember",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_OneHundredSeventyFiveMillionTermLoanFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "One Hundred Seventy Five Million Term Loan Facility [Member]",
        "label": "One Hundred Seventy Five Million Term Loan Facility [Member]",
        "terseLabel": "One Hundred Seventy Five Million Term Loan Facility [Member]"
       }
      }
     },
     "localname": "OneHundredSeventyFiveMillionTermLoanFacilityMember",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_OperatingCareCenters": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description containing the number of care centers owned by the entity as of the balance sheet date.",
        "label": "Operating Care Centers",
        "terseLabel": "Number of owned and operated care centers"
       }
      }
     },
     "localname": "OperatingCareCenters",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_ParkersburgWestVirginiaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Parkersburg, West Virginia [Member]",
        "label": "Parkersburg, West Virginia [Member]",
        "terseLabel": "Parkersburg, West Virginia"
       }
      }
     },
     "localname": "ParkersburgWestVirginiaMember",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_PaymentsForRepurchaseOfNoncontrollingInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow during the period for redemption of noncontrolling interests.",
        "label": "Payments For Repurchase Of Noncontrolling Interest",
        "negatedLabel": "Repurchase of noncontrolling interest"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfNoncontrollingInterest",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_Paymentsrelatedtotaxassetandworkingcapital": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments related to tax asset and working capital",
        "label": "Payments related to tax asset and working capital",
        "terseLabel": "Payments related to tax asset and working capital"
       }
      }
     },
     "localname": "Paymentsrelatedtotaxassetandworkingcapital",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_PayorClassAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payor Class [Axis]",
        "label": "Payor Class [Axis]",
        "terseLabel": "Payor Class [Axis]"
       }
      }
     },
     "localname": "PayorClassAxis",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amed_PayorClassDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Payor Class [Axis]",
        "label": "Payor Class [Domain]",
        "terseLabel": "Payor Class [Domain]"
       }
      }
     },
     "localname": "PayorClassDomain",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_PayorsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payors [Axis]",
        "label": "Payors [Axis]",
        "terseLabel": "Payors [Axis]"
       }
      }
     },
     "localname": "PayorsAxis",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amed_PayorsDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Payors [Axis]",
        "label": "Payors [Domain]",
        "terseLabel": "Payors [Domain]"
       }
      }
     },
     "localname": "PayorsDomain",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of adjusted EBITDA that guarantor subsidiaries represent",
        "label": "Percentage Of Earnings Before Interest Taxes Depreciation And Amortization From Subsidiaries",
        "terseLabel": "Percentage of adjusted EBITDA that guarantor subsidiaries represent"
       }
      }
     },
     "localname": "PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_PercentageOfPatientReceivablesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of patient receivables outstanding.",
        "label": "Percentage Of Patient Receivables Outstanding",
        "terseLabel": "Percentage of patient receivables outstanding"
       }
      }
     },
     "localname": "PercentageOfPatientReceivablesOutstanding",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of consolidated net revenues and adjusted EBITDA that guarantor wholly-owned subsidiaries represent",
        "label": "Percentage Of Revenue And Of Earnings Before Interest Taxes Depreciation And Amortization From Wholly Owned Subsidiaries",
        "terseLabel": "Percentage of consolidated revenue and adjusted EBITDA that guarantor wholly-owned subsidiaries represent"
       }
      }
     },
     "localname": "PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_PercentageOfTotalReimbursementOfOutlierPayment": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage at which total reimbursement is capped if cost of care is unusually costly.",
        "label": "Percentage Of Total Reimbursement Of Outlier Payment",
        "terseLabel": "Percentage of total reimbursement of outlier payment"
       }
      }
     },
     "localname": "PercentageOfTotalReimbursementOfOutlierPayment",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_PercentageofSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of Shares Outstanding",
        "label": "Percentage of Shares Outstanding",
        "terseLabel": "Percentage of shares outstanding"
       }
      }
     },
     "localname": "PercentageofSharesOutstanding",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_Percentageofclosingstockprice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of closing stock price",
        "label": "Percentage of closing stock price",
        "terseLabel": "Percentage of closing stock price"
       }
      }
     },
     "localname": "Percentageofclosingstockprice",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_PeriodOfCareAsEpisodicBasedRevenueDuration": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description containing the number of days in a home health period of care using PDGM",
        "label": "Period of Care As Episodic Based Revenue Duration",
        "terseLabel": "Period of care as episodic-based revenue (days)"
       }
      }
     },
     "localname": "PeriodOfCareAsEpisodicBasedRevenueDuration",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amed_PersonalCareMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Personal Care [Member]",
        "label": "Personal Care [Member]",
        "terseLabel": "Personal Care"
       }
      }
     },
     "localname": "PersonalCareMember",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_PriorCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Prior Credit Agreement [Member]",
        "label": "Prior Credit Agreement [Member]",
        "terseLabel": "Prior Credit Agreement [Member]"
       }
      }
     },
     "localname": "PriorCreditAgreementMember",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ProceedsFromBorrowingsUnderTermLoan": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from borrowings under the term loan.",
        "label": "Proceeds From Borrowings Under Term Loan",
        "terseLabel": "Proceeds from borrowings under term loan"
       }
      }
     },
     "localname": "ProceedsFromBorrowingsUnderTermLoan",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_ProceedsReceivedFromLoanPartyOfSubsidiary": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Proceeds Received From Loan Party Of Subsidiary",
        "label": "Proceeds Received From Loan Party Of Subsidiary",
        "terseLabel": "Proceeds Received From Loan Party Of Subsidiary"
       }
      }
     },
     "localname": "ProceedsReceivedFromLoanPartyOfSubsidiary",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_ProfessionalLiabilityInsuranceRetentionLimit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum potential amount of future payments the entity could be required to make related to a specific Professional Liability Claim.",
        "label": "Professional Liability Insurance Retention Limit",
        "terseLabel": "Professional liability insurance retention limit"
       }
      }
     },
     "localname": "ProfessionalLiabilityInsuranceRetentionLimit",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_PromissoryNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Promissory Notes [Member]",
        "label": "Promissory Notes [Member]",
        "terseLabel": "Promissory Notes [Member]"
       }
      }
     },
     "localname": "PromissoryNotesMember",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description containing the percentage of estimated payment that is requested at the start of care for an initial period of care.",
        "label": "Rate Of Request For Anticipated Payment Submitted For Initial Period Of Care",
        "terseLabel": "Rate of request for anticipated payment submitted for the initial episode of care"
       }
      }
     },
     "localname": "RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description containing the percentage of estimated payment that is requested at the start of care for any subsequent episodes of care.",
        "label": "Rate Of Request For Anticipated Payment Submitted For Subsequent Episodes Of Care",
        "terseLabel": "Rate of request for anticipated payment submitted for subsequent episodes of care"
       }
      }
     },
     "localname": "RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_RecoveryAmountOfOverpaymentMadeToSubsidiary": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Recovery amount of the overpayment made to the subsidiary.",
        "label": "Recovery Amount Of Overpayment Made To Subsidiary",
        "terseLabel": "Recovery amount of overpayment made to subsidiary"
       }
      }
     },
     "localname": "RecoveryAmountOfOverpaymentMadeToSubsidiary",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Recovery amount of overpayment made to subsidiary including interest",
        "label": "Recovery Amount of Overpayment Made To Subsidiary Including Interest",
        "terseLabel": "Recovery amount of overpayment made to subsidiary including interest"
       }
      }
     },
     "localname": "RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Recovery amount of over payment made to subsidiary including interest withheld",
        "label": "Recovery Amount Of Over Payment Made To Subsidiary Including Interest Withheld",
        "terseLabel": "Recovery amount of over payment made to subsidiary including interest withheld"
       }
      }
     },
     "localname": "Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_RevenueAdjustmentToMedicareRevenue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description of the provisions that reduce the amount of Medicare revenue recognized by the entity.",
        "label": "Revenue Adjustment To Medicare Revenue",
        "terseLabel": "Revenue adjustment to Medicare revenue"
       }
      }
     },
     "localname": "RevenueAdjustmentToMedicareRevenue",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue by payor class as a percentage of total net service revenue",
        "label": "Revenue by payor class as a percentage of total net service revenue",
        "terseLabel": "Revenue by payor class as a percentage of total net service revenue"
       }
      }
     },
     "localname": "Revenuebypayorclassasapercentageoftotalnetservicerevenue",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_RevolvingCreditFacilityTotal": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "label": "Revolving Credit Facility Total",
        "terseLabel": "Revolving Credit Facility Total"
       }
      }
     },
     "localname": "RevolvingCreditFacilityTotal",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_RoseRockHealthcareMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "RoseRock Healthcare [Member]",
        "label": "RoseRock Healthcare [Member]",
        "terseLabel": "RoseRock Healthcare [Member]"
       }
      }
     },
     "localname": "RoseRockHealthcareMember",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_SafeguardZoneProgramIntegrityContractorMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Safeguard Zone Program Integrity Contractor [Member]",
        "label": "Safeguard Zone Program Integrity Contractor [Member]",
        "terseLabel": "Safeguard Zone Program Integrity Contractor"
       }
      }
     },
     "localname": "SafeguardZoneProgramIntegrityContractorMember",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_SecondThresholdOfServicesRequired": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description containing the number of visits related to the second threshold of therapy services required.",
        "label": "Second Threshold Of Services Required",
        "terseLabel": "Second threshold of therapy services required (visits)"
       }
      }
     },
     "localname": "SecondThresholdOfServicesRequired",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_SecuritiesClassActionLawsuitMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities Class Action Lawsuit [Member]",
        "label": "Securities Class Action Lawsuit [Member]",
        "terseLabel": "Securities Class Action Lawsuit [Member]"
       }
      }
     },
     "localname": "SecuritiesClassActionLawsuitMember",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_SecuritiesClassActionLawsuitsettlement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Charge related to Securities Class Action Lawsuit settlement",
        "label": "Securities Class Action Lawsuit settlement",
        "terseLabel": "Securities Class Action Lawsuit settlement, net"
       }
      }
     },
     "localname": "SecuritiesClassActionLawsuitsettlement",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_ShareRepurchaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share Repurchase [Axis]",
        "label": "Share Repurchase [Axis]",
        "terseLabel": "Share Repurchase [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseAxis",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amed_ShareRepurchaseDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Share Repurchase [Axis]",
        "label": "Share Repurchase [Domain]",
        "terseLabel": "Share Repurchase [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseDomain",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ShareRepurchaseLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Line Items] for Share Repurchase [Table]",
        "label": "Share Repurchase [Line Items]",
        "terseLabel": "Share Repurchase [Line Items]"
       }
      }
     },
     "localname": "ShareRepurchaseLineItems",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amed_ShareRepurchaseTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share Repurchase [Table]",
        "label": "Share Repurchase [Table]",
        "terseLabel": "Share Repurchase [Table]"
       }
      }
     },
     "localname": "ShareRepurchaseTable",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period to employees as employer's matching contribution to the company's 401(K) plan",
        "label": "Stock Issued During Period Shares Four Zero One K Employer Match",
        "terseLabel": "Issuance of stock - 401(k) plan (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued during the period to employees as employer's matching contribution to the company's 401(K) plan",
        "label": "Stock Issued During Period Value Four Zero One K Employer Match",
        "terseLabel": "Issuance of stock - 401(k) plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_SupplementalDisclosuresOfNonCashActivityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Supplemental Disclosures of Non-Cash Activity",
        "label": "Supplemental Disclosures of Non-Cash Activity [Abstract]",
        "terseLabel": "Supplemental Disclosures of Non-Cash Activity:"
       }
      }
     },
     "localname": "SupplementalDisclosuresOfNonCashActivityAbstract",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "amed_SurrenderedShares": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shares of common stock surrendered by certain employees to satisfy obligations in connection with the vesting of stock. Shares held in Treasury Stock at cost.",
        "label": "Surrendered Shares",
        "negatedLabel": "Surrendered Shares"
       }
      }
     },
     "localname": "SurrenderedShares",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_SwingLineLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Swing Line Loan [Member]",
        "label": "Swing Line Loan [Member]",
        "terseLabel": "Swing Line Loan [Member]"
       }
      }
     },
     "localname": "SwingLineLoanMember",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ThirdThresholdOfTherapyServicesRequired": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description containing the number of visits related to the third threshold of therapy services required.",
        "label": "Third Threshold Of Therapy Services Required",
        "terseLabel": "Third threshold of therapy services required (visits)"
       }
      }
     },
     "localname": "ThirdThresholdOfTherapyServicesRequired",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_TotalLeverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ratio of debt to earnings before interest, taxes, depreciation and amortization.",
        "label": "Total Leverage Ratio",
        "terseLabel": "Consolidated leverage ratio"
       }
      }
     },
     "localname": "TotalLeverageRatio",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "amed_TwoHundredMillionRevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two Hundred Million Revolving Credit Facility [Member]",
        "label": "Two Hundred Million Revolving Credit Facility [Member]",
        "terseLabel": "200 Million Revolving Credit Facility"
       }
      }
     },
     "localname": "TwoHundredMillionRevolvingCreditFacilityMember",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_TypeofEquityMethodInvestmentAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of Equity Method Investment [Axis]",
        "label": "Type of Equity Method Investment [Axis]",
        "terseLabel": "Type of Equity Method Investment [Axis]"
       }
      }
     },
     "localname": "TypeofEquityMethodInvestmentAxis",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amed_TypeofEquityMethodInvestmentDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Type of Equity Method Investment [Axis]",
        "label": "Type of Equity Method Investment [Domain]",
        "terseLabel": "Type of Equity Method Investment [Domain]"
       }
      }
     },
     "localname": "TypeofEquityMethodInvestmentDomain",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_UnfavorableMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Unfavorable [Member]",
        "terseLabel": "Unfavorable"
       }
      }
     },
     "localname": "UnfavorableMember",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_UsDepartmentOfJusticeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "US Department of Justice",
        "label": "US Department of Justice [Member]",
        "terseLabel": "US Department of Justice"
       }
      }
     },
     "localname": "UsDepartmentOfJusticeMember",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_WorkersCompensationInsuranceRetentionLimit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum potential amount of future payments the entity could be required to make related to a specific Workers' Compensation Insurance Claim.",
        "label": "Workers Compensation Insurance Retention Limit",
        "terseLabel": "Workers compensation insurance retention limit"
       }
      }
     },
     "localname": "WorkersCompensationInsuranceRetentionLimit",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_WriteOffOfOtherComprehensiveIncome": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Write off of Other Comprehensive Income",
        "label": "Write off of Other Comprehensive Income",
        "negatedLabel": "Write-off of other comprehensive income"
       }
      }
     },
     "localname": "WriteOffOfOtherComprehensiveIncome",
     "nsuri": "http://www.amedisys.com/20200331",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Street Name"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Suite"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of each class"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Name of each exchange on which registered"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r135",
      "r193",
      "r196",
      "r318"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r134",
      "r193",
      "r195",
      "r317",
      "r320",
      "r321"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "stpr_FL": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "FLORIDA",
        "terseLabel": "Florida"
       }
      }
     },
     "localname": "FL",
     "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_MA": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "MASSACHUSETTS",
        "terseLabel": "Massachusetts"
       }
      }
     },
     "localname": "MA",
     "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_SC": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "SOUTH CAROLINA",
        "terseLabel": "South Carolina"
       }
      }
     },
     "localname": "SC",
     "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_TN": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "TENNESSEE",
        "terseLabel": "Tennessee [Member]"
       }
      }
     },
     "localname": "TN",
     "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "Accounting Standards Update 2016-02 [Member]"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r3",
      "r17",
      "r137",
      "r138",
      "r194"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Patient accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r25",
      "r163"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Property and equipment, accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r43",
      "r44",
      "r45"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r42",
      "r45",
      "r46",
      "r233"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Weighted-average amortization period"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by new accounting pronouncement.",
        "label": "Adjustments for New Accounting Pronouncements [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r201",
      "r202",
      "r205",
      "r206"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Non-cash compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllOtherSegmentsMember": {
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items.",
        "label": "Other Segments [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "AllOtherSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r81",
      "r254"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of deferred debt issuance costs/debt discount"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities (shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r130",
      "r291",
      "r304"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r7",
      "r41"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BaseRateMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum rate investor will accept.",
        "label": "Base Rate [Member]",
        "terseLabel": "Base Rate [Member]"
       }
      }
     },
     "localname": "BaseRateMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r215",
      "r216"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic": {
     "auth_ref": [
      "r213",
      "r214"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Earnings Per Share, Basic",
        "terseLabel": "Basic earnings (loss) per share"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaEarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted": {
     "auth_ref": [
      "r213",
      "r214"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Earnings Per Share, Diluted",
        "terseLabel": "Diluted earnings (loss) per share"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaEarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": {
     "auth_ref": [
      "r213",
      "r214"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.",
        "label": "Business Acquisition, Pro Forma Information [Table Text Block]",
        "terseLabel": "Business Acquisition, Pro Forma Information"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": {
     "auth_ref": [
      "r213",
      "r214"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Net Income (Loss)",
        "terseLabel": "Net income"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaNetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaRevenue": {
     "auth_ref": [
      "r213",
      "r214"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.",
        "label": "Business Acquisition, Pro Forma Revenue",
        "terseLabel": "Net service revenue"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaRevenue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r221",
      "r222",
      "r223"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Total purchase price for acquisition"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "ACQUISITIONS"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationIntegrationRelatedCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.",
        "label": "Business Combination, Integration Related Costs",
        "terseLabel": "Business Combination, Integration Related Costs"
       }
      }
     },
     "localname": "BusinessCombinationIntegrationRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "auth_ref": [
      "r218"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of assets acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "auth_ref": [
      "r218"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "auth_ref": [
      "r218"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "negatedLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r207",
      "r218"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "negatedLabel": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r218"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "terseLabel": "Acquisition, other intangibles recorded"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "auth_ref": [
      "r218"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "negatedLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r217",
      "r218"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt": {
     "auth_ref": [
      "r218"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt",
        "negatedLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "auth_ref": [
      "r217",
      "r218"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r87",
      "r212"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalLeaseObligationsMember": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A borrowing recorded for a lease meeting the criteria for capitalization. A lease is defined as an agreement conveying the right to use property, plant, or equipment (land or depreciable assets) usually for a stated period of time.",
        "label": "Capital Lease Obligations [Member]",
        "terseLabel": "Finance leases [Member]"
       }
      }
     },
     "localname": "CapitalLeaseObligationsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAcquiredFromAcquisition": {
     "auth_ref": [
      "r62"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).",
        "label": "Cash Acquired from Acquisition",
        "terseLabel": "Cash Acquired from Acquisition"
       }
      }
     },
     "localname": "CashAcquiredFromAcquisition",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r23",
      "r83"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r8",
      "r84",
      "r87",
      "r290"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r76",
      "r83",
      "r86"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r76",
      "r250"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r36",
      "r170",
      "r296",
      "r311"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies\u2014Note 5"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r169",
      "r177"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, authorized (shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, issued (shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r16",
      "r184"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, outstanding (shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValueOutstanding": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.",
        "label": "Common Stock, Value, Outstanding",
        "terseLabel": "Common stock, $0.001 par value, 60,000,000 shares authorized; 36,746,554 and 36,638,021 shares issued; and 32,370,345 and 32,284,051 shares outstanding"
       }
      }
     },
     "localname": "CommonStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r113",
      "r114",
      "r247",
      "r248"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r113",
      "r114",
      "r247",
      "r248",
      "r319"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r113",
      "r114",
      "r247",
      "r248",
      "r319"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]",
        "verboseLabel": "Organization, Consolidation and Presentation of Financial Statements [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r113",
      "r114",
      "r247",
      "r248"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Percent of net services revenue"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r111",
      "r113",
      "r114",
      "r115",
      "r247",
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r113",
      "r114",
      "r247",
      "r248"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r87",
      "r229",
      "r237",
      "r238"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of service, excluding depreciation and amortization"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "terseLabel": "Operating expenses",
        "totalLabel": "Operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "LONG-TERM OBLIGATIONS"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r11",
      "r12",
      "r13",
      "r292",
      "r293",
      "r303"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r13",
      "r181",
      "r293",
      "r303"
     ],
     "calculation": {
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Principal amount"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentDescriptionOfVariableRateBasis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The reference rate for the variable rate of the debt instrument, such as LIBOR or the US Treasury rate and the maturity of the reference rate used, such as three months or six months LIBOR.",
        "label": "Debt Instrument, Description of Variable Rate Basis",
        "terseLabel": "Description of variable rate basis"
       }
      }
     },
     "localname": "DebtInstrumentDescriptionOfVariableRateBasis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r253",
      "r255"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt instrument, face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r33",
      "r243"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.",
        "label": "Debt Instrument, Maturity Date",
        "terseLabel": "Maturity Date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r34",
      "r92",
      "r185",
      "r186",
      "r187",
      "r188",
      "r252",
      "r253",
      "r255",
      "r302"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross": {
     "auth_ref": [
      "r256"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs related to line of credit arrangements. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Line of Credit Arrangements, Gross",
        "terseLabel": "Deferred debt issuance cost"
       }
      }
     },
     "localname": "DebtIssuanceCostsLineOfCreditArrangementsGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r26",
      "r254"
     ],
     "calculation": {
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "negatedTerseLabel": "Deferred debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r208"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r81",
      "r90",
      "r209",
      "r210"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r81",
      "r162"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r81",
      "r127"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r53",
      "r95",
      "r98",
      "r100",
      "r101",
      "r102",
      "r106",
      "r300",
      "r314"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net income attributable to Amedisys, Inc. common stockholders, basic (usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Basic earnings per common share:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r53",
      "r95",
      "r98",
      "r100",
      "r101",
      "r102",
      "r106",
      "r300",
      "r314"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net income attributable to Amedisys, Inc. common stockholders, diluted (usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share, Diluted [Abstract]",
        "terseLabel": "Diluted earnings per common share:"
       }
      }
     },
     "localname": "EarningsPerShareDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r87",
      "r103",
      "r104",
      "r105"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Weighted-Average Shares Outstanding"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Payroll and employee benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityAndCostMethodInvestmentsPolicy": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the equity method of accounting for investments in common stock or other interests including unconsolidated domestic subsidiaries, corporate joint ventures, noncontrolling interests in real estate ventures, limited partnerships, and limited liability companies. Additionally, this element describes the entity's application of the cost method to equity investments or other interests that are not consolidated or accounted for under the equity method of accounting. The disclosure provided may include how equity method or cost investments are assessed for impairment.",
        "label": "Equity and Cost Method Investments, Policy [Policy Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "EquityAndCostMethodInvestmentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentAggregateCost": {
     "auth_ref": [
      "r24"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents the aggregate cost of investments accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Aggregate Cost",
        "terseLabel": "Equity method investment, aggregate cost"
       }
      }
     },
     "localname": "EquityMethodInvestmentAggregateCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentDividendsOrDistributions": {
     "auth_ref": [
      "r51",
      "r75",
      "r81",
      "r312"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.",
        "label": "Proceeds from Equity Method Investment, Distribution",
        "terseLabel": "Return on equity investment"
       }
      }
     },
     "localname": "EquityMethodInvestmentDividendsOrDistributions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EurodollarMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest rate based on U.S. dollar denominated deposits at foreign banks or foreign branches of U.S. banks.",
        "label": "Eurodollar [Member]",
        "terseLabel": "Eurodollar [Member]"
       }
      }
     },
     "localname": "EurodollarMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r240",
      "r241",
      "r242",
      "r244"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r197",
      "r198",
      "r200",
      "r241",
      "r272"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r197",
      "r198",
      "r200",
      "r241",
      "r273"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r197",
      "r198",
      "r200",
      "r241",
      "r274"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r197",
      "r198",
      "r200",
      "r241",
      "r275"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r87",
      "r245",
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r159"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Intangible assets, accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r153",
      "r156",
      "r159",
      "r161",
      "r276"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r153",
      "r158"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Loss (gain) on disposal of property and equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r57"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "General and Administrative Expense [Abstract]",
        "terseLabel": "General and administrative expenses:"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r148",
      "r149"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r150"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Goodwill recorded during period"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of patient service revenue recognized, net of contractual allowances and discounts, less the provision for bad debts related to patient service revenue plus all other revenue.",
        "label": "Health Care Organization, Revenue Net of Patient Service Revenue Provisions",
        "terseLabel": "Net service revenue"
       }
      }
     },
     "localname": "HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r50",
      "r95",
      "r289",
      "r298",
      "r315"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r51",
      "r81",
      "r128",
      "r146",
      "r297",
      "r312"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedLabel": "Equity in earnings from equity method investments",
        "terseLabel": "Equity in earnings from equity method investments"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r90",
      "r129",
      "r211"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r85"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Cash paid for income taxes, net of refunds received"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Patient accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities, net of impact of acquisitions:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other long-term obligations"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r99",
      "r104"
     ],
     "calculation": {
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Stock options (shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r155",
      "r160"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r155",
      "r160"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r152",
      "r157"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net of accumulated amortization of $9,341 and $7,044"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r49",
      "r126",
      "r251",
      "r254",
      "r301"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r73",
      "r77",
      "r85"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterestAndDividend": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.",
        "label": "Investment Income, Interest and Dividend",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterestAndDividend",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LaborAndRelatedExpense": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.",
        "label": "Labor and Related Expense",
        "terseLabel": "Salaries and benefits"
       }
      }
     },
     "localname": "LaborAndRelatedExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit [Member]"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.",
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Outstanding letters of credit"
       }
      }
     },
     "localname": "LettersOfCreditOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r22",
      "r295",
      "r309"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r28",
      "r92"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]",
        "terseLabel": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.",
        "label": "Line of Credit Facility, Commitment Fee Percentage",
        "terseLabel": "Commitment fee percentage"
       }
      }
     },
     "localname": "LineOfCreditFacilityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]",
        "terseLabel": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]",
        "terseLabel": "Line of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r28"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Credit facility, maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "auth_ref": [
      "r28"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).",
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "terseLabel": "Remaining availability under revolving credit facility"
       }
      }
     },
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r28",
      "r92"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]",
        "terseLabel": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit [Member]"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LoansPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Borrowing supported by a written promise to pay an obligation.",
        "label": "Loans Payable [Member]",
        "terseLabel": "Term Loan [Member]"
       }
      }
     },
     "localname": "LoansPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r13",
      "r182",
      "r293",
      "r305"
     ],
     "calculation": {
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "totalLabel": "Long-term obligations, including current portion"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligations": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.",
        "label": "Long-term Debt and Lease Obligation",
        "terseLabel": "Long-term obligations, less current portion"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as current.",
        "label": "Long-term Debt and Lease Obligation, Current",
        "terseLabel": "Current portion of long-term obligations"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "negatedTerseLabel": "Current portion of long-term obligations"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-term Debt, Fair Value",
        "terseLabel": "Long-term Debt, Fair Value"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term obligations, less current portion"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtWeightedAverageInterestRateOverTime": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average interest rate of long-term debt outstanding calculated over time.",
        "label": "Long-term Debt, Weighted Average Interest Rate, over Time",
        "terseLabel": "Weighted average interest rate (percent)"
       }
      }
     },
     "localname": "LongTermDebtWeightedAverageInterestRateOverTime",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r34",
      "r180"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r178",
      "r179"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r178",
      "r179"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r170"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Loss contingency accrual"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease": {
     "auth_ref": [
      "r170"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in loss contingency liability.",
        "label": "Loss Contingency Accrual, Period Increase (Decrease)",
        "terseLabel": "Loss contingency accrual, period increase (decrease)"
       }
      }
     },
     "localname": "LossContingencyAccrualCarryingValuePeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r178",
      "r179"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyReceivableCurrent": {
     "auth_ref": [
      "r179"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of receivable related to a loss contingency accrual that is expected to be collected within one year or the normal operating cycle, if longer. For example, an insurance recovery receivable.",
        "label": "Loss Contingency, Receivable, Current",
        "terseLabel": "Settlement amount to be paid by company's insurance carriers"
       }
      }
     },
     "localname": "LossContingencyReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyReceivableNoncurrent": {
     "auth_ref": [
      "r179"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of receivable related to a loss contingency accrual that is expected to be collected after one year or beyond the normal operating cycle, if longer. For example, an insurance recovery receivable.",
        "label": "Loss Contingency, Receivable, Noncurrent",
        "terseLabel": "Indemnity receivable"
       }
      }
     },
     "localname": "LossContingencyReceivableNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r39",
      "r294",
      "r308"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": {
     "auth_ref": [
      "r189"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders",
        "negatedLabel": "Noncontrolling interest distribution"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash Flows from Financing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash Flows from Investing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r76",
      "r79",
      "r82"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash Flows from Operating Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r47",
      "r48",
      "r52",
      "r82",
      "r104",
      "r299",
      "r313"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income attributable to Amedisys, Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r47",
      "r48",
      "r231",
      "r235"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Net income attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncompeteAgreementsMember": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party.",
        "label": "Noncompete Agreements [Member]",
        "terseLabel": "Noncompete Agreements [Member]"
       }
      }
     },
     "localname": "NoncompeteAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interests"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other expense, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfBusinessesAcquired": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of businesses acquired by the entity during the period.",
        "label": "Number of Businesses Acquired",
        "terseLabel": "Acquisition, number of care centers acquired"
       }
      }
     },
     "localname": "NumberOfBusinessesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable business segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfStatesInWhichEntityOperates": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of states the entity operates in as of the balance sheet date.",
        "label": "Number of States in which Entity Operates",
        "terseLabel": "Number of states with facilities"
       }
      }
     },
     "localname": "NumberOfStatesInWhichEntityOperates",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Operating income (loss)",
        "totalLabel": "Operating income",
        "verboseLabel": "Operating Income (Loss)"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r260"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r260"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, less current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r259"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right of use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r1",
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of general and administrative expense classified as other.",
        "label": "Other General and Administrative Expense",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term obligations"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Miscellaneous, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "auth_ref": [
      "r78"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period.",
        "label": "Payments for Legal Settlements",
        "terseLabel": "Payments for legal settlements"
       }
      }
     },
     "localname": "PaymentsForLegalSettlements",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r70"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Purchase of company stock",
        "terseLabel": "Purchase of company stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for loan and debt issuance costs.",
        "label": "Payments of Financing Costs",
        "negatedLabel": "Debt issuance costs",
        "terseLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "PaymentsOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedLabel": "Shares withheld upon stock vesting"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r65",
      "r224"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Payments to acquire business"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Acquisitions of businesses, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Investments in equity method investees",
        "terseLabel": "Payments to Acquire Investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost (reversal of cost) for pension benefits. Excludes other postretirement benefits.",
        "label": "Pension Cost (Reversal of Cost)",
        "terseLabel": "401(k) employer match"
       }
      }
     },
     "localname": "PensionExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (usd per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, authorized (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, issued (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, outstanding (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValueOutstanding": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders.",
        "label": "Preferred Stock, Value, Outstanding",
        "terseLabel": "Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or outstanding"
       }
      }
     },
     "localname": "PreferredStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r4",
      "r6",
      "r147"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from the sale of property and equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfRestrictedInvestments": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the sale of investments that are pledged or subject to withdrawal restrictions during the period.",
        "label": "Proceeds from Sale of Restricted Investments",
        "terseLabel": "Proceeds from sale of deferred compensation plan assets"
       }
      }
     },
     "localname": "ProceedsFromSaleOfRestrictedInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromShortTermDebt": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Proceeds from Short-term Debt",
        "terseLabel": "Proceeds from borrowings under revolving line of credit"
       }
      }
     },
     "localname": "ProceedsFromShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r68",
      "r204"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from issuance of stock upon exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from issuance of stock to employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r47",
      "r48",
      "r74",
      "r130",
      "r133",
      "r228",
      "r230",
      "r232",
      "r235",
      "r236"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income",
        "totalLabel": "Net income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r9",
      "r10",
      "r164",
      "r310"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net of accumulated depreciation of $98,472 and $96,137"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "auth_ref": [
      "r263",
      "r265",
      "r266"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of transactions with related party during the financial reporting period.",
        "label": "Related Party Transaction, Amounts of Transaction",
        "terseLabel": "Related Party Transaction, Amounts of Transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r199",
      "r264",
      "r265"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r199",
      "r264",
      "r265",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSRELATEDPARTYTRANSACTIONS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedLabel": "Principal payments of long-term obligations"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfShortTermDebt": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Repayments of Short-term Debt",
        "negatedLabel": "Repayments of borrowings under revolving line of credit"
       }
      }
     },
     "localname": "RepaymentsOfShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r86",
      "r290",
      "r306"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by category of cash or cash equivalent items which are restricted as to withdrawal or usage.",
        "label": "Restricted Cash and Cash Equivalents [Axis]",
        "terseLabel": "Restricted Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restricted Cash and Cash Equivalents Items [Line Items]",
        "terseLabel": "Restricted Cash and Cash Equivalents Items [Line Items]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsItemsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r19",
      "r189",
      "r307"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "terseLabel": "Revenue from Contract with Customer"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueRecognitionAndDeferredRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenue Recognition and Deferred Revenue [Abstract]",
        "terseLabel": "Revenue Recognition and Deferred Revenue [Abstract]"
       }
      }
     },
     "localname": "RevenueRecognitionAndDeferredRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue Recognition, Multiple-deliverable Arrangements [Line Items]",
        "terseLabel": "Revenue Recognition, Multiple-deliverable Arrangements [Line Items]"
       }
      }
     },
     "localname": "RevenueRecognitionMultipleDeliverableArrangementsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning the recognition of revenue arrangements under which the entity does or will perform multiple revenue-generating activities, categorized by type of arrangement, including certain revenue arrangements that include software elements. This item does not include multiple-deliverable arrangements for industries that prepare disclosures under specific requirements (for instance, construction-type and production-type contracts) otherwise provided for in the taxonomy.",
        "label": "Revenue Recognition, Multiple-deliverable Arrangements [Table]",
        "terseLabel": "Revenue Recognition, Multiple-deliverable Arrangements [Table]"
       }
      }
     },
     "localname": "RevenueRecognitionMultipleDeliverableArrangementsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r88",
      "r89"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility [Member]"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "auth_ref": [
      "r261",
      "r262"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "terseLabel": "Right of use assets obtained in exchange for finance lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r261",
      "r262"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right of use assets obtained in exchange for operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r215",
      "r216"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "auth_ref": [
      "r215",
      "r216"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisitions"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r34",
      "r92",
      "r185",
      "r186",
      "r187",
      "r188",
      "r252",
      "r253",
      "r255",
      "r302"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Long-Term Debt"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSLONGTERMOBLIGATIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock": {
     "auth_ref": [
      "r28",
      "r92"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Schedule of Line of Credit Facilities [Table Text Block]",
        "terseLabel": "Schedule of Commitment Fee Under Credit Facilities"
       }
      }
     },
     "localname": "ScheduleOfLineOfCreditFacilitiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSLONGTERMOBLIGATIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r91",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable": {
     "auth_ref": [
      "r8",
      "r86",
      "r290",
      "r306"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table]",
        "terseLabel": "Restrictions on Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of the major payor source of revenue for health care organizations.",
        "label": "Schedule of Revenue Sources, Health Care Organization [Table]",
        "terseLabel": "Schedule of Revenue Sources, Health Care Organization [Table]"
       }
      }
     },
     "localname": "ScheduleOfRevenueSourcesHealthCareOrganizationTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of patient service revenue (net of contractual allowances and discounts), by major payor source of revenue for health care organizations.",
        "label": "Schedule of Revenue Sources, Health Care Organization [Table Text Block]",
        "terseLabel": "Schedule of Revenue by Payor Class"
       }
      }
     },
     "localname": "ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r125",
      "r130",
      "r131",
      "r132",
      "r151"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r125",
      "r130",
      "r131",
      "r132",
      "r151"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of Operating Income of Reportable Segments"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SEGMENTINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).",
        "label": "Schedule of Weighted Average Number of Shares [Table Text Block]",
        "terseLabel": "Schedule of Weighted-Average Shares Outstanding"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "SEGMENT INFORMATION"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SEGMENTINFORMATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Non-cash compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r0",
      "r130",
      "r151",
      "r166",
      "r167",
      "r168",
      "r316"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r14",
      "r15",
      "r16",
      "r184"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r38",
      "r184"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r15",
      "r16",
      "r184",
      "r189"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of stock - employee stock purchase plan (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r15",
      "r16",
      "r184",
      "r189"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Issuance/(cancellation) of non-vested stock (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r15",
      "r16",
      "r184",
      "r189",
      "r203"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "terseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r15",
      "r16",
      "r184",
      "r189"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of stock - employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r184",
      "r189"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Issuance/(cancellation) of non-vested stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r38",
      "r184",
      "r189"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Stock Repurchase Program, Authorized Amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramExpirationDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expiration date for the purchase of an entity's own shares under a stock repurchase plan, in the CCYY-MM-DD format.",
        "label": "Stock Repurchase Program Expiration Date",
        "terseLabel": "Stock Repurchase Program Expiration Date"
       }
      }
     },
     "localname": "StockRepurchaseProgramExpirationDate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r16",
      "r20",
      "r21",
      "r144"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Amedisys, Inc. stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r226",
      "r227",
      "r234"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance, Stockholders Equity",
        "periodStartLabel": "Balance, Stockholders Equity",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENT"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUBSEQUENTEVENT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental Disclosures of Cash Flow Information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r145"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Patient Accounts Receivable"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TradeNamesMember": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trade Names [Member]",
        "terseLabel": "Trade Names [Member]"
       }
      }
     },
     "localname": "TradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r37",
      "r190"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r37",
      "r190"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "terseLabel": "Treasury stock at cost (shares)"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r16",
      "r184",
      "r189"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "terseLabel": "Shares repurchased (shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockTextBlock": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.",
        "label": "Treasury Stock [Text Block]",
        "terseLabel": "SHARE REPURCHASE"
       }
      }
     },
     "localname": "TreasuryStockTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASESHAREREPURCHASE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r37",
      "r190",
      "r191"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury stock, at cost 4,376,209 and 4,353,970 shares of common stock"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r184",
      "r189",
      "r190"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedLabel": "Shares repurchased"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.",
        "label": "Type of Adoption [Domain]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r107",
      "r108",
      "r109",
      "r110",
      "r116",
      "r117",
      "r118"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]",
        "terseLabel": "Effect of dilutive securities:"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r97",
      "r102"
     ],
     "calculation": {
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average shares outstanding, diluted (shares)",
        "totalLabel": "Weighted average number of shares outstanding - diluted (shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r96",
      "r102"
     ],
     "calculation": {
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average shares outstanding, basic (shares)",
        "verboseLabel": "Weighted average number of shares outstanding - basic (shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WriteOffOfDeferredDebtIssuanceCost": {
     "auth_ref": [
      "r60"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt.",
        "label": "Write off of Deferred Debt Issuance Cost",
        "terseLabel": "Write off of deferred debt issuance cost"
       }
      }
     },
     "localname": "WriteOffOfDeferredDebtIssuanceCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    }
   },
   "unitCount": 12
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8615-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8654-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8657-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8660-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8663-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8672-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8721-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9054-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e4975-111524"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=SL6953423-111524"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5212-111524"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5033-111524"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5093-111524"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14615-108349"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14394-108349"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14453-108349"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14472-108349"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12021-110248"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12053-110248"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/subtopic&trid=2208821"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31917-109318"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116868840&loc=d3e2207-128464"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5263-128473"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5263-128473"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4590271-111686"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-02)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355033-122828"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-03)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355100-122828"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13279-108611"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=68176171&loc=SL68176184-208336"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=84164817&loc=d3e45280-112737"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=119364159&loc=SL77916155-209984"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024"
  },
  "r322": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r323": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r324": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r325": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r326": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r327": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6787-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=SL94080555-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1500-109256"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6871965936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue Recognition</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We account for revenue from contracts with customers in accordance with ASU 2014-09, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue from Contracts with Customers (Topic 606)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> and ASU 2015-14, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (collectively, "ASC 606"), and as such, we recognize revenue in the period in which we satisfy our performance obligations under our contracts by transferring our promised services to our customers in amounts that reflect the consideration to which we expect to be entitled in exchange for providing patient care, which are the transaction prices allocated to the distinct services. The Company's cost of obtaining contracts is not material.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues are recognized as performance obligations are satisfied, which varies based on the nature of the services provided. Our performance obligation is the delivery of patient care services in accordance with the nature and frequency of services outlined in physicians' orders, which are determined by a physician based on a patient's specific goals.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company's performance obligations relate to contracts with a duration of less than one year; therefore, the Company has elected to apply the optional exemption provided by ASC 606 and is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We determine the transaction price based on gross charges for services provided, reduced by estimates for contractual and non-contractual revenue adjustments. Contractual revenue adjustments include adjustments provided to patients and third-party payors. Non-contractual revenue adjustments include discounts provided to self-pay, uninsured patients or other payors, adjustments resulting from payment reviews and adjustments arising from our inability to obtain appropriate billing documentation, authorizations or face-to-face documentation. Subsequent changes to the estimate of the transaction price are recorded as adjustments to net service revenue in the period of change. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third party payors and others for services provided. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Non-contractual revenue adjustments are recorded for self-pay, uninsured patients and other payors by major payor class based on our historical collection experience, aged accounts receivable by payor and current economic conditions. The non-contractual revenue adjustments represent the difference between amounts billed and amounts we expect to collect based on our collection history with similar payors. The Company assesses its ability to collect for the healthcare services provided at the time of patient admission based on the Company's verification of the patient's insurance coverage under Medicare, Medicaid, and other commercial or managed care insurance programs. Medicare represents approximately 74% of the Company's consolidated net service revenue for the three-month periods ended March&#160;31, 2020 and 2019. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Amounts due from third-party payors, primarily commercial health insurers and government programs (Medicare and Medicaid), include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to payment reviews based on our historical experience and success rates in the claim appeals and adjudication process.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We determine our estimates for non-contractual revenue adjustments related to our inability to obtain appropriate billing documentation, authorizations, or face-to-face documentation based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims. Revenue is recorded at amounts we estimate to be realizable for services provided.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenue by payor class as a percentage of total net service revenue is as follows:</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:92.690%;"><tr><td style="width:1.0%;"/><td style="width:71.659%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.618%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.904%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.619%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three-Month Periods Ended March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Home Health:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Medicare</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">46&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Non-Medicare - Episodic-based</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Non-Medicare - Non-episodic based</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Hospice (1):</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Medicare</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Non-Medicare</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Personal Care</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="11" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1) Acquired Compassionate Care Hospice on February 1, 2019, RoseRock Healthcare on April 1, 2019 and Asana Hospice on January 1, 2020.</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Home Health Revenue Recognition</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Medicare Revenue</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Effective January 1, 2020, the Centers for Medicare and Medicaid Services ("CMS") implemented a revised case-mix adjustment methodology, the Patient-Driven Groupings Model ("PDGM"), to better align payment with patient care needs and ensure that clinically complex and ill beneficiaries have adequate access to home health care. PDGM uses 30-day periods of care rather than 60-day episodes of care as the unit of payment, eliminates the use of the number of therapy visits provided in determining payment and relies more heavily on clinical characteristics and other patient information.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net service revenue is recorded based on the established Federal Medicare home health payment rate for a 30-day period of care ("billing period"). PDGM uses timing, admission source, functional impairment levels and principal and other diagnoses to case-mix adjust payments. The case-mix adjusted payment for a 30-day period of care is subject to additional adjustments based on certain variables, including, but not limited to (a) an outlier payment if our patient's care was unusually costly (capped at 10% of total reimbursement per provider number); (b)&#160;a low utilization payment adjustment (&#8220;LUPA&#8221;) if the number of visits provided was less than the established threshold, which ranges from two to six visits and varies for every case-mix group under PDGM; (c)&#160;a partial payment if a patient transferred to another provider or from another provider before completing the 30-day period of care; and (d) the applicable geographic wage index. Payment for non-routine supplies are now included in the 30-day payment rate.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Medicare can also make various adjustments to payments received if we are unable to produce appropriate billing documentation or acceptable authorizations. We estimate the impact of such adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record this estimate during the period in which services are rendered as a reduction to revenue and a corresponding reduction to patient accounts receivable. </span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Amounts due from Medicare include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to payment reviews based on our historical experience and success rates in the claim appeals and adjudication process.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Medicare home health benefit requires that beneficiaries be homebound (meaning that the beneficiary is unable to leave their home without a considerable and taxing effort), require intermittent skilled nursing, physical therapy or speech therapy services, and receive treatment under a plan of care established and periodically reviewed by a physician. In order to provide greater flexibility during the novel coronavirus pandemic ("COVID-19"), CMS has relaxed the definition of homebound status. During the pandemic, a beneficiary is considered homebound if they have been instructed by a physician not to leave their home because of a confirmed or suspected COVID-19 diagnosis or if the patient has a condition that makes them more susceptible to contracting COVID-19. Therefore, if a beneficiary is homebound due to COVID-19 and requires skilled services, the services will be covered under the Medicare home health benefit.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">All Medicare contracts are required to have a signed plan of care which represents a single performance obligation, comprising of the delivery of a series of distinct services that are substantially similar and have a similar pattern of transfer to the customer. Accordingly, the Company accounts for the series of services ("episode") as a single performance obligation satisfied over time, as the customer simultaneously receives and consumes the benefits of the goods and services provided. An episode starts the first day a billable visit is performed and ends 60 days later or upon discharge, if earlier, with multiple continuous episodes allowed.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As noted above, under PDGM, we are now reimbursed for 30-day periods of care rather than 60-day episodes of care. ASC 606 notes that if an entity has a right to consideration from a customer in an amount that corresponds directly with the value of the entity&#8217;s performance completed to date, the entity may recognize revenue in the amount to which the entity has a right to invoice. We have elected to apply the "right to invoice&#8221; practical expedient utilizing our historical average length of stay for each 30-day payment period as the measure of progress towards the satisfaction of our performance obligation.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A portion of reimbursement from each Medicare episode is billed near the start of each 30-day period of care, and cash is typically received before all services are rendered. The amount of revenue recognized for periods of care which are incomplete at period end is based on the company's historical average percentage of days complete on each 30-day period of care. Any cash received from Medicare for a request for anticipated payment (&#8220;RAP&#8221;) for a 30-day period of care that exceeds the associated revenue earned is recorded to accrued expenses within our condensed consolidated balance sheets.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Non-Medicare Revenue</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Episodic-based Revenue.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> We recognize revenue in a similar manner as we recognize Medicare revenue for amounts that are paid by other insurance carriers, including Medicare Advantage programs; however, these amounts can vary based upon the negotiated terms which generally range from 90% to 100% of Medicare rates.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Non-episodic based Revenue.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third parties and others for services provided and are deducted from gross revenue to determine net service revenue. We also make non-contractual revenue adjustments to non-episodic revenue based on historical experience, to reflect the estimated transaction price. We receive a minimal amount of our net service revenue from patients who are either self-insured or are obligated for an insurance co-payment.</span></div><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Hospice Revenue Recognition</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Hospice Medicare Revenue</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are predetermined daily or hourly rates for each of the four levels of care we deliver. The four levels of care are routine care, general inpatient care, continuous home care and respite care. Routine care accounted for 97%  and 98% of our total net Medicare hospice service revenue for each of the three-month periods ended March&#160;31, 2020 and March&#160;31, 2019, respectively. There are two separate payment rates for routine care: payments for the first 60 days of care and care beyond 60 days. In addition to the two routine rates, we may also receive a service intensity add-on (&#8220;SIA&#8221;). The SIA is based on visits made in the last seven days of life by a registered nurse (&#8220;RN&#8221;) or medical social worker (&#8220;MSW&#8221;) for patients in a routine level of care.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The performance obligation is the delivery of hospice services to the patient, as determined by a physician, each day the patient is on hospice care.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We make adjustments to Medicare revenue for non-contractual revenue adjustments, which include our inability to obtain appropriate billing documentation or acceptable authorizations and other reasons unrelated to credit risk. We estimate the impact of these non-contractual revenue adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record it during the period services are rendered.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additionally, our hospice service revenue is subject to certain limitations on payments from Medicare which are considered variable consideration. We are subject to an inpatient cap limit and an overall Medicare payment cap for each provider number. We monitor these caps on a provider-by-provider basis and estimate amounts due back to Medicare if we estimate a cap has been exceeded.&#160;We record these adjustments as a reduction to revenue and an increase in accrued expenses within our condensed consolidated balance sheet. Beginning for the cap year ending October&#160;31, 2017, providers are required to self-report </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">and pay their estimated cap liability by February 28</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">th</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of the following year. As of March&#160;31, 2020, we have recorded $5.5 million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2013 through September 30, 2020. As of December&#160;31, 2019, we had recorded $5.7 million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2013 through September 30, 2020.</span></div><div style="text-align:justify;margin-top:6pt;"><span><br/></span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Hospice Non-Medicare Revenue</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per day rates, as applicable. Contractual revenue adjustments are recorded for the difference between our standard rates and the contractual rates to be realized from patients, third party payors and others for services provided and are deducted from gross revenue to determine our net service revenue. We also make non-contractual adjustments to non-Medicare revenue based on historical experience, to reflect the estimated transaction price.</span></div><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Personal Care Revenue Recognition</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Personal Care Revenue</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We generate net service revenues by providing our services directly to patients based on authorized hours, visits or units determined by the relevant agency, at a rate that is either contractual or fixed by legislation. Net service revenue is recognized at the time services are rendered based on gross charges for the services provided, reduced by estimates for contractual and non-contractual revenue adjustments. We receive payment for providing such services from payors, including state and local governmental agencies, managed care organizations, commercial insurers and private consumers. Payors include the following elder service agencies: Aging Services Access Points (ASAPs), Senior Care Options (SCOs), Program of All-Inclusive Care for the Elderly (PACE) and the Veterans Administration (VA). </span></div><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash, Cash Equivalents and Restricted Cash </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash and cash equivalents include certificates of deposit and all highly liquid debt instruments with maturities of three months or less when purchased. Restricted cash includes cash that is not available for ordinary business use. As of March 31, 2020, we had $3.1&#160;million of restricted cash that was placed into escrow accounts related to the potential indemnity and working capital adjustment provisions within the Asana Hospice purchase agreement ($2.3&#160;million) and to secure the purchase of personal protective equipment from new suppliers in response to COVID-19 ($0.8&#160;million).</span></div><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Patient Accounts Receivable </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We report accounts receivable from services rendered at their estimated transaction price, which includes contractual and non-contractual revenue adjustments based on the amounts expected to be due from payors. Our patient accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other third-party payors and patients. As of March&#160;31, 2020, there is no single payor, other than Medicare, that accounts for more than 10% of our total outstanding patient receivables. Thus, we believe there are no other significant concentrations of receivables that would subject us to any significant credit risk in the collection of our patient accounts receivable. We write off accounts on a monthly basis once we have exhausted our collection efforts and deem an account to be uncollectible. We believe the collectibility risk associated with our Medicare accounts, which represent 58% of our patient accounts receivable at March&#160;31, 2020 and December&#160;31, 2019 is limited due to our historical collection rate of over 99% from Medicare and the fact that Medicare is a U.S. government payor. </span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We do not believe there are any significant concentrations of revenues from any payor that would subject us to any significant credit risk in the collection of our accounts receivable.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Medicare Home Health</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For our home health patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We submit a RAP for 20% of our estimated payment for each 30-day period of care. The full amount of the payment for each 30-day period of care is billed after the period of care has been completed (&#8220;final billed&#8221;). The RAP received for that billing period is then deducted from our final payment. If a final bill is not submitted within the greater of 90 days from the start of the 30-day period of care, or 60 days from the date the RAP was paid, </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">any RAPs received for that billing period will be recouped by Medicare from any other claims in process for that particular provider number. The RAP claim must then be resubmitted. CMS has mandated the full elimination of RAPs in 2021.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Medicare Hospice</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For our hospice patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We bill Medicare on a monthly basis for the services provided to the patient.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Non-Medicare Home Health, Hospice and Personal Care</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For our non-Medicare patients, our pre-billing process primarily begins with verifying a patient&#8217;s eligibility for services with the applicable payor. Once the patient has been confirmed for eligibility, we will provide services to the patient and bill the applicable payor. Our review and evaluation of non-Medicare accounts receivable includes a detailed review of outstanding balances and special consideration to concentrations of receivables from particular payors or groups of payors with similar characteristics that would subject us to any significant credit risk.</span></div><div style="text-align:justify;margin-top:16pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Fair Value of Financial Instruments</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.076%;"><tr><td style="width:1.0%;"/><td style="width:24.054%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.921%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.553%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.921%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.553%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.921%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.553%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.924%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value at Reporting Date Using</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Financial Instrument</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Carrying Value as of March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Quoted&#160;Prices&#160;in&#160;Active<br/>Markets for Identical<br/>Items<br/>(Level 1)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant<br/>Unobservable&#160;Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term obligations</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">391.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">383.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The three levels of inputs are as follows:</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Level&#160;1 &#8211; Quoted prices in active markets for identical assets and liabilities.</span></div><div style="padding-left:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Level&#160;2 &#8211; Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="padding-left:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Level&#160;3 &#8211; Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our deferred compensation plan assets are recorded at fair value and are considered a level 2 measurement. For our other financial instruments, including our cash and cash equivalents, patient accounts receivable, accounts payable, payroll and employee benefits and accrued expenses, we estimate the carrying amounts approximate fair value. </span></div><div style="text-align:justify;margin-top:16pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Weighted-Average Shares Outstanding</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net income per share attributable to Amedisys, Inc. common stockholders, calculated on the treasury stock method, is based on the weighted average number of shares outstanding during the period. The following table sets forth, for the periods indicated, shares used in our computation of the weighted-average shares outstanding, which are used to calculate our basic and diluted net income attributable to Amedisys, Inc. common stockholders (amounts in thousands):</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:90.497%;"><tr><td style="width:1.0%;"/><td style="width:69.082%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.054%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.607%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.057%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three-<br/>Month Periods<br/>Ended March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average number of shares outstanding - basic</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32,331&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32,001&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock options</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">594&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">559&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:20.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Non-vested stock and stock units</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">309&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">333&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average number of shares outstanding - diluted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33,234&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32,893&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Anti-dilutive securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">57&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">148&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:16pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Business Combinations</span></div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We account for acquisitions using the acquisition method of accounting in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 805, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Business Combinations</span>. Acquisitions are accounted for as purchases and are included in our condensed consolidated financial statements from their respective acquisition dates. Assets acquired and liabilities assumed, if any, are measured at fair value on the acquisition date using the appropriate valuation method. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>20
<FILENAME>0000896262-20-000010-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000896262-20-000010-xbrl.zip
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M[!U$Z6^>0KU"E.978:T+#)/4\0Q8%@XDU8Z$%#RS%"HH6['GM<[0#H:5<4S
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M!#8M*Q!>7IB>:&XP8ID6)-[+J; RG'H5M_L;8=2K$^83K5N8 DE:)[G-,*)
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M/6(.?GI;V8QX* 2HV4FYE*Q<>W]RZ-CD%+*+&UO6JGP@X;"7CU1^5.F%ZV;
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MZ.%@0Q0@F"-2<V.R5^T-PSO*8OHOQM.0_1XH=PS9[^[8;Z;:>IYEB%0 E<:
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MB\E8;:EJ;U!B.QIG'*Q)T!I)</7T6B3!.R?!F8I;%%SG##.0O(H@"@K &TU
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MT6JJ#KS.KMPK=.#!-W.\YRH*T-&[^IKPQ0FVYRZ/,Z3ZFU#]A1$(+G)*-0]
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M$7U?/KRE(46OO02O# 6AJAD,5:UI()(GXPF+T;0W%%G((; "4-RIW14(PP;
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ML^B)D+:]P3K&HONVH0KN&M==[I^DRI+MO_N::-X,5^YC'=2V['++JL9HZL3
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M+$5X%J.4++KD*8/D55&$'8G@N$E@<G8T$9=ME*@((XT^+AI%/0$!C@!'@"/
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M[UCS(B0B,S$A$Y&DLC10)KGU.@C%+4''6C,<:X>[7\ND0PR1"T4@,IU!1"W
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M-^<#U4('':M0C')20SED"U:3 %$2FZW,2BG_E?JQ4@#3\!X[2S:Z6GHAML3
M]379<N:[IBIR9H4 ZTP 88,"EP.%ZFRIY)(KF=L;DG:HPK(J),M'3Y97##FX
M'5.B2ME0DIP;Z::Y\S1S#SJEHE*F;,!9)R$D&S/+RBD34*5$ED267%;V [)D
M4UARIDJ*+*H1<Q$4T;*P9*%*EUT$J431);DEPFAD263)Q\:26/^& $> (\ 1
MX AP!#@"' &^/@#'$OU%-G#[<QJ&[FBN1']P4AE_(RS+;WS:P_7]+/5K^Y.#
M/3_QB(Z5A1PKV_,9#<FHY(U4$+6.( @+8$/R8'.R(2K)%'7M#;Z4SL;KGMF&
MJ9LK3GZ-SF;X,35B^L(UJ7'.YTQ-$6J4@'15W3UU 8IDHY"-4YZ8[ P+[0W5
M,5(@.2(Y/A)RQ+QV!/A: [RI;=_1]+D+^3[?\CVX0)QRD*Q6()A08(15(*50
MAA#K5<QH^B#Y/2;R0^F. $> (\ 1X AP!#@"' &^/@#'POI%-G!OT(?@1D=E
MJXY/4G]4U]5C"7WC8\G7#J9LQO>GH_%QZH]'AX/-LH'5XESON>O&G?Y3=](=
MNUX=6?%NE.+3.12\3/\Y[8ZZXW20AA^[(4V<-"]3&+SKUW^E]M>@:V8AU\S.
M?%3:$!^BH!*8TE7+8Z_!^Y@@6!F,-((FIJO0BZ++Z'JX[HE&F$FW&D2*F70(
M< 0X AP!OJH ;UA+;U2%&ZH*ST4I@Z!&:I7!4,E B!#!6F)!">)(L"FP'%$5
M1B)]7$2*F@("' &. $> (\ 1X AP!/CZ !SK7A?9P(/3X3#U8QI6;;[K0B L
M>+W!-O[2L"CE9-K:[&P/IJ5GZ$A9P)&R.Q]3C,)S1[T 0C,!X9D!(X6O7"J)
M)T4UC_60:67,)4?*KYAG@HE4ZT9YF$B% $> (\ 1X AP!#@"O($ 7\0J<TDE
MKHWB*;-J,H]AS@M)3/ R*"<<6F6-L<KV9U89HR8%90@PPRP(:@5X(B+$Q)PD
M2ADK/%IE2'F/AO)0IB/ $> (< 0X OR1 1P+%!<L4*SLG^&@URNK;'6+*51L
MD7$K=JM1-/X4ZQ57(Q1X,15[M]L?#+OCLYWI<6ZE,$QNE)X-!\=;<R<[.AQ<
M!,#Y!_XUZ!73%&W2Q6S2%_.10A6")BE3L-EX$$0(<,X4FU1)17*R,58IUUQ=
M;@QUIQ;INN=Y8"+3:O A)C(AP!'@"' $. (< 8X 1X CP!'@"' $. (< 8X
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M1<(@?RW2^JN"P<MJF_;SJU':K"" PF$!X;#_=%XGUKG(<>[!I2A 6.W JBR
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M^^KVD+%,3M\K=LQB_]N-,+IY=-(OJX7OE2>CR0!F%!='^G1GN.+?DV$@4UX
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M.3BW?BXG0[\<^*EB9";:WMP+' 4#K:JST/EOMC&X;SL_;<4,*X,T5GO3J)R
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MC,.N#NY]6-;P8FJFNJK_^W1PY31.H#KV7GL;+.-KG[]7PC^EZR.[0B<,F%W
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MC76V0&J'50CML P7.!M@S?-*E;9;+<-*MA:@7J860Y2!R_7BFO&%2H-U<GP
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M.Z.M8C;"AF L<:-< HN_L=:3<-O>T6SS:W<=70$6M_L3/QCE3;@N;49W7S?
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M!7AT7/1V.IE1^,QG$;9..>!61M(0_"R.#G9!(9+)]0GP(N"]G!2"J]F&V.S
MYCH]/\D!K@%(_O @%Q#F>D$84P%FMC^!^4O]\7&Y'0RI/SFM>@PO\0N%F.FO
M:D-4]MGU+U6Q?<T9BQ;'78OY. [Z^8[C\XM3"(,=U1X6+( -6:]E.&JST.>I
MAVL>=:8G90*&L7,>,Z=8ICBYA$6SP<R[LF!2@+.@KFQU*+ S<GDW3SK'HR)R
M55E(OF8<#\#5RU>5EYF#UDM<>@U2OIKYZT&'R:Y0V/_.6NW?1:MUMOL?8*I'
MPQ^WU?[NL.X52QYU,E@K?$@SURG+&\A+[OL] D%N^+? ;UI4_G.C #OK']".
M(%RG(&E% UY2(*GSWW=@3[:$I9"4M#1B;EG2 J"&,!IKJ;  S%UA33;#FG@Y
M:2+N4!%5'ZV=[(VVJ@EH4&J</!^/)O,3"/(G!J;=3V\$ -.H#98V)$23-X@G
MJ9!)W*((/I$0+D;G\IF"37Q%\@-D>0"_K<0$9]EL9EQ0V?-L;D%(#K-VJOWQ
MHN]JF[$  38[3Q;)&'+V"QS\_YLL:>.9OBNB/N,[.V@,YAT%E&C,$B7&"*L!
MD$>;:!3<$.N"M4JDF\HL[B*@C5&OQ3-L%_Z(JOMS*YQ%.-]^[+[<U^!Z".L,
MHAH[Q)5SR B9P'_B7*2<<E5\XS'=O"HS5PMGL8<-"6<# 2:=7S)2KJ*D10B'
M,89?[RHVB5A"K;#$!L69<4Y&IQG5QGFA$C.K6>'O)"TK?.Q7,[2WLP!PJH!9
M(U1;P_!BC@&V*@BP,WO_ZLN[>5;V8$LV(MF*7R5^Y[V7^R!O/A&2D"<2=*.C
M%#F>%21G'-SV)*0 \<.;] ;QRT[9:#B,E3 597@! /YLR*QR,7\*5/:G'4ZS
MN5J)R[;@[K;3S,<O&^7WC5\?%5Q6_7&&R8K<-!Y'(5CY*PZ'D_/!!SOLVT>=
MW</^Z%%G+WZTX !W^Y,).%W]HOK^OVQ8)U\$QGE%%)&,>%!MG!MA@C52<2<,
M\\80?-%*DA;&?>WXXAN\^W+?$*,4M@K%Z#'BV'!DDY.(ND2]-F"CDMUX+.7F
M597IM:YZ5/A_0"@J+M=&3M=82I["0!N3ETNE%B(YK8!4MHSTMO8=@-K(HT/"
M KKG5B2DN94H<9, ZM)@@LJV[*JRTP;G_[BZ^IOQLS5J;#'F^.1\X;<V;U+E
M37:W]C%7(GBBD8E1(AZ"1S8PB414U#@=M(J7:F^\,@(;X@GVG&OI8:$4II*"
M-Q>, LBV@JFM=C%S(*^.*H+=;<*G.8([Z'\J]1>GDX7L\#*=^4V)ZKMZM<4I
M'@&JFO%:APM!\356RZWQOIUNIB#D-()]=ER 1LX%J)1G/X,(E(@&"<9>)!%N
M8[P[@.LZ+L9A$YJN&/]N*9XY;GTY?%^%: IZS%R&RPQ_]7-O)/C[_%*U6]0H
MM$SLUS"QLY:)O65B;YG8?W@F]GL792RSK3::]_;DJS>"KO4@7U5FTRA\/_)5
MQ38)NRW?Z)T^I'132_9EF$R_ P?C6E';/33VNNKTUIJTGOH"<_A=3@K]!9HH
MEOH-7X'3<?2Q_R%O_*_;<N$^G)&7IW>])O._U[!+Q8,]07K9"S=>!.=HU"(P
M'@6X?((HHW&420<<W=49PZ^7%GPZ'8]S,_+RS5>SO?/@O?3J4.GQSOG;XS_[
MX)F3=]OOCMX=O7K_]CB/\=G'=__D4-,6?OL)_G?\Y^'%0Z5OC_[LOSW>^?AN
M[V]X)OS?\U?]MW0'=^'9[[;?X.[VJR/X'WSGC]2=MZ3]U/WT_GS?44M\D H)
M'07BL.+(.)<0$=SJZ+R-6FT\%IOBX72+67M+L%:M8AZL.1V/3N!-SJMZ6= ;
M)SF6MQZ]8GZ8W@(/PS(THO#7P()]&(9GC32TIN$NIJ&_9!K(/A:>4D5LKB7)
MK7Q)0EIQCX1TL-K2Y$Z_UY66M*U\'T0KWX=J '9/2HII>)#/BTQBIXPS9P?R
M"8 JG[ >G7M;:W"E-2A]V.]I"NPJ4S 3BB(398)'"02BDH?6'MS%'IPOV0.V
MSX4GA@F#L'6Y/(,;9+7*]D!1%P16GJ=L#UH"HS6U!S^V0[!S\>14ZPNLN?9O
MB\?7W08L,'IF&R#VC3 $,Q&0TEPA;DA$+H"+0'"*7 MOK'$Y7"1;GV ];<!7
M\ FN(+$S:U1.>2E;7E6#[)7*M0NU1U^7M>Y+QSA;L_)-S,I6ZS_<V78LI!K@
MGA_WM:%*6&R0T9XB'@@&_T%J1$P(F#!&O8L;CPG])@&E-M?0NA:WKW]H4O8G
M]GQ5OOZ[-T!^X,;AEP=N'>K4].('M<3\50E,:SCN8CCZ2X;CTWY4$3OC$O*:
M2\0)\4@; []Z3ZW2"I;>K#[__^OW\S=:D_%39R=@XX]'@T&5G3X^&8S.8^RX
M.(RIW^8EUM]*?/'$Q&4344L(?/M9+1]/:O%HK<5=K,7YDK4@^U13IUR,2!CO
M$+=&(\VQ0RD$%KG3B;( ;L:*BJ8O:BW:#$7K1EQV(\;36'7W&T[6A=BJ-0/?
MU0S40O&LEHE6]]]!]^\^7=+];#\I9S!."4F8?_ 4.$$.6X<H8Y$8*Y(/5Y0L
M?4=/8=W55NL/?(5JI87#S:TW\-.9@9DTO,C"L/!YJ_[OHOZ7,PQB7]MH-:8<
M,4GR80;ID7:8(,&%8H)KK](5%4HM]/_>ZO\K0/^'GIA>T0#CZR:GV_S#P\P_
MM ;DGB6N>UNGLQ-QGU[F=JY<1!HH#HBKII^FEH0B[+46-'<L(&EU@5.;:UA?
MX_+]?(MO<3R_%T^7202NJFAJ:YG:6J880%Q:*W$G*_%LR4KTMO:-591(:Y!1
M.J+<I@YI$QF2G"6F-%6!QHW'\IN4P;:53.ONAZS1)#95\&WJX2LK?B6$P=ZE
MW(25TZ ,=9&K&*E),0B[NAOK=1;@1^9C^,;J?&=9G1_L.[#+V$N&(M4. <(G
M2!,G41#4.<D"4Y( Z#=7=AYNDP<MP/^*D[AW78?=-6P>57]2/XK!AV$TS8Y)
MVUKJGN#L=C/:FLU+9O-'[_'\C4UG=\ET[F[M,QJC8!PC1D5"G'HPG5A+)(7P
M44=.C,#7]H5^Z+MM_13852;W7Z7)Z$KZ^7L3)=R=D_MA$2Y<.E0^;U%>4ZMV
M!GU?*G<ZO]RES[T2.FC+O B!<"^E=M)JJGDT6J44;<O)]0![Y??@L][6OJ=&
M4(,E\BI9Q(7-54C,(BPY#RXJ*O,A:7H37V&F6&J$+:_L'27,1A"IJ)T*QG/P
M9(R3@5LAP*X2J@UO)>QA2I@ JTMD\,$E,+@NUS@G:[*$)03:4&,AN;6.YAKG
M&\@8?BW'$^!CE,FH"VOXP3C6],]W$K9\AA,4%TB74YQK;!-.5$>1<1LCJA6V
MAREL_F/W8-\Q8ITU 8D<(N&)*:2I\ @S3P2120:=LCJ[2=@J_M4+*NT: 2P,
MJ2YF\G2 ;YDUO!""VTYELF- -M-U'\3, =\?%0:PZPB2C)0>=*]W!"8E>&FP
MYAZ$S1@5C4ARI6^Q()X (OQO83K.'-D7A7/&[M6'/1)?]#]<EK%_ZE%O58-^
M,XEI.GC13_$GEK#R\\M]0I5*) FPD#8SIX).,YYD@E]P 5ER7GF[9# ;"I?"
M5S[Y@0F_*O+%&7]]9L Y.1F//I9 T.#\3M1*7\"WOK6RKCC-G]IQW!T?6%#1
MM;[^$(?3V(NGNZENA_XZCC\ @*X_^2L326:ZS0?OEW\IXD3:>[D/ME0I1R-*
M$6>3GXD3=0@H"(=ME(Q$"PI8;?*;.5XS<^*DFO+.N)KSHH)A!XSF%<JCBE/L
MOP% +-_AE^+T3$"]%6+V!0JF?),^"-M!3?OE1Q-0X84:+-]R7>5T!:C8F;_%
MJ\S2%,/3_"ZM0%;P\PST=?*89P9I1+@$!\<E@)^2>$2P"BI(@26Q&7Z26W!>
M+[)=UY:^DJ"UEYWM>#*&3\IH 65N+0R^%99*>PGPAFD@"0=ED56*96&1R#DA
M$7@)WCONC:[:1E[587[FJX22\:PH!P\!):)C6/G#!OS%80#KV+5C?]AA-9'Q
M!6#P=2G>RCHKPZ+4/N0W T6MK6(V)AD92]PHE_9S(O'.#-IZC8#*%<13?/-:
M[/T%R$FWHSO=[D\\6*?I.*X)_RCMSC;8D_?Y^]WG[P[?[>U\ZGUZ=?3NZ(UX
M^^GOH]WM[AD\'^[W1[][M,,O;K#N\U<PMN[9.]A$W:,NZSWO'??V!D>]?[J\
M^VD+-AJ,_9^=\^[18>H='7P$2&"$5H3K@)(#G PS"I# $(("8]:"ZQVYH!<Y
M1Q5)A%(?K966,\VU<1Z#J";BJ;%47^0<?;';>X[VGKWJ=G:?O-AYOK6WL]M[
M?3V)XDK:K9N?NSQ.;@+F$EPT\ JX9.!Y>BO@9V=Y=(GB;TB#FV5N9SB!^:B2
M2#^QT'5?[EM&@S4N(J.P1EPJ!T+G,!*<6A$<8TRRBT+T0WEC+T8Y(Q7'QP 9
MW&F5AI^<5MSCV2Q5_*/92&4>^\+06XQ3)B(-_8KL]"INTEN3[JWDNUL'WCI#
M-F%_W8^W3HI-)N37X*TC;-/0V_+67?P0;Y+K/A3FFB%?>^W-0Q8MU=XM!_Q#
M4>TM ]@KRS3;!7ZH"[P=?3QV<5RO,3%K4AL'M_R\8Y7(+%Q0[K!.!RTO6?3J
MH.7=J.F9"$Q@PA6XK)@!RJ34DL#SP3#JKCK+P>X44EC$FW]8'ROJS76))]P7
M>5952D?^_-W1D\';O<-^[WGWX[N]5X.WQV_%NW_^/NSN;9V_.W[#ND=O/[X[
MGE<V-55*O4]_'G>?_WVX^WP'O_WTQZ#W_._^NZ/!X-T_SSYVM_\\?K?GSWM'
M?QR7&,1K?-8<"]_=?H\O(M]\S>[>DWX7QMK[% Y[V^_A7?_LO]L^/'S[Z=WQ
MN^=OSW;WGN'N\=^+\0S<W3O@.1WFM),I NRU"2.NJ47&!8&((.#>@/ME\R%S
MHL2*_'Z#^#I[&42^&-GA[R5J.HZ3T\ZXL-B?=I[D_A"O\B\G@^FDLW5R,H!]
MFO%=^2,@RV?3\2ADQ#:^YGM7'VH%$00%=/&DDM0L<6PQCH9[8ITS,BA&/0-/
M"DNR6KK94HN$9?'=J5\LC\:>5I7JSX;S8G5$6V'^KL*<"PDLL4E%CQB1$7&+
M'3*)6"2%B>! @YM.2F[W<G#N?[*H+J.57W_OA&F\-@ZDG:4D.B,BC9P%XK"E
M7 EIH]>)1WU3#O:W ,)4XG[!GN?D7QQ>KT.[]G0Z[I^>;\-UK;A]1W%[?]8[
MV&>4&&,<180YDH]88V2H%TA:0@WAECNF-A[_$=UX:L?G5?R7%^'BUP>>UJ?X
MO:UPOU?-[8]5QGY/J'BI>GU9ESVUX_$Y3%"+">^CUYI606?[Q&NIO0?P%F,^
MO0OV3@=O02E)R:P$_&8*@L,/Z?SN ZU,OV50XVL<\&IM1FLSULAF2.JY4508
ME\O$M3!!)QRC58E%07G,-H,80EN;\>ULQJ>9S6 B.B*-1"J7OG*7&'*16\0S
M-B5$*^=SQ;4BW^2,\,]M,[Y?VX<V2'J3%L, GC# J$"DYMYAXY3VR7B50N3*
MJ39(NB;*K;_@Z._ML(N._MM/._@=/&_WGW<P_C>BM_VDW]L#9W_O[<?>$;S'
M\R[O[;TZZM%7%QW]3]VM?4^P4()$I)(#B U+CYRQH#B92C8Q'PT%=2D$OBY(
M^BI^& T^Y'3ZTW$,_=,.K'4^QW&^$#0=#0?GF9:IU&>L3S"54FXYL02</GAE
M88--TC).'#5)IBO\OS:8^H"%OG>V;[F-SEJ*O,6 # )+R(#WCZSFRG.K ->9
M'$R]7*=]OV!JH@I'C366 D2+,BVY9C1J(P3@1'[C@98VF/I@Q8WT#O;!&8BY
MJ YII4#'XD21=A:CP+C3)CDO,?VL8&K;%.H+NWCW!$>MB_<5=^@\+*BHIXHH
M5\YI(\Y%R$RE#)&HL%6,><TCJ&^Z"K.T;:"^6N3O*S3D:Q7<5U)P%%"_8YBD
M@#WW@1EON?=:!(N5S4=LVQC6-U=P\QA6) (6/6#D0A2(&QR1T\PAZYPW7L8
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MXACXHP7(<%#7K.3"BH-)KM",[W,D8VFTL!_@^>-)J;S,\U&*5WYB4V$_V/[
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M\G#%U+R>NI-1'-K.]M3#@_8 @AP7X_>T_Z$_Z.R40XW%3H/%W8XPA##I[%2
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M4VA2#S6>+_'&6T'ZST3S<*.#'*V$'0ZXMEP=QUE49L,M>9UR4J[@Y KBEG.
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M5?+GCI%^HY/&P22CO.564^>9D0(+"1Z!98E]J9J %BI>JS9$[]/.O@2W <?
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MD]4NR*,Y&TO]T!8@K:^X[9SU0-PPIM('9Y!U 0!2SG<YCA72UC+/3(C:ZAL
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M"EHVSJ:<?<:=S!:($G_68RC!M&+%:>IGF7E7KY?K5!>\^71Z+;K%BD2"J/5
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M69Z+=[ON8%U=G%K*.\/-$M^DCA=&81A85N!C0@.AL4--,[9\-XB_N.;>ZMI
M+^R3NZT19WAG'],'D<FL^_*,7J#3[!-3#$$S.TC*,&5:QCE,\VN:A]^>%]O-
MXP;;/QOXW>>_/XT^?_UL??[Z:0S_3P"+TY._/YNG!_O?/QM'WT]^._I^ ]N_
M?L;Y1__\]B&!>9,3P'!XSOCG[[_T?[Z&UO'!!UC'(:SC V*[=?SGER#R73<P
MJ$JCP%6MR#95+PY-U:"Q2^+ !/[ISO>%TD+#TQW/]'S'M?20!D;HV$9,/1H'
MNF7X>Z 4AV2"J%E,Z=Z[L\/?T,FA')U\./UTO']^='HRW^UTED86&NWWSKI;
MYBLJ-YVP09)=YNEEW4,$;8L)_"*:%O/F%RBW;A4^)2> <KT2B-T>G>\8#&)H
MKF-P387U97).ANCI/FN6U8\[Y$].AJ<'1U\LR]0L3W-4+2">:@4H<!P3\# (
M;-N'4PEU$#APS)3>%#E% \NVKWU]V&^4$6;2U[Z*NIHJ\TN @LF4&[Q^SE7I
MSK/U"'#4*:M# +K.%;;K;O**NXW/>*561'[XH=76>6.K,4%3NVX1@XC+LI&!
M]5[0XGH@4I*4$) X \8?)663DE0HO*0J5KM-4[8S^"ZC+"P'!G+5=C87O899
M&MB8 22KVCU6I/Q6UINL>_'P#38=W28$1#=/$V,W\D6W^1A[*6.P6JP$C'.\
M!M40G[#YDT)A;""A8IX9^"Z:3;S/6V/,[8;EB9>E<-3@25\F5<+A&Q%@-J!N
M7L)>>?A:E+5CT7%1T@Y6GD['67TX<9ZF^15+0^?A)0Q5)B6/37+G2+>4+OW.
M4NHN:;<3.ZMB,IM.5TXGK-5T/,T8,I8#S  "-HLK[-X/*9M*?(2'$6&B >M:
MS=KEU4WG.<A3+.+-1TOI!4D'G<;R ]%5OEG6@)4NGA;B \S]C?+10QB2.7&Z
MB\;P+OS!2LD#ZDUA(/31 .=$5)[?XFY?]3ENSY9>DG3*KM.(6W8,%7D)=E"-
MV"\MF&9R-86(8G<DNG72.VRIYD9S=P%+T18JKTL?QYW&]^AFRTIX)DJ <[";
M115O?=R]7"1<CV%#7[Q)L!A>!.KK6O*IR!_A^+[2N$/EK)Z )Y_45; ;CYY(
M@ MY9FK3$ X35^,.C)HF2F/R362]X)I$74<Q:,1U4QR5 MDJK^IRUT#-PL H
M7R^%F2)((A!31&R%[K-A?1NKAT]3>AK/:]Y'+5_X]5K\^))U\),_OQ#B.)9I
MVRK\H:L6_%OU3"-0@S"(8LUU'4=SYW7J?PG:XF<N3CBE<?6&3*N\/G)V"9=_
M$V ^2X&L)R63DKZI_WC;P1=\GW_&M*VL>H.L!#LSI.3Z39(Q)L+F%2%MWQ]Z
MMLFBVE4!_X_J]8B(]Y!'O'^IHIL_6LY0,\S;?[_SY3M_=(>>YC_P76VHW_6C
M;1H/?%>N6*YX]17KRQ+(+XS^. T"9:-H^'][YEZ;LQ)A9(WI)L;D^]OZLQ )
M^-62ZLD\M\".B*AFB>_X@,WXC"%A"DS]!6=(^DWMJ-5?O 7JR])JT*SVM.2>
M]M[QY+M&I IP-X TW,U"4LCIS</2?0)8?A!52<[17E6/8;91W9/W,,.42I;N
MJ-29CK<"O<7>6@*!OD*[Y" ?7?91R1XVR1XV#,@[N8-0ZYC1.:D4EH"LU!O<
M-M:!A=Q9)A>/K2\!\+6BY1I@*7%C<[C!''<2)R1.-#CQ43A9&<_ N@,2.R1V
M--AQBJXUB1$2(QJ,.,<KJ#,8L0'%^/^$(:5Q?!^^P)"/@M]"-_^F 7A"JSJ8
M4[O7YPEL\Y![$&;V"XX_;19J#'T> S:.?]R_U".PK9!:IWN:&1NZ[]O$LYR
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MG-G.Z]ET'.65^'V>Z3%4:#%!(,)^L]_],8"GTGNCU#T]/_RF?2'$\%S+#]7
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M*H:/A,&6*#S."K 0*^+3ST#HYB*:(^$D46+>0%OZ@&5ZE^@ 0.F*QO8E5R
M0A$!%%( KC [RS+'M*Z;F,\\ZOD5<Z@C4V?X 1],PVAH2@VQUF:<H(K0.3V>
M1L#,40"O;CF+7^@XQ\7#;";=:/:N\A^[3\!YFQ[7%_C>!0+\E;&*!F?\AUIX
M\2"?R"['H@9!0EY4.(A%)]X+V)U-Q\R'\XHG#L/$?V4S@OK?.>A;RG_@<="H
MVEZFS[)E8SG>-5?Y]/YB+^)$A6M%'"IG8+/7TUB9:C*M\OH57OR5?2,*QL(N
M4S(IZ9OZCQMUM-EG=(%EU1L\1-"5)BFY?I-D;"]L7N&#\.VAZW WA.C"*]8C
M7!1#_MM<Z5S^H^T//=.X_?<[7[[[1VUHZ.8#7]:&^ET_VLX= ]_Y[DXNV5GR
MY7L:-2])H1OM;/^XMM'W+EB0\F.6O+AXL[= T=]T[68,1C-O(T]">4AS 7G"
M/3]AINK(D]VYD_TH%%5&OZAKW2S!?CNCWF"_#ACR4;!\EB+VW!2I?:)-<:I;
MR<98-R0?W#_@'E#WKB6':>B][L?0=TSM9QL@21B//EC=]"1A2,*0A'&#, Q)
M%QOHS[-FY3!F_ZRN''K;H!UV$MM_.:M(44TGY:9TPYN O LUMXZ8UT_+#P-8
M7W'M$6)L.1)\5C&VV\CM2^26R+VKR,WRUHRW$L5[H6X]U!>W#>K6>ZS4%OWR
MOA,>[H<C3I+LH\#65WR3GH/M1?%7^C,VG)>(+1%;\NZ^H7B?O%M;H&UULC";
MK@+]\&WME!?;-#;@QMX //N*IM)UL*.$H5N.) Q)&)(PGB+N^;+I@FF&O[#$
M]YV\!(BE>[-*.:"7-,TG[![42[IP\AM>L\IPVR15CC(L*%5?7.:MTI*+SBWU
M4];V\X^D_G:;(77W/94S2I63O***S6[4ZOI;?G^[:B^MO\^Q+LD%S<*$-MTL
M5KDZS<I,14UIO&ZE@;;>)Q]47.UF]ZLO6#'+IE":J!_ 2E9UKOUC0S,L0S")
MV VKSH"=_KF3(@?+%K_FHR2S1RZJDHH+AOCS$(""M]>F!5Y>P[MU&5[7NT@N
ML:=)<TU4],IE/4:JD#77K4O+)K#[+>\8NRJ-B9I+&]QR+:.>@#QT6Y2Y;0LA
M\U8@]:TUQ,3F$B\B%?\ 4K!3!OC]\=G>:R4!1&(% %GU>B2:8BIJT#*T;2X=
MBJI)2C%S6_ *N[#A9:WO;-(XP8)5O%X#+$L?*C!+TQ.FK <K^6540,]FE;S&
M4LAOO(O^S27%U3>O1XHQ='[&,@L%Q9IPG5).HN1&^U,IJEA@?05&AXHYU'ZN
M6S('I,3_M(69%%80@ ":6C\C)*(IO__9+=Z$M-748FY;(7[DMTJ5CP6PJK I
M>;$?Q]A9&^_(B5K,[%XAEEVJ8=?]GE6I@%DYZ_F$%3G#)$WX1]:G!? JI:R)
M(Y;UW/OX<?_]_MYKWI6%'1E)R[P^1> *K.!%PPWJ4^R<5X";RR?(/]DC8UY=
MF(GBTS@6]?;: B!LC;].HPN '&L^4#+5"]D38;>.,UKS+':_%I#ADN*]5#9B
M2":LY74[?T3Y8<'A8=V0%+>%V-(@(EXX[IPUJU)U<8%<M*)L/%%"&3;"$ .V
M^I.I#5S+''K.4/FU[LZ [)MTJI2('NPMMK-[NUA7*^2MFNIN1;P;5,::DK27
MA&>0<*BLQ$:7*X;U@"))3\A]VA(^>%KO24JS",C]LZ!YC94*K9&;G2SO^RX:
M5? RTPCCE*$51W%Q+(*8U(."2;/?8(L3)AF/<\ P8%H?#WX[!J[%6W(A?OV;
M9+Q<2UU\H.VPSHLEL.OO GVP^E^GU45S='W6@OC=>\71U(A<-RL7-8BP[)%B
M+OIIJ:T].=8,E?U&V4)Z3U@[$QJSN__8/2Q%K07I.R[(%*@S*;^5G"T UYV&
M2+#8\+&L53=0_\)DPH1#O?]7>Y_V/Y: )/@ PPD8&*9O*1C+GC=3">S#=W@+
MEGFI%;5M0V.&S8S;<@DE! QN0]&'YF+AQ&HW=^[Z=XHW(Q7=);20STZQ6A V
M@ /^RY:C#^UY2=:,,9D6Y504Q,+!?FV;@PG6O<^O]O/NT350@85J0^/GIN!'
M <HEJ]^N8N.O(ZRMF8:LI,A, SE^,DSPH$(Z[L+J<:7^1*FYEUCM3[^]VM]V
M%>Y[<NX">@4L#80!JXHY)M^P!D9186_&@([(99(C5M>:4:?Z9Y@SLVS"2H:&
MV 8QS:]$:P/.(6KFTE$'7^W]\=='4,&0,+LJ4E.6AY4/$4TI.5'/<[).7QDD
M06MH.C^SLIZL.T.7 75[/LYQ(JQJ6[>+('SP2E0ZK:O[(+T/O9]YE136<QO+
MG"8 ]D04'[NBS([,X[BD57>^RX3 J./D>].>&VP.9- +(,IW7Z(VS2K0\-)H
MHBZ=$L*)H8*?L=&88=P"F+/"VF;EM8E(D+#Z2*Q,*3:J(.%(M'&FK%,*KK6L
MR]7,=^W,6%_5L-,1<5)WD7M)AN^+;R^+*,];58G^.;>7?83OF?N'U02BQ2Q.
MM;U46$/Q"\+:'*+5 !8KOM'MJRJLCLY,T;2H9:?HMW!%Z;<FA#W@BBL0?L1Z
MW+(VB(R"L68XK.T22_$(&ILSC+"B(:SQ$J]Z +\Y!#*9[_\J^BIB9[MZ3YV6
MKKBH*"F+Z:2J^]]=L$K'9547:5Q0::HN?=B"(&+\1RP8.*@Z8<5QF)] ;)9[
M+.QJ-%3.$@XUU!=FNM*4K#DOX!,ET75=ANKZ=F@@D0-_G>2\SF<$+&H!6([J
MC<R4J!J(*FA\W%(9)95H>K-X_:(!JY%%@ >C)&TM:Q+5E27KQ;'- +A!W<,R
M;D!"28SEV2K4?!DBP!P1-M=)ZLZN3'#5G!Y9(.P<+69>@ H4F'*Z")4:S(Z;
M J2T@]<+V@5WQKB[M&F36Z&T)4V9&Q)X<L'<F!$%"9L*C\C>PE*?>UBS-;_:
M;I?CW6SF8-HT6)QF0NL V557#.\PD 5-DR<%NL'J_LC<\5+C?5/'%9 T+X!,
M>M9O69DMYAO#O#G(_I#91Y.\X@75 'L[:VKE?+W+-W714]Z.ON5O>=$XBFHK
M/F-=.&;0.40_DN@B@E7O!BTH4;GA?$JXS[C'/<)R7<C'DZQQR'45OL99WCX]
M$.99-2TR[D7@GC_FV(BX#( #02,#VY"+!K<*CPKD");_05#&K&D*\V:U"@X)
M0V33(H+15*I+ZMZBO%@?CP^P,G@ITRX'7-_*4&HU2R>,+-IJ>!/AF425\K_3
M9"*TUX\?#T%YY?+DNBD)R]J8ICGH<\"R1C2%S:A A9.4H67!S=:/];&V F^V
M%7FWT'*M_P&"T*;@Y("5P(3/)4E9C7P4B,CI1'G[KG:.W T-_8PYH040.$J(
M%N77-SOPP>Z$>=VV.J_58=080]XWL-&G:P1^<S>+$G7)U)D+"2PR;R*3VGHV
MQHK5.F_[[QB;S8JPAMQ;P'&L%L 1Y\FL('*MW(CS[K*S>$8'4$KX% IBJPGQ
M?X#C(O^$&3-!ITBQF%Q0!U3P<8D[6X\[LT:YP* 955(PMH15U9[7Q=$EP'&!
M-6L,.,[417.WVO*\M[V8T(W=02<B&;3^QZX-NH]%BS]A'?^8ZS>'P(]SU%)$
MY?9K'O3::YJ5@*A"NT14CF7-*5,0WF7:<1^TG4V:FJ^U0U/R]YV@T9]T35/J
MWHBWM$04+:"8+5@K8:7HTHZ5C#':RZQA(0H:O:76E =MI !%!W>F@RHTP29Y
M!>'NI8XYUUF%6FL@33?6AA4T?5LKWF6Q5N"[.OI0.8U%GU;>(S9E'='0L&:A
MS@$&.)6^]*F_HT\\'M.-AN$M><[T<'X[[^RKNS#S(NC,?<M@(L*]S(Z)*,"W
MWA,H=' 8U93I_=RT8!TM"%=IXP7^T_:L.P%#,1IZ54LQ.POW\WVWD>.+@HSO
M8>62C_1DJ8OY"',VTS%F=('Q44Y+I-:.>H@5BS$-+%2,GSLN]2Z5A"E)QO.T
M48L;X4=A#J-K16^*P,]5ZD-7S=]TUH87>,H]08T5/!6AS(PV*F?#43"18Y;\
M#+VF/HFFVXZF46V7"-0$K$WS:[2<:\9=YCRKL=:<L&7=*V=H_/QZT$F40-1L
M(M*HU[*X(1\R XSC^BX@$*;CQ#!,G;DCYHWJMJ\P2 ':%$Z#;!+6@*,!=<PC
MM][*4>"AP,898V9,O+SM'6-5@F@\45S.=.RZFV1A:Y(L=H4L;N/>#7]NO7/"
MAQX"<< B")/L41Y.V^PC%KC$EV8$?NT6!%V.M-*!IE3$03#%@^E87--L R3X
MXDRO!M3&A"=!8MZV8UZMJ2)#S?),G8RN2Q[7YOD#B%&H=6-> 6O=P1^=Z>O"
M'*ES037N1QH@\P/;("E'0@5E<?I)2KBKJDGIK<?F#]6?P*2^2/@"=]C9<,XB
M<FFJ\N9FPH,G)".+O*%KGP+!9K3^%;:&7:1ST1:N"8 EG<2 )O6B(M]H-NLX
MP'CDA)UJW9]F9LXW;48CI@=/\$'= H%Z7?)800)V(,6QQ<SH=&_2B;LN;NXJ
M>@OL!8ZF8I8=MHE54;[Q1E&D8$U]6I5S]H("<^E'8 :A;<A[OM5+;I;[EMF6
M5VBI-E!#8U1P58PV<K[*HP.6IK_Z]IIA(5BS\*^HUHEO&XEEWQ"F 40%N0+]
MI+$#NX/AZCLY&HW]W-BU34)Q/F5I;M.B"5QV[FWHVL\*)45ZW9T05@^D=?U6
MN4#8HI':!%G.81H0 3.]M0@F!39;8'8[F6;AB(6U&R?!)\K]PR+7O@Z" Q;Q
M?/E(Q&J9ZE,/-Q#)+VC2-XV!^,H+,=XN^P:17$L2T^JZ)L8F%VC6S<X(EZ43
M!CP'( 8Q77(/(>FF4=6I F,2T3DR;5(>1%;2+&$2L*"NVM/ T%@.<!"4R.@2
MT*"S/$",*\QL)JS3%7L)/Z8YL),Q*;\-,,"("5)9,IZ.!ZC3X@C"52R3(!^8
M!&EL2Q+D=E&BR'#"[)^(W[:<Y6X<N2Y;[;G"_(6ZC1HG%23&CQ\/X=DT";EN
MTZ47? 'IJ!FSO!Y/:F\*(_:Y.<K!;*)@*1R .,B)ZMN,S."ABQ0T>?QO?E5G
M;F%,NAPE-(U$*A"R#B%4RY9@V0 B0Q)$:5:G"(H%O&VR- CKF59@*'U.!HEF
M:CSI'#D$JA$X-D!BP"4@KI<G8L8I_<XODF27\%J.G?*0FW6ZLN$29CZ2,H&]
M-9[:C(HF<J"8P'_>BJ@DIN8P1Q(> 'JE";/L82J6O\-4C=EM#Y0R^=[YM0M1
M)HLRRG_%'SEH^?6=C%]2K*[RSMO\ ;2$4($=8JM>!@[^["Q0:AZ-?9F%"<9<
M"=@"L1UQ!D0CGHT0<6,_:!)"F,3/!0S@9>Q_6*MJF#%73KED!XNLQ1U@BR-
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MW].LV+$WTZQ8OWOD59H5/Z2 VN9[HBZNH#;?8+0'A05]V:MU:5!^$(Z)FPI
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M11]Z/]\"*R7B+:39XD!=K[D9; +F#6$&^+&<3I#1*8"?5\!C7\'KV*T4@!<
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M*KFDRK^GZ;6B#Q1#T_V!4G8@42H1C0%F;%7\5BRLBA8(#5(I5U09$1@@9UW
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M6\;0%2;8HC=) *H;R-.WPN6B=8?8NXV:N6[8=^HUG%G(=?\]*EH?U 55 R"
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M.S?.GN(ZE0D8&.53K,0A+YNM&3K2D%B),'Y-TI25A!GETV)C#JW=;DSBVL9
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M+#%88K#$**G$*$C>#4L-EAHL-?9&:EC5YN[+=I5-9A0IT6E?0KA/J33Z^@=
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M!R0AXRW!'7+M(JJ, Q$90B,5.'O)IQ7ZX[L4\XLCO#LTC1MX8=5S8Q(&()(
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M#C1)0 &*B&:R9?K7T]/?04__G;B1&RMR3JD@E&/A$H4N'X!(-(H"VR6A&(>
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MD.E]&%[X0Y?R"*)(QFJF4,>@E&B1/FE)T$S^4&;ADYQP6;IA*MKKAJDQ2%"
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M^N@8__WIZHO1\[%[IRV-(P.K"KCIKT[:Z<$)8'I?=>B3(L2.M6@G]Y"XP!W
MPX0S$0M5/+XO;9%$,$P<J>%C,8RH"1.6&7 <W:XI&V,&1SJ?6<RKZ@P-0U,2
M:-BX9L 8, :L-("Q<?U:QO7UZ>]L7+^B<7TC[@,_&$^-\_M8^A'UT+)'<BR,
MM)$:6[L,#4/#UBX#QH Q8 P86[MO9^V>GGQA:W>[UNZI\.S$4_D?7US_1U]$
MDFU?AH:A*8"J*( R8\ 8, :, 6/;]XUMW[/SSVS[;M?V/9,#UW?G3%^V>!D:
MAH8M7@:, 6/ &#"V>-_.XOUR\HDMWNU:O%]$7WH1!WH9&H:F2%JB 'J, 6/
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M960M,C R,# S,S$N>'-D[3WO<^(XLM_WK_#+EW>OZIB$P&0G4SM[Y1"8X98
M!V3F]KYL"5N ;HS%2G82[J]_W;(-YH=EFQ]COY=4;>T$6]WJ5K=:K5:K_<O?
M7N:.\42%9-S]=%%]=W5A4-?B-G.GGRX>1ZW*AXN__?K33[_\5Z7RS[M!Q[CG
MEC^GKF<T!"4>M8UGYLV,;S:5WXV)X'/C&Q??V1.I5'Y50 V^6 HVG7G&]=7U
MU?9;\=&VZ4W]0[U:J=$JK=1OZ4WE]L:^J9#;:M6N33[4/ECCOTX_VC5R9=W4
M2.76MJU*_8;<5,;7D]M*[;T-/ZSK>FU24TA?Y$=IS>B<&,"8*S^^R$\7,\];
M?+R\?'Y^?O=<>\?%]/+ZZJIZ^<^'SE UO0C;.LS]OM'Z92R<J'WM$E^/B:11
M<S*G]D9S?,#D4KZS^/P2V;VJU:I1:\3%--B9*SWB6BOLKC_?W]KVQ*6W7-!+
M:$$%LU8 W,T P]W*%APVLKT57)RJ]Y?!RPN#>)Y@8]^C+2[F]W1"? = ?/=/
MGSALPJ@-:N-05(R-!K'7'A%3ZG5AC.2"6#3#P/WZDV&@/-E\P85GN#N@$R+'
MBE0I/ "KWE:N0(]@Q ,-Z'"+>$JMXZSM %U2QY/XJ[)&\>Y%VA>7V0GP965*
MR"(_$7' @)#P27YB8NI=O;V]O7Q!?4TD8U<!5?L*_EFI7N?K-DF3L_<-ORH1
MW"EH6,_5?#1$<$?2L'^^92$E#MD- )&66Z2E>G,<+8?1<2@1^PU)1G%$ -CM
M^SP=2FJ]F_*G2YNRU-DHDX#PC_P3< .5]!8"<7W(1< *2OU56<-ODD!<EWL*
M#SX)GRT6S)WPX $\0DW^&*GS@$XB:[^SR.VQ&>J?CT18@CLI!N9R(?B""H]1
M&5\@%8*9H)-/%VC<*Y%1_\,BSCN@)&JRT\'FG,37EP!B^8YBM[/F)\* 2OKI
M0H)4'!J,4)G9M^DD+_L PESV_X)[AXSS<@\@U/D_S_A"T+R, X@$=^H0M4?X
M$;PW&/BG#0[>_86!SQX'[62W2W4:-(ZP1?C6&OCK%3C.\)]166\$*H:"^N5R
MN^T6%E]2N^?^JO[>9BX$#IMH +=L06:XS4FT%RQ\& V>;DA[W6&OT[XW1\W[
M.[-C=AO-X9=F<S3,/,R)"#1#7U5#?PWC/82!H]'8QU 9(2XC0/8FD=&P3P1P
M-:,> SJ/%L\F-KVL<"9GEY7QEPW<__-*93<<P?\?FMW1L-?J]9L#<]2&MX?(
M+0&37F:UJZNZ3F9KI$:O9:S1ODFK-1SU&K]]Z77NFX-A\Q^/[='OJU$\5GPZ
MU'IYUF'SD%V>\7[^VPAZ6L.^R;C5,(=?6IW>MZ,GY!J17G[OKZYNLLL/L1H*
M[2N25=<</0Z:<1NW'B'X97;O^X/F$(9(_>RU6FUXUFB;G?78997F*;K2R/NZ
M>E6M!JXEDY;#I2\H_ AZW;2W?S4V>C:@:R/>-[9>]1[3DC>]R".L+A$"N'BB
M]]0CS)$_4$]VNM;I3?T*_CNKWB"ZB"+C+R%-K\E'&SX^/)B#WV$M;G_NMEOM
MA@DCUFCT'KNC=O=S'T:TT6YF-B09L>EM1:VJ]D(;,@\1J\5\C=I8XS8BY&^R
MVQKM/G>8Q6CF29X3JTZ6UU?UZ]WYFUV6L'<*NWF;DML"&)&Q<VJAACAU(JU=
MO:\=)]*@DS>!;@_^@#Y1UZ<#:O%IT/6AR_3)^M.OS3?U8^PT- XI,&(DO*W&
MV24W7O;)DHN&0Z0\IX;LZT>O&3_7583L>,T8+PW5MZ$Z?U.)1%$UB)P1U\9_
MFG_Z[(DXP/%YM$+?E5XQ/M15&.YPQ<!>#>@]^"/6_YMN)+MJ0"7P:%H6]V&D
MP-I2&#58A,^[OF3O5J\SMW45ZCM<9T)"C(@28TW*VW*309 MPL17XOB43UK,
M):[%B--VI2?4*>%YC$S&/K6:4[VJJR#CX9J#5!B*#(-/C!4A1HR2-[U)E.$W
MBMFAU#:?J"!3.IP18+KG>Y@+AEFH9U&<K)WJ-:<*/LQ1FA.140GI, )"C!@E
MKU)SS,8_'MO#=J[#OPT8;>BHBM&C;;G%P5_I2.>+%>R!U$8$JK7:[D8PCN0U
M[OGC_!_J9VEQZ U8'7QMK4A>>]P[/AA]P3&WG1PAGFT4>NF\!Z\V13J T% 8
M7Z5T.KWNYU%S\-"[Z[0_YTL5V0>J7S1NJKN;4L12031&#,_K%L">1_G6E5PX
M]2O.S[7==7ZOR!*>OL(%:<]0XQTIVW=@C]7A[G1$\7K/V,MI!7/CU9O&#[!M
MRR99\,C#?G!SACU5L"L#^WHSFADD\4?U7#+^H_HFY<*E;-JVZA,#)Q/T)/#'
MN2:WMC.]+MS"=OL$NK"FP(B1\*8BP=BU*)7$M0?$H_+1M:EH")"UUR(6<QA>
M=CA>,3)WH56'ZZMZ=6<SF:0.V*4Z#5"=&JI7(^C66/?[I@/F4=O0+*CT,JW6
MJQG=M=>^+6WT'A[:(Y6:9G;O&ST56&QV\^1@Z5!H-T+7U]7=DY88-I54MX'O
M33 X"H?.JSPH]?.K5J_N[&"U@GOU\VS8_(Q#T^ZV>H,'97LR'T/L0NIG%;BZ
MNZ=0 1(CAN55#W[.9+8D>&W0X/I];4_RP:X@7F-P8'=$#\X-2,>DMV4W]>KN
M<?\>*;U9L.V![BTHCH<[;;L@#MB@#2C6,T!E'M+I06?UQ_2A%_//]6H6JPA/
M5UT:09^X]UOW:D3=ODXE^&(.FH-F_W'0^&(.FUL_,XM9CT6_O'VH[CDJ1PS&
M&L7.@]<KHH/M:@H:_6R[K5?3A?2Z[>F@V<&;AWUS,/I]-#"[0[.AMJ1)S[,*
M+C=>[72K755W#W9#5(;"9<21:5Z]B?;@C5MF?-I)6:O6JWE$^;JGY_#Q#J^(
M@WO0_ K_RYXTM@FFGUS7U=US^34&0Z%XO6-^>+JP'HU^EM3JU529O*;-P"^7
MFR7!@M\;9<.P:%A8LU')$47R!];GI$(V^'Q!7:G:MET83ZS+-Z >M%6DS!G6
MA!Q+3Q#+^W0Q(0[6/\*2:)\N\J!PF>.@?_[IPA,^5E#"(ID?P95GW!ZI"D>V
M+Q2*Z-V8.(@(7M Q8I ^4,$\']M\%MQ??+H(&C*/SB^,H$Q2\&3.79"Y6+;A
M#2)?UU/;&88^%1;*>0I[%U0HV%=(CUO?%X)A7<,$SE.@\C";B2W7GR,X]IF!
MI^:"26[3WJ1!!#5E\)-9=P2T*;Q)<[_J/X'#7#A.SF_P) +*P/+HF7_Q75M0
M^P%H 1B@D3M/()>-4Z?E YV/L4C6FNN XH#IO%A.+V=5V?6CS>>$96';E,0E
M7[A<@-KI6=O7LG#R\:!VG3M_M^S0(#MZ@)V.T([,:,]-X2PGDL*9?B O;.[/
M0Q/2>W;!A,[8HL5%@TOO@7HS;H<O$V=G+ASI' ?U6+/:V'S&R+0\GS@-A["Y
M[)/E7,?6WK8YR/^1"T?;M>G<91,6E/DTYWB7*)&SA-8EY:W%A/1&,W"!9MRQ
M>Y/1#&;48CFDX@G,AQS0/WTFL-1S K>9X<^T<##7HU,J<AI0$ZB2R@/+;DIW
M80JW+R;\M*D=K%CF5%#U/H4E+4SA+.%K/L';G;CVHG%KNT]4>MCJ7B%)7-$S
M0!;.7LM7%X"":XC4;@D^;YB#YA#,8?(4T\&4UMD.;+H4U,$O"GBP1WDA4E*\
M ?6,WPMPIQ99, \+."9YWCE0'#$,EIH)YQH'+'  3LJ2J&6 3_#'(F!L3FSJ
M<>R6V0RP,==R?)0TVC0PJ!Y^A6%&G63C>QKD)5V9S#":T&B;J19MNV'A\WS
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M)=PO?+G$^K+]SKUY;3C0^IC!?=UE),Y4!N$04+ H!F6) P"B$]/@(Z TFM1
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MVT*GDA:JMU^:94IAVBAC%R9=)EB6404"D966!>4 G=:<A! 2%Y!%#DVNJ'L
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MY,1J)5&,UJ%)79)L.ZGOQLC[VSYWDOVX#\'U:-[,@< ?UX"@\2E&EU@M+$I
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MU HZ/(8^< 'H*1)T$^7V'<(^F<((ED&=DV\E/J]BZR'8$%5B28IJ]&;/0D[
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MNL?*B^U)E]TXLH,BFF2[W@<2:/TLH"53!0QY6?5J$)>&81&!G&R339MB*8_
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M/<;+%_4AQS,XOUE,P\;:TC,)AL;,"X-FYBU]I;BC!4Z[8#H:DG>?_;3UVX?
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MK$]4Q\&T1]/3"L;U'9Q=-9E!KN%C#IG1=EIO=Y*%%J(5+ J#!G,N%IH<KW7
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MG$CW =C2Q;H7X>.X757DV4-'=A?&GK:/VT"-,PX_*;ZDU R1H@RZ9-[A3L?
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MCER3)((./CG!E.@EV=7//RJY5J!PV]KV^;?+;\&/X;__[9]02P,$%     @
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M14!E V3HV$5!<T-PDG7S>]-^M.R_US"__ZV6_=:PW]LU#)P[<8S4>2>H "B
MDT%QO#O^4W_J3_VI_Z1-M9N(T(S((@3Z ^%TC1/.'DHWS^?+RM'<DWMFQV,$
MO+] !.C:U0T8AMYFW[U35)E2E3W?%#=SL#6'&F7LN@_=M>XW'F?J6X/V+\'O
M,]:ID,] KJ "[YMN4BUX28,FGV\MUF#;FI:OIUX1"(MZ )TP12\K%$ UMR2Z
M41O[6,A"_"V$[G6LEB92NY8<A6WUMNY-MT9V/(1N?U5IE,VF:^#-W*6#M*W6
M,"\5/-:MMQ-9<XTVVO</[RY;\66VB)JT,XSKJGQK!]L/0\IW"RW6I*.*P:IY
M*=E#EJ[:*-N""I2]V#-;V5X7D&6IHD2HG7T*BO,)3)H:^*E_4U63&!%F"S:7
M,*&KIDY/R/O+B<!%][I6Z3$RS?)*(I!HZ:Z\%[ZSO(,1[7,9NZ<5[[,S^XH^
M5Z&.KQ.)*.E0J3)(Z7O=7FR4H5K61[BNK4/S0O[%JLH%\<^3Y%AH1O^':N4&
MS_2\"#?G<2TB$".WE3$C1A"*E790RIVO%)E541GE2$$UMY'^ ?ZHSHY?SOD]
MT$.[B)[+(/,5ZK'PE>CCED^;&QD,/-J9;#HZ>^2D6PV"O447<?$[#.Z>!S>*
MF98\\]/G<B("W":3M1>:-O+B-AX_$*6G6W*&,NA;-!KVWD;H[+2"QSEV)8@
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M[4XX=5=N=%?9#*XF0SZ/^:$X\M'OO@>:344[PCU<(-[["Q%(ID/#2VH/*)?
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M-X$E9(%FOOO'MD0+A.EUW\VW(,+-_S)A+JX[>I@+;?BJS9%2V=Z9@N(X 6T
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MD\\CF_#^9.J/F-%P-2@ZR9I\R<5+@*Q!+_8'/T#\E1]X3/S*#QK6XMD4>?P
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MESEUB>]/\Y$*("G;6./N+6TG"ZAVM72+S%'N+-_ 53B_^?FG6V7=I>G!ZA2
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M[3V)QB 5M<Y173E;>^T_0K4#;<:YW_H/)4E_<0!K,W_W$ .9UWC#SU31_>X
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M".$SZLG0*!:\JY/)T4?C8U +"K2D0(D*M*QF%-$):3<Y] 74T+3@@I$Q)YB
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M+[ZJ3N>BRIISLU*<\2R*)H09RU37 PE@(C!2&]:80Q)% 4R3,*4$I;''D'E
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MPBB2H50F!V8Q@BAB"2042RABG$8A#P(AC;QCG"68VA:HT0'DK?1ZEFE!M2^
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MAVJ/)$5*:6A>8+I_^::VQ&VTT>FZBB,^,6O5FKFZ\\+%?C%#?08&J^3;#N[
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M[EQ1&'@^]P2 Q9[+%8B1=E0M$M6FJ46G)Y8[J7_GKF7GA?'V),?DW-EQ''W
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MBL,]T-0Z"O>P!3=+_%.^6"?WKKW&VX32L<]$G/(0AEQ7 J5I ).$15#&A*
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M#$$4D1 F3.TZO#"*HTAQ"L'$^+[=H,.I$4DMLN815@D-RE9J0%_U/QJY+6Z
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MA3&2Q$L(2K T\I8V[G%J[+ 6&,RUQ-O71U?J5VI2L%U;PHXTSH^ &7_TBNO
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MZ4+6- [S5$#C2$"EX@2B6"60)IX'<8*D%($2B436KL.C4TR-#VHAUZWRNF2
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M+28P<KIW]MP%LIW'>H%G8"9S1J933\^CVO?0T7-WW-'[>1Y5ZU@WS^,7=O3
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M!%-[(_?VO$WM<4>;^ !&.TOX$G#>P8=@ZS#HSSP^!5"?1O'!'*.:PJ<TW#>
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MAEWJ7BN/,G_YIM\X;9>*2!(:*9CXU#2I#3$D5$6F%3U2OL=#:M>*_MQ$4[-
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M59"&@8)$,(\SPDA,A%.1E*/33.UU+$5T+$UR'#\[;_SEJ(SBB6_$Z_$S:8=
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MD,MKMW^?R*(-[C,M5^B#T?.7*LIIHRK8Z-JLZ,9/8)+73\0_]5K[<.A%Z+E
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M'")J<C\YB?32^$3$DB8>CMQZ#IZ<:VJ4MBTJH-JPIEO"NO8?/(VP'8'UA-O
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MS<M?F]I9!'%%PI!!0D@ 4:3W&I0P"G$H]>]CIJ+0:H=A.=[4&*(5%^S)"XS
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M.Z(/6O7A+%X#5X$X/?YK5X4XBXQ%E8CSS^AY)+XVW'BGMDE5FR9(48 S)),
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MBD:9"ZV='W)J;%9)K)>6,LM+-$+K?[QL#>3&8A;0VY&77T 'YJP]+%MY0=V
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M%M"(J8#!5"44HB346WR41#!,,ADC)C$EJ5L!S[ZB6*VU4>M[-B'8OQGAY5R
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M:=J*H8Q"!E'&!208Z1E!81*@F,M 1![;"+?C3HW1+-H)_R^O_80W$V#'8 /
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MAS2*E1)*\22V:O3:/<S46.L;G=/"K".SLIA<2)6[VE8G\+0\Q;T8I:%WHD;
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MZ3J+0XI1($.8XBB!* VT*:GT=A&S5$J.(KV1M.I*<&J J5F050:W_JY*RA^
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M1@HCF$8L@0A%(20I4U#PF$5IFJ4D<'.2G1]S:JQSNQ#R<6$.%(J-M)Y*5.\
M;>E#\PO?T$ZUSD+56Y%'J%5]B,\HY:IWAIU&Q>I#'*R+5A^YM1_OW"[X\E%^
M6]%552#^FI6K@O+5#'&4IB@(8$2EYIJ0!A#CF$,A@A G21(SE;EPS8EQIL<O
M1DRPD1/\TDKJZ)D_A:L=M7A :V ZZ0.4,X.<@<$G:YP::E2F.*/O2W8X=_DE
MR8'7BYVFG=M:GN67Y3SGSS,>H" 4-()A)O4&2&EFH!2E$'/"4$18&&56@2DN
M@TZ/*S8"]DD6/(.P'5'XQFU@UFA2"4TFQ$X?WYT"O:7>"55"@U^:_QVD-Y +
M;/[3#\^,^PK9B'9('$].M+SW%!GM3NI'_:]_^Y?V-_H_C);RW_[E_P)02P,$
M%     @ H$"G4->JB)P2CP  H2X& !4   !A;65D+3(P,C P,S,Q7W!R92YX
M;6S<O6ES6SF2+OQ]?D6]=;^^Z,*^=,S,#7GK5HS+\MBJKCOW"P-+PN(T1;I)
MRF7/K[\)DMJW0_* !^J(;I<DRT0N#Q*9B43FO_[O[^>3G[[!?#&>3?_M9_8G
M^O-/,(VS-)Y^^;>??SM]1^S/__O?_^5?_O7_(^3_O/KT_J<WLWAQ#M/E3Z_G
MX)>0?OICO#S[Z?<$B[__E.>S\Y]^G\W_/O[F"?GWU3]Z/?OZ8S[^<K;\B5-.
M[_[M_,\I@996,B*  9$.-'$Z:>(=8TED*VP,__^7/R?A:=3"$Y=2)%)[30+/
MC@B5\)O(I<AB]:&3\?3O?RY_!+^ GY"YZ6+U[;_]?+9<?OWS+[_\\<<??_H>
MYI,_S>9??N&4BE\N?_OGS:]_O_?[?XC5;S/GW"^KO[WZU<7XH5_$CV6__)]?
MWW^.9W#NR7BZ6/II+ LLQG]>K'[X?A;]<B7S9^GZZ='?*-^1RU\CY4>$<2+8
MG[XOTL___B\__;06QWPV@4^0?RK__>W3\:TE_3FD\>+'XD]Q=OY+^85?7L\0
M#DCJZI\N?WR%?_MY,3[_.H'+GYW-(?_;S^4?DJ)3*M8+_J_U/_SE>MVO<U@@
M5%9\OL<?;/Y]665[&N#[$J8)UGQ=KC"9Q5N_-"E2G5W]RXD/,%G]=)1@/%I]
MZE%8+.<^+D=!.QJ,R<1EBI R@A+\UA+0#&AV)BMA;[-<2%X@S2LE+"#^Z<OL
MVR_XP:@,YLH7I'Q!*-NHX'_=6W0MG=VHO]QYI_B[HYQ9Y,9ZXCU31'(AB/4B
MDX!\6 $J:934_L3?7/,V[3=U>S2//\WF">9H0"X7]?-X3\^WP;OYC5^^^CE^
M$(EGX\D5R<62]*&WY:P'^:V5@^3^_!-RG6$^A_1^K9M'F5MQMD2S"JO?[$/O
M_WGAY_B)DQ^?X.MLOAQ)99A#+@C/J#<I8R!6Q4PX3^"95=DKUR,$[BS?"0V\
M?33L(]5&@/$1YN-9>CM-;_! '@GP-DJ=B16H2*D0WH[R2(R163AGJ&6J1UC<
M6KP3*$3[H-A=HHU XG3NIXMQ$?P&ULG(I$2P:.]2(M)[A'7VCD3.61;"9\5I
MG^?%G?4[ 4.V#XR]Y#HP-MY.E^/ECW?C"7RX. \P'VDK C/<D&BX)Q*\(C:@
M3\ULSM08HW+4/6#B[KJ=L*#:Q<)><FP" Y_@R[@(8;K\@*[W2$MG)+.2I%SL
MFZ"66%D<(J2=,B.4<M ;#FZOW0D+NG4L["'/)O!PC '_',W92O"?4?[P>G8Q
M7<Y_O)XE&#%I@C8B$5 R$!DX8!#.%8G..B$@8)S>1ZC1@91.:#&MHZ4_:3<!
MGE/__3BA^,9YO,YH;*QB9-8S*BS1(JER,M+"B"?9"R6Y$8:K_F#S"!&= &-;
M!TP?$FX"*D<IH0H6F_^\'T^!C0SP*%WQG:)#T7"-=E(K(#J;& /-61C9&TP>
M(* 31%SK$-E7LHW"@X^\BB:ZH(F0NC!A./')HKMM,>BRVFK72Y[K40*Z);WH
MR\/'=J)M"1^O\<N3^>GLC^E(4,FXD)9D+3(>EI(2KP5'R2AC/#76Z#Y28(\L
MWPT;#6=$^Q!K2\A8.5,G\X_SV;?Q-,+(*>V!.73$0Z)$4H9\0$0^:&+<,NUD
M8GW#XPX-W3#2<)ZT-P&W!)2/L\723_[O^.O*Y4XF6!Y8(DGG7 RA(MXK3H"J
M"-$92*:/BZ#'*>@&DH;SICT)=V"(% MX- >_HEL;P&C+,Z+Q+$3GVGCBA!3$
MA*!$%@%"SGW<#MY8LQL,&LZ2[BS @15?[N(G'\]FT\N,'G<\&F^!&*48D<P:
M$K(#(A./(OOHT6_J0?EWU^T&@(93HWL)<F 0?(9X,4< ,QY.Q\L)C*+D@JV2
MN3P@Q08E$4 ; EQ:P9/WFOH>0'!WW6X@:#@GNI<@!P;!Z=R7RJ?//\[#;#**
M*8H4\=CR.@OT@WTD7GI.+ 6+QQEXTTMB_-:BW=3?<))S=Q$V8@#>?H]G?OH%
M5KE\'U6.'@)AS*(!<Z@YEZ0BW -DY6-VM(\[LH?6[H:$AK.7>PNTB9#A]<6\
MB&M]WUN C3JX6(PRFC>C01$7HR[GF29>Q$B2BT$QIHQ._5V>/DQ#-X TG[OL
M0<!- .5XBI^&XAA_@S=^Z3=LC;A4S)F"]1 2"L>A'PQ:$X"HT#.*.=+^;E<?
MIJ%;K5;S2<P>!-P$4$KIP/RU7\*7V?S'B!EA?0)!A,LHDQP$<0HD^LF:>6LD
M=[F_'.:MI;O!HOG\Y>[B; (-;\]A_@7-WE_FLS^69Z]GYU_]],<H!T-%1AD8
MH CJ9 0)(3!B$J=&T:Q!]G<M]B )W=#1?.9R?_$V@9+/YWXR>76Q&$]AL1@Y
M"3S@^5BN]CC^(1'D4:!F8PK*4IXI%[VAX];2W5#1?*IR=W&V@88SF$PNL6RR
M<"PH1WC,> @"%"PK3K34)D:%/\W]W7+<7+D;%AK.5^XIS":@@(2?ES*B6?S[
MYS.4V^+D8EE>&Y48?.1, BN!8IR5,/I6HMS/E P\Y]DX%Y+7?53]/D])-Z@T
MG-GL6=@#0^?H'*:IU#._FW@DG$5O4*TD6X>15M8!O:7D5V]A,%KWD'JY1;^U
M:#= -)SEW%V$C3P1>#=>1#_Y+_#S=_@3C+>YTBHH2;13HMSE&N(I]40;<+[<
M\E+:A\?YR/+=\-!PVK,/L3:%C/4;F#435O&D#)Z*:,/02]*6$LL%D$Q3 C1[
M(>;^L7&#@&[H:#@5VH]HVW XD(VYGQQ/$WS_#_@Q"B&;*#0E*OF2X7?H/'.A
MB:%.:T%5-+*_ZHD[BW?#1?L9T#U$.G3-Q#H)=VWU+A_-(:IMS"J45W+E'67B
MQ$%.1"L=,D@>HNDC[?G8^MU>(C:<\NQ%L$T8C+_-)A<H^_DZ4;<8"2$\6,L(
M!E?(  ^">(^R <F,2-0+;?NX5W]P\6ZP:#[EN8](F\#$[QAR_\=T]L?T,_C%
M; KI>+&X*$\: @6GN"3))@R_<\XD* A$^1*7NQA\Z"_M^0@1W3#2?.*S#Q'W
MAI5__>6>,-_C#W9N47+RX?/)^^,W1Z=OW[PZ>G_TX?7;SW]]^_;T\VW".[8M
M>?3#^FEETHW6/=N;7"S(%^^_CE85NL73/,GOQE,_C6-T-V?K)\M7P.+4H+<)
MGBAG2T%.9,0:IDARP0O!<TCI 9?M<I-EOP@K=6_67.\TF"P7ES^YN^6V(6Y7
MVW*YQM%B <O%%:N,63P02[VIHAB8Z]+.@0=#J L20)<7N@_D-O9G]389P[1.
MJ8:)2V/3@\P'/(UN4[_QMZZ8L,BQM8#&T4,L<;LG/J*;Q9Q@UELTEOR!^HZ^
M@'.'FF'QLX]Z'T3*/K)N #"O_>+L:)K*?][^XV+\S4^0F<71\K6?SW^,IU_^
MYB<7,'(\I8@..8'@+6XH&TFP(1-M*/5:".O, W=T^P.H$W4M &HO%,QJJZ0!
MG'T"E,PX+F'%UTBY;'34CJ0<*)$"7;C@T&!+XQ+S-%LGJEBDVV0,T_>I'G+V
M$'(#$#F*L?0.6'R""(CZ,($/L+PLC%(Z<4@,2$PA$,E\(C8SCNY^CD('AQ$B
MKW*$/4'4,!VBZL&G-P4T *:/<_CJQ^GM]Z\P7< E$R%2E8QS1-&R(SB3Q ?%
M"*,2DL@9,G_@!?;^*'J0FF'Z2-6#S_XB;P W)\LSF-^2S2A%:I51!F5"5UU=
M+7'.&B(S-XJE+$$]\'IN?]#<)V68;E/U$+.GL!N RVWB6?;"&6:)L52B+$1$
MK+-,(O-.>Z^T$J;*(;4U2'HO1JAX*NTLXMWQ,5OZ24_'T.PKS)<_/DX\BF.:
MBD/_M:0O\&0=@0&JLS'$@<3@TTH@7M",?P06? 0=] .7!WV<1H\3U8)+W$MT
MWIOD&[ R)\B)+\])WH-?P*?2@?PD_[: E;A&&N,^].0Q$I0FH6<F O%>6&)#
MR%J!UM+6.9^>HJH%W[@7'/4G^P: ])?9+/TQGDQ&0CK/; :B8ZGO\Q@5X@]P
M/V3'HO J*?- ,>7^F+DDH 7?MQ=X["31!I!PC.*>?AECC+<6!EK%M]_CY*)4
M?U[Q)'.4'EUTXA#-1*I2!,B,*Z7E*DEK: @/M [8'R5=B&O!%^X%0;UKH@%T
MO=DL6]I#GL.I_W[%VDCY$,O\"Q*21+>>ENI2C4ZATXGY&!ANDRJ8>IRD%ASF
M7I#4D]0;P,^-P/##;!HWOK^EB6F?4;O.XV$;&"=6TD2L\EY"2IRY*N'5@]0,
MT[^UAH.SMZP; ,R:_I&,@E*=2HN64 YA@]$A!$HP_,P03:*65G&%U\L/TZ&U
MVLWF5M)L(-9^/_9A/!DOQ[# >&_UL.5L-D&A+TKLM_QQ)1I(T2J0: P#QGS2
M:4<<CPK]-:XS]Y9E6L6.="5PV!B\>H5%%3TU8(-N\'4W_Z68\]993U+POCSD
M1FO*I2<TB!BBD[B58F7$-56%40<"C^-L'WTT@*S+B[F/_D>YE;NZ6J'!*HJ;
M$,J%BO1%+C:4_J9<126D3+)*5<;#Y#2#J+V4_<B5Z!Z2;P _;\^_3F8_ #[!
MI(PYO"^KD4N>>VTD2:JT7U< >-0#)UQ:E%(1DJERO?XL9<.>A950U:\^&@ 8
M;I/YQ8.,J"Q!FN")92X41M" B_)N4'/GHP?#] -%\+W8J(<I&C8Q7<],]2#_
M!H#T?C;]<@KS\S<0EJL:N*_C$AZ4U/M)F(R_K!1UQ9S1Z(,ZJ8E+"KU0KB1Q
MX 3QB3FA#64\5+E VXK*85/=E0!73T\-@/#VE<^E!"][NXV$4\(%R,2;DNG'
M#48L,$K )BJB!,5$%9/V-%G#YL,KP:Q'332 JX?.>0FEB629=QQ*MQX1B$U6
MDIQ\%C0&CG]]F,!PV"QX+3.UG\1;2&IU,K0C:S JILB&B3*7E_>&6!DEL=3C
M_Z1DC%5Y&M2-O&:<^(K)AO[UU(#%>L3^WK@G *VB,"BD"&5JAF$!_4O\-C&K
ME,T^2:ABP)ZEK!D_OQ[F^M5."W K5U$W1'>#DQR2@')M*8/!@!A4(D%8ARZD
M2)Y%*;-XH 5#3W=_#Y+4C%]?$6#]Z*,!9-U@8A2LC3H[AKL@KF;)E5J*2$DR
M)G+!&#>QML_5C+-^D.S[5A)OP.<JG?'&R_/5JSL\RF?38F-A&@LK.E-F)4\D
M<1.*2#"4+;U7&7Y%C3;1/-2MM(>7D(_3U(SG7@],?6FD 4MT7T+'TTVUU\?2
M,QZUMES.Q^%B62X<3F?%YB*_2 5^XI=5VW!87$='WN:8,10BP)(D4E'D7N1,
MJ PQ&>$9I"HIL'[9&+:8YB 0'E#O#:#^X^6Z*S&L7C#?;#>*H3B/,27"!./E
M50<0YU0@2FCJE7'"\BKAZ]-D#=WI8CC W'_9UY?V&L#BC<:W]UA)0@6F-2-<
M4H^>2H[$.ZN)HRPH892Q4M4ZWA^A:>AJH&90V)?>&H#@44JK>BH_^>C'Z7BZ
M21?=X'"D,M,,5";14@S=2Z<'6]P:%0,Z.\8[:JOT-7J>M&$S*PT!LF<M-H#+
MTSGXQ<7\Q_4F&V5P$IG@)&.T1J17ODP]5$0D2ST(_%^=Q@OW21DVX=(0[O;4
MTO8X<VN<3>'+JEREIXJ1B_.+5?G+*LM49A;,X0RFB_$W6#]@>#];E+<+)_G4
M?Q^IA";>Z-(:5"8B!;K>/G"#NTGH"-;1&*L<S%O2.6QBIR&,UM1O X;R$RS]
M> KIK9]/472+&^R^@3R.X^6H]"G-F7,2$P"1@6KBJ9"$@92))4Y]KI(I>IZT
M81-&#8&T9RTV@,O[PAUY$Q1WY6&JD65L,2W1F9;EUILQE4WTJDJYRGU2ALWR
M-(2[/;740(K\U_%T-K\<8XAB&1F:1)1*$)[+3:-3C 1? C#)E Z)9IVJ6+N[
MA S[!JLAC.VEH28MV2ZB''$3@%H#A&M@Y;FT)0&R)D)Y[=&O2,E4>1'8#_F=
MT-S[2(@&T3P &AJPLL]=3)0"R, <X\0G:XF4'/F)3A#F9>80@LVL2C^[YP@;
MU@H?^GY[?]WTAK5#]:;_N%+$&2S'T4]N<[%GH_K;GURW:_T37!RRA7W0S#H#
M@20?T# "5>M:&L$%"Y0)RF65VJ:#M+"_&5*A"G&-\O'X]016ZTS3T7FQX/^S
M^OFC7;M&0HG +<*(KMP7+G"; GHSPCB)NUA$&JM<=/?%P-"7B3WC\(E\S^'T
MW(";BM(<+^']^%MINW*[D<\-D=QD?12,YS:BF#'(,Z7%92">E\[=.7IFA1>>
M5NE]O3VI0U\]5L9L9=TU@,[;%_=XW)W,5U)-JUN#CS!?37X=11:5HRBZG%;M
M$%GI)2\5T=1I3I-2U%4)WKN1-_1]8V445M!1<\A;#Q@^NEB>S>;C_X$THMZS
M (83QM# 2UMZ;S+E"+)!#<,-IGR5V^VGR1KZAO&@2-M+)XTB;#46+(U$#*FT
M-".)E6YYGI8VC%:AT0Y:1E !8A6'^G&2AKX7' !9.^BB453=+#0**@MC12;
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M#=AAE=G @?EZMD"FR@2258'+FJO%Y]DDC;Q4X$NQ/K HB*3*$.=$)"D&X2R
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MZX(X9Q3*@S$+1@11YUJG(D_#UM+7"$M; 4 S>P%9W.SE5S"%/$;QTLQ0NI%
M$!$]$%.2RLZ1F,L<3@$JUFDQ\ @]PY;?U\/@?H)O(N#X.)\AW:M4H0S.4!!
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M:;\F $\M4[4K0&?^^F^>_D03?R[0IQ.9E\8CF4@9+?$Z21(3M49QDQ'/-4Q
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M(:M 7 +\0[F48Y+ >:6I\7=):60(78_)H=VDW 1.>IG"3'%#Z "V5!%&(H/
M YI130QUB8H0M$]5ZEL..).[?LYI1Q#5F:N]C49WQO%7F(]G"04P7_;7VN_V
MY:0/*1@7"=/( 0I.$>?*+"'G),5@QM%<YWJEK?OBOC&VEYS;@4O9*NO!&F\N
MYF6#K!98S05Z>_YU,OL!L!X:=#&/9WX!9;;MB"?N)8L,C_[@\,"0CH0@H,Q
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MF3DOB;.IO*ZT^)4'18QE3#+FA#7^(#C<]H2N=ATR-/)VU4Z;6'MUL1A/8;&
MQ6K\4)'L90OP$76@@_-HT[W79=R;)S8H3U"(@3J?E1)5WOMO0^2P=R1#8[$O
M[36!S>["''$0RH; 21"K%JC:$*^9)$S9++V*TK@JR.Q.XK W)@?&927-M9OI
MN7I>\8 @N?=@*<U$,0T8JK$R)%,(0IT*04H\'W*5WCW;D]K(O/ #97KZTED+
M<<S-$.W!(5E"1"V,LD3HB$ZP*(]ZH_:$E^9QD@4><I6> ,]2UF1VIS=H/!5*
M[ZVG%H%W.=H<.'=2$)5HN;AD$<V[8D19%;E6!A2M$Z0\2$Z3V9J#06Q[C;2
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MR%R,JH"S5@!':8NJ#_.^6W_A'1=NZ0G@:(C:D^^G@*DW\^MMMH=QFB4N(]C
M'5D%SH&+3 *=(F,YR\Z7T!NDOJ_;4CK$L1"U)]<;,+\?):;Q.O?&!/)!;$K$
M+-I)D%E 3)F.BB''<Y@8?UNIG<-X:P<QNS&P;)MU<QTC67?@4),3$DN 8#S]
MASD9J_6GY"!=.)I/\-Q)M#].\-R%SPT@Y5'J88RD_@)Y CD1U0HMAX \@2N>
M&YV=MG$0M=)\@N=.@OU1@N<N7&X )3^%Y9H5VTHNS;SSKLY#TAX4D_6QQ"C
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M\LB,S)TBK=VD?W?E\9(U>Y'^WDQLSIVDF^_=;;-.K4M&[1UHI6J_\DS\2*6
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M5$/M@J9'&NH(DCL=K?4^+!;TV:_X,Z["]+(G_?7HJP-ILI>I'UJGB21-'8I
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M^P^8+2V^4(&&YYC'[VJ-VM[@[*@><61L][V^54=/2))RK<"Z^Z ).2B]6BB
M=8I0'&-BQ:AGU>SN7E 95+7T#)8_7V4\6>-V61G-\_O"> Y#V\?9.7].&W\)
MS(.9;>]5\@7F<MFZ]+F4(;H\81%4>!V7Z+MA>>+UY.@ /(S;D1[7^@?XX^O\
M45/S?:!>8(C^=U$XF0J&$U2&(]0!T*>'2%OZV#L8*!ZYB]D=87EQ>]41-"%*
MP>Z5SMYE3^UQ3A)@MJ\E[9:!LP]OA9Y\Z?_IA5'Y6]Q=Z5NT_K]02P,$%
M  @ H$"G4+Y#P??R!   >Q,  !@   !A;65D+3(P,C S,3 S>&5X>#,R,BYH
M=&W=6%MOVDH0?C^_8DIUVD3"5R A0")1("U2"BFXRNG3T=I>PRIFUUTO(?37
MGUE?$)=$H4_)::0@>^>R,]]<=KR==_UQS_MQ.X"Y6L1P^_W3S; '%<.R[FH]
MR^I[??CB?;V!NFD[X$G"4Z:8X"2VK,&H I6Y4DG+LE:KE;FJF4+.+&]B:55U
M*Q8BI6:HPLI51Z_@+R7AU5^==X8!?1$L%Y0K""0EBH:P3!F?P5U(TWLPC(*K
M)Y*U9+.Y M=V;;@3\IX]D)RNF(KI5:FG8^7O'2O;I..+<'W5"=D#L/"RPL)F
M(VJ<^8%[X=?JYY'O-QR7- .'.$WW[*QV_J^#1EK(GLND:AW3R\J<ZKU;==<\
M;R2JO6*AFK<<V_Z[7<GXKCJ1X HWDRB</^8Z#C0I^J@,$K,9;V7^: 5:H*3[
M)+B?2;'DH1&(6,B6G/DG;J-1+?_!-NW3=DY[;V=_;:W B,B"Q>O61X\M: HC
MNH*)6!#^L9IBK(R42A;EC"G[1=%X]"-[7>6^G:.>F'%J%+XZ;N;=X''.?*:@
MYIKNKFM/.Q5@"*AL+XB<,6XHD;3<>O+FO>P-)M[P>MCK>L/Q",;7<#L9CGK#
MV^X-7 ]'77S$I_$U<@PF6!J3Z??NR -O#$X3OIM3LV?"=-#+A)U:PZ[^!E)O
M')GN%+K]\:TWZ._X77I[89]IN+PO YAV)Y^ZH\'4&/]S,_@!W9ZG*:YM/Y\W
M6UGBN&\H2^I/8S'D$ C.:: ;'ZR8FH.:4_BV)!(C&:]A0A,A%8@(N@L:LG2=
M5F'( Q-.--^']TW7M=L]L4@(7V=O3OL44-6UD MP;.,;1$)F.G_F.H'R$%OB
M5R*#^8?WSIG=KCG5O 5NJ\SW+37BGE68!D(I^&S"9\9Y%7IS1B.X9ISP@)$8
MQE'$ M2/IFH]A4U5F%-)_34@2;%H#4K 8@WW7*QB&LYH%9*E3)<$0X24K=S/
M(<DMS H 2 HD%(ENZ-LR.YPZ>0H#ID3ZA-/4&#_&= W=($-1)T\5Z01]:S3;
MS^910L(0#PTCII%JN:ZI>_16;IV]_=0Z<4[!0QR*#(J6,:93@%&)&>ZR235)
M?RZ9I/J<2S5 >\"?$$PG"4[C)#S=($N#I<2C&M4,'H,YX3-:PNM<U.H([$4;
M" __9'#='%S&L;P6)*M>+&1%D#7$U0RG$GG"="4GDJ8:Y*HFDS@&%,/=L7*0
MD"#J:363BC85A0K#;"+28&JN99S'2"149GNF>]5F_BE]L8_89 6*C6J=Y^)Y
MT:4.7'PE3]SC/,F-?RDN/K96L2@S7Q$_IGL<6:V0I1)EI62S7K[B"QE2J?V-
M29+25OG0WIH-M'S^SO  X*JE(X$'2A*3=8OQS/)LWV(4=1NF74RC"D=0%9;V
M%).JF=,L%1X2+YH;V2?I.\)6IC[? @U/,8\O*[7*WISLZ!YQ9&SWO7[01T]
MXF(MQ[J]TX0<U%XNY, Z>2B.,;$4S$;3Y'&CJ BJ7GH%RU^O,EZL<;NHC/KY
MIC!>P]#F<79.7]/&WP)S=T3;^VQ\@XE<]*WL4$H06A&S$$JPCLOR[9B\\"ER
M-/J[03O28\R3'?#QN_V9"7D3ES<8D?\=Z">WDB&Z"<)[ /3I(=)6=L0=# ]/
M7+-LCZLBOYAJ21KCV/5 MV]K]NYQ*D]+$A^3>ZEHNPB<?7CA\^+W_+-W0<5O
M?BV579!=_0=02P$"% ,4    " "@0*=0UO#<N8;. 0#Z-!< $0
M    @ $     86UE9"TR,#(P,#,S,2YH=&U02P$"% ,4    " "@0*=0P09J
M'%$6  #%XP  $0              @ &US@$ 86UE9"TR,#(P,#,S,2YX<V10
M2P$"% ,4    " "@0*=0W>9W("H;   N#0$ %0              @ $UY0$
M86UE9"TR,#(P,#,S,5]C86PN>&UL4$L! A0#%     @ H$"G4+019.Q?90
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M9"TR,#(P,#,S,5]P<F4N>&UL4$L! A0#%     @ H$"G4+[?BS<A"   ;B0
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%;00    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6885166464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="nump">$ 491,685<span></span>
</td>
<td class="nump">$ 467,340<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of service, excluding depreciation and amortization</a></td>
<td class="nump">285,737<span></span>
</td>
<td class="nump">275,274<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and administrative expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Salaries and benefits</a></td>
<td class="nump">101,566<span></span>
</td>
<td class="nump">94,830<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash compensation</a></td>
<td class="nump">5,909<span></span>
</td>
<td class="nump">6,615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">Other</a></td>
<td class="nump">49,265<span></span>
</td>
<td class="nump">43,402<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">5,338<span></span>
</td>
<td class="nump">2,895<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="nump">447,815<span></span>
</td>
<td class="nump">423,016<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">43,870<span></span>
</td>
<td class="nump">44,324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterestAndDividend', window );">Interest income</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(3,231)<span></span>
</td>
<td class="num">(3,349)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in earnings from equity method investments</a></td>
<td class="nump">477<span></span>
</td>
<td class="nump">1,216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Miscellaneous, net</a></td>
<td class="nump">263<span></span>
</td>
<td class="nump">236<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense, net</a></td>
<td class="num">(2,478)<span></span>
</td>
<td class="num">(1,873)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income taxes</a></td>
<td class="nump">41,392<span></span>
</td>
<td class="nump">42,451<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(9,346)<span></span>
</td>
<td class="num">(10,878)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">32,046<span></span>
</td>
<td class="nump">31,573<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income attributable to noncontrolling interests</a></td>
<td class="num">(244)<span></span>
</td>
<td class="num">(269)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Amedisys, Inc.</a></td>
<td class="nump">$ 31,802<span></span>
</td>
<td class="nump">$ 31,304<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic earnings per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income attributable to Amedisys, Inc. common stockholders, basic (usd per share)</a></td>
<td class="nump">$ 0.98<span></span>
</td>
<td class="nump">$ 0.98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, basic (shares)</a></td>
<td class="nump">32,331<span></span>
</td>
<td class="nump">32,001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted earnings per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income attributable to Amedisys, Inc. common stockholders, diluted (usd per share)</a></td>
<td class="nump">$ 0.96<span></span>
</td>
<td class="nump">$ 0.95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, diluted (shares)</a></td>
<td class="nump">33,234<span></span>
</td>
<td class="nump">32,893<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of patient service revenue recognized, net of contractual allowances and discounts, less the provision for bad debts related to patient service revenue plus all other revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterestAndDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterestAndDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6783047360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value of Financial Instruments (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases', window );">Debt Instrument Carrying Amount Excluding Finance Leases</a></td>
<td class="nump">$ 391,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term Debt, Fair Value</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term Debt, Fair Value</a></td>
<td class="nump">383,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term Debt, Fair Value</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Carrying Amount Excluding Finance Leases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DebtInstrumentCarryingAmountExcludingFinanceLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6885268896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($) </div>
<div>visit</div>
</th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration', window );">Episode of care as episodic-based revenue (days)</a></td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration', window );">Net service revenue episode payment rate (days)</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PeriodOfCareAsEpisodicBasedRevenueDuration', window );">Period of care as episodic-based revenue (days)</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PercentageOfTotalReimbursementOfOutlierPayment', window );">Percentage of total reimbursement of outlier payment</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_HistoricalCollectionRateFromMedicare', window );">Historical collection rate from Medicare</a></td>
<td class="nump">99.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_HospiceMedicareRevenueRateAccountedForRoutineCare', window );">Hospice Medicare revenue rate accounted for routine care</a></td>
<td class="nump">97.00%<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_LowUtilizationPaymentAdjustmentNumberOfVisits', window );">Low utilization payment adjustment, maximum number of visits</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NonMedicareRevenueTermRates', window );">Non-Medicare revenue term rates</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_LowUtilizationPaymentAdjustmentNumberOfVisits', window );">Low utilization payment adjustment, maximum number of visits</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NonMedicareRevenueTermRates', window );">Non-Medicare revenue term rates</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_HistoricalCollectionRateFromMedicare', window );">Historical collection rate from Medicare</a></td>
<td class="nump">99.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember', window );">Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_HistoricalCollectionRateFromMedicare', window );">Historical collection rate from Medicare</a></td>
<td class="nump">99.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CapYearAxis=amed_CapYearTwoThousandThirteenThroughTwoThousandTwentyMember', window );">Cap Year 2013 Through 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities', window );">Estimated amounts due back to Medicare | $</a></td>
<td class="nump">$ 5.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=amed_MedicareRevenueMember', window );">Medicare Revenue | Revenue from Contract with Customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of net services revenue</a></td>
<td class="nump">74.00%<span></span>
</td>
<td class="nump">74.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the number of days in a home health episode of care.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_EpisodeOfCareAsEpisodicBasedRevenueDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimate of obligations due Medicare upon demand due to overages for the inpatient cap and/or overall payment cap.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_HistoricalCollectionRateFromMedicare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Historical collection rate from Medicare.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_HistoricalCollectionRateFromMedicare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_HospiceMedicareRevenueRateAccountedForRoutineCare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the percentage of the entity's Hospice net Medicare service revenue that is derived from routine care.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_HospiceMedicareRevenueRateAccountedForRoutineCare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_LowUtilizationPaymentAdjustmentNumberOfVisits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the visit threshold for a low utilization payment adjustment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_LowUtilizationPaymentAdjustmentNumberOfVisits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NetServiceRevenuePeriodOfCarePaymentRateDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NonMedicareRevenueTermRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-Medicare Revenue Term Rates as a percentage of Medicare Term Rates</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NonMedicareRevenueTermRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PercentageOfTotalReimbursementOfOutlierPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage at which total reimbursement is capped if cost of care is unusually costly.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PercentageOfTotalReimbursementOfOutlierPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PeriodOfCareAsEpisodicBasedRevenueDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the number of days in a home health period of care using PDGM</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PeriodOfCareAsEpisodicBasedRevenueDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13537-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CapYearAxis=amed_CapYearTwoThousandThirteenThroughTwoThousandTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CapYearAxis=amed_CapYearTwoThousandThirteenThroughTwoThousandTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=amed_MedicareRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=amed_MedicareRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6885169712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>May 01, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-24260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AMEDISYS INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">11-3131700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Street Name</a></td>
<td class="text">3854 American Way<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Suite</a></td>
<td class="text">Suite A<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City</a></td>
<td class="text">Baton Rouge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State</a></td>
<td class="text">LA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">70816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">292-2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of each class</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AMED<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Name of each exchange on which registered</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,379,165<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000896262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6885509440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statement - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Noncontrolling Interests</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Stockholders Equity at Dec. 31, 2018</a></td>
<td class="nump">$ 482,633<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">$ 603,666<span></span>
</td>
<td class="num">$ (241,685)<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 119,550<span></span>
</td>
<td class="nump">$ 1,051<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,252,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock - employee stock purchase plan</a></td>
<td class="nump">782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock - employee stock purchase plan (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch', window );">Issuance of stock - 401(k) plan</a></td>
<td class="nump">2,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch', window );">Issuance of stock - 401(k) plan (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance/(cancellation) of non-vested stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance/(cancellation) of non-vested stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Non-cash compensation</a></td>
<td class="nump">6,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_SurrenderedShares', window );">Surrendered Shares</a></td>
<td class="num">(2,688)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,688)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interest distribution</a></td>
<td class="num">(366)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(366)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">31,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,304<span></span>
</td>
<td class="nump">269<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Stockholders Equity at Mar. 31, 2019</a></td>
<td class="nump">521,200<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">613,714<span></span>
</td>
<td class="num">(244,373)<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">150,854<span></span>
</td>
<td class="nump">954<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,337,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Stockholders Equity at Dec. 31, 2019</a></td>
<td class="nump">641,513<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">645,256<span></span>
</td>
<td class="num">(251,241)<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">246,383<span></span>
</td>
<td class="nump">1,063<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,638,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock - employee stock purchase plan</a></td>
<td class="nump">860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock - employee stock purchase plan (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch', window );">Issuance of stock - 401(k) plan</a></td>
<td class="nump">3,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch', window );">Issuance of stock - 401(k) plan (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance/(cancellation) of non-vested stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance/(cancellation) of non-vested stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">1,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Non-cash compensation</a></td>
<td class="nump">5,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_SurrenderedShares', window );">Surrendered Shares</a></td>
<td class="num">(4,050)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,050)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interest distribution</a></td>
<td class="num">(360)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(360)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome', window );">Write-off of other comprehensive income</a></td>
<td class="num">(15)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">32,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,802<span></span>
</td>
<td class="nump">244<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Stockholders Equity at Mar. 31, 2020</a></td>
<td class="nump">$ 680,144<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">$ 656,266<span></span>
</td>
<td class="num">$ (255,291)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 278,185<span></span>
</td>
<td class="nump">$ 947<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,746,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Impact of Write Off of Other Comprehensive Income</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period to employees as employer's matching contribution to the company's 401(K) plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period to employees as employer's matching contribution to the company's 401(K) plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_SurrenderedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares of common stock surrendered by certain employees to satisfy obligations in connection with the vesting of stock. Shares held in Treasury Stock at cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_SurrenderedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116855982&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6875346528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">ACQUISITIONS</a></td>
<td class="text">ACQUISITIONS<div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We complete acquisitions from time to time in order to pursue our strategy of increasing our market presence by expanding our service base and enhancing our position in certain geographic areas as a leading provider of home health, hospice and personal care services. The purchase price paid for acquisitions is negotiated through arm&#8217;s length transactions, with consideration based on our analysis of, among other things, comparable acquisitions and expected cash flows. Acquisitions are accounted for as purchases and are included in our condensed consolidated financial statements from their respective acquisition dates. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets because of the expected contributions of the acquisitions to our overall corporate strategy. We typically engage outside appraisal firms to assist in the fair value determination of identifiable intangible assets for significant acquisitions. The preliminary purchase price allocation is adjusted, as necessary, up to one year after the acquisition closing date if management obtains more information regarding asset valuations and liabilities assumed.</span></div><div style="text-align:justify;margin-top:16pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Home Health Division</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On March 1, 2020, we acquired the regulatory assets of a home health provider in Washington for a purchase price of $3.0&#160;million. The purchase price was paid with cash on hand on the date of the transaction. Based on the Company's preliminary valuation, we recorded goodwill of $2.8&#160;million and other intangibles (certificate of need) of $0.2&#160;million in connection with the acquisition.</span></div><div style="text-align:justify;margin-top:16pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Hospice Division</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On January 1, 2020, we acquired Asana Hospice ("Asana"), a hospice provider with locations in Pennsylvania, Ohio, Texas, Missouri and Kansas for a purchase price of $66.3&#160;million, net of cash acquired of $0.7&#160;million.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is in the process of finalizing its valuation of the assets acquired and liabilities assumed. Based on the Company's preliminary valuation, the total estimated consideration of $66.3&#160;million has been allocated to assets acquired and liabilities assumed as of the acquisition date as follows (amounts in millions):</span></div><div style="text-align:center;margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:79.970%;"><tr><td style="width:1.0%;"/><td style="width:73.137%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:22.863%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Patient accounts receivable</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease right of use assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Intangible assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Total assets acquired</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payroll and employee benefits</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Total liabilities assumed</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net identifiable assets acquired</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">59.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total estimated consideration</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">66.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:6pt;"><span><br/></span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Intangible assets acquired include licenses ($2.0&#160;million), acquired names ($1.3&#160;million) and non-compete agreements ($2.3&#160;million). The acquired names and non-compete agreements will be amortized over a weighted-average period of 2.0 years.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Asana contributed approximately $7.4&#160;million in net service revenue and an operating loss of $1.3&#160;million (inclusive of acquisition and integration costs totaling $1.1&#160;million and intangibles amortization totaling $0.5&#160;million) during the three-month period ended March 31, 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6878787536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Weighted-Average Shares Outstanding (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares outstanding - basic (shares)</a></td>
<td class="nump">32,331<span></span>
</td>
<td class="nump">32,001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock options (shares)</a></td>
<td class="nump">594<span></span>
</td>
<td class="nump">559<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NonVestedStockAndStockUnits', window );">Non-vested stock and stock units (shares)</a></td>
<td class="nump">309<span></span>
</td>
<td class="nump">333<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of shares outstanding - diluted (shares)</a></td>
<td class="nump">33,234<span></span>
</td>
<td class="nump">32,893<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (shares)</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">148<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NonVestedStockAndStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non vested stock and stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NonVestedStockAndStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1500-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6782312960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue by Payor Class (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue', window );">Revenue by payor class as a percentage of total net service revenue</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PayorClassAxis=amed_HomeHealthMedicareMember', window );">Home Health Medicare [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue', window );">Revenue by payor class as a percentage of total net service revenue</a></td>
<td class="nump">41.00%<span></span>
</td>
<td class="nump">46.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PayorClassAxis=amed_HomeHealthNonMedicareEpisodicBasedMember', window );">Home Health Non-Medicare - Episodic Based [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue', window );">Revenue by payor class as a percentage of total net service revenue</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PayorClassAxis=amed_HomeHealthNonMedicareNonEpisodicBasedMember', window );">Home Health Non-Medicare - Non-Episodic Based [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue', window );">Revenue by payor class as a percentage of total net service revenue</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PayorClassAxis=amed_HospiceMedicareMember', window );">Hospice Medicare [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue', window );">Revenue by payor class as a percentage of total net service revenue</a></td>
<td class="nump">33.00%<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PayorClassAxis=amed_HospiceNonMedicareMember', window );">Hospice Non-Medicare [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue', window );">Revenue by payor class as a percentage of total net service revenue</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PayorClassAxis=amed_PersonalCareMember', window );">Personal Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue', window );">Revenue by payor class as a percentage of total net service revenue</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue by payor class as a percentage of total net service revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PayorClassAxis=amed_HomeHealthMedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PayorClassAxis=amed_HomeHealthMedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PayorClassAxis=amed_HomeHealthNonMedicareEpisodicBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PayorClassAxis=amed_HomeHealthNonMedicareEpisodicBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PayorClassAxis=amed_HomeHealthNonMedicareNonEpisodicBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PayorClassAxis=amed_HomeHealthNonMedicareNonEpisodicBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PayorClassAxis=amed_HospiceMedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PayorClassAxis=amed_HospiceMedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PayorClassAxis=amed_HospiceNonMedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PayorClassAxis=amed_HospiceNonMedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PayorClassAxis=amed_PersonalCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PayorClassAxis=amed_PersonalCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6875369424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM OBLIGATIONS LONG-TERM OBLIGATIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Long-Term Debt</a></td>
<td class="text"><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Long-term debt consisted of the following for the periods indicated (amounts in millions):</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:91.812%;"><tr><td style="width:1.0%;"/><td style="width:65.356%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:13.923%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.596%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.925%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">$175.0 million Term Loan; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate (2.5% at March 31, 2020); due February&#160;4, 2024</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">170.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">171.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">$550.0 million Revolving Credit Facility; interest only payments; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate (2.4% at March 31, 2020); due February&#160;4, 2024</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">220.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">70.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Promissory notes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finance leases</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Principal amount of long-term obligations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">394.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">245.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred debt issuance costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">391.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">242.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current portion of long-term obligations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">379.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">232.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock', window );">Schedule of Commitment Fee Under Credit Facilities</a></td>
<td class="text">We are also subject to a commitment fee and letter of credit fee under the terms of the Amended Credit Agreement, as presented in the table below.<table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:92.251%;"><tr><td style="width:1.0%;"/><td style="width:9.251%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:25.258%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.908%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.836%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.908%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.839%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pricing Tier</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Consolidated Leverage Ratio</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commitment Fee</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Letter of Credit Fee</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Eurodollar Rate Loans</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Base Rate Loans</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">I</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#8805; 3.00 to 1.0</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.35%</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.75%</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.00%</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.00%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">II</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&lt; 3.00 to 1.0 but &#8805; 2.00 to 1.0</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.30%</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.50%</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.75%</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.75%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">III</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&lt; 2.00 to 1.0 but &#8805; 0.75 to 1.0</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.25%</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.25%</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.50%</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.50%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">IV</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&lt; 0.75 to 1.0</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.20%</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.00%</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.25%</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.25%</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(e),(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(e),(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6592149760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENT<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENT</a></td>
<td class="text">SUBSEQUENT EVENTS<div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Novel Coronavirus Pandemic ("COVID-19")</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2020, the World Health Organization declared COVID-19 a pandemic. As a healthcare at home company, we have been and will continue to be impacted by the effects of COVID-19; however, we remain committed to carrying out our mission of caring for our patients. We will continue to closely monitor the impact of COVID-19 on all aspects of our business, including the impacts to our employees, patients and suppliers; however, at this time, we are unable to estimate the ultimate impact the pandemic will have on our consolidated financial condition, results of operations or cash flows.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On March 27, 2020, the bipartisan Coronavirus Aid, Relief, and Economic Security Act ("CARES Act") was signed into legislation. The CARES Act provides for $100&#160;billion to healthcare providers, including hospitals on the front lines of the COVID-19 pandemic. Of this total allocated amount, $30&#160;billion was distributed immediately to providers based on their proportionate share of Medicare fee-for-service reimbursements in 2019. Healthcare providers must sign an attestation confirming receipt of the funds and agree to the terms and conditions of payment. We received approximately $100&#160;million from the first $30&#160;billion of funds distributed to healthcare providers in April 2020. Consistent with the terms and conditions for receipt of the payment, we will utilize the funds to cover lost revenue and health care costs related to COVID-19, and we will properly and fully document the use of these funds in required quarterly reports to the U.S. Department of Health and Human Services ("HHS").</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In order to properly attest to receipt of our payment, we are seeking clarity from HHS regarding the formula utilized to determine our receipt of funds and the total amount of funds available to us to be used towards lost revenue and health care expenses related to COVID-19. At this time, we have fully separated these funds into their own account and will not be utilizing any of them until additional clarity is received from HHS.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On April 24, 2020, HHS distributed an additional $20&#160;billion in funds to healthcare providers. We did not receive, nor apply, for any additional funds from this second distribution.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Acquisitions</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On April 23, 2020, we signed a definitive agreement to acquire Homecare Preferred Choice, Inc., doing business as AseraCare Hospice ("AseraCare Hospice"), a national hospice care provider with 44 locations, for a purchase price of $235&#160;million in cash, inclusive of $32&#160;million in payments related to the present value of the tax benefits created through the transaction (subject to customary adjustments at closing for working capital, cash indebtedness and transaction expenses). We will not use any of the funds we received from the CARES Act to fund the acquisition.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6875351424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Legal Proceedings - Ongoing</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are involved in the following legal actions:</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Subpoena Duces Tecum and Civil Investigative Demands Issued by the U.S. Department of Justice</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On May&#160;21, 2015, we received a Subpoena Duces Tecum (&#8220;Subpoena&#8221;) issued by the U.S. Department of Justice. The Subpoena requests the delivery of information regarding 53 identified hospice patients to the United States Attorney&#8217;s Office for the District of Massachusetts. It also requests the delivery of documents relating to our hospice clinical and business operations and related compliance activities. The Subpoena generally covers the period from January&#160;1, 2011 through May&#160;21, 2015. We are fully cooperating with the U.S. Department of Justice with respect to this investigation. </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On November&#160;3, 2015, we received a civil investigative demand (&#8220;CID&#8221;) issued by the U.S. Department of Justice pursuant to the federal False Claims Act relating to claims submitted to Medicare and/or Medicaid for hospice services provided through designated facilities in the Morgantown, West Virginia area. The CID requests the delivery of information to the United States Attorney&#8217;s Office for the Northern District of West Virginia regarding 66 identified hospice patients, as well as documents relating to our hospice clinical and business operations in the Morgantown area. The CID generally covers the period from January&#160;1, 2009 through August 31, 2015. We are fully cooperating with the U.S. Department of Justice with respect to this investigation. </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On June&#160;27, 2016, we received a CID issued by the U.S. Department of Justice pursuant to the federal False Claims Act relating to claims submitted to Medicare and/or Medicaid for hospice services provided through designated facilities in the Parkersburg, West Virginia area. The CID requests the delivery of information to the United States Attorney&#8217;s Office for the Southern District of West Virginia regarding 68 identified hospice patients, as well as documents relating to our hospice clinical and business operations in the Parkersburg area. The CID generally covers the period from January&#160;1, 2011 through June&#160;20, 2016. We are fully cooperating with the U.S. Department of Justice with respect to this investigation. </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Based on our analysis of sample claims data in connection with preliminary settlement discussions with the U.S. Department of Justice regarding the above matters, we have recorded a total of $6.5 million to accrued expenses in our condensed consolidated balance sheet related to this matter. Due to the ongoing nature of the investigations and current stage of the settlement discussions, we are unable to estimate a range of potential loss at this time, and we cannot predict the timing or outcome of these investigations.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition to the matters referenced in this note, we are involved in legal actions in the normal course of business, some of which seek monetary damages, including claims for punitive damages. We do not believe that these normal course actions, when finally concluded and determined, will have a material impact on our consolidated financial condition, results of operations or cash flows.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Legal fees related to all legal matters are expensed as incurred.</span></div><div style="text-align:justify;margin-top:16pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other Investigative Matters - Ongoing</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Compassionate Care Hospice Corporate Integrity Agreement</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On January 30, 2015, CCH entered into a corporate integrity agreement ("CIA") with the Office of Inspector General-HHS (&#8220;OIG&#8221;). The CIA required that CCH provide annual on-site compliance training; develop and implement policies to ensure compliance with federal health care program requirements; screen new and current employees to ensure that they are eligible to participate in federal health care programs;&#160;establish a compliance committee that contains both a Compliance Officer and a&#160;Chief Quality Officer; retain a Governing Authority expert who will periodically complete a compliance program review; and retain an independent review organization ("IRO") to complete claims reviews for hospice services rendered in New York. The OIG waived the claims review for the final year of the CCH CIA based on the closure of the New York operations. Additionally, the CIA required that CCH report substantial overpayments that CCH discovered it had received from federal health care programs, as well as probable violations of federal criminal, civil or administrative health care laws. Upon breach of the CIA, CCH could have become liable for payment of certain stipulated penalties, or could have been excluded from participation in federal health care programs. The CIA had a term of five years that ended on January 30, 2020. We filed our final annual report on March 25, 2020.</span></div><div style="text-align:justify;margin-top:16pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other Investigative Matters - Completed</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Corporate Integrity Agreement</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On April&#160;23, 2014, with no admissions of liability on our part, we entered into a settlement agreement with the U.S. Department of Justice relating to certain of our clinical and business operations. Concurrently with our entry into this agreement, we entered into a CIA with the OIG. The CIA formalized various aspects of our already existing ethics and compliance programs and contained other requirements designed to help ensure our ongoing compliance with federal health care program requirements. Among other things, the CIA required us to maintain our existing compliance program, executive compliance committee and compliance committee of the Board of Directors; provide certain compliance training; continue screening new and current employees to ensure they are eligible to participate in federal health care programs; engage an IRO to perform certain auditing and reviews and prepare certain reports regarding our compliance with federal health care programs, our billing submissions to federal health care programs and our compliance and risk mitigation programs; and provide certain reports and management certifications to the OIG. Additionally, the CIA specifically required that we report substantial overpayments that we discovered we had received from federal health care programs, as well as probable violations of federal health care laws. The corporate integrity agreement had a term of five years that ended on April 21, 2019. We filed our final annual report on July 19, 2019. On May 5, 2020, the Company received notice from the OIG that the Company's five-year CIA with the OIG has been completed. </span></div><div style="text-align:justify;margin-top:16pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Third Party Audits - Ongoing</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">From time to time, in the ordinary course of business, we are subject to audits under various governmental programs including Recovery Audit Contractors (&#8220;RACs&#8221;), Zone Program Integrity Contractors (&#8220;ZPICs&#8221;), Uniform Program Integrity Contractors ("UPICs"), Program Safeguard Contractors (&#8220;PSCs&#8221;) and Medicaid Integrity Contributors (&#8220;MICs&#8221;) in which third party firms engaged by CMS conduct extensive reviews of claims data to identify potential improper payments. We cannot predict the ultimate outcome of any regulatory reviews or other governmental audits and investigations.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In July 2010, our subsidiary that provides hospice services in Florence, South Carolina received from a ZPIC a request for records regarding a sample of 30 beneficiaries who received services from the subsidiary during the period of January&#160;1, 2008 through March&#160;31, 2010 (the &#8220;Review Period&#8221;) to determine whether the underlying services met pertinent Medicare payment requirements.&#160;We acquired the hospice operations subject to this review on August&#160;1, 2009; the Review Period covers time periods both before and after our ownership of these hospice operations.&#160;Based on the ZPIC&#8217;s findings for 16 beneficiaries, which were extrapolated to all claims for hospice services provided by the Florence subsidiary billed during the Review Period, on June&#160;6, 2011, the Medicare Administrative Contractor (&#8220;MAC&#8221;) for the subsidiary issued a notice of overpayment seeking recovery from our subsidiary of an alleged overpayment. We dispute these findings, and our Florence subsidiary has filed appeals through the Original Medicare Standard Appeals Process, in which we are seeking to have those findings overturned. An administrative law judge ("ALJ") hearing was held in early January 2015. On January&#160;18, 2016, we received a letter dated January&#160;6, 2016 referencing the ALJ hearing decision for the overpayment issued on June&#160;6, 2011. The decision was partially favorable with a new overpayment amount of $3.7 million with a balance owed of $5.6 million, including interest, based on 9 disputed claims (originally 16). We filed an appeal to the Medicare Appeals Council on the remaining 9 disputed claims and also argued that the statistical method used to select the sample was not valid.&#160;No assurances can be given as to the timing or outcome of the Medicare Appeals Council decision. As of March&#160;31, 2020, Medicare has withheld payments of $5.7 million (including additional interest) as part of their standard procedures once this level of the appeal process has been reached. In the event we are not able to recoup this alleged overpayment, we are entitled to be indemnified by the prior owners of the hospice operations for amounts relating to the period prior to August&#160;1, 2009. On January 10, 2019, an arbitration panel from the American Health Lawyers Association determined that the prior owners' liability for their indemnification obligation was $2.8 million. Accordingly, the Company reduced its indemnity receivable from $4.9 million to $2.8 million. </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In July 2016, the Company received a request for medical records from SafeGuard Services, L.L.C (&#8220;SafeGuard&#8221;), a ZPIC, related to services provided by some of the care centers that the Company acquired from Infinity Home Care, L.L.C. The review period covers time periods both before and after our ownership of the care centers, which were acquired on December&#160;31, 2015. In August 2017, the Company received Requests for Repayment from Palmetto GBA, LLC ("Palmetto") regarding Infinity Home Care of Lakeland, LLC ("Lakeland Care Centers") and Infinity Home Care of Pinellas, LLC ("Clearwater Care Center"). The Palmetto letters are based on a statistical extrapolation performed by SafeGuard which alleged an overpayment of $34.0 million for the Lakeland Care Centers on a universe of 72 Medicare claims totaling $0.2 million in actual claims payments using a 100% error rate and an overpayment of $4.8 million for the Clearwater Care Center on a universe of 70 Medicare claims totaling $0.2 million in actual claims payments using a 100% error rate.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Lakeland Request for Repayment covers claims between January 2, 2014 and September 13, 2016. The Clearwater Request for Repayment covers claims between January 2, 2015 and December 9, 2016. As a result of partially successful Level I and Level II Administrative Appeals, the alleged overpayment for the Lakeland Care Centers has been reduced to $26.0 million and the alleged overpayment for the Clearwater Care Center has been reduced to $3.3 million. The Company has now filed Level III Administrative Appeals, and will continue to vigorously pursue its appeal rights, which include contesting the methodology used by the ZPIC contractor to perform statistical extrapolation. The Company is contractually entitled to indemnification by the prior owners for all claims prior to December 31, 2015, for up to $12.6 million.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At this stage of the review, based on the information currently available to the Company, the Company cannot predict the timing or outcome of this review. The Company estimates a low-end potential range of loss related to this review of $6.5 million (assuming the Company is successful in seeking indemnity from the prior owners and unsuccessful in demonstrating that the extrapolation method used by SafeGuard was erroneous). The Company has reduced its high-end potential range of loss from $38.8 million (the maximum amount Palmetto claims has been overpaid for both the Lakeland Care Centers and the Clearwater Care Center, of which amount $12.6 million is subject to indemnification by the prior owners) to $29.3 million based on the partial success achieved by the Company in prosecuting its Level I and II Administrative Appeals.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March&#160;31, 2020, we have an accrued liability of approximately $17.4 million related to this matter. We expect to be indemnified by the prior owners for approximately $10.9 million of the total $12.6 million available indemnification related to this matter and have recorded this amount within other assets in our condensed consolidated balance sheet as of March&#160;31, 2020. The net of these two amounts, $6.5 million, was recorded as a reduction in revenue in our condensed consolidated statements of operations during 2017. As of March&#160;31, 2020, $1.5 million of receivables have been impacted by this payment suspension.</span></div><div style="text-align:justify;margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Insurance</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are obligated for certain costs associated with our insurance programs, including employee health, workers&#8217; compensation and professional liability. While we maintain various insurance programs to cover these risks, we are self-insured for a substantial portion of our potential claims. We recognize our obligations associated with these costs, up to specified deductible limits in the period in which a claim is incurred, including with respect to both reported claims and claims incurred but not reported. These costs have generally been estimated based on historical data of our claims experience. Such estimates, and the resulting reserves, are reviewed and updated by us on a quarterly basis.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our health insurance has an exposure limit of $1.3 million for any individual covered life. Our workers&#8217; compensation insurance has a retention limit of $1.0 million per incident and our professional liability insurance has a retention limit of $0.3 million per incident.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6887806096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM OBLIGATIONS - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">14 Months Ended</th>
<th class="th" colspan="1">36 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 04, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Feb. 04, 2024</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 847,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_TotalLeverageRatio', window );">Consolidated leverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ConsolidatedInterestCoverageRatio', window );">Consolidated interest coverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility, maximum borrowing capacity</a></td>
<td class="nump">$ 725,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 394,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 245,700,000<span></span>
</td>
<td class="nump">$ 394,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Term Loan [Member] | One Hundred Seventy Five Million Term Loan Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime', window );">Weighted average interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb.  04,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 170,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171,700,000<span></span>
</td>
<td class="nump">170,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member] | 550 Million Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 550,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">550,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime', window );">Weighted average interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb.  04,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Remaining availability under revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 299,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">299,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000,000.0<span></span>
</td>
<td class="nump">220,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit [Member] | 550 Million Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Outstanding letters of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_AmendedCreditAgreementMember', window );">Amended Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">Feb.  04,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate', window );">Additional interest rate above Federal Fund rate</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate', window );">Additional interest rate above Eurodollar rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries', window );">Percentage of consolidated revenue and adjusted EBITDA that guarantor wholly-owned subsidiaries represent</a></td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries', window );">Percentage of adjusted EBITDA that guarantor subsidiaries represent</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_AmendedCreditAgreementMember', window );">Amended Credit Agreement [Member] | 550 Million Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">$ 550,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_AmendedCreditAgreementMember', window );">Amended Credit Agreement [Member] | One Hundred Seventy Five Million Term Loan Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DebtInstrumentPeriodicPaymentPercentage', window );">Debt Instrument Periodic Payment Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">$ 175,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember', window );">Base Rate [Member] | Amended Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Description of variable rate basis</a></td>
<td class="text">Fluctuating rate per annum equal to the highest of (a)&#160;the federal funds rate plus 0.50% per annum, (b)&#160;the prime rate of interest established by the Administrative Agent, and (c)&#160;the Eurodollar Rate for an interest period of one month plus 1% per annum.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember', window );">Base Rate [Member] | Amended Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember', window );">Eurodollar [Member] | Amended Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Description of variable rate basis</a></td>
<td class="text">Rate at which Eurodollar deposits in the London interbank market for an interest period of one, two, three or six months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember', window );">Eurodollar [Member] | Term Loan [Member] | One Hundred Seventy Five Million Term Loan Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DebtInstrumentInterestRateatPeriodEnd', window );">Debt Instrument Interest Rate at Period End</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember', window );">Eurodollar [Member] | Revolving Credit Facility [Member] | 550 Million Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DebtInstrumentInterestRateatPeriodEnd', window );">Debt Instrument Interest Rate at Period End</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember', window );">Eurodollar [Member] | Amended Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Amended Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ProceedsReceivedFromLoanPartyOfSubsidiary', window );">Proceeds Received From Loan Party Of Subsidiary</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Amended Credit Agreement [Member] | One Hundred Seventy Five Million Term Loan Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DebtInstrumentPeriodicPaymentPercentage', window );">Debt Instrument Periodic Payment Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ConsolidatedInterestCoverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio of adjusted earnings before interest, taxes, depreciation and amortization to cash interest charges</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ConsolidatedInterestCoverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Interest Additional Interest Above Eurodollar Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Interest Additional Interest Above Federal Fund Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DebtInstrumentInterestRateatPeriodEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Interest Rate at Period End</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DebtInstrumentInterestRateatPeriodEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DebtInstrumentPeriodicPaymentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of the Term Loan that is required as periodic payments including both interest and principal payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DebtInstrumentPeriodicPaymentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of adjusted EBITDA that guarantor subsidiaries represent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of consolidated net revenues and adjusted EBITDA that guarantor wholly-owned subsidiaries represent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ProceedsReceivedFromLoanPartyOfSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds Received From Loan Party Of Subsidiary</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ProceedsReceivedFromLoanPartyOfSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_TotalLeverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio of debt to earnings before interest, taxes, depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_TotalLeverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The reference rate for the variable rate of the debt instrument, such as LIBOR or the US Treasury rate and the maturity of the reference rate used, such as three months or six months LIBOR.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescriptionOfVariableRateBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of long-term debt outstanding calculated over time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtWeightedAverageInterestRateOverTime</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_OneHundredSeventyFiveMillionTermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_OneHundredSeventyFiveMillionTermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=amed_AmendedCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=amed_AmendedCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_AmendedCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_AmendedCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_EurodollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6885046528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SHARE REPURCHASE Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Feb. 25, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ShareRepurchaseLineItems', window );"><strong>Share Repurchase [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock Repurchase Program, Authorized Amount</a></td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramExpirationDate', window );">Stock Repurchase Program Expiration Date</a></td>
<td class="text">Mar.  01,  2020<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ShareRepurchaseLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Share Repurchase [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ShareRepurchaseLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date for the purchase of an entity's own shares under a stock repurchase plan, in the CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6792744672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Property and equipment, accumulated depreciation</a></td>
<td class="nump">$ 98,472<span></span>
</td>
<td class="nump">$ 96,137<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, accumulated amortization</a></td>
<td class="nump">$ 9,341<span></span>
</td>
<td class="nump">$ 7,044<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (shares)</a></td>
<td class="nump">60,000,000<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (shares)</a></td>
<td class="nump">36,746,554<span></span>
</td>
<td class="nump">36,638,021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (shares)</a></td>
<td class="nump">32,370,345<span></span>
</td>
<td class="nump">32,284,051<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock at cost (shares)</a></td>
<td class="nump">4,376,209<span></span>
</td>
<td class="nump">4,353,970<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6871951504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS</a></td>
<td class="text">NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS<div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Amedisys, Inc., a Delaware corporation, (together with its consolidated subsidiaries, referred to herein as &#8220;Amedisys,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;) is a multi-state provider of home health, hospice and personal care services with approximately 74% of our revenue derived from Medicare for the three-month periods ended March&#160;31, 2020 and 2019. As of March&#160;31, 2020, we owned and operated 322 Medicare-certified home health care centers, 146 Medicare-certified hospice care centers and 12 personal-care care centers in 38 states within the United States and the District of Columbia.</span></div><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Basis of Presentation</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In our opinion, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly our financial position, our results of operations, and our cash flows in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) for interim financial reporting. Our results of operations for the interim periods presented are not necessarily indicative of the results of our operations for the entire year and have not been audited by our independent auditors.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This report should be read in conjunction with our consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December&#160;31, 2019, as filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on February 19, 2020 (the &#8220;Form 10-K&#8221;), which includes information and disclosures not included herein. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from the interim financial information presented, as allowed by SEC rules and regulations. </span></div><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recently Issued Accounting Pronouncements</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2019, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2019-12, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Income Taxes (Topic 740) - Simplifying the Accounting for Income Taxes,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> which simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and improves consistent application by clarifying and amending existing guidance. The ASU is effective for annual and interim periods beginning after December 15, 2020. Early adoption is permitted. While the Company does not expect a material impact upon adoption of ASU 2019-12, we are still evaluating the effect the standard will have on our consolidated financial statements and related disclosures and ongoing financial reporting.</span></div><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our accounting and reporting policies conform with U.S. GAAP. In preparing the unaudited condensed consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</span></div><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Principles of Consolidation</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">These unaudited condensed consolidated financial statements include the accounts of Amedisys, Inc. and our wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in our accompanying unaudited condensed consolidated financial statements, and business combinations accounted for as purchases have been included in our unaudited condensed consolidated financial statements from their respective dates of acquisition. In addition to our wholly owned subsidiaries, we also have certain equity investments that are accounted for as set forth below.</span></div><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Investments</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We consolidate investments when the entity is a variable interest entity and we are the primary beneficiary or if we have controlling interests in the entity, which is generally ownership in excess of 50%. Third party equity interests in our consolidated joint ventures are reflected as noncontrolling interests in our condensed consolidated financial statements.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We account for investments in entities in which we have the ability to exercise significant influence under the equity method if we hold 50% or less of the voting stock and the entity is not a variable interest entity in which we are the primary beneficiary. </span></div>The book value of investments that we account for under the equity method of accounting was $33.8 million and $35.7 million as of March&#160;31, 2020 and December&#160;31, 2019, respectively, and is reflected in other assets within our condensed consolidated balance sheets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6872144992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Patient Accounts Receivable Narrative (Details) - day<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PercentageOfPatientReceivablesOutstanding', window );">Percentage of patient receivables outstanding</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_AccountsReceivablePortionDerivedFromMedicare', window );">Accounts receivable derived from Medicare</a></td>
<td class="nump">58.00%<span></span>
</td>
<td class="nump">58.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_HistoricalCollectionRateFromMedicare', window );">Historical collection rate from Medicare</a></td>
<td class="nump">99.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare', window );">Rate of request for anticipated payment submitted for the initial episode of care</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare', window );">Maximum days to submit final bill from the start of episode</a></td>
<td class="nump">90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid', window );">Maximum days to submit final bill from the date the request for anticipated payment was paid</a></td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_AccountsReceivablePortionDerivedFromMedicare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Portion Derived From Medicare</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_AccountsReceivablePortionDerivedFromMedicare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_HistoricalCollectionRateFromMedicare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Historical collection rate from Medicare.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_HistoricalCollectionRateFromMedicare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the number of days from the start of the period of care in which the final bill must be submitted to Medicare.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PercentageOfPatientReceivablesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of patient receivables outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PercentageOfPatientReceivablesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the percentage of estimated payment that is requested at the start of care for an initial period of care.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6886066576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($) </div>
<div>care_center </div>
<div>state</div>
</th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfStatesInWhichEntityOperates', window );">Number of states with facilities | state</a></td>
<td class="nump">38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_MinimumPercentOwnershipForControllingInterestPercent', window );">Minimum ownership percentage for controlling interest (percent)</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_MaximumPercentOwnershipForEquityMethodPercent', window );">Maximum ownership percentage for equity method investment (percent)</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Equity method investment, aggregate cost | $</a></td>
<td class="nump">$ 33.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OperatingCareCenters', window );">Number of owned and operated care centers</a></td>
<td class="nump">322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember', window );">Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OperatingCareCenters', window );">Number of owned and operated care centers</a></td>
<td class="nump">146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember', window );">Personal Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OperatingCareCenters', window );">Number of owned and operated care centers</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue from Contract with Customer | Medicare Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of net services revenue</a></td>
<td class="nump">74.00%<span></span>
</td>
<td class="nump">74.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_MaximumPercentOwnershipForEquityMethodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the percentage ownership required in order for an investment to be treated under the equity method of accounting in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_MaximumPercentOwnershipForEquityMethodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_MinimumPercentOwnershipForControllingInterestPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the percentage ownership required in order for a variable interest entity (VIE) to be consolidated in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_MinimumPercentOwnershipForControllingInterestPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_OperatingCareCenters">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the number of care centers owned by the entity as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_OperatingCareCenters</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13537-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfStatesInWhichEntityOperates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of states the entity operates in as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfStatesInWhichEntityOperates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=amed_MedicareRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=amed_MedicareRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>167</ContextCount>
  <ElementCount>339</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>63</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>12</UnitCount>
  <MyReports>
    <Report instance="amed-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="amed-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="amed-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="amed-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="amed-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statement</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="amed-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="amed-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS</Role>
      <ShortName>NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="amed-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="amed-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2112103 - Disclosure - ACQUISITIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/ACQUISITIONS</Role>
      <ShortName>ACQUISITIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="amed-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2116104 - Disclosure - LONG-TERM OBLIGATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LONGTERMOBLIGATIONS</Role>
      <ShortName>LONG-TERM OBLIGATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="amed-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2122105 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="amed-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2124106 - Disclosure - SEGMENT INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SEGMENTINFORMATION</Role>
      <ShortName>SEGMENT INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="amed-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2128107 - Disclosure - SHARE REPURCHASE SHARE REPURCHASE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SHAREREPURCHASESHAREREPURCHASE</Role>
      <ShortName>SHARE REPURCHASE SHARE REPURCHASE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="amed-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2130108 - Disclosure - RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSRELATEDPARTYTRANSACTIONS</Role>
      <ShortName>RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="amed-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2132109 - Disclosure - SUBSEQUENT EVENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUBSEQUENTEVENT</Role>
      <ShortName>SUBSEQUENT EVENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="amed-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="amed-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="amed-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2313302 - Disclosure - ACQUISITIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/ACQUISITIONSTables</Role>
      <ShortName>ACQUISITIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/ACQUISITIONS</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="amed-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2317303 - Disclosure - LONG-TERM OBLIGATIONS LONG-TERM OBLIGATIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LONGTERMOBLIGATIONSLONGTERMOBLIGATIONSTables</Role>
      <ShortName>LONG-TERM OBLIGATIONS LONG-TERM OBLIGATIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="amed-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2325304 - Disclosure - SEGMENT INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SEGMENTINFORMATIONTables</Role>
      <ShortName>SEGMENT INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/SEGMENTINFORMATION</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="amed-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails</Role>
      <ShortName>NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="amed-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="amed-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue by Payor Class (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue by Payor Class (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="amed-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash and Cash Equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash and Cash Equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="amed-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Patient Accounts Receivable Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Patient Accounts Receivable Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="amed-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2410406 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value of Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value of Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="amed-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2411407 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Weighted-Average Shares Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Weighted-Average Shares Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="amed-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2414408 - Disclosure - ACQUISITIONS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails</Role>
      <ShortName>ACQUISITIONS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="amed-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2418410 - Disclosure - LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails</Role>
      <ShortName>LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="amed-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2419411 - Disclosure - LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails</Role>
      <ShortName>LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="amed-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2420412 - Disclosure - LONG-TERM OBLIGATIONS - Fees and Rates Under Credit Facilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails</Role>
      <ShortName>LONG-TERM OBLIGATIONS - Fees and Rates Under Credit Facilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="amed-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2421413 - Disclosure - LONG-TERM OBLIGATIONS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails</Role>
      <ShortName>LONG-TERM OBLIGATIONS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="amed-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2423414 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="amed-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2426415 - Disclosure - SEGMENT INFORMATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SEGMENTINFORMATIONNarrativeDetails</Role>
      <ShortName>SEGMENT INFORMATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="amed-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2427416 - Disclosure - SEGMENT INFORMATION - Operating Income of Reportable Segments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails</Role>
      <ShortName>SEGMENT INFORMATION - Operating Income of Reportable Segments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="amed-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2429417 - Disclosure - SHARE REPURCHASE Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails</Role>
      <ShortName>SHARE REPURCHASE Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="amed-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2431418 - Disclosure - RELATED PARTY TRANSACTIONS Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="amed-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2433419 - Disclosure - SUBSEQUENT EVENT - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails</Role>
      <ShortName>SUBSEQUENT EVENT - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="amed-20200331.htm">amed-20200331.htm</File>
    <File>amed-20200331.xsd</File>
    <File>amed-20200331_cal.xml</File>
    <File>amed-20200331_def.xml</File>
    <File>amed-20200331_lab.xml</File>
    <File>amed-20200331_pre.xml</File>
    <File>amed-20203103xexx311.htm</File>
    <File>amed-20203103xexx312.htm</File>
    <File>amed-20203103xexx321.htm</File>
    <File>amed-20203103xexx322.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>amed-20200331_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/stpr/2018-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6886298192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="nump">$ 394.3<span></span>
</td>
<td class="nump">$ 245.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Deferred debt issuance costs</a></td>
<td class="num">(3.3)<span></span>
</td>
<td class="num">(3.5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term obligations, including current portion</a></td>
<td class="nump">391.0<span></span>
</td>
<td class="nump">242.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term obligations</a></td>
<td class="num">(11.1)<span></span>
</td>
<td class="num">(9.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term obligations, less current portion</a></td>
<td class="nump">379.9<span></span>
</td>
<td class="nump">232.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Term Loan [Member] | One Hundred Seventy Five Million Term Loan Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="nump">170.6<span></span>
</td>
<td class="nump">171.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member] | 550 Million Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="nump">220.0<span></span>
</td>
<td class="nump">70.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_PromissoryNotesMember', window );">Promissory Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_CapitalLeaseObligationsMember', window );">Finance leases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="nump">$ 3.1<span></span>
</td>
<td class="nump">$ 3.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_OneHundredSeventyFiveMillionTermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_OneHundredSeventyFiveMillionTermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=amed_PromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=amed_PromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_CapitalLeaseObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_CapitalLeaseObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6782720896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENT - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 23, 2020 </div>
<div>USD ($) </div>
<div>care_center</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 24, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 27, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_FundingForHealthcareProvidersIncludingHospitals', window );">Funding for Healthcare Providers, Including Hospitals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements', window );">Funding Immediately Distributed to Healthcare Providers Based on Their 2019 Medicare Fee-For-Service Reimbursements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_FundingReceivedFromCARESAct', window );">Funding Received From CARES Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_AdditionalFundingDistributedToHealthcareProviders', window );">Additional Funding Distributed to Healthcare Providers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | AseraCare Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total purchase price for acquisition</a></td>
<td class="nump">$ 235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Paymentsrelatedtotaxassetandworkingcapital', window );">Payments related to tax asset and working capital</a></td>
<td class="nump">$ 32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfBusinessesAcquired', window );">Acquisition, number of care centers acquired | care_center</a></td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_AdditionalFundingDistributedToHealthcareProviders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional funding distributed to healthcare providers provided by the Coronavirus Aid, Relief and Economic Security (CARES) Act</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_AdditionalFundingDistributedToHealthcareProviders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_FundingForHealthcareProvidersIncludingHospitals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Funding for healthcare providers, including hospitals provided by the Coronavirus Aid, Relief and Economic Security (CARES) Act</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_FundingForHealthcareProvidersIncludingHospitals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Funding immediately distributed to healthcare providers based on their 2019 Medicare Fee-For-Service reimbursements provided by the Coronavirus Aid, Relief and Economic Security (CARES) Act</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_FundingReceivedFromCARESAct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Funding received by the Company from the Coronavirus Aid Relief and Economic Security (CARES) Act</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_FundingReceivedFromCARESAct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_Paymentsrelatedtotaxassetandworkingcapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments related to tax asset and working capital</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_Paymentsrelatedtotaxassetandworkingcapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfBusinessesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of businesses acquired by the entity during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfBusinessesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amed_AseraCareHospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amed_AseraCareHospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6885670144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Term Loan [Member] | One Hundred Seventy Five Million Term Loan Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">$ 175,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">Feb.  04,  2024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Term Loan [Member] | One Hundred Seventy Five Million Term Loan Facility [Member] | Eurodollar [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DebtInstrumentInterestRateatPeriodEnd', window );">Debt Instrument Interest Rate at Period End</a></td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member] | 550 Million Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">$ 550,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">Feb.  04,  2024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member] | 550 Million Revolving Credit Facility [Member] | Eurodollar [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DebtInstrumentInterestRateatPeriodEnd', window );">Debt Instrument Interest Rate at Period End</a></td>
<td class="nump">2.40%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DebtInstrumentInterestRateatPeriodEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Interest Rate at Period End</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DebtInstrumentInterestRateatPeriodEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_OneHundredSeventyFiveMillionTermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_OneHundredSeventyFiveMillionTermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_EurodollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6875410000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2020 </div>
<div>Segments</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable business segments</a></td>
<td class="nump">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6885474128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock', window );">Schedule of Revenue by Payor Class</a></td>
<td class="text"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenue by payor class as a percentage of total net service revenue is as follows:</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:92.690%;"><tr><td style="width:1.0%;"/><td style="width:71.659%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.618%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.904%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.619%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three-Month Periods Ended March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Home Health:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Medicare</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">46&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Non-Medicare - Episodic-based</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Non-Medicare - Non-episodic based</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Hospice (1):</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Medicare</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Non-Medicare</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Personal Care</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="11" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1) Acquired Compassionate Care Hospice on February 1, 2019, RoseRock Healthcare on April 1, 2019 and Asana Hospice on January 1, 2020.</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_FinancialInstrumentDetailsTableTextBlock', window );">Schedule of Fair Value of Financial Instruments</a></td>
<td class="text"><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.076%;"><tr><td style="width:1.0%;"/><td style="width:24.054%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.921%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.553%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.921%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.553%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.921%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.553%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.924%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value at Reporting Date Using</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Financial Instrument</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Carrying Value as of March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Quoted&#160;Prices&#160;in&#160;Active<br/>Markets for Identical<br/>Items<br/>(Level 1)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant<br/>Unobservable&#160;Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term obligations</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">391.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">383.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Schedule of Weighted-Average Shares Outstanding</a></td>
<td class="text">The following table sets forth, for the periods indicated, shares used in our computation of the weighted-average shares outstanding, which are used to calculate our basic and diluted net income attributable to Amedisys, Inc. common stockholders (amounts in thousands):<table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:90.497%;"><tr><td style="width:1.0%;"/><td style="width:69.082%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.054%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.607%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.057%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three-<br/>Month Periods<br/>Ended March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average number of shares outstanding - basic</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32,331&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32,001&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock options</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">594&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">559&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:20.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Non-vested stock and stock units</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">309&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">333&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average number of shares outstanding - diluted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33,234&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32,893&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Anti-dilutive securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">57&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">148&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_FinancialInstrumentDetailsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial instrument details, table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_FinancialInstrumentDetailsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of patient service revenue (net of contractual allowances and discounts), by major payor source of revenue for health care organizations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6875351424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE REPURCHASE SHARE REPURCHASE<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockTextBlock', window );">SHARE REPURCHASE</a></td>
<td class="text">SHARE REPURCHASE <div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">2019 Stock Repurchase Program</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On February 25, 2019, we announced that our Board of Directors authorized a stock repurchase program, under which we may repurchase up to $100 million of our outstanding common stock through March 1, 2020.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the terms of the program, we were allowed to repurchase shares from time to time in open market transactions, block purchases or in private transactions in accordance with applicable federal securities laws and other legal requirements. We were allowed to enter into Rule 10b5-1 plans to effect some or all of the repurchases. The timing and the amount of the repurchases would be determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors. </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We did not repurchase any shares pursuant to this stock repurchase program during the three-month periods ended March&#160;31, 2020 or March 31, 2019. The stock repurchase program expired on March 1, 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208821<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6886953456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM OBLIGATIONS - Fees and Rates Under Credit Facilities (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheOneMember', window );">Consolidated Leverage Ratio: Greater Than Equal To 3.00 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="nump">0.35%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_LetterOfCreditFee', window );">Letter Of Credit Fee</a></td>
<td class="nump">1.75%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheOneMember', window );">Consolidated Leverage Ratio: Greater Than Equal To 3.00 to 1.0 | Eurodollar [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheOneMember', window );">Consolidated Leverage Ratio: Greater Than Equal To 3.00 to 1.0 | Base Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheTwoMember', window );">Consolidated Leverage Ratio: Less Than 3.00 to 1.0 but Greater Than Equal To 2.00 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="nump">0.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_LetterOfCreditFee', window );">Letter Of Credit Fee</a></td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheTwoMember', window );">Consolidated Leverage Ratio: Less Than 3.00 to 1.0 but Greater Than Equal To 2.00 to 1.0 | Eurodollar [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">1.75%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheTwoMember', window );">Consolidated Leverage Ratio: Less Than 3.00 to 1.0 but Greater Than Equal To 2.00 to 1.0 | Base Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">0.75%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheThreeMember', window );">Consolidated Leverage Ratio: Less Than 2.00 to 1.0 but Greater Than Equal To 0.75 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="nump">0.25%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_LetterOfCreditFee', window );">Letter Of Credit Fee</a></td>
<td class="nump">1.25%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheThreeMember', window );">Consolidated Leverage Ratio: Less Than 2.00 to 1.0 but Greater Than Equal To 0.75 to 1.0 | Eurodollar [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheThreeMember', window );">Consolidated Leverage Ratio: Less Than 2.00 to 1.0 but Greater Than Equal To 0.75 to 1.0 | Base Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheFourMember', window );">Consolidated Leverage Ratio: Less Than 0.75 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="nump">0.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_LetterOfCreditFee', window );">Letter Of Credit Fee</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheFourMember', window );">Consolidated Leverage Ratio: Less Than 0.75 to 1.0 | Eurodollar [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">1.25%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheFourMember', window );">Consolidated Leverage Ratio: Less Than 0.75 to 1.0 | Base Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">0.25%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Consolidated Leverage Ratio: Greater Than Equal To 3.00 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ConsolidatedLeverageRatio', window );">Consolidated Leverage Ratio</a></td>
<td class="nump">3.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Consolidated Leverage Ratio: Less Than 3.00 to 1.0 but Greater Than Equal To 2.00 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ConsolidatedLeverageRatio', window );">Consolidated Leverage Ratio</a></td>
<td class="nump">2.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Consolidated Leverage Ratio: Less Than 2.00 to 1.0 but Greater Than Equal To 0.75 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ConsolidatedLeverageRatio', window );">Consolidated Leverage Ratio</a></td>
<td class="nump">0.75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Consolidated Leverage Ratio: Less Than 3.00 to 1.0 but Greater Than Equal To 2.00 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ConsolidatedLeverageRatio', window );">Consolidated Leverage Ratio</a></td>
<td class="nump">3.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Consolidated Leverage Ratio: Less Than 2.00 to 1.0 but Greater Than Equal To 0.75 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ConsolidatedLeverageRatio', window );">Consolidated Leverage Ratio</a></td>
<td class="nump">2.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Consolidated Leverage Ratio: Less Than 0.75 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ConsolidatedLeverageRatio', window );">Consolidated Leverage Ratio</a></td>
<td class="nump">0.75<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ConsolidatedLeverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consolidated Leverage Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ConsolidatedLeverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_LetterOfCreditFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the letters of credit, for the letters of credit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_LetterOfCreditFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_EurodollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6891202448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Operating Income of Reportable Segments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="nump">$ 491,685<span></span>
</td>
<td class="nump">$ 467,340<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of service, excluding depreciation and amortization</a></td>
<td class="nump">285,737<span></span>
</td>
<td class="nump">275,274<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">156,800<span></span>
</td>
<td class="nump">144,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">5,338<span></span>
</td>
<td class="nump">2,895<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="nump">447,815<span></span>
</td>
<td class="nump">423,016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="nump">43,870<span></span>
</td>
<td class="nump">44,324<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="nump">303,600<span></span>
</td>
<td class="nump">310,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of service, excluding depreciation and amortization</a></td>
<td class="nump">179,800<span></span>
</td>
<td class="nump">185,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">75,700<span></span>
</td>
<td class="nump">71,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="nump">256,500<span></span>
</td>
<td class="nump">258,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="nump">47,100<span></span>
</td>
<td class="nump">52,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember', window );">Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="nump">169,400<span></span>
</td>
<td class="nump">137,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of service, excluding depreciation and amortization</a></td>
<td class="nump">91,800<span></span>
</td>
<td class="nump">74,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">38,700<span></span>
</td>
<td class="nump">29,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">600<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="nump">131,100<span></span>
</td>
<td class="nump">103,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="nump">38,300<span></span>
</td>
<td class="nump">33,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember', window );">Personal Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="nump">18,700<span></span>
</td>
<td class="nump">20,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of service, excluding depreciation and amortization</a></td>
<td class="nump">14,100<span></span>
</td>
<td class="nump">15,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">3,400<span></span>
</td>
<td class="nump">3,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="nump">17,500<span></span>
</td>
<td class="nump">18,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of service, excluding depreciation and amortization</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">39,000<span></span>
</td>
<td class="nump">41,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">3,700<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="nump">42,700<span></span>
</td>
<td class="nump">42,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="num">$ (42,700)<span></span>
</td>
<td class="num">$ (42,700)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of patient service revenue recognized, net of contractual allowances and discounts, less the provision for bad debts related to patient service revenue plus all other revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6878758688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Basis of Presentation</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In our opinion, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly our financial position, our results of operations, and our cash flows in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) for interim financial reporting. Our results of operations for the interim periods presented are not necessarily indicative of the results of our operations for the entire year and have not been audited by our independent auditors.</span></div>This report should be read in conjunction with our consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December&#160;31, 2019, as filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on February 19, 2020 (the &#8220;Form 10-K&#8221;), which includes information and disclosures not included herein.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recently Issued Accounting Pronouncements</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2019, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2019-12, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Income Taxes (Topic 740) - Simplifying the Accounting for Income Taxes,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> which simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and improves consistent application by clarifying and amending existing guidance. The ASU is effective for annual and interim periods beginning after December 15, 2020. Early adoption is permitted. While the Company does not expect a material impact upon adoption of ASU 2019-12, we are still evaluating the effect the standard will have on our consolidated financial statements and related disclosures and ongoing financial reporting.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our accounting and reporting policies conform with U.S. GAAP. In preparing the unaudited condensed consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Principles of Consolidation</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">These unaudited condensed consolidated financial statements include the accounts of Amedisys, Inc. and our wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in our accompanying unaudited condensed consolidated financial statements, and business combinations accounted for as purchases have been included in our unaudited condensed consolidated financial statements from their respective dates of acquisition. In addition to our wholly owned subsidiaries, we also have certain equity investments that are accounted for as set forth below.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAndCostMethodInvestmentsPolicy', window );">Investments</a></td>
<td class="text"><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Investments</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We consolidate investments when the entity is a variable interest entity and we are the primary beneficiary or if we have controlling interests in the entity, which is generally ownership in excess of 50%. Third party equity interests in our consolidated joint ventures are reflected as noncontrolling interests in our condensed consolidated financial statements.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We account for investments in entities in which we have the ability to exercise significant influence under the equity method if we hold 50% or less of the voting stock and the entity is not a variable interest entity in which we are the primary beneficiary. </span></div>The book value of investments that we account for under the equity method of accounting was $33.8 million and $35.7 million as of March&#160;31, 2020 and December&#160;31, 2019, respectively, and is reflected in other assets within our condensed consolidated balance sheets.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue Recognition</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We account for revenue from contracts with customers in accordance with ASU 2014-09, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue from Contracts with Customers (Topic 606)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> and ASU 2015-14, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (collectively, "ASC 606"), and as such, we recognize revenue in the period in which we satisfy our performance obligations under our contracts by transferring our promised services to our customers in amounts that reflect the consideration to which we expect to be entitled in exchange for providing patient care, which are the transaction prices allocated to the distinct services. The Company's cost of obtaining contracts is not material.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues are recognized as performance obligations are satisfied, which varies based on the nature of the services provided. Our performance obligation is the delivery of patient care services in accordance with the nature and frequency of services outlined in physicians' orders, which are determined by a physician based on a patient's specific goals.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company's performance obligations relate to contracts with a duration of less than one year; therefore, the Company has elected to apply the optional exemption provided by ASC 606 and is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We determine the transaction price based on gross charges for services provided, reduced by estimates for contractual and non-contractual revenue adjustments. Contractual revenue adjustments include adjustments provided to patients and third-party payors. Non-contractual revenue adjustments include discounts provided to self-pay, uninsured patients or other payors, adjustments resulting from payment reviews and adjustments arising from our inability to obtain appropriate billing documentation, authorizations or face-to-face documentation. Subsequent changes to the estimate of the transaction price are recorded as adjustments to net service revenue in the period of change. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third party payors and others for services provided. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Non-contractual revenue adjustments are recorded for self-pay, uninsured patients and other payors by major payor class based on our historical collection experience, aged accounts receivable by payor and current economic conditions. The non-contractual revenue adjustments represent the difference between amounts billed and amounts we expect to collect based on our collection history with similar payors. The Company assesses its ability to collect for the healthcare services provided at the time of patient admission based on the Company's verification of the patient's insurance coverage under Medicare, Medicaid, and other commercial or managed care insurance programs. Medicare represents approximately 74% of the Company's consolidated net service revenue for the three-month periods ended March&#160;31, 2020 and 2019. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Amounts due from third-party payors, primarily commercial health insurers and government programs (Medicare and Medicaid), include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to payment reviews based on our historical experience and success rates in the claim appeals and adjudication process.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We determine our estimates for non-contractual revenue adjustments related to our inability to obtain appropriate billing documentation, authorizations, or face-to-face documentation based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims. Revenue is recorded at amounts we estimate to be realizable for services provided.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenue by payor class as a percentage of total net service revenue is as follows:</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:92.690%;"><tr><td style="width:1.0%;"/><td style="width:71.659%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.618%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.904%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.619%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three-Month Periods Ended March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Home Health:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Medicare</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">46&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Non-Medicare - Episodic-based</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Non-Medicare - Non-episodic based</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Hospice (1):</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Medicare</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Non-Medicare</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Personal Care</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="11" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1) Acquired Compassionate Care Hospice on February 1, 2019, RoseRock Healthcare on April 1, 2019 and Asana Hospice on January 1, 2020.</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Home Health Revenue Recognition</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Medicare Revenue</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Effective January 1, 2020, the Centers for Medicare and Medicaid Services ("CMS") implemented a revised case-mix adjustment methodology, the Patient-Driven Groupings Model ("PDGM"), to better align payment with patient care needs and ensure that clinically complex and ill beneficiaries have adequate access to home health care. PDGM uses 30-day periods of care rather than 60-day episodes of care as the unit of payment, eliminates the use of the number of therapy visits provided in determining payment and relies more heavily on clinical characteristics and other patient information.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net service revenue is recorded based on the established Federal Medicare home health payment rate for a 30-day period of care ("billing period"). PDGM uses timing, admission source, functional impairment levels and principal and other diagnoses to case-mix adjust payments. The case-mix adjusted payment for a 30-day period of care is subject to additional adjustments based on certain variables, including, but not limited to (a) an outlier payment if our patient's care was unusually costly (capped at 10% of total reimbursement per provider number); (b)&#160;a low utilization payment adjustment (&#8220;LUPA&#8221;) if the number of visits provided was less than the established threshold, which ranges from two to six visits and varies for every case-mix group under PDGM; (c)&#160;a partial payment if a patient transferred to another provider or from another provider before completing the 30-day period of care; and (d) the applicable geographic wage index. Payment for non-routine supplies are now included in the 30-day payment rate.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Medicare can also make various adjustments to payments received if we are unable to produce appropriate billing documentation or acceptable authorizations. We estimate the impact of such adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record this estimate during the period in which services are rendered as a reduction to revenue and a corresponding reduction to patient accounts receivable. </span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Amounts due from Medicare include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to payment reviews based on our historical experience and success rates in the claim appeals and adjudication process.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Medicare home health benefit requires that beneficiaries be homebound (meaning that the beneficiary is unable to leave their home without a considerable and taxing effort), require intermittent skilled nursing, physical therapy or speech therapy services, and receive treatment under a plan of care established and periodically reviewed by a physician. In order to provide greater flexibility during the novel coronavirus pandemic ("COVID-19"), CMS has relaxed the definition of homebound status. During the pandemic, a beneficiary is considered homebound if they have been instructed by a physician not to leave their home because of a confirmed or suspected COVID-19 diagnosis or if the patient has a condition that makes them more susceptible to contracting COVID-19. Therefore, if a beneficiary is homebound due to COVID-19 and requires skilled services, the services will be covered under the Medicare home health benefit.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">All Medicare contracts are required to have a signed plan of care which represents a single performance obligation, comprising of the delivery of a series of distinct services that are substantially similar and have a similar pattern of transfer to the customer. Accordingly, the Company accounts for the series of services ("episode") as a single performance obligation satisfied over time, as the customer simultaneously receives and consumes the benefits of the goods and services provided. An episode starts the first day a billable visit is performed and ends 60 days later or upon discharge, if earlier, with multiple continuous episodes allowed.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As noted above, under PDGM, we are now reimbursed for 30-day periods of care rather than 60-day episodes of care. ASC 606 notes that if an entity has a right to consideration from a customer in an amount that corresponds directly with the value of the entity&#8217;s performance completed to date, the entity may recognize revenue in the amount to which the entity has a right to invoice. We have elected to apply the "right to invoice&#8221; practical expedient utilizing our historical average length of stay for each 30-day payment period as the measure of progress towards the satisfaction of our performance obligation.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A portion of reimbursement from each Medicare episode is billed near the start of each 30-day period of care, and cash is typically received before all services are rendered. The amount of revenue recognized for periods of care which are incomplete at period end is based on the company's historical average percentage of days complete on each 30-day period of care. Any cash received from Medicare for a request for anticipated payment (&#8220;RAP&#8221;) for a 30-day period of care that exceeds the associated revenue earned is recorded to accrued expenses within our condensed consolidated balance sheets.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Non-Medicare Revenue</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Episodic-based Revenue.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> We recognize revenue in a similar manner as we recognize Medicare revenue for amounts that are paid by other insurance carriers, including Medicare Advantage programs; however, these amounts can vary based upon the negotiated terms which generally range from 90% to 100% of Medicare rates.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Non-episodic based Revenue.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third parties and others for services provided and are deducted from gross revenue to determine net service revenue. We also make non-contractual revenue adjustments to non-episodic revenue based on historical experience, to reflect the estimated transaction price. We receive a minimal amount of our net service revenue from patients who are either self-insured or are obligated for an insurance co-payment.</span></div><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Hospice Revenue Recognition</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Hospice Medicare Revenue</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are predetermined daily or hourly rates for each of the four levels of care we deliver. The four levels of care are routine care, general inpatient care, continuous home care and respite care. Routine care accounted for 97%  and 98% of our total net Medicare hospice service revenue for each of the three-month periods ended March&#160;31, 2020 and March&#160;31, 2019, respectively. There are two separate payment rates for routine care: payments for the first 60 days of care and care beyond 60 days. In addition to the two routine rates, we may also receive a service intensity add-on (&#8220;SIA&#8221;). The SIA is based on visits made in the last seven days of life by a registered nurse (&#8220;RN&#8221;) or medical social worker (&#8220;MSW&#8221;) for patients in a routine level of care.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The performance obligation is the delivery of hospice services to the patient, as determined by a physician, each day the patient is on hospice care.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We make adjustments to Medicare revenue for non-contractual revenue adjustments, which include our inability to obtain appropriate billing documentation or acceptable authorizations and other reasons unrelated to credit risk. We estimate the impact of these non-contractual revenue adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record it during the period services are rendered.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additionally, our hospice service revenue is subject to certain limitations on payments from Medicare which are considered variable consideration. We are subject to an inpatient cap limit and an overall Medicare payment cap for each provider number. We monitor these caps on a provider-by-provider basis and estimate amounts due back to Medicare if we estimate a cap has been exceeded.&#160;We record these adjustments as a reduction to revenue and an increase in accrued expenses within our condensed consolidated balance sheet. Beginning for the cap year ending October&#160;31, 2017, providers are required to self-report </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">and pay their estimated cap liability by February 28</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">th</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> of the following year. As of March&#160;31, 2020, we have recorded $5.5 million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2013 through September 30, 2020. As of December&#160;31, 2019, we had recorded $5.7 million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2013 through September 30, 2020.</span></div><div style="text-align:justify;margin-top:6pt;"><span><br/></span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Hospice Non-Medicare Revenue</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per day rates, as applicable. Contractual revenue adjustments are recorded for the difference between our standard rates and the contractual rates to be realized from patients, third party payors and others for services provided and are deducted from gross revenue to determine our net service revenue. We also make non-contractual adjustments to non-Medicare revenue based on historical experience, to reflect the estimated transaction price.</span></div><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Personal Care Revenue Recognition</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Personal Care Revenue</span></div>We generate net service revenues by providing our services directly to patients based on authorized hours, visits or units determined by the relevant agency, at a rate that is either contractual or fixed by legislation. Net service revenue is recognized at the time services are rendered based on gross charges for the services provided, reduced by estimates for contractual and non-contractual revenue adjustments. We receive payment for providing such services from payors, including state and local governmental agencies, managed care organizations, commercial insurers and private consumers. Payors include the following elder service agencies: Aging Services Access Points (ASAPs), Senior Care Options (SCOs), Program of All-Inclusive Care for the Elderly (PACE) and the Veterans Administration (VA).<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash, Cash Equivalents and Restricted Cash </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash and cash equivalents include certificates of deposit and all highly liquid debt instruments with maturities of three months or less when purchased. Restricted cash includes cash that is not available for ordinary business use. As of March 31, 2020, we had $3.1&#160;million of restricted cash that was placed into escrow accounts related to the potential indemnity and working capital adjustment provisions within the Asana Hospice purchase agreement ($2.3&#160;million) and to secure the purchase of personal protective equipment from new suppliers in response to COVID-19 ($0.8&#160;million).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Patient Accounts Receivable</a></td>
<td class="text"><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Patient Accounts Receivable </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We report accounts receivable from services rendered at their estimated transaction price, which includes contractual and non-contractual revenue adjustments based on the amounts expected to be due from payors. Our patient accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other third-party payors and patients. As of March&#160;31, 2020, there is no single payor, other than Medicare, that accounts for more than 10% of our total outstanding patient receivables. Thus, we believe there are no other significant concentrations of receivables that would subject us to any significant credit risk in the collection of our patient accounts receivable. We write off accounts on a monthly basis once we have exhausted our collection efforts and deem an account to be uncollectible. We believe the collectibility risk associated with our Medicare accounts, which represent 58% of our patient accounts receivable at March&#160;31, 2020 and December&#160;31, 2019 is limited due to our historical collection rate of over 99% from Medicare and the fact that Medicare is a U.S. government payor. </span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We do not believe there are any significant concentrations of revenues from any payor that would subject us to any significant credit risk in the collection of our accounts receivable.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Medicare Home Health</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For our home health patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We submit a RAP for 20% of our estimated payment for each 30-day period of care. The full amount of the payment for each 30-day period of care is billed after the period of care has been completed (&#8220;final billed&#8221;). The RAP received for that billing period is then deducted from our final payment. If a final bill is not submitted within the greater of 90 days from the start of the 30-day period of care, or 60 days from the date the RAP was paid, </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">any RAPs received for that billing period will be recouped by Medicare from any other claims in process for that particular provider number. The RAP claim must then be resubmitted. CMS has mandated the full elimination of RAPs in 2021.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Medicare Hospice</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For our hospice patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We bill Medicare on a monthly basis for the services provided to the patient.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Non-Medicare Home Health, Hospice and Personal Care</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For our non-Medicare patients, our pre-billing process primarily begins with verifying a patient&#8217;s eligibility for services with the applicable payor. Once the patient has been confirmed for eligibility, we will provide services to the patient and bill the applicable payor. Our review and evaluation of non-Medicare accounts receivable includes a detailed review of outstanding balances and special consideration to concentrations of receivables from particular payors or groups of payors with similar characteristics that would subject us to any significant credit risk.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="text-align:justify;margin-top:16pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Fair Value of Financial Instruments</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.076%;"><tr><td style="width:1.0%;"/><td style="width:24.054%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.921%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.553%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.921%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.553%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.921%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.553%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.924%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value at Reporting Date Using</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Financial Instrument</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Carrying Value as of March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Quoted&#160;Prices&#160;in&#160;Active<br/>Markets for Identical<br/>Items<br/>(Level 1)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant<br/>Unobservable&#160;Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term obligations</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">391.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">383.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The three levels of inputs are as follows:</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Level&#160;1 &#8211; Quoted prices in active markets for identical assets and liabilities.</span></div><div style="padding-left:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Level&#160;2 &#8211; Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="padding-left:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Level&#160;3 &#8211; Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities.</span></div>Our deferred compensation plan assets are recorded at fair value and are considered a level 2 measurement. For our other financial instruments, including our cash and cash equivalents, patient accounts receivable, accounts payable, payroll and employee benefits and accrued expenses, we estimate the carrying amounts approximate fair value.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Weighted-Average Shares Outstanding</a></td>
<td class="text">Weighted-Average Shares OutstandingNet income per share attributable to Amedisys, Inc. common stockholders, calculated on the treasury stock method, is based on the weighted average number of shares outstanding during the period.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text">Business Combinations<span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We account for acquisitions using the acquisition method of accounting in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 805, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Business Combinations</span>. Acquisitions are accounted for as purchases and are included in our condensed consolidated financial statements from their respective acquisition dates. Assets acquired and liabilities assumed, if any, are measured at fair value on the acquisition date using the appropriate valuation method. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355033-122828<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355100-122828<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAndCostMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the equity method of accounting for investments in common stock or other interests including unconsolidated domestic subsidiaries, corporate joint ventures, noncontrolling interests in real estate ventures, limited partnerships, and limited liability companies. Additionally, this element describes the entity's application of the cost method to equity investments or other interests that are not consolidated or accounted for under the equity method of accounting. The disclosure provided may include how equity method or cost investments are assessed for impairment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAndCostMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=SL6953423-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e5033-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e5212-111524<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e5093-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6875382272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT INFORMATION</a></td>
<td class="text">SEGMENT INFORMATION<div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our operations involve servicing patients through our three reportable business segments: home health, hospice and personal care. Our home health segment delivers a wide range of services in the homes of individuals who may be recovering from surgery, have a chronic disability or terminal illness or need assistance with completing important personal tasks. Our hospice segment provides palliative care and comfort to terminally ill patients and their families. Our personal care segment provides patients with assistance with the essential activities of daily living. The &#8220;other&#8221; column in the following tables consists of costs relating to executive management and administrative support functions, primarily information services, accounting, finance, billing and collections, legal, compliance, risk management, procurement, marketing, clinical administration, training, human resources and administration.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Management evaluates performance and allocates resources based on the operating income of the reportable segments, which includes an allocation of corporate expenses directly attributable to the specific segment and includes revenues and all other costs directly attributable to the specific segment. Segment assets are not reviewed by the company&#8217;s chief operating decision maker and therefore are not disclosed below (amounts in millions).</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:46.023%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:7.809%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.809%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.809%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.809%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.813%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three-Month Period Ended March 31, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Home<br/>Health</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Hospice</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Personal<br/>Care</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net service revenue</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">303.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">169.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">491.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">179.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">91.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">285.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">156.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation and amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">256.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">131.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">447.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating income (loss)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">47.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(42.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">43.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three-Month Period Ended March 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Home<br/>Health</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Hospice</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Personal<br/>Care</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net service revenue</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">310.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">137.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">467.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">185.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">74.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">275.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">71.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">144.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation and amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">258.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">103.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">423.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating income (loss)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">52.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(42.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6886204560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 174,756<span></span>
</td>
<td class="nump">$ 30,294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">3,056<span></span>
</td>
<td class="nump">66,196<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Patient accounts receivable</a></td>
<td class="nump">268,551<span></span>
</td>
<td class="nump">237,596<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">12,487<span></span>
</td>
<td class="nump">8,243<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">9,278<span></span>
</td>
<td class="nump">8,225<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">468,128<span></span>
</td>
<td class="nump">350,554<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation of $98,472 and $96,137</a></td>
<td class="nump">26,477<span></span>
</td>
<td class="nump">28,113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="nump">83,693<span></span>
</td>
<td class="nump">84,791<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">721,049<span></span>
</td>
<td class="nump">658,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net of accumulated amortization of $9,341 and $7,044</a></td>
<td class="nump">68,251<span></span>
</td>
<td class="nump">64,748<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred income taxes</a></td>
<td class="nump">20,199<span></span>
</td>
<td class="nump">21,427<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">52,287<span></span>
</td>
<td class="nump">54,612<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,440,084<span></span>
</td>
<td class="nump">1,262,745<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">31,147<span></span>
</td>
<td class="nump">31,259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and employee benefits</a></td>
<td class="nump">109,713<span></span>
</td>
<td class="nump">120,877<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">136,659<span></span>
</td>
<td class="nump">137,111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Current portion of long-term obligations</a></td>
<td class="nump">11,122<span></span>
</td>
<td class="nump">9,927<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">27,465<span></span>
</td>
<td class="nump">27,769<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">316,106<span></span>
</td>
<td class="nump">326,943<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term obligations, less current portion</a></td>
<td class="nump">379,942<span></span>
</td>
<td class="nump">232,256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, less current portion</a></td>
<td class="nump">54,926<span></span>
</td>
<td class="nump">56,128<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term obligations</a></td>
<td class="nump">8,966<span></span>
</td>
<td class="nump">5,905<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">759,940<span></span>
</td>
<td class="nump">621,232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies&#8212;Note 5</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValueOutstanding', window );">Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common stock, $0.001 par value, 60,000,000 shares authorized; 36,746,554 and 36,638,021 shares issued; and 32,370,345 and 32,284,051 shares outstanding</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">656,266<span></span>
</td>
<td class="nump">645,256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost 4,376,209 and 4,353,970 shares of common stock</a></td>
<td class="num">(255,291)<span></span>
</td>
<td class="num">(251,241)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">278,185<span></span>
</td>
<td class="nump">246,383<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Amedisys, Inc. stockholders&#8217; equity</a></td>
<td class="nump">679,197<span></span>
</td>
<td class="nump">640,450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="nump">947<span></span>
</td>
<td class="nump">1,063<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">680,144<span></span>
</td>
<td class="nump">641,513<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 1,440,084<span></span>
</td>
<td class="nump">$ 1,262,745<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>54
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M?_B=A5TP=FO_L?%)4';PZR[D%U!+ P04    " "=0*=0F5R<(Q &  "<)P
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MN'&!T;7!$L/ "P>C:V2> ZI8,L::OQY#A>GPN@:<KN$G#E2PA)5B8(P!7K"
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MU:^QRHL6)7A@(==N+2DK:K!,FOE++)'L(J!RE(*LQ7RS#LSH3-IQ(/Y9)NT
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MAG/CF/F<J26>DG,><YHUI\E(3C.$L,Q;@"KYD88QIUESNN].Z4;SUY/\"%@
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M73 _>MM,:S8Y#OOY!;'E&1=_ 5!+ P04    " "@0*=0XU!#6;0!  #2 P
M&    'AL+W=O<FMS:&5E=',O<VAE970X+GAM;'U386_<( S]*X@?4"XDW:I3
M$JG7:MJD33IUVOJ92YP$%>(,R*7[]P.29MD6[0M@X_?\;$P^H7FQ'8 CKUKU
MMJ"=<\.1,5MUH(6]P0%Z?].@T<)YT[3,#@9$'4%:,7XXO&-:R)Z6>?2=39GC
MZ)3LX6R(';46YN<)%$X%3>B;XTFVG0L.5N:#:.$KN&_#V7B+K2RUU-!;B3TQ
MT!3T/CF>LA ? [Y+F.SF3$(E%\278'RJ"WH(@D!!Y0*#\-L5'D"I0.1E_%@X
MZ9HR +?G-_8/L79?RT58>$#U+&O7%?2.DAH:,2KWA--'6.JYI60I_C-<0?GP
MH,3GJ%#9N))JM [UPN*E:/$Z[[*/^S3?9.D"VP?P!<!7P%W,P^9$4?FC<*+,
M#4[$S+T?1'CBY,A];ZK@C*V(=UZ\]=YKR1.>LVL@6F).<PS?Q"1K!//L:PJ^
ME^+$_X'S?7BZJS"-\/0/A>D^0;9+D$6"[+\E[L5D?R5AFYYJ,&V<)DLJ'/LX
MR1OO.K#W/+[)[_!YVK\(T\K>D@LZ_[*Q_PVB R_E<.-'J/,?;#44-"X<W_NS
MF<=L-AP.RP]BZS<N?P%02P,$%     @ H$"G4!Z9G(RU 0  T@,  !@   !X
M;"]W;W)K<VAE971S+W-H965T.2YX;6Q]4]MNW" 0_17$!X0UWERTLBUE4U6M
MU$BK1&V?67M\4;BX@-?)WV? CNNV5E^ &>:<.3,,V6CLBVL!/'E54KN<MM[W
M!\9<V8(2[LKTH/&F-E8)CZ9MF.LMB"J"E&1\M[MA2G2:%EGTG6R1F<'+3L/)
M$C<H)>S;$:09<YK0#\=3U[0^.%B1]:*!9_#?^Y-%BRTL5:= N\YH8J'.Z7UR
M..Y#? SXT<'H5F<2*CD;\Q*,KU5.=T$02"A]8!"X7> !I Q$*./7S$F7E &X
M/G^P?XZU8RUGX>#!R)]=Y=N<WE%202T&Z9_,^ 7F>JXIF8O_!A>0&!Z48([2
M2!=74@[.&S6SH!0E7J>]TW$?IYLTG6'; #X#^ *XBWG8E"@J_R2\*#)K1F*G
MWO<B/'%RX-B;,CAC*^(=BG?HO10\N<[8)1#-,<<IAJ]BDB6"(?N2@F^E./)_
MX'P;GFXJ3",\_4/AS3;!?I-@'PGV_RUQ*^;VKR1LU5,%MHG3Y$AI!ATG>>5=
M!O:>QS?Y'3Y-^Z.P3:<=.1N/+QO[7QOC :7LKG"$6OQ@BR&A]N%XBV<[C=ED
M>-///X@MW[AX!U!+ P04    " "@0*=09(2%P;4!  #2 P  &0   'AL+W=O
M<FMS:&5E=',O<VAE970Q,"YX;6Q]4V%OW" ,_2N('U 2[K;>3DFD7J=IDS;I
MU&G=9RYQ$E2(,R"7[M\/2)IE:]0O@(W?\[,QV8CFR;8 CCQKU=F<ML[U1\9L
MV8(6]@9[Z/Q-C48+YTW3,-L;$%4$:<5XDKQG6LB.%EGTG4V1X>"4[.!LB!VT
M%N;W"12..4WIB^-!-JT+#E9DO6C@.[@?_=EXBRTLE=3068D=,5#G]"X]GO8A
M/@8\2ACMZDQ")1?$IV!\J7*:!$&@H'2!0?CM"O>@5"#R,G[-G'1)&8#K\PO[
MIUB[K^4B+-RC^BDKU^;T0$D%M1B4>\#Q,\SUO*-D+OXK7$'Y\*#$YRA1V;B2
M<K .]<SBI6CQ/.VRB_LXW?#;&;8-X#. +X!#S,.F1%'Y1^%$D1D<B9EZWXOP
MQ.F1^]Z4P1E;$>^\>.N]UX*GAXQ= ]$<<YIB^"HF72*89U]2\*T4)_X*SK?A
MNTV%NPC?_:/PPS;!?I-@'PGV;Y:X$<.3_Y*P54\UF"9.DR4E#EV<Y)5W&=@[
M'M_D;_@T[=^$:61GR06=?]G8_QK1@9>2W/@1:OT'6PP%M0O'6W\VTYA-AL-^
M_D%L^<;%'U!+ P04    " "@0*=0UA'"<K,!  #2 P  &0   'AL+W=O<FMS
M:&5E=',O<VAE970Q,2YX;6Q]4V%OVR 0_2N('U 2DFY59%MJ.DVKM$I1IVV?
MB7VV48%S <?MOQ]@U_4V;U^ .^Z]>W<<V8#VR;4 GKQH95Q.6^^[ V.N;$$+
M=X4=F'!3H]7"!],VS'461)5 6C&^V7Q@6DA#BRSY3K;(L/=*&CA9XGJMA7T]
M@L(AIUOZYGB43>NC@Q59)QKX!OY[=[+!8C-+)348)]$0"W5.;[>'XS[&IX ?
M$@:W.)-8R1GQ*1KW54XW41 H*'UD$&&[P!TH%8F"C.>)D\XI(W!Y?F/_G&H/
MM9R%@SM4/V7EVYS>4%)!+7KE'W'X E,]UY1,Q7^%"Z@0'I6$'"4JEU92]LZC
MGEB"%"U>QEV:M _CS36?8.L /@'X#+A)>=B8*"G_)+PH,HL#L6/O.Q&?>'O@
MH3=E=*96I+L@W@7OI>!\F[%+))IBCF,,7\2\1[# /J?@:RF._"\X7X?O5A7N
M$GSWF\)_$.Q7"?:)8/_?$M=B=G\D88N>:K!-FB9'2NQ-FN2%=Q[8V_2([#U\
MG/8'81MI'#FC#R^;^E\C>@A2-E=AA-KPP69#0>WC\6,XVW',1L-C-_T@-G_C
MXA=02P,$%     @ H$"G4!$8U:ZU 0  T@,  !D   !X;"]W;W)K<VAE971S
M+W-H965T,3(N>&UL?5/;;M0P$/T5RQ]0[WK34E9)I&X1 @FD51'P[$TFB55?
M@NULRM\S=M(0(.+%]HSGG#DS'N>C=<^^ PCD12OC"]J%T!\9\U4'6O@;VX/!
MF\8Z+0*:KF6^=R#J!-**\=WNCFDA#2WSY#N[,K=#4-+ V1$_:"W<SQ,H.Q9T
M3U\=3[+M0G2P,N]%"U\@?.W/#BVVL-12@_'2&N*@*>C#_GC*8GP*^"9A]*LS
MB95<K'V.QL>ZH+LH"!14(3((W*[P"$I%(I3Q8^:D2\H(7)]?V=^GVK&6B_#P
M:-5W68>NH/>4U-"(084G.WZ N9Y;2N;B/\$5%(9')9BCLLJGE52##U;/+"A%
MBY=IER;MXW3#W\ZP;0"? 7P!W*<\;$J4E+\3092YLR-Q4^][$9]X?^38FRHZ
M4RO2'8KWZ+V6G&<YNT:B.>8TQ?!5S'Z)8,B^I.!;*4[\'SC?AA\V%1X2_/"'
MPMMM@FR3($L$V7]+W(JY^RL)6_54@VO3-'E2V<&D25YYEX%]X.E-?H=/T_Y9
MN%8:3RXVX,NF_C?6!D INQL<H0X_V&(H:$(\OL&SF\9L,H+MYQ_$EF]<_@)0
M2P,$%     @ H$"G4*;R5#"X 0  T@,  !D   !X;"]W;W)K<VAE971S+W-H
M965T,3,N>&UL;5/;;MP@$/T5Q <$+W::[<JVE$U4I5(CK5*U?6;ML8W"Q0&\
M3OZ^@!W72?T"S##GS)EAR$=MGFT'X-"K%,H6N'.N/Q!BJPXDLU>Z!^5O&FTD
M<]XT+;&] 59'D!2$)LD7(AE7N,RC[V3*7 ].< 4G@^P@)3-O1Q!Z+/ .OSN>
M>-NYX"!EWK,6?H+[U9^,M\C"4G,)RG*MD(&FP+>[PS$+\3'@-X?1KLXH5'+6
M^CD8W^L")T$0"*A<8&!^N\ ="!&(O(R7F1,O*0-P?7YG_Q9K][6<F84[+?[P
MVG4%WF-40\,&X9[T^ !S/=<8S<7_@ L('QZ4^!R5%C:NJ!JLTW)F\5(D>YUV
MKN(^3C=I-L.V 70&T 6PCWG(E"@JOV>.E;G1(S)3[WL6GGAWH+XW57#&5L0[
M+]YZ[Z6D]"8GET TQQRG&+J*V2T1Q+,O*>A6BB/]#TZWX>FFPC3"TP\*]]L$
MV29!%@FR#P1?/Y6X$9,FGY*054\EF#9.DT65'E2<Y)5W&=A;&M_D7_@T[8_,
MM%Q9=-;.OVSL?Z.U R\EN?(CU/D/MA@"&A>.-_YLIC&;#*?[^0>1Y1N7?P%0
M2P,$%     @ H$"G4(C[_B.V 0  T@,  !D   !X;"]W;W)K<VAE971S+W-H
M965T,30N>&UL=5-A;]P@#/TKB!]0[DBZ5:<D4J]5M4F;=.JT]3.7. DJA S(
MI?OW,R1-TR[[ MCX/3\;DXW&/KL6P),7K3J7T];[_L"8*UO0PEV9'CJ\J8W5
MPJ-I&^9Z"Z**(*T8W^T^,2UD1XLL^DZVR,S@E>S@9(D;M!;VSQ&4&7.ZIZ^.
M1]FT/CA8D?6B@1_@?_8GBQ9;6"JIH7/2=,1"G=/;_>&8AO@8\$O"Z%9G$BHY
M&_,<C*]53G=!$"@H?6 0N%W@#I0*1"CC]\Q)EY0!N#Z_LC_$VK&6LW!P9]23
MK'R;TQM**JC%H/RC&;_ 7,\U)7/QW^ ""L.#$LQ1&N7B2LK!>:-G%I2BQ<NT
MRR[NXW1SG<ZP;0"? 7P!W,0\;$H4E=\++XK,FI'8J?>]"$^\/W#L31F<L17Q
M#L4[]%X*GNPS=@E$<\QQBN&KF+<(ANQ+"KZ5XLC_@?-M>+*I,(GPY)W"_Q"D
MFP1I)$C?$20?2MR*23\D8:N>:K!-G"9'2C-T<9)7WF5@;WE\D[?P:=J_"]O(
MSI&S\?BRL?^U,1Y0RNX*1ZC%#[88"FH?CI_Q;*<QFPQO^OD'L>4;%W\!4$L#
M!!0    ( *! IU#*-A>XM0$  -(#   9    >&PO=V]R:W-H965T<R]S:&5E
M=#$U+GAM;'U3VV[;, S]%4$?4"5*>EE@&V@Z#!NP 4&'=<^*3=M"=?$D.>[^
M?I3L>MYJ]$42*9[#0XK*!NN>?0L0R(M6QN>T#:$[,.;+%K3P5[8#@S>U=5H$
M-%W#?.= 5 FD%>.;S0W30AI:9,EW<D5F^Z"D@9,COM=:N-]'4';(Z9:^.AYE
MTX;H8$76B0:^0_C1G1Q:;&:II ;CI37$09W3^^WAN(_Q*>!)PN 79Q(K.5O[
M'(TO54XW41 H*$-D$+A=X &4BD0HX]?$2>>4$;@\O[)_2K5C+6?AX<&JG[(*
M;4[O**F@%KT*CW;X#%,]UY1,Q7^%"R@,CTHP1VF53RLI>Q^LGEA0BA8OXRY-
MVH?QAG^88.L /@'X#+A+>=B8*"G_*((H,F<'XL;>=R(^\?; L3=E=*96I#L4
M[]%[*?CN.F.72#3%',<8OHC9SA$,V><4?"W%D;^!\W7X;E7A+L%W_RB\62?8
MKQ+L$\'^W1+78F[_2\(6/=7@FC1-GI2V-VF2%]YY8.]Y>I._X>.T?Q.ND<:3
MLPWXLJG_M;4!4,KF"D>HQ0\V&PKJ$(^W>';CF(U&L-WT@]C\C8L_4$L#!!0
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ML7YZ[^9ZOC!S8-6PO 5D?9#*/U!+ P04    " "@0*=0*9S6V[@!  #2 P
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MN'"\]6<SC=ED.-W//X@LW[C\ U!+ P04    " "@0*=0X<&!-\,!   W!
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MS4*8&(L$4"08$7BN.Q!!&$,K0B@2 @(:B"",060"12: 8/"G+A'&QR(1%(D
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M&R$.)D0!1"@5+# C:@(D"E.B0C!!(A)H5A@4%4(*$I%4#V9% 5B(!0M,BYJ
MB\*\J!!@H$A8& @30X 8$J C3 Q-((8P,11"#!*10 QA8@@1(PT8)H8F$$.8
M& HA!HE(6+,)$T,AQ" 1+80XF!A"Q BK+F%B: (QA(FA$&*02%H?&!/#@!@6
M5EW&Q/ $8A@3PR'$(!$+JRX+_\( ,2REBHGA"<0P)H9#B$$B%A9NQL1P"#%
M).[<C(EA0(ST5X<Q,3R!&,;$< @Q2"2M#QH3HQ$QPH!I3(R>0(S&Q.@08I!(
M6G4U)D8C8H0]1@MO+A.(T9@8C6"8WU8[B$POJH:9+$3!O&C "TN3 Z.@YQ-J
MQ2CH14BMBW>U2E$P+1J P,(N9S ()IWP2HI!,"J@UE&DU%6QZ=U<0,Y@7@Q
M00O[G,$H&)Y0+T;!Z)!Z=>@\-L*;/J!%"QNEP2B8V81:,0H&[0KO:IV'SF.#
M:3& %BU98!3,?7BM,XS"#.T)M[6.HM_-X^3JT*NT];X_[FNBC3M5_5GC5>OE
M2/&1^D.SG_+A//+OK-[G51.]N+9U97] MG.NM3Z;],Z/^<%FV\M#87=M=SOW
M]_5P#C@\M.XXGG$FEX/6]?]02P,$%     @ H$"G4!0,K;_Q!   G1P  !D
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M("^'(W9*79TPNL7L6XQ3Z3>*B*0)PQ!G(F$FDF0BI7$R.6%8>!&(W3CIKK\
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MBE#"@!S-D"/!&FT %4;T3]@ *@Q7*\(UNA5U-C"Q08NT ? 8;L\6AZ$H/%+
MC:@!_!C*#]F(WACZAB85W#T8](;&E!ZTNS, ,S.@]!A D.%>KDC*M/2<2AF
M9ICJ(T&U-0 T,Z#Z&,"0X1@*4O[6BHY'&>\O+"#-<O4'U%L+2+,#ZH\%"%FN
M_@3;[QO+U!^<,2#(,A5((1\ #3N@ EET,L&]^)",Z=F$3L@[[BTC4Q-\5 )
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M-M_+_G"UOZB+RW!P[-Y.K]?_ 5!+ P04    " "@0*=0(8?+!*H!  "_ P
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MI-ZF:L^'V34<)&O'L8RF_X;B+U!+ P04    " "@0*=0^99Q^T$"  #,!P
M&0   'AL+W=O<FMS:&5E=',O<VAE970S."YX;6R-5=N.VC 0_94H'[".G2LH
M1.K"5JW42FBK;9\-&!*M$Z>V(=N_K^V$",*P@@=B.^<R,_'8>2?DNRH9T]Y'
MS1NU\$NMVSE":ENRFJHGT;+&O-D+65-MIO* 5"L9W3E2S1$)@@35M&K\(G=K
M:UGDXJAYU;"U]-2QKJG\]\RXZ!8^]L\+K]6AU'8!%7E+#^P7TV_M6IH9&E5V
M5<T:58G&DVR_\+_@^0L.+<$A?E>L4Q=CSZ:R$>+=3K[O%GY@(V*<;;65H.9Q
M8DO&N54R<?P=1/W1TQ(OQV?UKRYYD\R&*K84_$^UT^7"SWQOQ_;TR/6KZ+ZQ
M(:'8]X;L?[ 3XP9N(S$>6\&5^_>V1Z5%/:B84&KZT3^KQCV[0?],@PED()"1
M$))/">% "$<"P9\2HH$0/4J(!T(\(: ^=U?,%=6TR*7H/-GOAY;:;8?GL?E<
M6[OHOHY[9^JIS.JIB*,X1R<K-&">>PRYPB37F"6$2:\Q*PB376->(,QLQ""3
MRY@0 1,B3B"\%(@#6" $!4(G$%T)X$F4/29QF,9A<&!_L$\$^D2 #YGX1#<^
MX7V;&+2) 9L0%DA @>3Q@J:@0 I$$$VV3PH5%#;)0),,,)GLXU5V8T+N5W,&
MVLP FP06P '<<,'C]<1W>A8#4:33IL6WV8;Q'1^XE3 !?+*I#[G=H^2.#=QP
M&.JXV=2F!\47-E$TL4$7AYZ]YWY2>:@:Y6V$-N>G.^7V0FAF]((GHU2:JW6<
M<+;7=IB:L>SOEWZB13O<G6B\P(O_4$L#!!0    ( *! IU ,7 _2!78  "+$
M 0 4    >&PO<VAA<F5D4W1R:6YG<RYX;6SLO6MO&UF2)OQY]E<DO*YM":#8
MO.ABE6<&H"79Q1Y;4DMR&SV#%R]29%+*+C*3DTE*UJ!__,;UG#AYH2C;5=-8
MS&*GNDK,/'DN<>+Z1,0_E^4J6F?I?ZZ3DWR=K?[EU<%A[U7T=3'/RG]Y=;]:
M+7_^XQ_+R7VRB,MNODPR^&66%XMX!?]9W/VQ7!9)/"WODV2UF/]QT.L=_G$1
MI]FK?_WG,OW7?U[]ZTG^D!317E3>QT52_O,?5__ZSW_$7_C78?0ISU;W9726
M39-I]==/<=&-AOU.-.@->O4?GZ)>RV_\T?\8W9:K(IZL_K_J[Z?Y9+U(LE5T
M\[1,JC_V>WM_;GWAS^NX6"7%_"FZ2I9YL:H^N"K6M0'=RY=)D>937&MT&J]J
MS^ER_]<__5/3HORDBS@KTU6:9RV3F,7SLC;Z6;9*5T_1^W2>1.?KQ6U25)_H
M[0WV!X>U[\J+5\E=BML)$SB/%[7A1Y_.3L?7?[V.QN<G+2.,LTE>P'QCG'HG
MNE[!'D1Y$1'=%4_PO]/ZWIVU#'83?XW&4]B.=)9.:,265?7[>\/^L'_4:UO8
M:#H%RBQQ0@50<>/JAF\.]J/1 LYO$F?1E_CIV;'6:?V Z8_1Z+EW3^"_JL^\
MBU=XW/GZKNU@S3(::.OCLU^]S,M5/(_^/5TV'L11[TW_L';/: 1@ (VO# 8'
MM6GD$_C&Y7V>M1'AX'BP-^@-^]6_WZ0K(-Q\%B7QY#Z:S..RQDQ.\L4"-NEZ
ME4]^[43+N(@>XODZB5[WNKU>/UH"2R N5!NZB*=I=A==/RUN\WD385?_AB3B
MYI)\G=S'V1W\(8L>[U/X2T%7)2GJ'.U\='TZJG$7.8J3=5'@_>9+33."HUS7
MUOG7.A]U-PR^"@PO?4B0P\0ZY 9> -</R.4N+VHD]S$N8%&CR22!I^"9*3_?
M,M897(X[G/.'(G]<W0-!+)9QUG9/KA?Q?!Z]6Y=IEM0/4A^Z3^"AS0.%9WY-
M0B:Z6*^ EC,\U-II @>=$A=]/X]KOSH6^SXMD5#_F@ 1O8<_UJ:XD4'+V\+N
M&]__<XW =4$P0 $OCT$@?HW^+:DMO ?_[\WQX>!P4*-_H1\[^399L[?7'^S5
M;]G)Q?GUQ<?QZ>CF[#1Z-_HX.C\YBZY_.3N[N089_OGZ--IYO1N]CM(LNKG/
MUR5L<FUII\E$I7;_N&V.<'V35?ES[>>XO(]@T&B"_Y+\YSJ%*PS/USYRE8 L
M2B=(E?AH]>=+D CTF<D$A4L)5W*2P%BW\]I.7!;),DZG<(U!N2GK5^MB=0^7
M9!+,N\9!<F2=FY^Y+$![*N"$<7FXLB722B?*0.0 *X&9KA?K.=VS:0)*U21E
MJ0:_O3Y^T]D_&M";KX\/._WA46V62[RC>/_F25PF49'>W=.X:_B/Y@E]R//I
M8SJO,3Q@(L#.4M@J>;%QCO$">=1_F3EVAOM]GN)1I[>_7R>+60+[,P7:F>3
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M&JSO@92B?F_OW]SB:%7,"DYAGQ 9ZKPT'>2.LW0.O]&T\/EKI$(?#S]3(4N
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M2;P-%[G -$A8S ,R+2 2W1VRZ5#Q+= 1- EU2MYC$]$&);:933BN%:@VP+2
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M>X0CRB:_:*HOG4[K*=R1O"/U;!8_Y,Y3W^BWC"5+!G53!?D^><8%8S0J)0Q
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M%^ZIZ/=:7!X3DX-(?&7B>()>[HP_^',EHX5KZ[J0$0FC4B<8SX%>IT_>T9K
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MQJ!KCKN1W E2VI4-_T*R?+GF^H9EXG:[X]26IEU!D<32,EXN04:7D:WX?%&
MOH<"U&V#5E_#S#!Z_))+L'0\EU3I(PM"K3PF3V)N9D637ZVQK3<V'J^:NJ B
M1'];(^AEY]7HXY]>[:("00>'2"S0\LG3 '\"1J7WF(-9M@3.F^9PDZ20L9]1
M'^93/W2N6B42^+K[]A0T+JJSH\=K#U#.MT)%K.>X%[D^42%X&D+HD-(D^<VH
MC-LQ?;K0ZZ%I2B=/NV093"NF](GNH4_0]G(\=>D%SIMRK,0RU7NUD\M9HV)T
MN&O4J#@3VE"EU-\)H8$3F.4$719\Z7TZ3_TS#KL?%W=KU5?IIF"YR))KW$I5
M0*T!R2F2_!1+ ]Q&E(D/8&I.L2PXE6TIN,RT5(6]2[');.Q4Z39/?OMR]-3:
M@(6^GW#,<1JB2Z=B\XD<5>J2L%CSN'\]G-U(2,-#HER3.\J6 <:52(,38O2N
M@RW%?/B M!Z24S3)-817K T<JB$3+M8OIG^=OSB=$C65U3S1+CS228FBAL)[
M01O/55CH]!KD%N7,+DRC)N$51D;S2%BT(9!DX1WO*501R;2X3;7O%FCCL#U.
M&1@M$FR DFD9LX_QXQ-.<"3IZE1$R?>3<V1I5_,'X]D1#I 6?@NDJ)MI'<RH
M48\9[5*-(])LG"7GK QN^I82%%?;4U5[,KW>[Q[;>%TXN-'<#EMLF%#?TD;*
MJG?1-U"C_D :M?92ZT0?NQ^[)Q[XI$]X_9W5N8X-N#0*Y]+<.^X60)ZELF9(
M>;V')C7.9BGM")6B.Z'F%30I32 D2;[\$6I-,*] *_'5R;):OL<!;;\0*G=I
M;3R *XWWX_Y?)4'KA\MX#IP/MN[#NQ$L[R/L^"O]&TA KQ77=P/G_C'^%78?
M4P+Y5?UO?N"$%_2*[:#F$2Z!]N=SK.?&(YS,0? ]4H<1,X:6(G'35= RM9UP
M[1L#CNX5.KJ;[/QADO#T)M5_A?M(EV'CJ7X]W#<H:Y7!C<OD&:PS@HG3VHX&
MU?[-016GH/">M":3QQQ#YQ*V,2=;)D7A:@1DC;/=-V!QG6SSCC;,MO=;S9;/
MSFW:E6$'GASE!LF0VGC5*5KL_J9U^SZU_:&B+F["A7[[)P[H$^ZJ'>L'1MRB
M&6/!%-IW"I7//Y Z[6,:0?Y]7,,AL\#GJ]H@]9ZA,2-EF7D31SXT-*HXWDUC
MMY!$X^!#7^8L+(EX3PK1HVALNM[V!1/@(:6RJN(1AN$?TKL<=/]R_J19'RD7
M1D?5PJ4T!RWD\?6$_=R$=R#%+9_G=T^LO8E.0+;^Q)M,Q@'<RB5J-1]-UT J
M]^H5D:H(;M)$2-_P9J33+6J,G&N=:U6A@5>I@>X$-!*@4ECV=,)(I45O^6"+
M[XLIBHZL+I05VZ-0G+D?[I7O&@NV3OZXEZ 7VCF9'")FSAV+0]".;^$28(-V
MJ"RB'K,Y%'/C,(8H-I_78)P"%AP&DM\Z"]^%-_*,*56;)9'&&D@.:QF$L@,N
M #*Y+,E=%15[.:Q^A85R-FX*ZUK#-X:![S"<YVNZ0/BYEM$4 2@TY:XL7W-!
M$I+FT<Y$E$4TLP'3U$0^&I!D)0-ZBWNPRTSJV-1+# A7>*F>*PB7>\0!N9OL
MCI["'"6%L:3DJN6XK:SGN3[RVJD\F=HPZJQ:++)OJT6V <^^:+WI+8T58A&5
M[_2,PBT7GM%SX3GXFUT]@^;)T2:%L#PVO?B0-2>9/(F25O,2*%Y3+Q^^$U)M
MEUU$U!UG(9TI[7WOT'WRB$&6M^C:%IW#=</>."E3N3Q$;(D3#O7D-H)XW3?L
M)P^[07DL @/(]#Q3I_X _9:([!*[2'P#B@<5$RWA"^HCIIP]7N_CF;H!?.C+
M&_.N**W6PL>&PD!/XO<,.[%(1'"6,'#,UY[%<N;WZ9RZE[I LD9JZA-@A,X#
M.YJI"F_YJXG\)//9'G?9GFI!0!,)-%7BN V LD%F9-HTG"O#5].E:CNTDG("
M)5(1RTV)3:*[E:D&;P852_"EFZ4MHGH-8VD<EWH@GMWD*AB7N"K'\T+GDNLH
MR&.X4@WZK"]_@*=-E.31QHQO<:5['6<T#50I?..P%O0M0FFEZ%GM1M=8^L0)
M8)]FR-HJ.WC1,J;?"M4>!"^Y7LIE1NV)C0)?6XC*U7'FM013/56@Y,%V?%^7
M#)"BK28A;@OCSJ38"[I@P2)?2T&3@GCM+)&L[@W$6_D@XLJ0<. 7^T&O_BZI
M\OF$(EW."]U,_5N-W3.+L6/7TN&NSSY@;EHT/G]_<?6)JM[6'DGNB%'X?FFM
MV6[1U\7\YQ(83?(OKY9R?*^:OD$;&.#<"=8KKA#JG^'2M,3+3MV;J30<$RC7
M(%/83LF3+'_>LMF&D(<IL"\C:&H![NPCHA&<PF-C=^RJ6R32Q4RIA"-MT@Q-
MXA-4G(5+*A1W"78L$&SOY)[[04[3THGO0BMR@:(WGS,@J:"Z]]*3P0,W)#).
M.L6"-B1;^36N8N!RNDB- =V%]4^7<)-3UCE<'V,8%?L8D1"6F<"-(D2E'HA<
MU+2(9C'0F&NH56UF4ON:O,\^^<IJ2($M2^&N/I^-\N9B;"X)IP)K#:K^D=37
M6G^3?+Y>9/4LR15+0BG=S/%EXFC6E^IA1@9HPK4U MU,VI1AC1E%=?OVE]:4
M*9U'T+?KZ0A4.^DX3(VML2J%5^X(V&@J #!HQDVK0[YKZ2_6D<XV-+H'M)E)
M4^E]@34!Z:UA(*HWL"ZTT63X=!?T"[<#TND23X^-4(?DT8K\I1DL4(]]!HDT
MG7)&H+N\>F?K)7(SV_N##DS1+R[?PO7=JS:SHN"'('X<%7+X7H8/BZ=@IC9I
MCTP5+QH7I)A^P+>,8QDJPDJTYPD; R[ .R&(L]\C%_9:@.GCLIH+\<+*H%/.
M-\91L?1B<V'Q;J4EUR<J!2)A[+.F4B#<LT28A.L(RTA0KA9]WE!A_G4T['%'
MRO[A<9>*@;_!&N"F9>7^,58%/\FYTJH,T!%4+*^Z4KPK*#77/\(B$C#&FZB_
MW^V[@0=O,%8D>/VF2^IHY @?'.*TL#3W\!@$;O_@$,:K50T+/TQU&0_=!S&@
M>  "U3=)<%\8'* MT!]B/7S0T ^B_0$\O+]_!!^YJ-Z '329=W%CCN!Q;.D)
M@[Z.N-/G#KY)/P[!D'K1&?:/O_T,P6S#J?2'1[#HUS!8I>WH_N$13/+;SY#.
MZ@B/KX_=,MP9'N&&;G6&?3BZ 1X=EEC?1RVMO[^_Y1GN1[@\&@$VM?'\WN #
M0,D'3+]\?@/LGM-^?@<#VJPAOH7G=Q"<'Y9UK^E0OXRNSJ*KL\O/5R>_C*[/
MHNH?JB^<<=&&]KH"SPU0^R+1";?, TU.RU$K.LS6<6<XN!1R1Q?;FO*Q7/_K
M.J@VBCD1X[\H<,;-]HK$U+P6-"^CZASX 14E\YAZ$GL]:\Z2467*6=CNA!4D
MDK/?/S=7N77SP)H]%*=")8%=#F8>TOVON>\<$(YVDPM[JMW.<4*^BQGU@T7M
MX 'EEGTV:FC;9YI.*Q#4]!)$'*BI<,?9634 5'5)[!XG(/K5&@;N]VX/]OK4
MXI0QR]Q>D2.-A:E98C9#X*?B5G5>^J (NWE:2B'=)C9$##+0:%4F[N4;+LX8
MCFCMV'KE0&D72A742:FAYQY0[V.E1,Q3/1]?+2? WV*X&4PWHJ5XF:XJ6]EQ
MPSCCPI3=,64&><J")YJJZ:Q$1+5"F9#"/&SRBC=?D,UM45I*D&$^=J5 UPVA
M1%J^ ;Q/0[/AK:ERD*NSCZ.;L]/H<G1U\]?HYFIT?CTZX;8H[3_5!A&G'L-V
M;^PM:.=M+QB^]<E3YSA[TV%>@QEZV#RG9T*"K@XM7,E/R32>YW?I5VKR14:A
M@+@IO""E;&()8L;S)^J3+IK=V\@D/0O*J=+CT)>\D8H\[*+'M-^7-L.A%3G'
M#2NN===OS[A=FW*J"7A92H#&K?X/I5D=\(H5ZOU,YM54UX"[EA4FY]HCERN3
MK(/(-M.QDKH_+_Z@;2KK[HG/[Z[/_OP9O0=G?X%_UGY?WY88-(4/G#V0=;E!
M8E;&NJ:2(W/,90)MZ2$MUB60*3JE0<'?>75R\9?QZ5[_^-4NXA4D4<IAWK_D
M!? Y@<A<V,1 +B>*.5(R +92D&$E(&N("S: G! 3C6^I>Y_[GC4%']$_'SAS
MM=@2G81^]:VOP?VH0#.7'R,-@Z6Q,TA7;I+*V1UD<#&,;R;-J]5V9S%3G1 9
M)4!P0+;I2A17S5?V$R*63QPX2'+R6'S/^OT KKFE2[;IA(X(-,B!*#&OQZTW
MS%AOSWD/\.$R88[L"!'X3.P?FW=]X>CIR.91W*844RK!_+4T.4JG'5#98)4S
M]I*>P?=RG)^OCC:A+&?0^*[QWS'7&1LF<+(7*0"@,J1E$"[6A\-^.*1]W7K<
M5, 'N=]A<%3D7%JAYTOKB\/$46AGB5.[' 7X:W A05F.$/GV?JQ8=+#TGYL%
M+F5*E3FX&UJZ0#06\S@J$R[3"OP/*;E/Q7V/Y\NZ S,Z1HO,@-/"DO>\590N
M;C%%A.,P<%U8FO[2L 5<7!TW6.LZEBOME)9APH, E)-TZ=0D;BU"T@,3=YZI
M[A=9O+)'I56#;@;EH_%CKE1G=S"?R<?M-K8<+JY;\H1(E3ZIL?"6*4M:@EVQ
MA43275JO4LQX--OA@C-S-#%M^SJ;!V4<=CQS)2E7D(*3OBDG9,Z]&+F4B=9@
M$6%GBE+P]RE")V U'T'0S#,M)U//+Q7.CQ_ZA7QJ"@&$>_C++]>(_!K;+M5N
M9D0J@B/5O6(6&\)'%2" PL3! [ X05C"!(7S>A[KSD[#% L<V'S'4Z"/SGI5
M7GZUR O.UKQU3>8?J9OXQJ-RIG7#:7E<B&/-Q%WYJ$K<8'XE." ^A)2"SZYK
MNI.,7()#UL\VRI,<\B)"O^O<8HAU-U-3ZE]WMFOREO>5+^..VUL39W:XUP-_
MR3"S4TFZZ6)5# 7Z> =+A9#M]]1Q02<S/@\H-QL-!^IDX"<D2%G3"[J2>BVJ
MHDB"F"O0<RD3GSU(Y6SH#I ?B:9]66CA\)/[G.RM<3;I=N ^L6TFEE&,N& 0
M<Y766+6_<>=<;AN-.8Y:_\CN$/.7_7W?2K?3WAEW,#RPR#Z4KB*6M)WEZV&
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MF 9"C-&$V.*B2"LIRZ91T4/,I^W[$+HD\A7!GO5#:!H_$"*0ED5"@?1-7\J
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MW'HZHSZG3I<X=ZJ$:61$:L)<:AC[QGS77P*]PS$$DM2Z<M=/BTGJYK[5'FS
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M="6JJ#XA!C?(-:-YV.LRV<ARI]@>KA^VS F_35^C#L3SF'IA950W<%+DCS;
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ME1?2S*W.S8*<5K3RM[Z<B&QEPU2Y743&F.>BR&]S+HN.^";_D#0YHI8T-,L
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MZ@B/KX]:I#O#(]S0K<ZP#T<WP*-#*;/?A]?Z^_M;GN%^A,NC$6!3&\_O#3X
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M:3Y/P_W=I7FDH3^2%W0 >85 7MF%S.;3*4V_M;<W&L71, IHG!,:!,D\SB,
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MC9@!  "W%P  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSQ=@];L)
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MF[](/HQ9'NJS[J? [ M02P$"% ,4    " "=0*=0'R// \     3 @  "P
M            @ $     7W)E;',O+G)E;'-02P$"% ,4    " "=0*=0)^B'
M#H(   "Q    $               @ 'I    9&]C4')O<',O87!P+GAM;%!+
M 0(4 Q0    ( )U IU O>?])[@   "L"   1              "  9D!  !D
M;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( )U IU"97)PC$ 8  )PG   3
M              "  ;8"  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%
M  @ G4"G4(0 8\8^ P  H \  !@              ( !]P@  'AL+W=O<FMS
M:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( *! IU ]OVEBH00  *H6   8
M              "  6L,  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"
M% ,4    " "@0*=0%WVAE)("  !N"0  &               @ %"$0  >&PO
M=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ H$"G4,K/*AKA P
M.!$  !@              ( !"A0  'AL+W=O<FMS:&5E=',O<VAE970T+GAM
M;%!+ 0(4 Q0    ( *! IU"8BXQ#]@0  -H8   8              "  2$8
M  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " "@0*=0QDM)
M[^T%  #8'P  &               @ %-'0  >&PO=V]R:W-H965T<R]S:&5E
M=#8N>&UL4$L! A0#%     @ H$"G4$B,TK.Q 0  T@,  !@
M ( !<",  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( *!
MIU#C4$-9M $  -(#   8              "  5<E  !X;"]W;W)K<VAE971S
M+W-H965T."YX;6Q02P$"% ,4    " "@0*=0'IF<C+4!  #2 P  &
M        @ %!)P  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%
M  @ H$"G4&2$A<&U 0  T@,  !D              ( !+"D  'AL+W=O<FMS
M:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " "@0*=0UA'"<K,!  #2 P
M&0              @ $8*P  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+
M 0(4 Q0    ( *! IU 1&-6NM0$  -(#   9              "  0(M  !X
M;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ H$"G4*;R5#"X
M 0  T@,  !D              ( ![BX  'AL+W=O<FMS:&5E=',O<VAE970Q
M,RYX;6Q02P$"% ,4    " "@0*=0B/O^([8!  #2 P  &0
M@ '=,   >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( *!
MIU#*-A>XM0$  -(#   9              "  <HR  !X;"]W;W)K<VAE971S
M+W-H965T,34N>&UL4$L! A0#%     @ H$"G4);%(.Y  @  U <  !D
M         ( !MC0  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4
M    " "@0*=0D/B@C- !  "<!   &0              @ $M-P  >&PO=V]R
M:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( *! IU IG-;;N $  -(#
M   9              "  30Y  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL
M4$L! A0#%     @ H$"G4.'!@3?# 0  -P0  !D              ( !(SL
M 'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " "@0*=0AM,V
MD[<!  #2 P  &0              @ $=/0  >&PO=V]R:W-H965T<R]S:&5E
M=#(P+GAM;%!+ 0(4 Q0    ( *! IU#5Y8[_E@(  ,,)   9
M  "  0L_  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @
MH$"G4&&YW"(# P  7@T  !D              ( !V$$  'AL+W=O<FMS:&5E
M=',O<VAE970R,BYX;6Q02P$"% ,4    " "@0*=0*88M:YD"  #*"@  &0
M            @ $210  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4
M Q0    ( *! IU#N^?: \@$  )\%   9              "  >)'  !X;"]W
M;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ H$"G4-I9BSL4 @
M008  !D              ( !"TH  'AL+W=O<FMS:&5E=',O<VAE970R-2YX
M;6Q02P$"% ,4    " "@0*=0%9-RUOT!   ?!@  &0              @ %6
M3   >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( *! IU K
M<))&/P(  ,\&   9              "  8I.  !X;"]W;W)K<VAE971S+W-H
M965T,C<N>&UL4$L! A0#%     @ H$"G4+[5X01A!   ;1<  !D
M     ( ! %$  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( *! IU![POV?2 4   T?   9              "
M ?AC  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ H$"G
M4.!'F]V\ 0  T@,  !D              ( !=VD  'AL+W=O<FMS:&5E=',O
M<VAE970S-"YX;6Q02P$"% ,4    " "@0*=0I5 U56L$  #)%@  &0
M        @ %J:P  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0
M   ( *! IU AA\L$J@$  +\#   9              "  0QP  !X;"]W;W)K
M<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ H$"G4)SR"AT@ @  )P8
M !D              ( ![7$  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q0
M2P$"% ,4    " "@0*=0^99Q^T$"  #,!P  &0              @ %$=
M>&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( *! IU ,7 _2
M!78  "+$ 0 4              "  ;QV  !X;"]S:&%R9613=')I;F=S+GAM
M;%!+ 0(4 Q0    ( *! IU!^CCYK5@(  %P,   -              "  ?/L
M  !X;"]S='EL97,N>&UL4$L! A0#%     @ H$"G4,>V/<N6 P  ZAD   \
M             ( !=.\  'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( *!
MIU"MHL>-F $  +<7   :              "  3?S  !X;"]?<F5L<R]W;W)K
M8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( *! IU#)4^7XH@$  !P8   3
M          "  0?U  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     O "\
*NPP  -KV      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6886889808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 32,046<span></span>
</td>
<td class="nump">$ 31,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">5,338<span></span>
</td>
<td class="nump">2,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash compensation</a></td>
<td class="nump">5,909<span></span>
</td>
<td class="nump">6,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionExpense', window );">401(k) employer match</a></td>
<td class="nump">3,291<span></span>
</td>
<td class="nump">2,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset', window );">Amortization and impairment of operating lease right of use assets</a></td>
<td class="nump">9,058<span></span>
</td>
<td class="nump">8,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss (gain) on disposal of property and equipment</a></td>
<td class="nump">55<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_WriteOffOfOtherComprehensiveIncome', window );">Write-off of other comprehensive income</a></td>
<td class="num">(15)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="nump">1,228<span></span>
</td>
<td class="nump">3,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in earnings from equity method investments</a></td>
<td class="num">(477)<span></span>
</td>
<td class="num">(1,216)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of deferred debt issuance costs/debt discount</a></td>
<td class="nump">220<span></span>
</td>
<td class="nump">213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions', window );">Return on equity investment</a></td>
<td class="nump">2,369<span></span>
</td>
<td class="nump">725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net of impact of acquisitions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Patient accounts receivable</a></td>
<td class="num">(25,459)<span></span>
</td>
<td class="num">(22,333)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Other current assets</a></td>
<td class="num">(5,756)<span></span>
</td>
<td class="num">(10,635)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">417<span></span>
</td>
<td class="num">(338)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(2,673)<span></span>
</td>
<td class="num">(11,140)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(13,627)<span></span>
</td>
<td class="nump">18,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term obligations</a></td>
<td class="nump">3,060<span></span>
</td>
<td class="num">(144)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(8,132)<span></span>
</td>
<td class="num">(8,139)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="num">(817)<span></span>
</td>
<td class="num">(844)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">6,035<span></span>
</td>
<td class="nump">20,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows from Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfRestrictedInvestments', window );">Proceeds from sale of deferred compensation plan assets</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from the sale of property and equipment</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(1,434)<span></span>
</td>
<td class="num">(1,198)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Investments in equity method investees</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(120)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisitions of businesses, net of cash acquired</a></td>
<td class="num">(69,349)<span></span>
</td>
<td class="num">(327,867)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(70,755)<span></span>
</td>
<td class="num">(328,912)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of stock upon exercise of stock options</a></td>
<td class="nump">1,184<span></span>
</td>
<td class="nump">356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from issuance of stock to employee stock purchase plan</a></td>
<td class="nump">860<span></span>
</td>
<td class="nump">782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Shares withheld upon stock vesting</a></td>
<td class="num">(4,050)<span></span>
</td>
<td class="num">(2,688)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CashDistributionToNoncontrollingInterest', window );">Noncontrolling interest distribution</a></td>
<td class="num">(360)<span></span>
</td>
<td class="num">(366)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ProceedsFromBorrowingsUnderTermLoan', window );">Proceeds from borrowings under term loan</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from borrowings under revolving line of credit</a></td>
<td class="nump">187,500<span></span>
</td>
<td class="nump">161,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Repayments of borrowings under revolving line of credit</a></td>
<td class="num">(37,500)<span></span>
</td>
<td class="num">(34,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Principal payments of long-term obligations</a></td>
<td class="num">(1,592)<span></span>
</td>
<td class="num">(559)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Debt issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(847)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">146,042<span></span>
</td>
<td class="nump">299,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">81,322<span></span>
</td>
<td class="num">(9,675)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">96,490<span></span>
</td>
<td class="nump">20,229<span></span>
</td>
<td class="nump">$ 20,229<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">177,812<span></span>
</td>
<td class="nump">10,554<span></span>
</td>
<td class="nump">$ 96,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Disclosures of Cash Flow Information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">1,755<span></span>
</td>
<td class="nump">725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes, net of refunds received</a></td>
<td class="nump">5,272<span></span>
</td>
<td class="nump">404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CashPaidForOperatingLeaseLiabilities', window );">Cash paid for operating lease liabilities</a></td>
<td class="nump">8,949<span></span>
</td>
<td class="nump">8,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CashPaidForFinanceLeaseLiabilities', window );">Cash paid for finance lease liabilities</a></td>
<td class="nump">499<span></span>
</td>
<td class="nump">384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_SupplementalDisclosuresOfNonCashActivityAbstract', window );"><strong>Supplemental Disclosures of Non-Cash Activity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right of use assets obtained in exchange for operating lease liabilities</a></td>
<td class="nump">6,437<span></span>
</td>
<td class="nump">91,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Right of use assets obtained in exchange for finance lease liabilities</a></td>
<td class="nump">254<span></span>
</td>
<td class="nump">808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations', window );">Reductions to right of use assets resulting from reductions to operating lease liabilities</a></td>
<td class="nump">$ 159<span></span>
</td>
<td class="nump">$ 625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization and Impairment of Operating Lease Right Of Use Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CashDistributionToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of dividends or other distributions to noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CashDistributionToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CashPaidForFinanceLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for finance lease liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CashPaidForFinanceLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CashPaidForOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for operating lease liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CashPaidForOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating lease liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of increase (decrease) In Operating Lease Right Of Use Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating lease, Reductions to ROU assets resulting from reductions to lease obligations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ProceedsFromBorrowingsUnderTermLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from borrowings under the term loan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ProceedsFromBorrowingsUnderTermLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_SupplementalDisclosuresOfNonCashActivityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplemental Disclosures of Non-Cash Activity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_SupplementalDisclosuresOfNonCashActivityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_WriteOffOfOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Write off of Other Comprehensive Income</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_WriteOffOfOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=SL94080555-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost (reversal of cost) for pension benefits. Excludes other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfRestrictedInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of investments that are pledged or subject to withdrawal restrictions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfRestrictedInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6885603936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 01, 2020</div></th>
<th class="th"><div>Jan. 01, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 491,685<span></span>
</td>
<td class="nump">$ 467,340<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,870<span></span>
</td>
<td class="nump">44,324<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,338<span></span>
</td>
<td class="nump">2,895<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember', window );">Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,400<span></span>
</td>
<td class="nump">137,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,300<span></span>
</td>
<td class="nump">33,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember', window );">Hospice [Member] | Asana Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66,300<span></span>
</td>
<td class="nump">66,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash Acquired from Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating lease right of use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill recorded during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationIntegrationRelatedCosts', window );">Business Combination, Integration Related Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember', window );">Hospice [Member] | Asana Hospice [Member] | Medicare license [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire business</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill recorded during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">303,600<span></span>
</td>
<td class="nump">310,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,100<span></span>
</td>
<td class="nump">52,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member] | Certificate of Need [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember', window );">Noncompete Agreements [Member] | Hospice [Member] | Asana Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted-average amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_AcquiredNamesOfBusinessMember', window );">Acquired Names of Business [Member] | Hospice [Member] | Asana Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted-average amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating lease right of use assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationIntegrationRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationIntegrationRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=116868840&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=116868840&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of patient service revenue recognized, net of contractual allowances and discounts, less the provision for bad debts related to patient service revenue plus all other revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amed_AsanaHospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amed_AsanaHospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=amed_MedicareLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=amed_MedicareLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=amed_CertificateOfNeedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=amed_CertificateOfNeedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_AcquiredNamesOfBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_AcquiredNamesOfBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6885557632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash and Cash Equivalents (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">$ 3,056<span></span>
</td>
<td class="nump">$ 66,196<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=amed_AsanaHospiceAquisitionMember', window );">Asana Hospice Aquisition [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=amed_COVID19PPEMember', window );">COVID-19 PPE [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=amed_AsanaHospiceAquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=amed_AsanaHospiceAquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=amed_COVID19PPEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=amed_COVID19PPEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6875489904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Operating Income of Reportable Segments</a></td>
<td class="text"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:46.023%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:7.809%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.809%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.809%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.809%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.813%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three-Month Period Ended March 31, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Home<br/>Health</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Hospice</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Personal<br/>Care</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net service revenue</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">303.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">169.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">491.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">179.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">91.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">285.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">156.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation and amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">256.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">131.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">447.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating income (loss)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">47.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(42.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">43.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three-Month Period Ended March 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Home<br/>Health</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Hospice</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Personal<br/>Care</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net service revenue</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">310.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">137.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">467.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">185.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">74.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">275.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">71.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">144.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation and amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">258.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">103.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">423.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating income (loss)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">52.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(42.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8721-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
